toolName,toolType,_pmid,_doi,_publicationTitle,_year,_confidence,_usageType,nf_specific,completeness_score,priority,strainNomenclature,animalModelGeneticDisorder,animalModelOfManifestation,targetAntigen,hostOrganism,clonality,organ,cellLineGeneticDisorder,cellLineManifestation,cellLineCategory,insertName,vectorType,vectorBackbone,promoter,softwareName,softwareType,softwareVersion,sourceRepository,modelType,derivationSource,cellTypes,organoidType,modelSystemType,patientDiagnosis,hostStrain,tumorType,assessmentName,assessmentType,targetPopulation,diseaseSpecific,numberOfItems,_context
NF1 patient-derived induced pluripotent stem cells (iPSCs),advanced_cellular_models,PMID:28392281,10.1016/j.expneurol.2017.04.001,Human stem cell modeling in neurofibromatosis type 1 (NF1).,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,other,patient tissue,pluripotent stem cells,,,,,,,,,,,the availability of NF1 patient-derived induced pluripotent stem cells (iPSCs) provides new opportunities to define the critical factors
129T2/SvEmsJ::C57Bl/6NTac Nf1+/- and Nf1+/+,animal_models,PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.95,Experimental Usage,True,1.00,High,129T2/SvEmsJ::C57Bl/6NTac Nf1+/- and Nf1+/+,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Experimental subjects were 8–12 week old 129T2/SvEmsJ::C57Bl/6NTac Nf1+/+ and Nf1+/- male and female mice that were generated via the F1 cross
C57BL6/J Nf1+/−;Trp53+/−,animal_models,PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.95,Experimental Usage,True,1.00,High,C57BL6/J Nf1+/−;Trp53+/−,Neurofibromatosis type 1,Malignant Peripheral Nerve Sheath Tumor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Murine MPNST tumor lines established from C57BL6/J Nf1+/−;Trp53+/− (NPcis) expressing GFP-Luciferase
Nf1 c.5425 C > T ; Arg1809Cys,animal_models,PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.95,Experimental Usage,True,1.00,High,Nf1 c.5425 C > T ; Arg1809Cys,Neurofibromatosis type 1,Non-tumor forming mutation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Heterozygous Nf1 c.5425 C > T ; Arg1809Cys-mutant mice were generated by CRISPR/Cas9 engineering directly into C57Bl/6J embryos
Nf1 flox/flox ; Hoxb7-Cre,animal_models,PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.95,Experimental Usage,True,1.00,High,Nf1 flox/flox ; Hoxb7-Cre,Neurofibromatosis type 1,Plexiform Neurofibroma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,conditional knockout Nf1 flox/flox ; Hoxb7-Cre mice were used
Nf1 f/neo ; hGFAP-Cre,animal_models,PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.95,Experimental Usage,True,1.00,High,Nf1 f/neo ; hGFAP-Cre,Neurofibromatosis type 1,Optic Nerve Glioma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Optic glioma-prone mice were generated with the R1809C mutation or a neomycin cassette inserted in exon 31 as the germline Nf1 allele and somatic Nf1 inactivation in neuroglial progenitor cells (Nf1 f/neo ; hGFAP-Cre mice)
Nf1-IF,animal_models,PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.95,Experimental Usage,True,1.00,High,Nf1-IF,Neurofibromatosis type 1,mammary adenocarcinomas,,,,,,,,,,,,,,,,,,,,,,,,,,,,,The Nf1 inframe indel (Nf1-IF) rats have a 54bp deletion in exon 20
Nf1-PS,animal_models,PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.95,Experimental Usage,True,1.00,High,Nf1-PS,Neurofibromatosis type 1,mammary adenocarcinomas,,,,,,,,,,,,,,,,,,,,,,,,,,,,,The Nf1 premature stop indel (Nf1-PS) rats have an 8-bp deletion in exon 20
Nf1-IFPS,animal_models,PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.95,Experimental Usage,True,1.00,High,Nf1-IFPS,Neurofibromatosis type 1,mammary adenocarcinomas,,,,,,,,,,,,,,,,,,,,,,,,,,,,,The Nf1 in-frame premature stop indel (Nf1-IFPS) rats have a 57-bp deletion in exon 20
Nf1 flox,animal_models,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,Experimental Usage,True,1.00,High,Nf1 flox,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Mouse lines used in this study were described before: Myf5 Cre, Lbx1 Cre, Nf1 flox"
Nf1+/-,animal_models,PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,,0.95,Experimental Usage,True,1.00,High,Nf1+/-,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Nf1 heterozygous (Nf1+/-) mice accurately reflect the dominant inheritance of NF1 and are regularly employed as a model of NF1
PLP CreERT2; Nf1 f/−; ROSA-LacZ,animal_models,PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.95,Experimental Usage,True,1.00,High,PLP CreERT2; Nf1 f/−; ROSA-LacZ,Neurofibromatosis type 1,Malignant Peripheral Nerve Sheath Tumor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,PLP CreERT2; Nf1 f/−; ROSA-LacZ mice was conditionally activated with a single subcutaneous dose of 4-hydroxytamoxifen
Nf1+/-,animal_models,PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,0.95,Experimental Usage,True,1.00,High,Nf1+/-,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Nf1 +/− mice were generated as previously described (11). In brief, Nf1 +/− mice maintained in the 129/Sv background (12) were crossed with wild-type C57Bl/6 mice."
Nf1(flox/-);Col2.3Cre(+),animal_models,PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,,0.95,Development,True,1.00,High,Nf1(flox/-);Col2.3Cre(+),Neurofibromatosis type 1,Spinal deformities,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"we report a novel murine NF1 model, Nf1(flox/-);Col2.3Cre(+) mice. These mice display short vertebral segments"
Nf1Dsk9/+,animal_models,PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,0.95,Experimental Usage,True,1.00,High,Nf1Dsk9/+,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"The NF1 mouse model used in this study has been described elsewhere. Dsk9 is a missense mutation in the GTPase-activating protein related domain of neurofibromin. Nf1Dsk9/+ (subsequently referred to as ""Nf1+/-"") mice were maintained on a mixed (C3HeB/FeJ x C57bl/6) background."
P0SchΔ39-121,animal_models,PMID:29408605,10.1016/j.neuroscience.2018.01.054,Nf2 Mutation in Schwann Cells Delays Functional Neural Recovery Following Injury.,,0.95,Experimental Usage,True,1.00,High,P0SchΔ39-121,Neurofibromatosis type 2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"P0SchΔ39-121 transgenic mice were obtained from Riken Bioresource Center (Tsukuba, Japan). P0SchΔ39-121 heterozygous mice express a dominant negative form of merlin"
"Trp53, Nf1, Suz12 triple mutant",animal_models,PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,,0.95,Experimental Usage,True,1.00,High,"Trp53, Nf1, Suz12 triple mutant",Neurofibromatosis type 1,tumors,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"The triple mutant line from the vendor carries Trp53, Nf1, Suz12 mutations on chromosome 11 and develops tumors at approximately four months, which is similar to conditions found in human NF1 patients"
Nf1Prx1-/-,animal_models,PMID:34935315,10.1117/1.JBO.26.12.125001,Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse reflectance spectroscopy.,,0.95,Experimental Usage,True,1.00,High,Nf1Prx1-/-,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,...two mouse models of genetic muscle disease: a type 1 neurofibromatosis (NF1) limb-mesenchyme knockout (Nf1Prx1-/-) and a muscular dystrophy mouse (mdx)...
Nf1 (+/-),animal_models,PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,,0.95,Experimental Usage,True,1.00,High,Nf1 (+/-),Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,male and female Nf1 (+/-) mice were mated for 12–16 hours
Nf1 (-/-),animal_models,PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,,0.95,Experimental Usage,True,1.00,High,Nf1 (-/-),Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"In order to obtain Nf1 (-/-) embryos, male and female Nf1 (+/-) mice were mated"
Nf1flox/flox;PostnCre,animal_models,PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.95,Experimental Usage,True,1.00,High,Nf1flox/flox;PostnCre,Neurofibromatosis type 1,Plexiform Neurofibroma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Genetically engineered Nf1flox/flox;PostnCre mice on a mixed C57BL/6 × 129/SV background were utilized for in vivo studies
NF1 R1947/+,animal_models,PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.95,Development,True,1.00,High,NF1 R1947/+,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Generation of NF1 NS/+ minipigs Generation of a swine nonsense mutation model of NF1 followed a similar strategy as previously described. Recurrent nonsense mutation R1947∗ NF1 is located within exon 41
Nf1+/- mice,animal_models,PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,0.95,Experimental Usage,True,1.00,High,Nf1+/- mice,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Mice heterozygous for the Nf1 mutation on a background of C57BL/6J were originally developed by Dr. Tyler Jacks
Nf1 hGFAP CKO,animal_models,PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,0.95,Experimental Usage,True,1.00,High,Nf1 hGFAP CKO,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"The mutant mice ( Nf1 hGFAP CKO) used were of the genotypes, hGFAP-cre+; Nf1 flox/KO  and hGFAP-cre+; Nf1 flox/flox"
Nf1+/–,animal_models,PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.95,Experimental Usage,True,1.00,High,Nf1+/–,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Nf1 heterozygous (Nf1+/–, C57BL/6) mice have been previously described"
Nf1 flox,animal_models,PMID:21681782,10.1002/ajh.22035,Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.,,0.95,Experimental Usage,True,1.00,High,Nf1 flox,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Mx1-Cre, Nf1 flox, and Nf1 fcr (Nf1 knockout) mice have been described previously"
Nf1 fcr,animal_models,PMID:21681782,10.1002/ajh.22035,Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.,,0.95,Experimental Usage,True,1.00,High,Nf1 fcr,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Mx1-Cre, Nf1 flox, and Nf1 fcr (Nf1 knockout) mice have been described previously"
Nf1 ±,animal_models,PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.95,Experimental Usage,True,1.00,High,Nf1 ±,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,heterozygous germline knockout mouse model of Neurofibromatosis type 1 (Nf1 ± mice)
Nf1 flox/flox,animal_models,PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.95,Experimental Usage,True,1.00,High,Nf1 flox/flox,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CX3CR1-CreER [ 71 ] were intercrossed with Nf1 flox/flox [ 1 ]
"Nf1 flox/mut; GFAP-Cre, Nf1+/− GFAP CKO",animal_models,PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.95,Experimental Usage,True,1.00,High,"Nf1 flox/mut; GFAP-Cre, Nf1+/− GFAP CKO",Neurofibromatosis type 1,Optic pathway glioma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"OPG mice (Nf1 flox/mut; GFAP-Cre, Nf1+/− GFAP CKO) mice were generated as previously described"
Postn-Cre; Nf2flox/flox,animal_models,PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,,0.95,Experimental Usage,True,1.00,High,Postn-Cre; Nf2flox/flox,Neurofibromatosis type 2,schwannomas,,,,,,,,,,,,,,,,,,,,,,,,,,,,,The Postn-Cre transgenic and conditional Nf2flox/flox knocking alleles were obtained from the Conway and Clapp labs at Indiana University School of Medicine
DhhCre;Nf1fl/fl,animal_models,PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,,0.95,Experimental Usage,True,1.00,High,DhhCre;Nf1fl/fl,Neurofibromatosis type 1,neurofibroma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Selumetinib was evaluated in the DhhCre;Nf1fl/fl genetically engineered mouse model of neurofibroma
Nf1Prx1,animal_models,PMID:24465906,10.1371/journal.pone.0086115,"Multiscale, converging defects of macro-porosity, microstructure and matrix mineralization impact long bone fragility in NF1.",,0.95,Experimental Usage,True,1.00,High,Nf1Prx1,Neurofibromatosis type 1,limb knock-out,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"we analyzed two conditional mouse models, Nf1Prx1 (limb knock-out) and Nf1Col1 (osteoblast specific knock-out)"
Nf1Col1,animal_models,PMID:24465906,10.1371/journal.pone.0086115,"Multiscale, converging defects of macro-porosity, microstructure and matrix mineralization impact long bone fragility in NF1.",,0.95,Experimental Usage,True,1.00,High,Nf1Col1,Neurofibromatosis type 1,osteoblast specific knock-out,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"we analyzed two conditional mouse models, Nf1Prx1 (limb knock-out) and Nf1Col1 (osteoblast specific knock-out)"
"Mx1-Cre, Nf1 flox/flox",animal_models,PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.",,0.95,Experimental Usage,True,1.00,High,"Mx1-Cre, Nf1 flox/flox",Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Mx1-Cre, Nf1 flox/flox mice (129SV × C57BL/6 J) were generated and somatic Nf1 inactivation was induced as described elsewhere"
Nf1 flox/flox; GFAP-Cre,animal_models,PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,0.95,Experimental Usage,True,1.00,High,Nf1 flox/flox; GFAP-Cre,Neurofibromatosis type 1,Optic glioma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Five-six week-old Nf1 GFAP CKO mice (Nf1 flox/flox; GFAP-Cre) were used. These mice lack Nf1 gene expression in GFAP+ (glial) cells
Nf1fl/fl;DhhCre,animal_models,PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,0.95,Experimental Usage,True,1.00,High,Nf1fl/fl;DhhCre,Neurofibromatosis type 1,Neurofibroma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"by in-house breeding to Nf1 and fl/ + DhhCre to obtain Nf1 fl/fl ;DhhCre or Nf1 mice, as previously described"
Nf1flox/flox,animal_models,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.95,Experimental Usage,True,1.00,High,Nf1flox/flox,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"R26tdTom/tdTom, Nf1flox/flox; Nf1flox/flox; Nf1+/−; and B6D2F1"
Nf1+/−,animal_models,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.95,Experimental Usage,True,1.00,High,Nf1+/−,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"R26tdTom/tdTom, Nf1flox/flox; Nf1flox/flox; Nf1+/−; and B6D2F1"
Nf2 flox2/flox2 ;p16 Ink4a*/*,animal_models,PMID:17924978,10.1111/j.1750-3639.2007.00105.x,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.,,0.95,Experimental Usage,True,1.00,High,Nf2 flox2/flox2 ;p16 Ink4a*/*,Neurofibromatosis type 2,Meningioma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"To obtain Nf2 flox2/flox2 ;p16 Ink4a*/* mice, Nf2 flox2/flox2 mice (4) on the FVB/N background were bred to p16 Ink4a*/* mice"
Nf1flox/flox;PostnCre+,animal_models,PMID:31527226,10.1158/1535-7163.MCT-19-0123,"Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of ",,0.95,Experimental Usage,True,1.00,High,Nf1flox/flox;PostnCre+,Neurofibromatosis type 1,Neurofibromas,,,,,,,,,,,,,,,,,,,,,,,,,,,,,The Nf1;flox/flox PostnCre+ mice were developed and bred by the Clapp Laboratory utilizing tools reported previously (18). Tumor formation is driven by the early embryonic conditional deletion of Nf1 in Schwann cell progenitors via the Periostin (Postn) promoter and Cre recombinase enzyme
Nf1 fl/+,animal_models,PMID:32839340,10.1073/pnas.2008391117,Brain-wide structural and functional disruption in mice with oligodendrocyte-specific ,,0.95,Experimental Usage,True,1.00,High,Nf1 fl/+,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Inducible Plp-Cre (66) and Nf1 fl/+ (67) mice were maintained on a pure C57BL/6 background
Postn-cre;Nf2f/f,animal_models,PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,0.95,Experimental Usage,True,1.00,High,Postn-cre;Nf2f/f,Neurofibromatosis type 2,Schwannoma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Postn-cre were crossed with floxed Nf2 gene (Postn-cre;Nf2f/f) as previously described.
Nf1+/− GFAP CKO,animal_models,PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,0.95,Experimental Usage,True,1.00,High,Nf1+/− GFAP CKO,Neurofibromatosis type 1,attention deficit,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Nf1 +/− GFAP CKO (CKO) and control littermate Nf1 flox/flox (WT) mice were maintained on an inbred C57BL/6 background
Tg(U6x:nf2a/b-4sgRNA),animal_models,PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,0.95,Development,True,1.00,High,Tg(U6x:nf2a/b-4sgRNA),Neurofibromatosis type 2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Transgenic lines used in this study were the ABWT (Zebrafish International Resource Center), Tg(HOTCre:Cas9) (a kind gift from Dr Wenbiao Chen, Vanderbilt University School of Medicine, Nashville, TN, USA), Tg(−7.2kb-sox10:mRFP) and Tg(U6x:nf2a/b-4sgRNA) (generated at the Bronner laboratory, Caltech) lines."
NF1 R1947X minipig,animal_models,PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,,0.95,Development,True,1.00,High,NF1 R1947X minipig,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"To generate a minipig model of NF1, we mimicked a recurrent nonsense mutation p.Arg1947X (R1947X) identified in 62 of 8100 (± 8) unrelated and symptomatic NF1 patients"
Nf1flox/mut;GFAP-Cre,animal_models,PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,0.95,Experimental Usage,True,1.00,High,Nf1flox/mut;GFAP-Cre,Neurofibromatosis type 1,Optic Nerve Glioma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Nf1 +/- GFAP CKO ( Nf1 flox/mut ;GFAP-Cre,  Nf1 -CKO) and littermate control ( Nf1 flox/flox ; CTL) mice were maintained on an inbred C57BL/6 background"
Nf1+/-,animal_models,PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,,0.95,Experimental Usage,True,1.00,High,Nf1+/-,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Nf1+/- and wildtype mice were generated as previously described. In brief, Nf1+/- mice maintained in the 129/Sv background were crossed with wild-type C57Bl/6 mice."
Nf1 (+/-),animal_models,PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,0.95,Experimental Usage,True,1.00,High,Nf1 (+/-),Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Generation of the...Nf1 (+/- Jacks et al., 1994)...In MNTB principal neurons of Nf1 (+/-) mice the average delay between EPSPs and APs was slightly smaller"
TRIM23,antibodies,PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.95,Experimental Usage,True,1.00,High,,,,TRIM23,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Immunohistochemical stain for TRIM23 (ThermoFisher, PA5-34624, 1:150, rabbit polyclonal)"
H3K27me3,antibodies,PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.95,Experimental Usage,True,1.00,High,,,,H3K27me3,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Immunohistochemistry for histone 3 lysine trimethylation (H3K27 me3) was performed using rabbit monoclonal antibodies (C36B11, 1:50 dilution; Cell Signaling Technology)"
MyHC type 1,antibodies,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,Experimental Usage,True,1.00,High,,,,MyHC type 1,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,mouse anti-MyHC type 1 (DSHB BA-D5; 1:500)
MyHC type 2A,antibodies,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,Experimental Usage,True,1.00,High,,,,MyHC type 2A,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,mouse anti-MyHC type 2A (DSHB SC-71; 1:200)
Pax7,antibodies,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,Experimental Usage,True,1.00,High,,,,Pax7,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,mouse anti-Pax7 (DSHB Pax7; 1:10)
MyHC type 2B,antibodies,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,Experimental Usage,True,1.00,High,,,,MyHC type 2B,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,mouse anti-MyHC type 2B (DSHB BF-F3)
RAS,antibodies,PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,0.95,Experimental Usage,True,1.00,High,,,,RAS,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"N-, K-, and H-RAS were detected with a 1:100 dilution of murine monoclonal pan-RAS antibody (BD Biosciences, San Diego, CA, USA, product #610002)."
N-RAS,antibodies,PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,0.95,Experimental Usage,True,1.00,High,,,,N-RAS,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"N-RAS was detected with a 1:400 dilution of a rabbit polyclonal N-RAS antibody (Santa Cruz, CA, USA, product #sc-519)."
RAB5A,antibodies,PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,0.95,Experimental Usage,True,1.00,High,,,,RAB5A,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"RAB5A was detected with a 1:250 dilution of a rabbit polyclonal RAB5A antibody (Santa Cruz, Santa Cruz, CA, USA, product #sc-309)."
GAPDH,antibodies,PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,0.95,Experimental Usage,True,1.00,High,,,,GAPDH,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"GAPDH was detected with a 1:1000 dilution of rabbit polyclonal antibody to GAPDH (Cell Signaling, Boston, MA, USA, product #2118)."
β-actin,antibodies,PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,0.95,Experimental Usage,True,1.00,High,,,,β-actin,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"β-actin was detected with a 1:25,000 dilution of murine monoclonal antibody to β-actin (Sigma, St. Louis, MI, USA, product #A5441)."
Ki67,antibodies,PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.95,Experimental Usage,True,1.00,High,,,,Ki67,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,...followed by a 12-min incubation with the CONFIRM anti-Ki67 (clone 30-9) rabbit monoclonal primary antibody (Roche)...
Ki67,antibodies,PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.95,Experimental Usage,True,1.00,High,,,,Ki67,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"mouse anti-Ki67 (550609, 1:500, BD Pharmingen)"
GFAP,antibodies,PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.95,Experimental Usage,True,1.00,High,,,,GFAP,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"mouse anti-GFAP (556330, 1:2000, BD Pharmingen)"
glutamine synthetase,antibodies,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.95,Experimental Usage,True,1.00,High,,,,glutamine synthetase,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"mouse anti-glutamine synthetase (GS), Sigma-Aldrich, Cat. #MAB302 (1/500)"
Merlin,antibodies,PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,0.95,Experimental Usage,True,1.00,High,,,,Merlin,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-GAPDH, rabbit anti-Histone 3, rabbit anti-Merlin, mouse anti-p53, mouse anti-Ki67, and rabbit anti-β-catenin, all from Cell Signaling"
NF1,antibodies,PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.95,Experimental Usage,True,1.00,High,,,,NF1,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,Rabbit anti-NF1 antibody (A300-140A) was purchased from Bethyl Laboratories
phospho-ERK1/2,antibodies,PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.95,Experimental Usage,True,1.00,High,,,,phospho-ERK1/2,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,rabbit anti-phospho-ERK1/2 (p44/42 MAPK) (Thr202/Tyr204) antibody (#9101)
ERK1/2,antibodies,PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.95,Experimental Usage,True,1.00,High,,,,ERK1/2,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,anti-ERK1/2 (p44/42 MAPK) antibody (#9102)
GFP,antibodies,PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.95,Experimental Usage,True,1.00,High,,,,GFP,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,rabbit anti-GFP antibody (#2555) were purchased from Cell Signaling Technologies
βIII-tubulin,antibodies,PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.95,Experimental Usage,True,1.00,High,,,,βIII-tubulin,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,The mouse anti-βIII-tubulin antibody Tuj1 was obtained from R&D system
NGFR,antibodies,PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.95,Experimental Usage,True,1.00,High,,,,NGFR,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,mouse anti-NGFR (p75) antibody (AB-N07) was purchased from Advanced Targeting System
S100B,antibodies,PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.95,Experimental Usage,True,1.00,High,,,,S100B,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,rabbit anti-S100B antibody (Z0311) was purchased from DAKO
βActin,antibodies,PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.95,Experimental Usage,True,1.00,High,,,,βActin,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"The anti-βActin (C-11, SC-1615HRP) HRP antibody was purchased from Santa Cruz Biotechnology"
HA,antibodies,PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.95,Experimental Usage,True,1.00,High,,,,HA,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,mouse anti-HA antibody (26183) was purchased from Invitrogen
Human Nuclear Antigen,antibodies,PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.95,Experimental Usage,True,1.00,High,,,,Human Nuclear Antigen,Rabbit,Recombinant,,,,,,,,,,,,,,,,,,,,,,,,,,Human Nuclear Antigen (HNA) recombinant rabbit Monoclonal Antibody (235-1 R) was purchased from ThermoFisher
"indoleamine 2,3-dioxygenase",antibodies,PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,,0.95,Experimental Usage,True,1.00,High,,,,"indoleamine 2,3-dioxygenase",Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"The slides were incubated in their prospective antibodies for 30 min: indoleamine 2,3-dioxygenase rabbit monoclonal (1:100, Abcam, Cambridge, UK)"
AHR,antibodies,PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,,0.95,Experimental Usage,True,1.00,High,,,,AHR,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"AHR antibody mouse monoclonal (1:50, Santa Cruz, Dallas, TX, USA)"
TDO2,antibodies,PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,,0.95,Experimental Usage,True,1.00,High,,,,TDO2,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"antibody-TDO2, rabbit/IgG polyclonal (1:100, Proteintech, Rosemont, IL, USA)"
MPP2,antibodies,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.95,Experimental Usage,True,1.00,High,,,,MPP2,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit monoclonal anti‐MPP2 (ab92536, Abcam) antibodies"
MMP9,antibodies,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.95,Experimental Usage,True,1.00,High,,,,MMP9,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit monoclonal anti‐MMP9 (ab137867, Abcam) rabbit polyclonal, and TOM20"
HK2,antibodies,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.95,Experimental Usage,True,1.00,High,,,,HK2,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies (rabbit monoclonal anti‐HK2, H.738.7, Thermo Scientific; mouse monoclonal anti‐TOM20"
TOM20,antibodies,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.95,Experimental Usage,True,1.00,High,,,,TOM20,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"mouse monoclonal anti‐TOM20, sc‐17764, Santa Cruz) were diluted 1:150"
MMP2,antibodies,PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,0.95,Experimental Usage,True,1.00,High,,,,MMP2,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"mouse monoclonal (CA-4001) matrix metalloproteinase (MMP)2...dilution 1 : 1000; incubation overnight at 4 °C, Abcam"
MMP9,antibodies,PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,0.95,Experimental Usage,True,1.00,High,,,,MMP9,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit monoclonal (EP1254) MMP9 (dilution 1 : 1000; incubation overnight at 4 °C, Abcam"
GAPDH,antibodies,PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,0.95,Experimental Usage,True,1.00,High,,,,GAPDH,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,GAPDH mouse mAb (6C5) (dilution 1 : 5000; incubation 1 h at room temperature; Advanced Immunochemical Inc.)
merlin,antibodies,PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,0.95,Experimental Usage,True,1.00,High,,,,merlin,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Rabbit polyclonal anti-merlin (1:100; Santa Cruz Biotechnology, Santa Cruz, CA)"
neurofibromin 1,antibodies,PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.95,Experimental Usage,True,1.00,High,,,,neurofibromin 1,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,Primary and secondary antibodies used were from Cell Signaling Technology: neurofibromin 1 (D7R7D) rabbit mAb 14623 (RRID: AB_2798543)
NF1,antibodies,PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,0.95,Experimental Usage,True,1.00,High,,,,NF1,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-NF1 D7R7D #14624 (Cell Signaling, rabbit, 2% BSA, 1:1000, overnight, 4 °C)"
FLAG,antibodies,PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,0.95,Experimental Usage,True,1.00,High,,,,FLAG,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Flag expression was assessed by western blot (Monoclonal ANTI-FLAG M2 antibody, Sigma-Aldrich, St. Louis, MO)"
ATRX,antibodies,PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.95,Experimental Usage,True,1.00,High,,,,ATRX,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"using an ATRX antibody (Rabbit polyclonal, 1:200 dilution, catalog# HPA001906 Sigma-Aldrich)"
DAXX,antibodies,PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.95,Experimental Usage,True,1.00,High,,,,DAXX,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Immunohistochemistry for DAXX (Rabbit polyclonal, 1:100 dilution, catalog# HPA008736, Atlas Antibodies) was performed manually"
H3K27me3,antibodies,PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.95,Experimental Usage,True,1.00,High,,,,H3K27me3,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"using a mouse monoclonal antibody (Abcam, Cat# ab6002, Cambridge, MA) at 1:1600 dilution"
Phospho-p44/42 ERK1/2,antibodies,PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,,0.95,Experimental Usage,True,1.00,High,,,,Phospho-p44/42 ERK1/2,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,Primary antibodies against Phospho-p44/42 ERK1/2 (p-ERK) (Cell Signaling Technologies #4370S) and p44/42 ERK1/2 (ERK) (Cell Signaling Technologies #4695S) were used at 1:100 dilution
p44/42 ERK1/2,antibodies,PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,,0.95,Experimental Usage,True,1.00,High,,,,p44/42 ERK1/2,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,Primary antibodies against Phospho-p44/42 ERK1/2 (p-ERK) (Cell Signaling Technologies #4370S) and p44/42 ERK1/2 (ERK) (Cell Signaling Technologies #4695S) were used at 1:100 dilution
phosphor-p44/p42 MAPK (ERK1/2),antibodies,PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,,0.95,Experimental Usage,True,1.00,High,,,,phosphor-p44/p42 MAPK (ERK1/2),Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Immunohistochemical staining for phosphor-p44/p42 MAPK (ERK1/2) (Thr202/Tyr204) (Cell Signaling Technology Catalog #4370, Rabbit mAb, 1:100 dilution)"
Ki67,antibodies,PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,0.95,Experimental Usage,True,1.00,High,,,,Ki67,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"proliferation marker protein Ki-67 (antigen Ki67, monoclonal mouse anti-human Ki67 antigen, clone MIB1, M7240, DAKO)"
p21,antibodies,PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,0.95,Experimental Usage,True,1.00,High,,,,p21,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"cyclin-dependent kinase inhibitor p21 (p21, monoclonal mouse anti-human p21 WAF1/Cip1 , M7202, DAKO)"
p53,antibodies,PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,0.95,Experimental Usage,True,1.00,High,,,,p53,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"tumor protein p53 (p53, monoclonal mouse anti-human p53 M7001, DAKO)"
bcl2,antibodies,PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,0.95,Experimental Usage,True,1.00,High,,,,bcl2,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"B-cell lymphoma 2 (bcl2, monoclonal mouse anti-human bcl2 oncoprotein, M887, DAKO)"
bcl6,antibodies,PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,0.95,Experimental Usage,True,1.00,High,,,,bcl6,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"B-cell lymphoma 6 (bcl6, monoclonal mouse anti-human bcl6 protein, M7211, DAKO)"
cyclin D1,antibodies,PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,0.95,Experimental Usage,True,1.00,High,,,,cyclin D1,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"cyclin D1 (monoclonal rabbit anti-human cyclin D1, M3642, DAKO)"
Ref-1,antibodies,PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.95,Experimental Usage,True,1.00,High,,,,Ref-1,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"stained for Ref-1 (mouse Ref-1 antibody, 1:200 dilution, Novus Biologicals, 13B8E5C2)"
p-STAT3,antibodies,PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.95,Experimental Usage,True,1.00,High,,,,p-STAT3,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"p-STAT3 (Y705) (rabbit monoclonal 1:25 dilution, Cell Signaling, D3A7)"
NPcis cell line,cell_lines,PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Murine MPNST tumor lines established from C57BL6/J Nf1+/−;Trp53+/− (NPcis) expressing GFP-Luciferase were used for the in vitro, and in vivo MPNST tumor growth experiments"
Primary Schwannoma Cells,cell_lines,PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 2,Schwannoma,Finite cell line,,,,,,,,,,,,,,,,,,,,,,Primary cells were isolated using the methods described by Rosenbaum et al. Schwannoma tissues were dissected
NF1-null HEK293T cell line,cell_lines,PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.95,Development,True,1.00,High,,,,,,,Kidney,Neurofibromatosis Type 1,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,An NF1-null HEK293T cell line was generated using CRISPR to knock out both alleles of NF1
S462TY,cell_lines,PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"The human NF1 MPNST cell line S462TY was the gift of N. Ratner (University of Cincinnati College of Medicine, Cincinnati, OH, USA). It was derived from a xenograft of S462 cells that grew in immune-deficient mice."
ST88-14,cell_lines,PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"The MPNST cell line ST88-14 was obtained from T. Glover (University of Michigan, Ann Arbor, MI, USA)."
ipNF05.5 (mixed clone),cell_lines,PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Plexiform Neurofibroma,,,,,,,,,,,,,,,,,,,,,,,"five cell lines had available transcriptome data, which were downloaded via syn22351884, including ipNF05.5 (mixed clone), ipNF05.5 (single clone)"
ipNF05.5 (single clone),cell_lines,PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Plexiform Neurofibroma,,,,,,,,,,,,,,,,,,,,,,,"five cell lines had available transcriptome data, which were downloaded via syn22351884, including ipNF05.5 (mixed clone), ipNF05.5 (single clone)"
ipNF95.11bC,cell_lines,PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Plexiform Neurofibroma,,,,,,,,,,,,,,,,,,,,,,,"including ipNF05.5 (mixed clone), ipNF05.5 (single clone), ipNF95.11bC, ipNF95.6, and ipnNF95.11c"
ipNF95.6,cell_lines,PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Plexiform Neurofibroma,,,,,,,,,,,,,,,,,,,,,,,"including ipNF05.5 (mixed clone), ipNF05.5 (single clone), ipNF95.11bC, ipNF95.6, and ipnNF95.11c"
ipnNF95.11c,cell_lines,PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Plexiform Neurofibroma,,,,,,,,,,,,,,,,,,,,,,,"including ipNF05.5 (mixed clone), ipNF05.5 (single clone), ipNF95.11bC, ipNF95.6, and ipnNF95.11c"
immortalized mouse Nf2 Schwann cells,cell_lines,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 2,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"immortalized mouse Nf2 Schwann cells, a gift from D. Lallemand (Centre National de la Recherche Scientifique, Institut Curie, Paris, France) (flox2/flox2)"
ST88-14,cell_lines,PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Human MPNST cell line ST88-14, S462 and a patient-derived xenoline RHT92 were kindly provided by Melissa L. Fishel"
S462,cell_lines,PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Human MPNST cell line ST88-14, S462 and a patient-derived xenoline RHT92 were kindly provided by Melissa L. Fishel"
ST88-14,cell_lines,PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"The ST88-14 (RRID: CVCL_8916) and M724 (MPNST724, RRID: CVCL_AU20) human MPNST cell lines were gifted by Dr. Jonathan A. Fletcher"
M724,cell_lines,PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"The ST88-14 (RRID: CVCL_8916) and M724 (MPNST724, RRID: CVCL_AU20) human MPNST cell lines were gifted by Dr. Jonathan A. Fletcher"
SNF96.2,cell_lines,PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"The SNF96.2 (CRL-2884, RRID: CVCL_K281) human MPNST cell line and the HEK-293T (CRL-3216, RRID: CVCL_0063) cell line were obtained from ATCC"
M1,cell_lines,PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"The M1, M3, M4, M5, and M6 human NF1-associated MPNST cell lines were gifted by Drs. William L. Gerald and Xiaoliang L. Xu"
M3,cell_lines,PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"The M1, M3, M4, M5, and M6 human NF1-associated MPNST cell lines were gifted by Drs. William L. Gerald and Xiaoliang L. Xu"
M4,cell_lines,PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"The M1, M3, M4, M5, and M6 human NF1-associated MPNST cell lines were gifted by Drs. William L. Gerald and Xiaoliang L. Xu"
M5,cell_lines,PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"The M1, M3, M4, M5, and M6 human NF1-associated MPNST cell lines were gifted by Drs. William L. Gerald and Xiaoliang L. Xu"
M6,cell_lines,PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"The M1, M3, M4, M5, and M6 human NF1-associated MPNST cell lines were gifted by Drs. William L. Gerald and Xiaoliang L. Xu"
dNF1‐KO,cell_lines,PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.95,Development,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,The dNF1‐KO cell line was generated using methods described previously
"ipnNF95.11C (hTERT NF1 ipnNF95.11c, RRID: CVCL_UI69)",cell_lines,PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Plexiform Neurofibroma,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"ipnNF95.11C (hTERT NF1 ipnNF95.11c, RRID: CVCL_UI69; NF −/− ) and ipNF95.11b 'C'"
"ipNF95.11b 'C' (hTERT NF1 ipNF95.11b C, RRID: CVCL_UI67)",cell_lines,PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Plexiform Neurofibroma,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"ipNF95.11b 'C' (hTERT NF1 ipNF95.11b C, RRID: CVCL_UI67; +/− NF1 ) cells"
"ipnNF09.4 (hTERT NF1 ipnNF09.4, RRID: CVCL_UI73)",cell_lines,PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Plexiform Neurofibroma,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"ipnNF09.4 (hTERT NF1 ipnNF09.4, RRID: CVCL_UI73; NF1 −/− ) and ipNF05.5"
"ipNF05.5 (hTERT NF1 ipNF05.5, RRID: CVCL_UI71)",cell_lines,PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Plexiform Neurofibroma,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"ipNF05.5 (hTERT NF1 ipNF05.5, RRID: CVCL_UI71; +/− NF1 ) cells"
HEI-193,cell_lines,PMID:21111000,10.1016/j.jneumeth.2010.10.021,A novel imaging-compatible sciatic nerve schwannoma model.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 2,Schwannoma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,Human schwannoma cell line HEI-193 was established from a benign schwannoma tumor from an NF2 patient immortalized with retroviral mediated HPV E6-E7 gene expression
SC4-immortalized Nf2-/- primary Schwann cells,cell_lines,PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 2,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,SC4-immortalized Nf2-/- primary Schwann cells were derived from Nf2-/- deficient mice
MPNST 88-14 cells,cell_lines,PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,MPNST 88-14 cells were cross-linked with 1% formaldehyde for 10 minutes on ice
MPNST S462-TY cells,cell_lines,PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,1.5 ×10 6 MPNST S462-TY cells suspended in Matrigel (BD) and expressing pLVX control or inducible-MAF were injected subcutaneously
S462 cells,cell_lines,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"human malignant peripheral nerve sheath tumor S462 cells, human plexiform neurofibroma PN 04.4 cells"
PN 04.4 cells,cell_lines,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Plexiform Neurofibroma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"human plexiform neurofibroma PN 04.4 cells, mouse breast cancer 4T1 cells"
sMPNST cells,cell_lines,PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"mouse malignant peripheral nerve sheath tumor cells (sMPNST cells, kindly provided by Lu Q. Le, UTSW, Dallas, TX)"
sNF96.2,cell_lines,PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"The human MPNST cell line sNF96.2, was kindly provided by Dr Abhijit Guha...We confirmed the reported germline mutation in exon 21 (3683delC)"
HEI-193,cell_lines,PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 2,Schwannoma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,HEI-193 schwannoma cells were a gift from Marco Giovannini and cultured in Dulbecco's Modified Eagle Medium
SNF02.2,cell_lines,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,Human MPNST cell lines SNF02.2 and SNF96.2 were propagated in DMEM/10% FBS plus L-glutamine and penicillin/streptomycin
SNF96.2,cell_lines,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,Human MPNST cell lines SNF02.2 and SNF96.2 were propagated in DMEM/10% FBS plus L-glutamine and penicillin/streptomycin
TM-31,cell_lines,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Brain,Neurofibromatosis Type 1,High Grade Glioma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"The NF1 patient-derived HGG cell line TM-31 (RRID:CVCL_6735), purchased from the RIKEN biorepository, is null for NF1, TP53, CDKN2A and ATRX"
17,cell_lines,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Brain,Neurofibromatosis Type 1,High Grade Glioma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Mouse NF1-HGG cell lines 17, 5653, and 5746 were derived from three distinct high-grade murine brain tumors sporadically developed by the NPcis genetically engineered mouse model"
5653,cell_lines,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Brain,Neurofibromatosis Type 1,High Grade Glioma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Mouse NF1-HGG cell lines 17, 5653, and 5746 were derived from three distinct high-grade murine brain tumors sporadically developed by the NPcis genetically engineered mouse model"
5746,cell_lines,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Brain,Neurofibromatosis Type 1,High Grade Glioma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Mouse NF1-HGG cell lines 17, 5653, and 5746 were derived from three distinct high-grade murine brain tumors sporadically developed by the NPcis genetically engineered mouse model"
icNF 97.2a,cell_lines,PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Cutaneous neurofibroma,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Immortalized cutaneous neurofibroma Schwann cell lines (icNF 97.2a, icNF 97.2b, and icNF 98.4d) were obtained from Dr. Margaret Wallace"
icNF 97.2b,cell_lines,PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Cutaneous neurofibroma,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Immortalized cutaneous neurofibroma Schwann cell lines (icNF 97.2a, icNF 97.2b, and icNF 98.4d) were obtained from Dr. Margaret Wallace"
icNF 98.4d,cell_lines,PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Cutaneous neurofibroma,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Immortalized cutaneous neurofibroma Schwann cell lines (icNF 97.2a, icNF 97.2b, and icNF 98.4d) were obtained from Dr. Margaret Wallace"
sNF96.2,cell_lines,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"sNF96.2 (a MPNST cell line derived from a patient with NF1, used as target cells)"
U87-MG,cell_lines,PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Brain,Neurofibromatosis Type 1,Glioblastoma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,U87-MG and HEK293T cells were purchased from ATCC. Cell lines were regularly passaged and were cultured in Dulbecco's Modified Eagle Medium
ipNF95.6,cell_lines,PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Plexiform Neurofibroma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,human ipNF95.6 plexiform neurofibroma cells (kindly provided by Dr. Margaret R. Wallace)
icNF97.2a,cell_lines,PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.95,Development,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Cutaneous neurofibroma,Finite cell line,,,,,,,,,,,,,,,,,,,,,,immortalized cNF cell lines through transduction with wild-type human telomerase reverse transcriptase (hTERT) and murine cyclin-dependent kinase 4 (mCdk4) genes
icNF97.2b,cell_lines,PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.95,Development,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Cutaneous neurofibroma,Finite cell line,,,,,,,,,,,,,,,,,,,,,,immortalized cNF cell lines through transduction with wild-type human telomerase reverse transcriptase (hTERT) and murine cyclin-dependent kinase 4 (mCdk4) genes
icNF98.4c,cell_lines,PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.95,Development,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Cutaneous neurofibroma,Finite cell line,,,,,,,,,,,,,,,,,,,,,,immortalized cNF cell lines through transduction with wild-type human telomerase reverse transcriptase (hTERT) and murine cyclin-dependent kinase 4 (mCdk4) genes
icNF98.4d,cell_lines,PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.95,Development,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Cutaneous neurofibroma,Finite cell line,,,,,,,,,,,,,,,,,,,,,,immortalized cNF cell lines through transduction with wild-type human telomerase reverse transcriptase (hTERT) and murine cyclin-dependent kinase 4 (mCdk4) genes
icNF00.10a,cell_lines,PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.95,Development,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Cutaneous neurofibroma,Finite cell line,,,,,,,,,,,,,,,,,,,,,,immortalized cNF cell lines through transduction with wild-type human telomerase reverse transcriptase (hTERT) and murine cyclin-dependent kinase 4 (mCdk4) genes
icNF04.9a,cell_lines,PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.95,Development,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Cutaneous neurofibroma,Finite cell line,,,,,,,,,,,,,,,,,,,,,,immortalized cNF cell lines through transduction with wild-type human telomerase reverse transcriptase (hTERT) and murine cyclin-dependent kinase 4 (mCdk4) genes
i28cNF,cell_lines,PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.95,Development,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Cutaneous neurofibroma,Finite cell line,,,,,,,,,,,,,,,,,,,,,,immortalized cNF cell lines through transduction with wild-type human telomerase reverse transcriptase (hTERT) and murine cyclin-dependent kinase 4 (mCdk4) genes
i18cNF,cell_lines,PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.95,Development,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Cutaneous neurofibroma,Finite cell line,,,,,,,,,,,,,,,,,,,,,,immortalized cNF cell lines through transduction with wild-type human telomerase reverse transcriptase (hTERT) and murine cyclin-dependent kinase 4 (mCdk4) genes
i21cNF,cell_lines,PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.95,Development,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Cutaneous neurofibroma,Finite cell line,,,,,,,,,,,,,,,,,,,,,,immortalized cNF cell lines through transduction with wild-type human telomerase reverse transcriptase (hTERT) and murine cyclin-dependent kinase 4 (mCdk4) genes
hTERT ipNF05.5,cell_lines,PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Plexiform neurofibroma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"The human pNF cell line hTERT ipNF05.5 (ATCC, CRL-3388) and the normal Schwann cell line hTERT ipn02.3 2λ (ATCC, CRL-3392)..."
"M14 (ST88-14, RRID:CVCL_8916)",cell_lines,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"NF1 patient-derived human MPNST cell lines M14 (ST88-14, RRID:CVCL_8916) and M10 (MPNST1) were kind gifts provided by Jonathan A. Fletcher"
M10 (MPNST1),cell_lines,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"NF1 patient-derived human MPNST cell lines M14 (ST88-14, RRID:CVCL_8916) and M10 (MPNST1) were kind gifts provided by Jonathan A. Fletcher"
NF90-8,cell_lines,PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"NF90-8 and ST88-14 MPNST cell lines were generously donated by T. Glover (University of Michigan, Ann Arbor, MI)"
ST88-14,cell_lines,PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"NF90-8 and ST88-14 MPNST cell lines were generously donated by T. Glover (University of Michigan, Ann Arbor, MI)"
ST88-14,cell_lines,PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"PDX cells and the MPNST cell line, ST88-14 (gift from Dr. Nancy Ratner, PhD, University of Cincinnati)"
ST88-14,cell_lines,PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"malignant peripheral nerve sheath tumour (MPNST) cell lines ST88-14, S462 and NF90-8"
S462,cell_lines,PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"malignant peripheral nerve sheath tumour (MPNST) cell lines ST88-14, S462 and NF90-8"
NF90-8,cell_lines,PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"malignant peripheral nerve sheath tumour (MPNST) cell lines ST88-14, S462 and NF90-8"
Mouse merlin-null schwannoma cells,cell_lines,PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,0.95,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 2,Schwannoma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,Mouse merlin-null schwannoma cells were generated in the laboratory of Dr. Cristina Fernandez-Valle by deleting the sequence coding for exon 2 in the Nf2 gene
Pediatric Quality of Life Inventory NF1 module,clinical_assessment_tools,PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Pediatric Quality of Life Inventory NF1 module,questionnaire,pediatric,Yes,16.0,The Pediatric Quality of Life Inventory NF1 module is a disease-specific health-related quality-of-life (QOL) measure assessing 16 domains. Responses on a five-point Likert scale are transformed to a scale of 0-100 (higher scores = better QOL); it produces mean domain and total scores.
cNF-Skindex,clinical_assessment_tools,PMID:38811427,10.1186/s41687-024-00732-w,Quality of life in individuals with neurofibromatosis type 1 associated cutaneous neurofibromas: validation of the Dutch cNF-Skindex.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,cNF-Skindex,questionnaire,adult,Yes,18.0,"The cNF-Skindex is an 18-item questionnaire, including three domains: 'functioning', 'emotions', and 'symptoms'. Each item is scored on a 7-point Likert scale"
PedsQL NF1 Module,clinical_assessment_tools,PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,PedsQL NF1 Module,questionnaire,all ages,Yes,74.0,PedsQL™ NF1 Module: This scale is a self-report measure assessing NF1 disease-specific QOL. Participants who were ages 21 years and older completed the 74-item self-report adult questionnaire
PedsQL™ NF1 Module,clinical_assessment_tools,PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",,0.95,Development,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,PedsQL™ NF1 Module,questionnaire,adult,Yes,74.0,"The objective of this study was to develop an NF1 HRQOL instrument as a module of PedsQL™ and to test for its initial feasibility, internal consistency reliability and validity in adults with NF1."
Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire,clinical_assessment_tools,PMID:28193237,10.1186/s12955-017-0607-y,Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire.,,0.95,Development,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire,questionnaire,adult,Yes,14.0,"The Impact of NF1 on Quality of Life (INF1-QOL) questionnaire was developed by a literature search for common terms, focus group (n = 6), semi-structured interviews (n = 21)"
Autism Observation Score for Infants (AOSI),clinical_assessment_tools,PMID:34049498,10.1186/s11689-021-09364-3,Early differences in auditory processing relate to Autism Spectrum Disorder traits in infants with Neurofibromatosis Type I.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Autism Observation Score for Infants (AOSI),structured interview,pediatric,Yes,,The Autism Observation Score for Infants (AOSI) is a standardised research assessment that examines ASD traits in infants...
NFTI-QOL,clinical_assessment_tools,PMID:24619350,10.1007/s00415-014-7303-1,Longitudinal evaluation of quality of life in 288 patients with neurofibromatosis 2.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,NFTI-QOL,questionnaire,adult,Yes,8.0,The disease-focused NF2 impact on quality of life (NFTI-QOL) patient questionnaire was assessed as an outcome measure for treatment in a multi-centre study.
Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS),clinical_assessment_tools,PMID:37174087,10.3390/cancers15092621,Vinblastine/Methotrexate for Debilitating and Progressive Plexiform Neurofibroma in Children and Young Adults with Neurofibromatosis Type 1: A Phase 2 Study.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS),scale,all ages,Yes,,...Analysis of functional responses for the cohort of participants with airway involvement were guided by the Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) sleep and pulmonary outcomes recommendations...
BoN (Burden of NF1) questionnaire,clinical_assessment_tools,PMID:31053133,10.1186/s13023-019-1067-8,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,,0.95,Development,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,BoN (Burden of NF1) questionnaire,questionnaire,adult,Yes,15.0,"This study sought to develop a self-administered questionnaire in French to assess the burden of NF1 (BoN), then translate and linguistically and cross-culturally validate it"
Autism Diagnostic Observation Scale 2nd Edition,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Autism Diagnostic Observation Scale 2nd Edition,structured interview,pediatric,Yes,,complete the Autism Diagnostic Observation Scale 2nd Edition and Autism Diagnostic Interview-Revised to determine whether they fulfil ASD diagnostic criteria
Autism Diagnostic Interview-Revised,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Autism Diagnostic Interview-Revised,structured interview,caregiver,Yes,95.0,complete the Autism Diagnostic Observation Scale 2nd Edition and Autism Diagnostic Interview-Revised to determine whether they fulfil ASD diagnostic criteria
PlexiQoL,clinical_assessment_tools,PMID:38499890,10.1186/s41687-024-00714-y,"The PlexiQoL, a patient-reported outcome measure on quality of life in neurofibromatosis type 1-associated plexiform neurofibroma: translation, cultural adaptation and validation into the Dutch language for the Netherlands.",,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,PlexiQoL,questionnaire,adult,Yes,18.0,The PlexiQoL questionnaire is a disease-specific QoL measure for adults with NF1-associated plexiform neurofibromas...consists of 18 items with a dichotomous response option
UK NF2 Genetic Severity Score,clinical_assessment_tools,PMID:28848060,10.1136/jmedgenet-2017-104519,Genetic Severity Score predicts clinical phenotype in NF2.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,UK NF2 Genetic Severity Score,scale,all ages,Yes,3.0,We have assessed NF2 clinical phenotype in 142 patients in relation to the UK NF2 Genetic Severity Score to validate its use as a clinical and research tool
PedsQL Neuromuscular 3.0,clinical_assessment_tools,PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,PedsQL Neuromuscular 3.0,questionnaire,caregiver,Yes,,"Quality of life was assessed by parent reported questionnaires, including the Pediatric Quality of Life (PedsQL™) Generic 4.0 and Neuromuscular (3.0) modules"
PAin INtensity Scale for plexiform neurofibromas (PAINS-pNF),clinical_assessment_tools,PMID:40304934,10.1186/s41687-025-00877-2,Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings.,,0.95,Development,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,PAin INtensity Scale for plexiform neurofibromas (PAINS-pNF),scale,all ages,Yes,,"the measures' instructions, items, and formatting were modified to create the PAin INtensity Scale for plexiform neurofibromas (PAINS-pNF)"
Pain Interference Index for plexiform neurofibromas (PII-pNF),clinical_assessment_tools,PMID:40304934,10.1186/s41687-025-00877-2,Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings.,,0.95,Development,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Pain Interference Index for plexiform neurofibromas (PII-pNF),questionnaire,all ages,Yes,,"the measures' instructions, items, and formatting were modified to create the PAin INtensity Scale for plexiform neurofibromas (PAINS-pNF) and the Pain Interference Index for plexiform neurofibromas (PII-pNF)"
PedsQL NF1 adult module,clinical_assessment_tools,PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,PedsQL NF1 adult module,questionnaire,adult,Yes,74.0,disease-specific questionnaires (PedsQL NF1 module and the NFTI-QOL for NF2)
NFTI-QOL,clinical_assessment_tools,PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,NFTI-QOL,questionnaire,adult,Yes,8.0,disease-specific questionnaires (PedsQL NF1 module and the NFTI-QOL for NF2)
PlexiQoL,clinical_assessment_tools,PMID:33085177,10.1002/mgg3.1530,The development of the PlexiQoL: A patient-reported outcome measure for adults with neurofibromatosis type 1-associated plexiform neurofibromas.,,0.95,Development,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,PlexiQoL,questionnaire,adult,Yes,18.0,The PlexiQoL is the first disease-specific PRO assessing the ability of adults with NF-1 associated pNFs to meet their basic human needs.
Novoalign tool v3.02.06,computational_tools,PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Novoalign tool v3.02.06,Analysis Software,v3.02.06,,,,,,,,,,,,,,,Sequence reads were mapped to the human reference genome (GRCh37/hg19) using Novoalign tool v3.02.06
PICARD tools v2.4.1,computational_tools,PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,PICARD tools v2.4.1,Analysis Software,v2.4.1,,,,,,,,,,,,,,,followed by marking and removing PCR duplicates by PICARD tools v2.4.1
Genome Analysis Toolkit (GATK) v3.6-0,computational_tools,PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Genome Analysis Toolkit (GATK) v3.6-0,Analysis Software,v3.6-0,,,,,,,,,,,,,,,Local realignment around insertions/deletions was achieved by Genome Analysis Toolkit (GATK) v3.6-0
Mutect v1.1.4,computational_tools,PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Mutect v1.1.4,Analysis Software,v1.1.4,,,,,,,,,,,,,,,Somatic single-nucleotide variants were identified using Mutect v1.1.4
AXION Biosystems integrated studio (AxIS) version 2.5.1,computational_tools,PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,AXION Biosystems integrated studio (AxIS) version 2.5.1,Analysis Software,2.5.1,,,,,,,,,,,,,,,All neurons were recorded for 3 min at a 4.5 standard deviation threshold level and 5000 Hz as a digital filter using AXION Biosystems integrated studio (AxIS) version 2.5.1 software
"Partek Flow software, version 10.0",computational_tools,PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,"Partek Flow software, version 10.0",Analysis Software,10.0,,,,,,,,,,,,,,,"The analysis for this paper was generated using Partek Flow software, version 10.0 using publicly available datasets"
STAR version 2.7.8a,computational_tools,PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,STAR version 2.7.8a,Analysis Software,2.7.8a,,,,,,,,,,,,,,,RNA-seq reads were aligned to the Ensembl release 100 top-level assembly with STAR version 2.7.8a
mfold computer program version 3.0,computational_tools,PMID:12057013,10.1186/1471-2164-3-13,Complex splicing pattern generates great diversity in human NF1 transcripts.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,mfold computer program version 3.0,Analysis Software,3.0,,,,,,,,,,,,,,,The mfold computer program version 3.0 was used to predict the RNA secondary structure and to calculate the folding free energy
CompuSyn software Version 1.0,computational_tools,PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,CompuSyn software Version 1.0,Analysis Software,1.0,,,,,,,,,,,,,,,"Drug–drug interactions were analyzed with CompuSyn software Version 1.0 (Informer Technologies, Los Angeles, CA, USA; software is available at https://www.compusyn.software.informer.com"
SPIN (Signal Processing in MR Version SVN Revision 1895),computational_tools,PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SPIN (Signal Processing in MR Version SVN Revision 1895),Analysis Software,SVN Revision 1895,http://mrc.wayne.edu,,,,,,,,,,,,,,Internally developed MR software SPIN (Signal Processing in MR (Version SVN Revision 1895); http://mrc.wayne.edu (accessed on 15 December 2023)) was used for tumor volume measurement.
Thermo Xcalibur 4.1,computational_tools,PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Thermo Xcalibur 4.1,Analysis Software,4.1,,,,,,,,,,,,,,,...The data were acquired automatically using Thermo Xcalibur 4.1 software (Thermo Fisher Scientific) and processed with the Spectronaut Pulsar software...
R software version 4.0.0,computational_tools,PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,R software version 4.0.0,Analysis Software,4.0.0,,,,,,,,,,,,,,,"...All analyses were performed using the R software for statistical computing, version 4.0.0, and package lmerTest, version 3.1-2..."
lmerTest package version 3.1-2,computational_tools,PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,lmerTest package version 3.1-2,Package/Library,3.1-2,,,,,,,,,,,,,,,"...using the R software for statistical computing, version 4.0.0, and package lmerTest, version 3.1-2..."
VivoQuant software version 4.0,computational_tools,PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,VivoQuant software version 4.0,Analysis Software,4.0,,,,,,,,,,,,,,,"ROIs were manually drawn with VivoQuant software version 4.0 (Invicro, Needham, MA, USA)"
MaxQuant version 1.3.05,computational_tools,PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,MaxQuant version 1.3.05,Analysis Software,1.3.05,,,,,,,,,,,,,,,Andromeda search engine integrated in MaxQuant version 1.3.05 programme was used to identify the proteins
ichorCNA tool (Broad v.0.2.0),computational_tools,PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ichorCNA tool (Broad v.0.2.0),Analysis Software,v.0.2.0,,,,,,,,,,,,,,,copy number–based estimation of tumor fraction were then performed using the ichorCNA tool (Broad v.0.2.0)
Imaris × 64 version 9.6–9.9,computational_tools,PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Imaris × 64 version 9.6–9.9,Analysis Software,9.6–9.9,,,,,,,,,,,,,,,"3-dimensional fluorescence images using Imaris × 64 version 9.6–9.9 (Bitplane, Zurich, Switzerland) algorithms"
MaxQuant version 1.6.10.43,computational_tools,PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,MaxQuant version 1.6.10.43,Analysis Software,1.6.10.43,,,,,,,,,,,,,,,MaxQuant version 1.6.10.43 [ 12 ] was used whilst enabling TMTpro 16-plex reporter ion quantitation
synergyfinder,computational_tools,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,synergyfinder,Web Application,,https://synergyfinder.fimm.fi/,,,,,,,,,,,,,,We used the percent viability compared to untreated cells to calculate a synergy score for each of the analyzed combinations (https://synergyfinder.fimm.fi/)
bwa-mem v0.7.10,computational_tools,PMID:32107864,10.1002/mgg3.1180,Expanding the Noonan spectrum/RASopathy NGS panel: Benefits of adding NF1 and SPRED1.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,bwa-mem v0.7.10,Analysis Software,v0.7.10,,,,,,,,,,,,,,,Sequence reads were aligned to the reference sequence (GRCh37) using bwa‐mem v0.7.10
"GATK, version 1.0.4705",computational_tools,PMID:32107864,10.1002/mgg3.1180,Expanding the Noonan spectrum/RASopathy NGS panel: Benefits of adding NF1 and SPRED1.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,"GATK, version 1.0.4705",Analysis Software,1.0.4705,,,,,,,,,,,,,,,"followed by variant calling using GATK, version 1.0.4705"
nf1_inactivation GitHub repository,computational_tools,PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,0.95,Development,True,1.00,High,,,,,,,,,,,,,,,nf1_inactivation GitHub repository,Pipeline,,https://github.com/greenelab/nf1_inactivation,,,,,,,,,,,,,,"All source code is available under a permissive open source license in the nf1_inactivation GitHub repository, https://github.com/greenelab/nf1_inactivation"
Cutaneous NF Github repository,computational_tools,PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.95,Development,True,1.00,High,,,,,,,,,,,,,,,Cutaneous NF Github repository,Web Application,,http://www.github.com/Sage-Bionetworks/dermalNF,,,,,,,,,,,,,,"All data is currently stored in the synapse web portal, and is accessible using code in the Cutaneous NF Github repository at http://www.github.com/Sage-Bionetworks/dermalNF"
QuPath (v0.4.3),computational_tools,PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,QuPath (v0.4.3),Analysis Software,v0.4.3,,,,,,,,,,,,,,,QuPath (v0.4.3) was used to quantify the percentage of cells with positive or negative immunostaining
nf-core sarek pipeline (v2.7.1),computational_tools,PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,nf-core sarek pipeline (v2.7.1),Pipeline,v2.7.1,,,,,,,,,,,,,,,WES and WGS data processing was performed with a modified version of the Nextflow nf-core 'sarek' data processing pipeline (v2.7.1)
nf-core rnaseq pipeline (v3.5),computational_tools,PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,nf-core rnaseq pipeline (v3.5),Pipeline,v3.5,,,,,,,,,,,,,,,Transcriptomic data processing was performed using the nf-core 'rnaseq' data processing pipeline (v3.5)
ATLAS.ti (Version 9),computational_tools,PMID:41602242,10.7759/cureus.100193,Perspectives of Patients and Providers on Chronic Pain Assessment in Neurofibromatosis Type 1 (NF1): A Qualitative Study.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ATLAS.ti (Version 9),Analysis Software,Version 9,,,,,,,,,,,,,,,"The coded transcripts were entered into ATLAS.ti (Version 9; Kansas City, MO)"
minfi,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,minfi,Package/Library,3.3,,,,,,,,,,,,,,,Raw IDAT data files were processed using the minfi Bioconductor package (version 3.3)
MuTect1,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,MuTect1,Analysis Software,v1.1.7,,,,,,,,,,,,,,,"Haplotype Caller, MuTect1 v1.1.7 and Strelka v1.0.13 were run to create raw variant call files"
Strelka,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Strelka,Analysis Software,v1.0.13,,,,,,,,,,,,,,,"Haplotype Caller, MuTect1 v1.1.7 and Strelka v1.0.13 were run to create raw variant call files"
Variant Effect Predictor,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Variant Effect Predictor,Analysis Software,v92,,,,,,,,,,,,,,,Raw VCF files were annotated with Variant Effect Predictor v92
Sequenza,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Sequenza,Analysis Software,v 2.1.2,,,,,,,,,,,,,,,"Additional analysis was applied to detect allele specific copy number profiles, loss of heterozygosity, and to estimate ploidy/cellularity using Sequenza for matched tumor/normal pairs"
BwaMem,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,BwaMem,Analysis Software,v0.7.12,,,,,,,,,,,,,,,WGS data were aligned against hg19 using BwaMem v0.7.12
Delly,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Delly,Analysis Software,0.8.1,,,,,,,,,,,,,,,Structural variant (SV) prediction for tumor and matched normal pairs was carried out using Delly (version 0.8.1)
MAVIS,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,MAVIS,Analysis Software,2.2.6,,,,,,,,,,,,,,,SVs were validated and visualized using MAVIS (version 2.2.6)
STAR aligner,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,STAR aligner,Analysis Software,2.4.2a,,,,,,,,,,,,,,,"The reads were aligned to the human reference genome, hg38 using the star aligner (version 2.4.2a)"
HtSeq,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,HtSeq,Analysis Software,0.11.0,,,,,,,,,,,,,,,The RNASeq reads were counted over gene exons using HtSeq (version 0.11.0)
DESeq2,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,DESeq2,Package/Library,1.26.0,,,,,,,,,,,,,,,DEseq2 (DESeq2_1.26.0) was used to normalize and difference in library preparation methods was corrected by limma
GSEA,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GSEA,Analysis Software,3.0,,,,,,,,,,,,,,,Pathways analysis was performed using DEG from indicated pairwise analysis by the Gene Set Enrichment Analysis (GSEA) software from the Broad Institute (version 3.0)
Cytoscape,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Cytoscape,Analysis Software,3.7.2,,,,,,,,,,,,,,,labeled by AutoAnnotate (version 1.2) in Cytoscape (Version 3.7.2)
RENOVO-NF1,computational_tools,PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,0.95,Development,True,1.00,High,,,,,,,,,,,,,,,RENOVO-NF1,Analysis Software,,https://github.com/mazzalab-ieo/renovo,,,,,,,,,,,,,,"Here, we optimized our random forest-based predictor RENOVO for NF1 variant interpretation. RENOVO was developed using an approach of 'database archaeology'"
NF Research Tools Database,computational_tools,PMID:35735230,10.1093/database/baac045,Centralizing neurofibromatosis experimental tool knowledge with the NF Research Tools Database.,,0.95,Development,True,1.00,High,,,,,,,,,,,,,,,NF Research Tools Database,Database,,https://tools.nf.synapse.org/,,,,,,,,,,,,,,"...the NF Research Tools Database, is an open-access database that enables the exploration and discovery of information about NF type 1-relevant animal models, cell lines, antibodies..."
Statistical Parametric Mapping toolbox (SPM8),computational_tools,PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Statistical Parametric Mapping toolbox (SPM8),Analysis Software,SPM8,,,,,,,,,,,,,,,"PET images were spatially processed using the Statistical Parametric Mapping toolbox (SPM8, Wellcome Trust Centre for Neuroimaging, 2008)"
STRING,computational_tools,PMID:38115252,10.1097/MD.0000000000036696,Identification of hub genes and drug candidates for NF2-related vestibular schwannoma by bioinformatics tools.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,STRING,Database,,https://string-db.org/,,,,,,,,,,,,,,The key module genes were uploaded to STRING (https://string-db.org/) to generate the PPI axis
Cytoscape,computational_tools,PMID:38115252,10.1097/MD.0000000000036696,Identification of hub genes and drug candidates for NF2-related vestibular schwannoma by bioinformatics tools.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Cytoscape,Analysis Software,v3.8.2,,,,,,,,,,,,,,,the results were visualized using the Cytoscape (v3.8.2) software
PredictProtein,computational_tools,PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,PredictProtein,Web Application,,https://www.PredictProtein.org,,,,,,,,,,,,,,Analyses of in silico protein modifications by the exon skipping were performed using the web-server version of PredictProtein
Seurat,computational_tools,PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Seurat,Package/Library,5.3.0,https://satijalab.org/seurat/,,,,,,,,,,,,,,"We processed the data using Seurat (Version: 5.3.0, https://satijalab.org/seurat/) in R (Version: 4.4.0)"
Seurat 3.1.0,computational_tools,PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Seurat 3.1.0,Package/Library,3.1.0,,,,,,,,,,,,,,,Raw sequencing reads were processed using CellRanger (10 × Genomics) and Seurat 3.1.0
Seurat v4.0.1,computational_tools,PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Seurat v4.0.1,Package/Library,v4.0.1,,,,,,,,,,,,,,,followed by analysis in R using the Seurat (v4.0.1) tool suite
QURNAs,computational_tools,PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,0.95,Development,True,1.00,High,,,,,,,,,,,,,,,QURNAs,Pipeline,,https://dataverse.nl/dataset.xhtml?persistentId=hdl:10411/LY8ZQ4,,,,,,,,,,,,,,an in-house developed tool (QURNAs) was used to calculate the enrichment score (ERS) for each splicing event
SNP & Variation Suite v8.3.4,computational_tools,PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SNP & Variation Suite v8.3.4,Analysis Software,v8.3.4,,,,,,,,,,,,,,,Quality control for targeted gene sequencing data was done using SNP & Variation Suite v8.3.4 (http://goldenhelix.com/products/SNP_Variation/index.html)
Haploview 4.2,computational_tools,PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Haploview 4.2,Analysis Software,4.2,,,,,,,,,,,,,,,"Haploview 4.2 (Barrett, Fry, Maller, & Daly, 2005) was used to generate LD plots across the genome based on D' and r2 values"
Varsome Clinical Software v.12.3.2,computational_tools,PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Varsome Clinical Software v.12.3.2,Analysis Software,v.12.3.2,,,,,,,,,,,,,,,"Candidate somatic variants, consisting of point mutations, insertions, and deletions were sorted out with Varsome Clinical Software v.12.3.2 (Saphetor, Lausanne, Switzerland)."
shNF1,genetic_reagents,PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,shNF1,Viral,,,,,,,,,,,,,,,,,,,,"were infected with sh NF1 1–3 lentiviral particles (Sigma; 39714, 39715, 39717)"
Nf1,genetic_reagents,PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,Nf1,Other,,,,,,,,,,,,,,,,,,,,"Nf1 Exon 8, F CCAGGACATCTCCAAGGATG"
NF1 DLR,genetic_reagents,PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,NF1 DLR,Plasmid,,,,,,,,,,,,,,,,,,,,The NF1 DLR plasmid was kindly provided by David Bedwell at University of Alabama. The R1497X Renilla-NF1-R1947X-Firefly insert contains 30 nucleotides
human neurofibromin,genetic_reagents,PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,human neurofibromin,Plasmid,,,,,,,,,,,,,,,,,,,,"GFP-tagged human neurofibromin, transcript variant 1 cDNA (RG220425, Origene)"
NF1 shRNA,genetic_reagents,PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,NF1 shRNA,Viral,,,,,,,,,,,,,,,,,,,,"Lentiviral vectors expressing NF1 small hairpin (sh) RNA and shCtr were purchased from Sigma (CAT# TRCN000023878, TRCN0000039713, and SHC202)"
NF1 shRNA,genetic_reagents,PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,NF1 shRNA,Viral,,,,,,,,,,,,,,,,,,,,"Lentiviral vectors expressing NF1 small hairpin (sh) RNA and shCtr were purchased from Sigma (CAT# TRCN000023878, TRCN0000039713, and SHC202)"
neurofibromin 2,genetic_reagents,PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,0.95,Experimental Usage,True,1.00,High,,,,,,,,,,,neurofibromin 2,Other,,,,,,,,,,,,,,,,,,,,"Small interfering RNA (siRNA) molecules (neurofibromin 2 ON-TARGETplus SMARTpool; Dharmacon, Lafayette, CO) were diluted in Opti-MEM"
NF1-associated MPNST-PDX,patient_derived_models,PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.95,Development,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,PDX,NF1-associated MPNST,NRG,MPNST,,,,,,We developed 13 NF1-associated MPNST-PDX and identified mutations
NF1-MPNST patient-derived xenografts,patient_derived_models,PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.95,Development,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,PDX,NF1-associated MPNST,NSG,MPNST,,,,,,we developed a collection of NF1-MPNST patient-derived xenografts (PDX). These PDX were compared with the primary tumors
Matrigel spheroids,advanced_cellular_models,PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,spheroid,cell line,,,,,,,,,,,,NF1-deficient MUT-45 spheroids grow larger than NF1-EV spheroids when grown in Matrigel
neurofibromaspheres,advanced_cellular_models,PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,spheroid,iPSC,"Schwann cells, fibroblasts",,,,,,,,,,,neurofibromaspheres were obtained by 3D culture of differentiating pNF iPSC-derived Schwann cells (SC) with pNF patient-derived NF1 fibroblasts
neurofibroma spheres,advanced_cellular_models,PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,spheroid,patient tissue,Schwann cells,,,,,,,,,,,"For mouse or human neurofibroma spheres, we chopped tissue into 1–3 mm³ pieces"
neurofibromasphere model,advanced_cellular_models,PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,spheroid,iPSC,"Schwann cells, fibroblasts",,,,,,,,,,,induced pluripotent stem cell-derived 3D neurofibromasphere model
R681X Nf1,animal_models,PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.9,Experimental Usage,True,1.00,High,R681X Nf1,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,heterozygous R681X and c.3827G > C Nf1-mutant mice were backcrossed to C57Bl/6J
Nf1(ob) (-/-),animal_models,PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,0.9,Experimental Usage,True,1.00,High,Nf1(ob) (-/-),Neurofibromatosis type 1,Bone healing defects,,,,,,,,,,,,,,,,,,,,,,,,,,,,,we assessed bone healing in the Nf1(ob) (-/-) conditional mouse model lacking Nf1 specifically in osteoblasts
y w Mer4,animal_models,PMID:24595234,10.1371/journal.pone.0090853,In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,,0.9,Experimental Usage,True,1.00,High,y w Mer4,Neurofibromatosis type 2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"crossed to female flies of the following genotype, y w Mer4"
Nf1Prx1,animal_models,PMID:21726432,10.1186/1741-7015-9-82,MIA is a potential biomarker for tumour load in neurofibromatosis type 1.,,0.9,Experimental Usage,True,1.00,High,Nf1Prx1,Neurofibromatosis type 1,bone dysplasia,,,,,,,,,,,,,,,,,,,,,,,,,,,,,mice bearing conditional inactivation of NF1 in the developing limbs...Nf1Prx1 mouse model might prove to be relevant biomarkers
Nf1flox/flox,animal_models,PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.9,Experimental Usage,True,1.00,High,Nf1flox/flox,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Nf1flox/flox (Zhu et al. 2001) and Nf1GFAP CKO (Bajenaru et al. 2002) mice were generated as previously described and maintained on a C57Bl/6 background
Nf1GFAP CKO,animal_models,PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.9,Experimental Usage,True,1.00,High,Nf1GFAP CKO,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Nf1flox/flox (Zhu et al. 2001) and Nf1GFAP CKO (Bajenaru et al. 2002) mice were generated as previously described and maintained on a C57Bl/6 background
Nf1 +/− GFAP CKO,animal_models,PMID:23225063,10.1002/ana.23793,Dopamine deficiency underlies learning deficits in neurofibromatosis-1 mice.,,0.9,Experimental Usage,True,1.00,High,Nf1 +/− GFAP CKO,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Nf1 +/− GFAP CKO (CKO) with one non-functional Nf1 allele in all somatic cells and complete Nf1 loss in GFAP+ (glial) cells
Nf1 +/−,animal_models,PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,,0.9,Experimental Usage,True,1.00,High,Nf1 +/−,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Nf1 +/− mice were obtained from Dr. Tyler Jacks at the Massachusetts Institute of Technology
Nf1 flox/flox,animal_models,PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,,0.9,Experimental Usage,True,1.00,High,Nf1 flox/flox,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Nf1 flox/flox mice were provided by Dr. Luis Parada at the University of Texas Southwestern Medical Center
cisNP,animal_models,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,True,1.00,High,cisNP,Neurofibromatosis type 1,Malignant Peripheral Nerve Sheath Tumor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"The cisNP mouse model has been previously described (27, 28)."
y [1] sc[*] v [1] sev [21]; P{y[+t7.7] v[+t1.8] = TKO.GS01796}attP40,animal_models,PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.9,Experimental Usage,True,1.00,High,y [1] sc[*] v [1] sev [21]; P{y[+t7.7] v[+t1.8] = TKO.GS01796}attP40,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,The Nf1 mutant fly line was generated by CRISPR/Cas9 using the sgRNA line: y [1] sc[*] v [1] sev [21]; P{y[+t7.7] v[+t1.8] = TKO.GS01796}attP40
P{ KK101909 }VIE‐260B,animal_models,PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.9,Experimental Usage,True,1.00,High,P{ KK101909 }VIE‐260B,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,dNf1 RNAi line: P{ KK101909 }VIE‐260B (VDRC #109637)
Nf1flox/flox,animal_models,PMID:34935315,10.1117/1.JBO.26.12.125001,Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse reflectance spectroscopy.,,0.9,Experimental Usage,True,1.00,High,Nf1flox/flox,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,...the NF1 mice bred from the Prx1-Cre transgenic mice and the Nf1flox/flox mice...
C57BL/6J,animal_models,PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,,0.9,Experimental Usage,True,1.00,High,C57BL/6J,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,C57BL/6J mice in which one allele of the NF1 gene has been targeted were generated as described elsewhere
NF1 fl/fl Tp53 fl/fl Eed fl/fl;Dhh-Cre,animal_models,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,True,1.00,High,NF1 fl/fl Tp53 fl/fl Eed fl/fl;Dhh-Cre,Neurofibromatosis type 1,Malignant Peripheral Nerve Sheath Tumor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,The NPE-mutant mice were generated by crossing NF1 fl/fl (JAX Nf1tm1Par/J) Tp53 fl/fl Eed fl/fl mice with Dhh-Cre mice
NF1 flox/−,animal_models,PMID:21551250,10.1158/0008-5472.CAN-10-4577,Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development.,,0.9,Experimental Usage,True,1.00,High,NF1 flox/−,Neurofibromatosis type 1,Plexiform Neurofibroma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,The NF1 flox/− mice are in a mixed genetic background of C57BL/6/Sv129 and have been described previously
Nf1fl/fl,animal_models,PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,Experimental Usage,True,1.00,High,Nf1fl/fl,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Nf1fl/fl, OPG Nf1fl/mut (Nf1+/−) and Nf1 (wild-type) mice were previously generated"
OPG Nf1fl/mut (Nf1+/−),animal_models,PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,Experimental Usage,True,1.00,High,OPG Nf1fl/mut (Nf1+/−),Neurofibromatosis type 1,Optic Nerve Glioma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Nf1fl/fl, OPG Nf1fl/mut (Nf1+/−) and Nf1 (wild-type) mice were previously generated"
Nf1 flox/flox,animal_models,PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.9,Experimental Usage,True,1.00,High,Nf1 flox/flox,Neurofibromatosis type 1,Optic Nerve Glioma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Optic chiasm was microdissected from 3-month-old Nf1 flox/flox, Nf1 +/− and Nf1 +/− GFAP CKO mice to generate primary optic nerve neurospheres"
Nf1 +/−,animal_models,PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.9,Experimental Usage,True,1.00,High,Nf1 +/−,Neurofibromatosis type 1,Optic Nerve Glioma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Optic chiasm was microdissected from 3-month-old Nf1 flox/flox, Nf1 +/− and Nf1 +/− GFAP CKO mice"
Nf1 +/− GFAP CKO,animal_models,PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.9,Experimental Usage,True,1.00,High,Nf1 +/− GFAP CKO,Neurofibromatosis type 1,Optic Nerve Glioma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Optic chiasm was microdissected from 3-month-old Nf1 flox/flox, Nf1 +/− and Nf1 +/− GFAP CKO mice"
Nf1 NcreER CKO,animal_models,PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,0.9,Experimental Usage,True,1.00,High,Nf1 NcreER CKO,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Nestin-cre ER +; Nf1 flox/flox  (tamoxifen+) mice were used as mutants ( Nf1 NcreER CKO)
Nf1+/-,animal_models,PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.9,Experimental Usage,True,1.00,High,Nf1+/-,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Nf1+/- mice were obtained from Tyler Jacks (Massachusetts Institute of Technology, Cambridge, MA, USA) and backcrossed 13 generations into the C57BL/6J strain."
Nf1flox/flox,animal_models,PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.9,Experimental Usage,True,1.00,High,Nf1flox/flox,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Nf1flox/flox mice were obtained from Luis Parada (University of Texas Southwestern Medical Center, Dallas, TX, USA) and maintained on C57BL/6J background."
NPcis,animal_models,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.9,Experimental Usage,True,1.00,High,NPcis,Neurofibromatosis type 1,High Grade Glioma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,sporadically developed by the NPcis genetically engineered mouse model. The germline of these mice is heterozygous for Nf1 and Tp53; mutant alleles are located in cis
Nf1 P1,animal_models,PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.9,Experimental Usage,True,1.00,High,Nf1 P1,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,The Nf1 P1 mutation was backcrossed six generations into the w CS10 genetic background and w CS10 flies were used as controls.
Nf2flox/flox,animal_models,PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,,0.9,Experimental Usage,True,1.00,High,Nf2flox/flox,Neurofibromatosis type 2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,conditional Nf2flox/flox knocking alleles were obtained from the Conway and Clapp labs
"Dhh::Cre, Nf1fl/fl, Pten",animal_models,PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.9,Experimental Usage,True,1.00,High,"Dhh::Cre, Nf1fl/fl, Pten",Neurofibromatosis type 1,Peripheral nerve sheath tumor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"The GEMM of high-grade PNSTs was generated as described previously. Dhh::Cre, Nf1fl/fl, Pten experimental class animals were randomized to a treatment or vehicle group"
Nf1^flox/flox;GFAP-Cre,animal_models,PMID:26883872,10.1016/j.jprot.2016.02.004,3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma.,,0.9,Experimental Usage,True,1.00,High,Nf1^flox/flox;GFAP-Cre,Neurofibromatosis type 1,Optic Nerve Glioma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Nf1^flox/flox;GFAP-Cre mice (OPG mice) were generated as previously described. All mice were maintained on a C57BL/6 background
Nf1(fl/fl);DhhCre,animal_models,PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,Experimental Usage,True,1.00,High,Nf1(fl/fl);DhhCre,Neurofibromatosis type 1,Neurofibroma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Genetic deletion of Stat3 in Schwann cell progenitors (SCPs) and Schwann cells (SCs) prevents neurofibroma formation
Stat3(fl/fl);Nf1(fl/fl);DhhCre,animal_models,PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,Experimental Usage,True,1.00,High,Stat3(fl/fl);Nf1(fl/fl);DhhCre,Neurofibromatosis type 1,Neurofibroma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Knockdown of Arid1b or Gsk3β in Stat3(fl/fl);Nf1(fl/fl);DhhCre SCPs rescues neurofibroma formation after in vivo transplantation
Nf1f/f;Trp53f/f;Nes-TK,animal_models,PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,0.9,Experimental Usage,True,1.00,High,Nf1f/f;Trp53f/f;Nes-TK,Neurofibromatosis type 1,Malignant Peripheral Nerve Sheath Tumor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,SKPs were isolated as previously reported from neonatal Nf1f/f;Trp53f/f;Nes-TK mice within 2 weeks of age
Nf1f/f;Trp53f/f;CGD,animal_models,PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,0.9,Experimental Usage,True,1.00,High,Nf1f/f;Trp53f/f;CGD,Neurofibromatosis type 1,Malignant Peripheral Nerve Sheath Tumor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,BC and DRG were harvested from the E13.5 embryos as described from Nf1f/f;Trp53f/f;CGD mice
Nf1-/-,animal_models,PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,0.9,Experimental Usage,True,1.00,High,Nf1-/-,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Several Nf1 alleles were used in these studies including Nf1 (germline mutant) mice (− Jacks et al., 1994)"
Nf1fl,animal_models,PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,0.9,Experimental Usage,True,1.00,High,Nf1fl,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Nf1 mice for conditional deletion (fl Zhu et al., 2001)"
Nf1/p53-/-,animal_models,PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,0.9,Experimental Usage,True,1.00,High,Nf1/p53-/-,Neurofibromatosis type 1,Malignant peripheral nerve sheath tumors,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Nf1/p53 cis mutant mice (− Cichowski et al., 1999)"
9a−/9a− Nf1,animal_models,PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,,0.9,Experimental Usage,True,1.00,High,9a−/9a− Nf1,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Homozygous 9a−/9a− Nf1 mutants and wild-type (WT) littermates in the hybrid B6/129T2 background
9a−/9a+ Nf1,animal_models,PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,,0.9,Experimental Usage,True,1.00,High,9a−/9a+ Nf1,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,crossing the obtained F1 mutant mice with each other to get homozygous 9a−/9a+ Nf1 mutants
Nf1flox/flox,animal_models,PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,,0.9,Experimental Usage,True,1.00,High,Nf1flox/flox,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Nf1flox/flox Nf1flox/null; GFAP-Cre (OPG-1), Nf1flox/R681*; GFAP-Cre (OPG-2), Nf1flox/null; Ptenflox/wt; GFAP-Cre (OPG-3), and Nf1flox/null; Olig2-Cre (OPG-4) mice"
Nf1flox/null; GFAP-Cre,animal_models,PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,,0.9,Experimental Usage,True,1.00,High,Nf1flox/null; GFAP-Cre,Neurofibromatosis type 1,Optic glioma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Nf1flox/null; GFAP-Cre (OPG-1), Nf1flox/R681*; GFAP-Cre (OPG-2), Nf1flox/null; Ptenflox/wt; GFAP-Cre (OPG-3), and Nf1flox/null; Olig2-Cre (OPG-4) mice"
Nf1flox/R681*; GFAP-Cre,animal_models,PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,,0.9,Experimental Usage,True,1.00,High,Nf1flox/R681*; GFAP-Cre,Neurofibromatosis type 1,Optic glioma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Nf1flox/null; GFAP-Cre (OPG-1), Nf1flox/R681*; GFAP-Cre (OPG-2), Nf1flox/null; Ptenflox/wt; GFAP-Cre (OPG-3), and Nf1flox/null; Olig2-Cre (OPG-4) mice"
Nf1flox/null; Ptenflox/wt; GFAP-Cre,animal_models,PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,,0.9,Experimental Usage,True,1.00,High,Nf1flox/null; Ptenflox/wt; GFAP-Cre,Neurofibromatosis type 1,Optic glioma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Nf1flox/null; GFAP-Cre (OPG-1), Nf1flox/R681*; GFAP-Cre (OPG-2), Nf1flox/null; Ptenflox/wt; GFAP-Cre (OPG-3), and Nf1flox/null; Olig2-Cre (OPG-4) mice"
Nf1flox/null; Olig2-Cre,animal_models,PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,,0.9,Experimental Usage,True,1.00,High,Nf1flox/null; Olig2-Cre,Neurofibromatosis type 1,Optic glioma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Nf1flox/null; GFAP-Cre (OPG-1), Nf1flox/R681*; GFAP-Cre (OPG-2), Nf1flox/null; Ptenflox/wt; GFAP-Cre (OPG-3), and Nf1flox/null; Olig2-Cre (OPG-4) mice"
cis Nf1+/−;P53+/−,animal_models,PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,Experimental Usage,True,1.00,High,cis Nf1+/−;P53+/−,Neurofibromatosis type 1,Malignant Peripheral Nerve Sheath Tumor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,cisMPNST cells were derived from spontaneous MPNSTs arising in cis Nf1+/−;P53+/− mice
Nf2 flox2/flox2,animal_models,PMID:17924978,10.1111/j.1750-3639.2007.00105.x,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.,,0.9,Experimental Usage,True,1.00,High,Nf2 flox2/flox2,Neurofibromatosis type 2,Meningioma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"To obtain Nf2 flox2/flox2 ;p16 Ink4a*/* mice, Nf2 flox2/flox2 mice (4) on the FVB/N background were bred to p16 Ink4a*/* mice"
H7;Nf1mut,animal_models,PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,0.9,Experimental Usage,True,1.00,High,H7;Nf1mut,Neurofibromatosis type 1,Plexiform Neurofibroma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,The H7;Nf1mut mice have been described previously (10). Mice were maintained in a clean mouse facility...
Nf1^flox/flox;GFAP-Cre,animal_models,PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.9,Experimental Usage,True,1.00,High,Nf1^flox/flox;GFAP-Cre,Neurofibromatosis type 1,Optic Nerve Glioma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Wild type ( Nf1 ), Tumor Progenitor ( flox/flox Nf1 ; GFAP-Cre), and OPG ( flox/flox Nf1 ; GFAP-Cre) mice were generated as previously described"
Nf1^flox/mut;GFAP-Cre,animal_models,PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.9,Experimental Usage,True,1.00,High,Nf1^flox/mut;GFAP-Cre,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Wild type ( Nf1 ), Tumor Progenitor ( flox/flox Nf1 ; GFAP-Cre), and OPG ( flox/flox Nf1 ; GFAP-Cre) mice were generated as previously described"
Nf1+/−,animal_models,PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,0.9,Experimental Usage,True,1.00,High,Nf1+/−,Neurofibromatosis type 1,Optic Nerve Glioma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Nf1+/ − mice [ 30 ] were bred with Nf1 f/wt mice to produce Nf1 flox/mut mice
Nf1flox/wt,animal_models,PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,0.9,Experimental Usage,True,1.00,High,Nf1flox/wt,Neurofibromatosis type 1,Optic Nerve Glioma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Nf1+/ − mice [ 30 ] were bred with Nf1 f/wt mice to produce Nf1 flox/mut mice
Nf1flox/mut,animal_models,PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,0.9,Experimental Usage,True,1.00,High,Nf1flox/mut,Neurofibromatosis type 1,Optic Nerve Glioma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Nf1+/ − mice [ 30 ] were bred with Nf1 f/wt mice to produce Nf1 flox/mut mice
Nf1flox/flox; Olig2-Cre,animal_models,PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,0.9,Experimental Usage,True,1.00,High,Nf1flox/flox; Olig2-Cre,Neurofibromatosis type 1,Optic Nerve Glioma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,intercrossed with Nf1 flox/flox ; Olig2-Cre mice to generate Nf1 flox/mut ; Olig2-Cre (FMOC) mice
Nf1flox/mut; Olig2-Cre,animal_models,PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,0.9,Experimental Usage,True,1.00,High,Nf1flox/mut; Olig2-Cre,Neurofibromatosis type 1,Optic Nerve Glioma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,intercrossed with Nf1 flox/flox ; Olig2-Cre mice to generate Nf1 flox/mut ; Olig2-Cre (FMOC) mice
Nf1flox/mut; GFAP-Cre,animal_models,PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,0.9,Experimental Usage,True,1.00,High,Nf1flox/mut; GFAP-Cre,Neurofibromatosis type 1,Optic Nerve Glioma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,while Nf1 flox/mut ; GFAP-Cre (FMC; [ 11 ]) and Nf1 flox/flox [ 31 ] control mice were established
Nf1flox/flox,animal_models,PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,0.9,Experimental Usage,True,1.00,High,Nf1flox/flox,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,while Nf1 flox/mut ; GFAP-Cre (FMC; [ 11 ]) and Nf1 flox/flox [ 31 ] control mice were established
Nf1flox/flox; Prom1-CreER,animal_models,PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,0.9,Experimental Usage,True,1.00,High,Nf1flox/flox; Prom1-CreER,Neurofibromatosis type 1,Optic Nerve Glioma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Nf1 flox/mut mice were also intercrossed with Nf1 flox/flox ; Prom1-Cre ER mice [ 22 ] to generate Nf1 flox/mut ; Prom1-Cre ER (FMPrC) mice
Nf1flox/mut; Prom1-CreER,animal_models,PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,0.9,Experimental Usage,True,1.00,High,Nf1flox/mut; Prom1-CreER,Neurofibromatosis type 1,Optic Nerve Glioma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Nf1 flox/mut mice were also intercrossed with Nf1 flox/flox ; Prom1-Cre ER mice [ 22 ] to generate Nf1 flox/mut ; Prom1-Cre ER (FMPrC) mice
PLP-CreERT:: Nf1 f/f ; Cdkn2a f/f,animal_models,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.9,Experimental Usage,True,1.00,High,PLP-CreERT:: Nf1 f/f ; Cdkn2a f/f,Neurofibromatosis type 1,Malignant Peripheral Nerve Sheath Tumor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Eed f/f mice (67, 68) were bred with PLP-CreERT:: Nf1 f/f ; Cdkn2a f/f mice"
Periostin-CRE;NF2 fl/fl,animal_models,PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,Experimental Usage,True,1.00,High,Periostin-CRE;NF2 fl/fl,Neurofibromatosis type 2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Periostin-CRE mice were provided by S.Conway (Indiana University) and crossed with NF2 fl/fl animals (RIKEN Bioresource Research Centre) to make Periostin-CRE;NF2 fl/fl animals
Periostin-CRE;NF2 fl/fl YAP fl/fl,animal_models,PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,Experimental Usage,True,1.00,High,Periostin-CRE;NF2 fl/fl YAP fl/fl,Neurofibromatosis type 2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,crossed with YAP fl/fl or TAZ fl/fl mice to generate Periostin-CRE;NF2 fl/fl YAP fl/fl (NF2 fl/fl YAP fl/fl -CRE+)
Periostin-CRE;NF2 fl/fl TAZ fl/fl,animal_models,PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,Experimental Usage,True,1.00,High,Periostin-CRE;NF2 fl/fl TAZ fl/fl,Neurofibromatosis type 2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Periostin-CRE;NF2 fl/fl TAZ fl/fl (NF2 fl/fl TAZ fl/fl -CRE+) mice, respectively, resulting in additional deletion of YAP or TAZ"
NPcis (Stock #008191),animal_models,PMID:34647023,10.1093/noajnl/vdab129,A genetic mouse model with postnatal ,,0.9,Experimental Usage,True,1.00,High,NPcis (Stock #008191),Neurofibromatosis type 1,Malignant Peripheral Nerve Sheath Tumor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"NPcis (Stock #008191), Nf1 (#017640), fl Trp53 (#008462), fl Plp-CreER (#005975), and T Nestin-Cre (#003771) were obtained from The Jackson Laboratory."
Nf1 (#017640),animal_models,PMID:34647023,10.1093/noajnl/vdab129,A genetic mouse model with postnatal ,,0.9,Experimental Usage,True,1.00,High,Nf1 (#017640),Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"NPcis (Stock #008191), Nf1 (#017640), fl Trp53 (#008462), fl Plp-CreER (#005975), and T Nestin-Cre (#003771) were obtained from The Jackson Laboratory."
TetOff-Osx-/-Nf1,animal_models,PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,0.9,Experimental Usage,True,1.00,High,TetOff-Osx-/-Nf1,Neurofibromatosis type 1,pseudoarthrosis,,,,,,,,,,,,,,,,,,,,,,,,,,,,,WT and Nf1 mice (herein called TetOff-Osx −/− Nf1 mice) were generated by crossing Osx −/− Nf1 flox/flox mice
Nf1+/-,animal_models,PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,0.9,Experimental Usage,True,1.00,High,Nf1+/-,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Nf1 +/− mice were obtained from Dr Tyler Jacks at the Massachusetts Institute of Technology (Cambridge, MA, USA) in a C57BL/6J.129 background and backcrossed for 13 generations into a C57BL/6J strain"
Nf2flox/flox,animal_models,PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,0.9,Experimental Usage,True,1.00,High,Nf2flox/flox,Neurofibromatosis type 2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Nf2flox/flox mice carrying a LoxP insertion in the Nf2 gene [13] were maintained at the Washington University School of Medicine
hGFAP-cre,animal_models,PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,Experimental Usage,True,1.00,High,hGFAP-cre,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Three independent Cre transgenic strains under the control of hGFAP, Math1 and L7 promoters were utilized to target an Nf1 mutation into different cell lineages"
Math1-cre,animal_models,PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,Experimental Usage,True,1.00,High,Math1-cre,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Three independent Cre transgenic strains under the control of hGFAP, Math1 and L7 promoters were utilized to target an Nf1 mutation into different cell lineages"
L7-cre,animal_models,PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,Experimental Usage,True,1.00,High,L7-cre,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Three independent Cre transgenic strains under the control of hGFAP, Math1 and L7 promoters were utilized to target an Nf1 mutation into different cell lineages"
Nf1 flox/flox,animal_models,PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,Experimental Usage,True,1.00,High,Nf1 flox/flox,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,The control mice for Nf1 hGFAP CKO mice are a pool of phenotypically indistinguishable mice: hGFAP-cre-; Nf1 flox/flox
Nestin-creER,animal_models,PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,Experimental Usage,True,1.00,High,Nestin-creER,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Tamoxifen inducible strain Nf1 NcreER CKO is described in later sections along with the tamoxifen administration protocol
Nf1 flox/flox-;Postn-Cre,animal_models,PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,Experimental Usage,True,1.00,High,Nf1 flox/flox-;Postn-Cre,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Tissue processing for wild-type (wt), Nf1 flox/flox- ;Postn-Cre and Nf1-Arf flox/flox ;Postn-Cre mouse tissues"
Nf1-Arf flox/flox ;Postn-Cre,animal_models,PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,Experimental Usage,True,1.00,High,Nf1-Arf flox/flox ;Postn-Cre,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Tissue processing for wild-type (wt), Nf1 flox/flox- ;Postn-Cre and Nf1-Arf flox/flox ;Postn-Cre mouse tissues"
Nf2 flox2/flox2,animal_models,PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,0.9,Experimental Usage,True,1.00,High,Nf2 flox2/flox2,Neurofibromatosis type 2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Schwann cells purified from sciatic nerve of Nf2 flox2/flox2 mice, as described previously"
tyrosine hydroxylase,antibodies,PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.9,Experimental Usage,True,1.00,High,,,,tyrosine hydroxylase,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,Anti-tyrosine hydroxylase (Rabbit polyclonal) EMD Millipore Cat#: AB152 RRID: AB_390204 IHC (1:1000)
tyrosine hydroxylase,antibodies,PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.9,Experimental Usage,True,1.00,High,,,,tyrosine hydroxylase,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,Anti-tyrosine hydroxylase (mouse monoclonal) ImmunoStar Cat#: 22941 RRID: AB_572268 IHC (1:1000)
GFP,antibodies,PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.9,Experimental Usage,True,1.00,High,,,,GFP,Mouse,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,Anti-GFP (mouse polyclonal) Aves Cat#: GFP-1020 RRID: AB_10000240 IHC (1:1000)
myc,antibodies,PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,0.9,Experimental Usage,True,1.00,High,,,,myc,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies were from Cell Signaling Technology (Danvers, U.S.A.) (rabbit anti-HA; mouse anti-HA; 9B11 mouse anti-myc)"
γH2A.X,antibodies,PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.9,Experimental Usage,True,1.00,High,,,,γH2A.X,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"mouse anti-γH2A.X primary antibody (1:500, Millipore, clone JBW301)"
β-actin,antibodies,PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,0.9,Experimental Usage,True,1.00,High,,,,β-actin,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies used in western blot analysis were: mouse anti-β-actin, mouse anti-α-tubulin, and mouse anti-α-smooth muscle actin (α-SMA), all from Sigma-Aldrich"
NHE1,antibodies,PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,0.9,Experimental Usage,True,1.00,High,,,,NHE1,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"mouse anti-NHE1 (clone 54), anti-Poly-ADP Ribose Polymerase (PARP), anti-cleaved PARP (Asp214) and anti-pSer807/811-Rb, all from Santa Cruz Biotechnology"
PD-1,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,True,1.00,High,,,,PD-1,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"250 μg mouse monoclonal anti–PD-1 antibody (BE0146, Bio X Cell)"
PD-L1,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,True,1.00,High,,,,PD-L1,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"100 μg mouse monoclonal anti–PD-L1 antibody (BE0146, Bio X Cell)"
CTLA-4,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,True,1.00,High,,,,CTLA-4,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"300 μg mouse monoclonal anti–CTLA-4 antibody (BE0164, Bio X Cell)"
Drosophila neurofibromin,antibodies,PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.9,Experimental Usage,True,1.00,High,,,,Drosophila neurofibromin,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"anti‐ Drosophila neurofibromin (mouse, ascites purified mAb21 and mAb30, 1 : 500 each)"
CalbindinD-28K,antibodies,PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.9,Experimental Usage,True,1.00,High,,,,CalbindinD-28K,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-CalbindinD-28K (rabbit polyclonal, 1:2000 Swant CB-38a, Marly, Switzerland"
CalbindinD-28K,antibodies,PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.9,Experimental Usage,True,1.00,High,,,,CalbindinD-28K,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"mouse monoclonal 1:1000 Sigma-Aldrich (clone CB-955), Munich, Germany"
Merlin,antibodies,PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.9,Experimental Usage,True,1.00,High,,,,Merlin,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-Merlin (rabbit polyclonal antibody, A-19 (sc-331) and C-18 (sc-332), 1:50; Santa Cruz"
Merlin,antibodies,PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.9,Experimental Usage,True,1.00,High,,,,Merlin,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-Merlin (rabbit polyclonal antibody, A-19 (sc-331) and C-18 (sc-332), 1:50; Santa Cruz"
Olig2,antibodies,PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.9,Experimental Usage,True,1.00,High,,,,Olig2,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-Olig2 (mouse monoclonal antibody, 1:500; Millipore (AB9610), Darmstadt, Germany)"
MBP,antibodies,PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.9,Experimental Usage,True,1.00,High,,,,MBP,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-MBP (mouse monoclonal antibody, 1:500; Chemikon (MAB384), Schwalbach, Germany)"
α-SMA,antibodies,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,True,1.00,High,,,,α-SMA,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"α-SMA (mouse; Sigma-Aldrich, clone 1A4, A2547), IBA1 (rabbit; Wako Chemicals, 019-19741)"
Nestin,antibodies,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,True,1.00,High,,,,Nestin,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Nestin (mouse; Millipore, MAB353), EYA4 (rabbit; Thermo Fisher Scientific, PA5-52113)"
Ki67,antibodies,PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,Experimental Usage,True,1.00,High,,,,Ki67,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"using mouse anti-Ki67 (1:2,000, BD Biosciences 556003 lot 8239549)"
CD8,antibodies,PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,Experimental Usage,True,1.00,High,,,,CD8,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-CD8 (1:500, Cell Signaling Technology 98941T lot 5)"
BRN3A,antibodies,PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,Experimental Usage,True,1.00,High,,,,BRN3A,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"mouse anti-BRN3A (1:200, Santa Cruz Biotechnology sc-8429 lot H1718)"
cleaved caspase-3,antibodies,PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,Experimental Usage,True,1.00,High,,,,cleaved caspase-3,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-cleaved caspase-3, 1:500, R&D Systems MAB835 lot KHK051810A"
TRAP1,antibodies,PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.9,Experimental Usage,True,1.00,High,,,,TRAP1,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,mouse monoclonal anti-human TRAP1 (sc-73604)
ATP50/OSCP,antibodies,PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.9,Experimental Usage,True,1.00,High,,,,ATP50/OSCP,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,mouse monoclonal anti ATP50/OSCP (ab110276) antibodies
ATPB,antibodies,PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.9,Experimental Usage,True,1.00,High,,,,ATPB,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,mouse monoclonal anti-ATPB (ab14730)
SDHA,antibodies,PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.9,Experimental Usage,True,1.00,High,,,,SDHA,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,anti SDHA (sc-166947)
Cyclophilin,antibodies,PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.9,Experimental Usage,True,1.00,High,,,,Cyclophilin,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,mouse monoclonal anti-Cyclophilin (ab110324) antibodies
CD13,antibodies,PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.9,Experimental Usage,True,1.00,High,,,,CD13,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"...incubated for 30 min in ice and in the dark with the following mouse anti-human monoclonal antibodies directly conjugated with fluorochromes: CD13/FITC (22A5, Caltag Medsystems, UK)..."
CD14,antibodies,PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.9,Experimental Usage,True,1.00,High,,,,CD14,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"...mouse anti-human monoclonal antibodies directly conjugated with fluorochromes: CD13/FITC (22A5, Caltag Medsystems, UK), CD14/PE (M5E2, BD Biosciences, CA, USA)..."
CD34,antibodies,PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.9,Experimental Usage,True,1.00,High,,,,CD34,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"...CD14/PE (M5E2, BD Biosciences, CA, USA), CD34/FITC (581, BD Biosciences), CD45/ALexa405 (HI30, Caltag Medsystems)..."
CD45,antibodies,PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.9,Experimental Usage,True,1.00,High,,,,CD45,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"...CD34/FITC (581, BD Biosciences), CD45/ALexa405 (HI30, Caltag Medsystems), CD90/PECy5 (5E10, BioLegend, CA, USA)..."
CD90,antibodies,PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.9,Experimental Usage,True,1.00,High,,,,CD90,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"...CD45/ALexa405 (HI30, Caltag Medsystems), CD90/PECy5 (5E10, BioLegend, CA, USA), CD105/APC (45A5A3, BioLegend)..."
CD105,antibodies,PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.9,Experimental Usage,True,1.00,High,,,,CD105,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"...CD90/PECy5 (5E10, BioLegend, CA, USA), CD105/APC (45A5A3, BioLegend), CD146/PE (P1H12, BD Biosciences)..."
CD146,antibodies,PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.9,Experimental Usage,True,1.00,High,,,,CD146,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"...CD105/APC (45A5A3, BioLegend), CD146/PE (P1H12, BD Biosciences), CD271/APC (C401457, BD Biosciences)..."
CD271,antibodies,PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.9,Experimental Usage,True,1.00,High,,,,CD271,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"...CD146/PE (P1H12, BD Biosciences), CD271/APC (C401457, BD Biosciences). Unstained cells were used as controls..."
Ki-67,antibodies,PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.9,Experimental Usage,True,1.00,High,,,,Ki-67,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"...Expression of Ki-67 was evaluated immunohistochemically using mouse monoclonal antibody anti-Ki-67 (1:80; M7240; Dako Corporation, CA, USA)..."
CXCL12,antibodies,PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.9,Experimental Usage,True,1.00,High,,,,CXCL12,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,purchased from Peprotech (goat anti-CXCL12 and rabbit anti CXCL12)
IBA-1,antibodies,PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.9,Experimental Usage,True,1.00,High,,,,IBA-1,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,Wako (rabbit anti-IBA-1)
CNPase,antibodies,PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.9,Experimental Usage,True,1.00,High,,,,CNPase,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,Sigma (mouse anti-CNPase)
Olig2,antibodies,PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.9,Experimental Usage,True,1.00,High,,,,Olig2,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,The rabbit anti Olig2 antibody (DF-308) was a gift from Dr. Charles Stiles
FLAG,antibodies,PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.9,Experimental Usage,True,1.00,High,,,,FLAG,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,Supernatants from cleared lysates were incubated with Anti-FLAG M2 affinity gel (Sigma) to immunoprecipitated FLAG-tagged protein complexes
FLAG,antibodies,PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.9,Experimental Usage,True,1.00,High,,,,FLAG,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,Primary antibodies used were FLAG-M2 and KRAS (Sigma)
Nf1,antibodies,PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.9,Experimental Usage,True,1.00,High,,,,Nf1,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,Immunoprecipitations were performed using 400 µg of total protein in 1 ml IP buffer incubated with 200 μl of mAb21 anti-Nf1 monoclonal antibody supernatant
β-tubulin,antibodies,PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.9,Experimental Usage,True,1.00,High,,,,β-tubulin,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-β-tubulin (mouse, Developmental Studies Hybridoma Bank E7, 1:10,000)"
β-actin,antibodies,PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.9,Experimental Usage,True,1.00,High,,,,β-actin,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,β-Actin was probed as a loading control using β-actin (13E5) rabbit mAb #4970 (RRID: AB_2223172)
S100,antibodies,PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,0.9,Experimental Usage,True,1.00,High,,,,S100,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"antibodies against S100 (monoclonal, mouse, 10 μg/mL, Ventana S100-4C4.9) to demonstrate human Schwann cell origin"
Ki67,antibodies,PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,0.9,Experimental Usage,True,1.00,High,,,,Ki67,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-Ki67 (monoclonal, mouse, 0.4 μg/mL, Ventana Ki-67-30.9) to evaluate proliferation fraction"
CD34,antibodies,PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,0.9,Experimental Usage,True,1.00,High,,,,CD34,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-CD34 (monoclonal, mouse, 0.8 μg/mL, Ventana QBEnd/10) to demonstrate vessel and stem cell formation"
p53,antibodies,PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,0.9,Experimental Usage,True,1.00,High,,,,p53,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-p53 (monoclonal, mouse, Ventana Bp-53-11), anti-p16 (monoclonal, mouse, 1 μg/mL, Ventana 725-4713)"
p16,antibodies,PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,0.9,Experimental Usage,True,1.00,High,,,,p16,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-p16 (monoclonal, mouse, 1 μg/mL, Ventana 725-4713), anti-vimentin (vimentin, monoclonal, mouse, 2.5 μg/mL, Ventana V9"
vimentin,antibodies,PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,0.9,Experimental Usage,True,1.00,High,,,,vimentin,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-vimentin (vimentin, monoclonal, mouse, 2.5 μg/mL, Ventana V9 and anti-actin (monoclonal, mouse, 0.02 μg/mL, Cell Margue 1A4)"
actin,antibodies,PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,0.9,Experimental Usage,True,1.00,High,,,,actin,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-actin (monoclonal, mouse, 0.02 μg/mL, Cell Margue 1A4). Staining was visualized using the ultraView™ Universal Alkaline Phosphatase Red Detection Kit"
Cdk1,antibodies,PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,True,1.00,High,,,,Cdk1,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies against Cdk1 (77055S), phospho-Cdk1 Tyr15 (9111T)... were purchased from Cell Signaling Technology"
phospho-Cdk1 Tyr15,antibodies,PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,True,1.00,High,,,,phospho-Cdk1 Tyr15,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies against Cdk1 (77055S), phospho-Cdk1 Tyr15 (9111T)... were purchased from Cell Signaling Technology"
Caspase-3,antibodies,PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,True,1.00,High,,,,Caspase-3,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies against... Caspase-3 (9662S), Cleaved Caspase-3 (9661S)... were purchased from Cell Signaling Technology"
Cleaved Caspase-3,antibodies,PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,True,1.00,High,,,,Cleaved Caspase-3,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies against... Caspase-3 (9662S), Cleaved Caspase-3 (9661S)... were purchased from Cell Signaling Technology"
Histone H3,antibodies,PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,True,1.00,High,,,,Histone H3,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies against... Histone H3 (9715S), Acetyl-Histone H3 Lys18 (9675S)... were purchased from Cell Signaling Technology"
Acetyl-Histone H3 Lys18,antibodies,PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,True,1.00,High,,,,Acetyl-Histone H3 Lys18,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies against... Histone H3 (9715S), Acetyl-Histone H3 Lys18 (9675S)... were purchased from Cell Signaling Technology"
SAPK/JNK,antibodies,PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,True,1.00,High,,,,SAPK/JNK,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies against... SAPK/JNK (9252T), phospho-SAPK/JNK Thr183/Tyr185 (4668T)... were purchased from Cell Signaling Technology"
phospho-SAPK/JNK Thr183/Tyr185,antibodies,PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,True,1.00,High,,,,phospho-SAPK/JNK Thr183/Tyr185,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies against... SAPK/JNK (9252T), phospho-SAPK/JNK Thr183/Tyr185 (4668T)... were purchased from Cell Signaling Technology"
p70S6 Kinase,antibodies,PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,True,1.00,High,,,,p70S6 Kinase,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies against... p70S6 Kinase (9202S), and phospho-p70 Thr389 S6 Kinase (9234S) were purchased from Cell Signaling Technology"
phospho-p70 Thr389 S6 Kinase,antibodies,PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,True,1.00,High,,,,phospho-p70 Thr389 S6 Kinase,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies against... p70S6 Kinase (9202S), and phospho-p70 Thr389 S6 Kinase (9234S) were purchased from Cell Signaling Technology"
BrdU,antibodies,PMID:18636037,10.1097/MAO.0b013e31817f7398,The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.,,0.9,Experimental Usage,True,1.00,High,,,,BrdU,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"mouse monoclonal anti-BrdU (1:800, Sigma-Aldrich, St. Louis, MO)"
S100,antibodies,PMID:18636037,10.1097/MAO.0b013e31817f7398,The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.,,0.9,Experimental Usage,True,1.00,High,,,,S100,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-S100 (1:800, Sigma-Aldrich, St. Louis, MO)"
tubulin,antibodies,PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,0.9,Experimental Usage,True,1.00,High,,,,tubulin,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-tubulin B-1-2-5 (Santa Cruz, mouse, 2% milk, 1:10000, 1 h, RT)"
EGFR,antibodies,PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,0.9,Experimental Usage,True,1.00,High,,,,EGFR,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-EGFR D38B1 #4267 (Cell Signaling, rabbit, 2% milk, 1:1000–1:2000, 1 h, RT)"
SUZ12,antibodies,PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,0.9,Experimental Usage,True,1.00,High,,,,SUZ12,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"SUZ12 D39F6 #3737 (Cell Signaling, rabbit, 2% milk, 1:1000, overnight, 4 °C)"
TRAP1,antibodies,PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,Experimental Usage,True,1.00,High,,,,TRAP1,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,Mouse monoclonal anti-rodent TRAP1 was from Becton Dickinson (Cat. #612344)
TRAP1,antibodies,PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,Experimental Usage,True,1.00,High,,,,TRAP1,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,mouse monoclonal anti-human TRAP1 was from Santa Cruz (Cat. #sc-73604)
β actin,antibodies,PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,Experimental Usage,True,1.00,High,,,,β actin,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,mouse monoclonal anti-β actin was from Santa Cruz (Cat. #sc-47778)
citrate synthetase,antibodies,PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,Experimental Usage,True,1.00,High,,,,citrate synthetase,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,rabbit polyclonal anti-citrate synthetase was from Abcam (Cat. #ab96600)
HIF1α,antibodies,PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,Experimental Usage,True,1.00,High,,,,HIF1α,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,rabbit polyclonal anti-HIF1α was from Novus Biologicals (Cat. #NB100-449)
HIF1α,antibodies,PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,Experimental Usage,True,1.00,High,,,,HIF1α,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,rabbit polyclonal anti-HIF1α was from GeneTex (Cat. #GTX131826)
phospho-ERK1/2,antibodies,PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,Experimental Usage,True,1.00,High,,,,phospho-ERK1/2,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,rabbit polyclonal anti-phospho-ERK1/2 was from Cell Signaling (Cat. #9101)
GLUT1,antibodies,PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,Experimental Usage,True,1.00,High,,,,GLUT1,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,rabbit polyclonal anti-glucose transporter GLUT1 was from Abcam (Cat. #ab652)
MBP,antibodies,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,Experimental Usage,True,1.00,High,,,,MBP,Rat,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,rat anti-MBP (1:200; Chemicon Millipore #MAB386)
HIF1α,antibodies,PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,Experimental Usage,True,1.00,High,,,,HIF1α,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"IHC was performed using a primary rabbit polyclonal anti HIF1α antibody (Novus Biologicals, Centennials, CO, USA)"
PGDS,antibodies,PMID:17924978,10.1111/j.1750-3639.2007.00105.x,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.,,0.9,Experimental Usage,True,1.00,High,,,,PGDS,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"PGDS immunohistochemistry was carried out on adjacent paraffin sections using affinity‐purified rabbit polyclonal antibodies (1:500; Santa Cruz, CA, USA sc‐14825)"
phospho-S6K (T389),antibodies,PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,True,1.00,High,,,,phospho-S6K (T389),Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies against phospho-AKT (S473), total AKT, and monoclonal rabbit anti-phospho-S6K (T389) were from Cell Signaling Technology"
Ras,antibodies,PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,0.9,Experimental Usage,True,1.00,High,,,,Ras,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Ras was detected with a 1:250 dilution of anti-pan Ras monoclonal antibody (BD Transduction Laboratories, San Jose, CA)"
β-Tubulin,antibodies,PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,0.9,Experimental Usage,True,1.00,High,,,,β-Tubulin,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"β-Tubulin was immunoblotted with a 1:2000 dilution of the E7 monoclonal antibody (Developmental Studies Hybridoma Bank, Iowa City, IA)"
pSmad3,antibodies,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Experimental Usage,True,1.00,High,,,,pSmad3,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibody anti-pSmad3, rabbit monoclonal Abcam Cat. # ab52903 RRID: AB_882596 1/200 dilution"
Zpr-1,antibodies,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Experimental Usage,True,1.00,High,,,,Zpr-1,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibody Zpr-1, mouse monoclonal Zebrafish International Resource Center Cat. # zpr-1 RRID: AB_10013803"
Zn-5,antibodies,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Experimental Usage,True,1.00,High,,,,Zn-5,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibody Zn-5, mouse monoclonal Zebrafish International Resource Center Cat. # zn-5 RRID: AB_10013770"
HuC/D,antibodies,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Experimental Usage,True,1.00,High,,,,HuC/D,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibody anti-HuC/D, rabbit polyclonal Abcam Cat. # ab210554 RRID: AB_210554 1/500 dilution"
PKC β1,antibodies,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Experimental Usage,True,1.00,High,,,,PKC β1,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibody anti-PKC β1, mouse monoclonal Santa Cruz Biotechnology Cat. # SC-8049 RRID: AB_628143"
glutamine synthetase,antibodies,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Experimental Usage,True,1.00,High,,,,glutamine synthetase,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibody anti-glutamine synthetase (GS), mouse monoclonal Sigma-Aldrich Cat. # MAB302 RRID: AB_2110656"
SOX9,antibodies,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Experimental Usage,True,1.00,High,,,,SOX9,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibody anti-SOX9, rabbit polyclonal Millipore Sigma Cat. # AB5535 RRID: AB_2239761 1/500 dilution"
BrdU,antibodies,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Experimental Usage,True,1.00,High,,,,BrdU,Rat,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibody anti-BrdU, rat monoclonal Thermo Fisher Cat. # MA 182088 RRID: AB_927214 1/500 dilution"
BrdU,antibodies,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Experimental Usage,True,1.00,High,,,,BrdU,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibody anti-BrdU, mouse monoclonal Thermo Fisher Cat. # B35128 RRID: AB_2536432 Clone MoBu-1"
KRAS,antibodies,PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,0.9,Experimental Usage,True,1.00,High,,,,KRAS,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"KRAS (Sigma; WH0003845M1, clone 3B10-2F2; does not detect proteins with E162L mutation)"
EGFP,antibodies,PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,0.9,Experimental Usage,True,1.00,High,,,,EGFP,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"EGFP (Thermo Fisher Scientific; 11575712, clone F56-6A1.2.3)"
p-ERK1/2,antibodies,PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,0.9,Experimental Usage,True,1.00,High,,,,p-ERK1/2,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"p-ERK1/2 (CST 4370, clone D13.14.4E)"
ERK1/2,antibodies,PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,0.9,Experimental Usage,True,1.00,High,,,,ERK1/2,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"ERK1/2 (CST 9107, clone 3A7)"
c-Met,antibodies,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.9,Experimental Usage,True,1.00,High,,,,c-Met,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,overnight incubation in a 1:250 dilution of total c-met rabbit polyclonal antibody (Santa Cruz)
phosphorylated c-Met,antibodies,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.9,Experimental Usage,True,1.00,High,,,,phosphorylated c-Met,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"1:50 dilution of phosphorylated c-met (phosphorylated tyrosine sites pY1230, pY1234, and pY1236) rabbit polyclonal antibody (Invitrogen)"
Ki67,antibodies,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.9,Experimental Usage,True,1.00,High,,,,Ki67,Rat,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,Other slides were stained in a 1:100 dilution of Ki67 rat monoclonal antibody (Dako)
p55/MPP1,antibodies,PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,0.9,Development,True,1.00,High,,,,p55/MPP1,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,The anti-p55 mouse monoclonal antibody was generated by immunizing BALB/c mice with the recombinant SH3-GUK segment of human erythrocyte p55 protein. The clone 2G4 was selected
BIM,antibodies,PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.9,Experimental Usage,True,1.00,High,,,,BIM,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-human N-terminal BIM (C34C5) (rabbit, Cell Signaling, #2933; 1:1000)"
b-tubulin,antibodies,PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.9,Experimental Usage,True,1.00,High,,,,b-tubulin,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-b-tubulin (mouse, Developmental Studies Hybridoma Bank E7, Iowa City, IA USA, 1:10,000)"
S100,antibodies,PMID:41001593,10.1080/23723556.2025.2561292,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor.,,0.9,Experimental Usage,True,1.00,High,,,,S100,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"S100 mouse monoclonal primary antibody (Cell Signaling Technology, Danvers, USA) diluted 1:1000"
kappa light chain,antibodies,PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.9,Experimental Usage,True,1.00,High,,,,kappa light chain,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"kappa light chain to identify plasma cells (rabbit monoclonal antibody, Sigma Aldrich, clone RM103, SAB5600201, 1:400)"
CD3,antibodies,PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.9,Experimental Usage,True,1.00,High,,,,CD3,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"CD3 to identify T cells (rabbit monoclonal, NeoMarkers Company, #RM-9107-S, 1:200)"
STAT3,antibodies,PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,Experimental Usage,True,1.00,High,,,,STAT3,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"STAT3 (mouse, 124H6), Cleaved PARP (poly-ADP ribose polymerase, rabbit, D64E10), total PARP (rabbit, #9542) (Cell Signaling"
Cleaved PARP,antibodies,PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,Experimental Usage,True,1.00,High,,,,Cleaved PARP,Rabbit,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Cleaved PARP (poly-ADP ribose polymerase, rabbit, D64E10)"
Actin,antibodies,PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,Experimental Usage,True,1.00,High,,,,Actin,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Actin (mouse, ACTN05(C4), NeoMarkers) at 1:1000 dilution"
ipNF 95.11b,cell_lines,PMID:39110684,10.1371/journal.pone.0308207,Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon nanotube fibers.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Plexiform Neurofibroma,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Immortalized NF1 patient derived Schwann cell (NF SC, NF-/-) line, ipNF 95.11b and Wild type Schwann cell (WT SC, NF+/+) line, ipn 02.8 were utilized for all experiments"
murine NF2 −/− Schwann cell line,cell_lines,PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 2,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"We used a murine NF2 −/− Schwann cell line (we obtained this as a gift from X. Breakefield, Massachusetts General Hospital) in our study."
HEI-193,cell_lines,PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 2,Vestibular schwannoma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,We have successfully grown murine NF2 −/− Schwann cells in syngeneic mice and human HEI-193 schwannoma cells in nude mice to establish schwannomas in the CPA model.
Nf1-/- mouse embryo fibroblasts,cell_lines,PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Embryonic tissue,Neurofibromatosis Type 1,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Nf1−/−, Nf1+/−, and wildtype mouse embryo fibroblasts were generated as previously described (15)."
Nf1+/- mouse embryo fibroblasts,cell_lines,PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Embryonic tissue,Neurofibromatosis Type 1,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Nf1−/−, Nf1+/−, and wildtype mouse embryo fibroblasts were generated as previously described (15)."
T265-2c,cell_lines,PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"T265-2c cells, ST88-14 cells and 90-8 cells, the human NF1-associated MPNST lines used in this study"
ST88-14,cell_lines,PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"T265-2c cells, ST88-14 cells and 90-8 cells, the human NF1-associated MPNST lines used in this study"
90-8,cell_lines,PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"T265-2c cells, ST88-14 cells and 90-8 cells, the human NF1-associated MPNST lines used in this study"
NF96.2,cell_lines,PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"MPNST-derived cell lines NF96.2, NF02.2, and NF94.3 (ATCC) and benign neurofibroma cell lines were maintained in 5% CO2 at 37C"
NF02.2,cell_lines,PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"MPNST-derived cell lines NF96.2, NF02.2, and NF94.3 (ATCC) and benign neurofibroma cell lines were maintained in 5% CO2 at 37C"
NF94.3,cell_lines,PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"MPNST-derived cell lines NF96.2, NF02.2, and NF94.3 (ATCC) and benign neurofibroma cell lines were maintained in 5% CO2 at 37C"
Ben-Men-1,cell_lines,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Brain,Neurofibromatosis Type 2,Meningioma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,Human cell lines included an NF2-null immortalized MN line Ben-Men-1
S462 cells,cell_lines,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"S462 cells were human NF1–related MPNST cells (SCC414, MilliporeSigma)."
cis MPNST cell line,cell_lines,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,The cis MPNST cell line was generated in the laboratory by harvesting tumors from cis MPNST mice.
HTS-Luc MPNST cell line,cell_lines,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,The HTS-Luc MPNST cell line was described before (48).
pNF9511bc,cell_lines,PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Plexiform Neurofibroma,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Immortalized human pNF cell lines pNF9511bc and ipNF03.3, immortalized human normal Schwann cell line ipn023λ, were generated by the Wallace's lab"
ipNF03.3,cell_lines,PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Plexiform Neurofibroma,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Immortalized human pNF cell lines pNF9511bc and ipNF03.3, immortalized human normal Schwann cell line ipn023λ, were generated by the Wallace's lab"
RHT92,cell_lines,PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Human MPNST cell line ST88-14, S462 and a patient-derived xenoline RHT92 were kindly provided by Melissa L. Fishel"
LN229,cell_lines,PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Brain,Neurofibromatosis Type 1,Glioma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,The NF1-deficient LN229 glioma cell line was kindly provided by Karisa Schreck of the Johns Hopkins University
3PNF_SiPSsv_MM_11,cell_lines,PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Plexiform Neurofibroma,Embryonic stem cell,,,,,,,,,,,,,,,,,,,,,,"as well as the pNF-derived NF1−/− iPSC 3MM (3PNF_SiPSsv_MM_11, Sex: XX)"
ST88‐14 (RRID: CVCL_8916),cell_lines,PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,Two million ST88‐14 (RRID: CVCL_8916) cells mixed 1 : 1 with Matrigel
Ben-Men-1 cells,cell_lines,PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Brain,Neurofibromatosis Type 2,Meningioma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Ben-Men-1 cells and primary meningioma cells were routinely grown in DMEM, 10% FBS and 100 U/ml Penicillin/Streptomycin"
iPNF95.6,cell_lines,PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Plexiform Neurofibroma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Human immortalized NF1−/− Schwann cells (iPNF95.6) were plated in triplicate at a density of 5,000 cells/well"
MPNST cell lines,cell_lines,PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,Normal human Schwann cells (NHSC) from trauma victims and MPNST cell lines were cultured as described
S462 cell line,cell_lines,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,cells were seeded at 1.0 × 104 (S462 cell-line) or 3.0 × 104 (2884 and 2885 cell-lines) cells/well
2884 cell line,cell_lines,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,cells were seeded at 1.0 × 104 (S462 cell-line) or 3.0 × 104 (2884 and 2885 cell-lines) cells/well
2885 cell line,cell_lines,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,cells were seeded at 1.0 × 104 (S462 cell-line) or 3.0 × 104 (2884 and 2885 cell-lines) cells/well
hTERT NF1 ipn02.3 2λ,cell_lines,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Immortalized SCs (hTERT NF1 ipn02.3 2λ, M. Wallace), NF cells [ipn95.11bC, American Type Culture Collection (ATCC)"
ipn95.11bC,cell_lines,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Neurofibroma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"NF cells [ipn95.11bC, American Type Culture Collection (ATCC): Neurofibromatosis Therapeutic Acceleration Program (NTAP)]"
sNF96.2,cell_lines,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"NF1-associated MPNST cells (sNF96.2, ATCC; MPNST642, MD Anderson; T265, A. Harder)"
MPNST642,cell_lines,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"NF1-associated MPNST cells (sNF96.2, ATCC; MPNST642, MD Anderson; T265, A. Harder)"
T265,cell_lines,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"NF1-associated MPNST cells (sNF96.2, ATCC; MPNST642, MD Anderson; T265, A. Harder)"
ipn97.4 immortalized human Schwann cells,cell_lines,PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"ipn97.4 immortalized human Schwann cells were obtained from Peggy Wallace. To create an isogenic NF1 null cell line, we utilized CRISPR Cas9 targeting..."
Schwann cells,cell_lines,PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,Schwann cells were isolated as previously described. Sciatic nerve or cutaneous neurofibroma were biopsied from WT or NF1 R1947/+ minipigs
ipNF06.2A,cell_lines,PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Neurofibroma,Finite cell line,,,,,,,,,,,,,,,,,,,,,,Immortalized human Schwann cell (HSC1λ) and immortalized neurofibroma cell (ipNF06.2A) were obtained from Dr. Margaret Wallace's laboratory
STS-26T,cell_lines,PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"MPNST cell lines (STS-26T, S462, S462TY, T265) were obtained from Dr. David Largaespada's laboratory"
S462,cell_lines,PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"MPNST cell lines (STS-26T, S462, S462TY, T265) were obtained from Dr. David Largaespada's laboratory"
S462TY,cell_lines,PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"MPNST cell lines (STS-26T, S462, S462TY, T265) were obtained from Dr. David Largaespada's laboratory"
T265,cell_lines,PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"MPNST cell lines (STS-26T, S462, S462TY, T265) were obtained from Dr. David Largaespada's laboratory"
NF1-1 hiPSC line,cell_lines,PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Blood,Neurofibromatosis Type 1,,Embryonic stem cell,,,,,,,,,,,,,,,,,,,,,,NF1-1 and NF1-2 hiPSC lines were reprogrammed using OSKM episomal technique by Phenocell from two patient-derived fibroblasts carrying NF1 mutations
NF1-2 hiPSC line,cell_lines,PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Blood,Neurofibromatosis Type 1,,Embryonic stem cell,,,,,,,,,,,,,,,,,,,,,,NF1-1 and NF1-2 hiPSC lines were reprogrammed using OSKM episomal technique by Phenocell from two patient-derived fibroblasts carrying NF1 mutations
LN319,cell_lines,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Brain,Neurofibromatosis Type 1,Glioblastoma Multiforme,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,The Glioblastoma Multiphorme (GBM) LN319 cell line was a gift from Dr. Karen Cichowski. LN319 is an adult sporadic GBM with full inactivation of NF1
ST8814,cell_lines,PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,ST8814 was derived from a patient with NF1-associated MPNST of the thigh
RT4-D6P2T schwannoma cells,cell_lines,PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 2,Schwannoma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,The rat RT4-D6P2T schwannoma cells was obtained from the Global Bioresource Center.
HEI-193,cell_lines,PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 2,Schwannoma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"The HEI-193, an HPV E6-E7 immortalized schwannoma cell line, was a kind gift from Dr. Weg M. Ongkeko"
ipNF95.11b C,cell_lines,PMID:40862755,10.3390/cells14161276,Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Plexiform neurofibroma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,The following immortalized human plexiform neurofibroma cell lines (Nf1−/−; hereafter called pNF1 cells) described in [23] were used: ipNF95.11b C and ipNF05.5 purchased from ATCC.
ipNF05.5,cell_lines,PMID:40862755,10.3390/cells14161276,Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Plexiform neurofibroma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,The following immortalized human plexiform neurofibroma cell lines (Nf1−/−; hereafter called pNF1 cells) described in [23] were used: ipNF95.11b C and ipNF05.5 purchased from ATCC.
ipNF95.11b C,cell_lines,PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Plexiform neurofibroma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"ipNF95.11b C was purchased from ATCC, and CRISPR technology was used to generate a homozygous NF1 knockout clone"
JH-2-002,cell_lines,PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Four patient-derived NF1-MPNST cell lines (JH-2-002, JH-2-031, JH-2-079c, and JH-2-103) were generated in our laboratories"
JH-2-031,cell_lines,PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Four patient-derived NF1-MPNST cell lines (JH-2-002, JH-2-031, JH-2-079c, and JH-2-103) were generated in our laboratories"
JH-2-079c,cell_lines,PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Four patient-derived NF1-MPNST cell lines (JH-2-002, JH-2-031, JH-2-079c, and JH-2-103) were generated in our laboratories"
JH-2-103,cell_lines,PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Four patient-derived NF1-MPNST cell lines (JH-2-002, JH-2-031, JH-2-079c, and JH-2-103) were generated in our laboratories"
ST88-14,cell_lines,PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"human MPNST cell lines (ST88-14, STS26T, S462, S462-TY, and T265)"
STS26T,cell_lines,PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"human MPNST cell lines (ST88-14, STS26T, S462, S462-TY, and T265)"
S462,cell_lines,PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"human MPNST cell lines (ST88-14, STS26T, S462, S462-TY, and T265)"
S462-TY,cell_lines,PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"human MPNST cell lines (ST88-14, STS26T, S462, S462-TY, and T265)"
T265,cell_lines,PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"human MPNST cell lines (ST88-14, STS26T, S462, S462-TY, and T265)"
S462-TY,cell_lines,PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,S462-TY cells were cultured in DMEM supplemented with 10% FBS and 1% penicillin/streptomycin at 37°C with 5% CO2
S462,cell_lines,PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,Human MPNST cell lines S462 and T265 were described previously...NF1 associated MPNST derived from S462 but not T265 cells form solid subcutaneous tumors
T265,cell_lines,PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,Human MPNST cell lines S462 and T265 were described previously...NF1 associated MPNST derived from S462 but not T265 cells form solid subcutaneous tumors
MPNST-NF1-08,cell_lines,PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"The establishment of the MPNST-SP-01, MPNST-NF1-08, and MPNST-NF1-9 cell lines at the Catalan Institute of Oncology is described..."
MPNST-NF1-9,cell_lines,PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"The establishment of the MPNST-SP-01, MPNST-NF1-08, and MPNST-NF1-9 cell lines at the Catalan Institute of Oncology is described..."
sNF96.2,cell_lines,PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"STS-26T (19), HS-PSS, HS-sch2 (20), S462 (21), and sNF96.2 (22) cell lines were previously established in other laboratories."
ipNF95.11b C,cell_lines,PMID:39061138,10.3390/cancers16142498,A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Plexiform Neurofibroma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,The following immortalized human plexiform neurofibroma cell lines (hereafter called pNF1 cells) described in [ 36 ] were used: ipNF95.11b C
ipNF95.11b C-RFP,cell_lines,PMID:39061138,10.3390/cancers16142498,A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Plexiform Neurofibroma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"ipNF95.11b C gifted from Dr. Margaret Wallace (University of Florida, USA) was lentivirally transduced with red fluorescent protein (RFP)"
ipNF 05.5,cell_lines,PMID:39061138,10.3390/cancers16142498,A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Plexiform Neurofibroma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"The following immortalized human plexiform neurofibroma cell lines (hereafter called pNF1 cells) described in [ 36 ] were used: ipNF95.11b C, ipNF95.11b C-RFP, and ipNF 05.5"
Ben-Men-1,cell_lines,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Brain,Neurofibromatosis Type 2,Meningioma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,Cell lines included immortalized NF2-deficient meningioma Ben-Men-1
AC007-hTERT,cell_lines,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Brain,Neurofibromatosis Type 2,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,immortalized arachnoid AC007-hTERT derived from an NF2 patient expressing heterozygous level of NF2
Meso-33,cell_lines,PMID:25026211,10.1016/j.ccr.2014.05.001,Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Lung,Neurofibromatosis Type 2,Mesothelioma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,plated in 0.34% low melting temperature agarose (FMC Bioproducts) in complete medium at 2×10 4 (Meso-33 cells)
FC-1801,cell_lines,PMID:25026211,10.1016/j.ccr.2014.05.001,Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 2,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"1.2×10 4 (FC-1801 cells) per well in 24-well Ultra Low Cluster Plates (Costar). For tumorigenicity assay, 1×10 6 FC-1801 cells were suspended"
K4622 grade II glioma cell line,cell_lines,PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Brain,Neurofibromatosis Type 1,Grade II glioma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,The mouse K4622 grade II glioma cell line was derived from a C57Bl/6 Nf1+/−; p53+/− mouse and was shown to be both Nf1- and p53-deficient
HSR-GBM1,cell_lines,PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Brain,Neurofibromatosis Type 1,Glioblastoma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Human-derived glioblastoma neurosphere lines (HSR-GBM1, JHH-520, JHU-0879, JHU-1016B, JHH-136) with diverse NF1 status were obtained and cultured"
JHH-520,cell_lines,PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Brain,Neurofibromatosis Type 1,Glioblastoma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Human-derived glioblastoma neurosphere lines (HSR-GBM1, JHH-520, JHU-0879, JHU-1016B, JHH-136) with diverse NF1 status were obtained and cultured"
JHU-0879,cell_lines,PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Brain,Neurofibromatosis Type 1,Glioblastoma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Human-derived glioblastoma neurosphere lines (HSR-GBM1, JHH-520, JHU-0879, JHU-1016B, JHH-136) with diverse NF1 status were obtained and cultured"
JHU-1016B,cell_lines,PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Brain,Neurofibromatosis Type 1,Glioblastoma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Human-derived glioblastoma neurosphere lines (HSR-GBM1, JHH-520, JHU-0879, JHU-1016B, JHH-136) with diverse NF1 status were obtained and cultured"
JHH-136,cell_lines,PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Brain,Neurofibromatosis Type 1,Glioblastoma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Human-derived glioblastoma neurosphere lines (HSR-GBM1, JHH-520, JHU-0879, JHU-1016B, JHH-136) with diverse NF1 status were obtained and cultured"
ST88-14,cell_lines,PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"We maintained MPNST cell lines ST88-14, STS26T, S520, S462, 88-3, 90-8 and YST1"
STS26T,cell_lines,PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"We maintained MPNST cell lines ST88-14, STS26T, S520, S462, 88-3, 90-8 and YST1"
S520,cell_lines,PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"We maintained MPNST cell lines ST88-14, STS26T, S520, S462, 88-3, 90-8 and YST1"
S462,cell_lines,PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"We maintained MPNST cell lines ST88-14, STS26T, S520, S462, 88-3, 90-8 and YST1"
88-3,cell_lines,PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"We maintained MPNST cell lines ST88-14, STS26T, S520, S462, 88-3, 90-8 and YST1"
90-8,cell_lines,PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"We maintained MPNST cell lines ST88-14, STS26T, S520, S462, 88-3, 90-8 and YST1"
YST1,cell_lines,PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"We maintained MPNST cell lines ST88-14, STS26T, S520, S462, 88-3, 90-8 and YST1"
Nf1−/− MEFs,cell_lines,PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,Experimental Usage,True,1.00,High,,,,,,,Embryonic tissue,Neurofibromatosis Type 1,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Mouse embryonic fibroblasts (MEFs) were derived from both wild type mice and syngenic neurofibromin 1 (Nf1)-knockout animals (Nf1+/+ and Nf1−/− MEFs, respectively)"
sMPNST cells,cell_lines,PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,sMPNST cells were established from Nf1- and p53-deficient skin precursors (SKP)
cisMPNST cells,cell_lines,PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,cisMPNST cells were derived from spontaneous MPNSTs arising in cis Nf1+/−;P53+/− mice
ipNF 04.4 cells,cell_lines,PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Plexiform Neurofibroma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,Human plexiform neurofibroma ipNF 04.4 cells were generated and provided by Dr. Margaret R. Wallace
S462,cell_lines,PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,Several cell lines derived from MPNSTs were used: S462 and ST88-14 (provided by Dr Nancy Ratner)
ST88-14,cell_lines,PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,Several cell lines derived from MPNSTs were used: S462 and ST88-14 (provided by Dr Nancy Ratner)
sNF96.2,cell_lines,PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,sNF96.2 (provided by Dr Thomas De Raedt)
90-8,cell_lines,PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,90-8 and the sporadic MPNST-derived STS-26T (provided by Dr Eric Legius)
ST8814,cell_lines,PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"MPNST cell lines STS26T, ST8814, ST88-3 S462, T265p21, S520, 90–8, and YST1...All cell lines were from NF1 patients except YST-1 and STS26T"
ST88-3,cell_lines,PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"MPNST cell lines STS26T, ST8814, ST88-3 S462, T265p21, S520, 90–8, and YST1...All cell lines were from NF1 patients except YST-1 and STS26T"
S462,cell_lines,PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"MPNST cell lines STS26T, ST8814, ST88-3 S462, T265p21, S520, 90–8, and YST1...All cell lines were from NF1 patients except YST-1 and STS26T"
T265p21,cell_lines,PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"MPNST cell lines STS26T, ST8814, ST88-3 S462, T265p21, S520, 90–8, and YST1...All cell lines were from NF1 patients except YST-1 and STS26T"
S520,cell_lines,PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"MPNST cell lines STS26T, ST8814, ST88-3 S462, T265p21, S520, 90–8, and YST1...All cell lines were from NF1 patients except YST-1 and STS26T"
90-8,cell_lines,PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"MPNST cell lines STS26T, ST8814, ST88-3 S462, T265p21, S520, 90–8, and YST1...All cell lines were from NF1 patients except YST-1 and STS26T"
JH-2-002 cell line,cell_lines,PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,Human MPNST cell lines JH-2–002 were obtained from the Johns Hopkins NF1 Biospecimen Repository
JH-2-103 cell line,cell_lines,PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,Human MPNST cell lines JH-2–103 were obtained from the Johns Hopkins NF1 Biospecimen Repository
ST-8814 cell line,cell_lines,PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,ST-8814 and S462 cells were obtained from Dr. Andrew Tee (Cardiff University)
S462 cell line,cell_lines,PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,ST-8814 and S462 cells were obtained from Dr. Andrew Tee (Cardiff University)
M1,cell_lines,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"NF1 patient-derived human MPNST cell lines M1, M3, M4, and M6 were kind gifts developed by William L. Gerald and Xiaoliang L. Xu at Memorial Sloan Kettering Cancer Center"
M3,cell_lines,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"NF1 patient-derived human MPNST cell lines M1, M3, M4, and M6 were kind gifts developed by William L. Gerald and Xiaoliang L. Xu at Memorial Sloan Kettering Cancer Center"
M4,cell_lines,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"NF1 patient-derived human MPNST cell lines M1, M3, M4, and M6 were kind gifts developed by William L. Gerald and Xiaoliang L. Xu at Memorial Sloan Kettering Cancer Center"
M6,cell_lines,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"NF1 patient-derived human MPNST cell lines M1, M3, M4, and M6 were kind gifts developed by William L. Gerald and Xiaoliang L. Xu at Memorial Sloan Kettering Cancer Center"
ipnNF95.11C,cell_lines,PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"...immortalized NF1 −/−, NF1 +/−, and NF1 +/+ cell lines [16], with the fluorescence intensity indicating survival and proliferation after treatment..."
ipNF05.5-MX,cell_lines,PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Plexiform Neurofibroma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"...NF1 −/− plexiform neurofibroma cell lines (PNF1 cells) ipNF05.5-MX, ipNF06.2A, ipNF95.11b C/T, and ipNF95.6 as test lines..."
ipNF06.2A,cell_lines,PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Plexiform Neurofibroma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"...NF1 −/− plexiform neurofibroma cell lines (PNF1 cells) ipNF05.5-MX, ipNF06.2A, ipNF95.11b C/T, and ipNF95.6 as test lines..."
ipNF95.11b C/T,cell_lines,PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Plexiform Neurofibroma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"...NF1 −/− plexiform neurofibroma cell lines (PNF1 cells) ipNF05.5-MX, ipNF06.2A, ipNF95.11b C/T, and ipNF95.6 as test lines..."
ipNF95.6,cell_lines,PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Plexiform Neurofibroma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"...NF1 −/− plexiform neurofibroma cell lines (PNF1 cells) ipNF05.5-MX, ipNF06.2A, ipNF95.11b C/T, and ipNF95.6 as test lines..."
NF95.11b,cell_lines,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Neurofibroma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Patient-derived neurofibroma (NF95.11b, NF95.6) or MPNST (SNF02.2, SNF94.3, SNF96.2, ST88-14) cell lines"
NF95.6,cell_lines,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Neurofibroma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Patient-derived neurofibroma (NF95.11b, NF95.6) or MPNST (SNF02.2, SNF94.3, SNF96.2, ST88-14) cell lines"
SNF02.2,cell_lines,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Patient-derived neurofibroma (NF95.11b, NF95.6) or MPNST (SNF02.2, SNF94.3, SNF96.2, ST88-14) cell lines"
SNF94.3,cell_lines,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Patient-derived neurofibroma (NF95.11b, NF95.6) or MPNST (SNF02.2, SNF94.3, SNF96.2, ST88-14) cell lines"
SNF96.2,cell_lines,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Patient-derived neurofibroma (NF95.11b, NF95.6) or MPNST (SNF02.2, SNF94.3, SNF96.2, ST88-14) cell lines"
ST88-14,cell_lines,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Patient-derived neurofibroma (NF95.11b, NF95.6) or MPNST (SNF02.2, SNF94.3, SNF96.2, ST88-14) cell lines"
BenMen-1,cell_lines,PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Brain,Neurofibromatosis Type 2,Meningioma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,meningioma cell lines BenMen-1 (Grade 1) and KT21-MG1 (Grade 3) were cultured in DMEM/10% FBS
KT21-MG1,cell_lines,PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Brain,Neurofibromatosis Type 2,Meningioma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,meningioma cell lines BenMen-1 (Grade 1) and KT21-MG1 (Grade 3) were cultured in DMEM/10% FBS
NF2 primary fibroblasts,cell_lines,PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,0.9,Experimental Usage,True,1.00,High,,,,,,,Skin,Neurofibromatosis Type 2,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,Patient primary fibroblasts carrying NF2 germline pathogenic variants were treated with the specific single or paired PMOs
Primary human vestibular schwannoma (VS) cell cultures,cell_lines,PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 2,Vestibular Schwannoma,Finite cell line,,,,,,,,,,,,,,,,,,,,,,Primary human vestibular schwannoma (VS) cell cultures were transduced with adenoviral vectors expressing Neurod1
ipNF95.11bC,cell_lines,PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Plexiform Neurofibroma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"pNF cell lines, ipNF95.11bC, ipnNF95.11c, ipNF05.5 Single Clone, and ipNF05.5 Mixed Clones were obtained from the American Type Culture Collection"
ipnNF95.11c,cell_lines,PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Plexiform Neurofibroma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"pNF cell lines, ipNF95.11bC, ipnNF95.11c, ipNF05.5 Single Clone, and ipNF05.5 Mixed Clones were obtained from the American Type Culture Collection"
ipNF05.5 Single Clone,cell_lines,PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Plexiform Neurofibroma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"pNF cell lines, ipNF95.11bC, ipnNF95.11c, ipNF05.5 Single Clone, and ipNF05.5 Mixed Clones were obtained from the American Type Culture Collection"
ipNF05.5 Mixed Clones,cell_lines,PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Plexiform Neurofibroma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"pNF cell lines, ipNF95.11bC, ipnNF95.11c, ipNF05.5 Single Clone, and ipNF05.5 Mixed Clones were obtained from the American Type Culture Collection"
Nf2-deficient spinal cord neural progenitor cells,cell_lines,PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 2,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,we leveraged primary mouse Nf2-deficient spinal cord neural progenitor cells
T265,cell_lines,PMID:41001593,10.1080/23723556.2025.2561292,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Human T265, S462, and NSF1 cell lines of malignant peripheral nerve sheath tumors (MPNSTs) being associated with neurofibromatosis type 1"
S462,cell_lines,PMID:41001593,10.1080/23723556.2025.2561292,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Human T265, S462, and NSF1 cell lines of malignant peripheral nerve sheath tumors (MPNSTs) being associated with neurofibromatosis type 1"
NSF1,cell_lines,PMID:41001593,10.1080/23723556.2025.2561292,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Human T265, S462, and NSF1 cell lines of malignant peripheral nerve sheath tumors (MPNSTs) being associated with neurofibromatosis type 1"
S462TY,cell_lines,PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"The S462TY cell line was a kind gift from Dr. Timothy Cripe (Nationwide Children's Hospital Columbus, Columbus, OH, USA)"
T265,cell_lines,PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"The MPNST cell lines STS26T, T265, and ST8814 have been reported before and were gifted by Dr. Nancy Ratner"
ST8814,cell_lines,PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"The MPNST cell lines STS26T, T265, and ST8814 have been reported before and were gifted by Dr. Nancy Ratner"
S462,cell_lines,PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Human MPNST cell lines (S462, T265, and NSF1) were analyzed and have been described in detail in our previous studies"
T265,cell_lines,PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Human MPNST cell lines (S462, T265, and NSF1) were analyzed and have been described in detail in our previous studies"
NSF1,cell_lines,PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"NSF1 cells were kindly provided by Dieter Kaufmann (University Hospital Ulm, Germany)"
S462,cell_lines,PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"NF1-associated S462, Cellosaurus RRID: CVCL_1Y70) were maintained at 37°C"
ipNF05.5,cell_lines,PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,Immortalised human Schwann cell lines with mutant NF1 (ipNF05.5 and 95.6) and wt NF1 (ipn02.3)
95.6,cell_lines,PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,Immortalised human Schwann cell lines with mutant NF1 (ipNF05.5 and 95.6) and wt NF1 (ipn02.3)
NIH Consensus Development Conference NF1 diagnostic criteria,clinical_assessment_tools,PMID:33817379,10.1016/j.heliyon.2021.e06518,Clinical assessment of the use of topical liquid diclofenac following laser microporation of cutaneous neurofibromas in individuals with neurofibromatosis type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,NIH Consensus Development Conference NF1 diagnostic criteria,structured interview,all ages,Yes,,"patients with a clinical diagnosis of NF1 according to the NIH Consensus Development Conference NF1 diagnostic criteria (NIH, 1998)"
Numerical Rating Scale-11,clinical_assessment_tools,PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Numerical Rating Scale-11,scale,all ages,Yes,1.0,The Numerical Rating Scale-11 is a self-report measure of pain intensity that was adapted to assess PN-related pain for NF1 clinical trials. Patients were asked to choose their most important tumor pain and rate it from 0 (no pain) to 10 (worst pain) in the past week.
Cirrus HD-OCT,clinical_assessment_tools,PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Cirrus HD-OCT,biomarker assay,pediatric,Yes,,"Optical coherence tomography images were obtained using Cirrus HD-OCT device (Cirrus; Carl Zeiss Meditec, Dublin, CA, USA)"
Rex Gauge durometer,clinical_assessment_tools,PMID:40529476,10.1016/j.xjidi.2025.100380,Using Durometers to Quantify Stiffness as an Outcome Measure for Cutaneous Neurofibroma in Neurofibromatosis Type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Rex Gauge durometer,performance test,all ages,Yes,,One was the Rex Gauge durometer (REX) produced by Rex Gauge LLC...used to measure cNF stiffness
Delfin SkinFibroMeter,clinical_assessment_tools,PMID:40529476,10.1016/j.xjidi.2025.100380,Using Durometers to Quantify Stiffness as an Outcome Measure for Cutaneous Neurofibroma in Neurofibromatosis Type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Delfin SkinFibroMeter,performance test,all ages,Yes,,"the other was the SkinFibroMeter (DEFLIN) made by Delfin Technologies...measure tissue induration, assessing tissue stiffness in quantitative units"
Vectra H1,clinical_assessment_tools,PMID:39225289,10.1111/srt.70020,Comparing 3D imaging devices for the measurement of cutaneous neurofibromas in patients with Neurofibromatosis Type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Vectra H1,performance test,adult,Yes,,"Images of up to eight cNFs from each participant were captured and analysed using each 3D imaging system: Vectra H1 (Canfield Scientific Inc, Fairfield, NJ, USA)"
LifeViz Micro,clinical_assessment_tools,PMID:39225289,10.1111/srt.70020,Comparing 3D imaging devices for the measurement of cutaneous neurofibromas in patients with Neurofibromatosis Type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,LifeViz Micro,performance test,adult,Yes,,"Images of up to eight cNFs from each participant were captured and analysed using each 3D imaging system: LifeViz Micro (QuantifiCare, Biot, France)"
Cherry Imaging,clinical_assessment_tools,PMID:39225289,10.1111/srt.70020,Comparing 3D imaging devices for the measurement of cutaneous neurofibromas in patients with Neurofibromatosis Type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Cherry Imaging,performance test,adult,Yes,,"Images of up to eight cNFs from each participant were captured and analysed using each 3D imaging system: Cherry Imaging (Yokneam, Israel)"
SRS-2,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,SRS-2,scale,caregiver,Yes,65.0,"SRS-2 65 items assessing the presence and severity of ASD symptoms including social awareness, social cognition, social communication"
8-item NF2 disease-specific quality of life score,clinical_assessment_tools,PMID:28848060,10.1136/jmedgenet-2017-104519,Genetic Severity Score predicts clinical phenotype in NF2.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,8-item NF2 disease-specific quality of life score,questionnaire,all ages,Yes,8.0,"Quality of life was assessed using the 8-item NF2 disease-specific quality of life score (0–24), with good internal reliability (Cronbach's α=0.87)"
Manchester Criteria,clinical_assessment_tools,PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Manchester Criteria,scale,all ages,Yes,,"patients who fitted Manchester Criteria for NF2 disease (Table S1 ) (Evans et al., 1992 ; Smith et al., 2017 ) were considered to have phenotypic specificity"
Ablon visibility index,clinical_assessment_tools,PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Ablon visibility index,scale,clinician-rated,Yes,,clinicians also rated the disease visibility using the Ablon visibility index
Fiber Photometry Trace Processing,computational_tools,PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Fiber Photometry Trace Processing,Analysis Software,,https://github.com/GradinaruLab/dLight1/blob/master/FP_Session_Processing2.m,,,,,,,,,,,,,,Fiber Photometry Trace Processing Gradinaru Lab FP_Session_Processing_2.m https://github.com/GradinaruLab/dLight1/blob/master/FP_Session_Processing2.m
gamlssTools,computational_tools,PMID:41468561,10.1212/WNL.0000000000214480,NF1-Specific Growth Charts for Head Circumference Over the First 3 Years of Life.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,gamlssTools,Package/Library,,https://github.com/BGDlab/gamlssTools,,,,,,,,,,,,,,...GAMLSS model visualization was performed using customized R functions (https://github.com/BGDlab/gamlssTools)...
Offline sorter x64 version 4,computational_tools,PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Offline sorter x64 version 4,Analysis Software,4,,,,,,,,,,,,,,,Representative traces of action potentials were extracted using the AXION Biosystems neural metric tool and Offline sorter x64 version 4 software
ImageJ 1.53a,computational_tools,PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ImageJ 1.53a,Analysis Software,1.53a,,,,,,,,,,,,,,,"Images were acquired using Image Studio Lite Version 5.2 software, and LAS AF Lite 3.2.0 software and analyzed using ImageJ 1.53a software"
STAR v2.7.8a,computational_tools,PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,STAR v2.7.8a,Analysis Software,v2.7.8a,,,,,,,,,,,,,,,GENCODE was used to map FASTQ files to GRCh38 (release 33 with STAR v2.7.8a basic two-pass mode)
iDEP 9.1,computational_tools,PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,iDEP 9.1,Analysis Software,9.1,,,,,,,,,,,,,,,principal component analysis was computed using iDEP 9.1
Trim Galore v0.6.0,computational_tools,PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Trim Galore v0.6.0,Analysis Software,v0.6.0,,,,,,,,,,,,,,,Trim Galore v0.6.0 was used to trim sequencing adapters from demultiplexed FASTQ files
LipidSearch v5.0,computational_tools,PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,LipidSearch v5.0,Analysis Software,v5.0,,,,,,,,,,,,,,,"Lipid identifications were assigned using LipidSearch (v5.0, Thermo Fisher Scientific)"
Compound Discoverer v3.2,computational_tools,PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Compound Discoverer v3.2,Analysis Software,v3.2,,,,,,,,,,,,,,,"Data was analyzed using Compound Discoverer (v 3.2, Thermo Fisher Scientific)"
SEDFIT 16.1,computational_tools,PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SEDFIT 16.1,Analysis Software,16.1,,,,,,,,,,,,,,,Time-corrected data were analyzed in SEDFIT 16.1 in terms of a continuous c(s) distribution of sedimenting species
SEDPHAT 14.0,computational_tools,PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SEDPHAT 14.0,Analysis Software,14.0,,,,,,,,,,,,,,,Data were analyzed globally in terms of a single noninteracting species in SEDPHAT 14.0 to obtain the molar mass
STAR 2.4.2a,computational_tools,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,STAR 2.4.2a,Analysis Software,2.4.2a,,,,,,,,,,,,,,,Mapping was performed using STAR 2.4.2a software with mouse genome (mm9)
GSEA software 4.0.1,computational_tools,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GSEA software 4.0.1,Analysis Software,4.0.1,,,,,,,,,,,,,,,Gene set enrichment analysis (GSEA) was performed with the entire gene list using GSEA software 4.0.1 desktop (Broad Institute)
DAVID 6.8,computational_tools,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,DAVID 6.8,Web Application,6.8,,,,,,,,,,,,,,,KEGG and gene ontology (GO) enrichment analysis was performed using the Signature Database (MSigDB) and DAVID 6.8
MaxQuant (v1.5.3.30),computational_tools,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,MaxQuant (v1.5.3.30),Analysis Software,v1.5.3.30,,,,,,,,,,,,,,,Five micrograms of each SCX fraction and a non-fractioned sample were used for proteome profiling and analysed by MaxQuant (v1.5.3.30)
VEP,computational_tools,PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,VEP,Analysis Software,version 95,,,,,,,,,,,,,,,"which includes best-practice variant filtering and annotation with VEP (Variant Effect Predictor, version 95)"
IBM SPSS Statistics software version 29.0.1.0,computational_tools,PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,IBM SPSS Statistics software version 29.0.1.0,Analysis Software,29.0.1.0,,,,,,,,,,,,,,,"In vivo S462TY sciatic nerve tumor xenograft data were analyzed using IBM SPSS Statistics software version 29.0.1.0 (IBM, Armonk, NY, USA)."
GraphPad Prism version 6.0h,computational_tools,PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GraphPad Prism version 6.0h,Analysis Software,6.0h,,,,,,,,,,,,,,,"Analysis was performed using GraphPad Prism version 6.0h (La Jolla, CA, USA)"
"ImageJ software (version 1.48; National Institutes of Health, Behesda, MD, USA)",computational_tools,PMID:25851896,10.3988/jcn.2015.11.2.172,Preclinical assessment of the anticancer drug response of plexiform neurofibroma tissue using primary cultures.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,"ImageJ software (version 1.48; National Institutes of Health, Behesda, MD, USA)",Analysis Software,1.48,,,,,,,,,,,,,,,"More than 200 cells were counted for each drug concentration using ImageJ software (version 1.48; National Institutes of Health, Behesda, MD, USA)"
DPP V1.0,computational_tools,PMID:39966622,10.1038/s41598-025-88589-x,The development of an artificial intelligence auto-segmentation tool for 3D volumetric analysis of vestibular schwannomas.,,0.9,Development,True,1.00,High,,,,,,,,,,,,,,,DPP V1.0,Analysis Software,V1.0,,,,,,,,,,,,,,,The helper (DPP V1.0) was trained using proprietary AI- and ML-based algorithms and information.
www.synapse.org/SynodosNF2,computational_tools,PMID:29897904,10.1371/journal.pone.0197350,Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2.,,0.9,Development,True,1.00,High,,,,,,,,,,,,,,,www.synapse.org/SynodosNF2,Database,,www.synapse.org/SynodosNF2,,,,,,,,,,,,,,This work has created an openly accessible resource (www.synapse.org/SynodosNF2) of fully characterized isogenic schwannoma and meningioma cell systems
NextGENe software v.2.3.4.1,computational_tools,PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,NextGENe software v.2.3.4.1,Analysis Software,v.2.3.4.1,,,,,,,,,,,,,,,"The data were analysed using NextGENe software v.2.3.4.1 (Softgenetics, PA, USA) with the default settings"
"Alamut Visual Plus, version 1.5.1",computational_tools,PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,"Alamut Visual Plus, version 1.5.1",Analysis Software,1.5.1,,,,,,,,,,,,,,,"Splice site prediction software (Alamut Visual Plus, version 1.5.1; Sophia Genetics) was used to identify variants likely to affect pre-mRNA splicing"
FMRIB software library (FSL),computational_tools,PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,FMRIB software library (FSL),Analysis Software,5.0,,,,,,,,,,,,,,,"fMRI data analyses were performed using tools from the FMRIB software library ( www.fmrib.ox.ac.uk/fsl ), version 5.0"
Burrows–Wheeler Aligner,computational_tools,PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Burrows–Wheeler Aligner,Analysis Software,0.7.8,,,,,,,,,,,,,,,Burrows–Wheeler Aligner (version 0.7.8) was utilized to map the paired-end clean reads
SAMtools,computational_tools,PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SAMtools,Analysis Software,1.0,,,,,,,,,,,,,,,SAMtools (version 1.0) is used for sorting the BAM file
GATK,computational_tools,PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GATK,Analysis Software,3.8,,,,,,,,,,,,,,,Single-nucleotide variant is then identified using GATK (version 3.8)
ANNOVAR,computational_tools,PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ANNOVAR,Analysis Software,2015Dec,,,,,,,,,,,,,,,subsequently annotated using ANNOVAR (version 2015Dec)
control-FREEC,computational_tools,PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,control-FREEC,Analysis Software,9.9,,,,,,,,,,,,,,,CNV is detected by control-FREEC (version 9.9)
RStudio,computational_tools,PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,RStudio,Analysis Software,1.2.5033,,,,,,,,,,,,,,,We developed R codes and used RStudio (version 1.2.5033)
APE,computational_tools,PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,APE,Package/Library,5.2,,,,,,,,,,,,,,,"R package ""Analyses of Phylogenetics and Evolution"" (APE, version 5.2)"
MEGAX,computational_tools,PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,MEGAX,Analysis Software,0.1,,,,,,,,,,,,,,,"MEGAX (version 0.1, for MAC) to generate SKY-based phylogenetic trees"
DESeq2,computational_tools,PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,DESeq2,Package/Library,v1.18.0,,,,,,,,,,,,,,,DESeq2 (v1.18.0) package was used to normalize count data and for differential gene expression analysis
GSEA,computational_tools,PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GSEA,Analysis Software,v3.0 beta2,,,,,,,,,,,,,,,Gene set enrichment analysis (GSEA) was performed using GSEA software v3.0 beta2
Human Splicing Finder (HSF) Version 2.4.1,computational_tools,PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Human Splicing Finder (HSF) Version 2.4.1,Web Application,2.4.1,,,,,,,,,,,,,,,Human Splicing Finder (HSF) Version 2.4.1 ( http://www.umd.be/HSF/ Assessing on 21 December 2020)
Combined Annotation Dependent Depletion (CADD) v1.6,computational_tools,PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Combined Annotation Dependent Depletion (CADD) v1.6,Web Application,v1.6,,,,,,,,,,,,,,,Combined Annotation Dependent Depletion (CADD) v1.6 ( https://cadd.gs.washington.edu/ Assessing on 21 December 2020)
STAR,computational_tools,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,STAR,Analysis Software,v. 2.5.2a,,,,,,,,,,,,,,,"Sequence reads were aligned to human reference genome Ensembl GRCh37 (v.75), using STAR (v. 2.5.2a)"
edgeR,computational_tools,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,edgeR,Package/Library,v. 3.18.1,,,,,,,,,,,,,,,Differentially expressed genes in pair-wise comparisons were identified by edgeR's quasi-likelihood F test (v. 3.18.1)
SynergyFinder,computational_tools,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SynergyFinder,Web Application,,https://synergyfinder.fimm.fi/,,,,,,,,,,,,,,Synergy scores were generated using the web-based SynergyFinder application (https://synergyfinder.fimm.fi/)
InVivo 3.2.0 software,computational_tools,PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,InVivo 3.2.0 software,Analysis Software,3.2.0,,,,,,,,,,,,,,,Sections were viewed and imaged using an Olympus BX61 upright light microscope and Q imaging Retiga Exi camera with InVivo 3.2.0 software (Media Cybernetics)
"Image J1.45s, version 1.44p",computational_tools,PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,"Image J1.45s, version 1.44p",Analysis Software,1.44p,,,,,,,,,,,,,,,"The width and equatorial length of the testes were measured on testicular histological images using Image J1.45s, version 1.44p (NIH, Bethesda, MD)"
netMHCpan-4.0,computational_tools,PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,netMHCpan-4.0,Analysis Software,4.0,,,,,,,,,,,,,,,Binding affinity of mutant and corresponding wild-type peptides to the patient's germline HLA alleles was predicted using netMHCpan-4.0
CatWalk XT,computational_tools,PMID:29408605,10.1016/j.neuroscience.2018.01.054,Nf2 Mutation in Schwann Cells Delays Functional Neural Recovery Following Injury.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,CatWalk XT,Analysis Software,ver. 8,,,,,,,,,,,,,,,"We used the CatWalk XT (ver. 8, Noldus Information Technology, Wageningen, The Netherlands) system to study the functional recovery of the nerve"
Agilent ChemStation software (version C.01.07),computational_tools,PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Agilent ChemStation software (version C.01.07),Analysis Software,C.01.07,,,,,,,,,,,,,,,An Agilent ChemStation software (version C.01.07) was used for data analysis
GenomeStudio (v. 2010.2),computational_tools,PMID:25329635,10.1371/journal.pgen.1004575,Genetic modifiers of neurofibromatosis type 1-associated café-au-lait macule count identified using multi-platform analysis.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GenomeStudio (v. 2010.2),Analysis Software,v. 2010.2,,,,,,,,,,,,,,,SNP-array analysis was done according to the manufacturer's protocol using GenomeStudio (v. 2010.2) software
MaxQuant (version 1.6.10.43),computational_tools,PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,MaxQuant (version 1.6.10.43),Analysis Software,1.6.10.43,,,,,,,,,,,,,,,Raw files were processed for label-free quantification by MaxQuant (version 1.6.10.43) LFQ using the Uniprot/Swiss-Prot mouse database
Perseus (version 1.6.10.50),computational_tools,PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Perseus (version 1.6.10.50),Analysis Software,1.6.10.50,,,,,,,,,,,,,,,LFQ intensities for kinases with at least two peptides were imported into Perseus (version 1.6.10.50)
FlowJo Software (version 9.9.6),computational_tools,PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,FlowJo Software (version 9.9.6),Analysis Software,9.9.6,,,,,,,,,,,,,,,"Data were acquired uncompensated and exported as FCS 3.0 files for analysis using FlowJo Software (version 9.9.6,Tree Star Inc)"
ImageJ (version 1.47),computational_tools,PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ImageJ (version 1.47),Analysis Software,1.47,,,,,,,,,,,,,,,AXL immunohistochemistry was analyzed using the IHC Profiler plugin for ImageJ (version 1.47)
HALO Image Analysis Software (version 2.3),computational_tools,PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,HALO Image Analysis Software (version 2.3),Analysis Software,2.3,,,,,,,,,,,,,,,"representative image were generated using HALO Image Analysis Software (version 2.3, Indica Labs)"
Drop-seq tools (version 1.12),computational_tools,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Drop-seq tools (version 1.12),Analysis Software,1.12,,,,,,,,,,,,,,,"FASTQ sequencing reads were processed, aligned to the mouse genome (mm10), and converted to digital gene expression matrices using the Drop-seq tools (version 1.12)"
Cellranger v5.0.1,computational_tools,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Cellranger v5.0.1,Analysis Software,v5.0.1,,,,,,,,,,,,,,,"For 10X Genomics datasets, we used Cellranger v5.0.1 to align reads to the hg19 human reference sequence"
Seurat (version 3.1.0),computational_tools,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Seurat (version 3.1.0),Package/Library,3.1.0,,,,,,,,,,,,,,,"For each sample dataset, unsupervised clustering was performed using R package Seurat (version 3.1.0)"
CytoTRACE version 0.3.3,computational_tools,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,CytoTRACE version 0.3.3,Package/Library,0.3.3,,,,,,,,,,,,,,,we used the R package CytoTRACE version 0.3.3 to predict differentiation status of SC lineage cells from mouse and human scRNA-seq data
DGIdb (version 3.0.2),computational_tools,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,DGIdb (version 3.0.2),Database,3.0.2,,,,,,,,,,,,,,,"were used to query the Washington University DGIdb (version 3.0.2), with a focus on expert-curated collections of druggable genes"
Trim Galore (version 0.6.10),computational_tools,PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Trim Galore (version 0.6.10),Analysis Software,0.6.10,,,,,,,,,,,,,,,The raw sequence reads were first trimmed using Trim Galore (version 0.6.10) to remove any primer adapter contamination
Broad's Genome Analysis ToolKit (version 4.6.0),computational_tools,PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Broad's Genome Analysis ToolKit (version 4.6.0),Analysis Software,4.6.0,,,,,,,,,,,,,,,The trimmed sequence reads were further analyzed using Broad's Genome Analysis ToolKit (version 4.6.0) following their Best Practices Guidelines
BWA (version 0.7.17-r1188),computational_tools,PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,BWA (version 0.7.17-r1188),Analysis Software,0.7.17-r1188,,,,,,,,,,,,,,,BWA (version 0.7.17-r1188) was used to align the trimmed sequences to GATKs hg38 genome from their Resource Bundle
Picard tools (version 3.2.0),computational_tools,PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Picard tools (version 3.2.0),Analysis Software,3.2.0,,,,,,,,,,,,,,,Duplicate reads were removed with Picard tools (version 3.2.0) and Base Quality Score Recalibration (BQSR) was then applied
ReAdW v. 3.5.1,computational_tools,PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ReAdW v. 3.5.1,Analysis Software,3.5.1,,,,,,,,,,,,,,,"The XCalibur RAW files were collected in profile mode, centroided and converted to MzXML using ReAdW v. 3.5.1"
MzXML2Search (included in TPP v. 3.5),computational_tools,PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,MzXML2Search (included in TPP v. 3.5),Analysis Software,3.5,,,,,,,,,,,,,,,The mgf files were then created using MzXML2Search (included in TPP v. 3.5) for all scans
Human Protein Atlas (proteinatlas.org),computational_tools,PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Human Protein Atlas (proteinatlas.org),Database,23.0,,,,,,,,,,,,,,,Subcellular localization was assessed for the PPI's using the Human Protein Atlas (proteinatlas.org) Subcellular section (Protein Atlas version 23.0)
HISAT2,computational_tools,PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,HISAT2,Analysis Software,36,,,,,,,,,,,,,,,"The RNA sequencing data were mapped to the Ensembl Sus Scrofa genome 11.1, release 103 using HISAT2"
StringTie,computational_tools,PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,StringTie,Analysis Software,37,,,,,,,,,,,,,,,"mapped to the Ensembl Sus Scrofa genome 11.1, release 103 using HISAT2 and quantified with StringTie"
Partek Flow software (v.9.0),computational_tools,PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Partek Flow software (v.9.0),Analysis Software,v.9.0,,,,,,,,,,,,,,,"The analysis for this Article was generated using Partek Flow software, v.9.0"
STAR (v.2.7.3a),computational_tools,PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,STAR (v.2.7.3a),Analysis Software,v.2.7.3a,,,,,,,,,,,,,,,RNA-seq reads were aligned to the Ensembl release 100 top-level assembly with STAR v.2.7.3a
ImageJ (v.2.0.0),computational_tools,PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ImageJ (v.2.0.0),Analysis Software,v.2.0.0,,,,,,,,,,,,,,,Images were taken using a Zeiss Axio Imager M2 and quantified using ImageJ (v.2.0.0)
Cell Profiler (v.3.1.9),computational_tools,PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Cell Profiler (v.3.1.9),Analysis Software,v.3.1.9,,,,,,,,,,,,,,,Cell proliferation was determined by dividing the number of EdU+ cells by the number of DAPI+ cells using Cell Profiler (v.3.1.9)
Stereo Investigator software (mbfbioscience v2019),computational_tools,PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Stereo Investigator software (mbfbioscience v2019),Analysis Software,v2019,,,,,,,,,,,,,,,Images were taken using a Zeiss Axio Imager M2 and the Stereo Investigator software (mbfbioscience v2019)
Image Lab software (v.6),computational_tools,PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Image Lab software (v.6),Analysis Software,v.6,,,,,,,,,,,,,,,imaged on a Bio-Rad Gel Doc imager using Image Lab software (v.6)
Image Studio Lite (v.5.0.21),computational_tools,PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Image Studio Lite (v.5.0.21),Analysis Software,v.5.0.21,,,,,,,,,,,,,,,and analysed using Image Studio Lite (v.5.0.21)
BWA-MEM v 0.7.12,computational_tools,PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,BWA-MEM v 0.7.12,Command-line Tool,v 0.7.12,,,,,,,,,,,,,,,read pairs were aligned to the hg19 reference genome using BWA-MEM v 0.7.12 with default parameters
GATK v3.6.0,computational_tools,PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GATK v3.6.0,Command-line Tool,v3.6.0,,,,,,,,,,,,,,,"PCR duplicate marking, indel realignment and base quality score recalibration were performed using Picard v1.72 and GATK v3.6.0"
Mutect V1.1.6,computational_tools,PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Mutect V1.1.6,Command-line Tool,V1.1.6,,,,,,,,,,,,,,,We identified somatic mutations using Mutect V1.1.6 and Strelka v1.0.13 for 20 tumors with matched peripheral blood controls
Strelka v1.0.13,computational_tools,PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Strelka v1.0.13,Command-line Tool,v1.0.13,,,,,,,,,,,,,,,We identified somatic mutations using Mutect V1.1.6 and Strelka v1.0.13 for 20 tumors with matched peripheral blood controls
STAR aligner (v.2.6.0),computational_tools,PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,STAR aligner (v.2.6.0),Command-line Tool,v.2.6.0,,,,,,,,,,,,,,,Sequence data was processed and aligned to human reference genome (hg38) using STAR aligner (v.2.6.0)
FusionCatcher v1.1.0,computational_tools,PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,FusionCatcher v1.1.0,Command-line Tool,v1.1.0,,,,,,,,,,,,,,,Fusion genes for cohort of PNSTs were identified using FusionCatcher v1.1.0 with default parameters
Seurat version 3.0,computational_tools,PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Seurat version 3.0,Package/Library,version 3.0,,,,,,,,,,,,,,,"The raw gene expression matrix was normalized, and variance stabilized by SCTransform in Suerat version 3.0"
inferCNV (v.1.1.1),computational_tools,PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,inferCNV (v.1.1.1),Package/Library,v.1.1.1,,,,,,,,,,,,,,,CNAs of neoplastic and non-neoplastic cells were inferred from the snRNA-seq data using inferCNV (v.1.1.1)
Partex Genomics Suite Version 6.6 beta,computational_tools,PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Partex Genomics Suite Version 6.6 beta,Analysis Software,6.6 beta,,,,,,,,,,,,,,,the resulting data analyzed using Partex Genomics Suite Version 6.6 beta
fastp v.0.2,computational_tools,PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,fastp v.0.2,Analysis Software,v.0.2,,,,,,,,,,,,,,,raw reads were quality filtered using fastp v.0.2
BWA v.0.7.17,computational_tools,PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,BWA v.0.7.17,Analysis Software,v.0.7.17,,,,,,,,,,,,,,,Quality-filtered reads were then aligned to the hg19 human genome assembly using BWA v.0.7.17
Samtools v.1.7,computational_tools,PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Samtools v.1.7,Analysis Software,v.1.7,,,,,,,,,,,,,,,Aligned reads were deduplicated with Samtools v.1.7
CRISPOR software,computational_tools,PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,CRISPOR software,Web Application,,http://crispor.tefor.net,,,,,,,,,,,,,,Single-guide RNAs (sgRNAs) were designed using CRISPOR software (http://crispor.tefor.net)
GraphPad Prism version 5.0d,computational_tools,PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GraphPad Prism version 5.0d,Analysis Software,5.0d,,,,,,,,,,,,,,,Analysis was performed using GraphPad Prism version 5.0d (GraphPad Software)
SPSS 18,computational_tools,PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SPSS 18,Analysis Software,18,,,,,,,,,,,,,,,"Statistical analyses were done using SPSS 18 version for Windows (SPSS Inc., Chicago IL, USA)"
SAS 9.3,computational_tools,PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SAS 9.3,Analysis Software,9.3,,,,,,,,,,,,,,,"Statistical analyses were done using SPSS 18 version for Windows (SPSS Inc., Chicago IL, USA) and SAS 9.3 version for Windows (SAS Institute Inc., Cary, NC, USA)"
minfi,computational_tools,PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,minfi,Package/Library,v.1.38.0,,,,,,,,,,,,,,,Methylation data were preprocessed using the combineArrays function within the minfi package (v.1.38.0) in R Bioconductor
Rtsne,computational_tools,PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Rtsne,Package/Library,v.0.15,,,,,,,,,,,,,,,Dimensionality reduction using t-distributed stochastic neighbor embedding (tSNE) was performed by Rtsne (v.0.15)
Limma,computational_tools,PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Limma,Package/Library,v.3.40.6,,,,,,,,,,,,,,,The lmFit function from the Limma package (v.3.40.6) was applied on a log-transformed b value matrix
ComplexHeatmap,computational_tools,PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ComplexHeatmap,Package/Library,v.2.8.0,,,,,,,,,,,,,,,Visualization was performed using the R package ComplexHeatmap (v.2.8.0)
Feature extractionTM software,computational_tools,PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Feature extractionTM software,Analysis Software,9.5.1.1,,,,,,,,,,,,,,,"microarray images were automatically analysed using Feature extractionTM software, version 9.5.1.1 (Agilent Technologies)"
Filtlong v0.2.0,computational_tools,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Filtlong v0.2.0,Command-line Tool,v0.2.0,https://github.com/rrwick/Filtlong,,,,,,,,,,,,,,ONT reads meeting a minimum Q-value of 10 were size- and chimera-filtered with Filtlong v0.2.0
Porechop v0.2.4,computational_tools,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Porechop v0.2.4,Command-line Tool,v0.2.4,https://github.com/rrwick/Porechop,,,,,,,,,,,,,,ONT reads meeting a minimum Q-value of 10 were size- and chimera-filtered with Filtlong v0.2.0 and Porechop v0.2.4
Flye v2.5,computational_tools,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Flye v2.5,Analysis Software,v2.5,,,,,,,,,,,,,,,"Filtered reads were assembled with Flye v2.5, enforcing a 10,000 bp overlap minimum"
GCpp v1.0.0-1807624,computational_tools,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GCpp v1.0.0-1807624,Analysis Software,v1.0.0-1807624,https://github.com/PacificBiosciences/gcpp,,,,,,,,,,,,,,Approximately 20× PacBio subread coverage was used with GCpp v1.0.0-1807624 to independently error-correct the ONT-based Flye assembly
purge_haplotigs,computational_tools,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,purge_haplotigs,Command-line Tool,,https://bitbucket.org/mroachawri/purge_haplotigs/src/master/,,,,,,,,,,,,,,The resulting error-corrected haploid assembly was deduplicated with purge_haplotigs commit be7e44b
Juicer v1.6.2,computational_tools,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Juicer v1.6.2,Analysis Software,v1.6.2,https://github.com/aidenlab/juicer,,,,,,,,,,,,,,"Juicer v1.6.2 and 3D-DNA v180114 were used to scaffold the deduplicated, error-corrected assembly with the Hi-C data"
3D-DNA v180114,computational_tools,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,3D-DNA v180114,Analysis Software,v180114,https://github.com/aidenlab/3d-dna,,,,,,,,,,,,,,"Juicer v1.6.2 and 3D-DNA v180114 were used to scaffold the deduplicated, error-corrected assembly with the Hi-C data"
BUSCO v5.7.0,computational_tools,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,BUSCO v5.7.0,Analysis Software,v5.7.0,https://busco.ezlab.org/,,,,,,,,,,,,,,We assessed the quality of our genome assembly using BUSCO v5.7.0 with mammalia_odb10
QUASTv5.0.2,computational_tools,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,QUASTv5.0.2,Analysis Software,v5.0.2,https://quast.sourceforge.net/,,,,,,,,,,,,,,We assessed the quality of our genome assembly using BUSCO v5.7.0 with mammalia_odb10 and QUASTv5.0.2
Liftoff v1.6.3,computational_tools,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Liftoff v1.6.3,Analysis Software,v1.6.3,https://github.com/agshumate/Liftoff,,,,,,,,,,,,,,Putative genes in the WMSTM draft genome were identified using Liftoff v1.6.3 with default parameters
SnapGeneTM Version 7.2.1,computational_tools,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SnapGeneTM Version 7.2.1,Analysis Software,7.2.1,,,,,,,,,,,,,,,aligned it to the S. scrofa reference coding sequence using the align sequences feature in SnapGeneTM Version 7.2.1
PyMOL Version 3.0.5,computational_tools,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,PyMOL Version 3.0.5,Analysis Software,3.0.5,,,,,,,,,,,,,,,"The structural predictions from WMSTM and human proteins were aligned using PyMOL (The PyMOL Molecular Graphics System, Version 3.0.5 Schrödinger, LLC.)"
Skewer v0.2.2.b,computational_tools,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Skewer v0.2.2.b,Command-line Tool,v0.2.2.b,,,,,,,,,,,,,,,"Adapters, low-quality bases, and primers were trimmed from reads to obtain a Phred score of 20 via the trimming software Skewer (v0.2.2.b)"
Tassel pipeline version 2,computational_tools,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Tassel pipeline version 2,Pipeline,version 2,,,,,,,,,,,,,,,The Tassel pipeline (version 2) was used to process sequence reads to single nucleotide polymorphism (SNP) genotypes
VCFtools v.0.1.16,computational_tools,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,VCFtools v.0.1.16,Command-line Tool,v.0.1.16,,,,,,,,,,,,,,,The population-wide inbreeding coefficient F was calculated with VCFtools (v.0.1.16)
Beagle v4.1,computational_tools,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Beagle v4.1,Analysis Software,v4.1,,,,,,,,,,,,,,,Beagle v4.1 was used to perform whole genome phasing and to impute missing data
itol v6.9.1,computational_tools,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,itol v6.9.1,Web Application,v6.9.1,https://itol.embl.de/,,,,,,,,,,,,,,A mid-point rooted topology was created from the VCF data using RAxML and visualized with itol v6.9.1
GENIE (Genomics Evidence Neoplasia Information Exchange),computational_tools,PMID:33507258,10.1001/jamanetworkopen.2020.35479,Assessment of RAS Dependency for BRAF Alterations Using Cancer Genomic Databases.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GENIE (Genomics Evidence Neoplasia Information Exchange),Database,v.7.0,,,,,,,,,,,,,,,cancer genomics databases including GENIE (Genomics Evidence Neoplasia Information Exchange)
Integrative Genomics Viewer,computational_tools,PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Integrative Genomics Viewer,Analysis Software,2.3.40,,,,,,,,,,,,,,,"Variants were also viewed manually on Integrative Genomics Viewer (IGV—version 2.3.40; Broad Institute, Cambridge, MA, USA)"
Alamut Visual,computational_tools,PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Alamut Visual,Analysis Software,2.6.1e,,,,,,,,,,,,,,,"on Alamut ® Visual (version 2.6.1e; Interactive Biosoftware, Rouen, France) to eliminate strand bias and reduce false positive calls"
FlowJo 7.6.5,computational_tools,PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,FlowJo 7.6.5,Analysis Software,7.6.5,,,,,,,,,,,,,,,"...analyzed with FACSDiva (BD Biosciences) or FlowJo 7.6.5 ( FlowJo.com ; Tree Star, OR, USA) software..."
"ImageJ software v.1.49 (NIH, USA)",computational_tools,PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,"ImageJ software v.1.49 (NIH, USA)",Analysis Software,v.1.49,,,,,,,,,,,,,,,"...Images were analyzed using ImageJ software v.1.49 (NIH, USA), and the percentage of stained area in each picture was obtained..."
Partek Flow software,computational_tools,PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Partek Flow software,Analysis Software,v10.0,,,,,,,,,,,,,,,"RNA sequencing analysis was generated using Partek Flow software, v10.0"
Imaris software,computational_tools,PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Imaris software,Analysis Software,9,,,,,,,,,,,,,,,"Images were 3D-rendered using Imaris software (Imaris 9, Oxford Instruments, Abingdon, UK)"
ChAMP,computational_tools,PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ChAMP,Package/Library,v2.18.3,,,,,,,,,,,,,,,Data were analyzed using a modified workflow that is similar to the ChAMP methylation array analysis procedure in R (v3.5.1)
STAR,computational_tools,PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,STAR,Analysis Software,v2.7.0f,,,,,,,,,,,,,,,"Sequencing lanes were merged, followed by alignment with STAR (v2.7.0f) to b37"
MACS version 1.4.2,computational_tools,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,MACS version 1.4.2,Analysis Software,1.4.2,,,,,,,,,,,,,,,peak calling was performed using Model-based analysis of ChIP-seq (MACS) version 1.4.2 ( http://liulab.dfci.harvard.edu/MACS ) with default parameters
3D Slicer,computational_tools,PMID:40437318,10.1186/s41747-025-00594-x,Quantitative MRI of dorsal root ganglion alterations in neurofibromatosis type 1 patients with or without pain.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,3D Slicer,Analysis Software,5.6.2,https://www.slicer.org/,,,,,,,,,,,,,,"The two readers independently performed three-dimensional selection of the volume of interest by manual segmentation of the DRG of levels L5 and S1 via 3D Slicer (The Slicer Community 2024: 3D Slicer, version 5.6.2)"
SimNIBS 3.2,computational_tools,PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SimNIBS 3.2,Analysis Software,3.2,https://simnibs.github.io/simnibs/build/html/index.html,,,,,,,,,,,,,,SimNIBS 3.2 ( https://simnibs.github.io/simnibs/build/html/index.html ) was used to estimate the electric field induced by tDCS
SPM8,computational_tools,PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SPM8,Analysis Software,8,http://www.fil.ion.ucl.ac.uk/spm/,,,,,,,,,,,,,,"the T1-weighted anatomical images were segmented into gray matter (GM), white matter (WM) and cerebrospinal fluid (CSF) using SPM8"
jMRUI5.1,computational_tools,PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,jMRUI5.1,Analysis Software,5.1,,,,,,,,,,,,,,,"Quantification was conducted using the Advanced Magnetic Resonance (AMARES) routine in the Java-based magnetic resonance user's interface (jMRUI5.1, EU project)"
SPM12,computational_tools,PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SPM12,Analysis Software,12,http://www.fil.ion.ucl.ac.uk/spm,,,,,,,,,,,,,,"Image processing and statistical analysis was carried out using SPM12 (Wellcome Department of Imaging Neuroscience, London)"
IGOR Pro 6.37,computational_tools,PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,IGOR Pro 6.37,Analysis Software,6.37,,,,,,,,,,,,,,,"IGOR Pro 6.37 (Lake Oswego, USA) was used for data analysis"
Prism 7,computational_tools,PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Prism 7,Analysis Software,7,,,,,,,,,,,,,,,"one-way ANOVA tests with Bonferroni post hoc tests were employed using Prism 7 (GraphPad Software, San Diego, CA, USA)"
SeqMule,computational_tools,PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SeqMule,Pipeline,,http://seqmule.usc.edu/,,,,,,,,,,,,,,We used SeqMule (http://seqmule.usc.edu/) pipeline as our primary variant calling pipeline.
primer 3 (v. 0.4.0),computational_tools,PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,primer 3 (v. 0.4.0),Web Application,v. 0.4.0,http://bioinfo.ut.ee/primer3-0.4.0/,,,,,,,,,,,,,,Twelve pairs of primers were designed using primer 3 (v. 0.4.0) (http://bioinfo.ut.ee/primer3-0.4.0/).
Mutalyzer 2.0,computational_tools,PMID:22384355,10.1534/g3.111.000687,The SPRED1 Variants Repository for Legius Syndrome.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Mutalyzer 2.0,Web Application,2.0,,,,,,,,,,,,,,,...the online batch position check tool Mutalyzer 2.0 (http://www.mutalyzer.nl/) was used to confirm genomic position of all SPRED1 gene variants...
FusionCharts v3,computational_tools,PMID:22384355,10.1534/g3.111.000687,The SPRED1 Variants Repository for Legius Syndrome.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,FusionCharts v3,Analysis Software,v3,,,,,,,,,,,,,,,...Graphics were generated using FusionCharts v3 (www.fusioncharts.com)...
DESeq2 (version 1.12.4),computational_tools,PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,DESeq2 (version 1.12.4),Package/Library,1.12.4,,,,,,,,,,,,,,,DESeq2 (version 1.12.4) was used to determine differentially expressed genes (DEGs) between two samples
Volocity software (Version 7.0.0),computational_tools,PMID:40862755,10.3390/cells14161276,Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Volocity software (Version 7.0.0),Analysis Software,7.0.0,,,,,,,,,,,,,,,"Image stacks were processed and reconstructed in 3D using Volocity software (Version 7.0.0; PerkinElmer, Waltham, MA, USA) for visualization and quantification"
CalcuSyn Version 2.1,computational_tools,PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,CalcuSyn Version 2.1,Analysis Software,2.1,,,,,,,,,,,,,,,"All data analysis was done using Calcusyn software (CalcuSyn Version 2.1, BioSoft)"
GeneSpring GX v7.3.1,computational_tools,PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GeneSpring GX v7.3.1,Analysis Software,v7.3.1,,,,,,,,,,,,,,,Statistical comparisons were done using R/Bioconductor packages and GeneSpring GX v7.3.1 (Agilent Technologies)
Cell Ranger pipeline v7.1.0,computational_tools,PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Cell Ranger pipeline v7.1.0,Pipeline,v7.1.0,,,,,,,,,,,,,,,resulting sequencing files were run through the Cell Ranger pipeline v7.1.0
Seurat v4.3.0–v5,computational_tools,PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Seurat v4.3.0–v5,Package/Library,v4.3.0–v5,,,,,,,,,,,,,,,"Data analysis was completed using R (v 4.3.0–v 4.3.1) Seurat [ 24 ,  25 ] (v4.3.0–v5)"
Illumina CASAVA software (v1.8),computational_tools,PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Illumina CASAVA software (v1.8),Analysis Software,v1.8,,,,,,,,,,,,,,,"primary processing of sequence data for both tumor and normal samples were performed using Illumina CASAVA software (v1.8), including masking of adapter sequences."
RealSeqS,computational_tools,PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,RealSeqS,Analysis Software,,https://zenodo.org/record/3656943#.YaZZCdDMKUk.32,,,,,,,,,,,,,,"RealSeqS uses a single primer pair to amplify about 750,000 loci scattered throughout the genome"
FlexImaging 4.0,computational_tools,PMID:26883872,10.1016/j.jprot.2016.02.004,3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,FlexImaging 4.0,Analysis Software,4.0,,,,,,,,,,,,,,,The 2-D IMS data sets were collected using FlexImaging 4.0 (Bruker Daltonics)
DAVID,computational_tools,PMID:32733557,10.1155/2020/5976465,"Gene Expression, Network Analysis, and Drug Discovery of Neurofibromatosis Type 2-Associated Vestibular Schwannomas Based on Bioinformatics Analysis.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,DAVID,Web Application,6.8,,,,,,,,,,,,,,,"The Database for Annotation, Visualization, and Integrated Discovery (DAVID) (Version 6.8, https://david.ncifcrf.gov/) was used to perform GO and KEGG pathway enrichment analysis"
Cytoscape,computational_tools,PMID:32733557,10.1155/2020/5976465,"Gene Expression, Network Analysis, and Drug Discovery of Neurofibromatosis Type 2-Associated Vestibular Schwannomas Based on Bioinformatics Analysis.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Cytoscape,Analysis Software,3.7.0,,,,,,,,,,,,,,,visualized the interaction using Cytoscape software (Version 3.7.0.)
Volocity software 7.0.0,computational_tools,PMID:39061138,10.3390/cancers16142498,A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Volocity software 7.0.0,Analysis Software,7.0.0,,,,,,,,,,,,,,,"Images were reconstructed in 3D using Volocity software 7.0.0 (PerkinElmer, Waltham, MA, USA)"
Nanoparticle Tracking Analysis software version 3.3 Dev Build 3.3.104,computational_tools,PMID:39061138,10.3390/cancers16142498,A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Nanoparticle Tracking Analysis software version 3.3 Dev Build 3.3.104,Analysis Software,3.3 Dev Build 3.3.104,,,,,,,,,,,,,,,"sEV depletion was determined by version 3.3 Dev Build 3.3.104 Nanoparticle Tracking Analysis software (Malvern Panalytical Ltd., Malvern, UK)"
Li-COR Image Studio Lite 5.0,computational_tools,PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Li-COR Image Studio Lite 5.0,Analysis Software,5.0,,,,,,,,,,,,,,,Densitometry was performed using Li-COR Image Studio Lite 5.0
BioNavigator software V.6.3,computational_tools,PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,BioNavigator software V.6.3,Analysis Software,V.6.3,,,,,,,,,,,,,,,software-based image analysis (BioNavigator software V.6.3 from PamGene)
CLC Genomics Workbench v6,computational_tools,PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,CLC Genomics Workbench v6,Analysis Software,v6,,,,,,,,,,,,,,,CLC Genomics Workbench v6 (Qiagen) was used to analyze data from I2HCP V1
Seurat V3.0,computational_tools,PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Seurat V3.0,Package/Library,V3.0,,,,,,,,,,,,,,,Data were analyzed by the Seurat V3.0 package in the R programming environment
STAR 2.4.2.8,computational_tools,PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,STAR 2.4.2.8,Analysis Software,2.4.2.8,,,,,,,,,,,,,,,The raw transcript counts were aligned to Refseq related to the build GRCh38-mm10 using STAR 2.4.2.8
AMBER16,computational_tools,PMID:33369425,10.1021/acs.jpcb.0c09742,Machine Learning of Allosteric Effects: The Analysis of Ligand-Induced Dynamics to Predict Functional Effects in TRAP1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,AMBER16,Analysis Software,16,,,,,,,,,,,,,,,Equilibration and production steps were performed using the AMBER16 MD engine
VMD (version 1.9.3),computational_tools,PMID:33369425,10.1021/acs.jpcb.0c09742,Machine Learning of Allosteric Effects: The Analysis of Ligand-Induced Dynamics to Predict Functional Effects in TRAP1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,VMD (version 1.9.3),Analysis Software,1.9.3,,,,,,,,,,,,,,,Descriptors were generated with in-house scripts using VMD (version 1.9.3) to calculate solvent accessible surface area
gromacs (version 4.6),computational_tools,PMID:33369425,10.1021/acs.jpcb.0c09742,Machine Learning of Allosteric Effects: The Analysis of Ligand-Induced Dynamics to Predict Functional Effects in TRAP1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,gromacs (version 4.6),Analysis Software,4.6,,,,,,,,,,,,,,,g_mindist tool of gromacs (version 4.6) to get residue–residue contacts
PredictSNP2,computational_tools,PMID:39373898,10.1007/s12031-024-02271-x,Identification of Pathogenic Missense Mutations of NF1 Using Computational Approaches.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,PredictSNP2,Web Application,,https://loschmidt.chemi.muni.cz/predictsnp/,,,,,,,,,,,,,,The effects of mutations on protein functions were analyzed using the PredictSNP2 tool (https://loschmidt.chemi.muni.cz/predictsnp/)
Align GVGD,computational_tools,PMID:39373898,10.1007/s12031-024-02271-x,Identification of Pathogenic Missense Mutations of NF1 Using Computational Approaches.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Align GVGD,Web Application,,http://agvgd.hci.utah.edu/agvgd_input.php,,,,,,,,,,,,,,Align-GVGD (http://agvgd.hci.utah.edu/agvgd_input.php) is another tool that applies the Grantham difference
CHOPCHOP,computational_tools,PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,CHOPCHOP,Web Application,,https://chopchop.cbu.uib.no/,,,,,,,,,,,,,,CHOPCHOP (https://chopchop.cbu.uib.no/) was used to identify the sgRNA sequence
Ethovision 11,computational_tools,PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Ethovision 11,Analysis Software,11,,,,,,,,,,,,,,,"Locomotor activity was analyzed using Ethovision 11 software (Noldus Information Technology, Wageningen, The Netherlands)"
Vevo software version 5.0.0,computational_tools,PMID:25340526,10.1371/journal.pone.0107760,Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Vevo software version 5.0.0,Analysis Software,5.0.0,,,,,,,,,,,,,,,Three-dimensional images of the xenografts were generated and analyzed using the Vevo software version 5.0.0 to calculate their size in volume
DESeq2 version 1.18.1,computational_tools,PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,DESeq2 version 1.18.1,Package/Library,1.18.1,,,,,,,,,,,,,,,The differential expression and fold change calculations on the RNA-Seq datasets were performed using the R package DESeq2 version 1.18.1
R v3.6.3,computational_tools,PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,R v3.6.3,Analysis Software,v3.6.3,,,,,,,,,,,,,,,"A Shapiro-Wilk test (base R v3.6.3, shapiro.test function) was used to test the normality"
WebGestalt webserver,computational_tools,PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,WebGestalt webserver,Web Application,,http://bioinfo.vanderbilt.edu/webgestalt/,,,,,,,,,,,,,,Gene set enrichment analysis was performed using the WebGestalt webserver (http://bioinfo.vanderbilt.edu/webgestalt/)
ichorCNA,computational_tools,PMID:39093127,10.1158/1078-0432.CCR-24-0797,Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ichorCNA,Analysis Software,v.0.2.0,,,,,,,,,,,,,,,copy-number–based estimation of tumor fraction were then performed using the ichorCNA tool (Broad v.0.2.0)
10x Genomics Cell Ranger 7.0.1,computational_tools,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,10x Genomics Cell Ranger 7.0.1,Analysis Software,7.0.1,,,,,,,,,,,,,,,BCL files were processed using 10x Genomics Cell Ranger 7.0.1
Seurat V3 package,computational_tools,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Seurat V3 package,Package/Library,V3,,,,,,,,,,,,,,,Each data set was analyzed individually from its raw count matrix using the Seurat V3 package [29]
Analyze 12.0,computational_tools,PMID:33082502,10.1038/s41598-020-74920-1,Image segmentation of plexiform neurofibromas from a deep neural network using multiple b-value diffusion data.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Analyze 12.0,Analysis Software,12.0,,,,,,,,,,,,,,,"Using the multispectral neural network (MSNN) modeling tool available in Analyze 12.0 (AnalyzeDirect, Overland Park, KS)"
MIM Encore 6.9.3,computational_tools,PMID:33082502,10.1038/s41598-020-74920-1,Image segmentation of plexiform neurofibromas from a deep neural network using multiple b-value diffusion data.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,MIM Encore 6.9.3,Analysis Software,6.9.3,,,,,,,,,,,,,,,"Measurements were made on a commercially available image analysis software (MIM Encore 6.9.3, MIM Software INC, Cleveland, OH)"
Genome Analysis Toolkit (GATK),computational_tools,PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Genome Analysis Toolkit (GATK),Analysis Software,,https://gatk.broadinstitute.org,,,,,,,,,,,,,,Variant calling of the germline samples was performed using The Genome Analysis Toolkit (https://gatk.broadinstitute.org)
MuTect,computational_tools,PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,MuTect,Analysis Software,,https://github.com/broadinstitute/mutect,,,,,,,,,,,,,,somatic variant calling was performed using either MuTect (https://github.com/broadinstitute/mutect)
Origin® 8,computational_tools,PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Origin® 8,Analysis Software,8,,,,,,,,,,,,,,,"Statistical significance was determined using Origin® 8 (OriginLab, Northampton, MA)"
FMRIB software library (FSL),computational_tools,PMID:28725547,10.1016/j.nicl.2017.06.032,Spatial working memory in neurofibromatosis 1: Altered neural activity and functional connectivity.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,FMRIB software library (FSL),Analysis Software,5.0,,,,,,,,,,,,,,,"FMRI data analyses were performed using the FMRIB software library (www.fmrib.ox.ac.uk/fsl), version 5.0"
MATLAB (2019a),computational_tools,PMID:37608248,10.1186/s11689-023-09492-y,Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memory.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,MATLAB (2019a),Analysis Software,2019a,,,,,,,,,,,,,,,MATLAB (2019a) and SPM12 (version 7771) were used to conduct data analyses
SPM12 (version 7771),computational_tools,PMID:37608248,10.1186/s11689-023-09492-y,Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memory.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SPM12 (version 7771),Analysis Software,7771,,,,,,,,,,,,,,,MATLAB (2019a) and SPM12 (version 7771) were used to conduct data analyses
EEGLAB (version 13.6.5b),computational_tools,PMID:37608248,10.1186/s11689-023-09492-y,Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memory.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,EEGLAB (version 13.6.5b),Package/Library,13.6.5b,,,,,,,,,,,,,,,Custom functions calling several functions from EEGLAB (version 13.6.5b) and FieldTrip (embedded in SPM release) were used
Cell Ranger 5.0.1,computational_tools,PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Cell Ranger 5.0.1,Analysis Software,5.0.1,,,,,,,,,,,,,,,"Cell Ranger 5.0.1 (10x Genomics, https://www.10xgenomics.com/) was used to process the raw sequencing data."
Seurat R package,computational_tools,PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Seurat R package,Package/Library,v4.0.2,,,,,,,,,,,,,,,The gene expression matrix from Cell Ranger was used as input to the Seurat R package (v4.0.2) for downstream analysis (53).
Proteome Discoverer 2.4,computational_tools,PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Proteome Discoverer 2.4,Analysis Software,2.4,,,,,,,,,,,,,,,Data were acquired by the facility core and analyzed using Proteome Discoverer 2.4 (Thermo Fisher Scientific)...
Salmon v1.8.0,computational_tools,PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Salmon v1.8.0,Analysis Software,v1.8.0,,,,,,,,,,,,,,,RNA-Seq data from real and in silico mixed samples was aligned with Salmon v1.8.0
nSolver Advanced Analysis Software version 4.0,computational_tools,PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,nSolver Advanced Analysis Software version 4.0,Analysis Software,4.0,,,,,,,,,,,,,,,"Quality control, normalization, differential expression and pathway analysis were performed using nSolver Advanced Analysis Software (version 4.0)"
Omics Playground v2.7.18,computational_tools,PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Omics Playground v2.7.18,Analysis Software,v2.7.18,,,,,,,,,,,,,,,Raw count matrices with sample metadata deposited on GEO were reanalyzed using the Omics Playground v2.7.18 Platform
IDEP.92,computational_tools,PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,IDEP.92,Web Application,0.92,,,,,,,,,,,,,,,"Principal Component Analysis (PCA) was conducted in IDEP.92 using log2 transformed, normalized counts as input"
HALO Image Analysis software version 2.0.5,computational_tools,PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,HALO Image Analysis software version 2.0.5,Analysis Software,2.0.5,,,,,,,,,,,,,,,Quantitative immunohistochemical analysis for BIRC5 and CENPF was conducted using the Cytonuclear IHC module of HALO Image Analysis software (version 2.0.5)
FastQC,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,FastQC,Analysis Software,0.11.5,,,,,,,,,,,,,,,The quality assessment of the raw reads was carried out using the FastQC tool (version 0.11.5)
AutoAnnotate,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,AutoAnnotate,Plugin,1.2,,,,,,,,,,,,,,,Highly related pathways were grouped into a theme and labeled by AutoAnnotate (version 1.2) in Cytoscape
Enrichment Map,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Enrichment Map,Plugin,3.1,,,,,,,,,,,,,,,GSEA results were visualized using the Enrichment Map app (Version 3.1) in Cytoscape
GnomAD,computational_tools,PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GnomAD,Database,v.2.1.1,,,,,,,,,,,,,,,the GnomAD v.2.1.1 (https://gnomad.broadinstitute.org) and 1000 genomes databases were used
1000 Genomes,computational_tools,PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,1000 Genomes,Database,2015 aug,,,,,,,,,,,,,,,"1000 genomes (https://www.internationalgenome.org, release 2015 aug) databases were used"
Salmon v1.4,computational_tools,PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Salmon v1.4,Analysis Software,v1.4,,,,,,,,,,,,,,,Raw FASTQ files were analyzed using the Salmon v1.4 alignment tool
BWA-MEM2 v2.1,computational_tools,PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,BWA-MEM2 v2.1,Analysis Software,v2.1,,,,,,,,,,,,,,,Reads were aligned to hg38 using BWA-MEM2 v2.1
GATK v4.1.9.0,computational_tools,PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GATK v4.1.9.0,Analysis Software,v4.1.9.0,,,,,,,,,,,,,,,Base quality score recalibration (BQSR) was performed with GATK v4.1.9.0 BaseRecalibrator
metilene v0.2-8,computational_tools,PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,metilene v0.2-8,Analysis Software,v0.2-8,,,,,,,,,,,,,,,Differentially methylated regions were detected using metilene v0.2-8
DELLY v1.1.3,computational_tools,PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,DELLY v1.1.3,Analysis Software,v1.1.3,,,,,,,,,,,,,,,Structural variants and copy number variation were called using DELLY v1.1.3
InterVar,computational_tools,PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,InterVar,Analysis Software,update-2021-08-version,,,,,,,,,,,,,,,Germline variants are annotated using InterVar (update-2021-08-version)
cNFOrganoidAnalysis,computational_tools,PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,Development,True,1.00,High,,,,,,,,,,,,,,,cNFOrganoidAnalysis,Analysis Software,,https://github.com/PNNL-CompBio/cNFOrganoidAnalysis,,,,,,,,,,,,,,All computational tools used to generate Figures 4 and 5 for this manuscript are available on https://github.com/PNNL-CompBio/cNFOrganoidAnalysis
Matlab 7.12.0,computational_tools,PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Matlab 7.12.0,Analysis Software,7.12.0,,,,,,,,,,,,,,,"implemented within Matlab 7.12.0 (MathWorks, Natick, MA, USA)"
MultiPLIER,computational_tools,PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,MultiPLIER,Analysis Software,,https://github.com/greenelab/multi-plier,,,,,,,,,,,,,,"We analyzed transcriptomic data from NF in the context of latent variables from MultiPLIER, a machine learning resource designed to aid in rare disease analyses [27]."
R 4.0.3,computational_tools,PMID:38115252,10.1097/MD.0000000000036696,Identification of hub genes and drug candidates for NF2-related vestibular schwannoma by bioinformatics tools.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,R 4.0.3,Analysis Software,4.0.3,,,,,,,,,,,,,,,Data standardization was performed using the R 4.0.3
GraphPad Prism software v7,computational_tools,PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GraphPad Prism software v7,Analysis Software,v7,,,,,,,,,,,,,,,Statistical analysis was carried out using GraphPad Prism software v7
CRISPRscan,computational_tools,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,CRISPRscan,Web Application,,https://www.crisprscan.org/,,,,,,,,,,,,,,CRISPRscan (https://www.crisprscan.org/) was used to identify gRNA target sequences in exon 1 of the tgfb3 gene
"STIM 2 (Neuroscan, Charlotte, NC, USA)",computational_tools,PMID:24559228,10.1186/1866-1955-6-4,Abnormal late visual responses and alpha oscillations in neurofibromatosis type 1: a link to visual and attention deficits.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,"STIM 2 (Neuroscan, Charlotte, NC, USA)",Analysis Software,2,,,,,,,,,,,,,,,"presented with the stimulation software STIM 2 (Neuroscan, Charlotte, NC, USA) with a display resolution of 1,280 × 1,024 × 32"
Scan 4.5 (Neuroscan),computational_tools,PMID:24559228,10.1186/1866-1955-6-4,Abnormal late visual responses and alpha oscillations in neurofibromatosis type 1: a link to visual and attention deficits.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Scan 4.5 (Neuroscan),Analysis Software,4.5,,,,,,,,,,,,,,,Data analysis was performed with Scan 4.5 (Neuroscan). We started the analysis by correcting the eye blinking artifacts
Alamut Visual version 2.15,computational_tools,PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Alamut Visual version 2.15,Analysis Software,2.15,,,,,,,,,,,,,,,Variants were imported into the clinical prediction software Alamut Visual version 2.15 (SOPHiA GENETICS)
gnomAD v2.1.1,computational_tools,PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,gnomAD v2.1.1,Database,v2.1.1,gnomad.broadinstitute.org,,,,,,,,,,,,,,Variant frequencies and ExAC constraint metrics were obtained from gnomAD v2.1.1 ( gnomad.broadinstitute.org )
Illumina bcl2fastq v1.8.4 software,computational_tools,PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Illumina bcl2fastq v1.8.4 software,Analysis Software,v1.8.4,,,,,,,,,,,,,,,FASTQ files were generated from Binary Cluster Files (.bcl) using the Illumina bcl2fastq v1.8.4 software with parameters set as per vendor's specifications
Burrows-Wheeler Aligner v0.7.10,computational_tools,PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Burrows-Wheeler Aligner v0.7.10,Analysis Software,v0.7.10,,,,,,,,,,,,,,,FASTQ files were aligned to the human genome reference hg19 (GRCh37) using the Burrows-Wheeler Aligner v0.7.10 algorithm with default settings
Picard Tools v1.119,computational_tools,PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Picard Tools v1.119,Analysis Software,v1.119,,,,,,,,,,,,,,,BAM files (.bam) were generated using Picard Tools v1.119
MDLVC v5.0,computational_tools,PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,MDLVC v5.0,Analysis Software,v5.0,,,,,,,,,,,,,,,variant calling was performed using in-house variant caller algorithm (MDLVC v5.0)
HaplotypeCaller (Genome Analysis Tool Kit 3.3),computational_tools,PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,HaplotypeCaller (Genome Analysis Tool Kit 3.3),Analysis Software,3.3,,,,,,,,,,,,,,,cross referenced with HaplotypeCaller (Genome Analysis Tool Kit 3.3) under discovery mode
Integrated Genomics Viewer v2.3.4 (IGV),computational_tools,PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Integrated Genomics Viewer v2.3.4 (IGV),Analysis Software,v2.3.4,,,,,,,,,,,,,,,"All variant calls were inspected using Integrated Genomics Viewer v2.3.4 (IGV; Broad Institute, MIT Harvard, Cambridge, MA)"
melodic v3.15,computational_tools,PMID:35087195,10.1038/s41380-021-01422-5,Altered canonical and striatal-frontal resting state functional connectivity in children with pathogenic variants in the Ras/mitogen-activated protein kinase pathway.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,melodic v3.15,Analysis Software,v3.15,,,,,,,,,,,,,,,we ran group-based ICA using melodic v3.15
Trimmomatic v 0.39,computational_tools,PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Trimmomatic v 0.39,Analysis Software,v 0.39,,,,,,,,,,,,,,,WES sequencing FASTQ files were trimmed using Trimmomatic v 0.39
GATK V4.2,computational_tools,PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GATK V4.2,Analysis Software,V4.2,,,,,,,,,,,,,,,GATK V4.2 base quality score recalibration (BQSR) was used to process BAM files
maftools v2.10.0,computational_tools,PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,maftools v2.10.0,Package/Library,v2.10.0,,,,,,,,,,,,,,,Somatic variant plots were created with maftools v2.10.0
CNVkit V2.0,computational_tools,PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,CNVkit V2.0,Analysis Software,V2.0,,,,,,,,,,,,,,,CNVkit V2.0 was used to infer and visualize copy number
Slingshot,computational_tools,PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Slingshot,Package/Library,2.12.0,,,,,,,,,,,,,,,"To explore differentiation trajectories among tumor clusters, we applied Slingshot (Version: 2.12.0)"
CellChatDB,computational_tools,PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,CellChatDB,Database,1.5.0,,,,,,,,,,,,,,,CellChatDB (version 1.5.0) was used to infer ligand–receptor interactions between and within individual subpopulations
Space Ranger,computational_tools,PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Space Ranger,Analysis Software,v1.2.1,,,,,,,,,,,,,,,"Sequencing data were processed with Space Ranger (10 × genomics, v1.2.1)"
DAVID,computational_tools,PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,DAVID,Web Application,6.8,,,,,,,,,,,,,,,"ontological analysis using DAVID (Database for Annotation, Visualization, and Integrated Discovery: https://david.ncifcrf.gov ; version 6.8)"
R Studio PKNCA package (version 0.9.3),computational_tools,PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,R Studio PKNCA package (version 0.9.3),Package/Library,0.9.3,,,,,,,,,,,,,,,Selumetinib plasma concentration–time data were analyzed using noncompartmental methods implemented in R (version 3.6) R Studio PKNCA package (version 0.9.3)
STAR mapper (Version 2.4.1d),computational_tools,PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,STAR mapper (Version 2.4.1d),Analysis Software,2.4.1d,,,,,,,,,,,,,,,RNAseq reads were mapped with the STAR mapper (Version 2.4.1d)
Alamut v2.15 (Interactive Biosoftware),computational_tools,PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Alamut v2.15 (Interactive Biosoftware),Analysis Software,v2.15,,,,,,,,,,,,,,,Alamut v2.15 (Interactive Biosoftware) was used to identify true splice-donor and acceptor sites
COSMIC Database,computational_tools,PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,COSMIC Database,Database,,www.sanger.ac.uk/genetics/CGP/cosmic,,,,,,,,,,,,,,"The Catalogue of Somatic Mutations in Cancer Database (COSMIC, www.sanger.ac.uk/genetics/CGP/cosmic, Wellcome Trust Sanger Institute, United Kingdom) was used to search for references"
nf-core/rnaseq (v3.11.2),computational_tools,PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,nf-core/rnaseq (v3.11.2),Pipeline,v3.11.2,,,,,,,,,,,,,,,Raw fastq files were processed using nf-core/rnaseq (v3.11.2)
salmon (v1.10.1),computational_tools,PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,salmon (v1.10.1),Analysis Software,v1.10.1,,,,,,,,,,,,,,,quantified using salmon: v1.10.1
sva R package (v3.42.0),computational_tools,PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,sva R package (v3.42.0),Package/Library,v3.42.0,,,,,,,,,,,,,,,ComBat from sva R package (v3.42.0) was used for batch correction
immunedeconv (v2.1.0),computational_tools,PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,immunedeconv (v2.1.0),Package/Library,v2.1.0,,,,,,,,,,,,,,,The batch corrected data was then analyzed using the immunedeconv (v2.1.0) package
ggplot2 (v3.4.4),computational_tools,PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ggplot2 (v3.4.4),Package/Library,v3.4.4,,,,,,,,,,,,,,,The analysis results were visualized using ggplot2 (v3.4.4) and ggridges (v0.5.5) libraries
ggridges (v0.5.5),computational_tools,PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ggridges (v0.5.5),Package/Library,v0.5.5,,,,,,,,,,,,,,,The analysis results were visualized using ggplot2 (v3.4.4) and ggridges (v0.5.5) libraries
FreeSurfer,computational_tools,PMID:38621478,10.1016/j.bpsc.2024.04.003,Influences of RASopathies on Neuroanatomical Variation in Children.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,FreeSurfer,Analysis Software,"5.3, 7.2.0",,,,,,,,,,,,,,,the data were processed using Freesurfer (https://surfer.nmr.mgh.harvard.edu version 5.3)...processed using Freesurfer (version 7.2.0)
CLC Genomics Workbench 22,computational_tools,PMID:41001593,10.1080/23723556.2025.2561292,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,CLC Genomics Workbench 22,Analysis Software,22,,,,,,,,,,,,,,,"Resulting FASTQ files were analyzed with CLC Genomics Workbench 22 (QIAGEN, Hilden, Germany)"
pCLAMP 9.2,computational_tools,PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,pCLAMP 9.2,Analysis Software,9.2,,,,,,,,,,,,,,,A MultiClamp 700B patch-clamp amplifier and pCLAMP 9.2 software (MDS Analytical Technologies) were used to acquire data
Volocity 4.2,computational_tools,PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Volocity 4.2,Analysis Software,4.2,,,,,,,,,,,,,,,The number of swellings per calyx was counted on 3D-rendered (Volocity 4.2; Improvision) images of calyces
ImageJ 1.46,computational_tools,PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ImageJ 1.46,Analysis Software,1.46,,,,,,,,,,,,,,,images of calyx terminals were binary thresholded using the built-in thresholding function of ImageJ 1.46 (isodata algorithm)
Disambiguate v1.0,computational_tools,PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Disambiguate v1.0,Analysis Software,v1.0,,,,,,,,,,,,,,,"For PDX sequence data, Disambiguate v1.0 was used to filter out mouse-derived reads"
Variant Effect Predictor (VEP),computational_tools,PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Variant Effect Predictor (VEP),Analysis Software,version 95,,,,,,,,,,,,,,,includes best-practices variant filtering and annotation with Variant Effect Predictor (VEP; version 95)
Cell Ranger,computational_tools,PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Cell Ranger,Pipeline,version 3.1.0,,,,,,,,,,,,,,,The standard 10X Genomics Cell Ranger (version 3.1.0) pipeline was used to extract FASTQ files
Seurat,computational_tools,PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Seurat,Package/Library,version 3.0,,,,,,,,,,,,,,,filtered_feature_bc_matrix was imported using the Read10X function in Seurat (version 3.0)
inferCNV,computational_tools,PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,inferCNV,Package/Library,,https://github.com/broadinstitute/infercnv,,,,,,,,,,,,,,Copy number variations of each PDX were inferred from scRNA-seq using the R package inferCNV
UPhyloplot2,computational_tools,PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,UPhyloplot2,Analysis Software,,https://github.com/harbourlab/UPhyloplot2,,,,,,,,,,,,,,The Uphyloplot2 (https://github.com/harbourlab/UPhyloplot2) was used to visualize the clonality
HISAT2 version 2.2.1,computational_tools,PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,HISAT2 version 2.2.1,Analysis Software,2.2.1,,,,,,,,,,,,,,,"To align the reads, we employed HISAT2 version 2.2.1 against the GRCh38 human genome"
StringTie version 2.2.1,computational_tools,PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,StringTie version 2.2.1,Analysis Software,2.2.1,,,,,,,,,,,,,,,Read counts were normalized by StringTie version 2.2.1
DEGseq version 1.48.0,computational_tools,PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,DEGseq version 1.48.0,Package/Library,1.48.0,,,,,,,,,,,,,,,Differential expression analysis was analyzed by DEGseq version 1.48.0
ClusterProfiler version 4.2.2,computational_tools,PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ClusterProfiler version 4.2.2,Package/Library,4.2.2,,,,,,,,,,,,,,,the GSEA KEGG method with ClusterProfiler version 4.2.2 was applied
STRING version 11.5,computational_tools,PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,STRING version 11.5,Web Application,11.5,https://string-db.org/,,,,,,,,,,,,,,protein–protein interaction analysis using STRING version 11.5
FlowJo™ software v10.8,computational_tools,PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,FlowJo™ software v10.8,Analysis Software,10.8,,,,,,,,,,,,,,,The data were analyzed by v10.8 of FlowJo™ software
GraphPad Prism version 9,computational_tools,PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GraphPad Prism version 9,Analysis Software,9,,,,,,,,,,,,,,,The analysis was performed using GraphPad Prism version 9
CNVKit version 0.9.11,computational_tools,PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,CNVKit version 0.9.11,Analysis Software,0.9.11,,,,,,,,,,,,,,,"Finally, to determine the profiles of the alterations in the number of copies, the CNV calling was also performed using the CNVKit version 0.9.11."
GEPIA,computational_tools,PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GEPIA,Web Application,,http://gepia.cancer-pku.cn/,,,,,,,,,,,,,,"Kaplan–Meier survival curves were generated using GEPIA (http://gepia.cancer-pku.cn/) on the TCGA-SARC, TCGA-LUAD and TCGA-LUSC RNA-seq expression dataset."
Cluster Profiler v.4.0,computational_tools,PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Cluster Profiler v.4.0,Package/Library,v.4.0,,,,,,,,,,,,,,,"Gene Ontology (GO) and pathway enrichment analysis was performed using Cluster Profiler v.4.0, selecting statistically significant terms and pathways."
FlowJo v10,computational_tools,PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,FlowJo v10,Analysis Software,v10,,,,,,,,,,,,,,,"data analyzed using FlowJo v10 (Becton Dickinson, RRID: SCR_008520)"
DESeq2,computational_tools,PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,DESeq2,Analysis Software,1.24.0,,,,,,,,,,,,,,,Differential gene expression analysis was then conducted with DESeq2 (1.24.0) (RRID: SCR_015687)
ImageJ (v1.48),computational_tools,PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ImageJ (v1.48),Analysis Software,v1.48,,,,,,,,,,,,,,,The volume of tumour spheroids was measured using ImageJ (v1.48) software
NF1 isoform 2,genetic_reagents,PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,NF1 isoform 2,Plasmid,,,,,,,,,,,,,,,,,,,,"Entry clones were produced by PCR amplification of portions of the NF1 gene from Addgene construct 70423, which contains a codon-optimized version of human NF1 isoform 2"
Merlin,genetic_reagents,PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,Merlin,Other,,,,,,,,,,,,,,,,,,,,"Merlin siRNA (SASI_Hs_01_00188862, Sigma) sense sequence 5′-CCUCAAAGCUUCGUGUUAA-3"
NF2,genetic_reagents,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,NF2,Viral,CSCW2,,,,,,,,,,,,,,,,,,,"full length cDNA coding sequence of NF2 (isoform 1, NCBI accession # NM_000268) cloned into the lentiviral vector CSCW2"
dNf1,genetic_reagents,PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,dNf1,Transposon,,UAS,,,,,,,,,,,,,,,,,,The UAS‐dNf1 transgene encodes full‐length dNf1 cDNA corresponding to the RF isoform
Nf2,genetic_reagents,PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,Nf2,Plasmid,,CMV,,,,,,,,,,,,,,,,,,the plasmid pcNf2hflag containing a CMV promoter and a neomycin resistance cassette was used
NF1-GRD,genetic_reagents,PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,NF1-GRD,Viral,Adenovirus,,,,,,,,,,,,,,,,,,,"MPNST cells were infected with purified Ad-NF1-GRD or control Ad-GFP, in triplicate, for 2 h in serum-free medium"
Nf1,genetic_reagents,PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,Nf1,Plasmid,,,,,,,,,,,,,,,,,,,,"The wild type (WT) mNf1 cDNA plasmid was developed by GeneCopoeia and is commercially available. The full-length, endogenous mouse cDNA (mNf1) containing Nf1 isoform 2"
NF1 capture probes,genetic_reagents,PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,NF1 capture probes,Other,,,,,,,,,,,,,,,,,,,,Capture probe set was designed and synthesized by Thermo Fisher Scientific for the Ion TargetSeq Custom Enrichment kit
NF1,genetic_reagents,PMID:34646065,10.1155/2021/9386823,Survival and ,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,NF1,Other,,,,,,,,,,,,,,,,,,,,"all samples were screened for large deletions using four TaqMan NF1 copy-number assays across the gene (ThermoFisher; Hs05477010, Hs06413401, Hs05512625, and Hs03960106)"
NF2 shRNA,genetic_reagents,PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,NF2 shRNA,Viral,Lentiviral,,,,,,,,,,,,,,,,,,,Lentiviral shRNA vectors were constructed using target sequences against the expression of NF2
NF2,genetic_reagents,PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,NF2,Plasmid,,,,,,,,,,,,,,,,,,,,"The plasmids HA-tagged NF2 (a gift from Dr. Y. J. LU, Tongji University, China)"
NF1,genetic_reagents,PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,NF1,Viral,,,,,,,,,,,,,,,,,,,,"CRISPR/Cas9 single-vector lentivirus was purchased from GeneChem (Shanghai, China)"
Nf1-eGFP,genetic_reagents,PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.9,Development,True,1.00,High,,,,,,,,,,,Nf1-eGFP,Plasmid,pUAST-attB,,,,,,,,,,,,,,,,,,,UAS-Nf1-eGFP transgenes were generated using an Nf1 mini-gene (full-length Nf1 cDNA corresponding to the RF isoform with addition of introns 9 and 10).
NF1,genetic_reagents,PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,NF1,Other,,,,,,,,,,,,,,,,,,,,Small interfering RNA (siRNA) targeting NF1 (s221793)
NF2,genetic_reagents,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,NF2,Viral,lenti-CRISPR,,,,,,,,,,,,,,,,,,,transfected using program U-023 with lenti-CRISPR-NF2_sg1 expressing a single guide RNA targeting human NF2 exon 8
NF1-GRD,genetic_reagents,PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,NF1-GRD,Viral,pMSCV,,,,,,,,,,,,,,,,,,,NF1-GRD sequence was introduced in Nf1−/− MEFs using the pMSCV-GRD vector
NF1,genetic_reagents,PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,NF1,Other,,,,,,,,,,,,,,,,,,,,Two predesigned siRNAs against human NF1 were purchased from MilliporeSigma (SASI_Hs01_00129008 and SASI_Hs01_00129006).
HA-Merlin,genetic_reagents,PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,HA-Merlin,Plasmid,pXJ40,,,,,,,,,,,,,,,,,,,cells were transfected with pXJ40-HA-Merlin and S518A pXJ40- HA-Merlin
S518A HA-Merlin,genetic_reagents,PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,S518A HA-Merlin,Plasmid,pXJ40,,,,,,,,,,,,,,,,,,,cells were transfected with pXJ40-HA-Merlin and S518A pXJ40- HA-Merlin
NF1 GRD,genetic_reagents,PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,NF1 GRD,Viral,MSCV,,,,,,,,,,,,,,,,,,,a virus expressing the full-length NF1 GTPase-activating related domain (NF1 GRD) and pac (MSCV-NF1 GRD-pac)
1276P NF1 GRD,genetic_reagents,PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,1276P NF1 GRD,Viral,MSCV,,,,,,,,,,,,,,,,,,,a virus expressing a GAP-inactive mutant of the NF1 GRD that harbors a known human mutation in the arginine finger loop (R1276P) and pac (MSCV-1276P NF1 GRD-pac)
Cas9 and sgRNAs targeting Nf1+Cdkn2a,genetic_reagents,PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,Cas9 and sgRNAs targeting Nf1+Cdkn2a,Viral,,,,,,,,,,,,,,,,,,,,adenovirus containing Cas9 and sgRNAs targeting Nf1+Cdkn2a were produced
JH-2-002,patient_derived_models,PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,PDX,NF1-associated tumor,NSG,,,,,,,JH-2-002 and JH-2-031 patient-derived xenografts (PDX) were obtained from the Johns Hopkins NF1 biospecimen repository
JH-2-031,patient_derived_models,PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,PDX,NF1-associated tumor,NSG,,,,,,,JH-2-002 and JH-2-031 patient-derived xenografts (PDX) were obtained from the Johns Hopkins NF1 biospecimen repository
patient-derived xenograft (PDX),patient_derived_models,PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,PDX,NF1-associated MPNST,CB17 SCID,MPNST,,,,,,"For MPNST M3 cell line-derived xenograft and patient-derived xenograft (PDX) studies, 2 × 10^6 and 3 × 10^6 cells, respectively"
JH-2-002 PDX,patient_derived_models,PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,PDX,NF1-associated MPNST,,MPNST,,,,,,"eight PDXs [JH-2-002, JH-2-031, JH-2-079c, WU-225, WU-386, WU-545, MN-2, and MN-3-002] were generated in our laboratories"
JH-2-031 PDX,patient_derived_models,PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,PDX,NF1-associated MPNST,,MPNST,,,,,,"eight PDXs [JH-2-002, JH-2-031, JH-2-079c, WU-225, WU-386, WU-545, MN-2, and MN-3-002] were generated in our laboratories"
JH-2-079c PDX,patient_derived_models,PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,PDX,NF1-associated MPNST,,MPNST,,,,,,"eight PDXs [JH-2-002, JH-2-031, JH-2-079c, WU-225, WU-386, WU-545, MN-2, and MN-3-002] were generated in our laboratories"
WU-225 PDX,patient_derived_models,PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,PDX,NF1-associated MPNST,,MPNST,,,,,,"eight PDXs [JH-2-002, JH-2-031, JH-2-079c, WU-225, WU-386, WU-545, MN-2, and MN-3-002] were generated in our laboratories"
WU-386 PDX,patient_derived_models,PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,PDX,NF1-associated MPNST,,MPNST,,,,,,"eight PDXs [JH-2-002, JH-2-031, JH-2-079c, WU-225, WU-386, WU-545, MN-2, and MN-3-002] were generated in our laboratories"
WU-545 PDX,patient_derived_models,PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,PDX,NF1-associated MPNST,,MPNST,,,,,,"eight PDXs [JH-2-002, JH-2-031, JH-2-079c, WU-225, WU-386, WU-545, MN-2, and MN-3-002] were generated in our laboratories"
MN-2 PDX,patient_derived_models,PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,PDX,NF1-associated MPNST,,MPNST,,,,,,"eight PDXs [JH-2-002, JH-2-031, JH-2-079c, WU-225, WU-386, WU-545, MN-2, and MN-3-002] were generated in our laboratories"
MN-3-002 PDX,patient_derived_models,PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,PDX,NF1-associated MPNST,,MPNST,,,,,,"eight PDXs [JH-2-002, JH-2-031, JH-2-079c, WU-225, WU-386, WU-545, MN-2, and MN-3-002] were generated in our laboratories"
Patient-derived xenograft (PDX) MPNST model,patient_derived_models,PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,PDX,MPNST,NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ,MPNST,,,,,,"For the patient-derived xenograft (PDX) MPNST model, tumor tissue was implanted subcutaneously directly into NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice"
MPNST-SP-01 PDOX,patient_derived_models,PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,PDX,sporadic MPNST,athymic nude,MPNST,,,,,,significantly reduced tumor growth in a sporadic PDOX model (MPNST-SP-01; sevenfold)
MPNST-NF1-09 PDOX,patient_derived_models,PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,PDX,NF1-associated MPNST,athymic nude,MPNST,,,,,,and in an NF1-PDOX model (MPNST-NF1-09; fourfold)
JH-2–002,patient_derived_models,PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,cell line,NF1-associated MPNST,,MPNST,,,,,,"Four patient-derived MPNST cell lines (JH-2–002, JH-2–009, JH-2–031 and JH-2–055)"
JH-2–009,patient_derived_models,PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,cell line,NF1-associated MPNST,,MPNST,,,,,,"Four patient-derived MPNST cell lines (JH-2–002, JH-2–009, JH-2–031 and JH-2–055)"
JH-2–031,patient_derived_models,PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,cell line,NF1-associated MPNST,,MPNST,,,,,,"Four patient-derived MPNST cell lines (JH-2–002, JH-2–009, JH-2–031 and JH-2–055)"
JH-2–055,patient_derived_models,PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,cell line,NF1-associated MPNST,,MPNST,,,,,,"Four patient-derived MPNST cell lines (JH-2–002, JH-2–009, JH-2–031 and JH-2–055)"
JH-2–060,patient_derived_models,PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,cell line,NF1-associated neurofibroma,,neurofibroma,,,,,,"three patient-derived neurofibroma cell lines (JH-2–060, JH-2–074 and JH-2–077)"
JH-2–074,patient_derived_models,PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,cell line,NF1-associated neurofibroma,,neurofibroma,,,,,,"three patient-derived neurofibroma cell lines (JH-2–060, JH-2–074 and JH-2–077)"
JH-2–077,patient_derived_models,PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,cell line,NF1-associated neurofibroma,,neurofibroma,,,,,,"three patient-derived neurofibroma cell lines (JH-2–060, JH-2–074 and JH-2–077)"
PDX JH-2–002,patient_derived_models,PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,PDX,NF1-associated MPNST,NSG,MPNST,,,,,,Minced tumor fragments from donor mice were implanted subcutaneously close to the sciatic nerves of 6 to 8-week-old athymic nude (NF90.8) or NSG (PDX JH-2–002) female mice
MPNST PDX-1,patient_derived_models,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,PDX,MPNST,CB-17 SCID,MPNST,,,,,,"MPNST PDX-1 tumors in CB-17 SCID mice (Taconic, RRID:IMSR_TAC:cb17sc) were enzymatically dissociated, followed by subcutaneous injection into flanks"
Cutaneous neurofibroma samples,patient_derived_models,PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,organoid,NF1-associated cutaneous neurofibroma,,cutaneous neurofibroma,,,,,,Cutaneous neurofibroma samples This work NF0001 – NF0012
human neurofibroma xenografts,patient_derived_models,PMID:15240917,10.1155/S1110724304308107,Survival of Human Neurofibroma in Immunodeficient Mice and Initial Results of Therapy With Pirfenidone.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,PDX,plexiform neurofibroma,SCID,neurofibroma,,,,,,Human neurofibromas were obtained from four patients with neurofibromatosis who underwent removal of plexiform neurofibroma
Patient-derived xenografts,patient_derived_models,PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,PDX,MPNST,NRG,MPNST,,,,,,tumor pieces were acquired from MPNST patients at time of surgical resection and implanted subcutaneously
RHT-92,patient_derived_models,PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,cell line,MPNST,,MPNST,,,,,,"Following resection, patient tissue (18-year-old female) was initially expanded as flank tumours, harvested and expanded as a cell line, which were referred to as 'RHT-92'"
primary cultures derived from plexiform neurofibromas,advanced_cellular_models,PMID:25851896,10.3988/jcn.2015.11.2.172,Preclinical assessment of the anticancer drug response of plexiform neurofibroma tissue using primary cultures.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,other,patient tissue,"Schwann cells, fibroblasts",,,,,,,,,,,Primary cultures containing tumor and nontumor stromal cells were utilized in a novel strategy to test drug responses...four primary cultures derived from plexiform neurofibromas
2.3-kb α1(I) collagen-cre Nf1 flox/flox,animal_models,PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,0.85,Experimental Usage,True,1.00,High,2.3-kb α1(I) collagen-cre Nf1 flox/flox,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,WT and mice were generated by crossing 2.3-kb α1(I) collagen-cre Nf1 flox/flox mice and Nf1 flox/flox mice
Nf1 flox/flox,animal_models,PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,0.85,Experimental Usage,True,1.00,High,Nf1 flox/flox,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,crossing 2.3-kb α1(I) collagen-cre Nf1 flox/flox mice and Nf1 flox/flox mice
4/FM7; T80-Gal4 y w Mer4,animal_models,PMID:24595234,10.1371/journal.pone.0090853,In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,,0.85,Experimental Usage,True,1.00,High,4/FM7; T80-Gal4 y w Mer4,Neurofibromatosis type 2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,surviving 4/FM7; T80-Gal4 y w Mer4 hemizygous males
Nf1flox,animal_models,PMID:21726432,10.1186/1741-7015-9-82,MIA is a potential biomarker for tumour load in neurofibromatosis type 1.,,0.85,Experimental Usage,True,1.00,High,Nf1flox,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,The female Nf1flox mice were crossed to male Nf1flox heterozygous Prx1-Cre-positive males
Nf1 mice,animal_models,PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,0.85,Citation Only,True,1.00,High,Nf1 mice,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,statin-mediated inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase restores the cognitive deficits in an NF1 mouse model
Mut3,animal_models,PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.85,Experimental Usage,True,1.00,High,Mut3,Neurofibromatosis type 1,astrocytomas,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"To generate Mut3 to Mut6 mice (see Fig. 1A for genetic configurations), we crossed Mut3 (8) or Mut4 males with wild-type (wt), loxP-Pten (Pten f hereafter; ref. 27)"
Mut4,animal_models,PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.85,Experimental Usage,True,1.00,High,Mut4,Neurofibromatosis type 1,astrocytomas,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"To generate Mut3 to Mut6 mice (see Fig. 1A for genetic configurations), we crossed Mut3 (8) or Mut4 males with wild-type (wt), loxP-Pten (Pten f hereafter; ref. 27)"
cisNP,animal_models,PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,0.85,Experimental Usage,True,1.00,High,cisNP,Neurofibromatosis type 1,Malignant Peripheral Nerve Sheath Tumor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"A spontaneous MPNST GEMM, cisNP, was previously described (Vogel et al., 1999)"
DhhCre,animal_models,PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.85,Experimental Usage,True,1.00,High,DhhCre,Neurofibromatosis type 1,Peripheral nerve sheath tumors,,,,,,,,,,,,,,,,,,,,,,,,,,,,,RNAseq data from murine peripheral nerve sheath tumors arising in DhhCre mice harboring Nf1-floxed alleles and Ink4a/Arf heterozygosity
Nf1flox/flox;PostnCre+,animal_models,PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.85,Experimental Usage,True,1.00,High,Nf1flox/flox;PostnCre+,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,RNAseq data from Nf1flox/flox;PostnCre+ and Nf1flox/flox;Arf flox/flox;PostnCre+ mice
Nf1flox/flox;Arf flox/flox;PostnCre+,animal_models,PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.85,Experimental Usage,True,1.00,High,Nf1flox/flox;Arf flox/flox;PostnCre+,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,RNAseq data from Nf1flox/flox;PostnCre+ and Nf1flox/flox;Arf flox/flox;PostnCre+ mice
P0-CRE,animal_models,PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.85,Experimental Usage,True,1.00,High,P0-CRE,Neurofibromatosis type 2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Schwann cell-specific NF2-null mice generated with the P0-CRE line and the sciatic nerve injury model have been described
DhhCre;Nf1f/f;Luciferase,animal_models,PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,0.85,Experimental Usage,True,1.00,High,DhhCre;Nf1f/f;Luciferase,Neurofibromatosis type 1,Plexiform Neurofibroma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pNF tumors were generated in nude mice by transplanting tumor cells harvested from dorsal root ganglia with DhhCre;Nf1f/f;Luciferase configuration
Osx-/-Nf1flox/flox,animal_models,PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,0.85,Experimental Usage,True,1.00,High,Osx-/-Nf1flox/flox,Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"generated by crossing Osx −/− Nf1 flox/flox mice ( 11 ) and Osx -tTA, tetO -cre; Nf1 flox/flox mice"
"Osx-tTA,tetO-cre;Nf1flox/flox",animal_models,PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,0.85,Experimental Usage,True,1.00,High,"Osx-tTA,tetO-cre;Nf1flox/flox",Neurofibromatosis type 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"crossing Osx −/− Nf1 flox/flox mice ( 11 ) and Osx -tTA, tetO -cre; Nf1 flox/flox mice ( 12 )"
Nf2 mice,animal_models,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.85,Experimental Usage,True,1.00,High,Nf2 mice,Neurofibromatosis type 2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p16/p19+/− mice were crossed to Nf2 mice to obtain all of the genotypes used herein. All mice were in a comparable FVB genetic background
SIAH,antibodies,PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.85,Experimental Usage,True,1.00,High,,,,SIAH,Mouse,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,Immunostaining for SIAH (24E6H3 mouse monoclonal antibody)
AC-CRISPR,cell_lines,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.85,Experimental Usage,True,1.00,High,,,,,,,Brain,Neurofibromatosis Type 2,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"NF2 AC-CRISPR, and two independent human primary MN"
MN1-LF,cell_lines,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.85,Experimental Usage,True,1.00,High,,,,,,,Brain,Neurofibromatosis Type 2,Meningioma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"we generated an immortalized human MN line, MN1-LF from an independent NF2-null human primary MN cell line"
Epstein-Barr virus-transformed cell lines,cell_lines,PMID:24958239,10.1186/gb-2014-15-6-r80,SVA retrotransposon insertion-associated deletion represents a novel mutational mechanism underlying large genomic copy number changes with non-recurrent breakpoints.,,0.85,Experimental Usage,True,1.00,High,,,,,,,Blood,Neurofibromatosis Type 1,,Hybrid cell line,,,,,,,,,,,,,,,,,,,,,,"Hybrid cell lines harboring only the chromosome 17 with the deletion were established for patients 659, 619, 1106, DA-77 and ASB4-55 using Epstein-Barr virus-transformed cell lines"
lymphoblastoid cell lines,cell_lines,PMID:25329635,10.1371/journal.pgen.1004575,Genetic modifiers of neurofibromatosis type 1-associated café-au-lait macule count identified using multi-platform analysis.,,0.85,Experimental Usage,True,1.00,High,,,,,,,Blood,Neurofibromatosis Type 1,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Lymphoblastoid cell lines (LCLs) from the first 79 participants (""EXPR"") were used in the gene expression screen to identify putative modifiers."
LUVA cells,cell_lines,PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.85,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,LUVA cells (Kerafast) were cultured in STEM PRO-34 SFM
NF37,cell_lines,PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.85,Experimental Usage,True,1.00,High,,,,,,,Dental pulp,Neurofibromatosis Type 1,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,...Two primary cell cultures were obtained from individuals with NF1 (NF1 group; NF37 and NF87) and three from individuals without NF1...
NF87,cell_lines,PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.85,Experimental Usage,True,1.00,High,,,,,,,Dental pulp,Neurofibromatosis Type 1,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,...Two primary cell cultures were obtained from individuals with NF1 (NF1 group; NF37 and NF87) and three from individuals without NF1...
NF1-null 293T cells,cell_lines,PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.85,Experimental Usage,True,1.00,High,,,,,,,Kidney,Neurofibromatosis Type 1,NF1 knockout,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,Generation of NF1-null 293T cells has been previously described (12).
Neurofibromatosis 1 fibroblasts,cell_lines,PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,0.85,Experimental Usage,True,1.00,High,,,,,,,Skin,Neurofibromatosis Type 1,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,applied treatments...in cultured Neurofibromatosis 1 fibroblasts
ST88-14,cell_lines,PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.85,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,ST88-14 is an established NF1-deficient MPNST cell line
H1838,cell_lines,PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.85,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"H1838 was obtained from the American Type Culture Collection (ATCC, Manassas, VA)"
WM3918,cell_lines,PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.85,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,WM3918 and M308 were obtained from Dr. David Solit at Memorial Sloan Kettering Cancer Center
M308,cell_lines,PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.85,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,WM3918 and M308 were obtained from Dr. David Solit at Memorial Sloan Kettering Cancer Center
STS26T,cell_lines,PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.85,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"STS26T, ST8814 and NF90.8 were kindly provided by Dr. Gregory Riggins at Johns Hopkins University"
ST8814,cell_lines,PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.85,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"STS26T, ST8814 and NF90.8 were kindly provided by Dr. Gregory Riggins at Johns Hopkins University"
NF90.8,cell_lines,PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.85,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"STS26T, ST8814 and NF90.8 were kindly provided by Dr. Gregory Riggins at Johns Hopkins University"
NF94.3,cell_lines,PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.85,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"NF94.3, NF96.2, NF10.1 and NF11.1 were kindly provided by Dr. Margaret Wallace at University of Florida"
NF96.2,cell_lines,PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.85,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"NF94.3, NF96.2, NF10.1 and NF11.1 were kindly provided by Dr. Margaret Wallace at University of Florida"
NF10.1,cell_lines,PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.85,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"NF94.3, NF96.2, NF10.1 and NF11.1 were kindly provided by Dr. Margaret Wallace at University of Florida"
NF11.1,cell_lines,PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.85,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"NF94.3, NF96.2, NF10.1 and NF11.1 were kindly provided by Dr. Margaret Wallace at University of Florida"
B76,cell_lines,PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.85,Experimental Usage,True,1.00,High,,,,,,,Brain,Neurofibromatosis Type 1,High-grade glioma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Adherent high-grade glioma lines with BRAF V600E alteration and varied NF1 status (B76, NGT-41, NMCG-1, DBTRG) were obtained"
NGT-41,cell_lines,PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.85,Experimental Usage,True,1.00,High,,,,,,,Brain,Neurofibromatosis Type 1,High-grade glioma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Adherent high-grade glioma lines with BRAF V600E alteration and varied NF1 status (B76, NGT-41, NMCG-1, DBTRG) were obtained"
NMCG-1,cell_lines,PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.85,Experimental Usage,True,1.00,High,,,,,,,Brain,Neurofibromatosis Type 1,High-grade glioma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Adherent high-grade glioma lines with BRAF V600E alteration and varied NF1 status (B76, NGT-41, NMCG-1, DBTRG) were obtained"
DBTRG,cell_lines,PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.85,Experimental Usage,True,1.00,High,,,,,,,Brain,Neurofibromatosis Type 1,High-grade glioma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Adherent high-grade glioma lines with BRAF V600E alteration and varied NF1 status (B76, NGT-41, NMCG-1, DBTRG) were obtained"
PNF-derived Schwann cells,cell_lines,PMID:25340526,10.1371/journal.pone.0107760,Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.,,0.85,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Plexiform Neurofibroma,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Schwann cells from the PNF were cultured and identified as previously described. After ensuring purity of 85%, PNF-derived Schwann cells were treated with nilotinib and imatinib"
NF1-/- iPSC-derived neural crest cells,cell_lines,PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.85,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,,Embryonic stem cell,,,,,,,,,,,,,,,,,,,,,,NF1–/– iPSC-derived neural crest cells were plated in SC differentiation media for 5 days
hTERT NF1 ipNF95.6 cell line,cell_lines,PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.85,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Neurofibroma,Finite cell line,,,,,,,,,,,,,,,,,,,,,,NF1 deficient neurofibroma Schwann cells (hTERT NF1 ipNF95.6) were obtained from Dr. Peggy Wallace
JW18.2,cell_lines,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,Subcutaneous allografts were performed by implanting 5 million JW18.2 or JW23.3 MPNST allografts cells
JW23.3,cell_lines,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,Experimental Usage,True,1.00,High,,,,,,,Nerve,Neurofibromatosis Type 1,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,Subcutaneous allografts were performed by implanting 5 million JW18.2 or JW23.3 MPNST allografts cells
National Institute of Health diagnostic criteria for NF1,clinical_assessment_tools,PMID:33963966,10.1007/s10803-021-05043-3,Cognitive and Electrophysiological Correlates of Working Memory Impairments in Neurofibromatosis Type 1.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,National Institute of Health diagnostic criteria for NF1,structured interview,all ages,Yes,,"Participants were children aged 12–17 years meeting the National Institute of Health (National Institutes of Health Consensus Development Conference, 1988) diagnostic criteria for NF1."
P.L.E.A.S.E.® device,clinical_assessment_tools,PMID:33817379,10.1016/j.heliyon.2021.e06518,Clinical assessment of the use of topical liquid diclofenac following laser microporation of cutaneous neurofibromas in individuals with neurofibromatosis type 1.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,P.L.E.A.S.E.® device,other,adult,Yes,,"cNFs were laser-porated using the P.L.E.A.S.E.® device with the following user-defined settings: density of 10%, 5 pulses per pore, repetition rate of 300 Hz"
Relaxation Response Resiliency Program for NF (3RP-NF),clinical_assessment_tools,PMID:37378983,10.1001/jamanetworkopen.2023.20599,Effect of Mind-Body Skills Training on Quality of Life for Geographically Diverse Adults With Neurofibromatosis: A Fully Remote Randomized Clinical Trial.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Relaxation Response Resiliency Program for NF (3RP-NF),structured interview,adult,Yes,,"mind-body skills training program, the Relaxation Response Resiliency Program for NF (3RP-NF)"
Health Enhancement Program for NF (HEP-NF),clinical_assessment_tools,PMID:37378983,10.1001/jamanetworkopen.2023.20599,Effect of Mind-Body Skills Training on Quality of Life for Geographically Diverse Adults With Neurofibromatosis: A Fully Remote Randomized Clinical Trial.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Health Enhancement Program for NF (HEP-NF),structured interview,adult,Yes,,health education program (Health Enhancement Program for NF; HEP-NF)
Dermus SkinScanner,clinical_assessment_tools,PMID:41598414,10.3390/jcm15020475,Dermoscopy-Guided High-Frequency Ultrasound Imaging of Subcentimeter Cutaneous and Subcutaneous Neurofibromas in Patients with Neurofibromatosis Type 1.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Dermus SkinScanner,biomarker assay,all ages,Yes,,"measurements were performed at the Department of Dermatology, Venereology and Dermatooncology, Semmelweis University, using a portable DG-HFUS device (Dermus SkinScanner, Dermus Ltd., Budapest, Hungary)"
MIA ELISA kit,clinical_assessment_tools,PMID:21726432,10.1186/1741-7015-9-82,MIA is a potential biomarker for tumour load in neurofibromatosis type 1.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,MIA ELISA kit,biomarker assay,all ages,Yes,,"The MIA ELISA kit was purchased from (Roche Diagnostics, Indianapolis, IN, USA) and the measurements were conducted"
Hannover classification system,clinical_assessment_tools,PMID:39824854,10.1038/s41598-025-85386-4,Comparison of 1D and 3D volume measurement techniques in NF2-associated vestibular schwannoma monitoring.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Hannover classification system,scale,all ages,Yes,,Tumor size was classified by the Hannover and Koos classification systems
Koos classification system,clinical_assessment_tools,PMID:39824854,10.1038/s41598-025-85386-4,Comparison of 1D and 3D volume measurement techniques in NF2-associated vestibular schwannoma monitoring.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Koos classification system,scale,all ages,Yes,,Tumor size was classified by the Hannover and Koos classification systems
Client Oriented Scale of Improvement-Tinnitus,clinical_assessment_tools,PMID:38321701,10.1177/17407745231217279,Patient-reported measures of tinnitus for individuals with neurofibromatosis type 2-related schwannomatosis: Recommendations for clinical trials.,,0.85,Citation Only,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Client Oriented Scale of Improvement-Tinnitus,scale,adult,Yes,,One measure was excluded (i.e. the Client Oriented Scale of Improvement-Tinnitus) because while it would be very useful for clinical settings
Children's Tumor Foundation NF Registry,clinical_assessment_tools,PMID:37269078,10.1177/17407745231178839,Perspectives of adolescents with neurofibromatosis 1 and cutaneous neurofibromas: Implications for clinical trials.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Children's Tumor Foundation NF Registry,other,all ages,Yes,,The survey link was distributed via email to 1160 adolescent caregivers in the Children's Tumor Foundation NF Registry
immunohistochemical staining,clinical_assessment_tools,PMID:40063513,10.1158/1078-0432.CCR-24-3029,DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,immunohistochemical staining,biomarker assay,clinician-rated,Yes,,Patients from our institutional cohort with adequate tumor samples for immunohistochemical staining of DLK1
Riccardi NF severity grade classification,clinical_assessment_tools,PMID:28193237,10.1186/s12955-017-0607-y,Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Riccardi NF severity grade classification,scale,adult,Yes,4.0,Disease severity was determined using the Riccardi NF severity grade classification 1 to 4. Grades 1 and 2 were amalgamated to ensure adequate numbers in each group
volumetric magnetic resonance imaging analysis,clinical_assessment_tools,PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,volumetric magnetic resonance imaging analysis,biomarker assay,pediatric,Yes,,Response to treatment was monitored by using volumetric magnetic resonance imaging analysis to measure the change in size of the plexiform neurofibroma
Likert scale questionnaire,clinical_assessment_tools,PMID:40737523,10.2196/71728,Clinician Perspectives of a Magnetic Resonance Imaging-Based 3D Volumetric Analysis Tool for Neurofibromatosis Type 2-Related Schwannomatosis: Qualitative Pilot Study.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Likert scale questionnaire,questionnaire,clinician-rated,Yes,25.0,A Likert scale questionnaire was used to survey clinicians' levels of agreement with 25 statements related to 2D and 3D tumor analyses.
NIH consensus criteria,clinical_assessment_tools,PMID:34049498,10.1186/s11689-021-09364-3,Early differences in auditory processing relate to Autism Spectrum Disorder traits in infants with Neurofibromatosis Type I.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,NIH consensus criteria,structured interview,all ages,Yes,,All participants had their diagnosis confirmed via molecular testing of cord blood samples or clinical diagnosis based on NIH consensus criteria
NIH Consensus Conference criteria,clinical_assessment_tools,PMID:37174087,10.3390/cancers15092621,Vinblastine/Methotrexate for Debilitating and Progressive Plexiform Neurofibroma in Children and Young Adults with Neurofibromatosis Type 1: A Phase 2 Study.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,NIH Consensus Conference criteria,scale,all ages,Yes,,"...ages ≤ 25 years with a diagnosis of NF1, as defined by the NIH Consensus Conference criteria [19]..."
Magnetom Avanto,clinical_assessment_tools,PMID:33082502,10.1038/s41598-020-74920-1,Image segmentation of plexiform neurofibromas from a deep neural network using multiple b-value diffusion data.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Magnetom Avanto,biomarker assay,all ages,Yes,,"All MRI sequences were performed on a 1.5 T scanner (Magnetom Avanto, Siemens Healthineers, Erlangen, Germany)"
hearing grade score,clinical_assessment_tools,PMID:28848060,10.1136/jmedgenet-2017-104519,Genetic Severity Score predicts clinical phenotype in NF2.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,hearing grade score,scale,all ages,Yes,6.0,"Hearing grade was assigned based on a score of 1–6, as used within the English NF2 service to indicate suitability for a hearing implant"
Manchester NF2 diagnostic criteria,clinical_assessment_tools,PMID:28848060,10.1136/jmedgenet-2017-104519,Genetic Severity Score predicts clinical phenotype in NF2.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,,,,,,,,,,,,,Manchester NF2 diagnostic criteria,structured interview,all ages,Yes,,all patients known to the Oxford NF2 centre who met the Manchester NF2 diagnostic criteria and consented to genetic testing were analysed
Prism7 (GraphPad),computational_tools,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Prism7 (GraphPad),Analysis Software,7,,,,,,,,,,,,,,,"Data statistical analyses were performed by unpaired two-tailed Student's t-test (Prism7, GraphPad)"
FlowJo software,computational_tools,PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,FlowJo software,Analysis Software,X10.0.7,,,,,,,,,,,,,,,data were processed with FlowJo software (version X10.0.7)
STRING database,computational_tools,PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,STRING database,Database,11.0,https://cn.string-db.org/,,,,,,,,,,,,,,We used the STRING database (version 11.0) (https://cn.string-db.org/)
Cytoscape,computational_tools,PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Cytoscape,Analysis Software,3.7.2,,,,,,,,,,,,,,,Cytoscape (version 3.7.2) was used to construct the network
AxioVision 4.6 software,computational_tools,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,AxioVision 4.6 software,Analysis Software,4.6,,,,,,,,,,,,,,,Imaging was performed using a Zeiss Stereo Discovery V12 and the AxioVision 4.6 software (Zeiss)
BWA-MEM,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,BWA-MEM,Analysis Software,0.7.17-r1188,,,,,,,,,,,,,,,Raw sequencing reads were mapped to the GRCh38 build of the human reference genome using BWA-MEM (46) version 0.7.17-r1188
GATK,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GATK,Analysis Software,4.1.8.0,,,,,,,,,,,,,,,"Aligned reads in BAM format were processed following the Genome Analysis Toolkit (GATK, version 4.1.8.0) Best Practices workflow"
Strelka2,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Strelka2,Analysis Software,2.9.2,,,,,,,,,,,,,,,"The germline short variant discovery workflow from GATK (version 4.1.8.0; ref. 47), Strelka2 (version 2.9.2; ref. 51)"
VarDict,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,VarDict,Analysis Software,1.8.2,,,,,,,,,,,,,,,and VarDict (version 1.8.2; ref. 52) were used to detect germline SNVs and INDELs in the WGS data
Annovar,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Annovar,Analysis Software,2018Apr16,,,,,,,,,,,,,,,Annovar (version 2018Apr16) was used to annotate all variants (53)
Manta,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Manta,Analysis Software,1.6.0,,,,,,,,,,,,,,,we called SVs in all matched normal samples using Manta (version 1.6.0; ref. 55)
LUMPY,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,LUMPY,Analysis Software,0.2.13,,,,,,,,,,,,,,,"LUMPY (version 0.2.13; ref. 56), SvABA (version 1.1.3; ref. 57), and Delly (version 0.8.3; refs. 57, 58)"
SvABA,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SvABA,Analysis Software,1.1.3,,,,,,,,,,,,,,,"LUMPY (version 0.2.13; ref. 56), SvABA (version 1.1.3; ref. 57), and Delly (version 0.8.3; refs. 57, 58)"
Delly,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Delly,Analysis Software,0.8.3,,,,,,,,,,,,,,,"LUMPY (version 0.2.13; ref. 56), SvABA (version 1.1.3; ref. 57), and Delly (version 0.8.3; refs. 57, 58)"
MuSE,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,MuSE,Analysis Software,v1.0rc,,,,,,,,,,,,,,,"Somatic SNVs were detected using Mutect2 (GATK version 4.1.8.0), MuSE (version v1.0rc; ref. 60)"
MSIprofiler,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,MSIprofiler,Analysis Software,,https://github.com/parklab/MSIprofiler,,,,,,,,,,,,,,Mutations at microsatellite loci were detected using MSIprofiler (https://github.com/parklab/MSIprofiler)
FACETS,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,FACETS,Analysis Software,0.12.1,,,,,,,,,,,,,,,"For WGS data, the software packages FACETS (version 0.12.1) and ascatNGS (version 2.5.1) were used to detect somatic copy-number alterations"
ascatNGS,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ascatNGS,Analysis Software,2.5.1,,,,,,,,,,,,,,,"For WGS data, the software packages FACETS (version 0.12.1) and ascatNGS (version 2.5.1) were used to detect somatic copy-number alterations"
ShatterSeek,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ShatterSeek,Analysis Software,0.7,,,,,,,,,,,,,,,Chromothripsis events were detected using ShatterSeek (version 0.7) using recommended cutoff values (72)
STAR,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,STAR,Analysis Software,2.7.4a,,,,,,,,,,,,,,,Sequencing reads were mapped to the transcriptome using the STAR aligner (version 2.7.4a; ref. 74)
HTSeq,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,HTSeq,Analysis Software,0.6.1p1,,,,,,,,,,,,,,,Gene-expression counts were generated using HTSeq (v.0.6.1p1; ref. 75)
ARRIBA,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ARRIBA,Analysis Software,2.1.0,,,,,,,,,,,,,,,Gene fusions were detected using ARRIBA (version 2.1.0; ref. 77)
TopHat-fusion,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,TopHat-fusion,Analysis Software,2.1.0,,,,,,,,,,,,,,,"TopHat-fusion (version 2.1.0; ref. 78), EricScript (version 0.5.5; ref. 79), and STAR-Fusion (version 1.10.1; ref. 80)"
EricScript,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,EricScript,Analysis Software,0.5.5,,,,,,,,,,,,,,,"TopHat-fusion (version 2.1.0; ref. 78), EricScript (version 0.5.5; ref. 79), and STAR-Fusion (version 1.10.1; ref. 80)"
STAR-Fusion,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,STAR-Fusion,Analysis Software,1.10.1,,,,,,,,,,,,,,,"TopHat-fusion (version 2.1.0; ref. 78), EricScript (version 0.5.5; ref. 79), and STAR-Fusion (version 1.10.1; ref. 80)"
minfi,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,minfi,Package/Library,1.34.0,,,,,,,,,,,,,,,Raw Methylation EPIC data were uniformly processed using the R package minfi (version 1.34.0; ref. 86)
survival,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,survival,Package/Library,2.30,,,,,,,,,,,,,,,Survival analysis was performed using the Cox proportional-hazards model as implemented in the R package survival (version 2.30; ref. 93)
Phoenix WinNonlin (Version 8.1),computational_tools,PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Phoenix WinNonlin (Version 8.1),Analysis Software,8.1,,,,,,,,,,,,,,,"A noncompartmental analysis was performed to estimate area under the concentration-time curve from time 0 to 12 hours (AUC 0-12h) after a single dose of mirdametinib using Phoenix WinNonlin (Version 8.1; Certara, Princeton, NJ)."
NONMEM (version 7.2),computational_tools,PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,NONMEM (version 7.2),Analysis Software,7.2,,,,,,,,,,,,,,,"A population pharmacokinetics (PK) analysis was also performed using nonlinear mixed effect modeling with NONMEM (version 7.2; ICON, Ellicott City, MD) with Perl speaks NONMEM version 3.6.2 and Pirana version 2.7.1 (Certara)."
"SAS, version 9.4",computational_tools,PMID:37378983,10.1001/jamanetworkopen.2023.20599,Effect of Mind-Body Skills Training on Quality of Life for Geographically Diverse Adults With Neurofibromatosis: A Fully Remote Randomized Clinical Trial.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,"SAS, version 9.4",Analysis Software,9.4,,,,,,,,,,,,,,,"We used SAS, version 9.4 (SAS Institute Inc), for analyses"
R 2.7.0,computational_tools,PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,R 2.7.0,Analysis Software,2.7.0,,,,,,,,,,,,,,,All analyses were performed on R 2.7.0.
Axio Vision Rel. 4.8 software,computational_tools,PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Axio Vision Rel. 4.8 software,Analysis Software,4.8,,,,,,,,,,,,,,,Images were captured and analyzed using Axio Vision Rel. 4.8 software (Carl Zeiss MicroImaging)
XenoBase version 3.5,computational_tools,PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,XenoBase version 3.5,Analysis Software,3.5,,,,,,,,,,,,,,,Heat maps were generated using XenoBase® version 3.5 from Affymetrix array data using MAS 5.0 normalization
StepOne Software v2.3,computational_tools,PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,StepOne Software v2.3,Analysis Software,v2.3,,,,,,,,,,,,,,,using StepOne Software v2.3 (Applied Biosystems) standard parameters
FSL version 5.0.7,computational_tools,PMID:32642741,10.1093/noajnl/vdaa037,Effect of age and neurofibromatosis type 1 status on white matter integrity in the optic radiations.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,FSL version 5.0.7,Analysis Software,5.0.7,,,,,,,,,,,,,,,"Postprocessing DTI analysis was performed using a previously described method for automated probabilistic tractography of the optic radiations. Briefly, using FSL version 5.0.7 (FMRIB)"
UN-SCAN-IT gel 6.1,computational_tools,PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,UN-SCAN-IT gel 6.1,Analysis Software,6.1,,,,,,,,,,,,,,,band intensities were quantified using UN-SCAN-IT gel 6.1 software
GraphPad 5 Prism software,computational_tools,PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GraphPad 5 Prism software,Analysis Software,5,,,,,,,,,,,,,,,"Differences between Nf1+/- and Nf1+/+ groups were analyzed by 2-tailed Student's t tests and were graphed using GraphPad 5 Prism software (San Diego, Calif., USA)"
"IBM SPSS for Windows, version 28",computational_tools,PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,"IBM SPSS for Windows, version 28",Analysis Software,version 28,,,,,,,,,,,,,,,"The data were analyzed using IBM SPSS for Windows, version 28"
GPower 3.1,computational_tools,PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GPower 3.1,Analysis Software,3.1,,,,,,,,,,,,,,,A post-hoc power analysis was conducted using GPower 3.1 (n = 19)
Ion Ampliseq Designer v3.0,computational_tools,PMID:25329635,10.1371/journal.pgen.1004575,Genetic modifiers of neurofibromatosis type 1-associated café-au-lait macule count identified using multi-platform analysis.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Ion Ampliseq Designer v3.0,Analysis Software,v3.0,,,,,,,,,,,,,,,"A targeted, multiplex PCR primer panel was designed using the custom Ion Ampliseq Designer v3.0"
Primer 3.0,computational_tools,PMID:33767727,10.3389/fgene.2021.603195,Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Primer 3.0,Analysis Software,3.0,,,,,,,,,,,,,,,Primers were designed based on the mutation sites found using Primer 3.0
Feature Extraction 10.5,computational_tools,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Feature Extraction 10.5,Analysis Software,10.5,,,,,,,,,,,,,,,Copy number estimates were extracted from the microarray image files using Feature Extraction 10.5 (Agilent)
Agilent Genomic Workbench 6.5,computational_tools,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Agilent Genomic Workbench 6.5,Analysis Software,6.5,,,,,,,,,,,,,,,data were analyzed in Agilent Genomic Workbench 6.5 (Agilent)
scREF,computational_tools,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,scREF,Analysis Software,,https://github.com/jumphone/scRef/archive/master.zip,,,,,,,,,,,,,,scREF is a reference-based toolkit for single-cell analysis for mapping a query RNA-seq dataset onto a reference
GraphPad Prism V9,computational_tools,PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GraphPad Prism V9,Analysis Software,V9,,,,,,,,,,,,,,,All graphs and statistical analyses were performed using GraphPad Prism V9
origin8.1,computational_tools,PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,origin8.1,Analysis Software,8.1,,,,,,,,,,,,,,,"Analysis was performed using Fitmaster and origin8.1 (OriginLab Corporation, MA)"
edgeR,computational_tools,PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,edgeR,Package/Library,v.3.22.3,,,,,,,,,,,,,,,Data was normalized by counts-per-million (CPM) and then subjected to trimmed means of M (TMM) using edgeR (v.3.22.3)
"Matlab script (Version 9.9.0, Natick, MA)",computational_tools,PMID:38173515,10.1016/j.heliyon.2023.e23445,Development of a semi-automatic segmentation technique based on mean magnetic resonance imaging intensity thresholding for volumetric quantification of plexiform neurofibromas.,,0.85,Development,True,1.00,High,,,,,,,,,,,,,,,"Matlab script (Version 9.9.0, Natick, MA)",Analysis Software,9.9.0,,,,,,,,,,,,,,,"The SSTMean method consisted of 4 main steps that were implemented in a Matlab script (Version 9.9.0, Natick, MA)."
Origin 8,computational_tools,PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Origin 8,Analysis Software,8,,,,,,,,,,,,,,,"Statistical significance was determined using Origin ® 8 (OriginLab, Northampton, MA)"
Prism 6.0,computational_tools,PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Prism 6.0,Analysis Software,6.0,,,,,,,,,,,,,,,Protein quantification and assessment of significance was determined in Prism 6.0
Prism 4.0,computational_tools,PMID:21681782,10.1002/ajh.22035,Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Prism 4.0,Analysis Software,4.0,,,,,,,,,,,,,,,"Graphing and statistical analysis was performed with Prism 4.0 (GraphPad Software, La Jolla, CA)"
minfi,computational_tools,PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,minfi,Package/Library,1.30,,,,,,,,,,,,,,,Data preprocessing and normalization was performed using minfi version 1.30 in R version 3.6.0
Seurat,computational_tools,PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Seurat,Package/Library,3.0,,,,,,,,,,,,,,,"Data were normalized, and variance stabilized by SCTransform in Seurat version 3.0"
Cell Ranger,computational_tools,PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Cell Ranger,Analysis Software,1.3.1,,,,,,,,,,,,,,,"Library demultiplexing, read alignment to human genome GRCh38, and unique molecular identifier (UMI) quantification was performed in Cell Ranger version 1.3.1"
HISAT2,computational_tools,PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,HISAT2,Analysis Software,2.0.3,,,,,,,,,,,,,,,Reads were aligned to GRCh38 using the splice-aware aligner HISAT2 version 2.0.3
Skyline,computational_tools,PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Skyline,Analysis Software,4.2.0.19072,,,,,,,,,,,,,,,All PRM data was analyzed by Skyline 4.2.0.19072
Signac,computational_tools,PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Signac,Package/Library,1.8.0,,,,,,,,,,,,,,,Preprocessing of single-nuclei RNA and ATAC data was performed using Signac v1.8.0
caret,computational_tools,PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,caret,Package/Library,6.0,,,,,,,,,,,,,,,a methylation-based classifier using differentially methylated probes from our discovery cohort of 66 tumors was used to construct a support vector machine (SVM) using caret version 6.0 in R version 3.6.0
Aardex MEMS Adherence Software (ElectronReader 0.9.9),computational_tools,PMID:39858077,10.3390/cancers17020295,A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Aardex MEMS Adherence Software (ElectronReader 0.9.9),Analysis Software,0.9.9,,,,,,,,,,,,,,,"diaries and pill bottles (including empty ones) were collected, and MEMS TM cap data were uploaded to Aardex MEMS TM Adherence Software (ElectronReader 0.9.9)."
Human Splicing Finder,computational_tools,PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Human Splicing Finder,Web Application,,http://www.umd.be/HSF/,,,,,,,,,,,,,,we also used the online Human Splicing Finder ( http://www.umd.be/HSF/ )
Sequencing Analysis software,computational_tools,PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Sequencing Analysis software,Analysis Software,5.4,,,,,,,,,,,,,,,the sequences were analyzed with the Sequencing Analysis software (version 5.4; Applied Biosystems)
Karyostudio 1.3 software,computational_tools,PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Karyostudio 1.3 software,Analysis Software,1.3,,,,,,,,,,,,,,,The analysis was performed using the Karyostudio 1.3 software (Illumina)
STAR,computational_tools,PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,STAR,Analysis Software,v2.7.8a,,,,,,,,,,,,,,,RNA sequencing reads were aligned to the hg38 Ensembl release 105 assembly with STAR v2.7.8a
glmmTMB,computational_tools,PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,glmmTMB,Package/Library,v0.2.2,,,,,,,,,,,,,,,Differentially methylated loci between cutaneous and plexiform neurofibromas were identified using a hierarchical generalized linear mixed model (GLMM) approach with a logit link function as implemented in glmmTMB (v0.2.2)
DMRcate,computational_tools,PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,DMRcate,Package/Library,v1.18.0,,,,,,,,,,,,,,,Differentially methylated regions were called using DMRcate (v1.18.0)
compartmap,computational_tools,PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,compartmap,Package/Library,v1.65.71,,,,,,,,,,,,,,,Chromatin compartments were computed at 100 kb resolution as previously described and implemented in compartmap (v1.65.71)
missMethyl,computational_tools,PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,missMethyl,Package/Library,v1.16.0,,,,,,,,,,,,,,,Enrichment of pathways and gene ontology (GO) terms was performed using the gometh function within the missMethyl (v1.16.0) package in R
PAMES,computational_tools,PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,PAMES,Package/Library,v0.2.3,,,,,,,,,,,,,,,Tissue purity was estimated by PAMES (v0.2.3)
SeSAMe,computational_tools,PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SeSAMe,Package/Library,v1.3.2,,,,,,,,,,,,,,,Copy number alterations were computed using SeSAMe (v1.3.2) with minor modifications for plotting functionality
edgeR,computational_tools,PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,edgeR,Package/Library,v3.27.14,,,,,,,,,,,,,,,Reverse-stranded gene counts were read into R (v3.6.1) using edgeR (v3.27.14)
betareg,computational_tools,PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,betareg,Package/Library,v3.1-2,,,,,,,,,,,,,,,Pairwise comparisons of beta-regressions calculated by betareg (v3.1–2)
emmeans,computational_tools,PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,emmeans,Package/Library,v1.4.2,,,,,,,,,,,,,,,Pairwise comparisons of beta-regressions calculated by betareg (v3.1–2) were done using emmeans (v1.4.2)
ggplot2,computational_tools,PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ggplot2,Package/Library,v3.2.1,,,,,,,,,,,,,,,"For all correlation plots, data were fit by stat_smooth using loess with span = 1 using ggplot2 (v3.2.1)"
GraphPad Prism version 6.0h,computational_tools,PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GraphPad Prism version 6.0h,Analysis Software,6.0h,,,,,,,,,,,,,,,"Analysis was performed using GraphPad Prism version 6.0h (La Jolla, CA, USA)"
Psychopy2,computational_tools,PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Psychopy2,Analysis Software,2,,,,,,,,,,,,,,,Psychopy2 software was used to display the stimuli and to record responses
SPSS version25,computational_tools,PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SPSS version25,Analysis Software,25,,,,,,,,,,,,,,,Statistical analyses were performed in SPSS version25 and R version 1.2
R version 1.2,computational_tools,PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,R version 1.2,Analysis Software,1.2,,,,,,,,,,,,,,,Statistical analyses were performed in SPSS version25 and R version 1.2
MATLAB R2014a,computational_tools,PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,MATLAB R2014a,Analysis Software,R2014a,,,,,,,,,,,,,,,"Image processing and statistical analysis was carried out using SPM12 (Wellcome Department of Imaging Neuroscience, London; http://www.fil.ion.ucl.ac.uk/spm ) and MATLAB R2014a"
Codon Code Aligner,computational_tools,PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Codon Code Aligner,Analysis Software,,http://www.codoncode.com/aligner/,,,,,,,,,,,,,,The sequencing traces were manually visualized in Codon Code Aligner software (http://www.codoncode.com/aligner/) to confirm the presence of candidate mutations.
"ABI Prism 7000 Sequence Detection System (Applied Biosystems, version 1.1 software)",computational_tools,PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,"ABI Prism 7000 Sequence Detection System (Applied Biosystems, version 1.1 software)",Analysis Software,1.1,,,,,,,,,,,,,,,"cDNA samples were then subjected to qPCR amplification on an ABI Prism 7000 Sequence Detection System (Applied Biosystems, version 1.1 software)"
ImageJ 1.54g software,computational_tools,PMID:40862755,10.3390/cells14161276,Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ImageJ 1.54g software,Analysis Software,1.54g,,,,,,,,,,,,,,,"Fluorescence intensity of P-glycoprotein was quantified using ImageJ 1.54g software (National Institutes of Health, Bethesda, MD, USA)."
Insight Toolkit,computational_tools,PMID:29958847,10.1016/j.neurad.2018.05.006,Radiomic biomarkers informative of cancerous transformation in neurofibromatosis-1 plexiform tumors.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Insight Toolkit,Package/Library,,www.itk.org/,,,,,,,,,,,,,,The pipeline for PN identification was developed in-house using the Insight Toolkit ( www.itk.org/ ) interfacing with the medical imaging visualization suite
Slicer,computational_tools,PMID:29958847,10.1016/j.neurad.2018.05.006,Radiomic biomarkers informative of cancerous transformation in neurofibromatosis-1 plexiform tumors.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Slicer,Analysis Software,,www.slicer.org/,,,,,,,,,,,,,,"using the Insight Toolkit ( www.itk.org/ ) interfacing with the medical imaging visualization suite, Slicer ( www.slicer.org/ )"
BWA version 0.7.15,computational_tools,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,BWA version 0.7.15,Command-line Tool,0.7.15,,,,,,,,,,,,,,,"The sequenced reads were mapped to the hg19 by Burrows-Wheeler Aligner (BWA version 0.7.15, default parameters, BWA-MEM algorithm)"
GATK MuTect2 (version 4.1),computational_tools,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GATK MuTect2 (version 4.1),Analysis Software,4.1,,,,,,,,,,,,,,,"Mutations were identified via GATK MuTect2 (version 4.1, default parameters)"
ANNOVAR (version 2016-02-01),computational_tools,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ANNOVAR (version 2016-02-01),Analysis Software,2016-02-01,,,,,,,,,,,,,,,"Mutations were annotated with software ANNOVAR (version 2016-02-01, default parameters)"
SAS 9.4,computational_tools,PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SAS 9.4,Analysis Software,9.4,,,,,,,,,,,,,,,"All statistical analyses were conducted using SAS 9.4 (SAS Institute, Cary, NC)"
ParaVision 6.0.1,computational_tools,PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ParaVision 6.0.1,Analysis Software,6.0.1,,,,,,,,,,,,,,,"B-GA12S HP gradients running ParaVision 6.0.1, Bruker BioSpin"
Trimmomatic (v0.33),computational_tools,PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Trimmomatic (v0.33),Analysis Software,v0.33,,,,,,,,,,,,,,,quality trimming via Trimmomatic (v0.33)
HISAT2 (v2.1.0),computational_tools,PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,HISAT2 (v2.1.0),Analysis Software,v2.1.0,,,,,,,,,,,,,,,alignment via HISAT2 (v2.1.0)
StringTie (v1.3.4d),computational_tools,PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,StringTie (v1.3.4d),Analysis Software,v1.3.4d,,,,,,,,,,,,,,,gene count quantification via StringTie (v1.3.4d)
DESeq2 (v1.42.0),computational_tools,PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,DESeq2 (v1.42.0),Package/Library,v1.42.0,,,,,,,,,,,,,,,"Differential expression analysis was performed using R statistical software (v4.3.1), tidyverse (v2.0.0), and DESeq2 (v1.42.0)"
TagIdent,computational_tools,PMID:26883872,10.1016/j.jprot.2016.02.004,3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,TagIdent,Web Application,,http://web.expasy.org/tagident/,,,,,,,,,,,,,,sequence tags of around 4–5 amino acids that were subsequently searched using TagIdent (http://web.expasy.org/tagident/)
protein prospector MS-product,computational_tools,PMID:26883872,10.1016/j.jprot.2016.02.004,3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,protein prospector MS-product,Web Application,,http://prospector.ucsf.edu/prospector/mshome.htm,,,,,,,,,,,,,,Proteins with matching intact molecular weights and containing the sequence observed were processed using protein prospector MS-product (http://prospector.ucsf.edu/prospector/mshome.htm)
GraphPad Prism 6.0,computational_tools,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GraphPad Prism 6.0,Analysis Software,6.0,,,,,,,,,,,,,,,"Growth curves were plotted using GraphPad Prism 6.0 software (San Diego, CA)"
Oligo 5.0 computer program,computational_tools,PMID:15255999,10.1186/1476-4598-3-20,"Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR.",,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Oligo 5.0 computer program,Analysis Software,5.0,,,,,,,,,,,,,,,"Primers for TBP, RPLP0 and the 489 target genes (List in annex; supplementary information) were chosen with the assistance of the Oligo 5.0 computer program (National Biosciences, Plymouth, MN)"
python 3.5.1,computational_tools,PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,python 3.5.1,Analysis Software,3.5.1,,,,,,,,,,,,,,,We used python 3.5.1 and Sci-kit Learn for machine learning implementations
R version 3.2.3,computational_tools,PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,R version 3.2.3,Analysis Software,3.2.3,,,,,,,,,,,,,,,We performed all preprocessing steps using R version 3.2.3
Labview 7.0,computational_tools,PMID:24465906,10.1371/journal.pone.0086115,"Multiscale, converging defects of macro-porosity, microstructure and matrix mineralization impact long bone fragility in NF1.",,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Labview 7.0,Analysis Software,7.0,,,,,,,,,,,,,,,"Both the camera and the tensile tester were controlled by customized software (Labview 7.0, National Instruments)"
GraphPad Prism version 5.01,computational_tools,PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.",,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GraphPad Prism version 5.01,Analysis Software,5.01,,,,,,,,,,,,,,,"AUCs were compared with two-way ANOVA followed by Bonferroni post-tests, using GraphPad Prism version 5.01"
STATA 11,computational_tools,PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.",,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,STATA 11,Analysis Software,11,,,,,,,,,,,,,,,"distributions were first checked for normality by using the Shapiro–Wilk's test with STATA 11 (StataCorp, College Station, TX)"
Schrödinger software suite release 2017–1,computational_tools,PMID:33369425,10.1021/acs.jpcb.0c09742,Machine Learning of Allosteric Effects: The Analysis of Ligand-Induced Dynamics to Predict Functional Effects in TRAP1.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Schrödinger software suite release 2017–1,Analysis Software,2017-1,,,,,,,,,,,,,,,"Briefly, the Schrödinger software suite release 2017–1 was used for system setup."
MATLAB version 2019b,computational_tools,PMID:33369425,10.1021/acs.jpcb.0c09742,Machine Learning of Allosteric Effects: The Analysis of Ligand-Induced Dynamics to Predict Functional Effects in TRAP1.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,MATLAB version 2019b,Analysis Software,2019b,,,,,,,,,,,,,,,The predictive power of the trained models was internally checked via 5-fold cross validation procedure available in MATLAB version 2019b
SNPeffect 4.0,computational_tools,PMID:39373898,10.1007/s12031-024-02271-x,Identification of Pathogenic Missense Mutations of NF1 Using Computational Approaches.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SNPeffect 4.0,Analysis Software,4.0,,,,,,,,,,,,,,,These mutations were subjected to further phenotyping analysis using SNPeffect 4.0
iMutant 2.0,computational_tools,PMID:39373898,10.1007/s12031-024-02271-x,Identification of Pathogenic Missense Mutations of NF1 Using Computational Approaches.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,iMutant 2.0,Analysis Software,2.0,,,,,,,,,,,,,,,We selected the iMutant 2.0 and MUpro algorithms to predict the thermodynamic parameter changes
Gel-Pro Analyzer 4.0 software,computational_tools,PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Gel-Pro Analyzer 4.0 software,Analysis Software,4.0,,,,,,,,,,,,,,,"Densitometry analysis was performed with Gel-Pro Analyzer 4.0 software (Media Cybernetics; Silver Spring, MD)"
Chipster software,computational_tools,PMID:25340526,10.1371/journal.pone.0107760,Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Chipster software,Analysis Software,,http://chipster.csc.fi/,,,,,,,,,,,,,,Alignment and analysis was performed using a Galaxy server and open source Chipster software (http://chipster.csc.fi/)
TopHat v2.0,computational_tools,PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,TopHat v2.0,Analysis Software,v2.0,,,,,,,,,,,,,,,Raw reads were mapped to the reference human genome hg19 using TopHat v2.0 with the -p 4 and -r210 arguments
Cufflinks v0.9.3,computational_tools,PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Cufflinks v0.9.3,Analysis Software,v0.9.3,,,,,,,,,,,,,,,Reads were quantified by both Cufflinks v0.9.3
R (version 4.3.1),computational_tools,PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,R (version 4.3.1),Analysis Software,4.3.1,,,,,,,,,,,,,,,"All statistical analyses were performed in R (version 4.3.1) using the 'survival', 'survminer', and 'stats' packages"
BSDA v1.2.0,computational_tools,PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,BSDA v1.2.0,Package/Library,v1.2.0,,,,,,,,,,,,,,,"compared to estimate the P value of the real observations (real P value) (using BSDA v1.2.0, z.test function)"
gdata v2.18.0,computational_tools,PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,gdata v2.18.0,Package/Library,v2.18.0,,,,,,,,,,,,,,,"resampled 10,000 times to produce 10,000 possible combinations of age-adjusted proportions (using gdata v2.18.0, resample function)"
ggplot2 v3.3.2,computational_tools,PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ggplot2 v3.3.2,Package/Library,v3.3.2,,,,,,,,,,,,,,,The distributions of bootstrapped P values were visualized using R (ggplot2 v3.3.2)
MedCalc,computational_tools,PMID:28589254,10.1007/s00259-017-3733-1,Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of ,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,MedCalc,Analysis Software,v16.8.4,,,,,,,,,,,,,,,"Statistical analysis was performed using SPSS (v22, Chicago, IL, USA) and MedCalc (v16.8.4, Ostend, Belgium) software"
Python sklearn,computational_tools,PMID:39093127,10.1158/1078-0432.CCR-24-0797,Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Python sklearn,Package/Library,v.1.3.2,,,,,,,,,,,,,,,We then used the Python sklearn library (v.1.3.2) decomposition module incorporating up to 20 components
ComplexHeatmap,computational_tools,PMID:39093127,10.1158/1078-0432.CCR-24-0797,Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ComplexHeatmap,Package/Library,v.2.14.0,,,,,,,,,,,,,,,were represented by heatmaps using ComplexHeatmap (v.2.14.0) with supervised clustering
SAS software Version 9.4,computational_tools,PMID:31053133,10.1186/s13023-019-1067-8,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SAS software Version 9.4,Analysis Software,9.4,,,,,,,,,,,,,,,"The data were analyzed using SAS software Version 9.4 (SAS Institute, Cary, NC, USA), with the significance level set at 0.05"
SPSS version 25,computational_tools,PMID:33519543,10.3389/fpsyt.2020.585700,Autism Spectrum Disorder Symptom Profile Across the RASopathies.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SPSS version 25,Analysis Software,25,,,,,,,,,,,,,,,"Data were analyzed in SPSS version 25 (SPSS Inc., Chicago, USA)"
cBioPortal,computational_tools,PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,cBioPortal,Web Application,,https://www.cbioportal.org/,,,,,,,,,,,,,,Somatic variants were queried in cBioPortal (https://www.cbioportal.org/)
Mutiwfn 3.7,computational_tools,PMID:39881370,10.1186/s13065-024-01353-6,"Spectrophotometric and computational characterization of charge transfer complex of selumetinib with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone and its utilization in developing an innovative green and high throughput microwell assay for analysis of bulk form and pharmaceutical formulation.",,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Mutiwfn 3.7,Analysis Software,3.7,,,,,,,,,,,,,,,"Mutiwfn 3.7, VMD, and the GAMESS-optimized SEL-DDQ complex were used in the hirshfeld surface HS study"
DYNAMIC software,computational_tools,PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,DYNAMIC software,Analysis Software,V7.1.4,,,,,,,,,,,,,,,"DYNAMIC software (V7.1.4) was used to obtain the normalized time autocorrelation function, polydispersity, and the absolute molecular mass"
Bindworks,computational_tools,PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Bindworks,Analysis Software,version 3.1.5,,,,,,,,,,,,,,,"The data were analyzed using the manufacturer provided software Bindworks (version 3.1.5, Calorimetry Sciences Corp. Lindon, UT)"
MantidPlot,computational_tools,PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,MantidPlot,Analysis Software,,http://www.mantidproject.org/,,,,,,,,,,,,,,Data reduction followed standard procedures that are implemented in MantidPlot (http://www.mantidproject.org/)
SPSS (Version 25),computational_tools,PMID:37608248,10.1186/s11689-023-09492-y,Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memory.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SPSS (Version 25),Analysis Software,25,,,,,,,,,,,,,,,Statistical analyses were conducted using SPSS (Version 25)
HaploReg v2,computational_tools,PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,HaploReg v2,Web Application,v2,,,,,,,,,,,,,,,mQTL putative genes were obtained from the HaploReg v2 web browser ( 36 )
SPM12 v7771,computational_tools,PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SPM12 v7771,Analysis Software,v7771,,,,,,,,,,,,,,,"Images were segmented using SPM12 v7771 (Wellcome Trust Centre for Neuroimaging, University College London, United Kingdom)"
MRIcroGL,computational_tools,PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,MRIcroGL,Analysis Software,,https://www.nitrc.org/projects/mricrogl,,,,,,,,,,,,,,"For visualization purposes, all thresholded SPM maps were imported into MRIcroGL (https://www.nitrc.org/projects/mricrogl)"
SPSS version 28.0,computational_tools,PMID:38499890,10.1186/s41687-024-00714-y,"The PlexiQoL, a patient-reported outcome measure on quality of life in neurofibromatosis type 1-associated plexiform neurofibroma: translation, cultural adaptation and validation into the Dutch language for the Netherlands.",,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SPSS version 28.0,Analysis Software,28.0,,,,,,,,,,,,,,,The statistical analyses were conducted using SPSS version 28.0
infercnvpy package,computational_tools,PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,infercnvpy package,Package/Library,,https://github.com/icbi-lab/infercnvpy,,,,,,,,,,,,,,the infercnvpy package (https://github.com/icbi-lab/infercnvpy) was used to detect copy number variations
GraphPad Prism 5.0,computational_tools,PMID:31527226,10.1158/1535-7163.MCT-19-0123,"Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of ",,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GraphPad Prism 5.0,Analysis Software,5.0,,,,,,,,,,,,,,,"GraphPad Prism 5.0 and 6.0 was used to perform all statistical analyses. Comparison of the means for nerve root volume, tumor number, KI-67 proliferation index"
GraphPad Prism 6.0,computational_tools,PMID:31527226,10.1158/1535-7163.MCT-19-0123,"Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of ",,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GraphPad Prism 6.0,Analysis Software,6.0,,,,,,,,,,,,,,,"GraphPad Prism 5.0 and 6.0 was used to perform all statistical analyses. Comparison of the means for nerve root volume, tumor number, KI-67 proliferation index"
cutpointR,computational_tools,PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,cutpointR,Package/Library,1.1.2,,,,,,,,,,,,,,,"For threshold optimization, we used cutpointR version 1.1.2, maximizing the 'accuracy' metric"
JSON-LD schema,computational_tools,PMID:35735230,10.1093/database/baac045,Centralizing neurofibromatosis experimental tool knowledge with the NF Research Tools Database.,,0.85,Development,True,1.00,High,,,,,,,,,,,,,,,JSON-LD schema,Other,2.0.0,https://github.com/nf-osi/nf-research-tools-schema,,,,,,,,,,,,,,...We constructed a JSON-LD schema from the data model to make it machine-readable (version 2.0.0 at the time of writing...
rare disease workflows,computational_tools,PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,rare disease workflows,Workflow,,https://github.com/Sage-Bionetworks/rare-disease-workflows/tree/main/rna-seq-workflow,,,,,,,,,,,,,,Our RNAseq analyses leverage the rare disease workflows at https://github.com/Sage-Bionetworks/rare-disease-workflows/tree/main/rna-seq-workflow
ConsensusClusterPlus,computational_tools,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ConsensusClusterPlus,Package/Library,v3.10,,,,,,,,,,,,,,,"To identify DNA methylation groups, ConsensusClusterPlus (Bioconductor v3.10) was used"
Clustree,computational_tools,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Clustree,Package/Library,,https://github.com/lazappi/clustree,,,,,,,,,,,,,,cluster number optimization was performed by comparing multiple cluster resolutions using Clustree
vcf2maf,computational_tools,PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,vcf2maf,Command-line Tool,,https://github.com/mskcc/vcf2maf,,,,,,,,,,,,,,"Variant call format (VCF) files were processed using ""vcf2maf"" (https://github.com/mskcc/vcf2maf)"
"MATLAB (R2008a, MathWorks, Natick, MA, USA)",computational_tools,PMID:24559228,10.1186/1866-1955-6-4,Abnormal late visual responses and alpha oscillations in neurofibromatosis type 1: a link to visual and attention deficits.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,"MATLAB (R2008a, MathWorks, Natick, MA, USA)",Analysis Software,R2008a,,,,,,,,,,,,,,,"Stimuli were generated with MATLAB (R2008a, MathWorks, Natick, MA, USA) and presented with the stimulation software STIM 2"
"IBM SPSS Statistics, version 19",computational_tools,PMID:24559228,10.1186/1866-1955-6-4,Abnormal late visual responses and alpha oscillations in neurofibromatosis type 1: a link to visual and attention deficits.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,"IBM SPSS Statistics, version 19",Analysis Software,19,,,,,,,,,,,,,,,"All statistical analyses were performed with IBM SPSS Statistics, version 19, software (IBM Corporation, Armonk, NY, USA)"
WGCNA package v1.69,computational_tools,PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,WGCNA package v1.69,Package/Library,v1.69,,,,,,,,,,,,,,,The conserved gene regulation networks and the correlation between drug responses and the gene network were determined using the WGCNA package v1.69
SynergyFinder,computational_tools,PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SynergyFinder,Web Application,,https://synergyfinder.org/,,,,,,,,,,,,,,Drug synergy was evaluated using the Bliss independence model via the SynergyFinder online platform (https://synergyfinder.org/)
Leiden Open Variation Database (LOVD),computational_tools,PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Leiden Open Variation Database (LOVD),Database,,www.lovd.nl,,,,,,,,,,,,,,The publically accessible variant databases included were Leiden Open Variation Database (LOVD) ( www.lovd.nl )
ClinVar NCBI,computational_tools,PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ClinVar NCBI,Database,,www.ncbi.nlm.nih.gov/clinvar,,,,,,,,,,,,,,ClinVar NCBI ( www.ncbi.nlm.nih.gov/clinvar )
Human Gene Mutation Database (HGMD),computational_tools,PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Human Gene Mutation Database (HGMD),Database,,www.hgmd.cf.ac.uk/ac/all.php,,,,,,,,,,,,,,the Human Gene Mutation Database (HGMD) ( www.hgmd.cf.ac.uk/ac/all.php )
Clinical Interpretation of Variants in Cancer (CIViC),computational_tools,PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Clinical Interpretation of Variants in Cancer (CIViC),Database,,https://civicdb.org/home,,,,,,,,,,,,,,Clinical Interpretation of Variants in Cancer (CIViC) ( https://civicdb.org/home )
Mastermind Genomic Search Engine,computational_tools,PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Mastermind Genomic Search Engine,Web Application,,https://www.genomenon.com/mastermind,,,,,,,,,,,,,,Mastermind Genomic Search Engine ( https://www.genomenon.com/mastermind )
UCSC LiftOver tool,computational_tools,PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,UCSC LiftOver tool,Web Application,,genome.ucsc.edu/cgi-bin/hgLiftOver,,,,,,,,,,,,,,UCSC LiftOver tool was used for any genomic co‐ordinate conversions between genome builds GRCh37/hg19 and GRCh38/hg38
alleleFrequencyApp,computational_tools,PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,alleleFrequencyApp,Web Application,,cardiodb.org/allelefrequencyapp,,,,,,,,,,,,,,Maximum credible population allele frequency was determined using the alleleFrequencyApp ( cardiodb.org/allelefrequencyapp )
COSMIC,computational_tools,PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,COSMIC,Database,,www.cancer.sanger.ac.uk,,,,,,,,,,,,,,"COSMIC ( www.cancer.sanger.ac.uk ) (Tate et al., 2019 ) was used in the investigation of variants that were observed in somatic samples"
CanVar-UK cancer predisposition gene variant database,computational_tools,PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,CanVar-UK cancer predisposition gene variant database,Database,,www.canvaruk.org,,,,,,,,,,,,,,CanVar‐UK cancer predisposition gene variant database ( www.canvaruk.org ) was used in the search for further variant information
GraphPad Prism version 8.0,computational_tools,PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GraphPad Prism version 8.0,Analysis Software,8.0,,,,,,,,,,,,,,,"Statistical analyses were performed using GraphPad Prism version 8.0 (San Diego, CA)"
SAS version 9.4,computational_tools,PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SAS version 9.4,Analysis Software,9.4,,,,,,,,,,,,,,,"Statistical analyses were performed using GraphPad Prism version 8.0 (San Diego, CA), SAS version 9.4 (Cary, NC)"
R version 3.3.2,computational_tools,PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,R version 3.3.2,Analysis Software,3.3.2,,,,,,,,,,,,,,,"Statistical analyses were performed using GraphPad Prism version 8.0 (San Diego, CA), SAS version 9.4 (Cary, NC), and R version 3.3.2"
R statistical software version 3.5.1,computational_tools,PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,R statistical software version 3.5.1,Analysis Software,3.5.1,,,,,,,,,,,,,,,All analyses were done with R statistical software version 3.5.1
Picard tools,computational_tools,PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Picard tools,Analysis Software,,https://github.com/broadinstitute/picard,,,,,,,,,,,,,,Duplicate read pair detection was carried out with Picard tools
Burrows-Wheeler Aligner (bwa-0.7.15),computational_tools,PMID:39669605,10.1016/j.gimo.2024.101816,Next-generation variant exon screening: Moving forward in routine genetic disease investigations.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Burrows-Wheeler Aligner (bwa-0.7.15),Command-line Tool,0.7.15,,,,,,,,,,,,,,,FASTQ files were first aligned to the human reference genome (hg19) by the Burrows-Wheeler Aligner (bwa-0.7.15)
Sambamba (v0.6.6),computational_tools,PMID:39669605,10.1016/j.gimo.2024.101816,Next-generation variant exon screening: Moving forward in routine genetic disease investigations.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Sambamba (v0.6.6),Command-line Tool,v0.6.6,https://github.com/biod/sambamba,,,,,,,,,,,,,,PCR duplications that cause bias in copy-number analysis were filtered out using Sambamba (v0.6.6)
Genome Analysis Toolkit (GATK),computational_tools,PMID:39669605,10.1016/j.gimo.2024.101816,Next-generation variant exon screening: Moving forward in routine genetic disease investigations.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Genome Analysis Toolkit (GATK),Analysis Software,3.8,,,,,,,,,,,,,,,SNVs/indel variants and SNPs were called using version 3.8 of the Genome Analysis Toolkit (GATK).
GTEx,computational_tools,PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GTEx,Database,V7,,,,,,,,,,,,,,,"eQTL results for all CALM‐associated SNPs and collated genes based on 749 normal skin tissues were then extracted from GTEx (V7, dbGaP Accession phs000424.v7.p2)"
Adobe Photoshop CS2,computational_tools,PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Adobe Photoshop CS2,Analysis Software,CS2,,,,,,,,,,,,,,,An attached Olympus DP72 camera and Adobe Photoshop CS2 were used to capture the images
SDS3.0,computational_tools,PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,SDS3.0,Analysis Software,3.0,,,,,,,,,,,,,,,"Allelic discrimination plots generated by SDS3.0, an Applied Biosystems program used to make genotyping calls"
Prizm v.4 (GraphPad),computational_tools,PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Prizm v.4 (GraphPad),Analysis Software,v.4,,,,,,,,,,,,,,,All analyses were performed using Prizm v.4 (GraphPad)
FACSDiva v6.1,computational_tools,PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,FACSDiva v6.1,Analysis Software,v6.1,,,,,,,,,,,,,,,FACSDiva v6.1 and FlowJo software v10.0.8 (BD Biosciences) were used to collect and analyze data
FlowJo software v10.0.8,computational_tools,PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,FlowJo software v10.0.8,Analysis Software,v10.0.8,,,,,,,,,,,,,,,FACSDiva v6.1 and FlowJo software v10.0.8 (BD Biosciences) were used to collect and analyze data
GraphPad Prism v8.3,computational_tools,PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,GraphPad Prism v8.3,Analysis Software,v8.3,,,,,,,,,,,,,,,The IC50s for each of the cell lines were determined using GraphPad Prism v8.3 (nonlinear regression and dose–response curve fitting)
HALO image analysis software v3.2,computational_tools,PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,HALO image analysis software v3.2,Analysis Software,v3.2,,,,,,,,,,,,,,,Tissues were scored for extent and intensity of staining using the HALO image analysis software v3.2
ZEN imaging software v2.3,computational_tools,PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ZEN imaging software v2.3,Analysis Software,v2.3,,,,,,,,,,,,,,,"Image acquisition was performed using a Zeiss LSM 880 with Airyscan confocal microscope (Zeiss, Oberkochen, Germany) and analyses performed with ZEN imaging software v2.3"
Igor 6.22A,computational_tools,PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Igor 6.22A,Analysis Software,6.22A,,,,,,,,,,,,,,,Electrophysiological data was analyzed with a custom written program in Igor 6.22A (WaveMetrics)
NeuroMatic,computational_tools,PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,NeuroMatic,Package/Library,2.00,,,,,,,,,,,,,,,"Electrophysiological data was analyzed with a custom written program in Igor 6.22A (WaveMetrics) NeuroMatic (version 2.00, kindly provided by Dr. J. Rothman)"
Trim Galore,computational_tools,PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Trim Galore,Analysis Software,,https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/,,,,,,,,,,,,,,All WES/WGS/RNA-seq samples were trimmed and quality controlled via Trim Galore (https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/)
Plotly v4.9.3,computational_tools,PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,Plotly v4.9.3,Package/Library,v4.9.3,https://plotly-r.com,,,,,,,,,,,,,,The VAF plot was generated using Plotly v4.9.3 in the R environment (available from https://plotly-r.com).
ggplot2 v3.5.1,computational_tools,PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,ggplot2 v3.5.1,Package/Library,v3.5.1,https://ggplot2.tidyverse.org,,,,,,,,,,,,,,The output was then visualized using ggplot2 v3.5.1 (https://ggplot2.tidyverse.org).
UpSetR Version 1.4.0,computational_tools,PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,UpSetR Version 1.4.0,Package/Library,1.4.0,,,,,,,,,,,,,,,Visualization of intersecting sets was performed with UpSetR Version 1.4.0 (R package).
salmon,computational_tools,PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,,,,,salmon,Analysis Software,1.4.0,,,,,,,,,,,,,,,quantified reads to the GENCODE M19 transcriptome using 'salmon' (1.4.0) aligner (RRID: SCR_017036)
NF1 gRNA,genetic_reagents,PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,NF1 gRNA,Other,,,,,,,,,,,,,,,,,,,,We targeted NF1's RASGAP GRD domain with clustered regularly interspaced short palindromic repeat (CRISPR) guides to the 21st exon
NF2,genetic_reagents,PMID:24595234,10.1371/journal.pone.0090853,In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,NF2,Plasmid,pUASt,,,,,,,,,,,,,,,,,,,Transgenes expressing the indicated NF2 proteins were cloned with N-terminal Flag epitope tags in the pUASt transformation vector.
NF1-area probes,genetic_reagents,PMID:24958239,10.1186/gb-2014-15-6-r80,SVA retrotransposon insertion-associated deletion represents a novel mutational mechanism underlying large genomic copy number changes with non-recurrent breakpoints.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,NF1-area probes,Other,,,,,,,,,,,,,,,,,,,,"The deletions analyzed in this study were identified by MLPA analysis (P122-C1 NF1-area kit, MRC-Holland, The Netherlands)"
NF1-targeting TALEN,genetic_reagents,PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,NF1-targeting TALEN,Other,,,,,,,,,,,,,,,,,,,,TALENs were designed to flank the region of NF1 in exon 41. Ossabaw minipig fetal fibroblasts isolated from day 38 embryos were transfected with TALENs
NF1 isoform-2,genetic_reagents,PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,NF1 isoform-2,Plasmid,,,,,,,,,,,,,,,,,,,,Point mutations in NF1 isoform-2 were generated by PCR mutagenesis of Addgene plasmid 70423.
NF1-GRD,genetic_reagents,PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,NF1-GRD,Plasmid,TTIGFP-MLUEX,,,,,,,,,,,,,,,,,,,The human NF1-GRD was amplified using the genomic deoxyribonucleic acid (gDNA) from HEK293T as polymerase chain reaction template and subcloned into TTIGFP-MLUEX vector
Nf1 RNAi,genetic_reagents,PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,Nf1 RNAi,Other,,,,,,,,,,,,,,,,,,,,The Nf1 RNAi line was obtained from the Vienna Drosophila RNAi Center (VDRC #109637)
NF2 TET,genetic_reagents,PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,NF2 TET,Other,,,,,,,,,,,,,,,,,,,,"at markers D22S193 (centromeric to NF2), NF2 TET and D22S929 (intragenic)"
NF1,genetic_reagents,PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,NF1,Plasmid,pFastBacHta,,,,,,,,,,,,,,,,,,,synthetic gene (GeneArt) encoding the human full-length NF1 (synNF1) was cloned into the pFastBacHta (Life Technology) vector
NF1 siRNA,genetic_reagents,PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,NF1 siRNA,Other,,,,,,,,,,,,,,,,,,,,"transfected with 4 siRNAs (FlexiTube, Qiagen, Hilden; Supplementary Table 2) designed for silencing the NF1 message"
Merlin isoform 1,genetic_reagents,PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,Merlin isoform 1,Plasmid,pET32a,,,,,,,,,,,,,,,,,,,"The human cDNA encoding the full-length Merlin isoform 1 was subcloned into the pET32a vector (EMD Biosciences, Inc), with a 6XHis plus thioredoxin tag"
Merlin siRNA,genetic_reagents,PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,Merlin siRNA,Other,,,,,,,,,,,,,,,,,,,,Merlin knockdown U251-S cells were treated with siRNA SMARTpool (Thermo Scientific) directed to Merlin
nf2a/b-4sgRNA,genetic_reagents,PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,0.85,Experimental Usage,True,1.00,High,,,,,,,,,,,nf2a/b-4sgRNA,Plasmid,pGGDestTol2LC,,,,,,,,,,,,,,,,,,,All four guides were cloned into the final destination vector pGGDestTol2LC-4sgRNA (nf2a/b-4sgRNA)
oviductal organoids,advanced_cellular_models,PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.95,Development,False,1.00,Medium,,,,,,,,,,,,,,,,,,,organoid,primary cell,oviductal epithelial cells,oviductal organoid,,,,,,,,,,establish organoid-based tumor progression models of HG-SOC from murine oviductal and OSE tissues
OSE organoids,advanced_cellular_models,PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.95,Development,False,1.00,Medium,,,,,,,,,,,,,,,,,,,organoid,primary cell,ovarian surface epithelium,OSE organoid,,,,,,,,,,establish organoid-based tumor progression models of HG-SOC from murine oviductal and OSE tissues
hiMGL cells,advanced_cellular_models,PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.95,Development,False,1.00,Medium,,,,,,,,,,,,,,,,,,,other,iPSC,Microglia-like cells,,,,,,,,,,,"hiMGL cells were generated from hiPSCs as previously described (McQuade et al., 2018) with minor modifications"
cNF organoids,advanced_cellular_models,PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.95,Development,False,1.00,Medium,,,,,,,,,,,,,,,,,,,organoid,patient tissue,"Schwann cells, fibroblasts, mast cells",cutaneous neurofibroma organoid,,,,,,,,,,Patient-derived cNF organoids closely recapitulate cellular and molecular features of parental tumors
3D microtissues,advanced_cellular_models,PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.95,Development,False,1.00,Medium,,,,,,,,,,,,,,,,,,,spheroid,patient tissue,,,,,,,,,,,,Selected PDX were harvested for assembly into 3D microtissues
NOD.CB17-Prkdc/NCrCrl,animal_models,PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,0.95,Experimental Usage,False,1.00,Medium,NOD.CB17-Prkdc/NCrCrl,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Female NOD SCID (NOD.CB17-Prkdc/NCrCrl) mice from Charles River Laboratories were housed in barrier facilities designed for immune-compromised animals.
"B6J.129(B6N)-Gt(ROSA)26Sor tm1(CAG-cas9*,-EGFP)Fezh/J",animal_models,PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.95,Experimental Usage,False,1.00,Medium,"B6J.129(B6N)-Gt(ROSA)26Sor tm1(CAG-cas9*,-EGFP)Fezh/J",No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"B6J.129(B6N)-Gt(ROSA)26Sor (JAX stock #026175) tm1(CAG-cas9*,-EGFP)Fezh/J mice strains were used for derivation of wild-type and Cas9/GFP-expressing organoids"
NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ,animal_models,PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.95,Experimental Usage,False,1.00,Medium,NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,NOD scid gamma (NSG; NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ mice were used. Transplantation experiments were performed
Crl:NU(NCr)‐Foxn1nu,animal_models,PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.95,Experimental Usage,False,1.00,Medium,Crl:NU(NCr)‐Foxn1nu,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,subcutaneously into the right flank of male CD‐1 nude mice (Athymic Nude Mice obtained from Charles River (Crl:NU(NCr)‐Foxn1nu))
Rosa26-LSL-Cas9 knockin,animal_models,PMID:39996452,10.1111/cns.70287,Cas9 Mouse Model of Skull Base Meningioma Driven by Combinational Gene Inactivation in Meningeal Cells.,,0.95,Experimental Usage,False,1.00,Medium,Rosa26-LSL-Cas9 knockin,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Twenty mice of Rosa26‐LSL‐Cas9 knockin were purchased from Jackson Laboratory (Strain #:024857, USA) and successfully bred in our lab."
Wisconsin Miniature SwineTM,animal_models,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.95,Development,False,1.00,Medium,Wisconsin Miniature SwineTM,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"The Wisconsin Miniature SwineTM (WMSTM) was developed to address these shortcomings. The WMSTM porcine model grows slower, reaching and maintaining human sizes at adulthood."
Balb/cAnNRj-Foxn1nu/Foxn1nu,animal_models,PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,0.95,Experimental Usage,False,1.00,Medium,Balb/cAnNRj-Foxn1nu/Foxn1nu,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Balb/c Nude (Balb/cAnNRj-Foxn1nu/Foxn1nu, Janvier), Foxn1 (Nu/Nu) Nude (Crl:NU-Foxn1nu, Charles River)"
Crl:NU-Foxn1nu,animal_models,PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,0.95,Experimental Usage,False,1.00,Medium,Crl:NU-Foxn1nu,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Foxn1 (Nu/Nu) Nude (Crl:NU-Foxn1nu, Charles River), SHO ® (SCID Hairless Outbred, Crl:SHO-PrkdcscidHrhr, Charles River)"
Crl:SHO-PrkdcscidHrhr,animal_models,PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,0.95,Experimental Usage,False,1.00,Medium,Crl:SHO-PrkdcscidHrhr,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"SHO ® (SCID Hairless Outbred, Crl:SHO-PrkdcscidHrhr, Charles River) and Shorn (ShrN NOD SCID, NOD.Cg-PrkdcscidHrhr/NCrHsd, Harlan)"
NOD.Cg-PrkdcscidHrhr/NCrHsd,animal_models,PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,0.95,Experimental Usage,False,1.00,Medium,NOD.Cg-PrkdcscidHrhr/NCrHsd,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Shorn (ShrN NOD SCID, NOD.Cg-PrkdcscidHrhr/NCrHsd, Harlan) mice were scheduled for xenotransplantations"
BALB/c nu/nu,animal_models,PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.95,Experimental Usage,False,1.00,Medium,BALB/c nu/nu,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2×10^6 cells were injected subcutaneously into flanks of 5-week old nude mice (BALB/c nu/nu)
NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ,animal_models,PMID:41023593,10.1186/s10020-025-01353-9,Selective inhibition of BRAF and CRAF sensitizes NF1-deficient malignant peripheral nerve sheath tumors to MEK inhibitors.,,0.95,Experimental Usage,False,1.00,Medium,NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"6- to 8-week-old NSG (NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ, strain #:005557, Jackson Laboratory or Johns Hopkins Oncology Animal Facility) and SCID female mice were used for in vivo efficacy studies"
"B6-Olig2tm2(TVA,cre)Rth/J",animal_models,PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,0.95,Experimental Usage,False,1.00,Medium,"B6-Olig2tm2(TVA,cre)Rth/J",No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Olig2-Cre mice (B6-Olig2 tm2 (TVA, cre)Rth /J; Jackson Laboratory; [ 20 ])"
B6.Cg-Gt(ROSA)26Sortm(CAGZsGreen1)Hze+/J,animal_models,PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,0.95,Experimental Usage,False,1.00,Medium,B6.Cg-Gt(ROSA)26Sortm(CAGZsGreen1)Hze+/J,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Rosa-GREEN mice (B6.Cg- Gt(ROSA)26Sor tm(CAGZsGreen1)Hze+ / J; Jackson Laboratory)
CB-17 SCID,animal_models,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.95,Experimental Usage,False,1.00,Medium,CB-17 SCID,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Eed-isogenic cells were infected with sgRNA lentiviruses for additional knockout of Cdkn2b followed by subcutaneous implantation into CB-17 SCID mice (Taconic, RRID:IMSR_TAC:cb17sc)"
Long-Evans,animal_models,PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,0.95,Experimental Usage,False,1.00,Medium,Long-Evans,No known disease,Optic Pathway Glioma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Twenty-four domestic rats of the Long-Evans strain (age 4 weeks with approximate weight of 150 g) were used as control and test recipients
NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ,animal_models,PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.95,Experimental Usage,False,1.00,Medium,NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ (NSG) male mice (6–8 weeks of age) were obtained from the on-site breeding colony
Survey of Well-being of Young Children (SWYC),clinical_assessment_tools,PMID:41468561,10.1212/WNL.0000000000214480,NF1-Specific Growth Charts for Head Circumference Over the First 3 Years of Life.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Survey of Well-being of Young Children (SWYC),questionnaire,pediatric,No,,"...developmental delay assessed with the Survey of Well-being of Young Children...SWYC surveys conducted on the same days, which assess developmental milestones..."
World Health Organization Quality of Life Brief Version (WHOQOL-BREF),clinical_assessment_tools,PMID:37378983,10.1001/jamanetworkopen.2023.20599,Effect of Mind-Body Skills Training on Quality of Life for Geographically Diverse Adults With Neurofibromatosis: A Fully Remote Randomized Clinical Trial.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,World Health Organization Quality of Life Brief Version (WHOQOL-BREF),questionnaire,adult,No,26.0,The 2 primary outcomes were the physical health and psychological QOL domain scores of the World Health Organization Quality of Life Brief Version (WHOQOL-BREF)
Tinnitus Functional Index,clinical_assessment_tools,PMID:38321701,10.1177/17407745231217279,Patient-reported measures of tinnitus for individuals with neurofibromatosis type 2-related schwannomatosis: Recommendations for clinical trials.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Tinnitus Functional Index,questionnaire,adult,No,,The Tinnitus Functional Index was identified as the most highly rated measure for the assessment of tinnitus in populations with neurofibromatosis type 2
PEERS® intervention,clinical_assessment_tools,PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,PEERS® intervention,structured interview,pediatric,No,14.0,The PEERS® intervention was administered by certified PEERS® providers...according to the PEERS® manual and the CARD telehealth manual
Social Skills Improvement System Social-Emotional Learning (SSIS-SEL),clinical_assessment_tools,PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Social Skills Improvement System Social-Emotional Learning (SSIS-SEL),questionnaire,all ages,No,51.0,The SSIS-SEL is a caregiver and self-report questionnaire measure examining social-emotional skills...Parent (51 items) and Student (46 items) forms
Pain Interference Index (PII),clinical_assessment_tools,PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,0.95,Development,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Pain Interference Index (PII),questionnaire,pediatric,No,6.0,The original PII measure is a six-item self-report questionnaire that assesses pain interference using the past 2 weeks as a recall period
Pain Interference Index-Parent report (PII-P),clinical_assessment_tools,PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,0.95,Development,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Pain Interference Index-Parent report (PII-P),questionnaire,caregiver,No,6.0,"The six-item PII-P is formatted and scored in the same manner as the self-report PII, with total scores ranging from 0 to 6"
RECIST 1.1,clinical_assessment_tools,PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,RECIST 1.1,scale,adult,No,,radiographic tumor burden was quantified by sum of the longest tumor diameters (SLD) per RECIST 1.1 criteria
Vineland Adaptive Behaviour Scale—third edition,clinical_assessment_tools,PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Vineland Adaptive Behaviour Scale—third edition,scale,caregiver,No,,Parent-rated Vineland Adaptive Behaviour Scale—third edition was administered to the parents to assess child adaptive behaviour
Conners 3 rating scale,clinical_assessment_tools,PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Conners 3 rating scale,scale,caregiver,No,27.0,Conners 3 rating scale was used as a standardized measure for parent reported ADHD symptoms. It consists of 27 items each rated on a 4-point Likert scale
Wechsler Intelligence Scale for Children–Revised,clinical_assessment_tools,PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Wechsler Intelligence Scale for Children–Revised,scale,pediatric,No,,"assessed at baseline using the Wechsler Intelligence Scale for Children–Revised, Dutch version"
Numerical Rating Scale (NRS-11),clinical_assessment_tools,PMID:32187457,10.1056/NEJMoa1912735,Selumetinib in Children with Inoperable Plexiform Neurofibromas.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Numerical Rating Scale (NRS-11),scale,pediatric,No,11.0,Children rated tumor pain intensity on a scale from 0 (no pain) to 10 (worst pain imaginable)...pain intensity (11-point Numerical Rating Scale [NRS-11])
Pediatric Quality of Life Inventory (PedsQL) Generic Core Scales,clinical_assessment_tools,PMID:32187457,10.1056/NEJMoa1912735,Selumetinib in Children with Inoperable Plexiform Neurofibromas.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Pediatric Quality of Life Inventory (PedsQL) Generic Core Scales,questionnaire,pediatric,No,,"health-related quality of life (Pediatric Quality of Life Inventory [PedsQL] Generic Core Scales)...PedsQL scores range from 0 to 100, with higher scores indicating better health-related quality of life"
Patient-Reported Outcomes Measurement Information System (PROMIS) Mobility short form,clinical_assessment_tools,PMID:32187457,10.1056/NEJMoa1912735,Selumetinib in Children with Inoperable Plexiform Neurofibromas.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Patient-Reported Outcomes Measurement Information System (PROMIS) Mobility short form,questionnaire,pediatric,No,,children and parents also completed the Patient-Reported Outcomes Measurement Information System (PROMIS) Mobility and Upper Extremity short forms to assess physical functioning
Patient-Reported Outcomes Measurement Information System (PROMIS) Upper Extremity short form,clinical_assessment_tools,PMID:32187457,10.1056/NEJMoa1912735,Selumetinib in Children with Inoperable Plexiform Neurofibromas.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Patient-Reported Outcomes Measurement Information System (PROMIS) Upper Extremity short form,questionnaire,pediatric,No,,children and parents also completed the Patient-Reported Outcomes Measurement Information System (PROMIS) Mobility and Upper Extremity short forms to assess physical functioning
"NCI Common Terminology Criteria for Adverse Events, version 4.0",clinical_assessment_tools,PMID:32187457,10.1056/NEJMoa1912735,Selumetinib in Children with Inoperable Plexiform Neurofibromas.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,"NCI Common Terminology Criteria for Adverse Events, version 4.0",scale,all ages,No,,"Adverse events were graded with the use of the NCI Common Terminology Criteria for Adverse Events, version 4.0"
Mullen Scales of Early Learning (MSEL),clinical_assessment_tools,PMID:34049498,10.1186/s11689-021-09364-3,Early differences in auditory processing relate to Autism Spectrum Disorder traits in infants with Neurofibromatosis Type I.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Mullen Scales of Early Learning (MSEL),scale,pediatric,No,,The Mullen Scales of Early Learning (MSEL) is a standardised measure that assesses developmental ability across five domains...
National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0,clinical_assessment_tools,PMID:37174087,10.3390/cancers15092621,Vinblastine/Methotrexate for Debilitating and Progressive Plexiform Neurofibroma in Children and Young Adults with Neurofibromatosis Type 1: A Phase 2 Study.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0,scale,all ages,No,,...Adverse events (AE) were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0...
Autism Diagnostic Interview Revised (ADI-R),clinical_assessment_tools,PMID:33519543,10.3389/fpsyt.2020.585700,Autism Spectrum Disorder Symptom Profile Across the RASopathies.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Autism Diagnostic Interview Revised (ADI-R),structured interview,pediatric,No,87.0,meeting ASD cut-off on the Autism Diagnostic Interview Revised (ADI-R)...Autism Diagnostic Interview-Revised (ADI-R) was used for detailed parent interviews
Autism Diagnostic Observation Schedule-2 (ADOS-2),clinical_assessment_tools,PMID:33519543,10.3389/fpsyt.2020.585700,Autism Spectrum Disorder Symptom Profile Across the RASopathies.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Autism Diagnostic Observation Schedule-2 (ADOS-2),structured interview,pediatric,No,4.0,scoring above the ASD cut-off on the Autism Diagnostic Observation Schedule-2 (ADOS-2)...The Autism Diagnostic Observation Schedule–second edition (ADOS-2) was used to measure current autism clinical profile
Vineland Adaptive Behaviour Scale (VABS-III),clinical_assessment_tools,PMID:37608248,10.1186/s11689-023-09492-y,Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memory.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Vineland Adaptive Behaviour Scale (VABS-III),scale,caregiver,No,,parent-reported Adaptive Behaviour Composite (ABC) scores on the Vineland Adaptive Behaviour Scale (VABS-III)
Brief Pain Inventory Short Form (BPI-SF),clinical_assessment_tools,PMID:41602242,10.7759/cureus.100193,Perspectives of Patients and Providers on Chronic Pain Assessment in Neurofibromatosis Type 1 (NF1): A Qualitative Study.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Brief Pain Inventory Short Form (BPI-SF),questionnaire,adult,No,,responses to the Brief Pain Inventory Short Form (BPI-SF) [ 8 ]...a pain severity aggregate score of ≥3 on the BPI-SF [ 8 ] for pain experienced in the previous 2 weeks
Structured Clinical Interview for DSM Self Report version (SCID-SR),clinical_assessment_tools,PMID:41602242,10.7759/cureus.100193,Perspectives of Patients and Providers on Chronic Pain Assessment in Neurofibromatosis Type 1 (NF1): A Qualitative Study.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Structured Clinical Interview for DSM Self Report version (SCID-SR),structured interview,adult,No,,Structured Clinical Interview for DSM Self Report version (SCID-SR) [ 20 ]...evidence of psychosis or schizophrenia on the SCID-SR [ 20 ]
Generalized Anxiety Disorder 7 Item version (GAD-7),clinical_assessment_tools,PMID:41602242,10.7759/cureus.100193,Perspectives of Patients and Providers on Chronic Pain Assessment in Neurofibromatosis Type 1 (NF1): A Qualitative Study.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Generalized Anxiety Disorder 7 Item version (GAD-7),scale,adult,No,7.0,Generalized Anxiety Disorder 7 Item version (GAD-7) [ 21 ]...evidence of moderate to severe depression or anxiety on the PHQ or GAD-7
Social Responsiveness Scale 2nd Edition,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Social Responsiveness Scale 2nd Edition,scale,caregiver,No,65.0,Children with NF1 that screen at risk for ASD on the parent-rated Social Responsiveness Scale 2nd Edition will be invited back to complete...
WAIS-III,clinical_assessment_tools,PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,WAIS-III,performance test,adult,No,,General intellectual functioning was assessed by the third version of the Brazilian Wechsler Intelligence Scales (WAIS-III for adults and WISC-III for children)
WISC-III,clinical_assessment_tools,PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,WISC-III,performance test,pediatric,No,,General intellectual functioning was assessed by the third version of the Brazilian Wechsler Intelligence Scales (WAIS-III for adults and WISC-III for children)
Wechsler Intelligence Scale for Children (WISC-III),clinical_assessment_tools,PMID:24559228,10.1186/1866-1955-6-4,Abnormal late visual responses and alpha oscillations in neurofibromatosis type 1: a link to visual and attention deficits.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Wechsler Intelligence Scale for Children (WISC-III),performance test,pediatric,No,,"We administered the Portuguese adapted version of the Wechsler Intelligence Scale for Children (WISC-III), in all participants with NF1"
6-minute-walk test,clinical_assessment_tools,PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,6-minute-walk test,performance test,pediatric,No,,"gross motor endurance by the 6MWT, which was completed barefoot on a point‐to‐point, 25‐m long, flat, straight, hard surfaced track"
PedsQL Generic 4.0,clinical_assessment_tools,PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,PedsQL Generic 4.0,questionnaire,caregiver,No,,"Quality of life was assessed by parent reported questionnaires, including the Pediatric Quality of Life (PedsQL™) Generic 4.0 and Neuromuscular (3.0) modules"
CBCL/6-18,clinical_assessment_tools,PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,CBCL/6-18,questionnaire,caregiver,No,113.0,"The Child Behavior Checklist for ages 6–18 or CBCL/6‐18 (©ASEBA 2020). The CBCL/6‐18 (©ASEBA 2020) consists of 113 questions, scored on a 3‐point Likert scale"
PedsQL 4.0 Generic Core Scales,clinical_assessment_tools,PMID:22961690,10.1002/pbc.24281,Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,PedsQL 4.0 Generic Core Scales,questionnaire,pediatric,No,23.0,"QOL was assessed with the PedsQL 4.0 Generic Core Scales at baseline and prior to cycles 4, 8, 12, 18, and 24. This 23-item questionnaire yields subscale scores..."
SF-36,clinical_assessment_tools,PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,SF-36,questionnaire,adult,No,36.0,"Patients completed generic measures (SF-36, EQ-5D-5L, and PROMIS pain interference)"
EQ-5D-5L,clinical_assessment_tools,PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,EQ-5D-5L,questionnaire,adult,No,5.0,"Patients completed generic measures (SF-36, EQ-5D-5L, and PROMIS pain interference)"
PROMIS pain interference short form 8a,clinical_assessment_tools,PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,PROMIS pain interference short form 8a,questionnaire,adult,No,8.0,"Patients completed generic measures (SF-36, EQ-5D-5L, and PROMIS pain interference)"
Distress Thermometer (DT),clinical_assessment_tools,PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Distress Thermometer (DT),scale,all ages,No,,The Distress Thermometer (DT) was designed as a brief screening tool to assess for distress in adult cancer patients...the adapted pediatric DT was used in this study for all ages.
dLight1.2,genetic_reagents,PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,dLight1.2,Viral,AAV,hSyn,,,,,,,,,,,,,,,,,,pAAV-hSyn-dLight1.2 Addgene Plasmid#: 111068 RRID: Addgene_111068 Gift on Lin Tian; produced by UC Davis Vector Core
dLight1,genetic_reagents,PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,dLight1,Viral,,,,,,,,,,,,,,,,,,,,We employed the genetically encoded optical dopamine sensor dLight1 to monitor dopaminergic neurotransmission in the ventral striatum of NF1 mice
Trim23,genetic_reagents,PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Trim23,Viral,,,,,,,,,,,,,,,,,,,,"separate lentiviral shRNAs targeting Trim23 (Sigma; TRCN0000308323, TRCN0000308321, TRCN0000308320)"
shCOL1A2,genetic_reagents,PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,shCOL1A2,Viral,,,,,,,,,,,,,,,,,,,,Human sh COL1A2 and mouse sh Col1a2 lentiviral particles (TRCN0000090043; TRCN0000090045; TRCN0000335210)
NF-targeting capsid,genetic_reagents,PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.95,Development,False,1.00,Medium,,,,,,,,,,,NF-targeting capsid,Viral,AAV,,,,,,,,,,,,,,,,,,,"This tailored vector, AAV-NF, exhibits greatly reduced liver uptake, enhanced tumor targeting across various NF1-related MPNST"
CRISPR-Cas9,genetic_reagents,PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,CRISPR-Cas9,Viral,LentiCRISPR-v2,,,,,,,,,,,,,,,,,,,"The LentiCRISPR-v2 (RRID: Addgene_52961), LentiGuide-Puro (RRID: Addgene_52963), and LentiCas9-Blast (RRID: Addgene_52962) vectors were purchased from Addgene"
Guide RNA,genetic_reagents,PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Guide RNA,Viral,LentiGuide-Puro,,,,,,,,,,,,,,,,,,,"The LentiCRISPR-v2 (RRID: Addgene_52961), LentiGuide-Puro (RRID: Addgene_52963), and LentiCas9-Blast (RRID: Addgene_52962) vectors were purchased from Addgene"
Cas9,genetic_reagents,PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Cas9,Viral,LentiCas9-Blast,,,,,,,,,,,,,,,,,,,"The LentiCRISPR-v2 (RRID: Addgene_52961), LentiGuide-Puro (RRID: Addgene_52963), and LentiCas9-Blast (RRID: Addgene_52962) vectors were purchased from Addgene"
MAF,genetic_reagents,PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,MAF,Viral,Lentivirus,,,,,,,,,,,,,,,,,,,"Constitutive expression used mCherry tagged MAF (EX-Y2046-Lv111, GeneCopoeia) and mCherry control lentivirus"
human FBXW11,genetic_reagents,PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,human FBXW11,Plasmid,,,,,,,,,,,,,,,,,,,,"Myc-DDK–tagged human FBXW11 transcript variant 3 cDNA (RC218905, Origene)"
GFP,genetic_reagents,PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,GFP,Viral,AAV5,CMV,,,,,,,,,,,,,,,,,,"control (GFP; AAV5-CMV-GFP, UNC) or Cre-recombinase fused to GFP (CRE; AAV5-CMV-Cre-GFP, UNC)"
Cre-GFP,genetic_reagents,PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Cre-GFP,Viral,AAV5,CMV,,,,,,,,,,,,,,,,,,"control (GFP; AAV5-CMV-GFP, UNC) or Cre-recombinase fused to GFP (CRE; AAV5-CMV-Cre-GFP, UNC)"
lentiCRISPRv2,genetic_reagents,PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,lentiCRISPRv2,Plasmid,lentiCRISPRv2,,,,,,,,,,,,,,,,,,,"cloned into the transfer plasmid lentiCRISPRv2 (Addgene, https://www.addgene.org/52961/)"
psPAX2,genetic_reagents,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,psPAX2,Plasmid,psPAX2,,,,,,,,,,,,,,,,,,,"Lentiviral transfer plasmid plus packaging plasmids psPAX2 (gift from Didier Trono, Addgene Plasmid #12260, RRID:Addgene_12260) and pCMV-VSV-G"
VSV-G,genetic_reagents,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,VSV-G,Plasmid,pCMV-VSV-G,CMV,,,,,,,,,,,,,,,,,,"pCMV-VSV-G (gift from Bob Weinberg, Addgene Plasmid #8454, RRID:Addgene_8454) were cotransfected intro HEK-293T cells"
shRNA,genetic_reagents,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,shRNA,Plasmid,LT3GEPIR,,,,,,,,,,,,,,,,,,,"Control (sh Ren.713), DNMT1, DNMT3A, and DNMT3B shRNAs were cloned into Tet-ON all-in-one plasmids LT3GEPIR (gift from Johannes Zuber, RRID:Addgene_111177)"
SUZ12,genetic_reagents,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.95,Experimental Usage,False,1.00,Medium,,,,,,,,,,,SUZ12,Plasmid,pLV-EF1α-IRES-Puro,EF1α,,,,,,,,,,,,,,,,,,"Human SUZ12 cDNA was cloned into pLV-EF1α-IRES-Puro (gift from Tobias Meyer, RRID:Addgene_85132)"
laminin,antibodies,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,Experimental Usage,True,0.67,Medium,,,,laminin,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,rabbit anti-laminin (Sigma-Aldrich L9393; 1:500)
myosin heavy chain,antibodies,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,Experimental Usage,True,0.67,Medium,,,,myosin heavy chain,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,mouse anti-myosin heavy chain (Sigma-Aldrich 05-716; 1:1000)
PPARG,antibodies,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,Experimental Usage,True,0.67,Medium,,,,PPARG,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Antibodies used were rabbit anti-PPARG (Cell Signaling Technology 2443)
phosphor (pThr172) AMPKa,antibodies,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,Experimental Usage,True,0.67,Medium,,,,phosphor (pThr172) AMPKa,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,rabbit anti-phosphor (pThr172) AMPKa (Cell Signaling Technology 2535)
AMPKα,antibodies,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,Experimental Usage,True,0.67,Medium,,,,AMPKα,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,rabbit anti-AMPKα (Cell Signaling Technology 2532)
β-actin,antibodies,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,Experimental Usage,True,0.67,Medium,,,,β-actin,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,mouse anti-β-actin (Cell Signaling Technology 58169)
β-tubulin,antibodies,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,Experimental Usage,True,0.67,Medium,,,,β-tubulin,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,mouse anti-β-tubulin (Sigma-Aldrich T8328)
phosphor (s235/236) S6,antibodies,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,Experimental Usage,True,0.67,Medium,,,,phosphor (s235/236) S6,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,rabbit anti-phosphor (s235/236) S6 (Cell Signaling Technology 4858)
phosphor (Ser473) AKT,antibodies,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,Experimental Usage,True,0.67,Medium,,,,phosphor (Ser473) AKT,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-phosphor (Ser473) AKT (Cell Signaling, #9271; 1:1000)"
phospho (Ser1101) IRS-1,antibodies,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,Experimental Usage,True,0.67,Medium,,,,phospho (Ser1101) IRS-1,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-phospho (Ser1101) IRS-1 (Cell Signaling, #2385; 1:1000)"
phospho (Ser636/639) IRS-1,antibodies,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,Experimental Usage,True,0.67,Medium,,,,phospho (Ser636/639) IRS-1,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-phospho (Ser636/639) IRS-1 (Cell Signaling, #2388; 1:1000)"
RAP1A,antibodies,PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,0.95,Experimental Usage,True,0.67,Medium,,,,RAP1A,Unknown,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Non-prenylated RAP1A was detected with a 1:250 dilution of a goat polyclonal RAP1A antibody (Santa Cruz, product #1482)."
collagen XV,antibodies,PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.95,Experimental Usage,True,0.67,Medium,,,,collagen XV,,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"...followed by an incubation with polyclonal anti-collagen XV (Sigma-Aldrich, HPA017913, 1:1000)..."
collagen XVIII,antibodies,PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.95,Experimental Usage,True,0.67,Medium,,,,collagen XVIII,,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"...or in-house monoclonal anti-collagen XVIII (ref. [ 46 ], DB144-N2, 7 µg/ml) primary antibody..."
p53,antibodies,PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.95,Experimental Usage,True,0.67,Medium,,,,p53,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-p53 (NCL-p53-CM5p, 1:1000, Leica Biosystems)"
Olig2,antibodies,PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.95,Experimental Usage,True,0.67,Medium,,,,Olig2,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-Olig2 (AB9610, 1:2000, EMD Millipore)"
Pten,antibodies,PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.95,Experimental Usage,True,0.67,Medium,,,,Pten,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-Pten (9559S, 1:1000, Cell Signaling)"
p-S6,antibodies,PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.95,Experimental Usage,True,0.67,Medium,,,,p-S6,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-p-S6 (5364S, 1:2000, Cell Signaling)"
p-Erk,antibodies,PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.95,Experimental Usage,True,0.67,Medium,,,,p-Erk,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-p-Erk (9101S, 1:2000, Cell Signaling)"
GFP,antibodies,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.95,Experimental Usage,True,0.67,Medium,,,,GFP,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies used in this study: Rabbit anti-GFP, Thermo Fisher, Cat. # A6455 (1/1000)"
mCherry,antibodies,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.95,Experimental Usage,True,0.67,Medium,,,,mCherry,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Mouse anti-mCherry, Abcam, Cat. # ab125096 (1:500)"
CD3,antibodies,PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.95,Experimental Usage,True,0.67,Medium,,,,CD3,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,Anti-mCD3 (145–2C11) and anti-mIL6 receptor (15A7) antibodies were purchased from BioXcell.
IL6 receptor,antibodies,PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.95,Experimental Usage,True,0.67,Medium,,,,IL6 receptor,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,Anti-mCD3 (145–2C11) and anti-mIL6 receptor (15A7) antibodies were purchased from BioXcell.
IL3,antibodies,PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.95,Experimental Usage,True,0.67,Medium,,,,IL3,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,anti-mIL3 antibody (MP2–8F8) was purchased from BD Biosciences.
GFP,antibodies,PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.95,Experimental Usage,True,0.67,Medium,,,,GFP,Unknown,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,Goat anti-GFP antibody (600-101-215) was purchased from Rockland Immunochemicals
p44/42 MAPK (ERK1/2),antibodies,PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,0.95,Experimental Usage,True,0.67,Medium,,,,p44/42 MAPK (ERK1/2),Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Western blotting was performed with rabbit primary antibodies for p44/42 MAPK (ERK1/2), p44/42 MAPK phosphorylated at threonine 202 and tyrosine 204 (p-ERK1/2), or phosphatidylinositol 3-kinase (PI3K), along with anti-rabbit conjugated secondary antibody, all purchased from New England Biolabs"
p44/42 MAPK phosphorylated at threonine 202 and tyrosine 204 (p-ERK1/2),antibodies,PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,0.95,Experimental Usage,True,0.67,Medium,,,,p44/42 MAPK phosphorylated at threonine 202 and tyrosine 204 (p-ERK1/2),Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Western blotting was performed with rabbit primary antibodies for p44/42 MAPK (ERK1/2), p44/42 MAPK phosphorylated at threonine 202 and tyrosine 204 (p-ERK1/2), or phosphatidylinositol 3-kinase (PI3K), along with anti-rabbit conjugated secondary antibody, all purchased from New England Biolabs"
phosphatidylinositol 3-kinase (PI3K),antibodies,PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,0.95,Experimental Usage,True,0.67,Medium,,,,phosphatidylinositol 3-kinase (PI3K),Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Western blotting was performed with rabbit primary antibodies for p44/42 MAPK (ERK1/2), p44/42 MAPK phosphorylated at threonine 202 and tyrosine 204 (p-ERK1/2), or phosphatidylinositol 3-kinase (PI3K), along with anti-rabbit conjugated secondary antibody, all purchased from New England Biolabs"
HK2,antibodies,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.95,Experimental Usage,True,0.67,Medium,,,,HK2,Unknown,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"primary goat polyclonal anti‐HK2 (sc‐6521, Santa Cruz) and rabbit monoclonal anti‐MPP2"
CD45,antibodies,PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,0.95,Experimental Usage,True,0.67,Medium,,,,CD45,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Tumors were stained first with CD45-Vioblue direct antibody conjugate (clone REA747, Miltenyi Biotec) for 30 min at 4 °C."
CD24,antibodies,PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,0.95,Experimental Usage,True,0.67,Medium,,,,CD24,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"CD45 negative cells were stained with calcein AM (Life Technologies) for viability and CD24-APC (human antibody, clone REA832, Miltenyi Biotec)"
CD44,antibodies,PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,0.95,Experimental Usage,True,0.67,Medium,,,,CD44,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"CD24-APC (human antibody, clone REA832, Miltenyi Biotec) and CD44-VioBlue (human antibody, clone REA690, Miltenyi Biotec)"
Iba-1,antibodies,PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.95,Experimental Usage,True,0.67,Medium,,,,Iba-1,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"goat monoclonal Iba-1 antibody targeting microglia (1:300; Abcam, Cambridge, UK)"
NF1,antibodies,PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,,0.95,Experimental Usage,True,0.67,Medium,,,,NF1,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"We performed NF1 immunohistochemistry using two different NF1 antibodies (NFC, Sigma-Aldrich; and iNF-07E, iNFixion Bioscience)"
NF1,antibodies,PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,,0.95,Experimental Usage,True,0.67,Medium,,,,NF1,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"We performed NF1 immunohistochemistry using two different NF1 antibodies (NFC, Sigma-Aldrich; and iNF-07E, iNFixion Bioscience)"
H3K27me3,antibodies,PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.95,Experimental Usage,True,0.67,Medium,,,,H3K27me3,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"IHC for H3K27me3 (Cell Signaling Technology, #9733, clone C36B11, 1:100 dilution) was performed on FFPE whole slide tissue sections"
"ABI Prism 7,000 Sequence Detection System",computational_tools,PMID:18670322,10.1097/MLG.0b013e318177e20b,Vestibular schwannoma quantitative polymerase chain reaction expression of estrogen and progesterone receptors.,,0.95,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,"ABI Prism 7,000 Sequence Detection System",Analysis Software,,,,,,,,,,,,,,,,"An ABI Prism 7,000 Sequence Detection System was used for all reactions with the following cycling parameters"
Simpleware ScanIP,computational_tools,PMID:39966622,10.1038/s41598-025-88589-x,The development of an artificial intelligence auto-segmentation tool for 3D volumetric analysis of vestibular schwannomas.,,0.95,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Simpleware ScanIP,Analysis Software,,,,,,,,,,,,,,,,"To create the tumor models for the ground truth dataset, an image processing software (Simpleware ScanIP, Synopsys) was used."
Simpleware,computational_tools,PMID:39966622,10.1038/s41598-025-88589-x,The development of an artificial intelligence auto-segmentation tool for 3D volumetric analysis of vestibular schwannomas.,,0.95,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Simpleware,Analysis Software,,,,,,,,,,,,,,,,"To create the tumor models an image processing software (Simpleware, Synopsys, Mountain View, CA) was used."
Spectronaut Pulsar,computational_tools,PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.95,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Spectronaut Pulsar,Analysis Software,,,,,,,,,,,,,,,,"...processed with the Spectronaut Pulsar software (Biognosys, Schlieren, Switzerland). Pulsar is a search engine, integrated into Spectronaut for spectral library generation..."
DINs (Deep Interactive Networks),computational_tools,PMID:34106871,10.1109/JBHI.2021.3087735,DINs: Deep Interactive Networks for Neurofibroma Segmentation in Neurofibromatosis Type 1 on Whole-Body MRI.,,0.95,Development,True,0.67,Medium,,,,,,,,,,,,,,,DINs (Deep Interactive Networks),Analysis Software,,,,,,,,,,,,,,,,we propose deep interactive networks (DINs) to address the above limitations. User interactions guide the model to recognize complicated tumors and quickly adapt to heterogeneous tumors.
Ion Torrent Personal Genome Machine—Ion Torrent PGM™,computational_tools,PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,0.95,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Ion Torrent Personal Genome Machine—Ion Torrent PGM™,Analysis Software,,,,,,,,,,,,,,,,NGS was performed on Ion Torrent Personal Genome Machine—Ion Torrent PGM™ (Thermo Fisher Scientific)
PERADIGM,computational_tools,PMID:41411243,10.1371/journal.pgen.1011976,PERADIGM: Phenotype embedding similarity-based rare disease gene mapping.,,0.95,Development,True,0.67,Medium,,,,,,,,,,,,,,,PERADIGM,Analysis Software,,,,,,,,,,,,,,,,"Here, we introduce PERADIGM ( Phenotype Embedding similarity-based RAre DIsease Gene Mapping), a novel framework that leverages natural language processing techniques"
edgeR,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.95,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,edgeR,Package/Library,,,,,,,,,,,,,,,,Differential gene expression analysis was performed using the R package edgeR in BioConductor
WGCNA,computational_tools,PMID:38115252,10.1097/MD.0000000000036696,Identification of hub genes and drug candidates for NF2-related vestibular schwannoma by bioinformatics tools.,,0.95,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,WGCNA,Package/Library,,,,,,,,,,,,,,,,"WGCNA, an R package, was used to conduct WGCNA"
Nf1 flox,genetic_reagents,PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,0.95,Experimental Usage,True,0.50,Medium,,,,,,,,,,,Nf1 flox,,,,,,,,,,,,,,,,,,,,,"mice with genotypes of hGFAP-cre-; Nf1 flox/flox , hGFAP-cre-; Nf1 flox/+ , hGFAP-cre+; Nf1 flox/+"
NF1,genetic_reagents,PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,0.95,Experimental Usage,True,0.50,Medium,,,,,,,,,,,NF1,,,,,,,,,,,,,,,,,,,,,sgRNA1 (5′-TAACTGCGCAACCTTCTTTA-3′) and sgRNA2 (5′-GTTAGCAGTTATAAATAGCC-3′) target the exon 6 of NF1 gene
NF1,genetic_reagents,PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,0.95,Experimental Usage,True,0.50,Medium,,,,,,,,,,,NF1,,,,,,,,,,,,,,,,,,,,,sgRNA1 (5′-TAACTGCGCAACCTTCTTTA-3′) and sgRNA2 (5′-GTTAGCAGTTATAAATAGCC-3′) target the exon 6 of NF1 gene
neurofibromin,antibodies,PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.95,Experimental Usage,True,0.33,Medium,,,,neurofibromin,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"neurofibromin – Bethyl (Bethyl, Cat# A300-140A, primary 1:500, secondary 1:2000)"
neurofibromin,antibodies,PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.95,Experimental Usage,True,0.33,Medium,,,,neurofibromin,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"H12 (Santa Cruz Biotechnology, Cat# sc-376886, primary 1:500, secondary 1:2000)"
neurofibromin,antibodies,PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.95,Experimental Usage,True,0.33,Medium,,,,neurofibromin,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"iNF-07E (gifted by iNFiXion Bioscience, Biointron, Cat# B21900201, primary 1:500, secondary 1:2000)"
collagen IV,antibodies,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,Experimental Usage,True,0.33,Medium,,,,collagen IV,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,The primary antibodies and dilutions used were goat anti-collagen IV (Millipore AB769; 1:500)
beta III tubulin,antibodies,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,Experimental Usage,True,0.33,Medium,,,,beta III tubulin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,anti-beta III tubulin antibody (Sigma-Aldrich AB9354; 1:500)
perilipin A/B,antibodies,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,Experimental Usage,True,0.33,Medium,,,,perilipin A/B,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,anti-perilipin A/B antibody (Sigma-Aldrich p1873; 1:250)
DIG-Fab,antibodies,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,Experimental Usage,True,0.33,Medium,,,,DIG-Fab,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"incubated with anti-DIG-Fab antibody coupled to alkaline phosphatase (Roche, 11093274910)"
BrdU,antibodies,PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.95,Experimental Usage,True,0.33,Medium,,,,BrdU,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rat anti-BrdU (ab6326, 1:500, Abcam)"
ABCC1,antibodies,PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,,0.95,Experimental Usage,True,0.33,Medium,,,,ABCC1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,incubated in primary antibodies against ABCC1 (Abcam ab24102) and S100 (Dako Z0311) at 1:50 and 1:400 dilution
S100,antibodies,PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,,0.95,Experimental Usage,True,0.33,Medium,,,,S100,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,incubated in primary antibodies against ABCC1 (Abcam ab24102) and S100 (Dako Z0311) at 1:50 and 1:400 dilution
TNFα,antibodies,PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.95,Experimental Usage,True,0.33,Medium,,,,TNFα,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Anti-mTNFα antibody (R023) was purchased from Sino Biological
CD11b,antibodies,PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.95,Experimental Usage,True,0.33,Medium,,,,CD11b,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibody, anti-CD11b (1:8000 dilution; catalogue number ab133357, Abcam) was applied at 36 °C for 40 min."
CD31,antibodies,PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.95,Experimental Usage,True,0.33,Medium,,,,CD31,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"CD31 (ab28364, 1:50, Abcam) and AXL (ab227871, 1:500, Abcam)"
AXL,antibodies,PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.95,Experimental Usage,True,0.33,Medium,,,,AXL,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"CD31 (ab28364, 1:50, Abcam) and AXL (ab227871, 1:500, Abcam)"
pAXL,antibodies,PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.95,Experimental Usage,True,0.33,Medium,,,,pAXL,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"pAXL (Cat#5724, 1:1000, Cell Signaling Technology), AXL (Cat#ab215205, 1:1000, Abcam)"
AXL,antibodies,PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.95,Experimental Usage,True,0.33,Medium,,,,AXL,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"pAXL (Cat#5724, 1:1000, Cell Signaling Technology), AXL (Cat#ab215205, 1:1000, Abcam)"
pAKT,antibodies,PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.95,Experimental Usage,True,0.33,Medium,,,,pAKT,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"pAKT (Cat #9271, 1:1000, Cell Signaling Technology), pGSK-3β (Cat#9323, 1:1000, Cell Signaling Technology)"
pGSK-3β,antibodies,PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.95,Experimental Usage,True,0.33,Medium,,,,pGSK-3β,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"pAKT (Cat #9271, 1:1000, Cell Signaling Technology), pGSK-3β (Cat#9323, 1:1000, Cell Signaling Technology)"
pMEK1/2,antibodies,PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.95,Experimental Usage,True,0.33,Medium,,,,pMEK1/2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"pMEK1/2 (Cat#9121, 1:1000, Cell Signaling Technology), and GAPDH (#CST-5174, 1:1000, Cell Signaling Technology)"
GAPDH,antibodies,PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.95,Experimental Usage,True,0.33,Medium,,,,GAPDH,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"pMEK1/2 (Cat#9121, 1:1000, Cell Signaling Technology), and GAPDH (#CST-5174, 1:1000, Cell Signaling Technology)"
GAPDH,antibodies,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.95,Experimental Usage,True,0.33,Medium,,,,GAPDH,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti‐GAPDH (#2118, Cell Signaling), ATP5A (ab14748, Abcam)"
ATP5A,antibodies,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.95,Experimental Usage,True,0.33,Medium,,,,ATP5A,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"ATP5A (ab14748, Abcam), anti‐UQCRC2 (ab14745, Abcam)"
UQCRC2,antibodies,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.95,Experimental Usage,True,0.33,Medium,,,,UQCRC2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti‐UQCRC2 (ab14745, Abcam), rabbit monoclonal anti‐MMP2 (ab92536, Abcam)"
TOM20,antibodies,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.95,Experimental Usage,True,0.33,Medium,,,,TOM20,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"TOM20 (sc‐11415, Santa Cruz) antibodies"
neurofibromin,antibodies,PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,0.95,Experimental Usage,True,0.33,Medium,,,,neurofibromin,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"incubated overnight with the primary anti-neurofibromin antibody (abcam, ab17963, 1/1000)"
neurofibromin/NF1,antibodies,PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.95,Experimental Usage,True,0.33,Medium,,,,neurofibromin/NF1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"neurofibromin/NF1 (sc-67, sc-376886, Santa Cruz Biotechnology and ab238142, Abcam)"
neurofibromin/NF1,antibodies,PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.95,Experimental Usage,True,0.33,Medium,,,,neurofibromin/NF1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"neurofibromin/NF1 (sc-67, sc-376886, Santa Cruz Biotechnology and ab238142, Abcam)"
neurofibromin/NF1,antibodies,PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.95,Experimental Usage,True,0.33,Medium,,,,neurofibromin/NF1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"neurofibromin/NF1 (sc-67, sc-376886, Santa Cruz Biotechnology and ab238142, Abcam)"
Flag,antibodies,PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.95,Experimental Usage,True,0.33,Medium,,,,Flag,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Flag (F7425, MilliporeSigma)"
GFP,antibodies,PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.95,Experimental Usage,True,0.33,Medium,,,,GFP,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"GFP (ab1218, Abcam, Western blotting and Invitrogen, IP)"
FBXW11/bTrCP2,antibodies,PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.95,Experimental Usage,True,0.33,Medium,,,,FBXW11/bTrCP2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"FBXW11/bTrCP2 (GTX33193, GeneTex and PA5-109715, Invitrogen, Thermo Fisher Scientific)"
ERK1/2,antibodies,PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.95,Experimental Usage,True,0.33,Medium,,,,ERK1/2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"ERK1/2 (9102, Cell Signaling Technology)"
pERK Thr202/Tyr204,antibodies,PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.95,Experimental Usage,True,0.33,Medium,,,,pERK Thr202/Tyr204,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-pERK Thr202/Tyr204 (4377, Cell Signaling Technology)"
HLA Class I ABC,antibodies,PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,0.95,Experimental Usage,True,0.33,Medium,,,,HLA Class I ABC,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"HLA-B (anti-HLA Class I ABC antibody, ab225636, Abcam, Cambridge, UK) for MHC I"
MHC Class II,antibodies,PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,0.95,Experimental Usage,True,0.33,Medium,,,,MHC Class II,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"DPB1 (anti-MHC Class II antibody, ab55152, Abcam, Cambridge, UK) for MHC II"
pERK,antibodies,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,Experimental Usage,True,0.33,Medium,,,,pERK,,,,,,,,,,,,,,,,,,,,,,,,,,,,The following antibodies were purchased from Cell signaling Technologies: pERK (Catalogue # 4370)
ERK,antibodies,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,Experimental Usage,True,0.33,Medium,,,,ERK,,,,,,,,,,,,,,,,,,,,,,,,,,,,total ERK (Catalogue # 9102)
pAKT,antibodies,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,Experimental Usage,True,0.33,Medium,,,,pAKT,,,,,,,,,,,,,,,,,,,,,,,,,,,,pAKT (Catalogue # 4060)
AKT,antibodies,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,Experimental Usage,True,0.33,Medium,,,,AKT,,,,,,,,,,,,,,,,,,,,,,,,,,,,total AKT (Catalogue # 4691)
Ubiquitin,antibodies,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,Experimental Usage,True,0.33,Medium,,,,Ubiquitin,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ubiquitin (Catalogue # 4289)
MYC,antibodies,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,Experimental Usage,True,0.33,Medium,,,,MYC,,,,,,,,,,,,,,,,,,,,,,,,,,,,MYC (Catalogue # 18583)
pCHEK1 S296,antibodies,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,Experimental Usage,True,0.33,Medium,,,,pCHEK1 S296,,,,,,,,,,,,,,,,,,,,,,,,,,,,pCHEK1 S296 (Catalogue # 90178)
BMI1,antibodies,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,Experimental Usage,True,0.33,Medium,,,,BMI1,,,,,,,,,,,,,,,,,,,,,,,,,,,,BMI1 (Catalogue # 5856)
H3K27Ac,antibodies,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,Experimental Usage,True,0.33,Medium,,,,H3K27Ac,,,,,,,,,,,,,,,,,,,,,,,,,,,,H3K27Ac (Catalogue # 8173)
H3,antibodies,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,Experimental Usage,True,0.33,Medium,,,,H3,,,,,,,,,,,,,,,,,,,,,,,,,,,,total H3 (Catalogue # 14269)
CDK9,antibodies,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,Experimental Usage,True,0.33,Medium,,,,CDK9,,,,,,,,,,,,,,,,,,,,,,,,,,,,CDK9 (Catalogue # 2316)
Vinculin,antibodies,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,Experimental Usage,True,0.33,Medium,,,,Vinculin,,,,,,,,,,,,,,,,,,,,,,,,,,,,Vinculin (Catalogue # 4650)
CPNase,antibodies,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,Experimental Usage,True,0.33,Medium,,,,CPNase,,,,,,,,,,,,,,,,,,,,,,,,,,,,CPNase (Catalogue # 5664)
MAG,antibodies,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,Experimental Usage,True,0.33,Medium,,,,MAG,,,,,,,,,,,,,,,,,,,,,,,,,,,,MAG (Catalogue # 9043)
Beta-Actin,antibodies,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,Experimental Usage,True,0.33,Medium,,,,Beta-Actin,,,,,,,,,,,,,,,,,,,,,,,,,,,,Beta-Actin (Catalogue # NB600-501) was purchased from Novus
pS2 RNApol II,antibodies,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,Experimental Usage,True,0.33,Medium,,,,pS2 RNApol II,,,,,,,,,,,,,,,,,,,,,,,,,,,,pS2 RNApol II (Catalogue # 04-1571-1) from EMD Millipore
SOX2,antibodies,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,Experimental Usage,True,0.33,Medium,,,,SOX2,,,,,,,,,,,,,,,,,,,,,,,,,,,,SOX2 (Catalogue # MAB2018) from R&D systems
NG2,antibodies,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,Experimental Usage,True,0.33,Medium,,,,NG2,,,,,,,,,,,,,,,,,,,,,,,,,,,,NG2 (Catalogue # PA5-17199) from Invitrogen
GAPDH,antibodies,PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,0.95,Experimental Usage,True,0.33,Medium,,,,GAPDH,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Antibodies against GAPDH (cat. no. 5174S)...were obtained from Cell Signaling Technology
phosphorylated PKA,antibodies,PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,0.95,Experimental Usage,True,0.33,Medium,,,,phosphorylated PKA,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,phosphorylated PKA (cat. no. 5661S)...were obtained from Cell Signaling Technology
PKA,antibodies,PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,0.95,Experimental Usage,True,0.33,Medium,,,,PKA,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,PKA (cat. no. 4782S)...were obtained from Cell Signaling Technology
phosphorylated CREB,antibodies,PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,0.95,Experimental Usage,True,0.33,Medium,,,,phosphorylated CREB,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,phosphorylated CREB (cat. no. 9198S)...were obtained from Cell Signaling Technology
CREB,antibodies,PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,0.95,Experimental Usage,True,0.33,Medium,,,,CREB,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,CREB (cat. no. 9197T) were obtained from Cell Signaling Technology
neurofibromin,antibodies,PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,0.95,Experimental Usage,True,0.33,Medium,,,,neurofibromin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Antibody against neurofibromin (cat. no. ab17963) was purchased from Abcam
p-RB1-S807/811,antibodies,PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.95,Experimental Usage,True,0.33,Medium,,,,p-RB1-S807/811,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"p-RB1-S807/811 (1:1000, no. 8516) and RB1 (no. 9309 and no. 9313, 1:500) from Cell Signaling Technology"
CD11b,antibodies,PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.95,Experimental Usage,True,0.33,Medium,,,,CD11b,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,CD11b at 1:100 dilution (abcam Cat # ab52478) for myeloid cells
SOX10,antibodies,PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.95,Experimental Usage,True,0.33,Medium,,,,SOX10,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,SOX10 at 1:500 dilution (abcam Cat # ab155279) for Schwann cells
Ki67 antigen,antibodies,PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.95,Experimental Usage,True,0.33,Medium,,,,Ki67 antigen,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies used for immunohistochemistry were against Ki67 antigen (Novocastra), glial fibrillary acidic protein (Gfap; Sigma)"
glial fibrillary acidic protein,antibodies,PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.95,Experimental Usage,True,0.33,Medium,,,,glial fibrillary acidic protein,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies used for immunohistochemistry were against Ki67 antigen (Novocastra), glial fibrillary acidic protein (Gfap; Sigma), Pten (NeoMarkers)"
Pten,antibodies,PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.95,Experimental Usage,True,0.33,Medium,,,,Pten,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"glial fibrillary acidic protein (Gfap; Sigma), Pten (NeoMarkers), nestin (BD Bioscience)"
nestin,antibodies,PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.95,Experimental Usage,True,0.33,Medium,,,,nestin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Pten (NeoMarkers), nestin (BD Bioscience), phosphorylated Akt (p-Akt; Cell Signaling)"
phosphorylated Akt,antibodies,PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.95,Experimental Usage,True,0.33,Medium,,,,phosphorylated Akt,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"nestin (BD Bioscience), phosphorylated Akt (p-Akt; Cell Signaling), BrdUrd (DAKO)"
BrdUrd,antibodies,PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.95,Experimental Usage,True,0.33,Medium,,,,BrdUrd,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"phosphorylated Akt (p-Akt; Cell Signaling), BrdUrd (DAKO), Olig2 (Chemicon)"
Olig2,antibodies,PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.95,Experimental Usage,True,0.33,Medium,,,,Olig2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"BrdUrd (DAKO), Olig2 (Chemicon), or doublecortin (Santa Cruz)"
doublecortin,antibodies,PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.95,Experimental Usage,True,0.33,Medium,,,,doublecortin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Olig2 (Chemicon), or doublecortin (Santa Cruz). We used microwave antigen retrieval for all antibodies, except for doublecortin antibody"
β3-tubulin,antibodies,PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.95,Experimental Usage,True,0.33,Medium,,,,β3-tubulin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies used were against β3-tubulin (TuJ1; Covance), Gfap (Dako), CNPase (Chemicon), or nestin"
Gfap,antibodies,PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.95,Experimental Usage,True,0.33,Medium,,,,Gfap,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"β3-tubulin (TuJ1; Covance), Gfap (Dako), CNPase (Chemicon), or nestin"
CNPase,antibodies,PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.95,Experimental Usage,True,0.33,Medium,,,,CNPase,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Gfap (Dako), CNPase (Chemicon), or nestin"
Pten,antibodies,PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.95,Experimental Usage,True,0.33,Medium,,,,Pten,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies used were against Pten (Cell Signaling), p-Akt, Akt, or β-actin (Sigma)"
β-actin,antibodies,PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.95,Experimental Usage,True,0.33,Medium,,,,β-actin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies used were against Pten (Cell Signaling), p-Akt, Akt, or β-actin (Sigma)"
phospho-MEK1 (Ser298),antibodies,PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.95,Experimental Usage,True,0.33,Medium,,,,phospho-MEK1 (Ser298),Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,The antibodies used in this study include... phospho-MEK1 (Ser298)... (Cell Signaling Technology)
phospho-Erk1/2 (Thr202/Tyr204),antibodies,PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.95,Experimental Usage,True,0.33,Medium,,,,phospho-Erk1/2 (Thr202/Tyr204),Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,The antibodies used in this study include... phospho-Erk1/2 (Thr202/Tyr204)... (Cell Signaling Technology)
phospho-Akt (Thr308),antibodies,PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.95,Experimental Usage,True,0.33,Medium,,,,phospho-Akt (Thr308),Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,The antibodies used in this study include... phospho-Akt (Thr308)... (Cell Signaling Technology)
Merlin,antibodies,PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.95,Experimental Usage,True,0.33,Medium,,,,Merlin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,The antibodies used in this study include... Merlin (Cell Signaling Technology)
phospho-Pak1–3 (Ser141),antibodies,PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.95,Experimental Usage,True,0.33,Medium,,,,phospho-Pak1–3 (Ser141),Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,The antibodies used in this study include... phospho-Pak1–3 (Ser141; Invitrogen)
p75,antibodies,PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,0.95,Experimental Usage,True,0.33,Medium,,,,p75,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,cell suspensions were stained with antibodies against p75 (Ab 1554; Chemicon)
NF1,antibodies,PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.95,Experimental Usage,True,0.33,Medium,,,,NF1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,NF1 (A300–140A) was obtained from Bethyl
MGMT,antibodies,PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.95,Experimental Usage,True,0.33,Medium,,,,MGMT,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,MGMT (sc-166528) was obtained from Santa Cruz Biotechnology
RAD51,antibodies,PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.95,Experimental Usage,True,0.33,Medium,,,,RAD51,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"incubated with RAD51(1:500 no. ab133534 Abcam) or yH2AX (1:200 no. 05–636, Millipore) antibody"
yH2AX,antibodies,PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.95,Experimental Usage,True,0.33,Medium,,,,yH2AX,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"incubated with RAD51(1:500 no. ab133534 Abcam) or yH2AX (1:200 no. 05–636, Millipore) antibody"
NF1,antibodies,PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.95,Experimental Usage,True,0.33,Medium,,,,NF1,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Primary antibodies included N-Terminal NF1 (Cell Signaling cat# D7R7D 1:1000)
beta-actin,antibodies,PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.95,Experimental Usage,True,0.33,Medium,,,,beta-actin,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,beta-actin (Cell Signaling cat# 3700 1:10000)
p-ERK,antibodies,PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.95,Experimental Usage,True,0.33,Medium,,,,p-ERK,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,p-ERK (Cell Signaling cat# 9101 1:1000)
ERK,antibodies,PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.95,Experimental Usage,True,0.33,Medium,,,,ERK,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,total ERK (Cell Signaling cat# 9102 1:1000)
p75,antibodies,PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.95,Experimental Usage,True,0.33,Medium,,,,p75,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"incubated for 30 minutes on ice with unconjugated primary antibody p75 (1:1,000, Ab3125, Abcam)"
S100B,antibodies,PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.95,Experimental Usage,True,0.33,Medium,,,,S100B,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"incubated with primary antibodies, p75 (1:100, Ab3125, Abcam), S100B (1:1,000, Z0311, Dako)"
MPZ,antibodies,PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.95,Experimental Usage,True,0.33,Medium,,,,MPZ,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"MPZ (1:100, Ab183868, Abcam), overnight at 4ºC"
NeuroD1,antibodies,PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,0.95,Experimental Usage,True,0.33,Medium,,,,NeuroD1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"The primary antibodies used were anti-NeuroD1 (Abcam, ab109224) and anti-β-actin (Sigma, A5316)"
β-actin,antibodies,PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,0.95,Experimental Usage,True,0.33,Medium,,,,β-actin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"The primary antibodies used were anti-NeuroD1 (Abcam, ab109224) and anti-β-actin (Sigma, A5316)"
phospho-ERK1/2,antibodies,PMID:24932921,10.1002/jbmr.2298,Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.,,0.95,Experimental Usage,True,0.33,Medium,,,,phospho-ERK1/2,,,,,,,,,,,,,,,,,,,,,,,,,,,,"The cells were labeled with Alexa Fluor 647-conjugated anti-phospho-ERK1/2 primary antibody (Cell Signaling Technology, MA, USA)"
LAMA2,antibodies,PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,0.95,Experimental Usage,True,0.33,Medium,,,,LAMA2,,,,,,,,,,,,,,,,,,,,,,,,,,,,"primary antibodies for LAMA2 (Abnova (Catalog #: H00003908-M01), 1:1000)"
SLC22A3,antibodies,PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,0.95,Experimental Usage,True,0.33,Medium,,,,SLC22A3,,,,,,,,,,,,,,,,,,,,,,,,,,,,"SLC22A3 (Novus Biologicals (Catalog #: NBP1-83976), 1:750)"
PRRX1,antibodies,PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,0.95,Experimental Usage,True,0.33,Medium,,,,PRRX1,,,,,,,,,,,,,,,,,,,,,,,,,,,,"PRRX1 (Thermo Fisher Scientific (Catalog#: MA5-26580), 1:200)"
SOX10,antibodies,PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,0.95,Experimental Usage,True,0.33,Medium,,,,SOX10,,,,,,,,,,,,,,,,,,,,,,,,,,,,"SOX10 (Roche (Catalog#: 760-4968), pre-diluted kit)"
nitrated Hsp90,antibodies,PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,0.95,Experimental Usage,True,0.33,Medium,,,,nitrated Hsp90,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,in-house developed antibodies specific for Hsp90 nitrated at Tyr 33 or Tyr 56 (dilution 1:200)
spheroid culture system,advanced_cellular_models,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,spheroid,cell line,,,,,,,,,,,,"Two thousand cells/well of 17, 5653, or 5746 glioma cell lines are plated in 96-well round-bottomed ultra-low attachment plates and used for spheroid drug screening"
3D tumor spheroid model,advanced_cellular_models,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,spheroid,cell line,"sNF96.2-luciferase cells, primary tumor cells",,,,,,,,,,,Their anti-tumor efficacy was further evaluated using a 3D tumor spheroid model
neurosphere cultures,advanced_cellular_models,PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,spheroid,primary cell,neural stem/progenitor cells,,,,,,,,,,,"We established and maintained neurosphere cultures as described (31) with some modifications. Briefly, we dissected out the lateral walls of the lateral ventricle or whole brain tumor"
B6N-Tyrc-Brd/BrdCrCrl,animal_models,PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.9,Experimental Usage,False,1.00,Medium,B6N-Tyrc-Brd/BrdCrCrl,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,injecting 1 × 10 5 cells into the medial flank 4-week-old male B6N-Tyrc-Brd/BrdCrCrl mice (Charles Rivers)
"athymic nude mice (Charles River, Stock No. 490)",animal_models,PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.9,Experimental Usage,False,1.00,Medium,"athymic nude mice (Charles River, Stock No. 490)",No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"8-week-old athymic nude mice (Charles River, Stock No. 490) underwent surgery to implant pNF progenitor cells"
Myf5 Cre,animal_models,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.9,Experimental Usage,False,1.00,Medium,Myf5 Cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Mouse lines used in this study were described before: Myf5 Cre
Lbx1 Cre,animal_models,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.9,Experimental Usage,False,1.00,Medium,Lbx1 Cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Mouse lines used in this study were described before: Myf5 Cre, Lbx1 Cre"
Rosa26 mTmG,animal_models,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.9,Experimental Usage,False,1.00,Medium,Rosa26 mTmG,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Mouse lines used in this study were described before: Myf5 Cre, Lbx1 Cre, Nf1 flox, and Rosa26 mTmG"
Balb/c,animal_models,PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,0.9,Experimental Usage,False,1.00,Medium,Balb/c,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Initial range-finding studies employed female Balb/c mice (Taconic Laboratories).
Nu/Nu,animal_models,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.9,Experimental Usage,False,1.00,Medium,Nu/Nu,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"3 × 10^6 p53−/−; Myc; Cas9 cells were injected into flanks of 6-8-week old, female, NCI Nu/Nu mice (Taconic)"
K14 Cre,animal_models,PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.9,Experimental Usage,False,1.00,Medium,K14 Cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"K14 Cre mice were available from the Jackson Laboratory (Bar Harbor, ME). All mice were maintained on a mix C57bl/6 background."
zebrafish,animal_models,PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,0.9,Experimental Usage,False,1.00,Medium,zebrafish,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,RNA transcripts were injected into zebrafish embryos at the single-cell stage. GFP signals in the zebrafish embryos indicated synthetic RNA expression
Nf1 flox/flox,animal_models,PMID:23225063,10.1002/ana.23793,Dopamine deficiency underlies learning deficits in neurofibromatosis-1 mice.,,0.9,Experimental Usage,False,1.00,Medium,Nf1 flox/flox,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,littermate control Nf1 flox/flox (CTL) mice were maintained on an inbred C57BL/6 background
hGFAP-cre+; p53floxE2–10/floxE2–10,animal_models,PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.9,Experimental Usage,False,1.00,Medium,hGFAP-cre+; p53floxE2–10/floxE2–10,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"p53 null CKO (p53ΔE2–10 CKO, hGFAP-cre+; p53floxE2–10/floxE2–10) and p53R172H CKO"
hGFAP-cre+; p53LSLR172H/floxE2–10,animal_models,PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.9,Experimental Usage,False,1.00,Medium,hGFAP-cre+; p53LSLR172H/floxE2–10,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p53R172H CKO (hGFAP-cre+; p53LSLR172H/floxE2–10) mice analyzed in this study
C57BL/6,animal_models,PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.9,Experimental Usage,False,1.00,Medium,C57BL/6,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Wild-type C57BL/6 and B6J.129(B6N)-Gt(ROSA)26Sor (JAX stock #026175) tm1(CAG-cas9*,-EGFP)Fezh/J mice strains were used"
1016 tuba1a:GFP,animal_models,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,Experimental Usage,False,1.00,Medium,1016 tuba1a:GFP,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"1016 tuba1a:GFP, gfap:GFP, hsp70:DN-MAML-GFP, gfap:mCherry and tp1:mCherry, fish were previously described"
gfap:GFP,animal_models,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,Experimental Usage,False,1.00,Medium,gfap:GFP,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"1016 tuba1a:GFP, gfap:GFP, hsp70:DN-MAML-GFP, gfap:mCherry and tp1:mCherry, fish were previously described"
hsp70:DN-MAML-GFP,animal_models,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,Experimental Usage,False,1.00,Medium,hsp70:DN-MAML-GFP,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"1016 tuba1a:GFP, gfap:GFP, hsp70:DN-MAML-GFP, gfap:mCherry and tp1:mCherry, fish were previously described"
gfap:mCherry,animal_models,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,Experimental Usage,False,1.00,Medium,gfap:mCherry,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"1016 tuba1a:GFP, gfap:GFP, hsp70:DN-MAML-GFP, gfap:mCherry and tp1:mCherry, fish were previously described"
tp1:mCherry,animal_models,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,Experimental Usage,False,1.00,Medium,tp1:mCherry,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"1016 tuba1a:GFP, gfap:GFP, hsp70:DN-MAML-GFP, gfap:mCherry and tp1:mCherry, fish were previously described"
"NOD.Cg-Prkdcscid Il2rgtm1Wjl Tg(CMV-IL3,CSF2,KITLG)1Eav/MloySzJ",animal_models,PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.9,Experimental Usage,False,1.00,Medium,"NOD.Cg-Prkdcscid Il2rgtm1Wjl Tg(CMV-IL3,CSF2,KITLG)1Eav/MloySzJ",No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"For the CART19 treatment, NSG-SGM3 (NSGS) mice (stock number 013062) were purchased from the Jackson Laboratory."
LysMcre Thfl/fl,animal_models,PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.9,Experimental Usage,False,1.00,Medium,LysMcre Thfl/fl,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"LysMcre mice were purchased from Jackson Laboratory (stock number 004781), in which a nuclear-localized Cre recombinase was inserted into the first coding exon of the lysozyme 2 (Lyz2 or LysM) gene"
NSG,animal_models,PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.9,Experimental Usage,False,1.00,Medium,NSG,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"150,000 cells in 3 µl were implanted in the sciatic nerve of NSG mice (female, 6–10 weeks old)"
CB17 SCID,animal_models,PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.9,Experimental Usage,False,1.00,Medium,CB17 SCID,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"subcutaneously injected into both flanks of 6- to 8-week-old female CB17 SCID mice (Taconic, RRID: MSR_TAC:cb17sc)"
y [1] M{w[+mC] = nos‐Cas9.P}ZH‐2A w[*],animal_models,PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.9,Experimental Usage,False,1.00,Medium,y [1] M{w[+mC] = nos‐Cas9.P}ZH‐2A w[*],No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,germline source of Cas9: y [1] M{w[+mC] = nos‐Cas9.P}ZH‐2A w[*] (Bloomington Stock #54591)
C57BL/6J,animal_models,PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.9,Experimental Usage,False,1.00,Medium,C57BL/6J,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Toxicity studies were performed using CD‐1 mice and C57BL/6J Inbred Mice (JAX® Mice Strain)
nu/nu,animal_models,PMID:21111000,10.1016/j.jneumeth.2010.10.021,A novel imaging-compatible sciatic nerve schwannoma model.,,0.9,Experimental Usage,False,1.00,Medium,nu/nu,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"implanted in 1 µl culture medium into the sciatic nerve of athymic mice (nu/nu, 5-week-old females; Cox 7 breeding facility, MGH)"
mdx,animal_models,PMID:34935315,10.1117/1.JBO.26.12.125001,Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse reflectance spectroscopy.,,0.9,Experimental Usage,False,1.00,Medium,mdx,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,...two mouse models of genetic muscle disease: a type 1 neurofibromatosis (NF1) limb-mesenchyme knockout (Nf1Prx1-/-) and a muscular dystrophy mouse (mdx)...
Prx1-Cre,animal_models,PMID:34935315,10.1117/1.JBO.26.12.125001,Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse reflectance spectroscopy.,,0.9,Experimental Usage,False,1.00,Medium,Prx1-Cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,...the NF1 mice bred from the Prx1-Cre transgenic mice and the Nf1flox/flox mice...
B10 mdx,animal_models,PMID:34935315,10.1117/1.JBO.26.12.125001,Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse reflectance spectroscopy.,,0.9,Experimental Usage,False,1.00,Medium,B10 mdx,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"The mdx mice (B10 mdx) were sourced from Australian Bioresources (ABR, Moss Vale). As these mice are on a C57BL/10 background..."
NG2-EYFP mice,animal_models,PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.9,Experimental Usage,False,1.00,Medium,NG2-EYFP mice,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"NG2-EYFP mice, which carry a YFP fluorescent protein gene instead of a NG2 gene, are healthy and fertile and do not show any obvious phenotype"
nu/nu,animal_models,PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.9,Experimental Usage,False,1.00,Medium,nu/nu,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,injected subcutaneously into the right flanks of 6 to 8-week-old female athymic nude (nu/nu) mice (Harlan)
Lats1/2-mut,animal_models,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,False,1.00,Medium,Lats1/2-mut,No known disease,Malignant Peripheral Nerve Sheath Tumor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Mouse MPNST mice (Lats1/2-mut) were generated by crossing floxed Lats1Lats2 mice with Dhh-Cre mice (JAX 012929) to obtain Lats1/2-mut offspring
C57BL/6J,animal_models,PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,0.9,Experimental Usage,False,1.00,Medium,C57BL/6J,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Wildtype C57BL/6J and Nf1 mice littermates were housed and bred in the Indiana University Laboratory Animal Research Center
NOD-Rag1 null IL2rg,animal_models,PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,Experimental Usage,False,1.00,Medium,NOD-Rag1 null IL2rg,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Immunodeficient NOD-Rag1 null IL2rg mice (The Jackson Laboratory) received approximately 3 million cells via subcutaneous flank injection
NOD-SCID-Prkdc scid,animal_models,PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,Experimental Usage,False,1.00,Medium,NOD-SCID-Prkdc scid,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,non-obese diabetic severe combined immune deficiency spontaneous male mice (NOD-SCID-Prkdc scid) received 5 × 10^6 cells
B6.Cg/NTac-Foxn1nu NE10,animal_models,PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.9,Experimental Usage,False,1.00,Medium,B6.Cg/NTac-Foxn1nu NE10,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Athymic (B6.Cg/NTac-Foxn1nu NE10) mice were purchased from Taconic Laboratories
Fbxw11tm1a(KOMP)Wtsi,animal_models,PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.9,Experimental Usage,False,1.00,Medium,Fbxw11tm1a(KOMP)Wtsi,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Fbxw11 heterozygous (Fbxw11+/–, C57BL/6NTac) mice were from Knockout Mouse Project (KOMP)"
Fbxw11fl/fl,animal_models,PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.9,Experimental Usage,False,1.00,Medium,Fbxw11fl/fl,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Fbxw11fl/fl (exon 4 targeted) mice were generated from the Fbxw11tm1a(KOMP)Wtsi strain by FLP-FRT recombination
p19 knockout,animal_models,PMID:21681782,10.1002/ajh.22035,Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.,,0.9,Experimental Usage,False,1.00,Medium,p19 knockout,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Mice with the p19 mutation were a kind gift from Dr. Martine Roussel at St. Jude's Children's Research Hospital
Mx1-Cre,animal_models,PMID:21681782,10.1002/ajh.22035,Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.,,0.9,Experimental Usage,False,1.00,Medium,Mx1-Cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Mx1-Cre, Nf1 flox, and Nf1 fcr (Nf1 knockout) mice have been described previously"
WMSTM-WT,animal_models,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,False,1.00,Medium,WMSTM-WT,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,The WMSTM-WT and WMSTM-FH lines are housed at the University of Wisconsin Swine Research and Teaching Center
WMSTM-FH,animal_models,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,False,1.00,Medium,WMSTM-FH,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,The WMSTM-WT and WMSTM-FH lines are housed at the University of Wisconsin Swine Research and Teaching Center
Lats1 lox/lox Lats2 lox/lox,animal_models,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,Experimental Usage,False,1.00,Medium,Lats1 lox/lox Lats2 lox/lox,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Lats1 mice ( lox/lox Lats2 lox/lox Heallen et al., 2011 ), on a mixed C57/Bl6;129Sv;FVBN background, were crossed with Dhh -Cre"
Dhh-Cre,animal_models,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,Experimental Usage,False,1.00,Medium,Dhh-Cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"were crossed with Dhh -Cre ( Jaegle et al., 2003 ) mice or Plp1 -CreERT (Stock 005975) mice, both on a C57/Bl6 background"
Plp1-CreERT (Stock 005975),animal_models,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,Experimental Usage,False,1.00,Medium,Plp1-CreERT (Stock 005975),No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Plp1 -CreERT (Stock 005975) mice, both on a C57/Bl6 background to obtain Lats1 ;Cre lox/+ Lats2 lox/+ +/− mice"
CAG-tdTomato (Stock 007909),animal_models,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,Experimental Usage,False,1.00,Medium,CAG-tdTomato (Stock 007909),No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"The reporter mice CAG-tdTomato (Stock 007909), CAG-CATEGFP (ccGFP) (Stock 024636) were obtained from the Jackson Laboratory"
CAG-CATEGFP (Stock 024636),animal_models,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,Experimental Usage,False,1.00,Medium,CAG-CATEGFP (Stock 024636),No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CAG-CATEGFP (ccGFP) (Stock 024636) were obtained from the Jackson Laboratory
Taz lox/lox Yap1 lox/lox,animal_models,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,Experimental Usage,False,1.00,Medium,Taz lox/lox Yap1 lox/lox,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Taz ( lox/lox Yap1 lox/lox Deng et al., 2017 ) mice, on a mixed C57/Bl6;129Sv;FVBN background"
MacGreen (Csf1r-eGFP),animal_models,PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.9,Experimental Usage,False,1.00,Medium,MacGreen (Csf1r-eGFP),No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,bred onto a wild type or MacGreen (Csf1r-eGFP; [ 58 ] C57/BL6 background
CX3CR1-CreER,animal_models,PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.9,Experimental Usage,False,1.00,Medium,CX3CR1-CreER,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CX3CR1-CreER [ 71 ] were intercrossed with Nf1 flox/flox
R26R-EYFP,animal_models,PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.9,Experimental Usage,False,1.00,Medium,R26R-EYFP,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,intercrossed with Nf1 flox/flox [ 1 ] and R26R-EYFP mice [ 63 ]
hGFAP-Cre,animal_models,PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.9,Experimental Usage,False,1.00,Medium,hGFAP-Cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,hGFAP-Cre +/+ were intercrossed with Nf1 flox/flox
Rabl6m/m C57Bl/6N,animal_models,PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.9,Experimental Usage,False,1.00,Medium,Rabl6m/m C57Bl/6N,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Mouse embryonic fibroblasts (MEFs) from wildtype and Rabl6m/m C57Bl/6N mice were isolated
Cnp-Cre; R26-lsl-SB11; T2/Onc15,animal_models,PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.9,Experimental Usage,False,1.00,Medium,Cnp-Cre; R26-lsl-SB11; T2/Onc15,No known disease,Malignant Peripheral Nerve Sheath Tumor,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Triple transgenic mice (Cnp-Cre; R26-lsl-SB11; T2/Onc15) undergo insertional mutagenesis in Schwann cells.
Postn-Cre,animal_models,PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,,0.9,Experimental Usage,False,1.00,Medium,Postn-Cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,The Postn-Cre transgenic and conditional Nf2flox/flox knocking alleles were obtained
JAX:002019,animal_models,PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.9,Experimental Usage,False,1.00,Medium,JAX:002019,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,NF1-proficient and NF1-deficient engineered clones were injected into the flanks of 6- to 7-week-old athymic nude mice (RRID: JAX:002019)
JAX:007799,animal_models,PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.9,Experimental Usage,False,1.00,Medium,JAX:007799,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"S462-TY cells (1.0 × 106) in 50% Matrigel (BD Biosciences) were injected subcutaneously into the flank of 6- to 7-week-old NOD-Rag1 null IL2rg null, NOD rag gamma, NOD-RG (NRG) mice (RRID: JAX:007799)"
loxP-Pten (Pten f),animal_models,PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.9,Experimental Usage,False,1.00,Medium,loxP-Pten (Pten f),No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"we crossed Mut3 (8) or Mut4 males with wild-type (wt), loxP-Pten (Pten f hereafter; ref. 27), p53 f (28), or p53 f ; Pten f females"
p53 f,animal_models,PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.9,Experimental Usage,False,1.00,Medium,p53 f,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"we crossed Mut3 (8) or Mut4 males with wild-type (wt), loxP-Pten (Pten f hereafter; ref. 27), p53 f (28), or p53 f ; Pten f females"
athymic Ncr Nu/Nu,animal_models,PMID:18636037,10.1097/MAO.0b013e31817f7398,The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.,,0.9,Experimental Usage,False,1.00,Medium,athymic Ncr Nu/Nu,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Xenografts were developed in male athymic Ncr Nu/Nu mice (National Cancer Institute, NIH, Bethesda, MD)"
Wnt-1-Cre+,animal_models,PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,0.9,Experimental Usage,False,1.00,Medium,Wnt-1-Cre+,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"For conditional deletion of Nf1 we used Wnt-1-Cre (+ Danielian et al., 1998)"
3.9Periostin-Cre+,animal_models,PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,0.9,Experimental Usage,False,1.00,Medium,3.9Periostin-Cre+,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"3.9Periostin-Cre (+ Lindsley et al., 2007)"
P0a-Cre+,animal_models,PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,0.9,Experimental Usage,False,1.00,Medium,P0a-Cre+,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"P0a-Cre (+ Giovannini et al., 2000) mice"
Ink4a-/-,animal_models,PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,0.9,Experimental Usage,False,1.00,Medium,Ink4a-/-,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Compound mutant mice were generated by mating Nf1 mice with +/− Ink4a mice (−/− Sharpless et al., 2001)"
Ink4aArf-/-,animal_models,PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,0.9,Experimental Usage,False,1.00,Medium,Ink4aArf-/-,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Ink4aArf mice (−/− Serrano et al., 1996)"
G12V H-Ras,animal_models,PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,G12V H-Ras,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,+/− H-Ras mice in C57BL/6JOlaHsd background were obtained by crossing heterozygous G12V H-Ras mice
NOD scid gamma,animal_models,PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.9,Experimental Usage,False,1.00,Medium,NOD scid gamma,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,NOD scid gamma (NSG) female and male mice were purchased from Johns Hopkins University Animal Resources Core
nu/nu Balb/c,animal_models,PMID:25340526,10.1371/journal.pone.0107760,Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.,,0.9,Experimental Usage,False,1.00,Medium,nu/nu Balb/c,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Athymic nude mice (female, nu/nu Balb/c, 6 weeks, 20 g) were obtained from Charles River Laboratories (Sulzfeld, Germany)."
Prss56Cre/Cre,animal_models,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,Prss56Cre/Cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"The following mouse lines were used and genotyped as described in the original publications: Prss56Cre/Cre, R26tdTom/tdTom; Prss56Cre/Cre"
R26tdTom/tdTom,animal_models,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,R26tdTom/tdTom,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"The following mouse lines were used and genotyped as described in the original publications: Prss56Cre/Cre, R26tdTom/tdTom; Prss56Cre/Cre"
B6D2F1,animal_models,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,B6D2F1,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Nf1+/−; and B6D2F1 (https://janvier-labs.com/en/fiche_produit/b6d2f1-mouse/)
nude,animal_models,PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,Experimental Usage,False,1.00,Medium,nude,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Experiments were performed in 8-week-old nude female mice (Charles River, Wilmington, MA)"
p16 Ink4a*/*,animal_models,PMID:17924978,10.1111/j.1750-3639.2007.00105.x,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.,,0.9,Experimental Usage,False,1.00,Medium,p16 Ink4a*/*,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Nf2 flox2/flox2 mice (4) on the FVB/N background were bred to p16 Ink4a*/* mice (11) on a FVB/N/129Ola mixed background
C.B-17/IcrHsd-Prkdc scid,animal_models,PMID:41023593,10.1186/s10020-025-01353-9,Selective inhibition of BRAF and CRAF sensitizes NF1-deficient malignant peripheral nerve sheath tumors to MEK inhibitors.,,0.9,Experimental Usage,False,1.00,Medium,C.B-17/IcrHsd-Prkdc scid,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"NSG and SCID (C.B-17/IcrHsd-Prkdc scid , Envigo) female mice were used for in vivo efficacy studies"
GFAP-Cre,animal_models,PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,0.9,Experimental Usage,False,1.00,Medium,GFAP-Cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Olig2-Cre mice (B6-Olig2 tm2 (TVA, cre)Rth /J; Jackson Laboratory; [ 20 ]) and GFAP-Cre mice [ 32 ]"
Plp-Cre,animal_models,PMID:32839340,10.1073/pnas.2008391117,Brain-wide structural and functional disruption in mice with oligodendrocyte-specific ,,0.9,Experimental Usage,False,1.00,Medium,Plp-Cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Inducible Plp-Cre (66) and Nf1 fl/+ (67) mice were maintained on a pure C57BL/6 background
NU/NU,animal_models,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,Experimental Usage,False,1.00,Medium,NU/NU,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Subcutaneous allografts were performed by implanting 5 million JW18.2 or JW23.3 MPNST allografts cells into the flanks of 5–6-week-old female NU/NU mice (Harlan Sprague Dawley)
Postn-cre,animal_models,PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,0.9,Experimental Usage,False,1.00,Medium,Postn-cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Periostin-cre (Postn-cre) were crossed with floxed Nf2 gene (Postn-cre;Nf2) as previously described.
Rosa26 LSL-Neurod1 (R26ND1),animal_models,PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,0.9,Experimental Usage,False,1.00,Medium,Rosa26 LSL-Neurod1 (R26ND1),No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Rosa26 (LSL-Neurod1 R26ND1) line that induces Neurod1 expression via cre-mediated excision of a stop codon
1016 tuba1a:GFP,animal_models,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Experimental Usage,False,1.00,Medium,1016 tuba1a:GFP,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Strain, strain background (Danio rerio) 1016 tuba1a:GFP Fausett and Goldman, 2006"
gfap:GFP,animal_models,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Experimental Usage,False,1.00,Medium,gfap:GFP,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Strain, strain background (Danio rerio) gfap:GFP Kassen et al., 2007"
tp1:mCherry,animal_models,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Experimental Usage,False,1.00,Medium,tp1:mCherry,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Strain, strain background (Danio rerio) tp1:mCherry Parsons et al., 2009"
zop:nsfb-EGFP,animal_models,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Experimental Usage,False,1.00,Medium,zop:nsfb-EGFP,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Strain, strain background (Danio rerio) zop:nsfb-EGFP Montgomery et al., 2010"
hsp70:ca-Alk5,animal_models,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Experimental Usage,False,1.00,Medium,hsp70:ca-Alk5,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Strain, strain background (Danio rerio) hsp70:ca-Alk5 Zhou et al., 2011"
hsp70:tgfb1b,animal_models,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Development,False,1.00,Medium,hsp70:tgfb1b,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Strain, strain background (Danio rerio) hsp70:tgfb1b This paper; Figure 5 tgfb1b expressed under the hsp70 promoter"
hsp70:tgfb3,animal_models,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Development,False,1.00,Medium,hsp70:tgfb3,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Strain, strain background (Danio rerio) hsp70:tgfb3 This paper; Figure 4 tgfb3 expressed under the hsp70 promoter"
fl Trp53 (#008462),animal_models,PMID:34647023,10.1093/noajnl/vdab129,A genetic mouse model with postnatal ,,0.9,Experimental Usage,False,1.00,Medium,fl Trp53 (#008462),No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"NPcis (Stock #008191), Nf1 (#017640), fl Trp53 (#008462), fl Plp-CreER (#005975), and T Nestin-Cre (#003771) were obtained from The Jackson Laboratory."
fl Plp-CreER (#005975),animal_models,PMID:34647023,10.1093/noajnl/vdab129,A genetic mouse model with postnatal ,,0.9,Experimental Usage,False,1.00,Medium,fl Plp-CreER (#005975),No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"NPcis (Stock #008191), Nf1 (#017640), fl Trp53 (#008462), fl Plp-CreER (#005975), and T Nestin-Cre (#003771) were obtained from The Jackson Laboratory."
T Nestin-Cre (#003771),animal_models,PMID:34647023,10.1093/noajnl/vdab129,A genetic mouse model with postnatal ,,0.9,Experimental Usage,False,1.00,Medium,T Nestin-Cre (#003771),No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"NPcis (Stock #008191), Nf1 (#017640), fl Trp53 (#008462), fl Plp-CreER (#005975), and T Nestin-Cre (#003771) were obtained from The Jackson Laboratory."
SCID,animal_models,PMID:15240917,10.1155/S1110724304308107,Survival of Human Neurofibroma in Immunodeficient Mice and Initial Results of Therapy With Pirfenidone.,,0.9,Experimental Usage,False,1.00,Medium,SCID,No known disease,Immunodeficiency for xenograft studies,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Mice with severe combined immunodeficiency (SCID) were used as recipients of human neurofibroma xenotransplants
Nf1 flox/flox,animal_models,PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,0.9,Experimental Usage,False,1.00,Medium,Nf1 flox/flox,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,control littermate Nf1 flox/flox (WT) mice were maintained on an inbred C57BL/6 background
Tg(HOTCre:Cas9),animal_models,PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,0.9,Experimental Usage,False,1.00,Medium,Tg(HOTCre:Cas9),No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Transgenic lines used in this study were the ABWT (Zebrafish International Resource Center), Tg(HOTCre:Cas9) (a kind gift from Dr Wenbiao Chen, Vanderbilt University School of Medicine)"
Tg(-7.2kb-sox10:mRFP),animal_models,PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,0.9,Experimental Usage,False,1.00,Medium,Tg(-7.2kb-sox10:mRFP),No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Transgenic lines used in this study were the ABWT (Zebrafish International Resource Center), Tg(HOTCre:Cas9) (a kind gift from Dr Wenbiao Chen, Vanderbilt University School of Medicine, Nashville, TN, USA), Tg(−7.2kb-sox10:mRFP)"
NOD-Rag1 null IL2rg (NRG),animal_models,PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,Experimental Usage,False,1.00,Medium,NOD-Rag1 null IL2rg (NRG),No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Tumor tissue was implanted dorsally into 5- to 6-week-old NOD- Rag1 null IL2rg (NRG) mice.
Nf1flox/flox,animal_models,PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,Nf1flox/flox,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Nf1 +/- GFAP CKO ( Nf1 flox/mut ;GFAP-Cre,  Nf1 -CKO) and littermate control ( Nf1 flox/flox ; CTL) mice were maintained on an inbred C57BL/6 background"
FVB/N.129-Cdkn2atm1Rdp,animal_models,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.9,Experimental Usage,False,1.00,Medium,FVB/N.129-Cdkn2atm1Rdp,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"p16/p19+/− (01XB2, FVB/N.129-Cdkn2atm1Rdp) mice, obtained from the Mouse Models of Human Cancers Consortium, were crossed to Nf2 mice"
R26 LacZR,animal_models,PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,R26 LacZR,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"The R26 LacZR allele was introduced to the control, Nf1 hGFAP CKO, Nf1 Math1 CKO, Nf1 L7 CKO and Nf1 NcreER CKO mice as a reporter"
Brief Pain Inventory Pain Interference subscale,clinical_assessment_tools,PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Brief Pain Inventory Pain Interference subscale,scale,all ages,No,7.0,The Brief Pain Inventory Pain Interference subscale assesses the impact of pain on daily functioning in seven areas from 0 (does not interfere) to 10 (completely interfered) in the past week; it yields a mean total score.
EQ-5D-5L,clinical_assessment_tools,PMID:38811427,10.1186/s41687-024-00732-w,Quality of life in individuals with neurofibromatosis type 1 associated cutaneous neurofibromas: validation of the Dutch cNF-Skindex.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,EQ-5D-5L,questionnaire,adult,No,5.0,"The EQ-5D-5L is a brief and generic health status measure that comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression"
SF-36,clinical_assessment_tools,PMID:38811427,10.1186/s41687-024-00732-w,Quality of life in individuals with neurofibromatosis type 1 associated cutaneous neurofibromas: validation of the Dutch cNF-Skindex.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,SF-36,questionnaire,adult,No,36.0,"The 36-item Short Form Survey (SF-36) is a generic health-related QoL measure. It comprises eight domains of health: physical function, limitations because of physical problems"
Perceived Stress Scale,clinical_assessment_tools,PMID:37378983,10.1001/jamanetworkopen.2023.20599,Effect of Mind-Body Skills Training on Quality of Life for Geographically Diverse Adults With Neurofibromatosis: A Fully Remote Randomized Clinical Trial.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Perceived Stress Scale,scale,adult,No,,Perceived Stress Scale score of 6 or higher
Wechsler Abbreviated Scale of Intelligence (WASI),clinical_assessment_tools,PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Wechsler Abbreviated Scale of Intelligence (WASI),performance test,all ages,No,,"Full‐Scale IQ of at least 70, as determined by the Wechsler Abbreviated Scale of Intelligence (WASI 15 )"
Brief Visuospatial Memory Test – Revised (BVMT),clinical_assessment_tools,PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Brief Visuospatial Memory Test – Revised (BVMT),performance test,all ages,No,,"the Brief Visuospatial Memory Test – Revised (BVMT, Immediate and Delayed 19 ; nonverbal declarative memory)"
Letter‐Number Sequencing task (LNS),clinical_assessment_tools,PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Letter‐Number Sequencing task (LNS),performance test,all ages,No,,the Letter‐Number Sequencing task (LNS 20 ; working memory)
Hopkins Verbal Learning Test (HVLT),clinical_assessment_tools,PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Hopkins Verbal Learning Test (HVLT),performance test,all ages,No,,Hopkins Verbal Learning Test (HVLT; verbal declarative memory 22 )
WISC‐III Object Assembly,clinical_assessment_tools,PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,WISC‐III Object Assembly,performance test,pediatric,No,,WISC‐III Object Assembly (visuoconstructive ability) 23
Achenbach Child Behavior Checklist (CBCL),clinical_assessment_tools,PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Achenbach Child Behavior Checklist (CBCL),questionnaire,pediatric,No,,Achenbach Child Behavior Checklist (CBCL; self‐ and parent‐report)
Young Adult Self Report (YASR),clinical_assessment_tools,PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Young Adult Self Report (YASR),questionnaire,adult,No,,"Young Adult Self Report (YASR) 24 ,  25"
Delis–Kaplan Executive Function Scale (D‐KEFS) verbal fluency,clinical_assessment_tools,PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Delis–Kaplan Executive Function Scale (D‐KEFS) verbal fluency,performance test,all ages,No,,Delis–Kaplan Executive Function Scale (D‐KEFS) verbal fluency (category and letter fluency) 27
Behavior Rating Inventory of Executive Function (BRIEF),clinical_assessment_tools,PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Behavior Rating Inventory of Executive Function (BRIEF),questionnaire,all ages,No,,Behavior Rating Inventory of Executive Function (BRIEF; General Executive Composite (GEC) score) 28
Patient-Reported Outcomes Rating Acceptance Tool for Endpoints (PRO-RATE),clinical_assessment_tools,PMID:38321701,10.1177/17407745231217279,Patient-reported measures of tinnitus for individuals with neurofibromatosis type 2-related schwannomatosis: Recommendations for clinical trials.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Patient-Reported Outcomes Rating Acceptance Tool for Endpoints (PRO-RATE),scale,clinician-rated,No,,The remaining 16 PROMs were submitted to a formal group review process using the Patient-Reported Outcomes Rating Acceptance Tool for Endpoints (PRO-RATE) form
Brief Symptom Inventory 18 (BSI-18),clinical_assessment_tools,PMID:32572180,10.1038/s41436-020-0873-7,Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Brief Symptom Inventory 18 (BSI-18),questionnaire,adult,No,18.0,Emotional and behavioral problems were measured using the Brief Symptom Inventory 18 (BSI-18) for adult respondents
Behavior Problem Index (BPI),clinical_assessment_tools,PMID:32572180,10.1038/s41436-020-0873-7,Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Behavior Problem Index (BPI),questionnaire,pediatric,No,,Emotional and behavioral problems were measured using...the Behavior Problem Index (BPI) for adolescents (<18 years of age)
CCSS Neurocognitive Questionnaire,clinical_assessment_tools,PMID:32572180,10.1038/s41436-020-0873-7,Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,CCSS Neurocognitive Questionnaire,questionnaire,adult,No,,"Neurocognitive outcomes were assessed for adult respondents with the CCSS Neurocognitive Questionnaire, which includes subscales measuring task efficiency, emotional regulation, organization, and memory"
"Common Terminology Criteria for Adverse Events, version 4.0 (CTCAE v4.0)",clinical_assessment_tools,PMID:32572180,10.1038/s41436-020-0873-7,Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,"Common Terminology Criteria for Adverse Events, version 4.0 (CTCAE v4.0)",scale,all ages,No,,"Chronic health conditions were classified and severity-graded according to the Common Terminology Criteria for Adverse Events, version 4.0 (CTCAE v4.0)"
Kaufman Brief Intelligence Test– Second Edition (KBIT-2),clinical_assessment_tools,PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Kaufman Brief Intelligence Test– Second Edition (KBIT-2),performance test,pediatric,No,,The KBIT-2 is a brief measure of cognitive abilities including verbal reasoning and nonverbal reasoning...administered at the adolescent intake appointment
Wechsler Individual Achievement Test– Third Edition (WIAT-III) Word Reading subtest,clinical_assessment_tools,PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Wechsler Individual Achievement Test– Third Edition (WIAT-III) Word Reading subtest,performance test,pediatric,No,,The WIAT-III Word Reading subtest examines the ability to accurately read words...administered at the adolescent intake appointment
Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version– Attention Deficit/Hyperactivity Disorder module (KSADS-ADHD),clinical_assessment_tools,PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version– Attention Deficit/Hyperactivity Disorder module (KSADS-ADHD),structured interview,caregiver,No,,The KSADS is a semi-structured caregiver interview to assess psychopathology...administered at the pre-test appointment to a caregiver
Social Communication Questionnaire (SCQ),clinical_assessment_tools,PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Social Communication Questionnaire (SCQ),questionnaire,caregiver,No,40.0,The SCQ is a caregiver-report questionnaire that examines ASD symptomatology...has 40 items that are rated as 'Yes' or 'No'
Social Responsiveness Scale– Second Edition (SRS-2),clinical_assessment_tools,PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Social Responsiveness Scale– Second Edition (SRS-2),questionnaire,caregiver,No,65.0,The SRS-2 is a caregiver-report questionnaire of social impairment...includes 65 items that are rated on a 4-point scale
Friendship Qualities Scale (FQS),clinical_assessment_tools,PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Friendship Qualities Scale (FQS),questionnaire,pediatric,No,23.0,The FQS is a self-report questionnaire examining the friendship qualities...rate 23 items using a 5-point scale
Quality of Socialization Questionnaire (QSQ),clinical_assessment_tools,PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Quality of Socialization Questionnaire (QSQ),questionnaire,all ages,No,,The QSQ is a caregiver and self-report questionnaire to gather information about the adolescent's get-togethers with peers
Test of Adolescent Social Skills Knowledge (TASSK),clinical_assessment_tools,PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Test of Adolescent Social Skills Knowledge (TASSK),questionnaire,pediatric,No,30.0,The TASSK is a self-report 30-item questionnaire that measures knowledge of specific social skills taught as part of the PEERS® intervention
Modified Brief Pain Inventory (MBPI),clinical_assessment_tools,PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Modified Brief Pain Inventory (MBPI),questionnaire,pediatric,No,12.0,"The MBPI, adapted from the adult Brief Pain Inventory, is a 12-item self-report questionnaire that measures pain interference"
Faces Pain Scale-Revised (FPS-R),clinical_assessment_tools,PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Faces Pain Scale-Revised (FPS-R),scale,pediatric,No,1.0,The FPS-R is a one-item tool designed to provide an overall indicator of pain intensity at the time of the assessment
NRS-11,clinical_assessment_tools,PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,NRS-11,scale,all ages,No,11.0,Numerical Rating Scale-11 (NRS-11): The NRS-11 is a self-report 11-point numeric scale that assesses pain intensity
BPI-PI Scale,clinical_assessment_tools,PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,BPI-PI Scale,questionnaire,all ages,No,7.0,Brief Pain Inventory (BPI)-Pain Interference (PI) Scale: The BPI-PI Scale is a 7-item self-report questionnaire that measures the extent to which pain interferes with daily functioning
PROMIS depression short form,clinical_assessment_tools,PMID:39858077,10.3390/cancers17020295,A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,PROMIS depression short form,questionnaire,adult,No,8.0,"The following PROMIS self-report short forms were administered: depression (8 items) [ 32 ], pain interference (6 items) [ 33 ], and cognitive function (8 items) [ 34 ]."
PROMIS pain interference short form,clinical_assessment_tools,PMID:39858077,10.3390/cancers17020295,A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,PROMIS pain interference short form,questionnaire,adult,No,6.0,"The following PROMIS self-report short forms were administered: depression (8 items) [ 32 ], pain interference (6 items) [ 33 ], and cognitive function (8 items) [ 34 ]."
PROMIS cognitive function short form,clinical_assessment_tools,PMID:39858077,10.3390/cancers17020295,A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,PROMIS cognitive function short form,questionnaire,adult,No,8.0,"The following PROMIS self-report short forms were administered: depression (8 items) [ 32 ], pain interference (6 items) [ 33 ], and cognitive function (8 items) [ 34 ]."
EuroQol (EQ 5D),clinical_assessment_tools,PMID:28193237,10.1186/s12955-017-0607-y,Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,EuroQol (EQ 5D),questionnaire,adult,No,5.0,"The EuroQol (EQ 5D) contains a global health score and covers Mobility, Self-care, Usual Activities, Pain/Discomfort, Anxiety and Depression"
visual analogue scale,clinical_assessment_tools,PMID:40437318,10.1186/s41747-025-00594-x,Quantitative MRI of dorsal root ganglion alterations in neurofibromatosis type 1 patients with or without pain.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,visual analogue scale,scale,adult,No,,The inclusion criteria for the pain group were an average pain score of ≥ 3 on the visual analogue 0–10 scale over the previous 10 weeks
Wechsler Adult and Children Intelligence Scales,clinical_assessment_tools,PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Wechsler Adult and Children Intelligence Scales,performance test,all ages,No,,"All participants completed the age-appropriate digit-span subtest of the Wechsler Adult and Children Intelligence Scales (Wechsler, 2002, 2004)"
Brazilian Wechsler Intelligence Scales (WAIS-III or WISC-III),clinical_assessment_tools,PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Brazilian Wechsler Intelligence Scales (WAIS-III or WISC-III),performance test,all ages,No,,General intellectual functioning was assessed by the third version of the Brazilian Wechsler Intelligence Scales (WAIS-III or WISC-III for adults and children
Rey complex figure test,clinical_assessment_tools,PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Rey complex figure test,performance test,pediatric,No,,Rey complex figure test (CFT) (delayed recall; assessing nonverbal long-term memory)
Stroop color word test,clinical_assessment_tools,PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Stroop color word test,performance test,pediatric,No,,the Stroop color word test
Beery developmental test of visual-motor integration,clinical_assessment_tools,PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Beery developmental test of visual-motor integration,performance test,pediatric,No,,the Beery developmental test of visual-motor integration
Humphrey Field Analyzer perimetry,clinical_assessment_tools,PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Humphrey Field Analyzer perimetry,performance test,pediatric,No,,Visual fields were assessed with the Humphrey Field Analyzer perimetry as previously described
World Health Organization Categories of Childhood VI scale,clinical_assessment_tools,PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,World Health Organization Categories of Childhood VI scale,scale,pediatric,No,,In children ≥4 years of age VA at initial visit was compared with World Health Organization Categories of Childhood VI scale for reference
Pain Interference Index,clinical_assessment_tools,PMID:32187457,10.1056/NEJMoa1912735,Selumetinib in Children with Inoperable Plexiform Neurofibromas.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Pain Interference Index,scale,pediatric,No,,"interference of pain in daily functioning (Pain Interference Index)...Scores on the Pain Interference Index range from 0 to 6, with higher scores indicating greater pain interference"
Global Impression of Change scale,clinical_assessment_tools,PMID:32187457,10.1056/NEJMoa1912735,Selumetinib in Children with Inoperable Plexiform Neurofibromas.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Global Impression of Change scale,scale,pediatric,No,7.0,perceived changes with treatment (Global Impression of Change scale)...Scores on the Global Impression of Change scale range from 1 (very much improved) to 7 (very much worse)
"National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0",clinical_assessment_tools,PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,"National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0",scale,all ages,No,,"Adverse events were graded according to National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0"
LIFE-R Questionnaire,clinical_assessment_tools,PMID:35723774,10.1007/s10072-022-06203-8,A randomized controlled trial of remote microphone listening devices to treat auditory deficits in children with neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,LIFE-R Questionnaire,questionnaire,pediatric,No,,Listening and communication ratings (LIFE-R Questionnaire) were obtained at baseline and at the end of each treatment phase.
Morris water maze,clinical_assessment_tools,PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Morris water maze,performance test,all ages,No,,The water maze task was performed as previously described. Before performing the water maze task
Rotarod,clinical_assessment_tools,PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Rotarod,performance test,all ages,No,,"Motor learning was assessed with the accelerating rotarod (Ugo Basile, Comerio Varese, Italy)"
Infant Behaviour Questionnaire-Revised (IBQ-R),clinical_assessment_tools,PMID:34049498,10.1186/s11689-021-09364-3,Early differences in auditory processing relate to Autism Spectrum Disorder traits in infants with Neurofibromatosis Type I.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Infant Behaviour Questionnaire-Revised (IBQ-R),questionnaire,caregiver,No,191.0,The IBQ-R is a parent-report questionnaire consisting of 191 items and 14 scales that relate to different aspects of infant temperament...
MacArthur Bates Communicative Development Inventory (CDI),clinical_assessment_tools,PMID:34049498,10.1186/s11689-021-09364-3,Early differences in auditory processing relate to Autism Spectrum Disorder traits in infants with Neurofibromatosis Type I.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,MacArthur Bates Communicative Development Inventory (CDI),questionnaire,caregiver,No,800.0,Parents completed the MacArthur Bates Communicative Development Inventory (CDI) long form measures early language abilities...
"International Classification of Diseases, 10th Revision (ICD-10)",clinical_assessment_tools,PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,"International Classification of Diseases, 10th Revision (ICD-10)",scale,all ages,No,,"a strong positive COVID-19 diagnostic code from the International Classification of Diseases, 10th Revision (ICD-10)"
Systematized Nomenclature of Medicine (SNOMED),clinical_assessment_tools,PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Systematized Nomenclature of Medicine (SNOMED),scale,all ages,No,,"diagnostic code from the International Classification of Diseases, 10th Revision (ICD-10) or Systematized Nomenclature of Medicine (SNOMED) tables"
Lansky performance status,clinical_assessment_tools,PMID:37174087,10.3390/cancers15092621,Vinblastine/Methotrexate for Debilitating and Progressive Plexiform Neurofibroma in Children and Young Adults with Neurofibromatosis Type 1: A Phase 2 Study.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Lansky performance status,scale,pediatric,No,,...Exclusion criteria included Lansky or Karnofsky performance statuses of less than 60...
Karnofsky performance status,clinical_assessment_tools,PMID:37174087,10.3390/cancers15092621,Vinblastine/Methotrexate for Debilitating and Progressive Plexiform Neurofibroma in Children and Young Adults with Neurofibromatosis Type 1: A Phase 2 Study.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Karnofsky performance status,scale,adult,No,,...Exclusion criteria included Lansky or Karnofsky performance statuses of less than 60...
Dermatology Life Quality Index (DLQI),clinical_assessment_tools,PMID:31053133,10.1186/s13023-019-1067-8,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Dermatology Life Quality Index (DLQI),questionnaire,adult,No,,all participants were asked to complete three previously validated self-administered questionnaires: the Dermatology Life Quality Index [DLQI] questionnaire
Perceived Stress Scale (PSS),clinical_assessment_tools,PMID:31053133,10.1186/s13023-019-1067-8,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Perceived Stress Scale (PSS),scale,adult,No,10.0,The PSS is the most widely used psychological instrument for measuring the perception of stress. Composed of 10 items rated from never to often
SF12,clinical_assessment_tools,PMID:31053133,10.1186/s13023-019-1067-8,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,SF12,questionnaire,adult,No,12.0,"The SF12 is a short version of the SF-36, namely a generic instrument to measure population health with a physical composite score and mental composite score calculated based on 12 questions"
Wechsler Abbreviated Scale of Intelligence-II (WASI-II),clinical_assessment_tools,PMID:33519543,10.3389/fpsyt.2020.585700,Autism Spectrum Disorder Symptom Profile Across the RASopathies.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Wechsler Abbreviated Scale of Intelligence-II (WASI-II),performance test,pediatric,No,,"The Wechsler Abbreviated Scale of Intelligence-II (WASI-II) was used to measure verbal intellectual functioning (VIQ), based on two subscales called Similarities and Vocabulary"
"Conners Parent Rating Scale (3rd edition, short form)",clinical_assessment_tools,PMID:33519543,10.3389/fpsyt.2020.585700,Autism Spectrum Disorder Symptom Profile Across the RASopathies.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,"Conners Parent Rating Scale (3rd edition, short form)",scale,caregiver,No,,"Conners Parent Rating Scale (3rd edition, short form) measured ADHD symptomatology. The two domains, inattention and hyperactivity, were used in the study and presented in T-score"
Wechsler Abbreviated Scale of Intelligence (WASI),clinical_assessment_tools,PMID:28725547,10.1016/j.nicl.2017.06.032,Spatial working memory in neurofibromatosis 1: Altered neural activity and functional connectivity.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Wechsler Abbreviated Scale of Intelligence (WASI),scale,adult,No,,"Full-Scale IQ ≥ 70 (as determined by the Wechsler Abbreviated Scale of Intelligence [WASI]; Wechsler, 2011)"
"Wechsler Adult Intelligence Scale, Version 4 (WAIS-IV)",clinical_assessment_tools,PMID:28725547,10.1016/j.nicl.2017.06.032,Spatial working memory in neurofibromatosis 1: Altered neural activity and functional connectivity.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,"Wechsler Adult Intelligence Scale, Version 4 (WAIS-IV)",scale,adult,No,,"same measures from the Wechsler Adult Intelligence Scale, Version 4 (WAIS-IV; Wechsler, 2014) for the healthy controls"
Spatial capacity working memory (SCAP) task,clinical_assessment_tools,PMID:28725547,10.1016/j.nicl.2017.06.032,Spatial working memory in neurofibromatosis 1: Altered neural activity and functional connectivity.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Spatial capacity working memory (SCAP) task,performance test,adult,No,,"Participants viewed a visual array presenting 1, 3, 5, or 7 circles on the screen followed by a probe circle"
Patient Health Questionnaire (PHQ),clinical_assessment_tools,PMID:41602242,10.7759/cureus.100193,Perspectives of Patients and Providers on Chronic Pain Assessment in Neurofibromatosis Type 1 (NF1): A Qualitative Study.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Patient Health Questionnaire (PHQ),questionnaire,adult,No,,responses to...Patient Health Questionnaire (PHQ) [ 19 ]...evidence of moderate to severe depression or anxiety on the PHQ or GAD-7
PHQ-9,clinical_assessment_tools,PMID:41602242,10.7759/cureus.100193,Perspectives of Patients and Providers on Chronic Pain Assessment in Neurofibromatosis Type 1 (NF1): A Qualitative Study.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,PHQ-9,questionnaire,adult,No,9.0,The PHQ-9 and GAD-7 are copyrighted by Pfizer Inc. and are freely available for research and clinical use
WPPSI-IV,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,WPPSI-IV,performance test,pediatric,No,,WPPSI-IV 10 subtests providing 5 indices and full scale IQ Y
WISC-V,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,WISC-V,performance test,pediatric,No,,WISC-V 10 subtests providing 5 indices and full scale IQ S
Wechslers Intelligence Scale for Children-Fourth edition (WISC-IV),clinical_assessment_tools,PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Wechslers Intelligence Scale for Children-Fourth edition (WISC-IV),performance test,pediatric,No,,Auditory working memory was assessed using the digit span forward and back task of the Wechslers Intelligence Scale for Children-Fourth edition (WISC-IV)
Vineland Adaptive Behavior Scale—third edition,clinical_assessment_tools,PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Vineland Adaptive Behavior Scale—third edition,scale,caregiver,No,,Parent-rated Vineland Adaptive Behavior Scale—third edition (Hill et al. 2017) was administered to the parents to assess child adaptive behavior
Conners 3 rating scale,clinical_assessment_tools,PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Conners 3 rating scale,scale,caregiver,No,27.0,Conners 3 rating scale(Conners et al. 2011) was used as a standardized measure for parent reported ADHD symptoms. It consists of 27 items each rated on a 4-point Likert scale
Nottingham Health Profile (NHP),clinical_assessment_tools,PMID:38499890,10.1186/s41687-024-00714-y,"The PlexiQoL, a patient-reported outcome measure on quality of life in neurofibromatosis type 1-associated plexiform neurofibroma: translation, cultural adaptation and validation into the Dutch language for the Netherlands.",,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Nottingham Health Profile (NHP),questionnaire,adult,No,38.0,The Nottingham Health Profile (NHP) questionnaire was used as comparator questionnaire to evaluate convergent validity...consists of 38 items that cover six subsections
Nine-Hole Peg Test,clinical_assessment_tools,PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Nine-Hole Peg Test,performance test,all ages,No,,The Nine-Hole Peg Test was performed as a measure of finger dexterity. It measures the time (in seconds) needed to complete the test
Rey-Osterrieth Complex Figure Test,clinical_assessment_tools,PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Rey-Osterrieth Complex Figure Test,performance test,all ages,No,,The Rey-Osterrieth Complex Figure Test was implemented as a measure of the visuospatial cognitive domain
Rey Auditory-Verbal Learning Test (RAVLT),clinical_assessment_tools,PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Rey Auditory-Verbal Learning Test (RAVLT),performance test,all ages,No,,Immediate (A6) and delayed recalls (A7) of the Brazilian-Portuguese version of the Rey Auditory-Verbal Learning Test (RAVLT) were taken as measures of verbal episodic memory
Five Digits Test (FDT),clinical_assessment_tools,PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Five Digits Test (FDT),performance test,all ages,No,,The Five Digits Test (FDT) is a numeric-Stroop paradigm designed to assess attentional processes
Noldus Cat-Walk XT system,clinical_assessment_tools,PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Noldus Cat-Walk XT system,performance test,all ages,No,,Gait was analyzed using the Noldus Cat-Walk XT system as before
Handwriting Speed Test,clinical_assessment_tools,PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Handwriting Speed Test,performance test,pediatric,No,,"Fine motor endurance was evaluated by the Handwriting Speed Test (Wallen et al., 1996) that gives a raw score in letters per minute"
A Developmental NEuroPSYchological Assessment (NEPSY-II),clinical_assessment_tools,PMID:35087195,10.1038/s41380-021-01422-5,Altered canonical and striatal-frontal resting state functional connectivity in children with pathogenic variants in the Ras/mitogen-activated protein kinase pathway.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,A Developmental NEuroPSYchological Assessment (NEPSY-II),performance test,pediatric,No,,select subtests from A Developmental NEuroPSYchological Assessment (NEPSY-II)
Numeric Rating Scale-11,clinical_assessment_tools,PMID:40304934,10.1186/s41687-025-00877-2,Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Numeric Rating Scale-11,scale,all ages,No,1.0,provided feedback about existing pain measures (Numeric Rating Scale-11 and Pain Interference Index) assessing these domains
Pain Interference Index,clinical_assessment_tools,PMID:40304934,10.1186/s41687-025-00877-2,Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Pain Interference Index,questionnaire,all ages,No,6.0,provided feedback about existing pain measures (Numeric Rating Scale-11 and Pain Interference Index) assessing these domains
H-score,clinical_assessment_tools,PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,H-score,scale,all ages,No,,We used the H-score for quantification of FAP immunohistochemistry: 1 × percentage of weak staining) + (2 × percentage of moderate staining) + (3 × percentage of strong staining). The H score ranges from 0 to 300
House and Brackmann facial nerve scale,clinical_assessment_tools,PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,House and Brackmann facial nerve scale,scale,clinician-rated,No,6.0,physicians also completed the House and Brackmann facial nerve scale that rates facial nerve impairments from 1—normal symmetric function to 6—indicating complete paralysis
Morris Water Maze,clinical_assessment_tools,PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Morris Water Maze,performance test,all ages,No,,Morris Water Maze testing for spatial learning and memory was conducted as previously described
Cogstate,clinical_assessment_tools,PMID:34377779,10.1212/NXG.0000000000000616,Impact of MEK Inhibitor Therapy on Neurocognitive Functioning in NF1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Cogstate,performance test,all ages,No,,Performance tasks (Cogstate) and observer-reported functioning (BRIEF) were the primary outcomes...computerized assessment battery (Cogstate) targeting neurocognitive processes
BRIEF,clinical_assessment_tools,PMID:34377779,10.1212/NXG.0000000000000616,Impact of MEK Inhibitor Therapy on Neurocognitive Functioning in NF1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,BRIEF,questionnaire,caregiver,No,,observer-reported functioning (BRIEF) were the primary outcomes...Behavior Rating Inventory of Executive Function; BRIEF
BBB open-field locomotor test,clinical_assessment_tools,PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,BBB open-field locomotor test,scale,all ages,No,22.0,"The 22-point (0–21) Basso, Beattie, and Bresnahan (BBB) open-field locomotor test was used to assess hindlimb locomotor function"
Children's Depression Inventory (CDI-S),clinical_assessment_tools,PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Children's Depression Inventory (CDI-S),questionnaire,pediatric,No,10.0,"The CDI–S (Kovacs, 1992) is a 10-item self-report measure for depression in children, ages 7 to 17 years."
Children's Depression Inventory Parent Version (CDI-P),clinical_assessment_tools,PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Children's Depression Inventory Parent Version (CDI-P),questionnaire,caregiver,No,,"The CDI Parent Version (CDI-P) is derived directly from the CDI, is scored identically and has similar psychometric properties...completed by caregivers of all patients, ages 7–21."
Brief Symptom Inventory 18 (BSI-18),clinical_assessment_tools,PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Brief Symptom Inventory 18 (BSI-18),questionnaire,adult,No,18.0,"The BSI-18 (Derogatis et al., 2004) is an 18-item self-report measure to screen for psychological distress and psychiatric disorders in individuals in the community or hospital settings."
Nottingham Health Profile,clinical_assessment_tools,PMID:33085177,10.1002/mgg3.1530,The development of the PlexiQoL: A patient-reported outcome measure for adults with neurofibromatosis type 1-associated plexiform neurofibromas.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Nottingham Health Profile,questionnaire,adult,No,,"The comparator measure used in the UK was the Nottingham Health Profile (NHP; Hunt et al., 1981)"
Short Form-36,clinical_assessment_tools,PMID:33085177,10.1002/mgg3.1530,The development of the PlexiQoL: A patient-reported outcome measure for adults with neurofibromatosis type 1-associated plexiform neurofibromas.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Short Form-36,questionnaire,adult,No,36.0,"the Short Form‐36 (SF‐36; Ware & Sherbourne, 1992) was used in the US"
Impact of Pediatric Illness (IPI) Scale,clinical_assessment_tools,PMID:24753394,10.1002/pbc.25041,Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Impact of Pediatric Illness (IPI) Scale,scale,pediatric,No,43.0,QOL was assessed using the Impact of Pediatric Illness (IPI) Scale for children 6–18 years of age
hChR2(H134R)-EYFP,genetic_reagents,PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,hChR2(H134R)-EYFP,Viral,AAV,hSyn,,,,,,,,,,,,,,,,,,pAAV-hSyn-hChR2(H134R)-EYFP Addgene Plasmid#: 26973 RRID: Addgene_26973 Gift of Karl Deisseroth
Cre,genetic_reagents,PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Cre,Viral,AAV9,Th,,,,,,,,,,,,,,,,,,AAV9-Th-PI-Cre-SV40 Addgene Plasmid#: 107788 RRID: Addgene_107788 Addgene viral prep#: 107788-AAV9
eNpHR3.0-eYFP,genetic_reagents,PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,eNpHR3.0-eYFP,Viral,AAV-DJ,Ef1α,,,,,,,,,,,,,,,,,,pAAV-DJ-Ef1α-DO-eNpHR3.0-eYFP-WPRE-pA Addgene Plasmid#: 37087 RRID: Addgene_37087 Gift of Bernardo Sabatini
mCherry,genetic_reagents,PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,mCherry,Viral,AAV-DJ,Ef1α,,,,,,,,,,,,,,,,,,pAAV-DJ-Ef1α-DO-mCherry-WPRE-pA Addgene Plasmid#: 37119 RRID: Addgene_37119 Gift of Bernardo Sabatini
tTA,genetic_reagents,PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,tTA,Viral,AAV,ihSyn1,,,,,,,,,,,,,,,,,,pAAV-ihSyn1-tTA-WPRE Addgene Plasmid#: 99120 RRID: Addgene_99120
tTA,genetic_reagents,PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,tTA,Viral,AAV,Th,,,,,,,,,,,,,,,,,,pAAV-Th-tTA-WPRE Addgene Plasmid#: 133268 RRID: Addgene_133268
mRuby,genetic_reagents,PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,mRuby,Viral,AAV,TRE,,,,,,,,,,,,,,,,,,pAAV-TRE-mRuby-WPRE Addgene Plasmid#: 99114 RRID: Addgene_99114
mTurquoise,genetic_reagents,PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,mTurquoise,Viral,AAV,TRE,,,,,,,,,,,,,,,,,,pAAV-TRE-mTurquoise-WPRE Addgene Plasmid#: 99113 RRID: Addgene_99113
GFP,genetic_reagents,PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,GFP,Viral,AAV,Th,,,,,,,,,,,,,,,,,,pAAV-Th-GFP-WPRE Addgene Plasmid#: 99128 RRID: Addgene_99128
iCAP-PHP.eB,genetic_reagents,PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,iCAP-PHP.eB,Plasmid,pUCmini,,,,,,,,,,,,,,,,,,,pUCmini-iCAP-PHP.eB Addgene Plasmid#: 103005 RRID: Addgene_103005
Human exome capture,genetic_reagents,PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Human exome capture,Other,,,,,,,,,,,,,,,,,,,,"subjected to exome enrichment using SureSelectXT Human All Exon version 5 (Agilent Technologies, Wilmington, DE, catalog# 5190-6210)"
LacZ,genetic_reagents,PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,LacZ,Viral,,,,,,,,,,,,,,,,,,,,Cells were transduced with either lentiviral control shLacZ (Genome Institute at Washington University)
Cre,genetic_reagents,PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Cre,Viral,,CMV,,,,,,,,,,,,,,,,,,"DRG-NSCs were isolated from E13.5 embryo DRG/nerve roots, and were infected with Ad-CMV-Cre"
pCR2.1-TOPO,genetic_reagents,PMID:12057013,10.1186/1471-2164-3-13,Complex splicing pattern generates great diversity in human NF1 transcripts.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,pCR2.1-TOPO,Plasmid,pCR2.1,,,,,,,,,,,,,,,,,,,The PCR products were cloned in the pCR2.1-TOPO-vector (Invitrogen) and transformed into TOP-10F' cells.
Cre,genetic_reagents,PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Cre,Viral,Ad5,CMV,,,,,,,,,,,,,,,,,,infection with adenovirus Ad5-CMV-Cre or Ad5-CMV-eGFP (2500 viral particles per cell; Vector Development Lab)
eGFP,genetic_reagents,PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,eGFP,Viral,Ad5,CMV,,,,,,,,,,,,,,,,,,infection with adenovirus Ad5-CMV-Cre or Ad5-CMV-eGFP (2500 viral particles per cell; Vector Development Lab)
gene expression assay,genetic_reagents,PMID:18670322,10.1097/MLG.0b013e318177e20b,Vestibular schwannoma quantitative polymerase chain reaction expression of estrogen and progesterone receptors.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,gene expression assay,Other,,,,,,,,,,,,,,,,,,,,"20× solution of primers and fluorophor-labeled probe (Taqman Gene Expression Assays; Applied Biosystems, Foster City, CA)"
mGeCKOa sgRNA library,genetic_reagents,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,mGeCKOa sgRNA library,Viral,,,,,,,,,,,,,,,,,,,,"We infected p53−/−; Myc; Cas9 hepatocytes with the mGeCKOa lentiviral library of 67,000 single-guide RNAs (sgRNAs), targeting 20,611 mouse genes"
Cre,genetic_reagents,PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Cre,Viral,Ad5,,,,,,,,,,,,,,,,,,,The Nf1 gene was inactivated in passage 1 Nf1flox/flox astrocytes by infection with adenovirus (Ad5) containing Cre recombinase
LacZ,genetic_reagents,PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,LacZ,Viral,Ad5,,,,,,,,,,,,,,,,,,,Control Nf1flox/flox astrocytes (wild-type) were treated identically with an adenovirus encoding LacZ
mApple,genetic_reagents,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,mApple,Plasmid,,,,,,,,,,,,,,,,,,,,mApple-N1 (Addgene plasmid no. 54567) was a gift from M. Davidson
ZO-1,genetic_reagents,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,ZO-1,Plasmid,,,,,,,,,,,,,,,,,,,,pSK ZO-1 (Addgene plasmid no. 30316) was a gift from J. Anderson and A. Fanning
GFP-NMHC II-B,genetic_reagents,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,GFP-NMHC II-B,Plasmid,,CMV,,,,,,,,,,,,,,,,,,CMV-GFP-NMHC II-B (Addgene plasmid no. 11348) was a gift from R. Adelstein
GFP-vinculin,genetic_reagents,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,GFP-vinculin,Plasmid,,,,,,,,,,,,,,,,,,,,pGFP(C3)-vinculin (Addgene plasmid no. 30312) was a gift from K. Hahn
venus-Scrib,genetic_reagents,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,venus-Scrib,Plasmid,,,,,,,,,,,,,,,,,,,,pKvenus-Scrib (Addgene plasmid no. 58738) was a gift from I. Macara
EGFP-hYAP1,genetic_reagents,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,EGFP-hYAP1,Plasmid,,,,,,,,,,,,,,,,,,,,"pEGFP-C3-hYAP1 and pEGFP C3-Lats1 (Addgene plasmid nos. 19053 and 17843, respectively) were gifts from M. Sudol"
EGFP-Lats1,genetic_reagents,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,EGFP-Lats1,Plasmid,,,,,,,,,,,,,,,,,,,,"pEGFP-C3-hYAP1 and pEGFP C3-Lats1 (Addgene plasmid nos. 19053 and 17843, respectively) were gifts from M. Sudol"
HA-AMOT p130,genetic_reagents,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,HA-AMOT p130,Plasmid,,,,,,,,,,,,,,,,,,,,HA-AMOT p130 (Addgene plasmid no. 32821) was a gift from K. Guan
NLuc,genetic_reagents,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,NLuc,Plasmid,pcDNA3.1,,,,,,,,,,,,,,,,,,,pcDNA3.1-ccdB-NLuc (Addgene plasmid no. 87067) was a gift from M. Taipale
4XBS2WT-Luc,genetic_reagents,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,4XBS2WT-Luc,Plasmid,,,,,,,,,,,,,,,,,,,,p4XBS2WT-Luc (Addgene plasmid no. 16593) was a gift from B. Vogelstein
8xGTIIC-luciferase,genetic_reagents,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,8xGTIIC-luciferase,Plasmid,,,,,,,,,,,,,,,,,,,,p8xGTIIC-luciferase (Addgene plasmid no. 34615) was a gift from S. Piccolo
p53 WT,genetic_reagents,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,p53 WT,Plasmid,pcDNA3,,,,,,,,,,,,,,,,,,,pcDNA3 p53 WT (Addgene plasmid no. 69003) was a gift from D. Meek
Trp53,genetic_reagents,PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Trp53,Other,,,,,,,,,,,,,,,,,,,,"Trp53 Exon 3, F AAGTCACAGCACATGACGG"
Brca1,genetic_reagents,PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Brca1,Other,,,,,,,,,,,,,,,,,,,,"Brca1 Exon 6, F GCGTCGATCATCCAGAGCGT"
Pten,genetic_reagents,PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Pten,Other,,,,,,,,,,,,,,,,,,,,"Pten Exon 6, R ATATACATAGCGCCTCTGAC"
SALSA MLPA P081/P082,genetic_reagents,PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,SALSA MLPA P081/P082,Other,,,,,,,,,,,,,,,,,,,,"using the SALSA MLPA kits P081/P082 (MRC Holland, Amsterdam, The Netherlands)"
beta-globin,genetic_reagents,PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,beta-globin,Plasmid,,,,,,,,,,,,,,,,,,,,"cloned into the beta-globin vector, as previously described"
Cas9,genetic_reagents,PMID:34630515,10.3389/fgene.2021.721045,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and ,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Cas9,Other,,,,,,,,,,,,,,,,,,,,1.95μm Cas9 (Cas9 Nuclease V3; IDT)
Cas9,genetic_reagents,PMID:34630515,10.3389/fgene.2021.721045,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and ,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Cas9,Other,,,,,,,,,,,,,,,,,,,,"The injection solution contained gRNAs, S. pyogenes Cas9 mRNA (PNA Bio Inc., Thousand Oaks, CA or Millipore Sigma, Burlington, MA)"
GRDC24,genetic_reagents,PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.9,Development,False,1.00,Medium,,,,,,,,,,,GRDC24,Viral,AAV,CBh,,,,,,,,,,,,,,,,,,pscAAV-GFP and pscAAV-GRDC24 (2163 bp between ITRs) were used to generate AAV-GFP and AAV-GRDC24
CRISPR-Cas9,genetic_reagents,PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,CRISPR-Cas9,Plasmid,,,,,,,,,,,,,,,,,,,,"NF1‐sg2 (ACACTGGAAAAATGTCTTGC), a sgRNA targeting human NF1 exon 3 in the lentiCRISPR v1 plasmid"
PDLIM2 shRNA,genetic_reagents,PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,PDLIM2 shRNA,Plasmid,pLKO.1-puro,,,,,,,,,,,,,,,,,,,Five different shRNA clones were tested... cloned into the plasmid pLKO.1-puro
Cre and gRNAs,genetic_reagents,PMID:39996452,10.1111/cns.70287,Cas9 Mouse Model of Skull Base Meningioma Driven by Combinational Gene Inactivation in Meningeal Cells.,,0.9,Development,False,1.00,Medium,,,,,,,,,,,Cre and gRNAs,Viral,pLenti,CMV,,,,,,,,,,,,,,,,,,"We then prepared lentivirus vector pLentiCre/gRNA, which could express the elements blocking the function of four genes: Nf2, P15"
Cre and gRNAs,genetic_reagents,PMID:39996452,10.1111/cns.70287,Cas9 Mouse Model of Skull Base Meningioma Driven by Combinational Gene Inactivation in Meningeal Cells.,,0.9,Development,False,1.00,Medium,,,,,,,,,,,Cre and gRNAs,Viral,AAV,pEFS,,,,,,,,,,,,,,,,,,"we constructed an AAV vector of pAAVCre/gRNA, which could import Cre and the four gRNAs"
MAF ORF,genetic_reagents,PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,MAF ORF,Viral,pLVX-Tight-Puro,,,,,,,,,,,,,,,,,,,Inducible expression used lentiviral vectors containing the MAF ORF or empty pLVX-Tight-Puro vector (GeneCopoeia)
Tet-On,genetic_reagents,PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Tet-On,Viral,pLVX,Tet-inducible,,,,,,,,,,,,,,,,,,in a modified pTight backbone (Clonetech) with pLVX-Tet-On doxycycline inducible vector (Clonetech)
AP-1 luciferase,genetic_reagents,PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,AP-1 luciferase,Plasmid,,AP-1,,,,,,,,,,,,,,,,,,Cells were transfected using FuGENE HD (Roche) with 100ng per well of an AP-1 luciferase (Stratagene) reporter vector
capture probe library,genetic_reagents,PMID:33767727,10.3389/fgene.2021.603195,Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,capture probe library,Other,,,,,,,,,,,,,,,,,,,,the capture probe from the Roche NimbleGen Sequence Capture SeqCap EZ Library was used to capture a total of 569 genes associated with hereditary dermatosis
ZEB1,genetic_reagents,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,ZEB1,Other,,,,,,,,,,,,,,,,,,,,"For siRNA knockdown targeting ZEB1 (Sigma-Aldrich, SASI_Hs02_00330526, SASI_Hs02_00330527, SASI_Hs02_00330530)"
ALDH1A1,genetic_reagents,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,ALDH1A1,Other,,,,,,,,,,,,,,,,,,,,"ALDH1A1 (Sigma-Aldrich, SASI_Hs01_00244055, SASI_Hs01_00244056, SASI_Hs02_00303091) in MPNST cell lines"
UPF1,genetic_reagents,PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,UPF1,Other,,,,,,,,,,,,,,,,,,,,"cells were transfected with 50 nm of siRNA targeting UPF1. In a pilot experiment, three custom and non-overlapping UPF1 duplexes were tested"
Cas9,genetic_reagents,PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Cas9,Plasmid,pX330,,,,,,,,,,,,,,,,,,,"To generate CRISPR/Cas9-modified ipNF06.2A cell lines, sequences were subcloned into pX330"
hGFAP-cre,genetic_reagents,PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,hGFAP-cre,Other,,,,,,,,,,,,,,,,,,,,The control mice used in this study are a pool of phenotypically indistinguishable mice with genotypes of hGFAP-cre-; Nf1 flox/flox
CRISPRv2,genetic_reagents,PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,CRISPRv2,Viral,lentiCRISPRv2,,,,,,,,,,,,,,,,,,,TRAP1 and CyPD expression were knocked out using the lenti CRISPRv2 system
Human All Exon,genetic_reagents,PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Human All Exon,Other,,,,,,,,,,,,,,,,,,,,We performed exome sequencing on five malignant meningiomas on the Illumina HiSeq2000 platform using Agilent SureSelect Human All Exon kits.
nuclear RFP,genetic_reagents,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,nuclear RFP,Viral,,EF1α,,,,,,,,,,,,,,,,,,"Cell lines were transduced with Incucyte Nuclight Red Lentivirus (Sartorius, Gottingen, Germany) such that they will produce an EF1α promoter driven nuclear restricted red fluorescent label"
B-Raf,genetic_reagents,PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,B-Raf,Other,,,,,,,,,,,,,,,,,,,,"siRNA for either B-Raf: AAAGAATTGGATCTGGATCAT, and C-Raf: TGTGCGAAATGGAATGAGCTT, both from Dharmacon"
C-Raf,genetic_reagents,PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,C-Raf,Other,,,,,,,,,,,,,,,,,,,,"siRNA for either B-Raf: AAAGAATTGGATCTGGATCAT, and C-Raf: TGTGCGAAATGGAATGAGCTT, both from Dharmacon"
P53 shRNA,genetic_reagents,PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,P53 shRNA,Viral,Lentiviral,,,,,,,,,,,,,,,,,,,P53 (5′-GA CTCCA GTGGT AA TCT A C-3′)
P53,genetic_reagents,PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,P53,Plasmid,,,,,,,,,,,,,,,,,,,,Flag-tagged P53 (Addgene; #10838)
RABL6A shRNA,genetic_reagents,PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,RABL6A shRNA,Viral,pLKO.1,,,,,,,,,,,,,,,,,,,"Human RABL6A and RB1 shRNAs in the pLKO.1 lentiviral vector (Open Biosystems, Huntsville, AL, USA)"
RB1 shRNA,genetic_reagents,PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,RB1 shRNA,Viral,pLKO.1,,,,,,,,,,,,,,,,,,,"Human RABL6A and RB1 shRNAs in the pLKO.1 lentiviral vector (Open Biosystems, Huntsville, AL, USA)"
shPTPN11,genetic_reagents,PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,shPTPN11,Plasmid,pLKO,Tet-regulated,,,,,,,,,,,,,,,,,,shRNAs targeting PTPN11 #5003 and #818 were subcloned into Tet-pLKO-puro vector
shPTPN11,genetic_reagents,PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,shPTPN11,Plasmid,pLKO,Tet-regulated,,,,,,,,,,,,,,,,,,shRNAs targeting PTPN11 #5003 and #818 were subcloned into Tet-pLKO-puro vector
KCNMA1,genetic_reagents,PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,KCNMA1,Other,,,,,,,,,,,,,,,,,,,,QuantiTech Qiagen primers:  KCNMA1  (cat# QT00024157)
PRKCE,genetic_reagents,PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,PRKCE,Other,,,,,,,,,,,,,,,,,,,,PRKCE  (cat# QT00016352)
OPCML,genetic_reagents,PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,OPCML,Other,,,,,,,,,,,,,,,,,,,,OPCML  (cat# QT01005361)
GRIK2,genetic_reagents,PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,GRIK2,Other,,,,,,,,,,,,,,,,,,,,GRIK2  (cat# QT00016597)
CADM2,genetic_reagents,PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,CADM2,Other,,,,,,,,,,,,,,,,,,,,CADM2  (cat# QT00048888)
CREB5,genetic_reagents,PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,CREB5,Other,,,,,,,,,,,,,,,,,,,,CREB5  (cat# QT00054488)
CAMK1D,genetic_reagents,PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,CAMK1D,Other,,,,,,,,,,,,,,,,,,,,CAMK1D  (cat# QT00036344)
ITGB8,genetic_reagents,PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,ITGB8,Other,,,,,,,,,,,,,,,,,,,,ITGB8  (cat# QT00038507)
End Repair Enzyme Mix,genetic_reagents,PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,End Repair Enzyme Mix,Other,,,,,,,,,,,,,,,,,,,,"5 µl of End Repair Enzyme Mix (cat# E6050, NEB, Ipswich, MA). The 100 µl end-repair mixture was incubated at 20°C for 30 min"
Klenow (exo-),genetic_reagents,PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Klenow (exo-),Other,,,,,,,,,,,,,,,,,,,,"42 µl of end-repaired DNA was mixed with 5 µl of 10 X dA Tailing Reaction Buffer and 3 µl of Klenow (exo-)(cat# E6053, NEB, Ipswich, MA)."
Quick T4 DNA ligase,genetic_reagents,PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Quick T4 DNA ligase,Other,,,,,,,,,,,,,,,,,,,,"10 µl of 5 X Ligation buffer and 5 µl of Quick T4 DNA ligase (cat# E6056, NEB, Ipswich, MA). The ligation mixture was incubated at 20°C for 15 min"
cfDNA Extraction Kit,genetic_reagents,PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,cfDNA Extraction Kit,Other,,,,,,,,,,,,,,,,,,,,"cfDNA from each of the plasma samples was purified using a BioChain cfDNA Extraction Kit (BioChain, cat #K5011610) using the manufacturer's recommended protocol."
circulating nucleic acid kit,genetic_reagents,PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,circulating nucleic acid kit,Other,,,,,,,,,,,,,,,,,,,,Cell-free DNA was extracted using the QIAGEN circulating nucleic acid kit (Catalog# 55114).
anti-HER1 CAR 806,genetic_reagents,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.9,Development,False,1.00,Medium,,,,,,,,,,,anti-HER1 CAR 806,Viral,,,,,,,,,,,,,,,,,,,,"To target HER1, we constructed CARs using three distinct scFvs (806, E2 and NEC)"
anti-HER1 CAR E2,genetic_reagents,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.9,Development,False,1.00,Medium,,,,,,,,,,,anti-HER1 CAR E2,Viral,,,,,,,,,,,,,,,,,,,,"To target HER1, we constructed CARs using three distinct scFvs (806, E2 and NEC)"
anti-HER1 CAR NEC,genetic_reagents,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.9,Development,False,1.00,Medium,,,,,,,,,,,anti-HER1 CAR NEC,Viral,,,,,,,,,,,,,,,,,,,,"To target HER1, we constructed CARs using three distinct scFvs (806, E2 and NEC)"
AHR,genetic_reagents,PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,AHR,Other,,,,,,,,,,,,,,,,,,,,siRNA targeting...AHR (s1200)
Luciferase-IRES-GFP,genetic_reagents,PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Luciferase-IRES-GFP,Transposon,,CAGG,,,,,,,,,,,,,,,,,,co-transposition was performed using 500 ng of the piggyBac (PB) transposon PB-CAGG-Luciferase-IRES-GFP-PGK-PuroR
shRNA,genetic_reagents,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,shRNA,Plasmid,pLKO,,,,,,,,,,,,,,,,,,,"6,091 shRNAs, cloned into the pLKO-puromycin system"
SGK1,genetic_reagents,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,SGK1,Plasmid,pLKO,,,,,,,,,,,,,,,,,,,pLKO-puro-based shRNAs targeting human SGK1 (TRCN0000194957)
PAK1,genetic_reagents,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,PAK1,Plasmid,pLKO,,,,,,,,,,,,,,,,,,,human PAK1 (TRCN0000197238)
RHEB,genetic_reagents,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,RHEB,Plasmid,pLKO,,,,,,,,,,,,,,,,,,,human RHEB (TRCN0000010424)
TaqMan PCR Core REAGENTS Kit,genetic_reagents,PMID:15255999,10.1186/1476-4598-3-20,"Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR.",,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,TaqMan PCR Core REAGENTS Kit,Other,,,,,,,,,,,,,,,,,,,,All PCR reactions were performed using an ABI Prism 7700 Sequence Detection System (Perkin-Elmer Applied Biosystems) and either the TaqMan ® PCR Core REAGENTS Kit
SYBR Green PCR Core Reagents kit,genetic_reagents,PMID:15255999,10.1186/1476-4598-3-20,"Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR.",,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,SYBR Green PCR Core Reagents kit,Other,,,,,,,,,,,,,,,,,,,,or the SYBR ® Green PCR Core Reagents kit (Perkin-Elmer Applied Biosystems)
Superscript II RNase H-reverse transcriptase,genetic_reagents,PMID:15255999,10.1186/1476-4598-3-20,"Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR.",,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Superscript II RNase H-reverse transcriptase,Other,,,,,,,,,,,,,,,,,,,,"100 units of Superscript II RNase H-reverse transcriptase (Invitrogen, Cergy Pontoise, France)"
GFP,genetic_reagents,PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,GFP,Viral,,,,,,,,,,,,,,,,,,,,subcloned as a Bgl II/Xho I fragment into the retroviral expression vector pBMN-I-GFP
GST-PID,genetic_reagents,PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,GST-PID,Plasmid,,,,,,,,,,,,,,,,,,,,A GST-PID (Pak1 amino acids 83–149) or Gst-PID L107F cDNA was subcloned
Gst-PID L107F,genetic_reagents,PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Gst-PID L107F,Plasmid,,,,,,,,,,,,,,,,,,,,A GST-PID (Pak1 amino acids 83–149) or Gst-PID L107F cDNA was subcloned
PTPN11,genetic_reagents,PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,PTPN11,Other,,,,,,,,,,,,,,,,,,,,"SMARTPool ON-TARGETplus Human PTPN11 siRNA (#L-003947–00-0005, Dharmacon) to knockdown (KD) the expression of non-targeting control (NTC) and SHP2"
I2HCP panel,genetic_reagents,PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",,0.9,Development,False,1.00,Medium,,,,,,,,,,,I2HCP panel,Other,,,,,,,,,,,,,,,,,,,,"we developed the I2HCP panel, a custom bait library covering 122 hereditary cancer genes"
β-catenin ΔN90,genetic_reagents,PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,β-catenin ΔN90,Viral,,,,,,,,,,,,,,,,,,,,"β-catenin overexpression lentivirus ΔN90 (Addgene, Cambridge MA)"
BstUI,genetic_reagents,PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,BstUI,Other,,,,,,,,,,,,,,,,,,,,"PCR products were then digested using the endonuclease BstUI in 30 μl volumes according to the manufacturer's specifications (New England Biolabs, Beverly, MA)"
Taq polymerase,genetic_reagents,PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Taq polymerase,Other,,,,,,,,,,,,,,,,,,,,"1 μl of 10X buffer, and 0.25 U of Taq polymerase (Qiagen, Valencia, CA)"
psPAX,genetic_reagents,PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,psPAX,Plasmid,,,,,,,,,,,,,,,,,,,,co-transfected with the packaging plasmids psPAX (Addgene #12260)
pMD2.G,genetic_reagents,PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,pMD2.G,Plasmid,,,,,,,,,,,,,,,,,,,,"and pMD2.G (Addgene, #12259)"
UAS:eGFP-KRAS G12D,genetic_reagents,PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,UAS:eGFP-KRAS G12D,Transposon,Tol2,UAS,,,,,,,,,,,,,,,,,,injected with Tol2(UAS:eGFP-KRAS G12D) plasmid
shSOX9,genetic_reagents,PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,shSOX9,Viral,,,,,,,,,,,,,,,,,,,,we infected MPNST cells at 70–90% confluence with lentiviral particles containing shRNAs targeting SOX9 (Open Biosystems; TRC library)
hTERT,genetic_reagents,PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,hTERT,Viral,,,,,,,,,,,,,,,,,,,,full length human telomerase reverse transcriptase cDNA
mCdk4,genetic_reagents,PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,mCdk4,Viral,,,,,,,,,,,,,,,,,,,,murine Cdk4 full-length cDNA
CRISPR-Cas9,genetic_reagents,PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,CRISPR-Cas9,Plasmid,lentiCRISPRv2,,,,,,,,,,,,,,,,,,,"Oligonucleotide pairs were annealed and cloned into the transfer plasmid lentiCRISPRv2 (Addgene, Watertown, MA, USA, #52961)"
pBABE vectors,genetic_reagents,PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,pBABE vectors,Viral,pBABE,,,,,,,,,,,,,,,,,,,pBABE vectors were used for expression of constitutively active (CA: S217E/S221E) and dominant negative (DN: S217A) MEK1 and hyperactive RAS (G12D mutant)
KIF15/KIF23 siRNA,genetic_reagents,PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,KIF15/KIF23 siRNA,Other,,,,,,,,,,,,,,,,,,,,"siRNA pool targeting KIF15, KIF23, or a non-targeting control (NTC; siGENOME SMARTpool, Dharmacon)"
Cas9,genetic_reagents,PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Cas9,Plasmid,pX330,U6,,,,,,,,,,,,,,,,,,pX330-U6-Chimeric_BB-CBh-HSpCas0 (Addgene)
RGS2,genetic_reagents,PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,RGS2,Plasmid,,,,,,,,,,,,,,,,,,,,pRGS2 surrogate reporter (Labomics)
PDE4A1,genetic_reagents,PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.9,Development,False,1.00,Medium,,,,,,,,,,,PDE4A1,Viral,,,,,,,,,,,,,,,,,,,,Full-length murine PDE4A1 or catalytically inactive PDE4A1-H229Q was cloned into a lentiviral packaging vector that also encodes mCherry fluorescent protein
PDE4A1-H229Q,genetic_reagents,PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.9,Development,False,1.00,Medium,,,,,,,,,,,PDE4A1-H229Q,Viral,,,,,,,,,,,,,,,,,,,,Full-length murine PDE4A1 or catalytically inactive PDE4A1-H229Q was cloned into a lentiviral packaging vector that also encodes mCherry fluorescent protein
Illumina Methylation EPIC Beadchip,genetic_reagents,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Illumina Methylation EPIC Beadchip,Other,,,,,,,,,,,,,,,,,,,,"Genomic DNA from human tumors were processed for methylation analysis using the Illumina Methylation EPIC Beadchip (#WG-317-1003, Illumina)"
dCas9-BFP-KRAB,genetic_reagents,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,dCas9-BFP-KRAB,Plasmid,pMH0001,SFFV,,,,,,,,,,,,,,,,,,"Lentivirus containing pMH0001 (UCOE-SFFV-dCas9-BFP-KRAB, #85969, Addgene) was produced"
sgRNA,genetic_reagents,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,sgRNA,Plasmid,pCRISPRia-v2,,,,,,,,,,,,,,,,,,,"Subsequent gene specific knockdowns were achieved by individually cloning single-guide RNA (sgRNA) protospacer sequences into the pCRISPRia-v2 vector (#84832, Addgene)"
ALDH1A1,genetic_reagents,PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,ALDH1A1,Plasmid,pLKO.1-puro,,,,,,,,,,,,,,,,,,,ALDH1A1 (TRCN0000026415)—5′-GCCAAATCATTCCTTGGAATTT-3′
TAZ,genetic_reagents,PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,TAZ,Plasmid,pLKO.1-puro,,,,,,,,,,,,,,,,,,,TAZ (TRCN0000307197)—5′-CGGACTTCATTCAAGAGGAAT-3′
YAP,genetic_reagents,PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,YAP,Plasmid,pLKO.1-puro,,,,,,,,,,,,,,,,,,,YAP (TRCN0000107266)—5′-GCCACCAAGCTAGATAAAGAA-3′
Scramble,genetic_reagents,PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Scramble,Plasmid,pLKO.1-puro,,,,,,,,,,,,,,,,,,,Scramble (TRC1/1.5; SHC002)—5′-CAACAAGATGAAGAGCACCAA-3′
PMOs,genetic_reagents,PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,PMOs,Other,,,,,,,,,,,,,,,,,,,,"The 25-mer-specific PMOs for four patients with splicing variants, and a pair of PMOs to induce exon skipping of exons 4, 8, and 11 of the NF2 gene were designed"
Gateway Gene Cloning system,genetic_reagents,PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Gateway Gene Cloning system,Other,,,,,,,,,,,,,,,,,,,,The NF2 gene was cloned using the Gateway Gene Cloning system (Invitrogen) after treatment to induce the exon-skipping to an FLAG Tag Expression Vector
FLAG Tag,genetic_reagents,PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,FLAG Tag,Plasmid,,,,,,,,,,,,,,,,,,,,The NF2 gene was cloned using the Gateway Gene Cloning system (Invitrogen) after treatment to induce the exon-skipping to an FLAG Tag Expression Vector
NeuroD1,genetic_reagents,PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,NeuroD1,Viral,,CMV,,,,,,,,,,,,,,,,,,"AdCMVNeuroD1 at 2 × 109 pfu/mL, or AdCMVNeuroD1 at 5 × 109 pfu/mL (ViraQuest, Inc.) were applied to the culture medium"
Tgfb3,genetic_reagents,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Tgfb3,Other,,,,,,,,,,,,,,,,,,,,"Sequence-based reagent Tgfb3-MO Gene Tools, LLC Lissamine-tagged, tgfb3-targeting Morpholino"
Tgfb1b,genetic_reagents,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Tgfb1b,Other,,,,,,,,,,,,,,,,,,,,"Sequence-based reagent Tgfb1b-MO Gene Tools, LLC Lissamine-tagged, tgfb1b-targeting Morpholino"
tgfb3-EGFP,genetic_reagents,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Development,False,1.00,Medium,,,,,,,,,,,tgfb3-EGFP,Plasmid,pCS2+,,,,,,,,,,,,,,,,,,,Recombinant DNA reagent pCS2+ tgfb3-EGFP This paper; Figure 3—figure supplement 1B Vector for generating RNA
nCas9n-nanos3'UTR,genetic_reagents,PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,nCas9n-nanos3'UTR,Plasmid,pCS2,,,,,,,,,,,,,,,,,,,"Recombinant DNA reagent pCS2-nCas9n-nanos3'UTR Addgene, Plasmid #62542"
pcDNA3.1,genetic_reagents,PMID:24932921,10.1002/jbmr.2298,Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,pcDNA3.1,Plasmid,pcDNA3.1,,,,,,,,,,,,,,,,,,,"PCR amplicons were cloned into pcDNA3.1 vector (Life Technologies, CA, USA)"
pCW57.1,genetic_reagents,PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,pCW57.1,Plasmid,pCW57.1,,,,,,,,,,,,,,,,,,,The plasmids pCW57.1 (Addgene plasmid 41393)
KRAS WT,genetic_reagents,PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,KRAS WT,Plasmid,pDONR223,,,,,,,,,,,,,,,,,,,pDONR223 KRAS WT (Addgene plasmid 81751)
KRAS G12D,genetic_reagents,PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,KRAS G12D,Plasmid,pDONR223,,,,,,,,,,,,,,,,,,,pDONR223 KRAS G12D (Addgene plasmid 81651)
Tp53,genetic_reagents,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Tp53,Other,,,,,,,,,,,,,,,,,,,,Cells were nucleofected with siRNA against Tp53 or miR34a (Dharmacon)
miR34a,genetic_reagents,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,miR34a,Other,,,,,,,,,,,,,,,,,,,,Cells were nucleofected with siRNA against Tp53 or miR34a (Dharmacon)
Cre,genetic_reagents,PMID:28392281,10.1016/j.expneurol.2017.04.001,Human stem cell modeling in neurofibromatosis type 1 (NF1).,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Cre,Other,,,,,,,,,,,,,,,,,,,,excisable lentiviral vectors have been developed using Cre/loxP technology
"OCT4, SOX2, MYC, KLF4, NANOG, LIN28",genetic_reagents,PMID:28392281,10.1016/j.expneurol.2017.04.001,Human stem cell modeling in neurofibromatosis type 1 (NF1).,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,"OCT4, SOX2, MYC, KLF4, NANOG, LIN28",Plasmid,oriP/EBNA1,,,,,,,,,,,,,,,,,,,"human fibroblasts have been successfully reprogrammed after a single transfection with oriP/EBNA1 (Epstein-Barr nuclear antigen-1)-based episomal vectors expressing OCT4, SOX2, MYC, KLF4, NANOG, LIN28"
c-abl siRNA,genetic_reagents,PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,c-abl siRNA,Other,,,,,,,,,,,,,,,,,,,,"c-abl siRNA oligonucleotides (Cat. no. sc-29844) were purchased from Santa Cruz Biotechnology, Inc."
NF-1,genetic_reagents,PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,NF-1,Viral,lentiviral,,,,,,,,,,,,,,,,,,,"cells were transfected with the control lentivirus (LV-vector), NF-1 sgRNA-CAS9 lentivirus (LV-NF-1), Rictor sgRNA-CAS9 lentivirus (LV-Rictor)"
Rictor,genetic_reagents,PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Rictor,Viral,lentiviral,,,,,,,,,,,,,,,,,,,"cells were transfected with the control lentivirus (LV-vector), NF-1 sgRNA-CAS9 lentivirus (LV-NF-1), Rictor sgRNA-CAS9 lentivirus (LV-Rictor)"
SpCas9,genetic_reagents,PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,SpCas9,Plasmid,,CMV,,,,,,,,,,,,,,,,,,"MCF7 cells (1 × 10 6 ) were transfected with 1 µg of a 12:1 DNA ratio of the pCMV-T7-(FZ) SpCas9-BPNLS(SV40)-3xFLAG-P2A-Puro-R plasmid (modified from RTW3027, Addgene #139987)"
CEP 8 (D8Z2),genetic_reagents,PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,CEP 8 (D8Z2),Other,,,,,,,,,,,,,,,,,,,,Probes used were a centromeric-enumerating probe Vysis CEP 8 (D8Z2) SpectrumGreen combined with locus-specific probe
LSI MYC,genetic_reagents,PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,LSI MYC,Other,,,,,,,,,,,,,,,,,,,,combined with locus-specific probe Vysis LSI MYC SpectrumOrange (Abbott Molecular)
exome capture reagent,genetic_reagents,PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,exome capture reagent,Other,,,,,,,,,,,,,,,,,,,,"The NGS library was executed using the Agilent Sure Select XT HS2 all exon v8 kit (Agilent, Santa Clara, CA, USA), following the manufacturer's instructions."
Ref-1,genetic_reagents,PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Ref-1,Other,,,,,,,,,,,,,,,,,,,,MPNST cells were transfected with Ref-1 #1 siRNA (sequence previously reported)
Ref-1,genetic_reagents,PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Ref-1,Other,,,,,,,,,,,,,,,,,,,,"LifeTech validated Ref-1 siRNA (s1447, Santa Cruz, Dallas, TX, USA)"
STAT3,genetic_reagents,PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,STAT3,Other,,,,,,,,,,,,,,,,,,,,"validated STAT3 siRNAs (sc-44275, sc-29493) and scrambled control"
Hsp90β,genetic_reagents,PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Hsp90β,Plasmid,pBad,,,,,,,,,,,,,,,,,,,"the human Hsp90β sequence was optimized and cloned into a pBad/Myc-Hisx6 vector (Invitrogen, Thermo Fisher Scientific)"
vestibular schwannoma xenografts,patient_derived_models,PMID:18636037,10.1097/MAO.0b013e31817f7398,The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.,,0.9,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,PDX,vestibular schwannoma,nude mouse,vestibular schwannoma,,,,,,Vestibular schwannoma xenografts were established in the interscapular fat pad in nude mice
DCT,antibodies,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.9,Experimental Usage,True,0.67,Medium,,,,DCT,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"DCT (PEP8h; gift from Dr. Vincent Hearing, National Institutes of Health)"
K14,antibodies,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.9,Experimental Usage,True,0.67,Medium,,,,K14,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"K14 (biotin-labeled, Thermo, clone LL002), LacZ (Abcam, ab9361), GFP/YFP (Aves, 1020)"
TOMM20,antibodies,PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.9,Experimental Usage,True,0.67,Medium,,,,TOMM20,Unknown,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"TOMM20 (Proteintech, 11802-1-AP)"
HSP90,antibodies,PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.9,Experimental Usage,True,0.67,Medium,,,,HSP90,Unknown,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"HSP90 (Proteintech, 13171-1-AP)"
FLAG,antibodies,PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.9,Experimental Usage,True,0.67,Medium,,,,FLAG,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies (Cell Signaling Technology) used for Western blotting were FLAG (rabbit, 14793)"
V5,antibodies,PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.9,Experimental Usage,True,0.67,Medium,,,,V5,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies (Cell Signaling Technology) used for Western blotting were V5 (rabbit, 13202)"
HA,antibodies,PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.9,Experimental Usage,True,0.67,Medium,,,,HA,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies (Cell Signaling Technology) used for Western blotting were HA (rabbit, 3724)"
KRAS,antibodies,PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.9,Experimental Usage,True,0.67,Medium,,,,KRAS,,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,KRAS (Sigma/Novus Biologicals WH0003845M1/H0003845M1)
S100,antibodies,PMID:25851896,10.3988/jcn.2015.11.2.172,Preclinical assessment of the anticancer drug response of plexiform neurofibroma tissue using primary cultures.,,0.9,Experimental Usage,True,0.67,Medium,,,,S100,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"cells were incubated with 2 µg/mL rabbit anti-human S100 antibody (DAKO, Glostrup, Denmark)"
Flag,antibodies,PMID:24595234,10.1371/journal.pone.0090853,In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,,0.9,Experimental Usage,True,0.67,Medium,,,,Flag,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Mouse anti-Flag (Sigma-Aldrich) was used at 1∶20,000"
CD28,antibodies,PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.9,Experimental Usage,True,0.67,Medium,,,,CD28,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,anti-CD28 mAb (eBioscience; cat. no. 16-0281-85)
CD69,antibodies,PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.9,Experimental Usage,True,0.67,Medium,,,,CD69,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,FITC-anti-CD69 mAb (eBioscience; cat. no. 11-0691-85; 1:100)
MIA,antibodies,PMID:21726432,10.1186/1741-7015-9-82,MIA is a potential biomarker for tumour load in neurofibromatosis type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,MIA,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"stained with monoclonal anti-human MIA antibody (R&D Systems, McKinley Place NE, Minneapolis) diluted at 1:40"
NF1GRP-D,antibodies,PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.9,Experimental Usage,True,0.67,Medium,,,,NF1GRP-D,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Rabbit anti-NF1GRP-D (Santa Cruz Biotechnology, Santa Cruz, CA) was used at a 1:200 dilution to detect neurofibromin expression"
Merlin,antibodies,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,Experimental Usage,True,0.67,Medium,,,,Merlin,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,Anti-Merlin monoclonal antibody 4B5 was made by W. Ip
NF2/merlin,antibodies,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,True,0.67,Medium,,,,NF2/merlin,,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,Anti-NF2/merlin polyclonal antibody has been previously described
CTLA-4,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,True,0.67,Medium,,,,CTLA-4,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"CTLA-4 (BE0164, Bio X Cell)"
human neurofibromin,antibodies,PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.9,Experimental Usage,True,0.67,Medium,,,,human neurofibromin,Rabbit,,,,,,,,,,,,,,,,,,,,,,,,,,,"anti‐human neurofibromin (rabbit, Infixion r07E, San Diego, CA USA, 1 : 1000)"
phospho-ERK,antibodies,PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.9,Experimental Usage,True,0.67,Medium,,,,phospho-ERK,Mouse,,,,,,,,,,,,,,,,,,,,,,,,,,,"anti‐phospho‐ERK (mouse, Sigma M8159, 1 : 2500)"
ERK,antibodies,PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.9,Experimental Usage,True,0.67,Medium,,,,ERK,Rabbit,,,,,,,,,,,,,,,,,,,,,,,,,,,"total ERK (rabbit, CST 9102, Danvers, MA USA, 1 : 1000)"
β-tubulin,antibodies,PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.9,Experimental Usage,True,0.67,Medium,,,,β-tubulin,Mouse,,,,,,,,,,,,,,,,,,,,,,,,,,,"anti‐β‐tubulin (mouse, Developmental Studies Hybridoma Bank E7, Iowa City, IA USA, 1 : 10 000)"
GAPDH,antibodies,PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.9,Experimental Usage,True,0.67,Medium,,,,GAPDH,Rabbit,,,,,,,,,,,,,,,,,,,,,,,,,,,"GAPDH (rabbit, Proteintech 10 494‐1‐AP, San Diego, CA USA, 1 : 15 000)"
PARP,antibodies,PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.9,Experimental Usage,True,0.67,Medium,,,,PARP,Rabbit,,,,,,,,,,,,,,,,,,,,,,,,,,,"anti‐PARP (rabbit, Cell Signaling 952, 1 : 1000)"
LC3B,antibodies,PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.9,Experimental Usage,True,0.67,Medium,,,,LC3B,Rabbit,,,,,,,,,,,,,,,,,,,,,,,,,,,"anti‐LC3B (rabbit, Cell Signaling 2775, 1 : 1000; CST Danvers, MA USA)"
CD8,antibodies,PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,CD8,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"CD8 (Leica NCL-L-CD8–4B11, 1:200)"
CD20,antibodies,PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,CD20,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"CD20 (Leica, NCL-L-CD20-L26, 1:200)"
NF2,antibodies,PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.9,Experimental Usage,True,0.67,Medium,,,,NF2,,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-NF2 clone C-18, 1:500, Santa Cruz, Heidelberg, Germany"
p-RHAMM (Thr703),antibodies,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.9,Experimental Usage,True,0.67,Medium,,,,p-RHAMM (Thr703),Unknown,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,The p-RHAMM (Thr703) polyclonal antibody is characterized in [11]
PDGFRβ,antibodies,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,True,0.67,Medium,,,,PDGFRβ,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"we used antibodies to PDGFRβ (rabbit; Abcam, ab32570), α-SMA (mouse; Sigma-Aldrich, clone 1A4, A2547)"
IBA1,antibodies,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,True,0.67,Medium,,,,IBA1,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"IBA1 (rabbit; Wako Chemicals, 019-19741), CD3 (rat; Bio-Rad, MCA1477)"
GLUT1,antibodies,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,True,0.67,Medium,,,,GLUT1,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"GLUT1 (rabbit; Abcam, ab652), cleaved caspase-3 (rabbit; Cell Signaling Technology, #9661)"
cleaved caspase-3,antibodies,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,True,0.67,Medium,,,,cleaved caspase-3,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"cleaved caspase-3 (rabbit; Cell Signaling Technology, #9661), BrdU (rat; Abcam, ab6326)"
VEGFA,antibodies,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,True,0.67,Medium,,,,VEGFA,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"VEGFA (rabbit; ABclonal, A0280), ALDH1A1 (rabbit; Proteintech, 15910-1-AP)"
ALDH1A1,antibodies,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,True,0.67,Medium,,,,ALDH1A1,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"ALDH1A1 (rabbit; Proteintech, 15910-1-AP), ZEB1 (rabbit; ABclonal, A5600)"
ZEB1,antibodies,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,True,0.67,Medium,,,,ZEB1,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"ZEB1 (rabbit; ABclonal, A5600), IGFBP2 (rabbit; Cell Signaling Technology, #3922)"
IGFBP2,antibodies,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,True,0.67,Medium,,,,IGFBP2,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"IGFBP2 (rabbit; Cell Signaling Technology, #3922), Nestin (mouse; Millipore, MAB353)"
EYA4,antibodies,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,True,0.67,Medium,,,,EYA4,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"EYA4 (rabbit; Thermo Fisher Scientific, PA5-52113), SOX2 (goat; Santa Cruz Biotechnology, sc-17320)"
YAP/TAZ,antibodies,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,True,0.67,Medium,,,,YAP/TAZ,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"YAP/TAZ (rabbit; Cell Signaling Technology, #8418). Secondary antibodies conjugated to Alexa Fluor 488"
GAP43,antibodies,PMID:21551250,10.1158/0008-5472.CAN-10-4577,Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development.,,0.9,Experimental Usage,True,0.67,Medium,,,,GAP43,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"GAP43 (rabbit, 1:1000, Abcam)"
S100β,antibodies,PMID:21551250,10.1158/0008-5472.CAN-10-4577,Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development.,,0.9,Experimental Usage,True,0.67,Medium,,,,S100β,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"S100β (rabbit, 1:5000, DAKO)"
PDGFRα,antibodies,PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,Experimental Usage,True,0.67,Medium,,,,PDGFRα,Unknown,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"goat anti-PDGFRα (1:2,000, R&D Systems AF1062 RRID: AB_2236897)"
S100β,antibodies,PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,Experimental Usage,True,0.67,Medium,,,,S100β,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-S100β (1:2,000, Abcam ab52642 lot GR3215095-1)"
IBA1,antibodies,PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,Experimental Usage,True,0.67,Medium,,,,IBA1,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-IBA1 (1:1,000, Abcam ab178846 lot GR3185035-4)"
NLGN3,antibodies,PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,Experimental Usage,True,0.67,Medium,,,,NLGN3,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-NLGN3, 1:500, Novus NBP1-90080 lot B118108"
β-actin,antibodies,PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,Experimental Usage,True,0.67,Medium,,,,β-actin,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-β-actin, 1:10,000, Cell Signaling 4970 lot 15"
ADAM10,antibodies,PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,Experimental Usage,True,0.67,Medium,,,,ADAM10,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-ADAM10, 1:250, Abcam ab124695 lot GR3244660-5"
caspase-3,antibodies,PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,Experimental Usage,True,0.67,Medium,,,,caspase-3,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-caspase-3, 1:1,000, Cell Signaling 9662 lot 19"
CCND1,antibodies,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.9,Experimental Usage,True,0.67,Medium,,,,CCND1,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Immunohistochemistry for CCND1 (SP4) monoclonal antibody (Neomarkers, Thermo Scientific, 1:50) and β-catenin (6B3) monoclonal antibody (Cell Signaling; 1:200)"
β-catenin,antibodies,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.9,Experimental Usage,True,0.67,Medium,,,,β-catenin,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Immunohistochemistry for CCND1 (SP4) monoclonal antibody (Neomarkers, Thermo Scientific, 1:50) and β-catenin (6B3) monoclonal antibody (Cell Signaling; 1:200)"
GFAP,antibodies,PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,GFAP,Unknown,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"glial fibrillary acidic protein (GFAP, DAKO, polyclonal, 1:3,000 dilution, no antigen retrieval)"
OLIG2,antibodies,PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,OLIG2,Unknown,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"OLIG2 (Immuno Bio Labs, polyclonal, 1:200 dilution, ER1 antigen retrieval)"
SOX10,antibodies,PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,SOX10,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"SOX10 (Cell Marque, clone EP268, dilution 1:250, ER2 antigen retrieval)"
synaptophysin,antibodies,PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,synaptophysin,Unknown,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"synaptophysin (Cell Marque, polyclonal, 1:100 dilution, ER2 antigen retrieval)"
p16,antibodies,PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,p16,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"p16 (MTM Labs, clone E6H4, undiluted, ER1 antigen retrieval)"
ATRX,antibodies,PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,ATRX,Unknown,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"ATRX (Sigma, polyclonal, 1:100 dilution)"
p53,antibodies,PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,p53,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"p53 (Biocare, clone DO-7, 1:100 dilution, ER2 antigen retrieval)"
histone H3 K27M mutant protein,antibodies,PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,histone H3 K27M mutant protein,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"histone H3 K27M mutant protein (RevMAb Biosciences, clone RM192, 1:600 dilution)"
histone H3 lysine 27 trimethylation,antibodies,PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,histone H3 lysine 27 trimethylation,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"histone H3 lysine 27 trimethylation (Cell Signaling, cat #9733, clone C36B11, 1:50 dilution, ER2 antigen retrieval)"
Ki-67,antibodies,PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,Ki-67,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Ki-67 (Dako, clone Mib1, 1:50 dilution, ER2 antigen retrieval)"
TAZ,antibodies,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,Experimental Usage,True,0.67,Medium,,,,TAZ,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"we used antibodies to TAZ (Rabbit; Proteintech 23306-1), YAP (Rabbit; Cell Signaling Technology, #4912)"
YAP,antibodies,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,Experimental Usage,True,0.67,Medium,,,,YAP,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"YAP (Rabbit; Cell Signaling Technology, #4912), TAZ/YAP (Rabbit; Cell Signaling Technology, #8418)"
TAZ/YAP,antibodies,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,Experimental Usage,True,0.67,Medium,,,,TAZ/YAP,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"TAZ/YAP (Rabbit; Cell Signaling Technology, #8418), Sox10 (Goat, Santa Cruz Biotechnology, sc-17342"
Sox10,antibodies,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,Experimental Usage,True,0.67,Medium,,,,Sox10,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Sox10 (Goat, Santa Cruz Biotechnology, sc-17342; Rabbit, Abcam ab180862), Krox20 (Rabbit; Covance, PRB-236P)"
Krox20,antibodies,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,Experimental Usage,True,0.67,Medium,,,,Krox20,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Krox20 (Rabbit; Covance, PRB-236P), MBP (Goat; Santa Cruz Biotechnology, sc-13914)"
Ki67,antibodies,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,Experimental Usage,True,0.67,Medium,,,,Ki67,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Ki67 (Rabbit; Thermo Fisher Scientific, RM-9106), BrdU (Rat; Abcam, ab6326)"
TEAD1,antibodies,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,Experimental Usage,True,0.67,Medium,,,,TEAD1,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"TEAD1 (Mouse, Santa Cruz Biotechnology sc-393976), neurofibromin (Rabbit, Santa Cruz Biotechnology sc-67)"
neurofibromin,antibodies,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,Experimental Usage,True,0.67,Medium,,,,neurofibromin,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"neurofibromin (Rabbit, Santa Cruz Biotechnology sc-67), P53 (Rabbit, Cell Signaling Technology, #9282)"
TEAD1,antibodies,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,Experimental Usage,True,0.67,Medium,,,,TEAD1,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"The antibodies used were as follows: TEAD1 (Mouse, BD Biosciences, 610922), H3K4me1 (Rabbit, Abcam, 8895)"
GFP,antibodies,PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.9,Experimental Usage,True,0.67,Medium,,,,GFP,Unknown,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"chicken polyclonal GFP antibody targeting eYFP (1:250; Abcam, Cambridge, UK)"
NeuN,antibodies,PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.9,Experimental Usage,True,0.67,Medium,,,,NeuN,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,mouse anti-NeuN targeting neurons (1:00; Synaptic Systems)
EGFR,antibodies,PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,0.9,Experimental Usage,True,0.67,Medium,,,,EGFR,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies used were: monoclonal anti-EGFR (1:250; Capralogics, Hardwick, MA)"
ErbB2,antibodies,PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,0.9,Experimental Usage,True,0.67,Medium,,,,ErbB2,Unknown,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"polyclonal anti-ErbB2 (1:250; Santa Cruz Biotechnology, Santa Cruz, CA)"
ErbB3,antibodies,PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,0.9,Experimental Usage,True,0.67,Medium,,,,ErbB3,Unknown,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,polyclonal anti-ErbB3 (1:250; Santa Cruz)
merlin,antibodies,PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,0.9,Experimental Usage,True,0.67,Medium,,,,merlin,Unknown,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"polyclonal anti-merlin (1:250, Santa Cruz)"
actin,antibodies,PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,0.9,Experimental Usage,True,0.67,Medium,,,,actin,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"monoclonal anti-actin (BD Biosciences, San Jose, CA)"
CXCL12,antibodies,PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.9,Experimental Usage,True,0.67,Medium,,,,CXCL12,Unknown,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,All antibodies used in this study were purchased from Peprotech (goat anti-CXCL12
Endoglin,antibodies,PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.9,Experimental Usage,True,0.67,Medium,,,,Endoglin,Unknown,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,R&D (Goat anti-Endoglin)
RABL6A,antibodies,PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.9,Experimental Usage,True,0.67,Medium,,,,RABL6A,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,RABL6A antibodies (monoclonal and polyclonal) were produced in the Quelle laboratory
phospho-ERK,antibodies,PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.9,Experimental Usage,True,0.67,Medium,,,,phospho-ERK,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies used for immunoblotting were: anti-Nf1 (mouse, mAb21, 1:10), anti-phospho-ERK (mouse, Sigma M8159, 1:2500)"
ERK,antibodies,PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.9,Experimental Usage,True,0.67,Medium,,,,ERK,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"total ERK (rabbit, CST 9102, 1:1000)"
GFP,antibodies,PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.9,Experimental Usage,True,0.67,Medium,,,,GFP,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies used were: rabbit anti-GFP (Invitrogen, A11122, 1:4000)"
nc82,antibodies,PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.9,Experimental Usage,True,0.67,Medium,,,,nc82,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"The following antibodies were used: rabbit anti-GFP (1:1000, Invitrogen), mouse anti-nc82 (1:50, DSHB)"
HER1,antibodies,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.9,Experimental Usage,True,0.67,Medium,,,,HER1,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-human HER1 (Abcam, ab52894)"
HER2,antibodies,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.9,Experimental Usage,True,0.67,Medium,,,,HER2,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-human HER2 (ZSGB-BIO, ZA-0023)"
VEGFR2,antibodies,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.9,Experimental Usage,True,0.67,Medium,,,,VEGFR2,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-human VEGFR2 (CST, 9698S)"
B7H3,antibodies,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.9,Experimental Usage,True,0.67,Medium,,,,B7H3,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-human B7H3 (CST, #14058)"
CD171,antibodies,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.9,Experimental Usage,True,0.67,Medium,,,,CD171,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-human CD171 (Abcam, ab208155)"
EGFRvIII,antibodies,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.9,Experimental Usage,True,0.67,Medium,,,,EGFRvIII,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-human EGFRvIII (ZSGB-BIO, ZA-0643)"
TGFβ1,antibodies,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.9,Experimental Usage,True,0.67,Medium,,,,TGFβ1,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-human TGFβ1 (Abcam, ab215715)"
PDL1,antibodies,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.9,Experimental Usage,True,0.67,Medium,,,,PDL1,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-human PDL1 (Genetex, GTX104763)"
S100,antibodies,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.9,Experimental Usage,True,0.67,Medium,,,,S100,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"rabbit anti-human S100 (ZSGB-BIO, ZA-0225)"
β-actin,antibodies,PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,0.9,Experimental Usage,True,0.67,Medium,,,,β-actin,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,Antibodies used in western blotting targeting β-actin (#13E5)
phospho-MEK1/2,antibodies,PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,0.9,Experimental Usage,True,0.67,Medium,,,,phospho-MEK1/2,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,phospho-MEK1/2 (#41G9)
phospho-ERK,antibodies,PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,0.9,Experimental Usage,True,0.67,Medium,,,,phospho-ERK,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,phospho-ERK (#D13.14.4E)
MMP1,antibodies,PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,0.9,Experimental Usage,True,0.67,Medium,,,,MMP1,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,MMP1 (#E9S9N)
NF1,antibodies,PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,0.9,Experimental Usage,True,0.67,Medium,,,,NF1,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,NF1 (#D7R7D)
collagen I,antibodies,PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,0.9,Experimental Usage,True,0.67,Medium,,,,collagen I,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,collagen I (#EPR7785)
Rheb,antibodies,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,True,0.67,Medium,,,,Rheb,,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Rheb (3M6 monoclonal; a generous gift from Richard Lamb, University of Liverpool, U.K.)"
NF2,antibodies,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,True,0.67,Medium,,,,NF2,,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,the NF2 polyclonal C26 antibody has been described
p-ERK,antibodies,PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,0.9,Experimental Usage,True,0.67,Medium,,,,p-ERK,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"p-ERK ½ (p44/42 MAPK) #9101 (Cell Signaling, rabbit, 2% BSA, 1:2000, overnight, 4 °C)"
Etv5,antibodies,PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,,0.9,Experimental Usage,True,0.67,Medium,,,,Etv5,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Rabbit anti-Etv5 antibody (Novus Biologicals) was diluted at 1:100 for immunohistochemistry
podoplanin,antibodies,PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,,0.9,Experimental Usage,True,0.67,Medium,,,,podoplanin,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"podoplanin (clone D2-40, Dako, 1:200), phospho-ERK (#9101, Cell Signaling, 1:250)"
CD11b,antibodies,PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,0.9,Experimental Usage,True,0.67,Medium,,,,CD11b,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-mouse monoclonal antibodies against CD11b (8G12/HPCA-2, Becton–Dickinson; San Jose, CA) bound to allophycocyanin (APC)"
CSF1,antibodies,PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,0.9,Experimental Usage,True,0.67,Medium,,,,CSF1,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,50 ng/mL Anti-CSF1 (R&D Systems MAB4161) in the same medium
tomato,antibodies,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,tomato,Rat,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,rat anti-tomato (1:1000; Kerafast #EST203)
RFP,antibodies,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,RFP,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,rabbit anti-RFP (1:1000; Rockland #600-401-379)
CD45,antibodies,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,CD45,Goat,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,goat anti-CD45 (1:100; Bio-Techne #AF114)
PDGFRα,antibodies,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,PDGFRα,Goat,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,goat anti-PDGFRα (1:100; R&D system #AF1062)
Ki67,antibodies,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,Ki67,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,rabbit anti-Ki67 (1:200; Abcam #ab15580)
P-ERK,antibodies,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,P-ERK,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,rabbit anti-P-ERK (1:250; Cell Signaling #9101)
cKIT,antibodies,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,cKIT,Goat,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,goat anti-cKIT (1:100; R&D system #AF1356)
F4/80,antibodies,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,F4/80,Rat,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,rat anti-F4/80 (1:400; Abcam #ab6640)
POSTN,antibodies,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,POSTN,Goat,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,goat anti-POSTN (1:400; BioTechne #AF2955)
TNC,antibodies,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,TNC,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,rabbit anti-TNC (1:100; Abcam #ab108930)
PGP9.5,antibodies,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,PGP9.5,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,rabbit anti-PGP9.5 (1:100; Abcam #ab108986)
nestin,antibodies,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,nestin,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,rabbit anti-nestin (1:100; Abcam # ab221660)
Aqp1,antibodies,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,Aqp1,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,mouse A488-anti-Aqp1 (1:100; Santa Cruz Biotech #sc-25287)
S100β,antibodies,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,S100β,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,mouse anti-S100β (1:300; Abcam #ab218516)
SOX9,antibodies,PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,0.9,Experimental Usage,True,0.67,Medium,,,,SOX9,Unknown,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"We performed SOX9 immunohistochemistry on formalin-fixed, paraffin-embedded sections with polyclonal anti-SOX9 antibody (Abcam, Cambridge, UK)"
CD56,antibodies,PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,Experimental Usage,True,0.67,Medium,,,,CD56,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,CD56 Biocare Medical CAT#CM164A
CD117/c-kit,antibodies,PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,Experimental Usage,True,0.67,Medium,,,,CD117/c-kit,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,CD117/c-kit Biocare Medical CAT#CME296AK; RRID: AB_10581782
NGFR,antibodies,PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,Experimental Usage,True,0.67,Medium,,,,NGFR,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,NGFR Biocare Medical CAT#ACI369A
PanCytokeratin,antibodies,PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,Experimental Usage,True,0.67,Medium,,,,PanCytokeratin,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,PanCytokeratin Biocare Medical CAT#CM011A; RRID: AB_2811020
SOX2,antibodies,PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,Experimental Usage,True,0.67,Medium,,,,SOX2,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,SOX2 Biocare Medical CAT#ACI3109A
SOX10,antibodies,PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,Experimental Usage,True,0.67,Medium,,,,SOX10,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,SOX10 Biocare Medical CAT#ACI3099A
S100,antibodies,PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,Experimental Usage,True,0.67,Medium,,,,S100,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,S100 Biocare Medical CAT#ACI3237A
c-Kit,antibodies,PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,Experimental Usage,True,0.67,Medium,,,,c-Kit,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,APC Anti-c-Kit antibody [YB5.B8] (ab95678)
S100A11,antibodies,PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,Experimental Usage,True,0.67,Medium,,,,S100A11,Unknown,Recombinant,,,,,,,,,,,,,,,,,,,,,,,,,,Recombinant PE Anti-S100A11 antibody [EPR11172] (ab211996)
CD34,antibodies,PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,Experimental Usage,True,0.67,Medium,,,,CD34,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,FITC Anti-CD34 antibody [4H11[APG]] (ab18227)
H3K27me3,antibodies,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,Experimental Usage,True,0.67,Medium,,,,H3K27me3,,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"H3K27me3 (Cell Signaling Technology, #9733, clone C36B11, 1:50 dilution)"
SOX10,antibodies,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,Experimental Usage,True,0.67,Medium,,,,SOX10,,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"SOX10 (Cell Marque, #383R-1, clone EP268, 1:50 dilution)"
NF2/Merlin,antibodies,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,Experimental Usage,True,0.67,Medium,,,,NF2/Merlin,,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"NF2/Merlin (Abcam, #ab88957, clone AF1G4, 1:2000 dilution)"
EGFR,antibodies,PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,0.9,Experimental Usage,True,0.67,Medium,,,,EGFR,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Rabbit anti-EGFR, Notch1 (Cell Signaling), and rabbit anti S518-Merlin (Abcam and Cell Signaling) were used at 1:1000 dilution"
Notch1,antibodies,PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,0.9,Experimental Usage,True,0.67,Medium,,,,Notch1,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Rabbit anti-EGFR, Notch1 (Cell Signaling), and rabbit anti S518-Merlin (Abcam and Cell Signaling) were used at 1:1000 dilution"
S518-Merlin,antibodies,PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,0.9,Experimental Usage,True,0.67,Medium,,,,S518-Merlin,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,rabbit anti S518-Merlin (Abcam and Cell Signaling) were used at 1:1000 dilution
S518-Merlin,antibodies,PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,0.9,Experimental Usage,True,0.67,Medium,,,,S518-Merlin,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,rabbit anti S518-Merlin (Abcam and Cell Signaling) were used at 1:1000 dilution
Caspase-3,antibodies,PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,0.9,Experimental Usage,True,0.67,Medium,,,,Caspase-3,,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Caspase-3 was detected with a 1:1000 dilution of anti-Caspase-3 polycolonal antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA)"
Phospho-Rb Ser 780,antibodies,PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,0.9,Experimental Usage,True,0.67,Medium,,,,Phospho-Rb Ser 780,,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Retinoblastoma protein (pRb) phosphorylated Serine 780 was detected with a 1:1000 dilution of anti-Phospho-Rb Ser 780 polyclonal antibody (Cell Signaling Technology, Danvers, MA)"
Cy3/Cy5,antibodies,PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.9,Experimental Usage,True,0.67,Medium,,,,Cy3/Cy5,,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"incubated with a monoclonal anti-Cy3/Cy5 antibody (ab52060, Abcam, 1:2500) for 1 h at room temperature"
FAP,antibodies,PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,,0.9,Experimental Usage,True,0.67,Medium,,,,FAP,Unknown,Recombinant,,,,,,,,,,,,,,,,,,,,,,,,,,"A recombinant anti-FAP antibody (clone ab207178, Abcam, Cambridge, UK) was applied at a dilution of 1:250"
BLBP,antibodies,PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,BLBP,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"BLBP (1:2000, rabbit, a kind gift from Dr. Todd Anthony)"
Calbindin,antibodies,PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,Calbindin,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Calbindin (1:1000, mouse, Sigma-Aldrich)"
GFAP,antibodies,PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,GFAP,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"GFAP (1:2000, rabbit, DAKO, Carpinteria, CA)"
NeuN,antibodies,PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,NeuN,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"NeuN (1:400, mouse, Millipore, Billerica, MA)"
GABARα6,antibodies,PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,GABARα6,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"GABARα6 (1:500, rabbit, Millipore)"
Ki-67,antibodies,PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,Ki-67,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Ki-67 (1:500, mouse, BD Pharmingen)"
Tbr2,antibodies,PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,Tbr2,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Tbr2 (1:1000, rabbit, Abcam)"
Calretinin,antibodies,PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,Calretinin,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Calretinin (1:1000, mouse, Millipore)"
MAP2,antibodies,PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,MAP2,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"MAP2 (1:1000, mouse, Sigma-Aldrich)"
P27,antibodies,PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,P27,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"P27 (1:250, rabbit, Santa Cruz Biotechnology, Dallas, TX)"
β-gal,antibodies,PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,β-gal,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"β-gal (1:1000, rabbit, 5 prime-3 prime, Gaithersburg, MD)"
p-Erk,antibodies,PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,p-Erk,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"p-Erk (1:200, rabbit, Cell Signaling, Beverly, MA)"
p-S6,antibodies,PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,p-S6,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"p-S6 (1:1000, rabbit, Cell Signaling)"
Nf1,antibodies,PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,Nf1,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Nf1 (1:1000, rabbit, Upstate, Lake Placid, NY)"
BIM,antibodies,PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.9,Experimental Usage,True,0.67,Medium,,,,BIM,Unknown,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies: anti-human C-terminal BIM (goat, Bio-RAD, Hercules, CA, USA, AHP2074; 1:1000)"
B220,antibodies,PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.9,Experimental Usage,True,0.67,Medium,,,,B220,Unknown,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"B220 to identify B cells (RRID: AB_323211, rat anti-mouse monoclonal, Serotec Company, Catalog #MCA1258G, 1:1200)"
HIF1-α,antibodies,PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,Experimental Usage,True,0.67,Medium,,,,HIF1-α,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"HIF1-α (rabbit, GTX127309, GeneTex, Irvine, CA, USA)"
PARP,antibodies,PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,Experimental Usage,True,0.67,Medium,,,,PARP,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"total PARP (rabbit, #9542) (Cell Signaling, Danvers, MA, USA)"
Vinculin,antibodies,PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,Experimental Usage,True,0.67,Medium,,,,Vinculin,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Vinculin (mouse, V284, Sigma, St. Louis, MO, USA)"
"NF1−/−−/− edited FiPS Ctrl1-SV4F-7, D12",cell_lines,PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,Unknown,Neurofibromatosis Type 1,,Embryonic stem cell,,,,,,,,,,,,,,,,,,,,,,"its isogenic NF1 iPSC generated by CRISPR (NF1−/−−/− edited FiPS Ctrl1-SV4F-7, D12, Sex: XY)"
CNVkit,computational_tools,PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CNVkit,Analysis Software,,,,,,,,,,,,,,,,Copy Number Variants were detected and plotted using CNVkit
SciClone,computational_tools,PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,SciClone,Analysis Software,,,,,,,,,,,,,,,,Clonality was addressed using SciClone
LMSz,computational_tools,PMID:41468561,10.1212/WNL.0000000000214480,NF1-Specific Growth Charts for Head Circumference Over the First 3 Years of Life.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,LMSz,Analysis Software,,,,,,,,,,,,,,,,...we implemented a recently described method called 'LMSz' to construct NF1-specific head circumference growth charts...
Splice Site Prediction by Neural Network (SSPNN),computational_tools,PMID:12057013,10.1186/1471-2164-3-13,Complex splicing pattern generates great diversity in human NF1 transcripts.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Splice Site Prediction by Neural Network (SSPNN),Web Application,,,,,,,,,,,,,,,,"The sequence environment of all donor- and acceptor sites was analysed using Splice Site Prediction by Neural Network (SSPNN, URL address:"
Agilent Seahorse XF-96,computational_tools,PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Agilent Seahorse XF-96,Analysis Software,,,,,,,,,,,,,,,,We measured cellular energetics using Agilent Seahorse XF-96 Glyco Stress Test and Mito Stress Test assays
SynergyFinder R package,computational_tools,PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,SynergyFinder R package,Package/Library,,,,,,,,,,,,,,,,Synergy was calculated using the SynergyFinder R package
CEAS R Package,computational_tools,PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CEAS R Package,Package/Library,,,,,,,,,,,,,,,,"ATP metrics were calculated following Mookerjee et al., 2017 and using the CEAS R Package"
FactoMineR R package,computational_tools,PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,FactoMineR R package,Package/Library,,,,,,,,,,,,,,,,PCA analysis was performed using the FactoMineR R package
Orbitrap Fusion Lumos mass spectrometer,computational_tools,PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Orbitrap Fusion Lumos mass spectrometer,Analysis Software,,,,,,,,,,,,,,,,"An Orbitrap Fusion Lumos mass spectrometer (Thermo Fisher Scientific Inc., Waltham, MA, USA)"
EMAN2 e2boxer,computational_tools,PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,EMAN2 e2boxer,Analysis Software,,,,,,,,,,,,,,,,Negatively-stained neurofibromin particles were autopicked using EMAN2 e2boxer using a box size of 326 pixels
Sphire,computational_tools,PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Sphire,Package/Library,,,,,,,,,,,,,,,,Reference-free 2D classification was carried out using the Iterative Stable Alignment and Clustering (ISAC) procedure implemented in a Sphire package
ATSAS,computational_tools,PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ATSAS,Package/Library,,,,,,,,,,,,,,,,The reduced SAXS and SANS data were analyzed using the ATSAS tools PRIMUS and GNOM for Guinier and P(r) analysis
DESeq2,computational_tools,PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,DESeq2,Analysis Software,,,,,,,,,,,,,,,,Differential expression analysis was performed with DESeq2 using default settings
CNVkit,computational_tools,PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CNVkit,Analysis Software,,,,,,,,,,,,,,,,"Whole exome sequencing (WES), RNA sequencing (RNA-Seq), and copy number analysis (CNVkit) were performed on each sample"
Illumina HiSeq4000,computational_tools,PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Illumina HiSeq4000,Other,,,,,,,,,,,,,,,,"Exome libraries were captured with an IDT exome reagent, then pooled with a WGS library for sequencing on an Illumina HiSeq4000 with at least 1000x coverage"
BWA-MEM,computational_tools,PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,BWA-MEM,Analysis Software,,,,,,,,,,,,,,,,Genomic data were aligned against reference sequence hg38 via BWA-MEM with Base Quality Score Recalibration (BQSR)
manta,computational_tools,PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,manta,Analysis Software,,,,,,,,,,,,,,,,Structural variants (SVs) and large indels were detected using manta
VarScan2,computational_tools,PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,VarScan2,Analysis Software,,,,,,,,,,,,,,,,"SNVs and small indels were detected using VarScan2, Strelka2, MuTect2, and Pindel"
Strelka2,computational_tools,PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Strelka2,Analysis Software,,,,,,,,,,,,,,,,"SNVs and small indels were detected using VarScan2, Strelka2, MuTect2, and Pindel"
MuTect2,computational_tools,PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MuTect2,Analysis Software,,,,,,,,,,,,,,,,"SNVs and small indels were detected using VarScan2, Strelka2, MuTect2, and Pindel"
Pindel,computational_tools,PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Pindel,Analysis Software,,,,,,,,,,,,,,,,"SNVs and small indels were detected using VarScan2, Strelka2, MuTect2, and Pindel"
GenVisR,computational_tools,PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,GenVisR,Analysis Software,,,,,,,,,,,,,,,,Waterfall somatic variant plots were created with GenVisR by including somatic variants that occurred in each area
COSMIC,computational_tools,PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,COSMIC,Database,,,,,,,,,,,,,,,,These variants were not reported as a somatic variant in COSMIC (Catalogue Of Somatic Mutations In Cancer) and ClinVar archive
ClinVar,computational_tools,PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ClinVar,Database,,,,,,,,,,,,,,,,These variants were not reported as a somatic variant in COSMIC (Catalogue Of Somatic Mutations In Cancer) and ClinVar archive
SIFT,computational_tools,PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,SIFT,Analysis Software,,,,,,,,,,,,,,,,"In order to predict clinical significance and predictions of the functional effects of these variants, each variant was reviewed on SIFT and Polyphen"
Polyphen,computational_tools,PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Polyphen,Analysis Software,,,,,,,,,,,,,,,,"In order to predict clinical significance and predictions of the functional effects of these variants, each variant was reviewed on SIFT and Polyphen"
SciClone,computational_tools,PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,SciClone,Analysis Software,,,,,,,,,,,,,,,,SciClone and ClonEvol were utilized to attempt to perform a phylogeny inference
ClonEvol,computational_tools,PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ClonEvol,Analysis Software,,,,,,,,,,,,,,,,SciClone and ClonEvol were utilized to attempt to perform a phylogeny inference
Partek Flow,computational_tools,PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Partek Flow,Analysis Software,,,,,,,,,,,,,,,,Pre/post quality control and full expectation-maximization (EM) quantification were run via Partek Flow
edgeR,computational_tools,PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,edgeR,Package/Library,,,,,,,,,,,,,,,,Gene counts and transcript counts were normalized by CPM (counts per million) by using edgeR package
gplots,computational_tools,PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,gplots,Package/Library,,,,,,,,,,,,,,,,Heatmap visualizations were created using gplots R package
PantherDB,computational_tools,PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,PantherDB,Database,,,,,,,,,,,,,,,,PantherDB was utilized to discover GO terms and pathways that may be affected by these genes
Illumina NovaSeq6000,computational_tools,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Illumina NovaSeq6000,Other,,,,,,,,,,,,,,,,which were sequenced on the Illumina NovaSeq6000 sequencing machine using S4 flow cells
DNA Engine Peltier Thermal cycler (PTC-200),computational_tools,PMID:18670322,10.1097/MLG.0b013e318177e20b,Vestibular schwannoma quantitative polymerase chain reaction expression of estrogen and progesterone receptors.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,DNA Engine Peltier Thermal cycler (PTC-200),Other,,,,,,,,,,,,,,,,"in a DNA Engine Peltier Thermal cycler (PTC-200; MJ Research, Watertown, MA) at 42°C for 1 minute"
WGCNA,computational_tools,PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,WGCNA,Package/Library,,,,,,,,,,,,,,,,"Key packages used include synapser [ 24 ], tidyverse [ 25 ], dplyr [ 26 ], WGCNA [ 27 ]"
ConsensusClusterPlus,computational_tools,PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ConsensusClusterPlus,Package/Library,,,,,,,,,,,,,,,,"Key packages used include synapser [ 24 ], tidyverse [ 25 ], dplyr [ 26 ], WGCNA [ 27 ], ggplot2 [ 28 ], enrichplot [ 29 ], and ConsensusClusterPlus [ 30 ]"
Mechanism Interrogation PlatE (MIPE 4.0) library,computational_tools,PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Mechanism Interrogation PlatE (MIPE 4.0) library,Database,,,,,,,,,,,,,,,,The drug screening data were contributed by Ferrer et al. using the Mechanism Interrogation PlatE (MIPE 4.0) library [ 6 ]
IDAPredict.2drug function package,computational_tools,PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,IDAPredict.2drug function package,Package/Library,,,,,,,,,,,,,,,,IDAPredict.2drug function package was used to predict the drug combination between DrugCluster pairs [ 23 ]
Barocycler NEP 2320,computational_tools,PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Barocycler NEP 2320,Other,,,,,,,,,,,,,,,,"...Pressure-based cell lysis was performed for 60 cycles of 50 s at 30 °C and 310 MPa using the Barocycler NEP 2320 instrument (Pressure BioSciences, Easton, MA, USA)..."
Easy-nLC 1200,computational_tools,PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Easy-nLC 1200,Other,,,,,,,,,,,,,,,,"...A nanoflow high-performance liquid chromatography system Easy-nLC 1200 coupled to the Q Exactive HF mass spectrometer (Thermo Fisher Scientific, Bremen, Germany)..."
Q Exactive HF mass spectrometer,computational_tools,PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Q Exactive HF mass spectrometer,Other,,,,,,,,,,,,,,,,"...Easy-nLC 1200 coupled to the Q Exactive HF mass spectrometer (Thermo Fisher Scientific, Bremen, Germany) equipped with a nano-electrospray ionization source..."
BenchMark Ultra system,computational_tools,PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,BenchMark Ultra system,Other,,,,,,,,,,,,,,,,...The Ki67 immunohistochemistry was performed using the BenchMark Ultra system (Roche)...
NanoZoomer S60 digital slide scanner,computational_tools,PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,NanoZoomer S60 digital slide scanner,Other,,,,,,,,,,,,,,,,"...imaged using the NanoZoomer S60 digital slide scanner (Hamamatsu, Hamamatsu City, Japan)..."
Pannoramic Midi FL slide scanner,computational_tools,PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Pannoramic Midi FL slide scanner,Other,,,,,,,,,,,,,,,,"...and Pannoramic Midi FL slide scanner (3DHistech Ltd, Budapest, Hungary)..."
g:Profiler,computational_tools,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,g:Profiler,Web Application,,,,,,,,,,,,,,,,GO analysis was performed using g:Profiler
BioVenn,computational_tools,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,BioVenn,Web Application,,,,,,,,,,,,,,,,Venn diagrams were generated using BioVenn
PathVisio software,computational_tools,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,PathVisio software,Analysis Software,,,,,,,,,,,,,,,,Proximity maps were generated using PathVisio software
"iPlan Net software (Brainlab, Feldkirchen, Germany)",computational_tools,PMID:39824854,10.1038/s41598-025-85386-4,Comparison of 1D and 3D volume measurement techniques in NF2-associated vestibular schwannoma monitoring.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,"iPlan Net software (Brainlab, Feldkirchen, Germany)",Analysis Software,,,,,,,,,,,,,,,,"postcontrast thin-sliced (≤ 3 mm) T1-weighted magnetic resonance (MR) sequences were uploaded into the iPlan Net software (Brainlab, Feldkirchen, Germany), and volumes were measured manually or in combination with semiautomated segmentation"
CRISPOR,computational_tools,PMID:34630515,10.3389/fgene.2021.721045,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and ,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CRISPOR,Web Application,,,,,,,,,,,,,,,,"Target sites within the genes of interest were selected using Massachusetts Institute of Technology's CRISPR design tool (now unavailable, previously: crispr.mit.edu, ), or later, CRISPOR"
ImageJ Cell Counter extension,computational_tools,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ImageJ Cell Counter extension,Plugin,,,,,,,,,,,,,,,,The target cell type was counted using the ImageJ Cell Counter extension (NIH)
Image Studio Lite software,computational_tools,PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Image Studio Lite software,Analysis Software,,,,,,,,,,,,,,,,Band intensity quantifications were done using Image Studio Lite software (RRID: SCR_013715)
3DQI software,computational_tools,PMID:34106871,10.1109/JBHI.2021.3087735,DINs: Deep Interactive Networks for Neurofibroma Segmentation in Neurofibromatosis Type 1 on Whole-Body MRI.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,3DQI software,Analysis Software,,,,,,,,,,,,,,,,Cai et al. perform volume measurements on the LRMRI data set using 3DQI software at Massachusetts General Hospital (MGH) and National Cancer Institute (NCI)
MEDx software,computational_tools,PMID:34106871,10.1109/JBHI.2021.3087735,DINs: Deep Interactive Networks for Neurofibroma Segmentation in Neurofibromatosis Type 1 on Whole-Body MRI.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MEDx software,Analysis Software,,,,,,,,,,,,,,,,Cai et al. perform volume measurements on the LRMRI data set using 3DQI software at Massachusetts General Hospital (MGH) and National Cancer Institute (NCI) and MEDx software at NCI
Image-Pro Plus software,computational_tools,PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Image-Pro Plus software,Analysis Software,,,,,,,,,,,,,,,,Computerized quantitative morphometric analysis was performed using Image-Pro Plus software (Media Cybernetics)
REDCap,computational_tools,PMID:37269078,10.1177/17407745231178839,Perspectives of adolescents with neurofibromatosis 1 and cutaneous neurofibromas: Implications for clinical trials.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,REDCap,Web Application,,,,,,,,,,,,,,,,"Surveys were created in REDCap, a secure web-based data capture tool"
Perseus,computational_tools,PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Perseus,Analysis Software,,,,,,,,,,,,,,,,"LFQ data generated by Maxquant were processed using Microsoft Excel and specially developed proteomics software, Perseus"
DAVID software,computational_tools,PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,DAVID software,Analysis Software,,,,,,,,,,,,,,,,"Functional enrichment analysis was performed using Benjamini-Hochberg multiple correction testing integrated in to the database for annotation, visualization and integrated discovery (DAVID) software"
log-rank Mantel-Cox test,computational_tools,PMID:40063513,10.1158/1078-0432.CCR-24-3029,DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,log-rank Mantel-Cox test,Analysis Software,,,,,,,,,,,,,,,,Kaplan-Meier plots were generated in GraphPad Prism and p-values were determined by log-rank Mantel-Cox test.
bulk RNA sequencing,computational_tools,PMID:40063513,10.1158/1078-0432.CCR-24-3029,DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,bulk RNA sequencing,Analysis Software,,,,,,,,,,,,,,,,"For patients in the institutional cohort whose samples underwent bulk RNA sequencing, whole exome sequencing and spatial transcriptomics profiling"
whole exome sequencing,computational_tools,PMID:40063513,10.1158/1078-0432.CCR-24-3029,DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,whole exome sequencing,Analysis Software,,,,,,,,,,,,,,,,"For patients in the institutional cohort whose samples underwent bulk RNA sequencing, whole exome sequencing and spatial transcriptomics profiling"
spatial transcriptomics profiling,computational_tools,PMID:40063513,10.1158/1078-0432.CCR-24-3029,DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,spatial transcriptomics profiling,Analysis Software,,,,,,,,,,,,,,,,"For patients in the institutional cohort whose samples underwent bulk RNA sequencing, whole exome sequencing and spatial transcriptomics profiling"
HumanRef-8_v2 Sentrix BeadChips,computational_tools,PMID:25329635,10.1371/journal.pgen.1004575,Genetic modifiers of neurofibromatosis type 1-associated café-au-lait macule count identified using multi-platform analysis.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,HumanRef-8_v2 Sentrix BeadChips,Analysis Software,,,,,,,,,,,,,,,,Amplified biotinylated cRNA (1.5 µg) was hybridized to HumanRef-8_v2 Sentrix BeadChips.
TRAP (Tiled Regression Analysis Package),computational_tools,PMID:25329635,10.1371/journal.pgen.1004575,Genetic modifiers of neurofibromatosis type 1-associated café-au-lait macule count identified using multi-platform analysis.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,TRAP (Tiled Regression Analysis Package),Analysis Software,,,,,,,,,,,,,,,,"""Tiled Regression"" as implemented in TRAP (Tiled Regression Analysis Package) was used to identify the set of independent significant variants"
XCELLigence Real Time Cell Analysis System,computational_tools,PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,XCELLigence Real Time Cell Analysis System,Analysis Software,,,,,,,,,,,,,,,,"The microelectronic biosensor XCELLigence Real Time Cell Analysis System (RTCA, Roche Diagnostics GmbH"
Illumina HiSeq X Ten System,computational_tools,PMID:33767727,10.3389/fgene.2021.603195,Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Illumina HiSeq X Ten System,Analysis Software,,,,,,,,,,,,,,,,"Sequencing was carried out on an Illumina HiSeq X Ten System (Illumina, San Diego, CA, United States)"
CIBERSORTx,computational_tools,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CIBERSORTx,Analysis Software,,,,,,,,,,,,,,,,We used CIBERSORTx to perform deconvolution analysis of bulk tumor data against Lats1/2-mut advanced SN tumor cell types
inferCNV,computational_tools,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,inferCNV,Analysis Software,,,,,,,,,,,,,,,,Malignant cells were identified by inferring large-scale chromosomal CNVs in each single cell based on a moving averaged expression profiles across chromosomal intervals by inferCNV
VECTOR,computational_tools,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,VECTOR,Analysis Software,,,,,,,,,,,,,,,,Cell-state transition directions were inferred by VECTOR based on the observation that quantile polarization of a cell's principal component values
Slingshot,computational_tools,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Slingshot,Package/Library,,,,,,,,,,,,,,,,Slingshot is a top performer for cellular trajectory from scRNA-seq data. We used Slingshot to model the pseudotime trajectory
ArchR,computational_tools,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ArchR,Package/Library,,,,,,,,,,,,,,,,"ArchR was used for all scATAC-seq analyses according to default parameters, including quality control and cell filtering"
CellChat,computational_tools,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CellChat,Package/Library,,,,,,,,,,,,,,,,"We used CellChat to infer the intercellular communication from scRNA-seq data for further data exploration, analysis, and visualization"
"Scaffold (Protein Sciences, Portland Oregon)",computational_tools,PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,"Scaffold (Protein Sciences, Portland Oregon)",Analysis Software,,,,,,,,,,,,,,,,"The list of peptide IDs generated based on SEQUEST or MASCOT search results were filtered separately using Scaffold (Protein Sciences, Portland Oregon)"
QIAGEN Ingenuity Pathway Analysis (IPA),computational_tools,PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,QIAGEN Ingenuity Pathway Analysis (IPA),Analysis Software,,,,,,,,,,,,,,,,Further Pathway analysis was conducted using QIAGEN Ingenuity Pathway Analysis (IPA)
Nikon Elements software,computational_tools,PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Nikon Elements software,Analysis Software,,,,,,,,,,,,,,,,The morphometric analysis of neurite lengths of transfected green fluorescent cells was performed with Nikon Elements software
Illumina Infinium MethylationEPIC BeadChip array,computational_tools,PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Illumina Infinium MethylationEPIC BeadChip array,Analysis Software,,,,,,,,,,,,,,,,"Methylation profiling was performed on bisulfite-treated DNA using the Illumina Infinium MethylationEPIC BeadChip array (Illumina, San Diego, USA)"
Affymetrix GeneChip Mouse Genome 430 2.0 Array,computational_tools,PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Affymetrix GeneChip Mouse Genome 430 2.0 Array,Analysis Software,,,,,,,,,,,,,,,,"Mouse optic glioma neurospheres, Nf1−/− TVZ NSCs (TVZ_Cre) and wild-type TVZ NSCs (TVZ_LacZ) RNA was subjected to Affymetrix GeneChip Mouse Genome 430 2.0 Array hybridization"
SSTMean,computational_tools,PMID:38173515,10.1016/j.heliyon.2023.e23445,Development of a semi-automatic segmentation technique based on mean magnetic resonance imaging intensity thresholding for volumetric quantification of plexiform neurofibromas.,,0.9,Development,True,0.67,Medium,,,,,,,,,,,,,,,SSTMean,Analysis Software,,,,,,,,,,,,,,,,A semi-automatic segmentation technique based on mean magnetic resonance imaging (MRI) intensity thresholding (SSTMean) was developed
deepTools bamPEFragmentSize,computational_tools,PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,deepTools bamPEFragmentSize,Analysis Software,,,,,,,,,,,,,,,,read-pair fragment sizes for cfDNA samples were calculated using deepTools bamPEFragmentSize
ultra-low-pass whole genome sequencing (ULP-WGS),computational_tools,PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ultra-low-pass whole genome sequencing (ULP-WGS),Analysis Software,,,,,,,,,,,,,,,,This multi-institutional study used fragment size analysis and ultra-low-pass whole genome sequencing (ULP-WGS) of plasma cell-free DNA
AnyMaze software,computational_tools,PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,AnyMaze software,Analysis Software,,,,,,,,,,,,,,,,The time spent near each wire cup was recorded and scored with the automated AnyMaze software
UCSF500 NGS Panel,computational_tools,PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,UCSF500 NGS Panel,Analysis Software,,,,,,,,,,,,,,,,Targeted next-generation sequencing was performed using the UCSF500 NGS Panel as previously described
limma package,computational_tools,PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,limma package,Package/Library,,,,,,,,,,,,,,,,The limma package was also used for differential expression and multiple testing was controlled using the false discovery rate
AlphaFold 3,computational_tools,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,AlphaFold 3,Web Application,,,,,,,,,,,,,,,,The WMSTM and human amino acid sequences were then input into AlphaFold 3 for structural predictions
Smart-seq2,computational_tools,PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Smart-seq2,Pipeline,,,,,,,,,,,,,,,,"Smart-seq2 whole transcriptome amplification, library construction, and sequencing were performed as previously published"
scdDblFinder,computational_tools,PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,scdDblFinder,Package/Library,,,,,,,,,,,,,,,,Doublets were identified by combining the results of two methods that were published recently and implemented in R packages—scdDblFinder
scran,computational_tools,PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,scran,Package/Library,,,,,,,,,,,,,,,,scdDblFinder and the doubletCells algorithm from scran
QuPath,computational_tools,PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,QuPath,Analysis Software,,,,,,,,,,,,,,,,Quantification of staining intensity was performed in QuPath
cBioPortal,computational_tools,PMID:33507258,10.1001/jamanetworkopen.2020.35479,Assessment of RAS Dependency for BRAF Alterations Using Cancer Genomic Databases.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,cBioPortal,Web Application,,,,,,,,,,,,,,,,databases in cBioPortal including TCGA (The Cancer Genome Atlas)
TCGA (The Cancer Genome Atlas),computational_tools,PMID:33507258,10.1001/jamanetworkopen.2020.35479,Assessment of RAS Dependency for BRAF Alterations Using Cancer Genomic Databases.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,TCGA (The Cancer Genome Atlas),Database,,,,,,,,,,,,,,,,databases in cBioPortal including TCGA (The Cancer Genome Atlas)
NanoDrop 2000,computational_tools,PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,NanoDrop 2000,Analysis Software,,,,,,,,,,,,,,,,"Purity of DNA was assessed by spectrophotometry using NanoDrop 2000 (Thermo Fisher Scientific, Waltham, MA, USA)"
Torrent Suite software,computational_tools,PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Torrent Suite software,Analysis Software,,,,,,,,,,,,,,,,Primary analyses of NGS data were performed using Torrent Suite software on the Ion Torrent Browser
Ingenuity Variant Analysis software,computational_tools,PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Ingenuity Variant Analysis software,Analysis Software,,,,,,,,,,,,,,,,"For variant interpretation, Ingenuity ® Variant Analysis™ software (Qiagen) and SNPnexus web server were used"
AB3130 Genetic Analyzer,computational_tools,PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,AB3130 Genetic Analyzer,Analysis Software,,,,,,,,,,,,,,,,"All variants were confirmed by Sanger sequencing in an AB3130 Genetic Analyzer (Applied Biosystems, Carlsbad, CA, USA)"
Illumina EPIC 850K methylation array,computational_tools,PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Illumina EPIC 850K methylation array,Analysis Software,,,,,,,,,,,,,,,,We interrogated the methylation profiles of 45 CNFs and 17 PNFs from NF1 subjects with the Illumina EPIC 850K methylation array.
wANNOVAR web server,computational_tools,PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,wANNOVAR web server,Web Application,,,,,,,,,,,,,,,,"We used wANNOVAR web server to annotate and prioritize variants, identified candidate genes with recurrent mutations"
Incucyte S3 Live-Cell Analysis System,computational_tools,PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Incucyte S3 Live-Cell Analysis System,Analysis Software,,,,,,,,,,,,,,,,"The total integrated intensity of RFP was monitored over the course of 72 hours, taking measurements every 2 hours with the Incucyte S3 Live-Cell Analysis System (Sartorius, Gottingen, Germany)"
RELION,computational_tools,PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,RELION,Analysis Software,,,,,,,,,,,,,,,,Data processing was done using the RELION (32) software package.
MiSeq-M01450,computational_tools,PMID:32107864,10.1002/mgg3.1180,Expanding the Noonan spectrum/RASopathy NGS panel: Benefits of adding NF1 and SPRED1.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MiSeq-M01450,Other,,,,,,,,,,,,,,,,followed by sequencing using the MiSeq‐M01450 instrument (150‐base paired end mode; Illumina)
VisCap,computational_tools,PMID:32107864,10.1002/mgg3.1180,Expanding the Noonan spectrum/RASopathy NGS panel: Benefits of adding NF1 and SPRED1.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,VisCap,Analysis Software,,,,,,,,,,,,,,,,Copy number variants (CNVs) were identified via an NGS‐based detection tool (VisCap)
Ingenuity Pathway Analysis (IPA),computational_tools,PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Ingenuity Pathway Analysis (IPA),Analysis Software,,,,,,,,,,,,,,,,Ingenuity pathway analysis (IPA) was also used to identify pathways that differ on treatment
CellChat,computational_tools,PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CellChat,Package/Library,,,,,,,,,,,,,,,,"After processing our snRNA-seq dataset in Seurat, downstream analysis in CellChat was conducted"
Bruker AutoFlex III mass spectrometer,computational_tools,PMID:26883872,10.1016/j.jprot.2016.02.004,3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Bruker AutoFlex III mass spectrometer,Analysis Software,,,,,,,,,,,,,,,,"MALDI IMS experiments were performed on a Bruker AutoFlex III mass spectrometer (Bruker Daltonics Billerica, MA, USA)"
Thermo LTQ Velos Orbitrap mass spectrometer,computational_tools,PMID:26883872,10.1016/j.jprot.2016.02.004,3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Thermo LTQ Velos Orbitrap mass spectrometer,Analysis Software,,,,,,,,,,,,,,,,"LC-MS/MS experiments were performed on a Thermo LTQ Velos Orbitrap mass spectrometer (Thermo Scientific, Waltham, MA, USA)"
GPL17586 Platform [HTA-2_0] Affymetrix Human Transcriptome Array 2.0,computational_tools,PMID:32733557,10.1155/2020/5976465,"Gene Expression, Network Analysis, and Drug Discovery of Neurofibromatosis Type 2-Associated Vestibular Schwannomas Based on Bioinformatics Analysis.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,GPL17586 Platform [HTA-2_0] Affymetrix Human Transcriptome Array 2.0,Analysis Software,,,,,,,,,,,,,,,,These microarray data were based on GPL17586 Platform [HTA-2_0] Affymetrix Human Transcriptome Array 2.0 [transcript (gene) version]
Bioconductor limma package,computational_tools,PMID:24980480,10.1186/1479-7364-8-10,Novel age-dependent targets in vestibular schwannomas.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Bioconductor limma package,Package/Library,,,,,,,,,,,,,,,,The Bioconductor limma package [20] was used to preprocess the expression data from Human Genome U133 Plus 2.0 Affymetrix Array
Image J software,computational_tools,PMID:18636037,10.1097/MAO.0b013e31817f7398,The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Image J software,Analysis Software,,,,,,,,,,,,,,,,"surface area of the tumor on each sequential image was determined using the measurement tool on Image J software (NIH, Bethesda, MD)"
Sci-kit Learn,computational_tools,PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Sci-kit Learn,Package/Library,,,,,,,,,,,,,,,,We used python 3.5.1 and Sci-kit Learn for machine learning implementations
WGCNA,computational_tools,PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,WGCNA,Package/Library,,,,,,,,,,,,,,,,We used the 'collapseRows()' function with the 'maxmean' method from the R package WGCNA
GeneChip Human Transcriptome Array 2.0,computational_tools,PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,GeneChip Human Transcriptome Array 2.0,Other,,,,,,,,,,,,,,,,"samples were labeled for the GeneChip Human Transcriptome Array 2.0 (HTA 2.0, Affymetrix)"
PLINK,computational_tools,PMID:41411243,10.1371/journal.pgen.1011976,PERADIGM: Phenotype embedding similarity-based rare disease gene mapping.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,PLINK,Analysis Software,,,,,,,,,,,,,,,,we implemented stringent quality control (QC) measures on the whole-exome sequencing (WES) data using PLINK [ 51 ]
Word2Vec,computational_tools,PMID:41411243,10.1371/journal.pgen.1011976,PERADIGM: Phenotype embedding similarity-based rare disease gene mapping.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Word2Vec,Package/Library,,,,,,,,,,,,,,,,We employed the Word2Vec embedding model to obtain static embedding vectors for the phenotypes
skyscan 1172,computational_tools,PMID:24465906,10.1371/journal.pone.0086115,"Multiscale, converging defects of macro-porosity, microstructure and matrix mineralization impact long bone fragility in NF1.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,skyscan 1172,Analysis Software,,,,,,,,,,,,,,,,Bone samples were analyzed with low (6 µm voxel) or high (up to 1 µm voxel) resolution microCT from skyscan 1172
BWA mem,computational_tools,PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,BWA mem,Analysis Software,,,,,,,,,,,,,,,,fastq files were mapped against the GRCh37 human genome assembly...using BWA mem
samtools,computational_tools,PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,samtools,Analysis Software,,,,,,,,,,,,,,,,a sorted bam file was created with samtools
bedtools,computational_tools,PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,bedtools,Analysis Software,,,,,,,,,,,,,,,,Exhaustive coverage metrics were produced using a combination of bedtools and custom R
VarScan2,computational_tools,PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,VarScan2,Analysis Software,,,,,,,,,,,,,,,,Variants...were called using VarScan2 with the following parameters
annovar,computational_tools,PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,annovar,Analysis Software,,,,,,,,,,,,,,,,variants were annotated with a combination of annovar and custom scripts
bam-readcount,computational_tools,PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,bam-readcount,Analysis Software,,,,,,,,,,,,,,,,bam-readcount was then used to compute additional quality parameters
regioneR,computational_tools,PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,regioneR,Package/Library,,,,,,,,,,,,,,,,Variants were filtered using the regioneR bioconductor package
DeSeq2,computational_tools,PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,DeSeq2,Package/Library,,,,,,,,,,,,,,,,Differentially expressed genes between GFP+ and GFP- tumor populations were analyzed by paired experiment design in the DeSeq2 package
GSVA package,computational_tools,PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,GSVA package,Package/Library,,,,,,,,,,,,,,,,The ssgesa was calculated by the GSVA package with default settings
Limma package,computational_tools,PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Limma package,Package/Library,,,,,,,,,,,,,,,,Limma package was used for generating the human 621-MPNST signature
iStable,computational_tools,PMID:39373898,10.1007/s12031-024-02271-x,Identification of Pathogenic Missense Mutations of NF1 Using Computational Approaches.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,iStable,Web Application,,,,,,,,,,,,,,,,"The iStable-integrated server, accessible at predictor.nchu.edu.tw/iStable, features two machine learning-based tools"
AlphaFold3,computational_tools,PMID:39373898,10.1007/s12031-024-02271-x,Identification of Pathogenic Missense Mutations of NF1 Using Computational Approaches.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,AlphaFold3,Analysis Software,,,,,,,,,,,,,,,,"we utilized AlphaFold3 to simulate both the wild-type and mutant NF1 structures, revealing the significant effects"
Vevo 2100 micro-imaging system,computational_tools,PMID:25340526,10.1371/journal.pone.0107760,Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Vevo 2100 micro-imaging system,Analysis Software,,,,,,,,,,,,,,,,"Sonographic measurement was performed using a Vevo 2100 micro-imaging system (VisualSonics, Amsterdam, Netherlands)"
ARACNe-AP algorithm,computational_tools,PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ARACNe-AP algorithm,Analysis Software,,,,,,,,,,,,,,,,the network was built using the ARACNe-AP algorithm. The ARACNe-AP algorithm reconstructs gene regulatory networks from large-scale gene expression data
Dragen program,computational_tools,PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Dragen program,Analysis Software,,,,,,,,,,,,,,,,Reads were mapped to the genome and variants identified using the Dragen program with default settings
GATK pipeline,computational_tools,PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,GATK pipeline,Pipeline,,,,,,,,,,,,,,,,The resulting VCF files were then sorted and updated to remove errors and analysed using the GATK pipeline
VarDict,computational_tools,PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,VarDict,Analysis Software,,,,,,,,,,,,,,,,Somatic mutations were called from BAM files exported by the Dragen alignment using the Java version of VarDict in paired mode
HudsonAlpha RNA-seq data analysis pipeline,computational_tools,PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,HudsonAlpha RNA-seq data analysis pipeline,Pipeline,,,,,,,,,,,,,,,,Post-processing of the sequencing reads from RNA-seq experiments for each sample was performed using HudsonAlpha's unique in-house RNA-seq data analysis pipeline
cBioportal,computational_tools,PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,cBioportal,Web Application,,,,,,,,,,,,,,,,The cBioportal website (cbioportal.org) was used to analyze The Cancer Genome Atlas (TCGA)—Firehose Legacy
Affymetrix Mouse Gene 2.0 ST array,computational_tools,PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Affymetrix Mouse Gene 2.0 ST array,Analysis Software,,,,,,,,,,,,,,,,All the probe sets on Affymetrix Mouse Gene 2.0 ST array (Mogene-2_0-st-v1.na33.2.mm10)
limma package,computational_tools,PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,limma package,Package/Library,,,,,,,,,,,,,,,,The Bioconductor/R limma package was used to define DEGs between two groups
DeepVariant,computational_tools,PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,DeepVariant,Analysis Software,,,,,,,,,,,,,,,,The pipeline was modified to add DeepVariant as an additional variant-calling method
XF24 Extracellular Flux Analyzer,computational_tools,PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,XF24 Extracellular Flux Analyzer,Analysis Software,,,,,,,,,,,,,,,,"OCR was assessed in real-time with the XF24 Extracellular Flux Analyzer (Agilent, North Billerica, MA, USA)"
LC-MS/MS (Quattro Premier),computational_tools,PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,LC-MS/MS (Quattro Premier),Analysis Software,,,,,,,,,,,,,,,,"Mass spectrometry analysis was carried out with an LC-MS/MS (Quattro Premier interfaced with an Acquity UPLC system, Waters)"
FACSCanto II flow cytometer,computational_tools,PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,FACSCanto II flow cytometer,Analysis Software,,,,,,,,,,,,,,,,"Samples were analyzed on a FACSCanto II flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA)"
FACSDiva software,computational_tools,PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,FACSDiva software,Analysis Software,,,,,,,,,,,,,,,,Data acquisition and analysis were performed using FACSDiva software
Ventana-785-Raman spectrometer,computational_tools,PMID:38603731,10.1371/journal.pone.0302017,Raman difference spectroscopy and U-Net convolutional neural network for molecular analysis of cutaneous neurofibroma.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Ventana-785-Raman spectrometer,Analysis Software,,,,,,,,,,,,,,,,"guiding the signals from the Raman probe to the spectrometer (Ventana-785-Raman, Ocean Optics, Rochester, New York, USA)"
GAMESS software,computational_tools,PMID:39881370,10.1186/s13065-024-01353-6,"Spectrophotometric and computational characterization of charge transfer complex of selumetinib with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone and its utilization in developing an innovative green and high throughput microwell assay for analysis of bulk form and pharmaceutical formulation.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,GAMESS software,Analysis Software,,,,,,,,,,,,,,,,Quantum mechanics/molecular mechanics (QM/MM) computations...were performed using the General Atomic and Molecular Electronic Structure System (GAMESS software)
Cytoscape,computational_tools,PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Cytoscape,Analysis Software,,,,,,,,,,,,,,,,Cytoscape ( 26 ) was used to create a graphic representation of the pink-module
nCounter Sprint Profiler,computational_tools,PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,nCounter Sprint Profiler,Analysis Software,,,,,,,,,,,,,,,,"Gene expression analysis was conducted on the nCounter Sprint Profiler (NanoString Technologies, Inc.)"
UCSC Xena browser,computational_tools,PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,UCSC Xena browser,Web Application,,,,,,,,,,,,,,,,Publicly available RNA sequencing data was also obtained from the TARGET TCGA GTEx database using the UCSC Xena browser (RRID:SCR_018938)
ComplexHeatmap R/Bioconductor package,computational_tools,PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ComplexHeatmap R/Bioconductor package,Package/Library,,,,,,,,,,,,,,,,were generated using the ComplexHeatmap R/Bioconductor package (RRID:SCR_017270)
Scanpy,computational_tools,PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Scanpy,Package/Library,,,,,,,,,,,,,,,,Data preprocessing and visualization was performed using Scanpy (RRID:SCR_018139) in Python
Illumina Infinium HumanMethylationEPIC (EPIC) array,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Illumina Infinium HumanMethylationEPIC (EPIC) array,Analysis Software,,,,,,,,,,,,,,,,Bisulfite-treated DNA from all tumor samples was then processed for methylation profiling using the Illumina Infinium HumanMethylationEPIC (EPIC) array
ConsensusClusterPlus,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ConsensusClusterPlus,Package/Library,,,,,,,,,,,,,,,,Subgroups were identified using ConsensusClusterPlus Bioconductor package
limma,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,limma,Package/Library,,,,,,,,,,,,,,,,We performed supervised analysis of methylation data using limma based modeling approach (Bioconductor)
Rtsne,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Rtsne,Package/Library,,,,,,,,,,,,,,,,"We used Rtsne package in Bioconductor to generate tSNE plots based on the top 10,000 most variably methylated CpG sites"
conumee,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,conumee,Package/Library,,,,,,,,,,,,,,,,"To generate compound CNV plots using the DNA methylation data, we used the conumee package in Bioconductor"
Haplotype Caller,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Haplotype Caller,Analysis Software,,,,,,,,,,,,,,,,"Haplotype Caller, MuTect1 v1.1.7 and Strelka v1.0.13 were run to create raw variant call files (VCFs)"
FusionCatcher,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,FusionCatcher,Analysis Software,,,,,,,,,,,,,,,,We used FusionCatcher to detect novel gene fusions
CIBERSORT,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CIBERSORT,Package/Library,,,,,,,,,,,,,,,,We used CIBERSORT Bioconductor package to perform deconvolution and estimate the abundances of cell types
BWA MEM,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,BWA MEM,Analysis Software,,,,,,,,,,,,,,,,Amplicon reads were aligned against the human reference genome hg19 with BWA MEM
GeneMapper software,computational_tools,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,GeneMapper software,Analysis Software,,,,,,,,,,,,,,,,electrophoresis data were analyzed using GeneMapper software (Life Technologies)
Agilent 1200 HPLC,computational_tools,PMID:31527226,10.1158/1535-7163.MCT-19-0123,"Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of ",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Agilent 1200 HPLC,Analysis Software,,,,,,,,,,,,,,,,Ketotifen was quantified in plasma and nerve tissue samples from ketotifen-treated Nf1;flox/flox PostnCre+ mice (n = 3) by HPLC-MS/MS (Agilent 1200 HPLC and ABI 3200 MS/MS)
ABI 3200 MS/MS,computational_tools,PMID:31527226,10.1158/1535-7163.MCT-19-0123,"Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of ",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ABI 3200 MS/MS,Analysis Software,,,,,,,,,,,,,,,,Ketotifen was quantified in plasma and nerve tissue samples from ketotifen-treated Nf1;flox/flox PostnCre+ mice (n = 3) by HPLC-MS/MS (Agilent 1200 HPLC and ABI 3200 MS/MS)
ClinVar,computational_tools,PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ClinVar,Database,,,,,,,,,,,,,,,,ClinVar data for NF1 variants were extracted from the ClinVar version 2024-07-03 available at: https://ftp.ncbi.nlm.nih.gov/pub/clinvar/
Mutation Taster,computational_tools,PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Mutation Taster,Web Application,,,,,,,,,,,,,,,,The effects on genes and proteins of the variants identified were predicted based on the Mutation Taster (http://www.mutationtaster.org)
HGMD,computational_tools,PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,HGMD,Database,,,,,,,,,,,,,,,,"HGMD (Human Genome Mutation Database—Institute of Medical Genetics, Cardiff, Wales, UK; http://www.hgmd.cf.ac.uk/ac/index.php"
LOVD,computational_tools,PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,LOVD,Database,,,,,,,,,,,,,,,,LOVD. (Leiden Open Variation Database; http://www.LOVD.nl.NF1)
PolyPhen-2,computational_tools,PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,PolyPhen-2,Web Application,,,,,,,,,,,,,,,,Novel variants with amino acid changes were further examined for their disease causing. potential using PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/bgi.shtml)
Human Splicing Finder,computational_tools,PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Human Splicing Finder,Web Application,,,,,,,,,,,,,,,,with the Human Splicing Finder (HSF; http://www.umd.be/HSF/)
ESE Finder,computational_tools,PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ESE Finder,Web Application,,,,,,,,,,,,,,,,and the ESE Finder (http://rulai.cshl.edu/cgibin/tools/ESE3/esefinder.cgi?process=home) tools
ANNOVAR,computational_tools,PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ANNOVAR,Analysis Software,,,,,,,,,,,,,,,,predicted the functional consequence of missense variants using ANNOVAR which included prediction scores from 20 prediction algorithms
ExplorDTI,computational_tools,PMID:32839340,10.1073/pnas.2008391117,Brain-wide structural and functional disruption in mice with oligodendrocyte-specific ,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ExplorDTI,Analysis Software,,,,,,,,,,,,,,,,Diffusion-weighted images were preprocessed using ExplorDTI (68)
Advanced Normalization Tools (ANTs),computational_tools,PMID:32839340,10.1073/pnas.2008391117,Brain-wide structural and functional disruption in mice with oligodendrocyte-specific ,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Advanced Normalization Tools (ANTs),Analysis Software,,,,,,,,,,,,,,,,"template, B0, for both controls and Plp-Nf1 fl/+ animals was created using Advanced Normalization Tools (ANTs) (70)"
Synapse collaborative science platform,computational_tools,PMID:35735230,10.1093/database/baac045,Centralizing neurofibromatosis experimental tool knowledge with the NF Research Tools Database.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Synapse collaborative science platform,Web Application,,,,,,,,,,,,,,,,...but all database tables and a variety of 'joined' tables are available for anyone to access on the Synapse collaborative science platform...
MCP-Counter,computational_tools,PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MCP-Counter,Analysis Software,,,,,,,,,,,,,,,,To assess the cell type of origin in the organoid models we used the tumor deconvolution algorithm MCP-Counter
BSBolt,computational_tools,PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,BSBolt,Analysis Software,,,,,,,,,,,,,,,,raw fastq files obtained by RRBS were analyzed using BSBolt
kernlab R library,computational_tools,PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,kernlab R library,Package/Library,,,,,,,,,,,,,,,,we used the Gaussian Process regression (GPR) implementation available within kernlab R library
PLIER,computational_tools,PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,PLIER,Package/Library,,,,,,,,,,,,,,,,"Key packages used include ""tidyverse"" [33], ""PLIER"" [26], ""synapser"" [34], ""tximport"" [35], ""immundeconv"" [35], and ""viper"" [32]."
Salmon,computational_tools,PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Salmon,Analysis Software,,,,,,,,,,,,,,,,raw fastq files were downloaded from Synapse and transcripts were quantified using the Salmon pseudo-alignment tool [36] with Gencode V29 transcriptome.
CIBERSORT,computational_tools,PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CIBERSORT,Analysis Software,,,,,,,,,,,,,,,,"we used two tumor deconvolution methods: CIBERSORT and MCP-counter, as implemented through the ""immunedeconv"" R package [29, 30, 31]."
MCP-counter,computational_tools,PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,MCP-counter,Analysis Software,,,,,,,,,,,,,,,,"we used two tumor deconvolution methods: CIBERSORT and MCP-counter, as implemented through the ""immunedeconv"" R package [29, 30, 31]."
metaVIPER,computational_tools,PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,metaVIPER,Analysis Software,,,,,,,,,,,,,,,,We applied the metaVIPER algorithm [32] to infer protein regulatory activity based on the tissue gene expression profiles.
NF Data Portal,computational_tools,PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,NF Data Portal,Database,,,,,,,,,,,,,,,,All data analyzed in this article are stored on the NF Data Portal [24] (http://nfdataportal.org)
clusterProfiler,computational_tools,PMID:38115252,10.1097/MD.0000000000036696,Identification of hub genes and drug candidates for NF2-related vestibular schwannoma by bioinformatics tools.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,clusterProfiler,Package/Library,,,,,,,,,,,,,,,,we performed FEA of the strongly associated modules using the clusterProfiler package of the R software
miRTarBase,computational_tools,PMID:38115252,10.1097/MD.0000000000036696,Identification of hub genes and drug candidates for NF2-related vestibular schwannoma by bioinformatics tools.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,miRTarBase,Database,,,,,,,,,,,,,,,,"we retrieved miRNA information from the miRTarBase database, including, over 50,000 experimentally validated miRNA-target associations"
limma,computational_tools,PMID:38115252,10.1097/MD.0000000000036696,Identification of hub genes and drug candidates for NF2-related vestibular schwannoma by bioinformatics tools.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,limma,Package/Library,,,,,,,,,,,,,,,,DEGs were identified between NF2-Vs and normal nerves using the R package limma
connectivity map (CMap),computational_tools,PMID:38115252,10.1097/MD.0000000000036696,Identification of hub genes and drug candidates for NF2-related vestibular schwannoma by bioinformatics tools.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,connectivity map (CMap),Database,,,,,,,,,,,,,,,,we uploaded our list of up- and down-regulated genes into the connectivity map (CMap) database
CLC-workbench,computational_tools,PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CLC-workbench,Analysis Software,,,,,,,,,,,,,,,,"Variants were validated by Sanger sequencing and analyzed using CLC-workbench (Qiagen, Hilden, Germany)"
Beta Imager 2000Z Digital Beta Imaging System,computational_tools,PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Beta Imager 2000Z Digital Beta Imaging System,Analysis Software,,,,,,,,,,,,,,,,"Quantitation was performed using the Beta Imager 2000Z Digital Beta Imaging System (Biospace, France)"
Siemens Focus F220,computational_tools,PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Siemens Focus F220,Analysis Software,,,,,,,,,,,,,,,,data acquired as 1h dynamic scans using the Siemens Focus F220 and Inveon scanners
fMRI Expert Analysis Tool (FEAT),computational_tools,PMID:35087195,10.1038/s41380-021-01422-5,Altered canonical and striatal-frontal resting state functional connectivity in children with pathogenic variants in the Ras/mitogen-activated protein kinase pathway.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,fMRI Expert Analysis Tool (FEAT),Analysis Software,,,,,,,,,,,,,,,,We used fMRI Expert Analysis Tool (FEAT) to model extracted time series
Multiple Imputation by Chained Equations (MICE),computational_tools,PMID:35087195,10.1038/s41380-021-01422-5,Altered canonical and striatal-frontal resting state functional connectivity in children with pathogenic variants in the Ras/mitogen-activated protein kinase pathway.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Multiple Imputation by Chained Equations (MICE),Package/Library,,,,,,,,,,,,,,,,using a predictive mean matching for mixed types and the Multiple Imputation by Chained Equations (MICE) package in R
CHOP-CHOP,computational_tools,PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CHOP-CHOP,Web Application,,,,,,,,,,,,,,,,gRNAs for zebrafish nf2a and nf2b (Table S1) were designed using CHOP-CHOP
CRISPResso2,computational_tools,PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CRISPResso2,Analysis Software,,,,,,,,,,,,,,,,"At least 10,000 high-quality reads were analyzed for each sample using CRISPResso2 (Clement et al., 2019)"
Cellpose,computational_tools,PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Cellpose,Analysis Software,,,,,,,,,,,,,,,,"images were further analyzed using Cellpose (Stringer et al., 2021) and ImageJ"
Xenosplit,computational_tools,PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Xenosplit,Analysis Software,,,,,,,,,,,,,,,,"For PDX sequence data, Xenosplit was used to filter mouse-derived reads"
Variant Effect Predictor (VEP),computational_tools,PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Variant Effect Predictor (VEP),Analysis Software,,,,,,,,,,,,,,,,Variant filtering and annotation were done using Variant Effect Predictor (VEP)
DESeq2 package,computational_tools,PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,DESeq2 package,Package/Library,,,,,,,,,,,,,,,,Gene counts and transcript counts were normalized by using the DESeq2 package
GEOquery,computational_tools,PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,GEOquery,Package/Library,,,,,,,,,,,,,,,,Expression matrices and corresponding phenotype metadata were processed using the GEOquery and Biobase R packages
Biobase,computational_tools,PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Biobase,Package/Library,,,,,,,,,,,,,,,,Expression matrices and corresponding phenotype metadata were processed using the GEOquery and Biobase R packages
CellRanger,computational_tools,PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CellRanger,Analysis Software,,,,,,,,,,,,,,,,Raw sequencing reads were processed using CellRanger (10 × Genomics)
NextSeq500 instrument (Illumina),computational_tools,PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,NextSeq500 instrument (Illumina),Analysis Software,,,,,,,,,,,,,,,,Paired-end sequencing (2x150bp) was performed on a NextSeq500 instrument (Illumina)
SnpEff,computational_tools,PMID:30274822,10.1016/j.ebiom.2018.09.039,Exhaustive non-synonymous variants functionality prediction enables high resolution characterization of the neurofibromin architecture.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,SnpEff,Analysis Software,,,,,,,,,,,,,,,,Variant annotation was performed using SnpEff and included annotations gathered in dbNSFP
PLINK,computational_tools,PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,PLINK,Analysis Software,,,,,,,,,,,,,,,,"multidimensional scaling (MDS) analysis estimating pairwise identity by descent (IBD) for all pairs of founders using independent SNPs in PLINK (Purcell et al., 2007)"
EMMAX,computational_tools,PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,EMMAX,Analysis Software,,,,,,,,,,,,,,,,"tests of association between each SNP and log‐transformed CALM number, adjusted for age, sex, and body surface area, were performed with EMMAX (Kang et al., 2010)"
METAL,computational_tools,PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,METAL,Analysis Software,,,,,,,,,,,,,,,,"Meta‐analyses between the CALM1 and CALM2 cohort studies were performed with METAL (Willer, Li, & Abecasis, 2010)"
ComPaSS-GWAS,computational_tools,PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,ComPaSS-GWAS,Analysis Software,,,,,,,,,,,,,,,,"The second approach for corroboration of SNP associations used ComPaSS‐GWAS (Sabourin et al., 2018), a method based on complementary pairs stability selection"
Peak Scanner software from Applied Biosystems,computational_tools,PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Peak Scanner software from Applied Biosystems,Analysis Software,,,,,,,,,,,,,,,,The UCSF Genome Core using Peak Scanner software from Applied Biosystems performed PCR fragment analyses
HALO imaging analysis software,computational_tools,PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,HALO imaging analysis software,Analysis Software,,,,,,,,,,,,,,,,"analyzed with the HALO imaging analysis software (Indica Labs, Corrales, NM)"
CosinorPy Python package,computational_tools,PMID:41001593,10.1080/23723556.2025.2561292,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CosinorPy Python package,Package/Library,,,,,,,,,,,,,,,,numerical and graphical analysis was done using the CosinorPy Python package
Seahorse Wave Pro software,computational_tools,PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Seahorse Wave Pro software,Analysis Software,,,,,,,,,,,,,,,,"The analysis was performed with Seahorse Wave Pro software (Agilent Technologies, Santa Clara, CA, USA)"
Agilent Tapestation 4200,computational_tools,PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Agilent Tapestation 4200,Analysis Software,,,,,,,,,,,,,,,,Fragmented gDNAs were tested for size distribution and concentration using an Agilent Tapestation 4200 and Qubit dsDNA High Sensitivity kit.
Illumina NextSeq550Dx,computational_tools,PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Illumina NextSeq550Dx,Analysis Software,,,,,,,,,,,,,,,,"The samples were then sequenced on an Illumina NextSeq550Dx, which generated paired-end reads of 151 bp."
SynergyFinder,computational_tools,PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,SynergyFinder,Analysis Software,,,,,,,,,,,,,,,,data analyzed using SynergyFinder (RRID: SCR-019318)
CIBERSORT,computational_tools,PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,CIBERSORT,Analysis Software,,,,,,,,,,,,,,,,DEGs were mapped to their human orthologs and were further analyzed using CIBERSORT (RRID: SCR_016955)
HALO (Indica Labs),computational_tools,PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,HALO (Indica Labs),Analysis Software,,,,,,,,,,,,,,,,"HALO (Indica Labs) or Aperio (Leica Biosystems, Wetzlar, Germany) Image Analysis software was used"
Aperio Image Analysis (Leica Biosystems),computational_tools,PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,Aperio Image Analysis (Leica Biosystems),Analysis Software,,,,,,,,,,,,,,,,"HALO (Indica Labs) or Aperio (Leica Biosystems, Wetzlar, Germany) Image Analysis software was used"
XF96 Extracellular Flux Analyzer (Agilent Technologies),computational_tools,PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,0.9,Experimental Usage,True,0.67,Medium,,,,,,,,,,,,,,,XF96 Extracellular Flux Analyzer (Agilent Technologies),Analysis Software,,,,,,,,,,,,,,,,Oxygen consumption rate (OCR) was measured in schwannoma and normal Schwann cells 24 h post protein delivery using an XF96 Extracellular Flux Analyzer
Nf1 KO,genetic_reagents,PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,0.9,Experimental Usage,True,0.50,Medium,,,,,,,,,,,Nf1 KO,,,,,,,,,,,,,,,,,,,,,"hGFAP-cre±; Nf1 KO/+ . The mutant mice ( Nf1 hGFAP CKO) used were of the genotypes, hGFAP-cre+; Nf1 flox/KO"
NF1,genetic_reagents,PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,0.9,Experimental Usage,True,0.50,Medium,,,,,,,,,,,NF1,,,,,,,,,,,,,,,,,,,,,synthetic gene (GeneArt) encoding the human full-length NF1 (synNF1)
NF1-eGFP,genetic_reagents,PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,0.9,Experimental Usage,True,0.50,Medium,,,,,,,,,,,NF1-eGFP,,,,,,,,,,,,,,,,,,,,,full-length human neurofibromin with C-terminal eGFP tag (synNF1eGFP)
Cleaved-caspase 3,antibodies,PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.9,Experimental Usage,True,0.33,Medium,,,,Cleaved-caspase 3,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Immunohistochemical staining for Cleaved-caspase 3 at 1:500 (Cell Signaling Technology, Danvers, MA)"
Ki67,antibodies,PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.9,Experimental Usage,True,0.33,Medium,,,,Ki67,,,,,,,,,,,,,,,,,,,,,,,,,,,,prediluted Ki67 (790–4286; Ventana)
GFAP,antibodies,PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.9,Experimental Usage,True,0.33,Medium,,,,GFAP,,,,,,,,,,,,,,,,,,,,,,,,,,,,"serially sectioned (5 μm) and immunostained with GFAP, Iba1, Ki67, CD3, Midkine, GAP43, CD34, Factor XIIIa, SOX10, neurofilament-200, and Col1a2"
Iba1,antibodies,PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.9,Experimental Usage,True,0.33,Medium,,,,Iba1,,,,,,,,,,,,,,,,,,,,,,,,,,,,"serially sectioned (5 μm) and immunostained with GFAP, Iba1, Ki67, CD3, Midkine, GAP43, CD34, Factor XIIIa, SOX10, neurofilament-200, and Col1a2"
Ki67,antibodies,PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.9,Experimental Usage,True,0.33,Medium,,,,Ki67,,,,,,,,,,,,,,,,,,,,,,,,,,,,"serially sectioned (5 μm) and immunostained with GFAP, Iba1, Ki67, CD3, Midkine, GAP43, CD34, Factor XIIIa, SOX10, neurofilament-200, and Col1a2"
SOX10,antibodies,PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.9,Experimental Usage,True,0.33,Medium,,,,SOX10,,,,,,,,,,,,,,,,,,,,,,,,,,,,"serially sectioned (5 μm) and immunostained with GFAP, Iba1, Ki67, CD3, Midkine, GAP43, CD34, Factor XIIIa, SOX10, neurofilament-200, and Col1a2"
Rbpms,antibodies,PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.9,Experimental Usage,True,0.33,Medium,,,,Rbpms,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary RGCs, hippocampal neurons, DRG neurons, sh NF1 Schwann cells, and hiPSC-sensory neurons were immunostained with appropriate primary (RGCs: Rbpms, Tuj-1"
Tuj-1,antibodies,PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.9,Experimental Usage,True,0.33,Medium,,,,Tuj-1,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary RGCs, hippocampal neurons, DRG neurons, sh NF1 Schwann cells, and hiPSC-sensory neurons were immunostained with appropriate primary (RGCs: Rbpms, Tuj-1"
Peripherin,antibodies,PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.9,Experimental Usage,True,0.33,Medium,,,,Peripherin,,,,,,,,,,,,,,,,,,,,,,,,,,,,"DRG neurons: Peripherin, ISL1, Tuj-1"
ISL1,antibodies,PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.9,Experimental Usage,True,0.33,Medium,,,,ISL1,,,,,,,,,,,,,,,,,,,,,,,,,,,,"DRG neurons: Peripherin, ISL1, Tuj-1"
P-cadherin,antibodies,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.9,Experimental Usage,True,0.33,Medium,,,,P-cadherin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"The primary antibodies used in this study were P-cadherin (R&D Systems, AF761), DCT (PEP8h; gift from Dr. Vincent Hearing)"
LacZ,antibodies,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.9,Experimental Usage,True,0.33,Medium,,,,LacZ,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"K14 (biotin-labeled, Thermo, clone LL002), LacZ (Abcam, ab9361), GFP/YFP (Aves, 1020)"
GFP/YFP,antibodies,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.9,Experimental Usage,True,0.33,Medium,,,,GFP/YFP,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"LacZ (Abcam, ab9361), GFP/YFP (Aves, 1020), Krox20 (Covance, PRB-236P)"
Krox20,antibodies,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.9,Experimental Usage,True,0.33,Medium,,,,Krox20,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"GFP/YFP (Aves, 1020), Krox20 (Covance, PRB-236P), and KIT (Cell Signaling, 3074)"
KIT,antibodies,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.9,Experimental Usage,True,0.33,Medium,,,,KIT,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Krox20 (Covance, PRB-236P), and KIT (Cell Signaling, 3074). For immunofluorescent staining"
pERα S118,antibodies,PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.9,Experimental Usage,True,0.33,Medium,,,,pERα S118,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"pERα S118 (Sigma, Cat# SAB450399)"
pERK T202/Y204,antibodies,PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.9,Experimental Usage,True,0.33,Medium,,,,pERK T202/Y204,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"pERK T202/Y204 (Cell Signaling Technology, Cat#9101L)"
pAKT S473,antibodies,PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.9,Experimental Usage,True,0.33,Medium,,,,pAKT S473,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"pAKT S473 (Cell Signaling Technology, Cat#9271L)"
β-tubulin,antibodies,PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.9,Experimental Usage,True,0.33,Medium,,,,β-tubulin,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"β-tubulin (Cell Signaling Technology, Cat#2146, primary 1:500, secondary 1:2000)"
HLA-DR,antibodies,PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.9,Experimental Usage,True,0.33,Medium,,,,HLA-DR,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"stained with anti-HLA-DR Percp-cy5.5 (eBioscience, 0.015 µg/test, San Diego, CA, USA)"
CD33,antibodies,PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.9,Experimental Usage,True,0.33,Medium,,,,CD33,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-CD33 APC (eBioscience, 0.125 µg/test)"
CD11b,antibodies,PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.9,Experimental Usage,True,0.33,Medium,,,,CD11b,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-CD11b FITC antibodies (eBioscience, 0.5 µg/test)"
CD9,antibodies,PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.9,Experimental Usage,True,0.33,Medium,,,,CD9,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"primary antibodies against CD9 (Proteintech, 60232-1-Ig, Wuhan, China)"
CD81,antibodies,PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.9,Experimental Usage,True,0.33,Medium,,,,CD81,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"CD81 (Proteintech, 66866-1-Ig)"
AKT,antibodies,PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.9,Experimental Usage,True,0.33,Medium,,,,AKT,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"AKT (CST, #9272S, Danvers, MA, USA)"
p-AKT,antibodies,PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.9,Experimental Usage,True,0.33,Medium,,,,p-AKT,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"p-AKT (CST, #4051S)"
ERK,antibodies,PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.9,Experimental Usage,True,0.33,Medium,,,,ERK,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"ERK (CST, #4695)"
p-ERK,antibodies,PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.9,Experimental Usage,True,0.33,Medium,,,,p-ERK,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"p-ERK (CST, #9101S)"
pEGFR,antibodies,PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.9,Experimental Usage,True,0.33,Medium,,,,pEGFR,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Western blots to verify protein expression levels were run on Tris acetate or Bolt gels and probed with a series of antibodies: pEGFR (Cell Signaling 3777)
vinculin,antibodies,PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.9,Experimental Usage,True,0.33,Medium,,,,vinculin,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,vinculin (Cell Signaling 19301)
HMGA2,antibodies,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.9,Experimental Usage,True,0.33,Medium,,,,HMGA2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"1:400 anti-Hmga2 (Biocheck), 1:100 anti-beta-Catenin (BD bioscience), 1:100 anti-Ck19 (Abcam)"
beta-Catenin,antibodies,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.9,Experimental Usage,True,0.33,Medium,,,,beta-Catenin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"1:400 anti-Hmga2 (Biocheck), 1:100 anti-beta-Catenin (BD bioscience), 1:100 anti-Ck19 (Abcam)"
CK19,antibodies,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.9,Experimental Usage,True,0.33,Medium,,,,CK19,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"1:400 anti-Hmga2 (Biocheck), 1:100 anti-beta-Catenin (BD bioscience), 1:100 anti-Ck19 (Abcam)"
SOX9,antibodies,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.9,Experimental Usage,True,0.33,Medium,,,,SOX9,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"1:1000 anti-Sox9 (Millipore); 1:10,000 anti-Hsp90 (BD Biosciences)"
HSP90,antibodies,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.9,Experimental Usage,True,0.33,Medium,,,,HSP90,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"1:1000 anti-Sox9 (Millipore); 1:10,000 anti-Hsp90 (BD Biosciences)"
p-ERK,antibodies,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.9,Experimental Usage,True,0.33,Medium,,,,p-ERK,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,1:1000 anti-pErk (Cell Signaling)
K1,antibodies,PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.9,Experimental Usage,True,0.33,Medium,,,,K1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"K1 (BioLegend, 905601, 1:100)"
NF1,antibodies,PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.9,Experimental Usage,True,0.33,Medium,,,,NF1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"NF1 (Santa Cruz; sc-67, 1:100)"
H3K27Me3,antibodies,PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.9,Experimental Usage,True,0.33,Medium,,,,H3K27Me3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"H3K27Me3 (Cell Signaling, 9733 S, 1:500)"
S100,antibodies,PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.9,Experimental Usage,True,0.33,Medium,,,,S100,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"S100 (DAKO, Z0311, 1:5000)"
NF1,antibodies,PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.9,Experimental Usage,True,0.33,Medium,,,,NF1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"NF1 (Santa Cruz; H-12, 1:100)"
LUMICAN,antibodies,PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.9,Experimental Usage,True,0.33,Medium,,,,LUMICAN,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"LUMICAN (Santa Cruz; sc-166871, 1:200)"
CD3,antibodies,PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.9,Experimental Usage,True,0.33,Medium,,,,CD3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,precoated with indicated doses of anti-CD3 Ab (eBioscience; cat. no. 16-0031-86)
CD4,antibodies,PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.9,Experimental Usage,True,0.33,Medium,,,,CD4,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,CD4 [eBioscience; cat. no. 17-0042-83; 1:100]
CD8,antibodies,PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.9,Experimental Usage,True,0.33,Medium,,,,CD8,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,CD8 [Lifetech; cat. no. A15836; 1:100]
FoxP3,antibodies,PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.9,Experimental Usage,True,0.33,Medium,,,,FoxP3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,FoxP3 [eBioscience; cat. no. 12-57773-80; 1:100]
B220,antibodies,PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.9,Experimental Usage,True,0.33,Medium,,,,B220,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,B220 [eBioscience; cat. no. 11-0452-85; 1:100]
CD45,antibodies,PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.9,Experimental Usage,True,0.33,Medium,,,,CD45,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,CD45 [eBioscience; cat. no. 25-0451-82; 1:100]
GFAP,antibodies,PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.9,Experimental Usage,True,0.33,Medium,,,,GFAP,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Immunofluorescence staining was performed using the following primary antibodies: GFAP (Sigma; St. Louis, MO)"
AQP4,antibodies,PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.9,Experimental Usage,True,0.33,Medium,,,,AQP4,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"AQP4, NG2, O4, LHX2 (Chemicon International; Temecula, CA)"
NG2,antibodies,PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.9,Experimental Usage,True,0.33,Medium,,,,NG2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"AQP4, NG2, O4, LHX2 (Chemicon International; Temecula, CA)"
O4,antibodies,PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.9,Experimental Usage,True,0.33,Medium,,,,O4,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"AQP4, NG2, O4, LHX2 (Chemicon International; Temecula, CA)"
LHX2,antibodies,PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.9,Experimental Usage,True,0.33,Medium,,,,LHX2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"AQP4, NG2, O4, LHX2 (Chemicon International; Temecula, CA)"
APC,antibodies,PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.9,Experimental Usage,True,0.33,Medium,,,,APC,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"APC (Calbiochem; San Diego, CA)"
FOXG1,antibodies,PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.9,Experimental Usage,True,0.33,Medium,,,,FOXG1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"FOXG1, FOXP2 (Abcam; Cambridge, MA)"
FOXP2,antibodies,PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.9,Experimental Usage,True,0.33,Medium,,,,FOXP2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"FOXG1, FOXP2 (Abcam; Cambridge, MA)"
HOXB3,antibodies,PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.9,Experimental Usage,True,0.33,Medium,,,,HOXB3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"HOXB3 (Santa Cruz Biotechnology; Santa Cruz, CA)"
GFAP,antibodies,PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.9,Experimental Usage,True,0.33,Medium,,,,GFAP,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Immunohistochemical staining was performed using GFAP (Zymed, San Francisco, CA)"
Ki-67,antibodies,PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.9,Experimental Usage,True,0.33,Medium,,,,Ki-67,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Ki-67 (BD Pharmingen, San Diego, CA) antibodies followed by Vectastain ABC development"
α-tubulin,antibodies,PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.9,Experimental Usage,True,0.33,Medium,,,,α-tubulin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"α-tubulin (Sigma, St. Louis, MO) was employed for normalization and densitometric analysis"
GFP,antibodies,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,Experimental Usage,True,0.33,Medium,,,,GFP,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Horseradish peroxidase (HRP) conjugated an antibody specific for GFP (cat. no. 600–103-215) was from Rockland
RFP,antibodies,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,Experimental Usage,True,0.33,Medium,,,,RFP,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,specific for RFP (cat no. ab34767) was from Abcam
phosphorylated ERK Thr202/Tyr204,antibodies,PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,0.9,Experimental Usage,True,0.33,Medium,,,,phosphorylated ERK Thr202/Tyr204,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Phosphorylated ERK Thr202/Tyr204 (catalog #4376), phosphorylated Akt Ser473 (#9271) and phosphorylated S6 Ser235/236 (#2211) (all from Cell Signaling, Beverly, MA)"
phosphorylated Akt Ser473,antibodies,PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,0.9,Experimental Usage,True,0.33,Medium,,,,phosphorylated Akt Ser473,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Phosphorylated ERK Thr202/Tyr204 (catalog #4376), phosphorylated Akt Ser473 (#9271) and phosphorylated S6 Ser235/236 (#2211) (all from Cell Signaling, Beverly, MA)"
phosphorylated S6 Ser235/236,antibodies,PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,0.9,Experimental Usage,True,0.33,Medium,,,,phosphorylated S6 Ser235/236,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Phosphorylated ERK Thr202/Tyr204 (catalog #4376), phosphorylated Akt Ser473 (#9271) and phosphorylated S6 Ser235/236 (#2211) (all from Cell Signaling, Beverly, MA)"
γH2AX Ser139,antibodies,PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,0.9,Experimental Usage,True,0.33,Medium,,,,γH2AX Ser139,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Coverslips were permeabilized and probed with anti-γH2AX Ser139 antibody (Millipore), followed by anti-rabbit AlexaFluor 488 secondary antibody"
Olig2,antibodies,PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.9,Experimental Usage,True,0.33,Medium,,,,Olig2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Guinea pig anti-Olig2 (1:10000, a kind gift of home-made antibody from Dr. B. Novitch)"
PAX8,antibodies,PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.9,Experimental Usage,True,0.33,Medium,,,,PAX8,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"PAX8 Proteintech, 10336-1-AP 1:2000 Overnight, RT Citrate buffer, pH 6.0"
Ac-alpha-Tubulin,antibodies,PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.9,Experimental Usage,True,0.33,Medium,,,,Ac-alpha-Tubulin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Ac-alpha-Tubulin Santa Cruz, sc-23950 1:2000 Overnight, RT Citrate buffer, pH 6.0"
KI67,antibodies,PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.9,Experimental Usage,True,0.33,Medium,,,,KI67,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"KI67 Monosan, MONX10283 1:2000 Overnight, RT Citrate buffer, pH 6.0"
Cytokeratin-8,antibodies,PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.9,Experimental Usage,True,0.33,Medium,,,,Cytokeratin-8,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Cytokeratin-8 Santa Cruz, sc-101459 1:50 Overnight, RT Citrate buffer, pH 6.0"
GFP,antibodies,PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.9,Experimental Usage,True,0.33,Medium,,,,GFP,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"GFP Life Technologies, A11122 1:1000 Overnight, RT Citrate buffer, pH 6.0"
Cleaved Caspase-3,antibodies,PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.9,Experimental Usage,True,0.33,Medium,,,,Cleaved Caspase-3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Cleaved Caspase-3 (D175) Cell Signaling Technology, #9661L 1:500 Overnight, RT Citrate buffer, pH 6.0"
p53,antibodies,PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.9,Experimental Usage,True,0.33,Medium,,,,p53,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"probed with antibodies directed against p53 (sc-6243, 1:250, Santa Cruz Biotechnology)"
GAPDH,antibodies,PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.9,Experimental Usage,True,0.33,Medium,,,,GAPDH,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"GAPDH (LN2100751, 1:1000, Labned)"
ERBB3 Y1197,antibodies,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,True,0.33,Medium,,,,ERBB3 Y1197,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies recognizing ERRB3 Y1197, ERBB3, EPHA2 S897... were from Cell Signaling"
ERBB3,antibodies,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,True,0.33,Medium,,,,ERBB3,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies recognizing ERRB3 Y1197, ERBB3, EPHA2 S897... were from Cell Signaling"
EPHA2 S897,antibodies,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,True,0.33,Medium,,,,EPHA2 S897,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies recognizing ERRB3 Y1197, ERBB3, EPHA2 S897... were from Cell Signaling"
NDRG1 T346,antibodies,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,True,0.33,Medium,,,,NDRG1 T346,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies recognizing... NDRG1 T346, Akt S473... were from Cell Signaling"
Akt S473,antibodies,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,True,0.33,Medium,,,,Akt S473,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies recognizing... NDRG1 T346, Akt S473, Akt T308... were from Cell Signaling"
Akt T308,antibodies,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,True,0.33,Medium,,,,Akt T308,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies recognizing... Akt S473, Akt T308, Akt... were from Cell Signaling"
Akt,antibodies,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,True,0.33,Medium,,,,Akt,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies recognizing... Akt T308, Akt, p70S6K T389... were from Cell Signaling"
p70S6K T389,antibodies,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,True,0.33,Medium,,,,p70S6K T389,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies recognizing... Akt, p70S6K T389, p70S6K... were from Cell Signaling"
p70S6K,antibodies,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,True,0.33,Medium,,,,p70S6K,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies recognizing... p70S6K T389, p70S6K, ribosomal S6 S240/244... were from Cell Signaling"
ribosomal S6 S240/244,antibodies,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,True,0.33,Medium,,,,ribosomal S6 S240/244,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies recognizing... p70S6K, ribosomal S6 S240/244, S6... were from Cell Signaling"
S6,antibodies,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,True,0.33,Medium,,,,S6,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies recognizing... ribosomal S6 S240/244, S6, IGF1R Y1135/36/IR Y1150/51... were from Cell Signaling"
IGF1R Y1135/36/IR Y1150/51,antibodies,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,True,0.33,Medium,,,,IGF1R Y1135/36/IR Y1150/51,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies recognizing... S6, IGF1R Y1135/36/IR Y1150/51, IGF1R... were from Cell Signaling"
IGF1R,antibodies,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,True,0.33,Medium,,,,IGF1R,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies recognizing... IGF1R Y1135/36/IR Y1150/51, IGF1R, FOXO1/3a T24/T32... were from Cell Signaling"
FOXO1/3a T24/T32,antibodies,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,True,0.33,Medium,,,,FOXO1/3a T24/T32,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies recognizing... IGF1R, FOXO1/3a T24/T32, and FOXO3 were from Cell Signaling"
FOXO3,antibodies,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,True,0.33,Medium,,,,FOXO3,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies recognizing... FOXO1/3a T24/T32, and FOXO3 were from Cell Signaling"
EPHA2,antibodies,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,True,0.33,Medium,,,,EPHA2,,,,,,,,,,,,,,,,,,,,,,,,,,,,Other antibodies included EPHA2 (Santa Cruz)
secreted form of NRG1,antibodies,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,True,0.33,Medium,,,,secreted form of NRG1,,,,,,,,,,,,,,,,,,,,,,,,,,,,Other antibodies included... secreted form of NRG1 (R&D Systems)
NDRG1,antibodies,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,True,0.33,Medium,,,,NDRG1,,,,,,,,,,,,,,,,,,,,,,,,,,,,Other antibodies included... NDRG1 (Abcam)
GAPDH,antibodies,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,True,0.33,Medium,,,,GAPDH,,,,,,,,,,,,,,,,,,,,,,,,,,,,Other antibodies included... and GAPDH (EMD Millipore)
STING,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,True,0.33,Medium,,,,STING,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"STING (13647S, Cell Signaling Technology)"
TBK1,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,True,0.33,Medium,,,,TBK1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"TBK1 (3504T, Cell Signaling Technology)"
p-TBK1,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,True,0.33,Medium,,,,p-TBK1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"p-TBK1 (s172) (5483T, Cell Signaling Technology)"
IRF3,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,True,0.33,Medium,,,,IRF3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"IRF3 (MA5-32348, Invitrogen, Thermo Fisher Scientific)"
p-IRF3,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,True,0.33,Medium,,,,p-IRF3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"p-IRF3 (4947S, Cell Signaling Technology)"
NF-κB,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,True,0.33,Medium,,,,NF-κB,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"NF-κB (ab16502, Abcam)"
p-NF-κB,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,True,0.33,Medium,,,,p-NF-κB,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"p–NF-κB (3033S, Cell Signaling Technology)"
PD-L1,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,True,0.33,Medium,,,,PD-L1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"PD-L1 (ab213480, Abcam, 66248-1-Ig, Proteintech)"
GAPDH,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,True,0.33,Medium,,,,GAPDH,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"GAPDH (SC-32233, Santa Cruz Biotechnology)"
vinculin,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,True,0.33,Medium,,,,vinculin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"vinculin (4650S, Cell Signaling Technology)"
Foxp3,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,True,0.33,Medium,,,,Foxp3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Foxp3 (ab215206, Abcam)"
CD20,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,True,0.33,Medium,,,,CD20,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"CD20 (BS-0080R, Bioss)"
CD3,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,True,0.33,Medium,,,,CD3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"CD3 (ab16669, Abcam)"
CD4,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,True,0.33,Medium,,,,CD4,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"CD4 (ab183685, Abcam)"
Iba1,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,True,0.33,Medium,,,,Iba1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Iba1 (019-19741, Thermo Fisher Scientific)"
iNOS,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,True,0.33,Medium,,,,iNOS,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"iNOS (ab15323, Abcam)"
mannose receptor,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,True,0.33,Medium,,,,mannose receptor,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"mannose receptor (ab64693, Abcam)"
p-H3,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,True,0.33,Medium,,,,p-H3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"p-H3 (ser10) (9701s, Cell Signaling Technology)"
cleaved caspase 3,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,True,0.33,Medium,,,,cleaved caspase 3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"cleaved caspase 3 (9661S, Cell Signaling Technology)"
cleaved PARP,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,True,0.33,Medium,,,,cleaved PARP,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"cleaved PARP (9488S, Cell Signaling Technology)"
PD-1,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,True,0.33,Medium,,,,PD-1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti–PD-1 (ab214421, Abcam; 66220-1-Ig, Proteintech) antibodies"
NF1,antibodies,PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.9,Experimental Usage,True,0.33,Medium,,,,NF1,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Western blotting and an antibody specific for NF1 (Abcam, Cambridge, United Kingdom; ab238142)"
ATRX,antibodies,PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.9,Experimental Usage,True,0.33,Medium,,,,ATRX,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Primary ATRX antibody was from Sigma-Aldrich (HPA001906) and was used at 1:200 dilution
CD3,antibodies,PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.9,Experimental Usage,True,0.33,Medium,,,,CD3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies were incubated at 4 °C overnight: CD3 (Dako, A0452, 1:200)"
GZMB,antibodies,PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.9,Experimental Usage,True,0.33,Medium,,,,GZMB,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"GZMB (Leica, PA0291, ready to use)"
CD68,antibodies,PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.9,Experimental Usage,True,0.33,Medium,,,,CD68,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"CD68 (Sigma, HPA048982, 1:2,000)"
Merlin,antibodies,PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,0.9,Experimental Usage,True,0.33,Medium,,,,Merlin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"The antibodies used in the study included: Merlin (1:1000), pMerlin (1:500), HDAC1 (1:1000) and PDLIM2 (1:500) from Cell Signaling Technology"
phospho-Merlin,antibodies,PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,0.9,Experimental Usage,True,0.33,Medium,,,,phospho-Merlin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"The antibodies used in the study included: Merlin (1:1000), pMerlin (1:500), HDAC1 (1:1000) and PDLIM2 (1:500) from Cell Signaling Technology"
HDAC1,antibodies,PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,0.9,Experimental Usage,True,0.33,Medium,,,,HDAC1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"The antibodies used in the study included: Merlin (1:1000), pMerlin (1:500), HDAC1 (1:1000) and PDLIM2 (1:500) from Cell Signaling Technology"
PDLIM2,antibodies,PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,0.9,Experimental Usage,True,0.33,Medium,,,,PDLIM2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"The antibodies used in the study included: Merlin (1:1000), pMerlin (1:500), HDAC1 (1:1000) and PDLIM2 (1:500) from Cell Signaling Technology"
PDLIM2,antibodies,PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,0.9,Experimental Usage,True,0.33,Medium,,,,PDLIM2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,PDLIM2 (1:500) from Santa Cruz Biotechnology and GAPDH (1:50.000) from Millipore
GAPDH,antibodies,PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,0.9,Experimental Usage,True,0.33,Medium,,,,GAPDH,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,PDLIM2 (1:500) from Santa Cruz Biotechnology and GAPDH (1:50.000) from Millipore
Merlin,antibodies,PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.9,Experimental Usage,True,0.33,Medium,,,,Merlin,,,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-Merlin (clone A-19 and C-18, 1:50, Santa Cruz Biotechnology, Heidelberg, Germany; or HPA003097, 1:100, Atlas Antibodies"
GFP,antibodies,PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.9,Experimental Usage,True,0.33,Medium,,,,GFP,,,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-GFP (A11122, 1:500, Thermo Fisher, Schwerte, Germany)"
Ki67,antibodies,PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.9,Experimental Usage,True,0.33,Medium,,,,Ki67,,,,,,,,,,,,,,,,,,,,,,,,,,,,"anti Ki67 (15580, 1:500, Abcam, Cambridge, UK)"
phospho-Histone H3,antibodies,PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.9,Experimental Usage,True,0.33,Medium,,,,phospho-Histone H3,,,,,,,,,,,,,,,,,,,,,,,,,,,,"anti phospho-Histone H3 (pH3-Ser10, 06–570, 1:1000, Millipore, Darmstadt, Germany)"
phospho S518-Merlin,antibodies,PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.9,Experimental Usage,True,0.33,Medium,,,,phospho S518-Merlin,,,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-phospho S518-Merlin 1:1000, and anti-cyclophilin B 1:4000, Abcam, Cambridge, UK"
cyclophilin B,antibodies,PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.9,Experimental Usage,True,0.33,Medium,,,,cyclophilin B,,,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-phospho S518-Merlin 1:1000, and anti-cyclophilin B 1:4000, Abcam, Cambridge, UK"
MAF,antibodies,PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.9,Experimental Usage,True,0.33,Medium,,,,MAF,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Tumor paraffin sections stained for MAF (Imgenex), pS6, pERK (Cell Signaling), and DEPTOR (Novus)"
pS6,antibodies,PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.9,Experimental Usage,True,0.33,Medium,,,,pS6,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Tumor paraffin sections stained for MAF (Imgenex), pS6, pERK (Cell Signaling), and DEPTOR (Novus)"
pERK,antibodies,PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.9,Experimental Usage,True,0.33,Medium,,,,pERK,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Tumor paraffin sections stained for MAF (Imgenex), pS6, pERK (Cell Signaling), and DEPTOR (Novus)"
DEPTOR,antibodies,PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.9,Experimental Usage,True,0.33,Medium,,,,DEPTOR,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Tumor paraffin sections stained for MAF (Imgenex), pS6, pERK (Cell Signaling), and DEPTOR (Novus)"
SOX9,antibodies,PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.9,Experimental Usage,True,0.33,Medium,,,,SOX9,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Membranes were probed with antibodies for MAF (Imgenex), SOX9 (Santa Cruz), S100β (Dako)"
S100β,antibodies,PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.9,Experimental Usage,True,0.33,Medium,,,,S100β,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies used were S100β (Dako), MBP (Chemicon), and BLBP (Millipore)"
MBP,antibodies,PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.9,Experimental Usage,True,0.33,Medium,,,,MBP,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies used were S100β (Dako), MBP (Chemicon), and BLBP (Millipore)"
BLBP,antibodies,PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.9,Experimental Usage,True,0.33,Medium,,,,BLBP,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies used were S100β (Dako), MBP (Chemicon), and BLBP (Millipore)"
cleaved-caspase 3,antibodies,PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.9,Experimental Usage,True,0.33,Medium,,,,cleaved-caspase 3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Membranes were probed with antibodies for MAF (Imgenex), SOX9 (Santa Cruz), S100β (Dako), MBP (Chemicon), BLBP (Millipore), DEPTOR (Novus), cleaved-caspase 3"
β-ACTIN,antibodies,PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.9,Experimental Usage,True,0.33,Medium,,,,β-ACTIN,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"p473AKT, AKT, and β-ACTIN (Cell Signaling) as a loading control"
CD3,antibodies,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,True,0.33,Medium,,,,CD3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"CD3 (rat; Bio-Rad, MCA1477), GLUT1 (rabbit; Abcam, ab652)"
BrdU,antibodies,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,True,0.33,Medium,,,,BrdU,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"BrdU (rat; Abcam, ab6326), VEGFA (rabbit; ABclonal, A0280)"
SOX2,antibodies,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,True,0.33,Medium,,,,SOX2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"SOX2 (goat; Santa Cruz Biotechnology, sc-17320), and YAP/TAZ (rabbit; Cell Signaling Technology, #8418)"
neurofibromin,antibodies,PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.9,Experimental Usage,True,0.33,Medium,,,,neurofibromin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Blots were probed overnight at 4 °C with either the neurofibromin antibody (Cell Signaling Technologies Cat. #: 14623 S; Danvers, MA, USA)"
p75 NGFR,antibodies,PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.9,Experimental Usage,True,0.33,Medium,,,,p75 NGFR,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Schwann cells were isolated from contaminating fibroblasts via p75 NGFR antibody-mediated magnetic cell selection
B-Actin,antibodies,PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,Experimental Usage,True,0.33,Medium,,,,B-Actin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibodies for B-Actin(1:1000, Cat #8457S, Cell Signaling Technologies)"
Vinculin,antibodies,PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,Experimental Usage,True,0.33,Medium,,,,Vinculin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Vinculin(1:30000, Cat #V9264, Sigma Aldrich)"
PTCH1,antibodies,PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,Experimental Usage,True,0.33,Medium,,,,PTCH1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"PTCH1(1:500,Cat#MAB41051, R&D systems)"
APC,antibodies,PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,Experimental Usage,True,0.33,Medium,,,,APC,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"APC(1:500, Cat #15270, Abcam)"
β-catenin,antibodies,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.9,Experimental Usage,True,0.33,Medium,,,,β-catenin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Sections were then incubated overnight at 4°C in a humidified chamber with primary antibody (β-catenin, 1:100, Cell Signaling)"
activated β-catenin,antibodies,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.9,Experimental Usage,True,0.33,Medium,,,,activated β-catenin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"The primary antibodies used in this study were activated β-catenin (1:1000), total β-catenin (1:100), GSK3B (1:1000), AXIN1 (1:1000), and GAPDH (1:2000) (Cell Signaling)"
β-catenin,antibodies,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.9,Experimental Usage,True,0.33,Medium,,,,β-catenin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"The primary antibodies used in this study were activated β-catenin (1:1000), total β-catenin (1:100), GSK3B (1:1000), AXIN1 (1:1000), and GAPDH (1:2000) (Cell Signaling)"
GSK3B,antibodies,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.9,Experimental Usage,True,0.33,Medium,,,,GSK3B,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"The primary antibodies used in this study were activated β-catenin (1:1000), total β-catenin (1:100), GSK3B (1:1000), AXIN1 (1:1000), and GAPDH (1:2000) (Cell Signaling)"
AXIN1,antibodies,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.9,Experimental Usage,True,0.33,Medium,,,,AXIN1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"The primary antibodies used in this study were activated β-catenin (1:1000), total β-catenin (1:100), GSK3B (1:1000), AXIN1 (1:1000), and GAPDH (1:2000) (Cell Signaling)"
GAPDH,antibodies,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.9,Experimental Usage,True,0.33,Medium,,,,GAPDH,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"The primary antibodies used in this study were activated β-catenin (1:1000), total β-catenin (1:100), GSK3B (1:1000), AXIN1 (1:1000), and GAPDH (1:2000) (Cell Signaling)"
beta-Actin,antibodies,PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,0.9,Experimental Usage,True,0.33,Medium,,,,beta-Actin,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Anti-beta-Actin antibody (Santa Cruz Biotechnologies, sc4778, 1/10,000) was used to verify equal protein loading"
vinculin,antibodies,PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,0.9,Experimental Usage,True,0.33,Medium,,,,vinculin,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-vinculin (abcam, ab129002, 1/1000) was used to verify equal protein loading"
CD16/CD32,antibodies,PMID:21681782,10.1002/ajh.22035,Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.,,0.9,Experimental Usage,True,0.33,Medium,,,,CD16/CD32,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Blocking antibody (anti-CD16/CD32) was added to the cell suspensions and incubated 15 min
SOX10,antibodies,PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.9,Experimental Usage,True,0.33,Medium,,,,SOX10,,,,,,,,,,,,,,,,,,,,,,,,,,,,"labeled with primary antibodies including SOX10 to mark schwannoma cells (API 3099, Biocare; labeling validated in schwannoma and melanoma)"
Pericentrin,antibodies,PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.9,Experimental Usage,True,0.33,Medium,,,,Pericentrin,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Pericentrin (PA5-54109, Thermo Fisher Scientific; labeling validated by Pericentrin knockdown) and γTubulin (T5192, Sigma; labeling validated in human and chicken cells) to mark centrosomes"
γTubulin,antibodies,PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.9,Experimental Usage,True,0.33,Medium,,,,γTubulin,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Pericentrin (PA5-54109, Thermo Fisher Scientific; labeling validated by Pericentrin knockdown) and γTubulin (T5192, Sigma; labeling validated in human and chicken cells) to mark centrosomes"
Acetylated Tubulin,antibodies,PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.9,Experimental Usage,True,0.33,Medium,,,,Acetylated Tubulin,,,,,,,,,,,,,,,,,,,,,,,,,,,,"and Acetylated Tubulin to mark cilia (T6793, Sigma; labeling validated in vertebrate and invertebrate organisms)"
CD3,antibodies,PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.9,Experimental Usage,True,0.33,Medium,,,,CD3,,,,,,,,,,,,,,,,,,,,,,,,,,,,"slides were subjected to antigen retrieval and labeled with CD3 (A0452, Agilent Technologies, Santa Clara, CA; labeling validated by over-expression)"
CD68,antibodies,PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.9,Experimental Usage,True,0.33,Medium,,,,CD68,,,,,,,,,,,,,,,,,,,,,,,,,,,,"or CD68 (M0814, Agilent Technologies; labeling validated using human B-cell lymphoma) primary antibodies"
OCT3/4,antibodies,PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.9,Experimental Usage,True,0.33,Medium,,,,OCT3/4,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Pluripotency of hiPSCs was confirmed through immunocytochemistry for pluripotency markers (OCT3/4, NANOG, TRA-1-60 and SSEA-4)"
NANOG,antibodies,PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.9,Experimental Usage,True,0.33,Medium,,,,NANOG,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Pluripotency of hiPSCs was confirmed through immunocytochemistry for pluripotency markers (OCT3/4, NANOG, TRA-1-60 and SSEA-4)"
TRA-1-60,antibodies,PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.9,Experimental Usage,True,0.33,Medium,,,,TRA-1-60,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Pluripotency of hiPSCs was confirmed through immunocytochemistry for pluripotency markers (OCT3/4, NANOG, TRA-1-60 and SSEA-4)"
SSEA-4,antibodies,PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.9,Experimental Usage,True,0.33,Medium,,,,SSEA-4,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Pluripotency of hiPSCs was confirmed through immunocytochemistry for pluripotency markers (OCT3/4, NANOG, TRA-1-60 and SSEA-4)"
IBA1,antibodies,PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.9,Experimental Usage,True,0.33,Medium,,,,IBA1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Cells were next stained with anti-IBA1 antibody (Table S1) in TBS containing 5% donkey serum overnight
MKK3,antibodies,PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.9,Experimental Usage,True,0.33,Medium,,,,MKK3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,incubated at 4 °C overnight in primary antibody; MKK3 (Cell Signaling #5674)
p38,antibodies,PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.9,Experimental Usage,True,0.33,Medium,,,,p38,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,p38 (Cell Signaling #9219)
phospho-p38,antibodies,PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.9,Experimental Usage,True,0.33,Medium,,,,phospho-p38,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,phospho-p38 (Cell Signaling # 4511)
phospho-ERK1/2,antibodies,PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.9,Experimental Usage,True,0.33,Medium,,,,phospho-ERK1/2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,phospho-ERK1/2 (Cell Signaling #9101)
β-Actin,antibodies,PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.9,Experimental Usage,True,0.33,Medium,,,,β-Actin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,β-Actin (Cell Signaling #3700)
Sox10,antibodies,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,Experimental Usage,True,0.33,Medium,,,,Sox10,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Sox10 (Goat, Santa Cruz Biotechnology, sc-17342; Rabbit, Abcam ab180862), Krox20 (Rabbit; Covance, PRB-236P)"
BrdU,antibodies,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,Experimental Usage,True,0.33,Medium,,,,BrdU,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"BrdU (Rat; Abcam, ab6326), α-SMA (Mouse; Sigma, clone 1A4, A2547)"
neurofibromin,antibodies,PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.9,Experimental Usage,True,0.33,Medium,,,,neurofibromin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-neurofibromin (#A300; Bethyl Laboratories, Montgomery, TX, USA)"
phospho-Akt,antibodies,PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.9,Experimental Usage,True,0.33,Medium,,,,phospho-Akt,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-phospho-Akt XP (#4060), anti-Akt (#2938S), anti-phospho-Erk XP (#4370), anti-Erk (#4695S; Cell Signaling, Danvers, MA, USA)"
Akt,antibodies,PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.9,Experimental Usage,True,0.33,Medium,,,,Akt,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-phospho-Akt XP (#4060), anti-Akt (#2938S), anti-phospho-Erk XP (#4370), anti-Erk (#4695S; Cell Signaling, Danvers, MA, USA)"
phospho-Erk,antibodies,PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.9,Experimental Usage,True,0.33,Medium,,,,phospho-Erk,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-phospho-Akt XP (#4060), anti-Akt (#2938S), anti-phospho-Erk XP (#4370), anti-Erk (#4695S; Cell Signaling, Danvers, MA, USA)"
Erk,antibodies,PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.9,Experimental Usage,True,0.33,Medium,,,,Erk,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-phospho-Akt XP (#4060), anti-Akt (#2938S), anti-phospho-Erk XP (#4370), anti-Erk (#4695S; Cell Signaling, Danvers, MA, USA)"
CD31,antibodies,PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.9,Experimental Usage,True,0.33,Medium,,,,CD31,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-phospho-endothelial nitric oxide synthase (eNOS) (612392) and FITC-anti-CD31 (BD Laboratories, San Jose, CA, USA)"
CD11b,antibodies,PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.9,Experimental Usage,True,0.33,Medium,,,,CD11b,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"incubated with anti-mouse CD11b antibodies coupled to magnetic beads (Miltenyi Biotech, Bergisch Gladbach, Germany)"
merlin,antibodies,PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.9,Experimental Usage,True,0.33,Medium,,,,merlin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Immunoblotting analysis was performed with antibodies specific for merlin (# HPA003097, Sigma-Aldrich"
p53,antibodies,PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.9,Experimental Usage,True,0.33,Medium,,,,p53,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"p53 (# P6874, Sigma-Aldrich; # 2524, Cell Signaling)"
MDM2,antibodies,PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.9,Experimental Usage,True,0.33,Medium,,,,MDM2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"MDM2 (# M43084 and # SAB4300601, Sigma-Aldrich)"
cyclinD1,antibodies,PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.9,Experimental Usage,True,0.33,Medium,,,,cyclinD1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"cyclinD1 (# C7464, Sigma-Aldrich)"
caspase-3,antibodies,PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.9,Experimental Usage,True,0.33,Medium,,,,caspase-3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"caspase-3 (# 9662, Cell Signaling)"
GFAP,antibodies,PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.9,Experimental Usage,True,0.33,Medium,,,,GFAP,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Invitrogen (Rat anti-GFAP)
p-PKA substrate,antibodies,PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.9,Experimental Usage,True,0.33,Medium,,,,p-PKA substrate,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Cell Signaling Technology (p-PKA substrate, pan-AKT and pS473-AKT)"
AKT,antibodies,PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.9,Experimental Usage,True,0.33,Medium,,,,AKT,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Cell Signaling Technology (p-PKA substrate, pan-AKT and pS473-AKT)"
pS473-AKT,antibodies,PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.9,Experimental Usage,True,0.33,Medium,,,,pS473-AKT,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Cell Signaling Technology (p-PKA substrate, pan-AKT and pS473-AKT)"
CXCR4,antibodies,PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.9,Experimental Usage,True,0.33,Medium,,,,CXCR4,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Leinco (pan-CXCR4)
phosphorylated CXCR4,antibodies,PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.9,Experimental Usage,True,0.33,Medium,,,,phosphorylated CXCR4,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Antibody directed against phosphorylated CXCR4 (pCXCR4) was developed in our lab
P-glycoprotein,antibodies,PMID:40862755,10.3390/cells14161276,Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures.,,0.9,Experimental Usage,True,0.33,Medium,,,,P-glycoprotein,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Anti-P-glycoprotein primary antibody and Cy3-conjugated secondary antibody were purchased from Abcam (Cambridge, UK; ab170904) and Jackson ImmunoResearch"
S100,antibodies,PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.9,Experimental Usage,True,0.33,Medium,,,,S100,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"primary antibody (S100 (Santa Cruz 1:100), Ki67 (Novocastra 1:200))"
Ki67,antibodies,PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.9,Experimental Usage,True,0.33,Medium,,,,Ki67,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"primary antibody (S100 (Santa Cruz 1:100), Ki67 (Novocastra 1:200))"
p-AKT S473,antibodies,PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.9,Experimental Usage,True,0.33,Medium,,,,p-AKT S473,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,The primary antibodies used in this study were: p-AKT S473 (Cell Signaling 1:100)
p-4EBP,antibodies,PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.9,Experimental Usage,True,0.33,Medium,,,,p-4EBP,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,p-4EBP (Cell Signaling 1:500)
p-ERK,antibodies,PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.9,Experimental Usage,True,0.33,Medium,,,,p-ERK,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,p-ERK (Cell Signaling 1:1000)
GAPDH,antibodies,PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.9,Experimental Usage,True,0.33,Medium,,,,GAPDH,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,GAPDH (Cell Signaling 1:2000)
RB1,antibodies,PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.9,Experimental Usage,True,0.33,Medium,,,,RB1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"p-RB1-S807/811 (1:1000, no. 8516) and RB1 (no. 9309 and no. 9313, 1:500) from Cell Signaling Technology"
RB1,antibodies,PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.9,Experimental Usage,True,0.33,Medium,,,,RB1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"p-RB1-S807/811 (1:1000, no. 8516) and RB1 (no. 9309 and no. 9313, 1:500) from Cell Signaling Technology"
p16,antibodies,PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.9,Experimental Usage,True,0.33,Medium,,,,p16,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"human p16 (ab108349, 1:1000) and GAPDH (1:5000, no. Ab8245) from Abcam"
GAPDH,antibodies,PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.9,Experimental Usage,True,0.33,Medium,,,,GAPDH,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"human p16 (ab108349, 1:1000) and GAPDH (1:5000, no. Ab8245) from Abcam"
p16,antibodies,PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.9,Experimental Usage,True,0.33,Medium,,,,p16,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"mouse p16 (sc-1207, 1:200) from Santa Cruz Biotechnology"
FOXR2,antibodies,PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.9,Experimental Usage,True,0.33,Medium,,,,FOXR2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Immunohistochemistry (IHC) for FOXR2 (1:100, SIGMA) was performed"
GAPDH,antibodies,PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.9,Experimental Usage,True,0.33,Medium,,,,GAPDH,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,probed with antibodies against FOXR2 (SIGMA) and GAPDH (Cell Signaling Tech.)
CNPase,antibodies,PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.9,Experimental Usage,True,0.33,Medium,,,,CNPase,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Immunofluorescence on tissue sections and cell lines with antibodies probing FOXR2 (SIGMA) and CNPase (Santa Cruz)
Nuclear Pore Complex Proteins,antibodies,PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,Experimental Usage,True,0.33,Medium,,,,Nuclear Pore Complex Proteins,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Nuclei were then stained with 1–1.5ug (depending on pellet size) of TotalSeq™ anti-Nuclear Pore Complex Proteins Hashtag Antibody's (B0451, B0452, B0453, or B0457)"
Nuclear Pore Complex Proteins,antibodies,PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,Experimental Usage,True,0.33,Medium,,,,Nuclear Pore Complex Proteins,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Nuclei were then stained with 1–1.5ug (depending on pellet size) of TotalSeq™ anti-Nuclear Pore Complex Proteins Hashtag Antibody's (B0451, B0452, B0453, or B0457)"
Nuclear Pore Complex Proteins,antibodies,PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,Experimental Usage,True,0.33,Medium,,,,Nuclear Pore Complex Proteins,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Nuclei were then stained with 1–1.5ug (depending on pellet size) of TotalSeq™ anti-Nuclear Pore Complex Proteins Hashtag Antibody's (B0451, B0452, B0453, or B0457)"
Nuclear Pore Complex Proteins,antibodies,PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,Experimental Usage,True,0.33,Medium,,,,Nuclear Pore Complex Proteins,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Nuclei were then stained with 1–1.5ug (depending on pellet size) of TotalSeq™ anti-Nuclear Pore Complex Proteins Hashtag Antibody's (B0451, B0452, B0453, or B0457)"
S100β,antibodies,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.9,Experimental Usage,True,0.33,Medium,,,,S100β,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"S100β- Alexa Fluor 647 (Abcam, ab196175)"
AHR,antibodies,PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,0.9,Experimental Usage,True,0.33,Medium,,,,AHR,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibody for Aryl hydrocarbon receptor (AHR, #H-211)"
CD31,antibodies,PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,,0.9,Experimental Usage,True,0.33,Medium,,,,CD31,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Anti-CD31 (Abcam, ab7388) for vasculature"
S100B,antibodies,PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,,0.9,Experimental Usage,True,0.33,Medium,,,,S100B,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Anti-S100B (Atlas Antibodies, HPA015768-100UL) antibodies for S100B protein"
phospho-S6 (Ser240/244),antibodies,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,True,0.33,Medium,,,,phospho-S6 (Ser240/244),,,,,,,,,,,,,,,,,,,,,,,,,,,,"co-incubation with AlexaFlour488 conjugated-pS6 (Ser240/244) antibody (Cell Signaling Technology; Beverly, MA)"
phospho-S6 (S240/244),antibodies,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,True,0.33,Medium,,,,phospho-S6 (S240/244),,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies for phospho-S6 (S240/244), S6, phospho-p70 S6K (T389)"
S6,antibodies,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,True,0.33,Medium,,,,S6,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies for phospho-S6 (S240/244), S6, phospho-p70 S6K (T389)"
phospho-p70 S6K (T389),antibodies,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,True,0.33,Medium,,,,phospho-p70 S6K (T389),,,,,,,,,,,,,,,,,,,,,,,,,,,,"phospho-p70 S6K (T389), p70 S6K, phospho-Akt (S473)"
p70 S6K,antibodies,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,True,0.33,Medium,,,,p70 S6K,,,,,,,,,,,,,,,,,,,,,,,,,,,,"p70 S6K, phospho-Akt (S473), Akt"
phospho-Akt (S473),antibodies,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,True,0.33,Medium,,,,phospho-Akt (S473),,,,,,,,,,,,,,,,,,,,,,,,,,,,"phospho-Akt (S473), Akt, phospho-NDRG1 (T346)"
Akt,antibodies,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,True,0.33,Medium,,,,Akt,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Akt, phospho-NDRG1 (T346), SGK1"
phospho-NDRG1 (T346),antibodies,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,True,0.33,Medium,,,,phospho-NDRG1 (T346),,,,,,,,,,,,,,,,,,,,,,,,,,,,"phospho-NDRG1 (T346), SGK1, phospho-PAK1 (S144)"
SGK1,antibodies,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,True,0.33,Medium,,,,SGK1,,,,,,,,,,,,,,,,,,,,,,,,,,,,"SGK1, phospho-PAK1 (S144), PAK1"
phospho-PAK1 (S144),antibodies,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,True,0.33,Medium,,,,phospho-PAK1 (S144),,,,,,,,,,,,,,,,,,,,,,,,,,,,"phospho-PAK1 (S144), PAK1, and 4EBP1"
PAK1,antibodies,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,True,0.33,Medium,,,,PAK1,,,,,,,,,,,,,,,,,,,,,,,,,,,,"PAK1, and 4EBP1 were from Cell Signaling Technology"
4EBP1,antibodies,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,True,0.33,Medium,,,,4EBP1,,,,,,,,,,,,,,,,,,,,,,,,,,,,"PAK1, and 4EBP1 were from Cell Signaling Technology"
NDRG1,antibodies,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,True,0.33,Medium,,,,NDRG1,,,,,,,,,,,,,,,,,,,,,,,,,,,,"NDRG1 (Abcam; Cambridge, MA)"
Rac1,antibodies,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,True,0.33,Medium,,,,Rac1,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Rac1 (BD Biosciences; San Jose, CA)"
GAPDH,antibodies,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,Experimental Usage,True,0.33,Medium,,,,GAPDH,,,,,,,,,,,,,,,,,,,,,,,,,,,,GAPDH (EMD Millipore)
Pak1,antibodies,PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.9,Experimental Usage,True,0.33,Medium,,,,Pak1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,The antibodies used in this study include Pak1; Pak2; Mek1/2... (Cell Signaling Technology)
Pak2,antibodies,PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.9,Experimental Usage,True,0.33,Medium,,,,Pak2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,The antibodies used in this study include Pak1; Pak2; Mek1/2... (Cell Signaling Technology)
Mek1/2,antibodies,PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.9,Experimental Usage,True,0.33,Medium,,,,Mek1/2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,The antibodies used in this study include Pak1; Pak2; Mek1/2... (Cell Signaling Technology)
Erk1/2,antibodies,PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.9,Experimental Usage,True,0.33,Medium,,,,Erk1/2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,The antibodies used in this study include... Erk1/2... (Cell Signaling Technology)
Akt,antibodies,PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.9,Experimental Usage,True,0.33,Medium,,,,Akt,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,The antibodies used in this study include... Akt... (Cell Signaling Technology)
GST,antibodies,PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.9,Experimental Usage,True,0.33,Medium,,,,GST,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,The antibodies used in this study include... GST (Santa Cruz Biotechnology)
β-actin,antibodies,PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.9,Experimental Usage,True,0.33,Medium,,,,β-actin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,The antibodies used in this study include... β-actin (Sigma)
DUSP6,antibodies,PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,True,0.33,Medium,,,,DUSP6,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Antibodies against DUSP6 (# ab76310) were from Abcam
cyclin D1,antibodies,PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,True,0.33,Medium,,,,cyclin D1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Antibodies against cyclin D1 (sc-718 and sc-8396) were from Santa Cruz Biotechnology
cyclin D1,antibodies,PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,True,0.33,Medium,,,,cyclin D1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Antibodies against cyclin D1 (sc-718 and sc-8396) were from Santa Cruz Biotechnology
Ki-67,antibodies,PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,True,0.33,Medium,,,,Ki-67,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary antibody, anti-Ki-67 (1:200 dilution; # Ab16667, lot number GR3185488–1, Abcam)"
panendothelial cell antigen,antibodies,PMID:24465906,10.1371/journal.pone.0086115,"Multiscale, converging defects of macro-porosity, microstructure and matrix mineralization impact long bone fragility in NF1.",,0.9,Experimental Usage,True,0.33,Medium,,,,panendothelial cell antigen,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"panendothelial cell antigen (550563, BD Pharmingen, USA) and anti-ratAlexa555 (A11081, Invitrogen, USA)"
S100β,antibodies,PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,Experimental Usage,True,0.33,Medium,,,,S100β,,,,,,,,,,,,,,,,,,,,,,,,,,,,"incubated overnight at 4°C with antibody: anti-S100β, Dako, Carpinteria, CA"
Ki67,antibodies,PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,Experimental Usage,True,0.33,Medium,,,,Ki67,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Ki67 (Novacastra Leica Microsystems, Buffalo Grove, IL)"
P-Stat3 (Y705),antibodies,PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,Experimental Usage,True,0.33,Medium,,,,P-Stat3 (Y705),,,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-P-Stat3 (Y705), anti-cleaved caspase 3, β-catenin (Cell Signaling, Danvers, MA)"
cleaved caspase 3,antibodies,PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,Experimental Usage,True,0.33,Medium,,,,cleaved caspase 3,,,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-P-Stat3 (Y705), anti-cleaved caspase 3, β-catenin (Cell Signaling, Danvers, MA)"
β-catenin,antibodies,PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,Experimental Usage,True,0.33,Medium,,,,β-catenin,,,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-P-Stat3 (Y705), anti-cleaved caspase 3, β-catenin (Cell Signaling, Danvers, MA)"
P-Jak2,antibodies,PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,Experimental Usage,True,0.33,Medium,,,,P-Jak2,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Western blots were performed using antibodies recognizing P-Jak2, Jak2, P-Stat3, Stat3, P-β-catenin, β-catenin, P-GSK3β, GSK3β, and β-actin (Cell Signaling, MA)"
Jak2,antibodies,PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,Experimental Usage,True,0.33,Medium,,,,Jak2,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Western blots were performed using antibodies recognizing P-Jak2, Jak2, P-Stat3, Stat3, P-β-catenin, β-catenin, P-GSK3β, GSK3β, and β-actin (Cell Signaling, MA)"
P-Stat3,antibodies,PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,Experimental Usage,True,0.33,Medium,,,,P-Stat3,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Western blots were performed using antibodies recognizing P-Jak2, Jak2, P-Stat3, Stat3, P-β-catenin, β-catenin, P-GSK3β, GSK3β, and β-actin (Cell Signaling, MA)"
Stat3,antibodies,PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,Experimental Usage,True,0.33,Medium,,,,Stat3,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Western blots were performed using antibodies recognizing P-Jak2, Jak2, P-Stat3, Stat3, P-β-catenin, β-catenin, P-GSK3β, GSK3β, and β-actin (Cell Signaling, MA)"
P-β-catenin,antibodies,PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,Experimental Usage,True,0.33,Medium,,,,P-β-catenin,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Western blots were performed using antibodies recognizing P-Jak2, Jak2, P-Stat3, Stat3, P-β-catenin, β-catenin, P-GSK3β, GSK3β, and β-actin (Cell Signaling, MA)"
P-GSK3β,antibodies,PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,Experimental Usage,True,0.33,Medium,,,,P-GSK3β,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Western blots were performed using antibodies recognizing P-Jak2, Jak2, P-Stat3, Stat3, P-β-catenin, β-catenin, P-GSK3β, GSK3β, and β-actin (Cell Signaling, MA)"
GSK3β,antibodies,PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,Experimental Usage,True,0.33,Medium,,,,GSK3β,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Western blots were performed using antibodies recognizing P-Jak2, Jak2, P-Stat3, Stat3, P-β-catenin, β-catenin, P-GSK3β, GSK3β, and β-actin (Cell Signaling, MA)"
β-actin,antibodies,PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,Experimental Usage,True,0.33,Medium,,,,β-actin,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Western blots were performed using antibodies recognizing P-Jak2, Jak2, P-Stat3, Stat3, P-β-catenin, β-catenin, P-GSK3β, GSK3β, and β-actin (Cell Signaling, MA)"
CD16/32,antibodies,PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,0.9,Experimental Usage,True,0.33,Medium,,,,CD16/32,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Mouse Fc receptor was blocked by TruStain FcX™ (anti-mouse CD16/32) antibody (BioLegend, Cat# 101320)"
CD31,antibodies,PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,0.9,Experimental Usage,True,0.33,Medium,,,,CD31,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"endothelial, erythroid, and immune cells were gated out by PE-conjugated CD31, Ter119, and CD45 antibodies (BioLegend, Cat# 102410)"
Ter119,antibodies,PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,0.9,Experimental Usage,True,0.33,Medium,,,,Ter119,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"endothelial, erythroid, and immune cells were gated out by PE-conjugated CD31, Ter119, and CD45 antibodies (BioLegend, Cat# 116208)"
CD45,antibodies,PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,0.9,Experimental Usage,True,0.33,Medium,,,,CD45,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"endothelial, erythroid, and immune cells were gated out by PE-conjugated CD31, Ter119, and CD45 antibodies (BioLegend, Cat# 103112)"
α4 integrin,antibodies,PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,0.9,Experimental Usage,True,0.33,Medium,,,,α4 integrin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"antibodies against p75 (Ab 1554; Chemicon) and α 4 integrin (Becton-Dickinson, San Jose, CA)"
BrdU,antibodies,PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,0.9,Experimental Usage,True,0.33,Medium,,,,BrdU,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,cells were stained for BrdU using a flow-cytometry kit (BD Pharmingen; cat#559619)
"Lineage markers (CD3e, CD11b, CD45R/B220, Ly6G/Ly6C, TER-119)",antibodies,PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.",,0.9,Experimental Usage,True,0.33,Medium,,,,"Lineage markers (CD3e, CD11b, CD45R/B220, Ly6G/Ly6C, TER-119)",,,,,,,,,,,,,,,,,,,,,,,,,,,,"Total BM cells were labeled with biotin-conjugated α-Lin Abs, consisting of α-CD3e, α-CD11b, α-CD45R/B220, α-Ly6G/Ly6C, and α-TER-119 Abs"
ERK,antibodies,PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.9,Experimental Usage,True,0.33,Medium,,,,ERK,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies against total ERK, phospho-ERKthr202/tyr204, phospho-MEKser217/221, cleaved PARP, RAD51, BRCA2 and GAPDH were obtained from Cell Signaling Technology"
phospho-ERK,antibodies,PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.9,Experimental Usage,True,0.33,Medium,,,,phospho-ERK,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies against total ERK, phospho-ERKthr202/tyr204, phospho-MEKser217/221, cleaved PARP, RAD51, BRCA2 and GAPDH were obtained from Cell Signaling Technology"
phospho-MEK,antibodies,PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.9,Experimental Usage,True,0.33,Medium,,,,phospho-MEK,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies against total ERK, phospho-ERKthr202/tyr204, phospho-MEKser217/221, cleaved PARP, RAD51, BRCA2 and GAPDH were obtained from Cell Signaling Technology"
cleaved PARP,antibodies,PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.9,Experimental Usage,True,0.33,Medium,,,,cleaved PARP,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies against total ERK, phospho-ERKthr202/tyr204, phospho-MEKser217/221, cleaved PARP, RAD51, BRCA2 and GAPDH were obtained from Cell Signaling Technology"
RAD51,antibodies,PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.9,Experimental Usage,True,0.33,Medium,,,,RAD51,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies against total ERK, phospho-ERKthr202/tyr204, phospho-MEKser217/221, cleaved PARP, RAD51, BRCA2 and GAPDH were obtained from Cell Signaling Technology"
BRCA2,antibodies,PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.9,Experimental Usage,True,0.33,Medium,,,,BRCA2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies against total ERK, phospho-ERKthr202/tyr204, phospho-MEKser217/221, cleaved PARP, RAD51, BRCA2 and GAPDH were obtained from Cell Signaling Technology"
GAPDH,antibodies,PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.9,Experimental Usage,True,0.33,Medium,,,,GAPDH,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies against total ERK, phospho-ERKthr202/tyr204, phospho-MEKser217/221, cleaved PARP, RAD51, BRCA2 and GAPDH were obtained from Cell Signaling Technology"
phospho-ERK,antibodies,PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,,0.9,Experimental Usage,True,0.33,Medium,,,,phospho-ERK,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"podoplanin (clone D2-40, Dako, 1:200), phospho-ERK (#9101, Cell Signaling, 1:250)"
ERK1/2,antibodies,PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,0.9,Experimental Usage,True,0.33,Medium,,,,ERK1/2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Anti-ERK1/2 (p44/42 MAPK (Erk1/2); Cell Signaling Technology; 1:1000)
phospho-ERK1/2,antibodies,PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,0.9,Experimental Usage,True,0.33,Medium,,,,phospho-ERK1/2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,anti-phopho ERK1/2 (Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204); Cell Signaling Technology; 1:1000)
p75/NGFR,antibodies,PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,0.9,Experimental Usage,True,0.33,Medium,,,,p75/NGFR,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-p75/NGFR (C40-1457, Becton–Dickinson) bound to phycoerythrin (PE)"
SOX9,antibodies,PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,0.9,Experimental Usage,True,0.33,Medium,,,,SOX9,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"probed membranes with anti-SOX9 (Santa Cruz Biotechnology, Santa Cruz, CA; 1:700)"
β-actin,antibodies,PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,0.9,Experimental Usage,True,0.33,Medium,,,,β-actin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"then re-probed with anti-β-actin (Cell Signaling Technology, Inc. #4967) as a loading control"
KIF11,antibodies,PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,True,0.33,Medium,,,,KIF11,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,incubated with anti-KIF11 antibody (Proteintech)
KIF15,antibodies,PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,True,0.33,Medium,,,,KIF15,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,anti-KIF15 antibody (Proteintech)
Ki67,antibodies,PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,True,0.33,Medium,,,,Ki67,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Ki67 (Ventana Medical Systems)
α-tubulin,antibodies,PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,True,0.33,Medium,,,,α-tubulin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,anti-α-tubulin (Sigma-Aldrich)
α-tubulin,antibodies,PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,True,0.33,Medium,,,,α-tubulin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,anti-α-tubulin-Alexa488 antibody (Life Technologies)
phospho-AKT (S473),antibodies,PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,True,0.33,Medium,,,,phospho-AKT (S473),Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies against phospho-AKT (S473), total AKT, and monoclonal rabbit anti-phospho-S6K (T389) were from Cell Signaling Technology"
AKT,antibodies,PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,True,0.33,Medium,,,,AKT,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies against phospho-AKT (S473), total AKT, and monoclonal rabbit anti-phospho-S6K (T389) were from Cell Signaling Technology"
S6K1,antibodies,PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,True,0.33,Medium,,,,S6K1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Total S6K1 antibody was used as previously described
CD31,antibodies,PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,True,0.33,Medium,,,,CD31,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Sections were incubated with rat anti-CD31 antibodies (BD bioscience) at 1:40 dilution for 60 min at room temperature
Mib1,antibodies,PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,True,0.33,Medium,,,,Mib1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"For Mib1 detection, paraffin sections were treated with TRS or antigen retrieval followed by a prediluted Mib1 antibody (DAKO)"
Ly6G,antibodies,PMID:35118381,10.1093/noajnl/vdab184,Neutrophil depletion enhanced the ,,0.9,Experimental Usage,True,0.33,Medium,,,,Ly6G,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Depletion of neutrophils via anti-Ly6G antibody or bone marrow suppression using hydroxyurea significantly improved tumor clearance.
CD31,antibodies,PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,Experimental Usage,True,0.33,Medium,,,,CD31,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"CD31 (3528S, 1:100, Cell Signaling)"
Survivin,antibodies,PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,Experimental Usage,True,0.33,Medium,,,,Survivin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Survivin (MA5–15077, 1:200, Invitrogen)"
CENPF,antibodies,PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,Experimental Usage,True,0.33,Medium,,,,CENPF,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"CENPF (PA5–84637, 1:200, Invitrogen)"
H3K27me3,antibodies,PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,Experimental Usage,True,0.33,Medium,,,,H3K27me3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"H3K27me3 (9733S, 1:100, Cell Signaling)"
CENPF,antibodies,PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,Experimental Usage,True,0.33,Medium,,,,CENPF,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"CENPF (ab223847, 1:1000 dilution, Abcam)"
Vinculin,antibodies,PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,Experimental Usage,True,0.33,Medium,,,,Vinculin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Vinculin (ab219649, 1:1000 dilution, Abcam)"
CD34,antibodies,PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,Experimental Usage,True,0.33,Medium,,,,CD34,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,CD34 Santa Cruz Biotechnology CAT#SC-74499; RRID: AB_1120394
S100B,antibodies,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,Experimental Usage,True,0.33,Medium,,,,S100B,,,,,,,,,,,,,,,,,,,,,,,,,,,,"S100B (Ventana, #760-2523, 1:2 dilution)"
pERK,antibodies,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,Experimental Usage,True,0.33,Medium,,,,pERK,,,,,,,,,,,,,,,,,,,,,,,,,,,,"pERK (Cell Signaling Technologies, #4370, 1:1000 dilution)"
ERK,antibodies,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,Experimental Usage,True,0.33,Medium,,,,ERK,,,,,,,,,,,,,,,,,,,,,,,,,,,,"total ERK (Cell Signaling Technologies, #4695, 1:1000 dilution)"
beta tubulin,antibodies,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,Experimental Usage,True,0.33,Medium,,,,beta tubulin,,,,,,,,,,,,,,,,,,,,,,,,,,,,"beta tubulin (Developmental Hybridoma Studies Bank, #E7, 1:10,000 dilution)"
pAKT,antibodies,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,Experimental Usage,True,0.33,Medium,,,,pAKT,,,,,,,,,,,,,,,,,,,,,,,,,,,,"pAKT (Cell Signaling Technologies, #4060, 1:1000 dilution)"
AKT,antibodies,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,Experimental Usage,True,0.33,Medium,,,,AKT,,,,,,,,,,,,,,,,,,,,,,,,,,,,"total AKT (Cell Signaling Technologies, # 4685, 1:1000 dilution)"
pMEK,antibodies,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,Experimental Usage,True,0.33,Medium,,,,pMEK,,,,,,,,,,,,,,,,,,,,,,,,,,,,"pMEK (Cell Signaling Technologies, #9121, 1:1000 dilution)"
MEK,antibodies,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,Experimental Usage,True,0.33,Medium,,,,MEK,,,,,,,,,,,,,,,,,,,,,,,,,,,,"total MEK (Cell Signaling Technologies, #8727, 1:1000 dilution)"
pPAK,antibodies,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,Experimental Usage,True,0.33,Medium,,,,pPAK,,,,,,,,,,,,,,,,,,,,,,,,,,,,"pPAK (Cell Signaling Technologies, #2601, 1:1000 dilution)"
Caspase-3,antibodies,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,Experimental Usage,True,0.33,Medium,,,,Caspase-3,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Caspase-3 (Cell Signaling Technologies, #9662, 1:1000 dilution)"
Caspase-7,antibodies,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,Experimental Usage,True,0.33,Medium,,,,Caspase-7,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Caspase-7 (Cell Signaling Technologies, #9492, 1:1,000 dilution)"
ALDH1A1,antibodies,PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,Experimental Usage,True,0.33,Medium,,,,ALDH1A1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,ALDH1A1 (1:200; ab52492; Abcam)
YAP,antibodies,PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,Experimental Usage,True,0.33,Medium,,,,YAP,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,YAP (1:100; #14074; CST)
TAZ,antibodies,PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,Experimental Usage,True,0.33,Medium,,,,TAZ,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,TAZ (1:100; sc-48805; Santa Cruz)
Ki67,antibodies,PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,Experimental Usage,True,0.33,Medium,,,,Ki67,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Ki67 (1:100; ab15580; Abcam)
Neurofilament,antibodies,PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,Experimental Usage,True,0.33,Medium,,,,Neurofilament,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Neurofilament (1:1000; ab4680; Abcam)
S100,antibodies,PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,Experimental Usage,True,0.33,Medium,,,,S100,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,S100 (pre-diluted; GA504; Dako)
Pan-TEAD,antibodies,PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,Experimental Usage,True,0.33,Medium,,,,Pan-TEAD,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Pan-TEAD (1:1000; #13295; CST)
GAPDH,antibodies,PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,Experimental Usage,True,0.33,Medium,,,,GAPDH,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,GAPDH (1:5000; AB2302; Merck)
CTGF,antibodies,PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,Experimental Usage,True,0.33,Medium,,,,CTGF,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"CTGF (1:500, ab6992, Abcam)"
Actin,antibodies,PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,0.9,Experimental Usage,True,0.33,Medium,,,,Actin,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,An actin immunocytochemistry assay was performed to study the cytoskeletal organization after PMO treatment using Phalloidin (Molecular Probes)
S100,antibodies,PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,0.9,Experimental Usage,True,0.33,Medium,,,,S100,,,,,,,,,,,,,,,,,,,,,,,,,,,,incubated with primary antibodies overnight at 4°C: S100-fluorescein isothiocyanate (FITC) (major protein expressed by C6 cells)
β-tubulin III,antibodies,PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,0.9,Experimental Usage,True,0.33,Medium,,,,β-tubulin III,,,,,,,,,,,,,,,,,,,,,,,,,,,,β-tubulin III-FITC (neurofibroma presence)
Ki67,antibodies,PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,0.9,Experimental Usage,True,0.33,Medium,,,,Ki67,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ki67-FITC (proliferation marker)
Vimentin,antibodies,PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,0.9,Experimental Usage,True,0.33,Medium,,,,Vimentin,,,,,,,,,,,,,,,,,,,,,,,,,,,,Vimentin-antigen presenting cell (APC) (expressed by C6 cells)
Foxp3,antibodies,PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,0.9,Experimental Usage,True,0.33,Medium,,,,Foxp3,,,,,,,,,,,,,,,,,,,,,,,,,,,,Foxp3-APC and CD45 (immune response markers)
CD45,antibodies,PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,0.9,Experimental Usage,True,0.33,Medium,,,,CD45,,,,,,,,,,,,,,,,,,,,,,,,,,,,Foxp3-APC and CD45 (immune response markers)
GFAP,antibodies,PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,0.9,Experimental Usage,True,0.33,Medium,,,,GFAP,,,,,,,,,,,,,,,,,,,,,,,,,,,,"labeled overnight at room temperature with the following conjugated primary antibodies: S100-FITC, Vimentin-FTIC, CD45-APC, Ki67-APC, and GFAP-APC"
DARPP32,antibodies,PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,0.9,Experimental Usage,True,0.33,Medium,,,,DARPP32,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Western blots and immunohistochemistry (IHC) using DARPP32, p-MAPK, total MAPK (Cell Signaling)"
p-MAPK,antibodies,PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,0.9,Experimental Usage,True,0.33,Medium,,,,p-MAPK,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Western blots and immunohistochemistry (IHC) using DARPP32, p-MAPK, total MAPK (Cell Signaling)"
total MAPK,antibodies,PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,0.9,Experimental Usage,True,0.33,Medium,,,,total MAPK,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Western blots and immunohistochemistry (IHC) using DARPP32, p-MAPK, total MAPK (Cell Signaling)"
p-DARPP32,antibodies,PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,0.9,Experimental Usage,True,0.33,Medium,,,,p-DARPP32,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,total MAPK (Cell Signaling) and p-DARPP32 (Abcam) antibodies
merlin,antibodies,PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,0.9,Experimental Usage,True,0.33,Medium,,,,merlin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Subsequently, the blot was incubated with a 1:1000 dilution of anti-merlin antibody overnight at 4°C"
"HLA-A,B,C",antibodies,PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,Experimental Usage,True,0.33,Medium,,,,"HLA-A,B,C",,,,,,,,,,,,,,,,,,,,,,,,,,,,"following Biolegend antibodies and stains: anti-human HLA-A,B,C (311405)"
H-2,antibodies,PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,Experimental Usage,True,0.33,Medium,,,,H-2,,,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-mouse H-2 (125505), Mouse IgG1, κ Isotype Ctrl (FC) Antibody"
human nuclei,antibodies,PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,Experimental Usage,True,0.33,Medium,,,,human nuclei,,,,,,,,,,,,,,,,,,,,,,,,,,,,"using the following antibodies: human nuclei (ab254080, Abcam)"
Ki-67,antibodies,PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,Experimental Usage,True,0.33,Medium,,,,Ki-67,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Ki-67 (RM9106S1, Fisher Scientific), S-100 b (sc-393919, Santa Cruz Biotechnology)"
S-100 b,antibodies,PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,Experimental Usage,True,0.33,Medium,,,,S-100 b,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Ki-67 (RM9106S1, Fisher Scientific), S-100 b (sc-393919, Santa Cruz Biotechnology)"
H3K27me3,antibodies,PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,Experimental Usage,True,0.33,Medium,,,,H3K27me3,,,,,,,,,,,,,,,,,,,,,,,,,,,,"H3K27me3 (9733, Cell Signaling Technologies), pERK (4370, Cell Signaling Technologies)"
pERK,antibodies,PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,Experimental Usage,True,0.33,Medium,,,,pERK,,,,,,,,,,,,,,,,,,,,,,,,,,,,"H3K27me3 (9733, Cell Signaling Technologies), pERK (4370, Cell Signaling Technologies)"
Phospho-ERK1/2,antibodies,PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,0.9,Experimental Usage,True,0.33,Medium,,,,Phospho-ERK1/2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"using an anti-Phospho-ERK1/2 antibody (Cell Signaling cat#9101, dilution 1:1000)"
ERK1/2,antibodies,PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,0.9,Experimental Usage,True,0.33,Medium,,,,ERK1/2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"ananti-ERK1/2 antibody (Cell Signaling cat#9102, dilution 1:1000)"
phospho P-Met,antibodies,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.9,Experimental Usage,True,0.33,Medium,,,,phospho P-Met,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies against phospho P-Met, Akt, P-Akt, and MAPK (1:1,000 dilution), from Cell Signaling"
Akt,antibodies,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.9,Experimental Usage,True,0.33,Medium,,,,Akt,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies against phospho P-Met, Akt, P-Akt, and MAPK (1:1,000 dilution), from Cell Signaling"
P-Akt,antibodies,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.9,Experimental Usage,True,0.33,Medium,,,,P-Akt,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies against phospho P-Met, Akt, P-Akt, and MAPK (1:1,000 dilution), from Cell Signaling"
MAPK,antibodies,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.9,Experimental Usage,True,0.33,Medium,,,,MAPK,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies against phospho P-Met, Akt, P-Akt, and MAPK (1:1,000 dilution), from Cell Signaling"
c-Met,antibodies,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.9,Experimental Usage,True,0.33,Medium,,,,c-Met,,,,,,,,,,,,,,,,,,,,,,,,,,,,"and against c-Met, P-Erk and β-actin (1:1,000), from Santa Cruz"
P-Erk,antibodies,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.9,Experimental Usage,True,0.33,Medium,,,,P-Erk,,,,,,,,,,,,,,,,,,,,,,,,,,,,"and against c-Met, P-Erk and β-actin (1:1,000), from Santa Cruz"
β-actin,antibodies,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.9,Experimental Usage,True,0.33,Medium,,,,β-actin,,,,,,,,,,,,,,,,,,,,,,,,,,,,"and against c-Met, P-Erk and β-actin (1:1,000), from Santa Cruz"
p53,antibodies,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.9,Experimental Usage,True,0.33,Medium,,,,p53,,,,,,,,,,,,,,,,,,,,,,,,,,,,"and p53 (1:500, NCL-p53-505, Novocastra) were used"
CD24,antibodies,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.9,Experimental Usage,True,0.33,Medium,,,,CD24,,,,,,,,,,,,,,,,,,,,,,,,,,,,1 × 106 MM cells were incubated with or without 10 μL of anti-CD24 FITC-labeled antibody (BD Biosciences)
CD3,antibodies,PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,Experimental Usage,True,0.33,Medium,,,,CD3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Each specimen was stained for hematoxylin and eosin (H&E), CD3, CD8, CD11c, CD19, CD163, CSF1R, FOXP3..."
CD8,antibodies,PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,Experimental Usage,True,0.33,Medium,,,,CD8,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Each specimen was stained for hematoxylin and eosin (H&E), CD3, CD8, CD11c, CD19, CD163, CSF1R, FOXP3..."
CD11c,antibodies,PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,Experimental Usage,True,0.33,Medium,,,,CD11c,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Each specimen was stained for hematoxylin and eosin (H&E), CD3, CD8, CD11c, CD19, CD163, CSF1R, FOXP3..."
CD19,antibodies,PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,Experimental Usage,True,0.33,Medium,,,,CD19,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Each specimen was stained for hematoxylin and eosin (H&E), CD3, CD8, CD11c, CD19, CD163, CSF1R, FOXP3..."
CD163,antibodies,PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,Experimental Usage,True,0.33,Medium,,,,CD163,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Each specimen was stained for hematoxylin and eosin (H&E), CD3, CD8, CD11c, CD19, CD163, CSF1R, FOXP3..."
CSF1R,antibodies,PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,Experimental Usage,True,0.33,Medium,,,,CSF1R,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Each specimen was stained for hematoxylin and eosin (H&E), CD3, CD8, CD11c, CD19, CD163, CSF1R, FOXP3..."
FOXP3,antibodies,PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,Experimental Usage,True,0.33,Medium,,,,FOXP3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Each specimen was stained for hematoxylin and eosin (H&E), CD3, CD8, CD11c, CD19, CD163, CSF1R, FOXP3..."
PD-L1,antibodies,PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,Experimental Usage,True,0.33,Medium,,,,PD-L1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Each specimen was stained for hematoxylin and eosin (H&E), CD3, CD8, CD11c, CD19, CD163, CSF1R, FOXP3, human leukocyte antigen (HLA)-class I, and PD-L1"
Abl,antibodies,PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,0.9,Experimental Usage,True,0.33,Medium,,,,Abl,,,,,,,,,,,,,,,,,,,,,,,,,,,,"equivalent protein (500 µg) was incubated overnight at 4°C with anti-Abl (K12; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA)"
c-abl,antibodies,PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,0.9,Experimental Usage,True,0.33,Medium,,,,c-abl,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Total c-abl protein was detected using an antibody from BD Biosciences (Cat. no. 554148, San Jose, CA, USA)"
TGF-β,antibodies,PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,0.9,Experimental Usage,True,0.33,Medium,,,,TGF-β,,,,,,,,,,,,,,,,,,,,,,,,,,,,"TGF-β neutralizing antibodies were obtained from R&D Systems, Inc. (Cat. no. AF-101-NA) and utilized as suggested by the manufacturer"
neurofibromin,antibodies,PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.9,Experimental Usage,True,0.33,Medium,,,,neurofibromin,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anti-neurofibromin antibody primary WB CST
BrdU,antibodies,PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,Experimental Usage,True,0.33,Medium,,,,BrdU,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"BrdU (1:1000, rat, Abcam, Cambridge, MA)"
S100,antibodies,PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.9,Experimental Usage,True,0.33,Medium,,,,S100,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"IHC was performed using the Avidin/Biotin blocking kit (Vector Labs, SP-2001) staining with antibodies against S100 (1:250 dilution; catalog ab41548, Abcam)"
KI-67,antibodies,PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.9,Experimental Usage,True,0.33,Medium,,,,KI-67,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"staining with antibodies against S100 (1:250 dilution; catalog ab41548, Abcam), KI-67 (prediluted; catalog 790-4286, Ventana)"
COL4A,antibodies,PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.9,Experimental Usage,True,0.33,Medium,,,,COL4A,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"KI-67 (prediluted; catalog 790-4286, Ventana), and COL4A (1:1000 dilution; catalog ab6586, Abcam)"
histone H3 (tri methyl K27),antibodies,PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.9,Experimental Usage,True,0.33,Medium,,,,histone H3 (tri methyl K27),Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Immunolabeling for anti-histone H3 (tri methyl K27) (1:200 dilution; catalog ab6002, Abcam)"
XBP1,antibodies,PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,Experimental Usage,True,0.33,Medium,,,,XBP1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"The sheared chromatin was immunoprecipitated with 5 μg of anti-XBP1 antibodies (Cell Signaling Technology, Danvers, MA, USA)"
GAPDH,antibodies,PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,Experimental Usage,True,0.33,Medium,,,,GAPDH,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"The primary antibodies used in the study include anti-GAPDH (Proteintech Group Inc., Rosemont, IL, USA)"
α-tubulin,antibodies,PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,Experimental Usage,True,0.33,Medium,,,,α-tubulin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-α-tubulin (Proteintech Group Inc., Rosemont, IL, USA)"
XBP1u,antibodies,PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,Experimental Usage,True,0.33,Medium,,,,XBP1u,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-XBP1u (Abcepta, Reservoir Victoria, Australia)"
XBP1s,antibodies,PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,Experimental Usage,True,0.33,Medium,,,,XBP1s,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,anti-XBP1s (Cell Signaling)
Parkin,antibodies,PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,Experimental Usage,True,0.33,Medium,,,,Parkin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-Parkin (Cell Signaling, Danvers, MA, USA)"
PINK1,antibodies,PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,Experimental Usage,True,0.33,Medium,,,,PINK1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-PINK1 (Genetex, Hsinchu, Taiwan)"
LC3B,antibodies,PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,Experimental Usage,True,0.33,Medium,,,,LC3B,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-LC3B (Cell Signaling, Danvers, MA, USA)"
GLUT1,antibodies,PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,Experimental Usage,True,0.33,Medium,,,,GLUT1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-GLUT1 (Proteintech Group Inc., Rosemont, IL, USA) antibodies"
ATP5H,antibodies,PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,Experimental Usage,True,0.33,Medium,,,,ATP5H,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"the primary antibodies, anti-ATP5H (Thermo Fisher Scientific, Waltham, MA, USA)"
LC3,antibodies,PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,Experimental Usage,True,0.33,Medium,,,,LC3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"anti-LC3 antibodies (Cell Signaling, Danvers, MA, USA)"
phospho-RB1 S807/811,antibodies,PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.9,Experimental Usage,True,0.33,Medium,,,,phospho-RB1 S807/811,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"incubated with phospho-RB1 S807/811 antibody (Cell Signaling Technology, no. 8516, 1:1600)"
PD-L1,antibodies,PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.9,Experimental Usage,True,0.33,Medium,,,,PD-L1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,bi-weekly intraperitoneal injections of 10 mg/kg anti-PDL1 antibody (BioXCell BE0101)
merlin,antibodies,PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,0.9,Experimental Usage,True,0.33,Medium,,,,merlin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"The absence of merlin in schwannoma cells was confirmed regularly by Western blot (1:2000, Cat. No. 12888, Cell Signaling Technology)"
Ki-67,antibodies,PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,0.9,Experimental Usage,True,0.33,Medium,,,,Ki-67,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Cells were stained with antibodies specific for Ki-67 (1:800 dilution, Cat. no. 9449, Cell Signaling)"
S462 spheres,advanced_cellular_models,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,spheroid,cell line,MPNST cells,,,,,,,,,,,The culture of S462 spheres followed the protocol in [22]
TAME chips,advanced_cellular_models,PMID:40862755,10.3390/cells14161276,Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,other,cell line,"pNF1 cells, fibroblasts",,,,,,,,,,,We employed 3D cultures grown in the patented microfluidic culture devices called TAME (tissue architecture and microenvironment engineering; Patent# US10227556B2) chips [24] for all experiments
3D rBM overlay model,advanced_cellular_models,PMID:39061138,10.3390/cancers16142498,A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,spheroid,cell line,"Schwann cells, fibroblasts",,,,,,,,,,,We used a 3D rBM overlay model according to previous publications for live-cell imaging by confocal microscopy
embryonic mouse spheres,advanced_cellular_models,PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,spheroid,primary cell,DRG cells,,,,,,,,,,,"Embryonic mouse spheres, dissociated from E12.5 DRG with 0.25% Trypsin 20 min. at 37°C"
K14Cre,animal_models,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.85,Experimental Usage,False,1.00,Medium,K14Cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"K14Cre (Dassule et al. 2000), K14CreERT (Vasioukhin et al. 1999), TyrCreERT2 (Bosenberg et al. 2006)... mice were purchased from the Jackson Laboratory"
K14CreERT,animal_models,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.85,Experimental Usage,False,1.00,Medium,K14CreERT,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"K14Cre (Dassule et al. 2000), K14CreERT (Vasioukhin et al. 1999), TyrCreERT2 (Bosenberg et al. 2006)... mice were purchased from the Jackson Laboratory"
TyrCreERT2,animal_models,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.85,Experimental Usage,False,1.00,Medium,TyrCreERT2,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"K14Cre (Dassule et al. 2000), K14CreERT (Vasioukhin et al. 1999), TyrCreERT2 (Bosenberg et al. 2006)... mice were purchased from the Jackson Laboratory"
R26-rtTA,animal_models,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.85,Experimental Usage,False,1.00,Medium,R26-rtTA,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"R26-rtTA (Belteki et al. 2005), and tetO-DTA (Lee et al. 1998) mice were purchased from the Jackson Laboratory"
tetO-DTA,animal_models,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.85,Experimental Usage,False,1.00,Medium,tetO-DTA,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"R26-rtTA (Belteki et al. 2005), and tetO-DTA (Lee et al. 1998) mice were purchased from the Jackson Laboratory"
K14-Scf,animal_models,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.85,Experimental Usage,False,1.00,Medium,K14-Scf,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,K14-Scf (Kunisada et al. 1998a) was kindly provided by Dr. John Harris (University of Massachusetts Medical School)
Krox20Cre,animal_models,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.85,Experimental Usage,False,1.00,Medium,Krox20Cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Krox20Cre (Voiculescu et al. 2000), DhhCre (Skucas et al. 2013), PLPCreERT2 (Leone et al. 2003)... were described previously"
DhhCre,animal_models,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.85,Experimental Usage,False,1.00,Medium,DhhCre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Krox20Cre (Voiculescu et al. 2000), DhhCre (Skucas et al. 2013), PLPCreERT2 (Leone et al. 2003)... were described previously"
PLPCreERT2,animal_models,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.85,Experimental Usage,False,1.00,Medium,PLPCreERT2,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Krox20Cre (Voiculescu et al. 2000), DhhCre (Skucas et al. 2013), PLPCreERT2 (Leone et al. 2003)... were described previously"
CMVCreERT,animal_models,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.85,Experimental Usage,False,1.00,Medium,CMVCreERT,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"CMVCreERT (Hayashi and McMahon 2002), R26-LacZ, and R26-YFP were described previously"
R26-LacZ,animal_models,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.85,Experimental Usage,False,1.00,Medium,R26-LacZ,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"CMVCreERT (Hayashi and McMahon 2002), R26-LacZ, and R26-YFP were described previously"
R26-YFP,animal_models,PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.85,Experimental Usage,False,1.00,Medium,R26-YFP,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"CMVCreERT (Hayashi and McMahon 2002), R26-LacZ, and R26-YFP were described previously"
Long Evans,animal_models,PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.85,Experimental Usage,False,1.00,Medium,Long Evans,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Twenty-seven female Long Evans rats (age 12 weeks, approximate weight 200 g, Charles River. Wilmington, MA) were used in the experiments."
FVB/C57BL/6,animal_models,PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.85,Experimental Usage,False,1.00,Medium,FVB/C57BL/6,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Syngeneic immune-competent FVB/C57BL/6 mice, both male and female, 10–12 weeks old, are used for implantation of the mouse NF2 −/− Schwann cell line."
nude mice (nu/nu),animal_models,PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.85,Experimental Usage,False,1.00,Medium,nude mice (nu/nu),No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"When using human VS cell lines, such as the established human HEI-193 cell line or other immortalized human VS cell lines, immune-deficient mice (e.g., nude mice (nu/nu) or NOD SCID mice) should be used."
NOD SCID,animal_models,PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.85,Experimental Usage,False,1.00,Medium,NOD SCID,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"When using human VS cell lines, such as the established human HEI-193 cell line or other immortalized human VS cell lines, immune-deficient mice (e.g., nude mice (nu/nu) or NOD SCID mice) should be used."
p53 flox/flox,animal_models,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.85,Experimental Usage,False,1.00,Medium,p53 flox/flox,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p53 mice were crossed with Albumin-Cre mice (Jackson Laboratories) flox/flox
Albumin-Cre,animal_models,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.85,Experimental Usage,False,1.00,Medium,Albumin-Cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,p53 mice were crossed with Albumin-Cre mice (Jackson Laboratories) flox/flox
Kras LSL-G12D/+,animal_models,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.85,Experimental Usage,False,1.00,Medium,Kras LSL-G12D/+,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Kras G12D;shp53 mouse cholangiocarcinoma was generated as in using Kras LSL-G12D/+ liver progenitor cells
Col2.3Cre,animal_models,PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,,0.85,Experimental Usage,False,1.00,Medium,Col2.3Cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Col2.3Cre transgenic mice were generated as described elsewhere. In this model, the 2.3 α1(I) Collagen promoter is used to selectively drive Cre expression"
ROSA26,animal_models,PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,,0.85,Experimental Usage,False,1.00,Medium,ROSA26,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Col2.3Cre transgenic mice were crossed with ROSA26 reporter mice. LacZ staining was performed to assess Cre recombination
p53floxE2–10,animal_models,PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.85,Experimental Usage,False,1.00,Medium,p53floxE2–10,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,The floxed p53 alleles (p53floxE2–10) and (p53LSLR172H) have been described previously
p53LSLR172H,animal_models,PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.85,Experimental Usage,False,1.00,Medium,p53LSLR172H,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,The floxed p53 alleles (p53floxE2–10) and (p53LSLR172H) have been described previously
athymic nude mice,animal_models,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.85,Experimental Usage,False,1.00,Medium,athymic nude mice,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Athymic nude mice were purchased from Charles River Laboratories (stock no. 553).
C57Bl/6,animal_models,PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.85,Experimental Usage,False,1.00,Medium,C57Bl/6,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"For subcutaneous CT26 tumour implantation, LPS and CLP experiments, female C57Bl/6 and BALB/C mice of 6–8 weeks were purchased from Harlan Laboratories."
BALB/C,animal_models,PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.85,Experimental Usage,False,1.00,Medium,BALB/C,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"For subcutaneous CT26 tumour implantation, LPS and CLP experiments, female C57Bl/6 and BALB/C mice of 6–8 weeks were purchased from Harlan Laboratories."
FVB,animal_models,PMID:29408605,10.1016/j.neuroscience.2018.01.054,Nf2 Mutation in Schwann Cells Delays Functional Neural Recovery Following Injury.,,0.85,Experimental Usage,False,1.00,Medium,FVB,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"WT FVB mice were obtained from Jackson Labs (Bar Harbor, ME)"
C57BL/6,animal_models,PMID:34935315,10.1117/1.JBO.26.12.125001,Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse reflectance spectroscopy.,,0.85,Experimental Usage,False,1.00,Medium,C57BL/6,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,C57BL/6 mice (B6) and mice (NF1) were bred in-house at the Transgenic Facility at The Children's Hospital at Westmead...
C57Bl6/J,animal_models,PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.85,Experimental Usage,False,1.00,Medium,C57Bl6/J,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Mice for cell cultures were obtained from breedings of C57Bl6/J mice (Janvier Labs, France)"
NOD/SCID,animal_models,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,Experimental Usage,False,1.00,Medium,NOD/SCID,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Four-month-old male NOD/SCID mice were anesthetized with isofluorane and orthotopically implanted with 1 mm3 piece of explant tumour
CAG-tdTomato (stock no. 007909),animal_models,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.85,Experimental Usage,False,1.00,Medium,CAG-tdTomato (stock no. 007909),No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"The reporter mice CAG-tdTomato (stock no. 007909), CAG-CAT-EGFP (ccGFP) (stock no. 024636) C57/Bl6;FVBN obtained from The Jackson Laboratory"
CAG-CAT-EGFP (stock no. 024636),animal_models,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.85,Experimental Usage,False,1.00,Medium,CAG-CAT-EGFP (stock no. 024636),No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"The reporter mice CAG-tdTomato (stock no. 007909), CAG-CAT-EGFP (ccGFP) (stock no. 024636) C57/Bl6;FVBN obtained from The Jackson Laboratory"
NBSGW (JAX 026622),animal_models,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.85,Experimental Usage,False,1.00,Medium,NBSGW (JAX 026622),No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Female immunodeficient NBSGW (JAX 026622) mice of 6 to 8 weeks were used for allograft transplantations
NCR nude,animal_models,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.85,Experimental Usage,False,1.00,Medium,NCR nude,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Female athymic NCR nude mice of 6 to 8 weeks were used for xenograft transplantations
PLPCre-ERT2,animal_models,PMID:21551250,10.1158/0008-5472.CAN-10-4577,Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development.,,0.85,Experimental Usage,False,1.00,Medium,PLPCre-ERT2,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"For conditional ablation of NF1, we used a tamoxifen-inducible Cre line, the PLPCre-ERT2 transgenic mice"
ROSA26R,animal_models,PMID:21551250,10.1158/0008-5472.CAN-10-4577,Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development.,,0.85,Experimental Usage,False,1.00,Medium,ROSA26R,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"The LacZ reporter mice, ROSA26R, were obtained from the Jackson Laboratories"
Thy1::ChR2-YFP (line 20),animal_models,PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.85,Experimental Usage,False,1.00,Medium,Thy1::ChR2-YFP (line 20),No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Thy1::ChR2-YFP (line 20) and Nlgn3KO mice were acquired from the Jackson Laboratory (012350 and 008394, respectively)"
Nlgn3KO,animal_models,PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.85,Experimental Usage,False,1.00,Medium,Nlgn3KO,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Thy1::ChR2-YFP (line 20) and Nlgn3KO mice were acquired from the Jackson Laboratory (012350 and 008394, respectively)"
Foxn1 nu/nu,animal_models,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.85,Experimental Usage,False,1.00,Medium,Foxn1 nu/nu,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.5 million cells in serum-free DMEM with 33% Matrigel Basement Membrane (BD Biosciences) were injected into the back flanks of athymic Foxn1 nu/nu mice (Charles Rivers Laboratory)
Balb/c,animal_models,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.85,Experimental Usage,False,1.00,Medium,Balb/c,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,CT26 and 4T1 subcutaneous grafts in Balb/c mice
C57BL/6J,animal_models,PMID:21681782,10.1002/ajh.22035,Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.,,0.85,Experimental Usage,False,1.00,Medium,C57BL/6J,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Recipient C57BL/6J × 129/Sv F1 mice were sublethally irradiated
129/Sv,animal_models,PMID:21681782,10.1002/ajh.22035,Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.,,0.85,Experimental Usage,False,1.00,Medium,129/Sv,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,recipient animals were generated by crossing 129/Sv mice to C57BL/6J mice
Tie2cre,animal_models,PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.85,Experimental Usage,False,1.00,Medium,Tie2cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Tie2cre (4128) and VE-cadherin cre (VEcre, 6137) mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA)"
VE-cadherin cre,animal_models,PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.85,Experimental Usage,False,1.00,Medium,VE-cadherin cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Tie2cre (4128) and VE-cadherin cre (VEcre, 6137) mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA)"
BALB/c nude,animal_models,PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.85,Experimental Usage,False,1.00,Medium,BALB/c nude,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,RT4-D6P2T or HEI-193 cells were subcutaneously inoculated into the back of 4-week-old BALB/c nude mice (male)
NRG,animal_models,PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.85,Experimental Usage,False,1.00,Medium,NRG,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Nonobese diabetic Rag gamma (NRG; no. 007799) female mice were purchased from the Jackson Laboratory
w CS10,animal_models,PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.85,Experimental Usage,False,1.00,Medium,w CS10,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,The Nf1 P1 mutation was backcrossed six generations into the w CS10 genetic background and w CS10 flies were used as controls.
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ,animal_models,PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.85,Experimental Usage,False,1.00,Medium,NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"For the patient-derived xenograft (PDX) MPNST model, tumor tissue was implanted subcutaneously directly into NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice"
athymic nude,animal_models,PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.85,Experimental Usage,False,1.00,Medium,athymic nude,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"using athymic nude six-week-old male mice, in which no tumor was engrafted"
#002019,animal_models,PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.85,Experimental Usage,False,1.00,Medium,#002019,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Athymic nude (# 002019) and NOD scid gamma (NSG, # 005557) female mice were purchased from the Jackson Laboratory"
#005557,animal_models,PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.85,Experimental Usage,False,1.00,Medium,#005557,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Athymic nude (# 002019) and NOD scid gamma (NSG, # 005557) female mice were purchased from the Jackson Laboratory"
athymic female nude mice,animal_models,PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.85,Experimental Usage,False,1.00,Medium,athymic female nude mice,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"We injected 5×10^5 mouse sphere cells/injection subcutaneously into athymic female nude mice (Harlan, Indianapolis, IN)"
C57BL/6JOlaHsd,animal_models,PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,,0.85,Experimental Usage,False,1.00,Medium,C57BL/6JOlaHsd,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Experimental mice were obtained by crossing Nf1 mice (in C57BL/6JOlaHsd background)
129T2/SvEmsJ,animal_models,PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,,0.85,Experimental Usage,False,1.00,Medium,129T2/SvEmsJ,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"with 129T2/SvEmsJ (Jackson Laboratories, Bar Harbor, ME, USA)"
Tg(4xhre-tata:eGFP)ia,animal_models,PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.85,Experimental Usage,False,1.00,Medium,Tg(4xhre-tata:eGFP)ia,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,The male Zebrafish reporter line for HIF1α Tg(4xhre-tata:eGFP)ia was outcrossed with female wild-type Zebrafish
Tg(ptf1a:Gal4)/UAS:eGFPKRAS G12D,animal_models,PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.85,Experimental Usage,False,1.00,Medium,Tg(ptf1a:Gal4)/UAS:eGFPKRAS G12D,No known disease,pancreatic adenocarcinoma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"generating the final transgenic line Tg(ptf1a:Gal4)/UAS:eGFPKRAS G12D, as described"
nu/nu,animal_models,PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,0.85,Experimental Usage,False,1.00,Medium,nu/nu,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Athymic nu/nu mice were anesthetized in isoflurane and injected s.c. with 10^6 STS26T cells in the left flank
Eed f/f,animal_models,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.85,Experimental Usage,False,1.00,Medium,Eed f/f,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Eed-isogenic mouse MPNST cells were generated as follows: Eed f/f mice (67, 68) were bred with PLP-CreERT:: Nf1 f/f ; Cdkn2a f/f mice"
tg(Atoh1-cre)8,animal_models,PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,0.85,Experimental Usage,False,1.00,Medium,tg(Atoh1-cre)8,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,we used the following mouse lines: tg(Atoh1-cre)8; R26smo and tg(Neurod1-cre)29 to generate fast and slow growing medulloblastoma
tg(Neurod1-cre)29,animal_models,PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,0.85,Experimental Usage,False,1.00,Medium,tg(Neurod1-cre)29,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,we used the following mouse lines: tg(Atoh1-cre)8; R26smo and tg(Neurod1-cre)29 to generate fast and slow growing medulloblastoma
ABWT,animal_models,PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,0.85,Experimental Usage,False,1.00,Medium,ABWT,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Transgenic lines used in this study were the ABWT (Zebrafish International Resource Center)
Sprague‒Dawley,animal_models,PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.85,Experimental Usage,False,1.00,Medium,Sprague‒Dawley,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"NSCs were obtained from the fetal brains of embryonic Day 14 pregnant Sprague‒Dawley rats (Experimental Animal Center of Southern Medical University, Guangzhou, China)"
Fmr1 KO,animal_models,PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,0.85,Experimental Usage,False,1.00,Medium,Fmr1 KO,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Generation of the Fmr1 KO (Mientjes et al., 2006)...Calyces from both Tsc1(+/-) and from Fmr1 knock-out (KO) mice showed increased volume"
H-ras G12V,animal_models,PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,0.85,Experimental Usage,False,1.00,Medium,H-ras G12V,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Generation of the...H-ras mice (G12V Schuhmacher et al., 2008) has been described previously"
Tsc1 (+/-),animal_models,PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,0.85,Experimental Usage,False,1.00,Medium,Tsc1 (+/-),No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Tsc1 animals were obtained by crossing the +/- Tsc1 line (f/+ Meikle et al., 2005)...Calyces from both Tsc1(+/-) and from Fmr1 knock-out (KO) mice showed increased volume"
NSG,animal_models,PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.85,Experimental Usage,False,1.00,Medium,NSG,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Tumor tissue was implanted s.c. into the flank of 5- to 6-week-old NSG mice (The Jackson Laboratory).
C57BL/6N,animal_models,PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.85,Experimental Usage,False,1.00,Medium,C57BL/6N,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,viral injection into the left sciatic nerve of wild-type C57BL/6N mice
NOD scid gamma,animal_models,PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.85,Experimental Usage,False,1.00,Medium,NOD scid gamma,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,injected into the left sciatic nerve of immunodeficient (NOD scid gamma) mice
NOD RAG1/2−/− IL2Rγ−/−,animal_models,PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.85,Experimental Usage,False,1.00,Medium,NOD RAG1/2−/− IL2Rγ−/−,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,implanted subcutaneously with Matrigel in immunodeficient NRG (NOD RAG1/2−/− IL2Rγ−/−) mice
Centers for Disease Control (CDC) growth charts,clinical_assessment_tools,PMID:41468561,10.1212/WNL.0000000000214480,NF1-Specific Growth Charts for Head Circumference Over the First 3 Years of Life.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Centers for Disease Control (CDC) growth charts,scale,pediatric,No,,...We used the LMS method from Centers for Disease Control (CDC) growth charts on head circumference to compute Z scores...
DPOAE,clinical_assessment_tools,PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,DPOAE,performance test,all ages,No,,We measure hearing function by DPOAE and ABR tests
ABR,clinical_assessment_tools,PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,ABR,performance test,all ages,No,,We measure hearing function by DPOAE and ABR tests
Digit Cancellation,clinical_assessment_tools,PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Digit Cancellation,performance test,all ages,No,,Digit Cancellation (attention/inhibitory control) 21
Neuropsychological Assessment Battery (NAB) Mazes,clinical_assessment_tools,PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Neuropsychological Assessment Battery (NAB) Mazes,performance test,all ages,No,,the Neuropsychological Assessment Battery (NAB) Mazes 26
Spatial capacity working memory (SCAP) task,clinical_assessment_tools,PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Spatial capacity working memory (SCAP) task,performance test,all ages,No,,"A spatial working memory functional MRI paradigm, designed to be analogous to the behavioral tasks used in the mouse model"
Pain Rating Scale (PRS),clinical_assessment_tools,PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Pain Rating Scale (PRS),scale,pediatric,No,2.0,The PRS is a two-item visual analogue scale (VAS) developed by the authors that assesses pain intensity
Pain Rating Scale-Parent version (PRS-P),clinical_assessment_tools,PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Pain Rating Scale-Parent version (PRS-P),scale,caregiver,No,2.0,The Pain Rating Scale-Parent version (PRS-P) is similar to the VAS self-report PRS in terms of item content and format
Hematoxylin and eosin (H&E),clinical_assessment_tools,PMID:40063513,10.1158/1078-0432.CCR-24-3029,DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Hematoxylin and eosin (H&E),biomarker assay,clinician-rated,No,,Hematoxylin and eosin (H&E)-stained tissue sections from each tumor were reviewed by a board-certified pathologist
"Human AXL DuoSet ELISA kit (R&D Systems, DY154)",clinical_assessment_tools,PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,"Human AXL DuoSet ELISA kit (R&D Systems, DY154)",biomarker assay,all ages,No,,"Levels of circulating sAXL were measured in human plasma using the Human AXL DuoSet ELISA kit (R&D Systems, DY154)"
"Mouse AXL DuoSet ELISA kit (R&D Systems, DY854)",clinical_assessment_tools,PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,"Mouse AXL DuoSet ELISA kit (R&D Systems, DY854)",biomarker assay,all ages,No,,"Levels of circulating sAXL were measured in mouse plasma using the Mouse AXL DuoSet ELISA kit (R&D Systems, DY854)"
3-chamber social preference task,clinical_assessment_tools,PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,3-chamber social preference task,performance test,all ages,No,,The 3-chamber SP task occurred over 2 days as described previously
Open field test,clinical_assessment_tools,PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Open field test,performance test,all ages,No,,"mice were placed in the dark in an open chamber (40 × 40 cm, 30 cm height) for 60 minutes while activity was recorded"
Delay discounting task,clinical_assessment_tools,PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Delay discounting task,performance test,all ages,No,,mice were trained to identify which side of a T maze had a large reward (4 Cocoa Krispies) compared with the small reward (1 Cocoa Krispie)
Cliff avoidance reaction test,clinical_assessment_tools,PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Cliff avoidance reaction test,performance test,all ages,No,,"a round, plastic platform (diameter, 20 cm; thickness, 2 cm) supported by a plastic rod (height, 50 cm) was used to assess the CAR"
PedsQL™ 4.0 Generic Core Scales,clinical_assessment_tools,PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",,0.85,Citation Only,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,PedsQL™ 4.0 Generic Core Scales,scale,all ages,No,,"The NF1 HRQOL format, instructions, and Likert response scale are similar to the PedsQL™ 4.0 Generic Core Scales and other PedsQL™ Disease-Specific Modules."
Life Events Checklist (LEC),clinical_assessment_tools,PMID:39858077,10.3390/cancers17020295,A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Life Events Checklist (LEC),questionnaire,adult,No,22.0,"Participants completed the Life Events Checklist, adapted from Elliott-DeSorbo et al. [ 30 ], to document stressful events in the past three months. The score is the number of stressful events endorsed (range 0–22)."
Rating of Overall Stress Scale (ROSS),clinical_assessment_tools,PMID:39858077,10.3390/cancers17020295,A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Rating of Overall Stress Scale (ROSS),scale,adult,No,,Participants rated their stress in the past month from 0 (not stressed) to 10 (very stressed). This measure was adapted from Leidy et al. [ 31 ].
MEMS Cap,clinical_assessment_tools,PMID:39858077,10.3390/cancers17020295,A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,MEMS Cap,performance test,adult,No,,"Participants' study drug bottles were fitted with a MEMS TM cap at baseline. Having been given instructions to take the drug 12 h apart, adherence was defined as opening the bottle 11–13 h since their last dose."
Impact of Pediatric Illness Scale,clinical_assessment_tools,PMID:27021207,10.1002/ajmg.a.37623,Acceptance and commitment therapy in youth with neurofibromatosis type 1 (NF1) and chronic pain and their parents: A pilot study of feasibility and preliminary efficacy.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Impact of Pediatric Illness Scale,scale,pediatric,No,,"...response of three or higher on a pain interference item (1–5 scales) from a self-report or parent-report QOL measure (Impact of Pediatric Illness Scale [ Wolters et al., 2010 ])"
NeuroConn DC-STIMULATOR MR,clinical_assessment_tools,PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,NeuroConn DC-STIMULATOR MR,performance test,pediatric,No,,AtDCS was delivered via a NeuroConn DC-STIMULATOR MR with the anode placed over F3 position in the international 10–20 system
Corsi block-tapping task,clinical_assessment_tools,PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Corsi block-tapping task,performance test,all ages,No,,"All participants completed...the Corsi block-tapping task (Kessels et al., 2000, 2008). Both are span tasks where the examiner presents a growing sequence"
School Achievement Test,clinical_assessment_tools,PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,School Achievement Test,performance test,pediatric,No,,"We adopted the arithmetic subtest from the School Achievement Test (Stein, 1994), as an objective measure of school performance"
cancellation test,clinical_assessment_tools,PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,cancellation test,performance test,pediatric,No,,performance on the cancellation test (speed; assessing attention)
judgment of line orientation task,clinical_assessment_tools,PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,judgment of line orientation task,performance test,pediatric,No,,and the judgment of line orientation task
Teller acuity cards,clinical_assessment_tools,PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Teller acuity cards,performance test,pediatric,No,,In the youngest group VA was assessed with Teller acuity cards or Cardiff acuity cards
Cardiff acuity cards,clinical_assessment_tools,PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Cardiff acuity cards,performance test,pediatric,No,,In the youngest group VA was assessed with Teller acuity cards or Cardiff acuity cards
Lea cards,clinical_assessment_tools,PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Lea cards,performance test,pediatric,No,,while older children were tested with Lea or KM (Konstantin Moutakis) cards
KM (Konstantin Moutakis) cards,clinical_assessment_tools,PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,KM (Konstantin Moutakis) cards,performance test,pediatric,No,,while older children were tested with Lea or KM (Konstantin Moutakis) cards
Response Evaluation Criteria In Solid Tumors (RECIST),clinical_assessment_tools,PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,,0.85,Citation Only,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Response Evaluation Criteria In Solid Tumors (RECIST),scale,all ages,No,,The use of standard response criteria (Response Evaluation Criteria In Solid Tumors [RECIST] and World Health Organization [WHO] criteria)
World Health Organization (WHO) criteria,clinical_assessment_tools,PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,,0.85,Citation Only,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,World Health Organization (WHO) criteria,scale,all ages,No,,The use of standard response criteria (Response Evaluation Criteria In Solid Tumors [RECIST] and World Health Organization [WHO] criteria)
CNC-word test,clinical_assessment_tools,PMID:35723774,10.1007/s10072-022-06203-8,A randomized controlled trial of remote microphone listening devices to treat auditory deficits in children with neurofibromatosis type 1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,CNC-word test,performance test,pediatric,No,,Speech perception ability in background noise was evaluated in device-active and inactive conditions using the CNC-word test.
compound motor action potential (CMAP),clinical_assessment_tools,PMID:25012216,10.1186/s40478-014-0082-1,A neuronal function of the tumor suppressor protein merlin.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,compound motor action potential (CMAP),biomarker assay,all ages,No,,"When significantly reduced, the compound motor action potential (CMAP) – correlating with the number of functional axons – is an indicator for axonal damage."
EGI 128-electrode Hydrocel Sensor Net,clinical_assessment_tools,PMID:34049498,10.1186/s11689-021-09364-3,Early differences in auditory processing relate to Autism Spectrum Disorder traits in infants with Neurofibromatosis Type I.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,EGI 128-electrode Hydrocel Sensor Net,biomarker assay,pediatric,No,,"We recorded EEG data with an EGI (Philips Neuro, Oregon, USA) 128-electrode Hydrocel Sensor Net, with the vertex electrode..."
Logical Observation Identifiers Names and Codes (LOINC),clinical_assessment_tools,PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Logical Observation Identifiers Names and Codes (LOINC),scale,all ages,No,,"NF1-relevant diagnosis codes from SNOMED, ICD-9/10, Logical Observation Identifiers Names and Codes (LOINC), and Nebraska Lexicon"
University of Maryland Letter–Number Sequencing (LNS) task,clinical_assessment_tools,PMID:28725547,10.1016/j.nicl.2017.06.032,Spatial working memory in neurofibromatosis 1: Altered neural activity and functional connectivity.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,University of Maryland Letter–Number Sequencing (LNS) task,performance test,adult,No,,"Working memory capacity was measured behaviorally using the University of Maryland Letter–Number Sequencing (LNS) task (Gold et al., 1997)"
TEA-Ch Sky Search,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,TEA-Ch Sky Search,performance test,pediatric,No,,TEA-Ch Sky Search Assessing the ability to selectively attend to and identify 20 visual targets among distractors S
TEA-Ch Score!,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,TEA-Ch Score!,performance test,pediatric,No,,TEA-Ch Score! 10 trials assessing the ability to sustain attention by mentally counting aurally administered tones S
Shape School,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Shape School,performance test,pediatric,No,60.0,"Shape School 4 conditions (each with 15 items) assessing inhibition, task-switching and working memory abilities"
NEPSY-II Inhibition,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,NEPSY-II Inhibition,performance test,pediatric,No,6.0,NESPY-II Inhibition 6 items assessing the ability to inhibit automatic responses in favour of novel responses
Tower of Hanoi,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Tower of Hanoi,performance test,pediatric,No,6.0,"Tower of Hanoi 6 items assessing set shifting, response inhibition, working memory and the ability to hold a set of rules in mind"
TEA-Ch Creature Counting,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,TEA-Ch Creature Counting,performance test,pediatric,No,,TEA-Ch Creature Counting 7 trials assessing the ability to accurately switch and redirect attention to count up/down S
WIAT-II Abbreviated,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,WIAT-II Abbreviated,performance test,pediatric,No,,"WIAT-II Abbreviated 3 subtests assessing numerical operations, spelling and single word reading S"
NEPSY-II Affect Recognition,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,NEPSY-II Affect Recognition,performance test,pediatric,No,36.0,NEPSY-II Affect Recognition 36 items assessing the ability to match facial expressions from photographs of children's faces
Benton Facial Recognition Test,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Benton Facial Recognition Test,performance test,pediatric,No,13.0,Benton Facial Recognition Test 13 items assessing the ability to recognise a target face from a selection of distractors S
NEPSY-II ToM,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,NEPSY-II ToM,performance test,pediatric,No,21.0,"NEPSY-II ToM 21 items assessing the ability to comprehend the perspectives, intentions and beliefs of another person"
Reading the Mind in the Eyes Test-Child,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Reading the Mind in the Eyes Test-Child,performance test,pediatric,No,28.0,Reading the Mind in the Eyes Test-Child 28 items assessing the ability to determine a person's thoughts or feelings based on a picture of only their eyes
Faux Pas Task,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Faux Pas Task,performance test,pediatric,No,20.0,Faux Pas Task 20 short stories assessing the ability to identify a social faux pas S
Strange Stories,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Strange Stories,performance test,pediatric,No,14.0,"Strange Stories 14 short stories assessing the ability to attribute mental states (eg, desires, beliefs or intentions)"
CELF-Preschool-2,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,CELF-Preschool-2,performance test,pediatric,No,,"CELF-Preschool-2 2 subtests assessing knowledge of grammatical rules in a sentence completion task and the ability to name objects, people and activities Y"
CELF-4 Formulated Sentences,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,CELF-4 Formulated Sentences,performance test,pediatric,No,28.0,CELF-4 Formulated Sentences 28 items assessing the ability to formulate semantically and grammatically correct spoken sentences
NEPSY-II Comprehension of Instructions,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,NEPSY-II Comprehension of Instructions,performance test,pediatric,No,33.0,NEPSY-II Comprehension of Instructions 33 items assessing the ability to comprehend and follow multistep instructions of increasing complexity
CADS,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,CADS,scale,caregiver,No,26.0,CADS 26 items assessing ADHD symptoms of impulsivity/hyperactivity and inattention Y
Conners 3,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Conners 3,scale,caregiver,No,110.0,Conners 3 110 items assessing ADHD symptom and comorbid disorders including oppositional defiant and conduct problems
BRIEF-Preschool,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,BRIEF-Preschool,scale,caregiver,No,63.0,"BRIEF-Preschool 63 items assessing executive functions within the home environment, including working memory, mental set shifting"
BRIEF,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,BRIEF,scale,caregiver,No,86.0,"BRIEF 86 items assessing executive functions in the home environment, including working memory, mental set shifting, response inhibition"
ABAS-3: 0–5 years,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,ABAS-3: 0–5 years,scale,caregiver,No,241.0,"ABAS-3: 0–5 years 241 items assessing adaptive functioning skills, including communication, community use, preacademics"
ABAS-3: 5–21 years,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,ABAS-3: 5–21 years,scale,caregiver,No,232.0,"ABAS-3: 5–21 years 232 items assessing adaptive functioning skills, including communication, community use, functional academics"
SSIS Rating Scale,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,SSIS Rating Scale,scale,caregiver,No,79.0,"SSIS Rating Scale 79 items assessing social skills, problem behaviours and academic competence Y, S"
Sensory Profile 2,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Sensory Profile 2,scale,caregiver,No,86.0,"Sensory Profile 2 86 items assessing sensory processing, including auditory, visual, taste/smell, movement, body position, touch"
CBCL: 1.5–5 years,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,CBCL: 1.5–5 years,scale,caregiver,No,100.0,"CBCL: 1.5–5 years 100 items assessing internalising and externalising problems, emotional reactivity, anxiety/depression"
CBCL: 6–18 years,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,CBCL: 6–18 years,scale,caregiver,No,113.0,"CBCL: 6–18 years 113 items assessing internalising and externalising problems, emotional reactivity, anxiety/depression"
CCC-2,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,CCC-2,scale,caregiver,No,70.0,"CCC-2 70 items assessing speech, syntax, semantics, coherence, inappropriate initiation, stereotyped language, use of context"
n-back task,clinical_assessment_tools,PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,n-back task,performance test,pediatric,No,24.0,Verbal and visuospatial working memory was assessed using the n-back task. The task was programmed in-house using E-Prime software.
Corsi block task,clinical_assessment_tools,PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Corsi block task,performance test,pediatric,No,,Memory span was assessed using a computerized Corsi block task on the Psychology Experiment Building Language (PEBL)
Rotarod,clinical_assessment_tools,PMID:32839340,10.1073/pnas.2008391117,Brain-wide structural and functional disruption in mice with oligodendrocyte-specific ,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Rotarod,performance test,all ages,No,,Gross motor coordination function was evaluated using the Rotarod (Med Associates)
Category Fluency Test,clinical_assessment_tools,PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Category Fluency Test,performance test,all ages,No,,"Assessment of this cognitive domain was performed by a Category Fluency Test (""animals"")"
Lexical Fluency Test,clinical_assessment_tools,PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Lexical Fluency Test,performance test,all ages,No,,"and by Lexical Fluency Test letters (F, A, and S)"
Corsi block-tapping task,clinical_assessment_tools,PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Corsi block-tapping task,performance test,all ages,No,,"For working memory evaluation, we used the Digit Span according to the WAIS-III or WISC-III, and the Corsi block-tapping task"
Tower of London Test,clinical_assessment_tools,PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Tower of London Test,performance test,all ages,No,,The Tower of London Test was used as a measure of Planning Skills
GE Discovery 690,clinical_assessment_tools,PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,GE Discovery 690,biomarker assay,all ages,No,,"Resting-state 18F-FDG PET/CT brain images were acquired in a GE Discovery 690 (GE Healthcare, Millwalke, EUA) scanner"
MC-780MA Tanita Tokyo body composition analyzer,clinical_assessment_tools,PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,MC-780MA Tanita Tokyo body composition analyzer,performance test,pediatric,No,,Body fat was measured using the MC‐780MA Tanita Tokyo body composition analyzer. The MC‐780MA body composition analyzer divides the human body into five sections
Wechsler Intelligence Scale,clinical_assessment_tools,PMID:35087195,10.1038/s41380-021-01422-5,Altered canonical and striatal-frontal resting state functional connectivity in children with pathogenic variants in the Ras/mitogen-activated protein kinase pathway.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Wechsler Intelligence Scale,scale,pediatric,No,,Participants completed age-appropriate versions of the Wechsler Intelligence Scale
Tanner staging,clinical_assessment_tools,PMID:35087195,10.1038/s41380-021-01422-5,Altered canonical and striatal-frontal resting state functional connectivity in children with pathogenic variants in the Ras/mitogen-activated protein kinase pathway.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Tanner staging,scale,pediatric,No,,Pubertal status was assessed by an experienced physician using Tanner staging
NRS-11,clinical_assessment_tools,PMID:40304934,10.1186/s41687-025-00877-2,Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,NRS-11,scale,all ages,No,1.0,"The self-report NRS-11 has been used in numerous studies, including as a primary outcome measure, to assess pain intensity"
PII,clinical_assessment_tools,PMID:40304934,10.1186/s41687-025-00877-2,Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,PII,questionnaire,all ages,No,6.0,The PII is a 6-item questionnaire developed to assess the extent to which pain interferes with six different aspects of daily functioning
Quantikine™ human VEGF immunoassay kit,clinical_assessment_tools,PMID:22961690,10.1002/pbc.24281,Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Quantikine™ human VEGF immunoassay kit,biomarker assay,pediatric,No,,"Plasma VEGF and soluble VEGFR2 (sVEGFR2) were quantified at baseline and at steady-state on day 28 ± 1 of cycle 1 using commercial available human VEGF and sVEGFR2 immunoassay kits (Quantikine™, R&D Systems, Minneapolis, MN)"
Quantikine™ human sVEGFR2 immunoassay kit,clinical_assessment_tools,PMID:22961690,10.1002/pbc.24281,Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Quantikine™ human sVEGFR2 immunoassay kit,biomarker assay,pediatric,No,,"Plasma VEGF and soluble VEGFR2 (sVEGFR2) were quantified at baseline and at steady-state on day 28 ± 1 of cycle 1 using commercial available human VEGF and sVEGFR2 immunoassay kits (Quantikine™, R&D Systems, Minneapolis, MN)"
virtual optokinetic system (VOS),clinical_assessment_tools,PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,virtual optokinetic system (VOS),performance test,all ages,No,,Visual acuity (n=20 mice per group) was assessed using the virtual optokinetic system (VOS) under photopic conditions
Behavior Rating Inventory of Executive Function,clinical_assessment_tools,PMID:34377779,10.1212/NXG.0000000000000616,Impact of MEK Inhibitor Therapy on Neurocognitive Functioning in NF1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Behavior Rating Inventory of Executive Function,questionnaire,caregiver,No,,a consistent parent completed a questionnaire of executive functioning (Behavior Rating Inventory of Executive Function; BRIEF)
Wechsler Intelligence Scales,clinical_assessment_tools,PMID:38621478,10.1016/j.bpsc.2024.04.003,Influences of RASopathies on Neuroanatomical Variation in Children.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Wechsler Intelligence Scales,scale,pediatric,No,,We administered age-appropriate versions of the Wechsler Intelligence Scales to measure global cognitive ability
Lansky Score,clinical_assessment_tools,PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Lansky Score,scale,pediatric,No,,Medical providers completed a Lansky score for patients 17 years and younger...These scores indicate the disease severity and functional capabilities of the patient
Karnofsky Score,clinical_assessment_tools,PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Karnofsky Score,scale,adult,No,,a Karnofsky score for patients 18 years and older. These scores indicate the disease severity and functional capabilities of the patient...range from 0–100 in increments of 10
NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3,clinical_assessment_tools,PMID:24753394,10.1002/pbc.25041,Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3,scale,all ages,No,,Adverse events were graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3.
DNA extraction kit,genetic_reagents,PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,DNA extraction kit,Other,,,,,,,,,,,,,,,,,,,,Genomic DNA (gDNA) was extracted from blood or frozen tissue using Qiagen DNeasy Blood & Tissue kit (Qiagen Ca#69506)
TRIzol LS,genetic_reagents,PMID:12057013,10.1186/1471-2164-3-13,Complex splicing pattern generates great diversity in human NF1 transcripts.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,TRIzol LS,Other,,,,,,,,,,,,,,,,,,,,RNA was isolated from fresh blood leukocytes from two normal individuals using TRIzol LS Reagent (Invitrogen) according to the manufacturer's instructions.
SuperScript II,genetic_reagents,PMID:12057013,10.1186/1471-2164-3-13,Complex splicing pattern generates great diversity in human NF1 transcripts.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,SuperScript II,Other,,,,,,,,,,,,,,,,,,,,Total RNA (2 μg) was reverse transcribed using SuperScript II Reverse transcriptase (Invitrogen) and random hexamers (Amersham Biosciences).
Thermo Sequenase,genetic_reagents,PMID:12057013,10.1186/1471-2164-3-13,Complex splicing pattern generates great diversity in human NF1 transcripts.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Thermo Sequenase,Other,,,,,,,,,,,,,,,,,,,,All transcripts with a different restriction pattern were sequenced (primer sequences available upon request) using the Thermo Sequenase fluorescent labelled primer cycle sequencing kit (Amersham Biosciences)
dispase grade II,genetic_reagents,PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,dispase grade II,Other,,,,,,,,,,,,,,,,,,,,"enzymatically digested with dispase grade II (1.25 U/mL, Roche, Basel, Switzerland)"
collagenase type I,genetic_reagents,PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,collagenase type I,Other,,,,,,,,,,,,,,,,,,,,"collagenase type I (160 U/mL, Sigma, St. Louis, MO, USA)"
Gateway entry vector,genetic_reagents,PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Gateway entry vector,Plasmid,,,,,,,,,,,,,,,,,,,,PCR amplicons were cloned into pDonr255 and fully sequence-verified
baculovirus expression vector,genetic_reagents,PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,baculovirus expression vector,Plasmid,pFastBac1,,,,,,,,,,,,,,,,,,,Gateway LR recombination was used to generate final expression clones in baculovirus Destination vectors pDest-635 (pFastBac1 with N-terminal His 6 tag)
baculovirus expression vector,genetic_reagents,PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,baculovirus expression vector,Plasmid,pFastBac1,,,,,,,,,,,,,,,,,,,pDest-636 (pFastBac1 with N-terminal His 6 -MBP tag)
E. coli expression vector,genetic_reagents,PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,E. coli expression vector,Plasmid,,,,,,,,,,,,,,,,,,,,"E. coli Destination vector pDest-566 (N-terminal His6-MBP tag, Addgene catalog no. 11517)"
exome capture,genetic_reagents,PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,exome capture,Other,,,,,,,,,,,,,,,,,,,,"Exome libraries were captured with an IDT exome reagent, then pooled with a WGS library for sequencing"
RNA library preparation,genetic_reagents,PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,RNA library preparation,Other,,,,,,,,,,,,,,,,,,,,"RNA was prepared with a TrueSeq stranded total RNA library kit, then sequenced on an Illumina HISeq4000"
TruSeq DNA PCR Free 350bp,genetic_reagents,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,TruSeq DNA PCR Free 350bp,Other,,,,,,,,,,,,,,,,,,,,Between 350 and 500 ng of tumor DNA were used to prepare DNA sequencing libraries using the TruSeq DNA PCR Free 350bp kit
truXTRAC FFPE DNA,genetic_reagents,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,truXTRAC FFPE DNA,Other,,,,,,,,,,,,,,,,,,,,DNA extraction from FFPE tissue samples was performed using the Covaris truXTRAC FFPE DNA kit with the E220 Evolution-focused ultrasonicator system
Kapa HyperPlus,genetic_reagents,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Kapa HyperPlus,Other,,,,,,,,,,,,,,,,,,,,"Exome libraries were prepared using the Roche Kapa HyperPlus kit, captured using the HyperExome kit Roche"
HumanMethylationEPIC,genetic_reagents,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,HumanMethylationEPIC,Other,,,,,,,,,,,,,,,,,,,,Tumor DNA derived from fresh-frozen tumors and paired normal nerve samples was used for whole-genome DNA methylation array profiling using the HumanMethylationEPIC beadchip platform
EZ DNA methylation Gold,genetic_reagents,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,EZ DNA methylation Gold,Other,,,,,,,,,,,,,,,,,,,,350 ng of DNA were bisulfite converted using the Zymo EZ DNA methylation Gold kit (Zymo Research Corp.)
RNA extraction reagent,genetic_reagents,PMID:18670322,10.1097/MLG.0b013e318177e20b,Vestibular schwannoma quantitative polymerase chain reaction expression of estrogen and progesterone receptors.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,RNA extraction reagent,Other,,,,,,,,,,,,,,,,,,,,"total RNA was extracted from VS and control nerve samples using the Trizol reagent (Gibco Invitrogen, Carlsbad, CA)"
reverse transcription kit,genetic_reagents,PMID:18670322,10.1097/MLG.0b013e318177e20b,Vestibular schwannoma quantitative polymerase chain reaction expression of estrogen and progesterone receptors.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,reverse transcription kit,Other,,,,,,,,,,,,,,,,,,,,"mRNA (5 μg per 50 μL sample) was reverse transcribed using the Gene AMP kit (Perkin-Elmer; Waltham, MA)"
PCR master mix,genetic_reagents,PMID:18670322,10.1097/MLG.0b013e318177e20b,Vestibular schwannoma quantitative polymerase chain reaction expression of estrogen and progesterone receptors.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,PCR master mix,Other,,,,,,,,,,,,,,,,,,,,"Taqman Universal PCR Master Mix (2× buffer containing polymerase; Applied Biosystems, Foster City, CA)"
GLuc,genetic_reagents,PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,GLuc,Viral,,,,,,,,,,,,,,,,,,,,"NF2 −/− cells should be transduced before use so they express the GLuc reporter gene, which is a secreted reporter that can be detected in the blood of tumor-bearing animals."
GLuc,genetic_reagents,PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,GLuc,Viral,,,,,,,,,,,,,,,,,,,,"GLuc vector and assay kits are commercially available from various biotech companies, such as Thermo Fisher Scientific (cat. no. 16146) and New England BioLabs (cat. no. N8084S)."
GLuc,genetic_reagents,PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,GLuc,Viral,,,,,,,,,,,,,,,,,,,,"GLuc vector and assay kits are commercially available from various biotech companies, such as Thermo Fisher Scientific (cat. no. 16146) and New England BioLabs (cat. no. N8084S)."
Cas9/sgRNA,genetic_reagents,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Cas9/sgRNA,Plasmid,pX330,,,,,,,,,,,,,,,,,,,sgRNA oligos (IDT) were annealed and cloned into the pX330 vector (addgene 42230)
sgRNA,genetic_reagents,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,sgRNA,Viral,lentiV2,,,,,,,,,,,,,,,,,,,sgRNA oligos (IDT) were annealed and cloned into the pX330 vector (addgene 42230) or lentiV2 (addgene 52961)
Myc,genetic_reagents,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Myc,Plasmid,pT3,EF1α,,,,,,,,,,,,,,,,,,"pX330.sgNf1 (20 μg), pT3-EF1α-Myc (5 μg), and CMV-SB10 transposase (1 μg) plasmids were delivered"
SB10 transposase,genetic_reagents,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,SB10 transposase,Plasmid,,CMV,,,,,,,,,,,,,,,,,,"pX330.sgNf1 (20 μg), pT3-EF1α-Myc (5 μg), and CMV-SB10 transposase (1 μg) plasmids were delivered"
apterous-Gal4,genetic_reagents,PMID:24595234,10.1371/journal.pone.0090853,In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,apterous-Gal4,Other,,,,,,,,,,,,,,,,,,,,ectopic expression of the NF2 isoforms under the control of the apterous-Gal4 driver
Complete Mini protease inhibitors,genetic_reagents,PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Complete Mini protease inhibitors,Other,,,,,,,,,,,,,,,,,,,,"...sonicated for five cycles of 30 s on, 30 s off in 50 µL of 100 mM triethylammonium bicarbonate buffer supplemented with Complete Mini protease inhibitors (Roche, Basel, Switzerland)..."
S-Trap micro spin columns,genetic_reagents,PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,S-Trap micro spin columns,Other,,,,,,,,,,,,,,,,,,,,"...After acidification with phosphoric acid and addition of the S-Trap binding buffer, the samples were applied to S-Trap micro spin columns (ProtiFi, Farmingdale, NY, USA)..."
UltraView Universal DAB detection kit,genetic_reagents,PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,UltraView Universal DAB detection kit,Other,,,,,,,,,,,,,,,,,,,,...and detection with the UltraView Universal DAB detection kit (Roche)...
Dako EnVision kit,genetic_reagents,PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Dako EnVision kit,Other,,,,,,,,,,,,,,,,,,,,"...The labeling was carried out using the peroxidase-based Dako EnVision kit (Agilent Dako, Santa Clara, CA, USA)..."
RASopathy gene panel,genetic_reagents,PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,RASopathy gene panel,Other,,,,,,,,,,,,,,,,,,,,"Target sequencing was performed using the Haloplex custom target enrichment system (Agilent Technologies, CA, USA) on the MiSeq sequencing platform"
Site-directed mutagenesis reagents,genetic_reagents,PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Site-directed mutagenesis reagents,Other,,,,,,,,,,,,,,,,,,,,"We introduced a single-base substitution into the corresponding expression vector using Q5® Site-Directed Mutagenesis Kit (NEB, UK)"
Luciferase reporter,genetic_reagents,PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Luciferase reporter,Plasmid,,Gal4,,,,,,,,,,,,,,,,,,"We introduced pGal-LUC (Clontech), pGal-ELK1 and the expression plasmids into HEK-293T cells"
ELK1,genetic_reagents,PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,ELK1,Plasmid,,Gal4,,,,,,,,,,,,,,,,,,"We introduced pGal-LUC (Clontech), pGal-ELK1 and the expression plasmids into HEK-293T cells"
Dual luciferase reporter,genetic_reagents,PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Dual luciferase reporter,Other,,,,,,,,,,,,,,,,,,,,"The luciferase activity was measured using a Dual-Luciferase® Reporter assay system (Promega, WI, USA)"
Renilla luciferase,genetic_reagents,PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Renilla luciferase,Plasmid,,SV40,,,,,,,,,,,,,,,,,,"Transfection efficiencies were normalised to the control plasmid, which was pSV-RLuc (Promega, WI, USA) expressing Renilla luciferase"
GFP fusion vector,genetic_reagents,PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,GFP fusion vector,Plasmid,pCMV6-AC-GFP,CMV,,,,,,,,,,,,,,,,,,"the in-frame coding sequence of RAF1, A2ML1 and RIT1 were subcloned into the pCMV6-AC-GFP vector such that the GFP coding sequence was fused in-frame"
T7 transcription reagents,genetic_reagents,PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,T7 transcription reagents,Other,,,,,,,,,,,,,,,,,,,,"GFP-tagged RNA transcripts were synthesised using the mMESSAGE mMACHINE T7 Transcription Kit (Thermo Fisher Scientific, MA, USA)"
cmlc1 probe,genetic_reagents,PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,cmlc1 probe,Other,,,,,,,,,,,,,,,,,,,,"PFA fixed embryos were probed with digoxigenin-labelled cmlc1, which is a cardiac development marker for zebrafish, by in situ hybridization"
ZsGreen,genetic_reagents,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,ZsGreen,Plasmid,pTRE3G-BI,,,,,,,,,,,,,,,,,,,"The Tet-inducible plasmids, pTRE3G-BI-ZsGreen and pCMV-Tet3G, were purchased from Tanaka Holdings"
Tet3G,genetic_reagents,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Tet3G,Plasmid,,CMV,,,,,,,,,,,,,,,,,,"The Tet-inducible plasmids, pTRE3G-BI-ZsGreen and pCMV-Tet3G, were purchased from Tanaka Holdings"
H-RAS,genetic_reagents,PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,H-RAS,Plasmid,,,,,,,,,,,,,,,,,,,,HA-H-RAS was expressed together with either wild-type (WT) or variant NF in COS-7 or HEK 293 T cells
SPRED1,genetic_reagents,PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,SPRED1,Plasmid,,,,,,,,,,,,,,,,,,,,FLAG-SPRED1 (WT or variant) and NF (WT or variant) were coexpressed in HEK 293 T cells
RAF-RBD,genetic_reagents,PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,RAF-RBD,Other,,,,,,,,,,,,,,,,,,,,GTP-bound RAS was subsequently isolated using glutathione-agarose beads coated with recombinant GST-RAF-RBD
BNIP3,genetic_reagents,PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,BNIP3,Other,,,,,,,,,,,,,,,,,,,,BNIP3 and HIF-1α siRNA (siGENOME SMARTPool) was purchased from Thermo Scientific
HIF-1α,genetic_reagents,PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,HIF-1α,Other,,,,,,,,,,,,,,,,,,,,BNIP3 and HIF-1α siRNA (siGENOME SMARTPool) was purchased from Thermo Scientific
PAXgene,genetic_reagents,PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,PAXgene,Other,,,,,,,,,,,,,,,,,,,,"blood was collected in PAXgene whole blood samples (Becton Dickinson, Franklin Lakes, NJ, USA)"
PAXgene Blood RNA System,genetic_reagents,PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,PAXgene Blood RNA System,Other,,,,,,,,,,,,,,,,,,,,"extraction was carried out with the PAXgene™ Blood RNA System (Qiagen, Hilden, Germany)"
Haloplex HS,genetic_reagents,PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Haloplex HS,Other,,,,,,,,,,,,,,,,,,,,"library preparation with a Haloplex HS or SureSelect kits (Agilent Technologies, Santa Clara, CA, USA)"
SureSelect,genetic_reagents,PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,SureSelect,Other,,,,,,,,,,,,,,,,,,,,"library preparation with a Haloplex HS or SureSelect kits (Agilent Technologies, Santa Clara, CA, USA)"
Gentra Puregene,genetic_reagents,PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Gentra Puregene,Other,,,,,,,,,,,,,,,,,,,,"using the Gentra Puregene kit (Puregene Cell and Tissue kit plus Qiagen GmbH, Hilden, Germany)"
Lipofectamine 2000,genetic_reagents,PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Lipofectamine 2000,Other,,,,,,,,,,,,,,,,,,,,"transfected with 1 µg of the wild type or the mutated minigene using Lipofectamine 2000 (ThermoFisher Scientific, Watham, MA, USA)"
TRIzol,genetic_reagents,PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,TRIzol,Other,,,,,,,,,,,,,,,,,,,,"total RNA was extracted with TRIzolTM (ThermoFisher Scientific, Watham, MA, USA)"
SuperScript II,genetic_reagents,PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,SuperScript II,Other,,,,,,,,,,,,,,,,,,,,"retrotranscribed using SuperScript II reverse transcriptase (ThermoFisher Scientific, Watham, MA, USA)"
TOPO TA,genetic_reagents,PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,TOPO TA,Plasmid,,,,,,,,,,,,,,,,,,,,"purified bands were subcloned using the TOPO TA Cloning kit (ThermoFisher Scientific, Watham, MA, USA)"
NHE1,genetic_reagents,PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,NHE1,Other,,,,,,,,,,,,,,,,,,,,"NHE1 siRNA: ON-TARGET SMART pool (Thermo Scientific); NBCn1 siRNA (SASI_Hs01_00030755, Sigma-Aldrich)"
Human Phospho-RTK Array,genetic_reagents,PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Human Phospho-RTK Array,Other,,,,,,,,,,,,,,,,,,,,"MPNST cells were seeded in 15-cm dishes, allowed cell attachment overnight, treated the next day with the desired drug concentrations, harvested at the experiment endpoint, and lysed using the lysis buffer provided by Human Phospho-RTK Array Kit (R&D)"
Cas9,genetic_reagents,PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Cas9,Plasmid,,,,,,,,,,,,,,,,,,,,WT S2R+ cells were co‐transfected with the pl018 plasmid to express Cas9
GFP,genetic_reagents,PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,GFP,Plasmid,,Actin,,,,,,,,,,,,,,,,,,co‐transfected with the pl018 plasmid to express Cas9 and the sgRNA (CGCTTCTCCCTTGTCATATC) and pAct‐GFP plasmid
Human All Exon capture probes,genetic_reagents,PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Human All Exon capture probes,Other,,,,,,,,,,,,,,,,,,,,"Sequencing libraries were generated from 1 μg genomic DNA using Agilent SureSelect Human All Exon kit (Agilent Technologies, California, USA)"
Fluc and mCherry,genetic_reagents,PMID:21111000,10.1016/j.jneumeth.2010.10.021,A novel imaging-compatible sciatic nerve schwannoma model.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Fluc and mCherry,Viral,,,,,,,,,,,,,,,,,,,,These cell lines have been transduced with lentivirus expressing Fluc and mCherry genes as described previously
empty vector,genetic_reagents,PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,empty vector,Plasmid,pcDNA3.1,,,,,,,,,,,,,,,,,,,An empty vector pcDNA3.1 was used as a control
GFP,genetic_reagents,PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,GFP,Viral,Adenovirus,,,,,,,,,,,,,,,,,,,"MPNST cells were infected with purified Ad-NF1-GRD or control Ad-GFP, in triplicate"
DNA extraction reagent,genetic_reagents,PMID:33767727,10.3389/fgene.2021.603195,Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,DNA extraction reagent,Other,,,,,,,,,,,,,,,,,,,,"Genomic DNA was extracted from the peripheral blood, skin lesions, hair, oral mucosa, and tumor tissues separately using the AxyPrep Blood Genomic DNA Miniprep Kit (Axygen, Corning, Jiangsu, China)"
DNA extraction reagent,genetic_reagents,PMID:33767727,10.3389/fgene.2021.603195,Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,DNA extraction reagent,Other,,,,,,,,,,,,,,,,,,,,"Genomic DNA was extracted from the peripheral blood, skin lesions, hair, oral mucosa, and tumor tissues separately using the AxyPrep Blood Genomic DNA Miniprep Kit (Axygen, Corning, Jiangsu, China) and DNeasy Blood & Tissue Kit (Qiagen, Germany)"
DNA quantification reagent,genetic_reagents,PMID:33767727,10.3389/fgene.2021.603195,Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,DNA quantification reagent,Other,,,,,,,,,,,,,,,,,,,,"quantified with a Qubit 2.0 Fluorometer using the Qubit dsDNA HS Assay Kit (Life Technologies, Thermo Fisher Scientific, Inc.)"
pLKO.1,genetic_reagents,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,pLKO.1,Plasmid,pLKO.1,,,,,,,,,,,,,,,,,,,"Lentivirus packaging, envelope and control non-hairpin (NHP) pLKO.1 plasmids (Addgene)"
shRHAMM,genetic_reagents,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,shRHAMM,Viral,,,,,,,,,,,,,,,,,,,,shRNA against RHAMM and TPX2 (Sigma)
shTPX2,genetic_reagents,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,shTPX2,Viral,,,,,,,,,,,,,,,,,,,,shRNA against RHAMM and TPX2 (Sigma)
ZEB1,genetic_reagents,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,ZEB1,Viral,,,,,,,,,,,,,,,,,,,,"T265, was infected by nontarget control or lentiviral vectors carrying ZEB1 shRNA lentivirus for 48 hours"
Cas9,genetic_reagents,PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Cas9,Other,,,,,,,,,,,,,,,,,,,,we utilized CRISPR Cas9 targeting of NF1 exon 2 to create inactivating indels in NF1 on both alleles
StrepII tag,genetic_reagents,PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,StrepII tag,Other,,,,,,,,,,,,,,,,,,,,"We utilized a StepTactin XT System from IBA Lifesciences (Gottingen, Germany). Whole cell lysates were generated by collecting cells and lysing them"
PBSB,genetic_reagents,PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,PBSB,Transposon,,,,,,,,,,,,,,,,,,,,we used Gateway cloning to transfer the DLR insert to a hygromycin-resistant PiggyBac Sleeping Beauty (PBSB) transposon vector
Lipofectamine,genetic_reagents,PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Lipofectamine,Other,,,,,,,,,,,,,,,,,,,,Neurite outgrowth was determined from low-density hippocampal neurons transfected with EGFP using Lipofectamine
DNA extraction reagent,genetic_reagents,PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,DNA extraction reagent,Other,,,,,,,,,,,,,,,,,,,,"DNA was extracted from fresh-frozen tumor tissue and normal tissue using the DNeasy Blood and Tissue Kit (Qiagen, USA)"
RNA extraction reagent,genetic_reagents,PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,RNA extraction reagent,Other,,,,,,,,,,,,,,,,,,,,"Total RNA was isolated from tumor using the RNeasy Mini Kit (Qiagen, USA)"
LacZ,genetic_reagents,PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,LacZ,Viral,Ad5,,,,,,,,,,,,,,,,,,,Wild-type and Nf1 −/− NSCs were generated from Nf1 flox/flox mouse brains following infection with Ad5-LacZ and Ad5-Cre adenovirus
Cre,genetic_reagents,PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Cre,Viral,Ad5,,,,,,,,,,,,,,,,,,,Wild-type and Nf1 −/− NSCs were generated from Nf1 flox/flox mouse brains following infection with Ad5-LacZ and Ad5-Cre adenovirus
Abcg1,genetic_reagents,PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Abcg1,Plasmid,pLKO.1,,,,,,,,,,,,,,,,,,,"Abcg1 shRNA or control shGFP-containing pLKO.1 plasmid was co-transfected with pMDLg/pRRE, pRSV-REV and pCMV-VSV-G"
GSK3B,genetic_reagents,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,GSK3B,Viral,,,,,,,,,,,,,,,,,,,,"Three independent shRNAs targeting AXIN1, GSK3B, CTNNB1, TNKS, RSPO2, and a non-silencing (NS) control shRNA were purchased from OpenBiosystems"
AXIN1,genetic_reagents,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,AXIN1,Viral,,,,,,,,,,,,,,,,,,,,"Three independent shRNAs targeting AXIN1, GSK3B, CTNNB1, TNKS, RSPO2, and a non-silencing (NS) control shRNA were purchased from OpenBiosystems"
CTNNB1,genetic_reagents,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,CTNNB1,Viral,,,,,,,,,,,,,,,,,,,,"Three independent shRNAs targeting AXIN1, GSK3B, CTNNB1, TNKS, RSPO2, and a non-silencing (NS) control shRNA were purchased from OpenBiosystems"
TNKS,genetic_reagents,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,TNKS,Viral,,,,,,,,,,,,,,,,,,,,"Three independent shRNAs targeting AXIN1, GSK3B, CTNNB1, TNKS, RSPO2, and a non-silencing (NS) control shRNA were purchased from OpenBiosystems"
RSPO2,genetic_reagents,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,RSPO2,Viral,,,,,,,,,,,,,,,,,,,,"Three independent shRNAs targeting AXIN1, GSK3B, CTNNB1, TNKS, RSPO2, and a non-silencing (NS) control shRNA were purchased from OpenBiosystems"
CTNNB1 S33Y,genetic_reagents,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,CTNNB1 S33Y,Viral,,CAGGS,,,,,,,,,,,,,,,,,,A dsRed control and CTNNB1 S33Y were cloned into a vector containing a CAGGS promoter to drive cDNA expression followed by an IRES-GFP
GSK3B,genetic_reagents,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,GSK3B,Plasmid,,CAGGS,,,,,,,,,,,,,,,,,,GSK3B and Luciferase cDNA (Invitrogen) were each cloned into a vector containing a CAGGS promoter to drive cDNA expression followed by an IRES-GFP
cfDNA extraction reagent,genetic_reagents,PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,cfDNA extraction reagent,Other,,,,,,,,,,,,,,,,,,,,"cfDNA was extracted from 2 to 8 mL of plasma using the QIAamp Circulating Nucleic Acid kit (Qiagen, Hilden, Germany)"
DNA extraction reagent,genetic_reagents,PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,DNA extraction reagent,Other,,,,,,,,,,,,,,,,,,,,"germline DNA extraction using the DNeasy Blood and Tissue kit (Qiagen, Hilden, Germany)"
DNA extraction reagent,genetic_reagents,PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,DNA extraction reagent,Other,,,,,,,,,,,,,,,,,,,,"germline DNA from PBMCs was collected in and extracted using PAXgene Blood DNA tubes and kit (PreAnalytix, Germantown, Maryland)"
DNA/RNA extraction reagent,genetic_reagents,PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,DNA/RNA extraction reagent,Other,,,,,,,,,,,,,,,,,,,,"Nucleic acids were isolated from tumor FFPE samples using the manufacturer's protocol with the AllPrep DNA/RNA FFPE kit (Qiagen, Hilden, Germany)"
library preparation reagent,genetic_reagents,PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,library preparation reagent,Other,,,,,,,,,,,,,,,,,,,,"Sequencing libraries were constructed from cfDNA using commercial kits per the manufacturers' instructions: TruSeq Nano (Illumina, San Diego, California)"
library preparation reagent,genetic_reagents,PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,library preparation reagent,Other,,,,,,,,,,,,,,,,,,,,"Sequencing libraries were constructed using commercial kits: Kapa HyperPrep (Roche, Basel, Switzerland) for WUSTL samples"
Cyclophilin D,genetic_reagents,PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Cyclophilin D,Plasmid,pSUMO,,,,,,,,,,,,,,,,,,,The human CypD expression system was constructed by building the pSUMO-Cyclophilin D plasmid
mito-GFP1-9,genetic_reagents,PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,mito-GFP1-9,Plasmid,pcDNA3,,,,,,,,,,,,,,,,,,,co-transfected with a combination of plasmids pcDNA3 mito-GFP1-9
TRAP1-GFP10,genetic_reagents,PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,TRAP1-GFP10,Plasmid,pcDNA3,,,,,,,,,,,,,,,,,,,pcDNA3-TRAP1-GFP10
CyPD-GFP11,genetic_reagents,PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,CyPD-GFP11,Plasmid,pcDNA3,,,,,,,,,,,,,,,,,,,pcDNA3CyPD-GFP11
ATP50-GFP11,genetic_reagents,PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,ATP50-GFP11,Plasmid,pcDNA3,,,,,,,,,,,,,,,,,,,pcDNA3ATP50-GFP11
DNA extraction reagent,genetic_reagents,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,DNA extraction reagent,Other,,,,,,,,,,,,,,,,,,,,High molecular weight (HMW) DNA (25 µg) was extracted from leukocytes using the Circulomics Nanobind CBB Big DNA kit
sequencing library preparation,genetic_reagents,PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,sequencing library preparation,Other,,,,,,,,,,,,,,,,,,,,Sequencing libraries were prepared from 3 µg of input DNA using the SQK-LSK109 ligation sequencing kit
papain,genetic_reagents,PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,papain,Other,,,,,,,,,,,,,,,,,,,,Tumors were mechanically and enzymatically dissociated using a papain-based tumor dissociation kit (Miltenyi Biotec).
DNA extraction reagent,genetic_reagents,PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,DNA extraction reagent,Other,,,,,,,,,,,,,,,,,,,,"Extraction of DNA from leukocytes and purification were performed with QIAamp DNA Blood Mini kit (Qiagen, Valencia, CA, USA)"
DNA methylation conversion reagent,genetic_reagents,PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,DNA methylation conversion reagent,Other,,,,,,,,,,,,,,,,,,,,"500 ng of DNA from each sample was bisulfite converted using the Zymo EZ DNA Methylation Kit (Zymo Research, Irvine, CA USA)"
targeted region arrays,genetic_reagents,PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,targeted region arrays,Other,,,,,,,,,,,,,,,,,,,,"We next designed custom NimbleGen targeted region arrays on five candidate genes, and sequenced four additional malignant meningiomas."
DNA FFPE extraction,genetic_reagents,PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,DNA FFPE extraction,Other,,,,,,,,,,,,,,,,,,,,"DNA samples were extracted from the tumor FFPE slides from these patients using QIAamp DNA FFPE kit (Qiagen, Valencia, CA, USA)"
AMpure XP,genetic_reagents,PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,AMpure XP,Other,,,,,,,,,,,,,,,,,,,,"Next, we purified DNA fragments using AMpure XP beads (Beckman, Brea, CA, USA)."
AccuPrime Taq High Fidelity,genetic_reagents,PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,AccuPrime Taq High Fidelity,Other,,,,,,,,,,,,,,,,,,,,"The PCR mixture contained 5 μl of 10X AccuPrime™ PCR Buffer, 0.3 μl of AccuPrime™ Taq High Fidelit"
COMT val158met probe,genetic_reagents,PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,COMT val158met probe,Other,,,,,,,,,,,,,,,,,,,,"Genotyping was performed using a real-time PCR system in the allelic discrimination mode...using the TaqMan Genotyping Master Mix (Applied Biosystems, Foster City, CA, USA)"
non-targeting control,genetic_reagents,PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,non-targeting control,Other,,,,,,,,,,,,,,,,,,,,"Transfection with a non-targeting, random sequence siRNA (Dharmacon) or Lipofectamine ™ 2000 alone served as separate negative controls."
Ras Binding Domain,genetic_reagents,PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Ras Binding Domain,Other,,,,,,,,,,,,,,,,,,,,"To determine the activity of Ras the EZ-Detect Ras Activation Kit (cat. 89855 from Pierce, Rockford, IL) was used"
CXCL12,genetic_reagents,PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,CXCL12,Viral,,,,,,,,,,,,,,,,,,,,Murine CXCL12 cDNA was subcloned into the lentiviral vector
firefly luciferase-GFP fusion,genetic_reagents,PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,firefly luciferase-GFP fusion,Viral,,human ubiquitin-C,,,,,,,,,,,,,,,,,,A second packaging vector (FUW-FLG) encoding a fusion of firefly luciferase and enhanced green fluorescent protein
Spred1(EVH1),genetic_reagents,PMID:28831766,10.1007/s12104-017-9768-1,NMR resonance assignments of the EVH1 domain of neurofibromin's recruitment factor Spred1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Spred1(EVH1),Plasmid,pET,,,,,,,,,,,,,,,,,,,Construction of pET-Spred1(EVH1) encoding the EVH1 domain of human Spred1 (Ser13–Ser130) preceded by a non-native translation initiating methionine
Tet-inducible,genetic_reagents,PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Tet-inducible,Viral,pLIX403,TRE3G,,,,,,,,,,,,,,,,,,the lentiviral attR1-attR2 Gateway destination vector pLIX403 (Addgene 41395) was modified to attR4-attR2 by Gibson assembly
DNA extraction kit,genetic_reagents,PMID:32107864,10.1002/mgg3.1180,Expanding the Noonan spectrum/RASopathy NGS panel: Benefits of adding NF1 and SPRED1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,DNA extraction kit,Other,,,,,,,,,,,,,,,,,,,,DNA was extracted from peripheral blood samples using PureGene Blood Core Kit B (Qiagen)
Tet-pLKO-puro,genetic_reagents,PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Tet-pLKO-puro,Plasmid,pLKO,,,,,,,,,,,,,,,,,,,"shRNAs targeting PTPN11 #5003 and #818 were subcloned into Tet-pLKO-puro vector (Addgene, no. 21915)"
TTIGFP-MLUEX,genetic_reagents,PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,TTIGFP-MLUEX,Plasmid,,Tet-regulated promoter,,,,,,,,,,,,,,,,,,The human NF1-GRD was amplified using the genomic deoxyribonucleic acid (gDNA) from HEK293T as polymerase chain reaction template and subcloned into TTIGFP-MLUEX vector
SB11,genetic_reagents,PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,SB11,Other,,,,,,,,,,,,,,,,,,,,a conditionally expressed SB transposase enzyme (R26-lsl-SB11)
T2/Onc15,genetic_reagents,PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,T2/Onc15,Transposon,,,,,,,,,,,,,,,,,,,,a concatomer of oncogenic transposons (T2/Onc15)
shRNA,genetic_reagents,PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,shRNA,Viral,GIPZ,,,,,,,,,,,,,,,,,,,shRNA GIPZ lentiviral constructs were purchased from Openbiosystems
FOXR2,genetic_reagents,PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,FOXR2,Transposon,piggyBac,,,,,,,,,,,,,,,,,,,FOXR2 cDNA (Open Biosystems) was cloned into the Gateway Vector System (Invitrogen) and subcloned into a piggyBac (PB) transposon vector
FOXR2,genetic_reagents,PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,FOXR2,Other,,,,,,,,,,,,,,,,,,,,TALENs targeting FOXR2 were designed using TALE-NT and constructed
HPRT,genetic_reagents,PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,HPRT,Other,,,,,,,,,,,,,,,,,,,,An HPRT TALEN pair served as a control
TruSeq library construction kit,genetic_reagents,PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,TruSeq library construction kit,Other,,,,,,,,,,,,,,,,,,,,"Genomic DNA from tumor and normal samples were fragmented and used for Illumina TruSeq library construction (Illumina, San Diego, CA) according to the manufacturer's instructions."
SureSelect v.4,genetic_reagents,PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,SureSelect v.4,Other,,,,,,,,,,,,,,,,,,,,"Exonic regions were captured in solution using the Agilent SureSelect v.4 kit (Agilent, Santa Clara, CA)."
gRNA,genetic_reagents,PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,gRNA,Plasmid,,U6,,,,,,,,,,,,,,,,,,U6-gRNA vectors were produced as previously described and introduced into iHSCs that are proficient for NF1
RNasin RNase inhibitor,genetic_reagents,PMID:15255999,10.1186/1476-4598-3-20,"Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,RNasin RNase inhibitor,Other,,,,,,,,,,,,,,,,,,,,"20 units of RNasin RNase inhibitor (Promega, Madison, WI)"
Non-targeting control,genetic_reagents,PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Non-targeting control,Other,,,,,,,,,,,,,,,,,,,,"RNAi was performed using ON-TARGETplus Non-targeting Pool (#D-001810–10-05, Dharmacon)"
SureSelect bait library V1,genetic_reagents,PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,SureSelect bait library V1,Other,,,,,,,,,,,,,,,,,,,,"We used Agilent eArray to design our SureSelect bait library V1 (Agilent, California, USA), covering 106 genes"
SureSelect bait library V2,genetic_reagents,PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,SureSelect bait library V2,Other,,,,,,,,,,,,,,,,,,,,The bait library V2 included 122 genes responsible for most of the cancer predisposition syndromes
shRNAs,genetic_reagents,PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,shRNAs,Viral,,,,,,,,,,,,,,,,,,,,"We infected secondary Nf1 neurofibroma spheres or fl/fl;DhhCre Stat3 DRG/neurofibroma spheres with shRNAs and non-target control (Sigma, St Louis, MO, USA)"
D22S193,genetic_reagents,PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,D22S193,Other,,,,,,,,,,,,,,,,,,,,checked for loss of heterozygosity in tumor DNA at markers D22S193 (centromeric to NF2)
D22S929,genetic_reagents,PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,D22S929,Other,,,,,,,,,,,,,,,,,,,,"NF2 TET and D22S929 (intragenic), and D22S268 and D22S430"
D22S268,genetic_reagents,PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,D22S268,Other,,,,,,,,,,,,,,,,,,,,"D22S929 (intragenic), and D22S268 and D22S430 (telomeric to NF2)"
D22S430,genetic_reagents,PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,D22S430,Other,,,,,,,,,,,,,,,,,,,,and D22S268 and D22S430 (telomeric to NF2)
NucLight red,genetic_reagents,PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,NucLight red,Viral,,,,,,,,,,,,,,,,,,,,Cell lines were infected with NucLight red lentivirus and stably selected in puromycin
DNeasy mini kit,genetic_reagents,PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,DNeasy mini kit,Other,,,,,,,,,,,,,,,,,,,,"Genomic DNA (gDNA) was extracted from both frozen tumour and blood tissues using the DNeasy mini kit (Qiagen, Valencia, CA, USA)"
NEBNext DNA Library Prep Reagent Set,genetic_reagents,PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,NEBNext DNA Library Prep Reagent Set,Other,,,,,,,,,,,,,,,,,,,,"Standard whole genome library prep was done using the NEBNext DNA Library Prep Reagent Set for Illumina (New England BioLabs Inc., Ipswich, MA, USA)"
KAPA Library Quantification Kit,genetic_reagents,PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,KAPA Library Quantification Kit,Other,,,,,,,,,,,,,,,,,,,,Accurate quantification for sequencing applications was determined using the qPCR-based KAPA Biosystems Library Quantification Kit
HumanOmni2.5-8,genetic_reagents,PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,HumanOmni2.5-8,Other,,,,,,,,,,,,,,,,,,,,"SNP array sample prep was done using the HumanOmni2.5–8 (Illumina, Inc., San Diego, CA, USA)"
miRNeasy mini kit,genetic_reagents,PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,miRNeasy mini kit,Other,,,,,,,,,,,,,,,,,,,,"Total RNA containing both mRNA as well as microRNA fractions was extracted from the tissues using the miRNeasy mini kit (Qiagen, Valencia, CA, USA)"
NEBNext Magnetic Oligo d(T)25 Beads,genetic_reagents,PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,NEBNext Magnetic Oligo d(T)25 Beads,Other,,,,,,,,,,,,,,,,,,,,Poly-adenylated RNAs were isolated using NEBNext Magnetic Oligo d(T)25 Beads
NEBNext mRNA Library Prep Reagent Set,genetic_reagents,PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,NEBNext mRNA Library Prep Reagent Set,Other,,,,,,,,,,,,,,,,,,,,"The NEBNext mRNA Library Prep Reagent Set for Illumina (New England BioLabs Inc., Ipswich, MA, USA) was then used to prepare individually bar-coded"
TruSeq SBS HS v4 Kit,genetic_reagents,PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,TruSeq SBS HS v4 Kit,Other,,,,,,,,,,,,,,,,,,,,"Paired-end sequencing (25 million, 50-bp, paired-end reads) was performed using a 200 Cycle TruSeq SBS HS v4 Kit"
QIAamp Circulating Nucleic Acid kit,genetic_reagents,PMID:39093127,10.1158/1078-0432.CCR-24-0797,Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,QIAamp Circulating Nucleic Acid kit,Other,,,,,,,,,,,,,,,,,,,,cfDNA was extracted from 2 to 8 mL of plasma using the QIAamp Circulating Nucleic Acid kit (Qiagen)
Qubit dsDNA High-Sensitivity Assay kit,genetic_reagents,PMID:39093127,10.1158/1078-0432.CCR-24-0797,Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Qubit dsDNA High-Sensitivity Assay kit,Other,,,,,,,,,,,,,,,,,,,,Extracted DNA concentration was measured using the Qubit dsDNA High-Sensitivity Assay kit (Thermo-Fisher)
KAPA HyperPrep kit,genetic_reagents,PMID:39093127,10.1158/1078-0432.CCR-24-0797,Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,KAPA HyperPrep kit,Other,,,,,,,,,,,,,,,,,,,,cfDNA sequencing libraries were constructed from 10 to 60 ng of isolated DNA using the KAPA HyperPrep kit (Roche)
xGen UDI-UMI Adapters,genetic_reagents,PMID:39093127,10.1158/1078-0432.CCR-24-0797,Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,xGen UDI-UMI Adapters,Other,,,,,,,,,,,,,,,,,,,,cfDNA sequencing libraries were constructed from 10 to 60 ng of isolated DNA using the KAPA HyperPrep kit (Roche) and xGen UDI-UMI Adapters (IDT)
TruSight Oncology 500,genetic_reagents,PMID:39093127,10.1158/1078-0432.CCR-24-0797,Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,TruSight Oncology 500,Other,,,,,,,,,,,,,,,,,,,,Tissue genomic profiling was performed by Clinical Laboratory Improvement Amendments–certified molecular laboratories using TruSight Oncology 500 (Illumina)
GFP,genetic_reagents,PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,GFP,Viral,,,,,,,,,,,,,,,,,,,,lentiviral particles containing shRNAs targeting SOX9 (Open Biosystems; TRC library) or GFP (Addgene)
hTERT and mCdk4,genetic_reagents,PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,hTERT and mCdk4,Viral,pTYcPPT,EF1α,,,,,,,,,,,,,,,,,,"The vector pTYcPPT, containing the elongation factor 1 alpha promoter, was used to separately clone hTERT and mCdk4"
Hematoxylin & Eosin,genetic_reagents,PMID:38603731,10.1371/journal.pone.0302017,Raman difference spectroscopy and U-Net convolutional neural network for molecular analysis of cutaneous neurofibroma.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Hematoxylin & Eosin,Other,,,,,,,,,,,,,,,,,,,,Four standard 10-μm-thick sections were stained with Hematoxylin & Eosin for each specimen
Cre,genetic_reagents,PMID:17924978,10.1111/j.1750-3639.2007.00105.x,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Cre,Viral,,,,,,,,,,,,,,,,,,,,Cre recombinase was targeted to the mouse leptomeninges by direct injection of 3 µL (1 × 10 8 plaque‐forming units) of adCre suspension
firefly luciferase-eGFP fusion,genetic_reagents,PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,firefly luciferase-eGFP fusion,Viral,FUW,human ubiquitin C,,,,,,,,,,,,,,,,,,A second packaging vector (FUW-FLG) encoding a fusion of firefly luciferase and enhanced green fluorescent protein driven by the human ubiquitin C promoter
CAS9,genetic_reagents,PMID:41023593,10.1186/s10020-025-01353-9,Selective inhibition of BRAF and CRAF sensitizes NF1-deficient malignant peripheral nerve sheath tumors to MEK inhibitors.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,CAS9,Other,,,,,,,,,,,,,,,,,,,,"Conditional gene expression, CRISPR-CAS9, and shRNA-mediated knockdown were used to perform gain/loss-of-function experiments"
shRNA,genetic_reagents,PMID:41023593,10.1186/s10020-025-01353-9,Selective inhibition of BRAF and CRAF sensitizes NF1-deficient malignant peripheral nerve sheath tumors to MEK inhibitors.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,shRNA,Other,,,,,,,,,,,,,,,,,,,,"CRISPR-CAS9, and shRNA-mediated knockdown were used to perform gain/loss-of-function experiments to explore the effect of reconstituting the GTPase-activating protein-related domain of NF1"
Cre,genetic_reagents,PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Cre,Viral,,CMV,,,,,,,,,,,,,,,,,,"Cre recombinase expressing adenovirus (Ad5CMVCre-GFP High Titer, University of Iowa Viral Vector Core)"
DNA extraction reagent,genetic_reagents,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,DNA extraction reagent,Other,,,,,,,,,,,,,,,,,,,,DNA was purified using the Qiagen DNeasy Extraction kit and 0.5 µg was subjected to bisulfite treatment
Bisulfite treatment reagent,genetic_reagents,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Bisulfite treatment reagent,Other,,,,,,,,,,,,,,,,,,,,"0.5 µg was subjected to bisulfite treatment (Qiagen, EpiTect plus)"
Exome capture reagent,genetic_reagents,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Exome capture reagent,Other,,,,,,,,,,,,,,,,,,,,Libraries were constructed from > 200 ng starting genomic DNA using the Agilent SureSelect Human All Exon V5 + UTRs kit
Library preparation reagent,genetic_reagents,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Library preparation reagent,Other,,,,,,,,,,,,,,,,,,,,Genomic DNA (0.5–1 µg) libraries were generated using the Illumina TruSeq PCR-free DNA library preparation kit
RNA library preparation reagent,genetic_reagents,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,RNA library preparation reagent,Other,,,,,,,,,,,,,,,,,,,,"Tumor RNA libraries were prepared from 200 ng of RNA and the Illumina TruSeq mStranded Total RNA (N = 18, RIN > 8)"
RNA depletion reagent,genetic_reagents,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,RNA depletion reagent,Other,,,,,,,,,,,,,,,,,,,,"Illumina TruSeq mStranded Total RNA (N = 18, RIN > 8) and Ribo-Zero Gold (N = 6, RIN < 8) kits"
Reverse transcription reagent,genetic_reagents,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Reverse transcription reagent,Other,,,,,,,,,,,,,,,,,,,,"To validate fusions, purified RNAs were reverse-transcribed using SuperScript VILO kit"
PCR purification reagent,genetic_reagents,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,PCR purification reagent,Other,,,,,,,,,,,,,,,,,,,,PCR products were purified using the Qiagen MinElute PCR purification kit and run on a 1.2% agarose gel
Target enrichment reagent,genetic_reagents,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Target enrichment reagent,Other,,,,,,,,,,,,,,,,,,,,Library preparation for NGS was accomplished using the HaloPlex PCR target enrichment system (Agilent Technologies Inc.)
Sequencing reagent,genetic_reagents,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Sequencing reagent,Other,,,,,,,,,,,,,,,,,,,,"Sequencing was performed using MiSeq reagent kit version 2, 300 cycles, on the MiSeq instrument"
Microsatellite markers,genetic_reagents,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Microsatellite markers,Other,,,,,,,,,,,,,,,,,,,,"Loss of heterozygosity (LOH) in 22q was investigated using microsatellites D22S420, D22S539, D22S1174, D22S315, D22S1154, D22S1163, D22S280, D22S277, D22S283, D22S423, D22S274, and D22S1169 from the ABI PRISM Linkage Mapping set version 2.5"
MLPA probe set,genetic_reagents,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,MLPA probe set,Other,,,,,,,,,,,,,,,,,,,,"SMARCB1, NF2 and 22q11 MLPA test kits (MRC-Holland, P044_B1, P258_C1 and P324_A2) were used"
MLPA probe set,genetic_reagents,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,MLPA probe set,Other,,,,,,,,,,,,,,,,,,,,"SMARCB1, NF2 and 22q11 MLPA test kits (MRC-Holland, P044_B1, P258_C1 and P324_A2) were used"
MLPA probe set,genetic_reagents,PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,MLPA probe set,Other,,,,,,,,,,,,,,,,,,,,"SMARCB1, NF2 and 22q11 MLPA test kits (MRC-Holland, P044_B1, P258_C1 and P324_A2) were used"
shRNA library,genetic_reagents,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,shRNA library,Viral,LT3GEPIR mir-E,,,,,,,,,,,,,,,,,,,A doxycycline-inducible pooled human epigenome-focused lentiviral shRNA plasmid library in the LT3GEPIR mir-E backbone
sgRNA,genetic_reagents,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,sgRNA,Plasmid,pL-CRISPR.EFS.Blast,EFS,,,,,,,,,,,,,,,,,,Control and SUZ12 sgRNA targeting the VEFS functional domain were cloned into pL-CRISPR.EFS.Blast (plasmid was generated by replacing tagRFP in Addgene Plasmid #57819)
All-Prep Universal Kit,genetic_reagents,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,All-Prep Universal Kit,Other,,,,,,,,,,,,,,,,,,,,"DNA and RNA were isolated from cell lines, human samples, or mouse allografts using the All-Prep Universal Kit (#80224, QIAGEN)"
Kapa Hyper Prep Kit,genetic_reagents,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Kapa Hyper Prep Kit,Other,,,,,,,,,,,,,,,,,,,,"Sequencing libraries were prepared using the Kapa Hyper Prep Kit (#07962312001, Roche)"
Nimblegen SeqCap EZ Human Exome Kit,genetic_reagents,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Nimblegen SeqCap EZ Human Exome Kit,Other,,,,,,,,,,,,,,,,,,,,exome capture was performed using the Nimblegen SeqCap EZ Human Exome Kit v3.0 (Roche)
TruSeq RNA Library Prep Kit v2,genetic_reagents,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,TruSeq RNA Library Prep Kit v2,Other,,,,,,,,,,,,,,,,,,,,"Library preparation was performed using the TruSeq RNA Library Prep Kit v2 (#RS-122-2001, Illumina)"
Chromium Single Cell 3′ Library & Gel Bead Kit v3.1,genetic_reagents,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Chromium Single Cell 3′ Library & Gel Bead Kit v3.1,Other,,,,,,,,,,,,,,,,,,,,Single-nuclei or single-cell RNA sequencing was performed using the Chromium Single Cell 3′ Library & Gel Bead Kit v3.1 on a 10× Chromium controller
CellTiter 96 Non-Radioactive Cell Proliferation Assay,genetic_reagents,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,CellTiter 96 Non-Radioactive Cell Proliferation Assay,Other,,,,,,,,,,,,,,,,,,,,"Viability assays were carried out with the CellTiter 96 Non-Radioactive Cell Proliferation Assay (#G410, Promega)"
RNeasy Mini Kit,genetic_reagents,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,RNeasy Mini Kit,Other,,,,,,,,,,,,,,,,,,,,"RNA was extracted from cell lines using the RNeasy Mini Kit (#74106, QIAGEN)"
iScript cDNA Synthesis kit,genetic_reagents,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,iScript cDNA Synthesis kit,Other,,,,,,,,,,,,,,,,,,,,"cDNA was synthesized from RNA using iScript cDNA Synthesis kit (#1708891, Bio-Rad)"
PowerUp SYBR Green Master Mix,genetic_reagents,PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,PowerUp SYBR Green Master Mix,Other,,,,,,,,,,,,,,,,,,,,"Real-time QPCR was performed using PowerUp SYBR Green Master Mix (#A25918, Thermo Fisher Scientific)"
I2HCP panel,genetic_reagents,PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,I2HCP panel,Other,,,,,,,,,,,,,,,,,,,,Genetic testing was performed using the customized I2HCP panel in blood or tissue when available.
Endo-Porter,genetic_reagents,PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Endo-Porter,Other,,,,,,,,,,,,,,,,,,,,Endo-Porter (Gene Tools) was used as vehicle to deliver PMOs into cells at 6 μM
Click-iT EdU Alexa Fluor 488,genetic_reagents,PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Click-iT EdU Alexa Fluor 488,Other,,,,,,,,,,,,,,,,,,,,"AClick-iT EdU Alexa Fluor 488 Flow Cytometry Assay Kit (Molecular Probes, Invitrogen) was used, according to the manufacturer's protocol, to determine cell proliferation"
RealTime-Glo MT,genetic_reagents,PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,RealTime-Glo MT,Other,,,,,,,,,,,,,,,,,,,,Cell viability was assessed using RealTime-Glo MT Cell Viability Assay (Promega) following the manufacturer's instructions
Lipofectamine LTX,genetic_reagents,PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Lipofectamine LTX,Other,,,,,,,,,,,,,,,,,,,,"The expression vector was transfected into HeLa cells (Lipofectamine LTX with Plus Reagent, Invitrogen)"
empty vector,genetic_reagents,PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,empty vector,Viral,,CMV,,,,,,,,,,,,,,,,,,"Adenovirus (Ad) CMVempty vector (EV) at 5 × 109 pfu/mL, AdCMVNeuroD1 at 2 × 109 pfu/mL"
644 cancer gene panel,genetic_reagents,PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,644 cancer gene panel,Other,,,,,,,,,,,,,,,,,,,,Genomic regions of interest were captured using an Agilent custom-designed bait set covering the full coding regions of 644 cancer associated genes
Human Exome,genetic_reagents,PMID:24932921,10.1002/jbmr.2298,Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Human Exome,Other,,,,,,,,,,,,,,,,,,,,"Whole-exome capture was performed using either the SeqCap EZ Human Exome Library (Nimblegen, Basel, Switzerland)"
Human Exome,genetic_reagents,PMID:24932921,10.1002/jbmr.2298,Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Human Exome,Other,,,,,,,,,,,,,,,,,,,,"Whole-exome capture was performed using either the SeqCap EZ Human Exome Library (Nimblegen, Basel, Switzerland) or TruSeq Exome kit (Illumina, San Diego, CA)"
LNTH-1363S,genetic_reagents,PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,LNTH-1363S,Other,,,,,,,,,,,,,,,,,,,,"After administration of 179 MBq [68Ga]Ga-LNTH-1363S, (FAP-directed radiotracer; mass dose, 90 ug)"
GFP,genetic_reagents,PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,GFP,Viral,Ad5,CMV,,,,,,,,,,,,,,,,,,"containing either Ad5-CMV-GFP or Ad5-CMV-cre (Vector development lab, Baylor College of Medicine)"
Cre,genetic_reagents,PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Cre,Viral,Ad5,CMV,,,,,,,,,,,,,,,,,,"containing either Ad5-CMV-GFP or Ad5-CMV-cre (Vector development lab, Baylor College of Medicine)"
pac,genetic_reagents,PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,pac,Viral,MSCV,,,,,,,,,,,,,,,,,,,a virus expressing the selectable marker gene alone (MSCV-pac)
Scrambled siRNA,genetic_reagents,PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Scrambled siRNA,Other,,,,,,,,,,,,,,,,,,,,Scrambled oligonucleotides (Cat. no. sc-36869) or vehicle only was used as controls
MSCV,genetic_reagents,PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,MSCV,Viral,,,,,,,,,,,,,,,,,,,,Murine stem cell virus (MSCV) infection was employed to express human WT or mutant (L64P patient mutation) merlin
PD0325901,genetic_reagents,PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,PD0325901,Other,,,,,,,,,,,,,,,,,,,,"MEK inhibitor (MEKi, PD0325901, Sigma-Aldrich, St. Louis, MO) was dissolved in DMSO at a concentration of 25 mg/ml"
pGEX 4T-1,genetic_reagents,PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,pGEX 4T-1,Plasmid,pGEX,,,,,,,,,,,,,,,,,,,"Human MCL-1-glutathione-S-transferase (GST) and BCL-XL-GST fusion proteins were cloned into the pGEX 4T-1 expression plasmid (available from Addgene, Watertown, MA, USA)"
Custom gene panel,genetic_reagents,PMID:41001593,10.1080/23723556.2025.2561292,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Custom gene panel,Other,,,,,,,,,,,,,,,,,,,,Transcript level of the following genes were analyzed using an Illumina custom panel
DNA extraction reagent,genetic_reagents,PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,DNA extraction reagent,Other,,,,,,,,,,,,,,,,,,,,"The gDNA was purified starting from formalin-fixed paraffin-embedded (FFPE) samples obtained at surgical resection, using the Magcore DNA FFPE One-Step Kit (Code 405)."
DNA quantification reagent,genetic_reagents,PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,DNA quantification reagent,Other,,,,,,,,,,,,,,,,,,,,Fragmented gDNAs were tested for size distribution and concentration using an Agilent Tapestation 4200 and Qubit dsDNA High Sensitivity kit.
PSME3,genetic_reagents,PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,0.85,Experimental Usage,False,1.00,Medium,,,,,,,,,,,PSME3,Plasmid,pSG5,SV40,,,,,,,,,,,,,,,,,,stably transfected with plasmid pSG5 vector and encoding PSME3 cDNA harbor PA28у cDNA under a constitutive SV40 promotor
HA,antibodies,PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,0.85,Experimental Usage,True,0.67,Medium,,,,HA,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies were from Cell Signaling Technology (Danvers, U.S.A.) (rabbit anti-HA; mouse anti-HA; 9B11 mouse anti-myc)"
HA,antibodies,PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,0.85,Experimental Usage,True,0.67,Medium,,,,HA,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Antibodies were from Cell Signaling Technology (Danvers, U.S.A.) (rabbit anti-HA; mouse anti-HA; 9B11 mouse anti-myc)"
V5,antibodies,PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,0.85,Experimental Usage,True,0.67,Medium,,,,V5,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Invitrogen (mouse anti-V5), Sigma-Aldrich (St. Louis, U.S.A.) (mouse and rabbit anti-FLAG)"
FLAG,antibodies,PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,0.85,Experimental Usage,True,0.67,Medium,,,,FLAG,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Sigma-Aldrich (St. Louis, U.S.A.) (mouse and rabbit anti-FLAG), and LI-COR Biosciences"
FLAG,antibodies,PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,0.85,Experimental Usage,True,0.67,Medium,,,,FLAG,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Sigma-Aldrich (St. Louis, U.S.A.) (mouse and rabbit anti-FLAG), and LI-COR Biosciences"
S100A10,antibodies,PMID:26883872,10.1016/j.jprot.2016.02.004,3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma.,,0.85,Experimental Usage,True,0.67,Medium,,,,S100A10,,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,optic nerve sections were incubated with polyclonal anti-S100A10 antibodies (1:1000; R&D Systems)
"Na+,K+-ATPase",antibodies,PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,0.85,Experimental Usage,True,0.67,Medium,,,,"Na+,K+-ATPase",Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Markers for membrane, cytosolic and nuclear fractions were: rabbit anti- Na + , K + - ATPase, GAPDH, and PARP (Cell Signaling)"
S-100,antibodies,PMID:15240917,10.1155/S1110724304308107,Survival of Human Neurofibroma in Immunodeficient Mice and Initial Results of Therapy With Pirfenidone.,,0.85,Experimental Usage,True,0.67,Medium,,,,S-100,Rabbit,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Human S-100 A and B protein was detected using rabbit antiserum (Dako Corp, Carpinteria, Calif)"
NF2/merlin,antibodies,PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,0.85,Experimental Usage,True,0.67,Medium,,,,NF2/merlin,Unknown,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,Another anti-merlin polyclonal antibody (A-19) was purchased from Santa Cruz Biotechnology
ColIA,antibodies,PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,0.85,Experimental Usage,True,0.67,Medium,,,,ColIA,,Monoclonal,,,,,,,,,,,,,,,,,,,,,,,,,,"Fibroblasts were stained for 30 min at 4°C with 1 µg/ml of FITC-conjugated anti-ColIA monoclonal antibody (Pharmingen, San Diego, CA, USA)"
Brn3a,antibodies,PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.85,Experimental Usage,True,0.33,Medium,,,,Brn3a,,,,,,,,,,,,,,,,,,,,,,,,,,,,labeled overnight at room temperature with the following conjugated primary antibodies: Brn3a-FITC
RBPMS,antibodies,PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.85,Experimental Usage,True,0.33,Medium,,,,RBPMS,,,,,,,,,,,,,,,,,,,,,,,,,,,,"labeled overnight at room temperature with the following conjugated primary antibodies: Brn3a-FITC, RBPMS-APC"
Thy1.1,antibodies,PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.85,Experimental Usage,True,0.33,Medium,,,,Thy1.1,,,,,,,,,,,,,,,,,,,,,,,,,,,,Thy1.1-APC (ganglion cell marker)
Caspase9,antibodies,PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.85,Experimental Usage,True,0.33,Medium,,,,Caspase9,,,,,,,,,,,,,,,,,,,,,,,,,,,,Caspase9-FITC (apoptosis marker)
Ki67,antibodies,PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.85,Experimental Usage,True,0.33,Medium,,,,Ki67,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ki67-FITC (proliferation marker)
Cmyc,antibodies,PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.85,Experimental Usage,True,0.33,Medium,,,,Cmyc,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Cmyc-FITC, Oct4-APC (stemness markers)"
Oct4,antibodies,PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.85,Experimental Usage,True,0.33,Medium,,,,Oct4,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Cmyc-FITC, Oct4-APC (stemness markers)"
NeuN,antibodies,PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.85,Experimental Usage,True,0.33,Medium,,,,NeuN,,,,,,,,,,,,,,,,,,,,,,,,,,,,NeuN-APC (neuronal marker)
CD45,antibodies,PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.85,Experimental Usage,True,0.33,Medium,,,,CD45,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Every 5th section was stained with CD45-PE, IBA1-FITC (immune cell marker)"
IBA1,antibodies,PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.85,Experimental Usage,True,0.33,Medium,,,,IBA1,,,,,,,,,,,,,,,,,,,,,,,,,,,,"CD45-PE, IBA1-FITC (immune cell marker)"
GFAP,antibodies,PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.85,Experimental Usage,True,0.33,Medium,,,,GFAP,,,,,,,,,,,,,,,,,,,,,,,,,,,,Every 6th section was stained with GFAP-PE (Muller cells marker)
STEM121,antibodies,PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.85,Experimental Usage,True,0.33,Medium,,,,STEM121,,,,,,,,,,,,,,,,,,,,,,,,,,,,STEM121-FITC (human cell marker)
Erk1/2,antibodies,PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,0.85,Experimental Usage,True,0.33,Medium,,,,Erk1/2,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Western blot analyses were performed using anti-total and anti-phospho Erk1/2 (Cell Signaling, Danvers, MA, USA) antibodies"
phospho-Erk1/2,antibodies,PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,0.85,Experimental Usage,True,0.33,Medium,,,,phospho-Erk1/2,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Western blot analyses were performed using anti-total and anti-phospho Erk1/2 (Cell Signaling, Danvers, MA, USA) antibodies"
H3K27me3,antibodies,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,0.33,Medium,,,,H3K27me3,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"FFPE tissue blocks were collected for each fresh-frozen tumor which underwent multiomic profiling and were used for pathology review, IHC (MYF-4, H3K7me3, S100, and Sox10)"
MYF-4,antibodies,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,0.33,Medium,,,,MYF-4,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"FFPE tissue blocks were collected for each fresh-frozen tumor which underwent multiomic profiling and were used for pathology review, IHC (MYF-4, H3K7me3, S100, and Sox10)"
S100,antibodies,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,0.33,Medium,,,,S100,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"FFPE tissue blocks were collected for each fresh-frozen tumor which underwent multiomic profiling and were used for pathology review, IHC (MYF-4, H3K7me3, S100, and Sox10)"
Sox10,antibodies,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,0.33,Medium,,,,Sox10,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"FFPE tissue blocks were collected for each fresh-frozen tumor which underwent multiomic profiling and were used for pathology review, IHC (MYF-4, H3K7me3, S100, and Sox10)"
HMB45,antibodies,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,0.33,Medium,,,,HMB45,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Additional IHC (HMB45 and Melan-A) was performed to exclude melanoma
Melan-A,antibodies,PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,Experimental Usage,True,0.33,Medium,,,,Melan-A,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Additional IHC (HMB45 and Melan-A) was performed to exclude melanoma
CD90,antibodies,PMID:25851896,10.3988/jcn.2015.11.2.172,Preclinical assessment of the anticancer drug response of plexiform neurofibroma tissue using primary cultures.,,0.85,Experimental Usage,True,0.33,Medium,,,,CD90,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"cells were incubated with 2 µg/mL anti-human CD90 antibody (Dianova, Hamburg, Germany)"
s-100b,antibodies,PMID:39110684,10.1371/journal.pone.0308207,Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon nanotube fibers.,,0.85,Experimental Usage,True,0.33,Medium,,,,s-100b,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Schwann cells were incubated with antibody against s-100b (Sigma) as the primary overnight at 1:400 ratio
Merlin,antibodies,PMID:24595234,10.1371/journal.pone.0090853,In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,,0.85,Experimental Usage,True,0.33,Medium,,,,Merlin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,guinea-pig anti-Merlin [8] was used at 1∶5000
GLAST,antibodies,PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.85,Experimental Usage,True,0.33,Medium,,,,GLAST,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,GLAST (a gift from Dr. Watanabe; (Shibata et al. 1997))
DDK tag,antibodies,PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,0.85,Experimental Usage,True,0.33,Medium,,,,DDK tag,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,The expression of the DDK-tagged transcript was validated by Western blot using anti-DDK antibodies
YAP1,antibodies,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.85,Experimental Usage,True,0.33,Medium,,,,YAP1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Antibody specific for YAP1 was from Cell Signaling Inc.
HIF-1α,antibodies,PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,0.85,Experimental Usage,True,0.33,Medium,,,,HIF-1α,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"HIF-1α, BECLIN1, BIM, BCL-xL, β-tubulin, Ferritin HC and transferrin receptor-1 (TfR1/CD71; Santa Cruz Biotechnology Inc., Santa Cruz, CA)"
BNIP3,antibodies,PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,0.85,Experimental Usage,True,0.33,Medium,,,,BNIP3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"BNIP3 (Sigma, St. Louis, MO)"
BECLIN1,antibodies,PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,0.85,Experimental Usage,True,0.33,Medium,,,,BECLIN1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"HIF-1α, BECLIN1, BIM, BCL-xL, β-tubulin, Ferritin HC and transferrin receptor-1 (TfR1/CD71; Santa Cruz Biotechnology Inc., Santa Cruz, CA)"
LC3,antibodies,PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,0.85,Experimental Usage,True,0.33,Medium,,,,LC3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"LC3 (Abgent, San Diego, CA)"
GAPDH,antibodies,PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,0.85,Experimental Usage,True,0.33,Medium,,,,GAPDH,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"GAPDH, BCL-2 and PUMA (Cell Signaling, Danvers, MA)"
CD8α,antibodies,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.85,Experimental Usage,True,0.33,Medium,,,,CD8α,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,CD8α (PA5-81344)
S100,antibodies,PMID:21111000,10.1016/j.jneumeth.2010.10.021,A novel imaging-compatible sciatic nerve schwannoma model.,,0.85,Experimental Usage,True,0.33,Medium,,,,S100,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"S100 (1:400, Dako, Glostrun Denman, Carpinteria, CA) was visualized using fluorescent immunohistochemistry"
EMA,antibodies,PMID:39996452,10.1111/cns.70287,Cas9 Mouse Model of Skull Base Meningioma Driven by Combinational Gene Inactivation in Meningeal Cells.,,0.85,Experimental Usage,True,0.33,Medium,,,,EMA,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"examined for EMA, vimentin, and Ki‐67 (as detected by MIB‐1 antibody) via immunohistochemical (IHC) staining. The primary antibodies were all obtained from Abcam."
vimentin,antibodies,PMID:39996452,10.1111/cns.70287,Cas9 Mouse Model of Skull Base Meningioma Driven by Combinational Gene Inactivation in Meningeal Cells.,,0.85,Experimental Usage,True,0.33,Medium,,,,vimentin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"examined for EMA, vimentin, and Ki‐67 (as detected by MIB‐1 antibody) via immunohistochemical (IHC) staining. The primary antibodies were all obtained from Abcam."
Ki-67,antibodies,PMID:39996452,10.1111/cns.70287,Cas9 Mouse Model of Skull Base Meningioma Driven by Combinational Gene Inactivation in Meningeal Cells.,,0.85,Experimental Usage,True,0.33,Medium,,,,Ki-67,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"examined for EMA, vimentin, and Ki‐67 (as detected by MIB‐1 antibody) via immunohistochemical (IHC) staining. The primary antibodies were all obtained from Abcam."
S100,antibodies,PMID:33767727,10.3389/fgene.2021.603195,Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing.,,0.85,Experimental Usage,True,0.33,Medium,,,,S100,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Immunohistochemical analysis showed scattered S100 positivity in tumor cell nuclei
CD34,antibodies,PMID:33767727,10.3389/fgene.2021.603195,Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing.,,0.85,Experimental Usage,True,0.33,Medium,,,,CD34,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,strong and diffuse CD34 positivity in the tumor cell cytoplasm
RHAMM,antibodies,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,Experimental Usage,True,0.33,Medium,,,,RHAMM,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Antibodies were sourced as follows: RHAMM (Epitomics)
TPX2,antibodies,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,Experimental Usage,True,0.33,Medium,,,,TPX2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,TPX2 (Novus)
nestin,antibodies,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,Experimental Usage,True,0.33,Medium,,,,nestin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,nestin (Covance)
Tuj1,antibodies,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,Experimental Usage,True,0.33,Medium,,,,Tuj1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Tuj1 (Covance)
β-actin,antibodies,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,Experimental Usage,True,0.33,Medium,,,,β-actin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,β-actin (Sigma)
AURKA,antibodies,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,Experimental Usage,True,0.33,Medium,,,,AURKA,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"AURKA, phospho (p)-AURKA (Thr288), p-histone H3 (Ser10), and caspase 9 (Cell Signalling)"
phospho-AURKA (Thr288),antibodies,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,Experimental Usage,True,0.33,Medium,,,,phospho-AURKA (Thr288),Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,phospho (p)-AURKA (Thr288)
p-histone H3 (Ser10),antibodies,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,Experimental Usage,True,0.33,Medium,,,,p-histone H3 (Ser10),Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,p-histone H3 (Ser10)
caspase 9,antibodies,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,Experimental Usage,True,0.33,Medium,,,,caspase 9,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,caspase 9 (Cell Signalling)
tau 1,antibodies,PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,0.85,Experimental Usage,True,0.33,Medium,,,,tau 1,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Additionally, axons were identified by immunolabeling with tau 1 antibodies (not shown)"
Tuj-1,antibodies,PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.85,Experimental Usage,True,0.33,Medium,,,,Tuj-1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"cells were fixed with 4% paraformaldehyde and stained with antibodies against Tuj-1 (neuron), O4 (oligodendrocyte) and GFAP (astrocyte)"
O4,antibodies,PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.85,Experimental Usage,True,0.33,Medium,,,,O4,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"cells were fixed with 4% paraformaldehyde and stained with antibodies against Tuj-1 (neuron), O4 (oligodendrocyte) and GFAP (astrocyte)"
GFAP,antibodies,PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.85,Experimental Usage,True,0.33,Medium,,,,GFAP,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"cells were fixed with 4% paraformaldehyde and stained with antibodies against Tuj-1 (neuron), O4 (oligodendrocyte) and GFAP (astrocyte)"
MMP3,antibodies,PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,0.85,Experimental Usage,True,0.33,Medium,,,,MMP3,,,,,,,,,,,,,,,,,,,,,,,,,,,,"MMP3 (dilution 1 : 50; incubation overnight at 4 °C, Santa Cruz Biotechnology, Inc.)"
GAPDH,antibodies,PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.85,Experimental Usage,True,0.33,Medium,,,,GAPDH,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"and anti-GAPDH (Novus, Littleton, CO, USA)"
S100 B,antibodies,PMID:34646065,10.1155/2021/9386823,Survival and ,,0.85,Experimental Usage,True,0.33,Medium,,,,S100 B,,,,,,,,,,,,,,,,,,,,,,,,,,,,immunohistochemical S100 B data from a pathology service...An S100 B immunonegative tumor phenotype was associated with a significantly worse outcome
MPM-2,antibodies,PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.85,Experimental Usage,True,0.33,Medium,,,,MPM-2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"cells were labeled with MPM-2 antibody (Upstate Biotechnology, Lake Placid, NY)"
Ras,antibodies,PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.85,Experimental Usage,True,0.33,Medium,,,,Ras,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Detection of Ras was done by immunoblotting using the supplied pan-Ras antibody
Cyclin D1,antibodies,PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.85,Experimental Usage,True,0.33,Medium,,,,Cyclin D1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Membranes were blotted with antibodies specific for Cyclin D1, ERK, phospho-ERK, B-Raf, and Ku-70 (Santa Cruz Biotechnology)"
ERK,antibodies,PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.85,Experimental Usage,True,0.33,Medium,,,,ERK,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Membranes were blotted with antibodies specific for Cyclin D1, ERK, phospho-ERK, B-Raf, and Ku-70 (Santa Cruz Biotechnology)"
phospho-ERK,antibodies,PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.85,Experimental Usage,True,0.33,Medium,,,,phospho-ERK,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Membranes were blotted with antibodies specific for Cyclin D1, ERK, phospho-ERK, B-Raf, and Ku-70 (Santa Cruz Biotechnology)"
B-Raf,antibodies,PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.85,Experimental Usage,True,0.33,Medium,,,,B-Raf,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Membranes were blotted with antibodies specific for Cyclin D1, ERK, phospho-ERK, B-Raf, and Ku-70 (Santa Cruz Biotechnology)"
phospho-MEK1/2,antibodies,PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.85,Experimental Usage,True,0.33,Medium,,,,phospho-MEK1/2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"phospho-MEK1/2 [Ser217/221] and phospho Rb[S807/S811] (Cell Signaling Technology, Beverly, MA)"
phospho-Rb,antibodies,PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.85,Experimental Usage,True,0.33,Medium,,,,phospho-Rb,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"phospho-MEK1/2 [Ser217/221] and phospho Rb[S807/S811] (Cell Signaling Technology, Beverly, MA)"
β-actin,antibodies,PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.85,Experimental Usage,True,0.33,Medium,,,,β-actin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"The β-actin antibody (# AA128, Beyotime) was used to ensure equal loading of total protein"
KRAS,antibodies,PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.85,Experimental Usage,True,0.33,Medium,,,,KRAS,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Primary antibodies used were FLAG-M2 and KRAS (Sigma)
HA,antibodies,PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.85,Experimental Usage,True,0.33,Medium,,,,HA,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"HA, HSP70, and Ubiquitin (Cell Signaling)"
HSP70,antibodies,PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.85,Experimental Usage,True,0.33,Medium,,,,HSP70,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"HA, HSP70, and Ubiquitin (Cell Signaling)"
Ubiquitin,antibodies,PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.85,Experimental Usage,True,0.33,Medium,,,,Ubiquitin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"HA, HSP70, and Ubiquitin (Cell Signaling)"
RAS,antibodies,PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.85,Experimental Usage,True,0.33,Medium,,,,RAS,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,pan-RAS (Abcam)
GST,antibodies,PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.85,Experimental Usage,True,0.33,Medium,,,,GST,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,GST and Vinculin (Bethyl Laboratories)
Vinculin,antibodies,PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.85,Experimental Usage,True,0.33,Medium,,,,Vinculin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,GST and Vinculin (Bethyl Laboratories)
RASA1,antibodies,PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.85,Experimental Usage,True,0.33,Medium,,,,RASA1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,RASA1 (Santa Cruz Biotechnology)
HER1,antibodies,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.85,Experimental Usage,True,0.33,Medium,,,,HER1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"HER1-PE (352904), CD4-PE (317410), CD8a-APC (301014)"
CD4,antibodies,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.85,Experimental Usage,True,0.33,Medium,,,,CD4,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"HER1-PE (352904), CD4-PE (317410), CD8a-APC (301014)"
CD8a,antibodies,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.85,Experimental Usage,True,0.33,Medium,,,,CD8a,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"CD4-PE (317410), CD8a-APC (301014), CD45RO-PE (304206)"
CD45RO,antibodies,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.85,Experimental Usage,True,0.33,Medium,,,,CD45RO,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"CD8a-APC (301014), CD45RO-PE (304206), and CCR7-Percp (353242)"
CCR7,antibodies,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.85,Experimental Usage,True,0.33,Medium,,,,CCR7,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"CD45RO-PE (304206), and CCR7-Percp (353242) (all from BioLegend)"
MEK1/2,antibodies,PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,0.85,Experimental Usage,True,0.33,Medium,,,,MEK1/2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Antibodies used in western blotting targeting...MEK1/2
S100 protein,antibodies,PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,0.85,Experimental Usage,True,0.33,Medium,,,,S100 protein,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,anti-S100 protein antibody (Nichirei Biosciences Inc.)
S100,antibodies,PMID:15255999,10.1186/1476-4598-3-20,"Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR.",,0.85,Experimental Usage,True,0.33,Medium,,,,S100,,,,,,,,,,,,,,,,,,,,,,,,,,,,They were all S100-positive by immunostaining. The MPNSTs all arose from plexiform neurofibromas and showed very weak S100 immunostaining
Ki67,antibodies,PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,0.85,Experimental Usage,True,0.33,Medium,,,,Ki67,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"immunostaining with Ki67 (BD PharMingen, Pasadena CA) antibodies was performed as previously described"
phospho-histone-H3 (Ser 10),antibodies,PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,0.85,Experimental Usage,True,0.33,Medium,,,,phospho-histone-H3 (Ser 10),Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Primary phospho-histone-H3 (Ser 10) antibody was purchased from Abcam, Inc."
α-tubulin,antibodies,PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,0.85,Experimental Usage,True,0.33,Medium,,,,α-tubulin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"using α-tubulin (Sigma, St. Louis MO), β-actin or non-phospho-STAT3, AKT, S6, and 4EBP1 antibodies for normalization"
p-AKT,antibodies,PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,0.85,Experimental Usage,True,0.33,Medium,,,,p-AKT,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"The membranes were incubated with antibodies against p-AKT, total AKT, and β-Actin (SantaCruz Biotechnology, Santa Cruz, USA)"
AKT,antibodies,PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,0.85,Experimental Usage,True,0.33,Medium,,,,AKT,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"The membranes were incubated with antibodies against p-AKT, total AKT, and β-Actin (SantaCruz Biotechnology, Santa Cruz, USA)"
β-Actin,antibodies,PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,0.85,Experimental Usage,True,0.33,Medium,,,,β-Actin,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"The membranes were incubated with antibodies against p-AKT, total AKT, and β-Actin (SantaCruz Biotechnology, Santa Cruz, USA)"
Ago2,antibodies,PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,0.85,Experimental Usage,True,0.33,Medium,,,,Ago2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Bound RNA and protein of interest is immunoprecipitated using the Ago2 antibody (Cell Signaling Technology, Beverly, MA, USA) at a dilution of 1:50"
GAPDH,antibodies,PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,0.85,Experimental Usage,True,0.33,Medium,,,,GAPDH,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,anti-GAPDH; Santa Cruz Biotechnology Inc.; 1:3000
F4/80,antibodies,PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,0.85,Experimental Usage,True,0.33,Medium,,,,F4/80,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,anti-F4/80 bound to Cy5.5 on ice in a solution containing phosphate-buffered saline
S-100β,antibodies,PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,0.85,Experimental Usage,True,0.33,Medium,,,,S-100β,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,We assessed the purity of Schwann cell cultures by immunofluorescent staining with an S-100β antibody
Olig2,antibodies,PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.85,Experimental Usage,True,0.33,Medium,,,,Olig2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Antibody directed against Olig2 (DF-308) was a gift of Dr. Charles Stiles (Dana Farber Cancer Institute)
GAPDH,antibodies,PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,0.85,Experimental Usage,True,0.33,Medium,,,,GAPDH,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Markers for membrane, cytosolic and nuclear fractions were: rabbit anti- Na + , K + - ATPase, GAPDH, and PARP (Cell Signaling)"
PARP,antibodies,PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,0.85,Experimental Usage,True,0.33,Medium,,,,PARP,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Markers for membrane, cytosolic and nuclear fractions were: rabbit anti- Na + , K + - ATPase, GAPDH, and PARP (Cell Signaling)"
Gal α 1-3Gal,antibodies,PMID:15240917,10.1155/S1110724304308107,Survival of Human Neurofibroma in Immunodeficient Mice and Initial Results of Therapy With Pirfenidone.,,0.85,Experimental Usage,True,0.33,Medium,,,,Gal α 1-3Gal,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Fluorescein-conjugated IB4 (Vector Laboratories, Burlingame, Calif) diluted in PBS"
Sox10,antibodies,PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,0.85,Experimental Usage,True,0.33,Medium,,,,Sox10,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Anti-Sox10 antibody staining on HCR-processed sections was performed according to Kamenev et al. (2021)
pDARPP32,antibodies,PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,0.85,Experimental Usage,True,0.33,Medium,,,,pDARPP32,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Western blots were performed using pDARPP32 (1:500, Cell Signaling), DARPP32 (1:1000, Cell Signaling)"
DARPP32,antibodies,PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,0.85,Experimental Usage,True,0.33,Medium,,,,DARPP32,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"Western blots were performed using pDARPP32 (1:500, Cell Signaling), DARPP32 (1:1000, Cell Signaling)"
pERK1/2,antibodies,PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,0.85,Experimental Usage,True,0.33,Medium,,,,pERK1/2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"pERK1/2 (1:1000, Cell Signaling), and ERK1/2 (1:1000, Cell Signaling) primary antibodies"
ERK1/2,antibodies,PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,0.85,Experimental Usage,True,0.33,Medium,,,,ERK1/2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"pERK1/2 (1:1000, Cell Signaling), and ERK1/2 (1:1000, Cell Signaling) primary antibodies"
pan-cytokeratin,antibodies,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.85,Experimental Usage,True,0.33,Medium,,,,pan-cytokeratin,,,,,,,,,,,,,,,,,,,,,,,,,,,,Additional slides were incubated with antibodies against pan-cytokeratin and cytokeratin 8 (Sigma)
cytokeratin 8,antibodies,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.85,Experimental Usage,True,0.33,Medium,,,,cytokeratin 8,,,,,,,,,,,,,,,,,,,,,,,,,,,,Additional slides were incubated with antibodies against pan-cytokeratin and cytokeratin 8 (Sigma)
mesothelin,antibodies,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.85,Experimental Usage,True,0.33,Medium,,,,mesothelin,,,,,,,,,,,,,,,,,,,,,,,,,,,,Additional slides were incubated with antibodies against pan-cytokeratin and cytokeratin 8 (Sigma) or mesothelin (Santa Cruz)
ColIA,antibodies,PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,0.85,Experimental Usage,True,0.33,Medium,,,,ColIA,,,,,,,,,,,,,,,,,,,,,,,,,,,,"All tissues were sectioned (5 µm thickness), mounted onto slides and stained with PE-conjugated anti-ColIA antibody and counterstained with DAPI"
Flag,antibodies,PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,0.85,Experimental Usage,True,0.33,Medium,,,,Flag,,,,,,,,,,,,,,,,,,,,,,,,,,,,"equivalent protein (500 µg) was incubated overnight at 4°C with anti-Abl (K12; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) or anti-Flag (Sigma-Aldrich)"
Nestin,antibodies,PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.85,Experimental Usage,True,0.33,Medium,,,,Nestin,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Anti-Nestin antibody primary IF CST (Danvers, USA)"
SOX2,antibodies,PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.85,Experimental Usage,True,0.33,Medium,,,,SOX2,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anti-SOX2 antibody primary IF CST
MAP2,antibodies,PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.85,Experimental Usage,True,0.33,Medium,,,,MAP2,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anti-MAP2 antibody primary IF and WB CST
β3-Tubulin,antibodies,PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.85,Experimental Usage,True,0.33,Medium,,,,β3-Tubulin,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anti-β3-Tubulin antibody primary IF and WB CST
GFAP,antibodies,PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.85,Experimental Usage,True,0.33,Medium,,,,GFAP,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anti-GFAP antibody primary IF and WB CST
NF-200,antibodies,PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.85,Experimental Usage,True,0.33,Medium,,,,NF-200,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anti-NF-200 antibody primary IF and WB CST
NeuN,antibodies,PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.85,Experimental Usage,True,0.33,Medium,,,,NeuN,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anti-NeuN antibody primary IF and WB CST
cleaved caspase-3,antibodies,PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.85,Experimental Usage,True,0.33,Medium,,,,cleaved caspase-3,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anti-cleaved caspase-3 antibody primary IF and WB CST
P-mTOR,antibodies,PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.85,Experimental Usage,True,0.33,Medium,,,,P-mTOR,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anti-P-mTOR antibody primary WB CST
Rictor,antibodies,PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.85,Experimental Usage,True,0.33,Medium,,,,Rictor,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anti-Rictor antibody primary WB CST
GAPDH,antibodies,PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.85,Experimental Usage,True,0.33,Medium,,,,GAPDH,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anti-GAPDH antibody primary WB CST
Bcl-2,antibodies,PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.85,Experimental Usage,True,0.33,Medium,,,,Bcl-2,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anti-Bcl-2 antibody primary IF and WB CST
CNPase,antibodies,PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.85,Experimental Usage,True,0.33,Medium,,,,CNPase,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anti-CNPase antibody primary IF and WB CST
myelin basic protein,antibodies,PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.85,Experimental Usage,True,0.33,Medium,,,,myelin basic protein,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anti-myelin basic protein (MBP) antibody primary IF and WB CST
cleaved caspase-3,antibodies,PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,0.85,Experimental Usage,True,0.33,Medium,,,,cleaved caspase-3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"cleaved caspase-3+ cells (1∶500 dilution; Cell Signaling Technology, Beverly MA)"
pErbB2,antibodies,PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,0.85,Experimental Usage,True,0.33,Medium,,,,pErbB2,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,stained with pErbB2 (1∶50 dilution) as previously described [14]
RABL6A,antibodies,PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.85,Experimental Usage,True,0.33,Medium,,,,RABL6A,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Immunostaining for SIAH (24E6H3 mouse monoclonal antibody) and RABL6A was conducted
optic glioma neurospheres,advanced_cellular_models,PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,,,,,spheroid,primary cell,Neural stem cells,neurosphere,,,,,,,,,,"Optic chiasm was microdissected from 3-month-old Nf1 flox/flox, Nf1 +/− and Nf1 +/− GFAP CKO mice to generate primary optic nerve neurospheres"
BioCoat Matrigel invasion chambers (Becton Dickinson),advanced_cellular_models,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,,,,,other,other,,,,,,,,,,,,In vitro invasion of MM cell from Nf2+/−;p16/p19+/− wild-type mice were measured using 24-well BioCoat Matrigel invasion chambers (Becton Dickinson)
nude mice,animal_models,PMID:25026211,10.1016/j.ccr.2014.05.001,Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.,,0.8,Experimental Usage,False,1.00,Medium,nude mice,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1×10 6 FC-1801 cells were suspended in Ca/Mg-free PBS and injected subcutaneously into the right flank of nude mice.
R26LacZ,animal_models,PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,0.8,Experimental Usage,False,1.00,Medium,R26LacZ,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,we used the widely available R26LacZ reporter mice to verify that the Postn-cre effectively and exclusively recombines
SCID mice,animal_models,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.8,Experimental Usage,False,1.00,Medium,SCID mice,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.5 × 106 or 1.0 × 106 murine MM cells were injected into the tail vein of recipient SCID mice
BALB/c,animal_models,PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,0.8,Experimental Usage,False,1.00,Medium,BALB/c,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,The anti-p55 mouse monoclonal antibody was generated by immunizing BALB/c mice with the recombinant SH3-GUK segment
CAGG-Cre,animal_models,PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,0.8,Experimental Usage,False,1.00,Medium,CAGG-Cre,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Tsc1 animals were obtained by crossing the +/- Tsc1 line (f/+ Meikle et al., 2005) once with CAGG-Cre mice to obtain germ-line deletion"
GFAP,antibodies,PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,0.8,Experimental Usage,True,1.00,Medium,,,,GFAP,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,mouse anti-GFAP (Chemicon) and rabbit anti-GFAP (SIGMA)
NF-H,antibodies,PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,0.8,Experimental Usage,True,1.00,Medium,,,,NF-H,Rabbit,Polyclonal,,,,,,,,,,,,,,,,,,,,,,,,,,rabbit anti-NF-H (Chemicon); and mouse anti-Caspr
Nf1 flox/flox calvaria osteoblasts,cell_lines,PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,Bone,Neurofibromatosis Type 1,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,Calvaria osteoblasts were extracted by multiple collagenase/trypsine digestion from 4-day-old Nf1 flox/flox pups
optic glioma cells,cell_lines,PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,Nerve,Neurofibromatosis Type 1,Optic Nerve Glioma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,Optic glioma cells were isolated from the optic nerves of three-month-old Nf1OPG mice
TVZ NSCs,cell_lines,PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,Brain,Neurofibromatosis Type 1,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,TVZ NSCs were established from the third ventricle of 3-month-old Nf1 flox/flox and Nf1+/− mice
Wild-type and Nf1-/- primary astrocytes,cell_lines,PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,Brain,Neurofibromatosis Type 1,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,Wild-type and Nf1-/- primary astrocytes were generated and maintained as previously described
E13.5 DRG neurosphere cells,cell_lines,PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,Nerve,Neurofibromatosis Type 1,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Isolation and culture of E13.5 DRG neurosphere cells were performed as previously described (6, 9, 52)."
Nf1flox/flox bone marrow stromal cells,cell_lines,PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,Bone,Neurofibromatosis Type 1,,,,,,,,,,,,,,,,,,,,,,,,ex vivo-based cell culture approach based on the use of Nf1(flox/flox) bone marrow stromal cells
P300 event-related potential,clinical_assessment_tools,PMID:33963966,10.1007/s10803-021-05043-3,Cognitive and Electrophysiological Correlates of Working Memory Impairments in Neurofibromatosis Type 1.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,P300 event-related potential,biomarker assay,pediatric,No,,The aim of this study was to investigate P300 event-related potential (ERP) associated with WM in NF1...EEG was recorded during a WM nback task.
Dermlite DL3,clinical_assessment_tools,PMID:33817379,10.1016/j.heliyon.2021.e06518,Clinical assessment of the use of topical liquid diclofenac following laser microporation of cutaneous neurofibromas in individuals with neurofibromatosis type 1.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Dermlite DL3,other,adult,Yes,,"visual and dermatoscopy observations (using the Dermlite DL3 [3Gen, San Jan Capistrano, CA, USA]) noting color and presence of necrosis"
hind-limb clasping test,clinical_assessment_tools,PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,hind-limb clasping test,performance test,all ages,No,,"cerebellar ataxia using behavior tests, including hind-limb clasping, and ledge and gait tests"
ledge test,clinical_assessment_tools,PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,ledge test,performance test,all ages,No,,"In the CPA model, we found that the ledge test, which evaluates coordination, is the most sensitive test"
gait test,clinical_assessment_tools,PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,gait test,performance test,all ages,No,,"cerebellar ataxia using behavior tests, including hind-limb clasping, and ledge and gait tests"
rotarod assay,clinical_assessment_tools,PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,rotarod assay,performance test,all ages,No,,"Balance, motor strength, and coordination can be assayed by rotarod assay"
RECIST guidelines,clinical_assessment_tools,PMID:39824854,10.1038/s41598-025-85386-4,Comparison of 1D and 3D volume measurement techniques in NF2-associated vestibular schwannoma monitoring.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,RECIST guidelines,scale,all ages,No,,"the maximum linear (tumor) diameter (MLD) in axial and coronal (medial to lateral and caudal to rostral/cranial, in total four measurements per MRI) planes were measured according to the RECIST guidelines"
5-point Likert-type scales,clinical_assessment_tools,PMID:37269078,10.1177/17407745231178839,Perspectives of adolescents with neurofibromatosis 1 and cutaneous neurofibromas: Implications for clinical trials.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,5-point Likert-type scales,scale,pediatric,Yes,,Survey questions used 5-point Likert-type scales to measure ordered scale responses
NF Disease Severity Scale,clinical_assessment_tools,PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,NF Disease Severity Scale,scale,clinician-rated,Yes,,"the NF Disease Severity Scale, adapted by our group from Ablon, asks the medical professional to rate the patient's symptoms as mild, moderate, or severe"
NF1 Disease Complications Scale,clinical_assessment_tools,PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,NF1 Disease Complications Scale,scale,clinician-rated,Yes,18.0,"the NF1 Disease Complications Scale, is a checklist designed by a multi-disciplinary team of medical experts in NF1 at the National Institutes of Health"
FragEL DNA Fragmentation Detection Kit (Sigma Aldrich #QIA21),clinical_assessment_tools,PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,FragEL DNA Fragmentation Detection Kit (Sigma Aldrich #QIA21),biomarker assay,all ages,No,,The FragEL™ DNA Fragmentation Detection Kit (Sigma Aldrich #QIA21) was used according to manufacturer's instructions
"Caspase 3/7 Glo activity (#G8093, Promega)",clinical_assessment_tools,PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,"Caspase 3/7 Glo activity (#G8093, Promega)",biomarker assay,all ages,No,,"Caspase 3/7 Glo activity (#G8093, Promega) was measured by luminescence after 24 hours of treatment"
PedsQL™ Arthritis Module,clinical_assessment_tools,PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",,0.8,Citation Only,True,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,PedsQL™ Arthritis Module,questionnaire,all ages,Yes,,"Pertinent questions were drawn from the existing PedsQL™ Arthritis, Cancer, Cerebral Palsy and Family Impact Modules"
PedsQL™ Cancer Module,clinical_assessment_tools,PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",,0.8,Citation Only,True,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,PedsQL™ Cancer Module,questionnaire,all ages,Yes,,"Pertinent questions were drawn from the existing PedsQL™ Arthritis, Cancer, Cerebral Palsy and Family Impact Modules"
PedsQL™ Cerebral Palsy Module,clinical_assessment_tools,PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",,0.8,Citation Only,True,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,PedsQL™ Cerebral Palsy Module,questionnaire,all ages,Yes,,"Pertinent questions were drawn from the existing PedsQL™ Arthritis, Cancer, Cerebral Palsy and Family Impact Modules"
PedsQL™ Family Impact Module,clinical_assessment_tools,PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",,0.8,Citation Only,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,PedsQL™ Family Impact Module,questionnaire,caregiver,No,,"Pertinent questions were drawn from the existing PedsQL™ Arthritis, Cancer, Cerebral Palsy and Family Impact Modules"
Barriers to Adherence Questionnaire,clinical_assessment_tools,PMID:39858077,10.3390/cancers17020295,A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Barriers to Adherence Questionnaire,questionnaire,adult,Yes,16.0,The barriers to adherence measure was created by the study team; participants were asked to think of times they missed a dose of their study drug in the past month and marked which of 16 possible reasons caused them to miss a dose.
NIH Consensus Development Conference 1987 diagnostic criteria,clinical_assessment_tools,PMID:28193237,10.1186/s12955-017-0607-y,Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,NIH Consensus Development Conference 1987 diagnostic criteria,structured interview,all ages,Yes,,Adults (18 years or older) who fulfilled the diagnostic criteria for NF1 (NIH Consensus Development Conference 1987) and attended the National NF1 service
Pain Management Inventory,clinical_assessment_tools,PMID:27021207,10.1002/ajmg.a.37623,Acceptance and commitment therapy in youth with neurofibromatosis type 1 (NF1) and chronic pain and their parents: A pilot study of feasibility and preliminary efficacy.,,0.8,Development,True,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Pain Management Inventory,scale,pediatric,Yes,,...two scales developed by the authors for the current study assessed pain management techniques used by the patients (Pain Management Inventory)
Post-Treatment Questionnaire,clinical_assessment_tools,PMID:27021207,10.1002/ajmg.a.37623,Acceptance and commitment therapy in youth with neurofibromatosis type 1 (NF1) and chronic pain and their parents: A pilot study of feasibility and preliminary efficacy.,,0.8,Development,True,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Post-Treatment Questionnaire,questionnaire,pediatric,Yes,,...treatment adherence and study satisfaction (Post-Treatment Questionnaire). Details on these measures are in Table I
Brazilian Criterion for Economic Classification (CCEB),clinical_assessment_tools,PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Brazilian Criterion for Economic Classification (CCEB),questionnaire,adult,No,10.0,Socioeconomic status (SES) was assessed using the Brazilian Criterion for Economic Classification (CCEB) according to the criteria established
prism adaptation task,clinical_assessment_tools,PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,prism adaptation task,performance test,pediatric,No,,performance on a prism adaptation task (measurement of adaptation of the angle of hand movements in response to prism glass distortion)
Responsibility for Medication Questionnaire,clinical_assessment_tools,PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Responsibility for Medication Questionnaire,questionnaire,pediatric,No,,Adherence to the dosing schedule was assessed by administration of the Responsibility for Medication Questionnaire
nerve conduction velocity,clinical_assessment_tools,PMID:25012216,10.1186/s40478-014-0082-1,A neuronal function of the tumor suppressor protein merlin.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,nerve conduction velocity,performance test,all ages,No,,"By measuring nerve properties as conduction velocity or potential amplitudes of the signal, it is possible to characterize the origin of peripheral nerve diseases."
Nebraska Lexicon,clinical_assessment_tools,PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Nebraska Lexicon,scale,all ages,No,,"NF1-relevant diagnosis codes from SNOMED, ICD-9/10, Logical Observation Identifiers Names and Codes (LOINC), and Nebraska Lexicon"
"mouse cytokine array (panel A, R&D system)",clinical_assessment_tools,PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,"mouse cytokine array (panel A, R&D system)",biomarker assay,all ages,No,,"Mouse cytokine protein expressions were quantified using mouse cytokine array (panel A, R&D system, Minneapolis, MN)"
adaptive auditory n-back task,clinical_assessment_tools,PMID:37608248,10.1186/s11689-023-09492-y,Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memory.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,adaptive auditory n-back task,performance test,pediatric,No,,"performance on an adaptive auditory n-back task, and performance on a non-adaptive visual n-back task performed during EEG"
non-adaptive visual n-back task,clinical_assessment_tools,PMID:37608248,10.1186/s11689-023-09492-y,Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memory.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,non-adaptive visual n-back task,performance test,pediatric,No,,"performance on an adaptive auditory n-back task, and performance on a non-adaptive visual n-back task performed during EEG"
MEGA-PRESS,clinical_assessment_tools,PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,MEGA-PRESS,biomarker assay,pediatric,No,,"acquire two GABA-edited magnetic resonance spectra using the localised spectroscopy sequence MEGA-PRESS, developed by CMRR"
64-channel Neuroscan system,clinical_assessment_tools,PMID:24559228,10.1186/1866-1955-6-4,Abnormal late visual responses and alpha oscillations in neurofibromatosis type 1: a link to visual and attention deficits.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,64-channel Neuroscan system,biomarker assay,pediatric,No,,"EEG signal was recorded from six parieto-occipital channels (PO3, POZ, PO4, O1, OZ and O2) using a 64-channel Neuroscan system"
Citec hand-held dynamometer,clinical_assessment_tools,PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Citec hand-held dynamometer,performance test,pediatric,No,,"Maximal isometric strength of three muscle groups involved in prime movements, including grip strength, ankle dorsiflexion, and plantarflexion were tested using hand‐held dynamometry"
Ras activation assay (Millipore),clinical_assessment_tools,PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Ras activation assay (Millipore),biomarker assay,all ages,No,,"Ras activation (Millipore), cAMP (New East Biosciences), TUNEL (Roche Diagnostics), and dopamine (Rocky Mountain Diagnostics) measurements"
cAMP assay (New East Biosciences),clinical_assessment_tools,PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,cAMP assay (New East Biosciences),biomarker assay,all ages,No,,"Ras activation (Millipore), cAMP (New East Biosciences), TUNEL (Roche Diagnostics), and dopamine (Rocky Mountain Diagnostics) measurements"
TUNEL assay (Roche Diagnostics),clinical_assessment_tools,PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,TUNEL assay (Roche Diagnostics),biomarker assay,all ages,No,,"Ras activation (Millipore), cAMP (New East Biosciences), TUNEL (Roche Diagnostics), and dopamine (Rocky Mountain Diagnostics) measurements"
dopamine assay (Rocky Mountain Diagnostics),clinical_assessment_tools,PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,dopamine assay (Rocky Mountain Diagnostics),biomarker assay,all ages,No,,"Ras activation (Millipore), cAMP (New East Biosciences), TUNEL (Roche Diagnostics), and dopamine (Rocky Mountain Diagnostics) measurements"
Wood's lamp,clinical_assessment_tools,PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Wood's lamp,other,all ages,Yes,,"A Wood's lamp, which makes CALMs more visible, was used for CALM counting in CALM1, but not in CALM2."
Rotarod apparatus,clinical_assessment_tools,PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Rotarod apparatus,performance test,all ages,No,,Motor function and motor learning were evaluated by rotarod apparatus
Distress Thermometer Acceptability and Feasibility Scales,clinical_assessment_tools,PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,,0.8,Development,True,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,Distress Thermometer Acceptability and Feasibility Scales,scale,all ages,Yes,,"Patients, primary caregivers, and the child's primary medical provider rated on a scale of 1–4 how easy or difficult the DT was to complete...The DT Acceptability and Feasibility Scales were developed by the study investigators"
STIR MRI,clinical_assessment_tools,PMID:24753394,10.1002/pbc.25041,Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,,,,,STIR MRI,biomarker assay,all ages,Yes,,STIR MRI of up to three clinically relevant index PN was performed for volumetric analysis
ImageJ (v1.53a),computational_tools,PMID:39110684,10.1371/journal.pone.0308207,Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon nanotube fibers.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,ImageJ (v1.53a),Analysis Software,v1.53a,,,,,,,,,,,,,,,Fiber diameter and angle were measured using ImageJ (v1.53a) with at least 200 fibers per fiber type
NIH ImageJ (version 1.53a),computational_tools,PMID:39110684,10.1371/journal.pone.0308207,Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon nanotube fibers.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,NIH ImageJ (version 1.53a),Analysis Software,version 1.53a,,,,,,,,,,,,,,,"The images were analyzed using NIH ImageJ (version 1.53a) software. Aspect ratio, which is the longest length of the cell divided by the shortest length"
Perl speaks NONMEM version 3.6.2,computational_tools,PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,Perl speaks NONMEM version 3.6.2,Package/Library,3.6.2,,,,,,,,,,,,,,,"A population pharmacokinetics (PK) analysis was also performed using nonlinear mixed effect modeling with NONMEM (version 7.2; ICON, Ellicott City, MD) with Perl speaks NONMEM version 3.6.2 and Pirana version 2.7.1 (Certara)."
Pirana version 2.7.1,computational_tools,PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,Pirana version 2.7.1,Analysis Software,2.7.1,,,,,,,,,,,,,,,"A population pharmacokinetics (PK) analysis was also performed using nonlinear mixed effect modeling with NONMEM (version 7.2; ICON, Ellicott City, MD) with Perl speaks NONMEM version 3.6.2 and Pirana version 2.7.1 (Certara)."
SAS version 9.4,computational_tools,PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,SAS version 9.4,Analysis Software,9.4,,,,,,,,,,,,,,,"The pain and QOL data were summarized with descriptive statistics (means, standard deviation [SD]) via SAS version 9.4 (Cary, NC)."
SPSS version 28.0,computational_tools,PMID:38811427,10.1186/s41687-024-00732-w,Quality of life in individuals with neurofibromatosis type 1 associated cutaneous neurofibromas: validation of the Dutch cNF-Skindex.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,SPSS version 28.0,Analysis Software,28.0,,,,,,,,,,,,,,,Statistical analyses were performed using SPSS version 28.0
FastQC (version 0.11.2),computational_tools,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,FastQC (version 0.11.2),Analysis Software,0.11.2,,,,,,,,,,,,,,,All sequencing datasets were evaluated using FastQC (version 0.11.2) to ensure high quality
Bowtie (version 1.0.0),computational_tools,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,Bowtie (version 1.0.0),Analysis Software,1.0.0,,,,,,,,,,,,,,,We first built an index using all sgRNAs in each sample and then used Bowtie (version 1.0.0) to map the sgRNA sequences
BWA version 0.7.5,computational_tools,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,BWA version 0.7.5,Analysis Software,0.7.5,,,,,,,,,,,,,,,We mapped the reads to the reference genomic sequence using BWA version 0.7.5 and SAMtools
SAMtools (version 0.1.19),computational_tools,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,SAMtools (version 0.1.19),Analysis Software,0.1.19,,,,,,,,,,,,,,,We mapped the reads to the reference genomic sequence using BWA version 0.7.5 and SAMtools (version 0.1.19)
VarScan2 (version 2.3),computational_tools,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,VarScan2 (version 2.3),Analysis Software,2.3,,,,,,,,,,,,,,,We then used VarScan2 (version 2.3) to identify insertions and deletions with the 'pileup2indel' mode
STAR (version 2.3.0e),computational_tools,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,STAR (version 2.3.0e),Analysis Software,2.3.0e,,,,,,,,,,,,,,,We aligned RNA-seq reads to the mm10 genome using STAR (version 2.3.0e) with default parameters
DESeq (version 1.18.0),computational_tools,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,DESeq (version 1.18.0),Package/Library,1.18.0,,,,,,,,,,,,,,,We then determined differential expression using DESeq (version 1.18.0) and accounted for possible batch effects
AxioVision 4.1 software,computational_tools,PMID:21726432,10.1186/1741-7015-9-82,MIA is a potential biomarker for tumour load in neurofibromatosis type 1.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,AxioVision 4.1 software,Analysis Software,4.1,,,,,,,,,,,,,,,"Images were collected using a DMR HC microscope...and evaluated using AxioVision 4.1 software (Zeiss, Jena, Germany)"
analySIS 5.0 software,computational_tools,PMID:21726432,10.1186/1741-7015-9-82,MIA is a potential biomarker for tumour load in neurofibromatosis type 1.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,analySIS 5.0 software,Analysis Software,5.0,,,,,,,,,,,,,,,"Stained sections were analyzed using the BX51 microscope...and analySIS 5.0 software (Soft imaging system GmbH, Münster, Germany)"
Gel-Pro Analyzer 4.0,computational_tools,PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,Gel-Pro Analyzer 4.0,Analysis Software,4.0,,,,,,,,,,,,,,,"α-tubulin (Sigma, St. Louis, MO) was employed for normalization and densitometric analysis using Gel-Pro Analyzer 4.0 (Media Cybernetics, Bethesda, MD)"
GraphPad Prism 4.0,computational_tools,PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,GraphPad Prism 4.0,Analysis Software,4.0,,,,,,,,,,,,,,,"Statistical analyses were performed using GraphPad Prism 4.0 software (GraphPad, La Jolla, CA)"
Graphpad Prism 6,computational_tools,PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,Graphpad Prism 6,Analysis Software,6,,,,,,,,,,,,,,,Statistical significance was determined by ANOVA followed by Bonferroni's posthoc test for multiple comparisons and student's t-test for two groups using Graphpad Prism 6 software
piXarray 100 DSR System,computational_tools,PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,piXarray 100 DSR System,Analysis Software,1.0.6,,,,,,,,,,,,,,,"X-rays were taken using a piXarray 100 DSR System with Biopix Software (Version No: 1.0.6., Bioptics, Inc. Tucson, AZ)"
XCT Research SA + peripheral quantitative computed tomography (pQCT) scanner,computational_tools,PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,XCT Research SA + peripheral quantitative computed tomography (pQCT) scanner,Analysis Software,5.50,,,,,,,,,,,,,,,"Whole axial bone was placed in the gantry of a XCT Research SA + peripheral quantitative computed tomography (pQCT) scanner (Stratec Medizintechnik GmbH, Pforzheim, Germany) with Software Version 5.50"
MtestwR software,computational_tools,PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,MtestwR software,Analysis Software,R 1.4.2,,,,,,,,,,,,,,,"biomechanical testing was conducted utilizing Testresouse R systems with MtestwR software version: R 1.4.2 (TestResources Inc. Shakopee, MN)"
Affymetrix Expression Console MAS 5.0,computational_tools,PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,Affymetrix Expression Console MAS 5.0,Analysis Software,MAS 5.0,,,,,,,,,,,,,,,Microarray data was analyzed using Affymetrix expression console MAS 5.0 method
"Statistical Package for Social Studies (SPSS 10.0 for Windows, SPSS Inc.)",computational_tools,PMID:39824854,10.1038/s41598-025-85386-4,Comparison of 1D and 3D volume measurement techniques in NF2-associated vestibular schwannoma monitoring.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,"Statistical Package for Social Studies (SPSS 10.0 for Windows, SPSS Inc.)",Analysis Software,10.0,,,,,,,,,,,,,,,"Statistical evaluation was performed using the Statistical Package for Social Studies (SPSS 10.0 for Windows, SPSS Inc.)"
JMP Pro 15.0.0,computational_tools,PMID:34630515,10.3389/fgene.2021.721045,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and ,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,JMP Pro 15.0.0,Analysis Software,15.0.0,,,,,,,,,,,,,,,"Logistic regressions were performed in JMP (JMP Pro 15.0.0, SAS Institute Inc., Cary, NC)"
fastQC,computational_tools,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,fastQC,Analysis Software,v.0.10.1,,,,,,,,,,,,,,,Quality checking of sequence reads was assessed by fastQC (v.0.10.1)
R version 3.5.1,computational_tools,PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,R version 3.5.1,Analysis Software,3.5.1,,,,,,,,,,,,,,,Statistical analysis was performed using GraphPad Prism 7 and R version 3.5.1.
SAS version 9.4,computational_tools,PMID:32572180,10.1038/s41436-020-0873-7,Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,SAS version 9.4,Analysis Software,9.4,,,,,,,,,,,,,,,"Statistical analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC) and R version 3.5.0"
R version 3.5.0,computational_tools,PMID:32572180,10.1038/s41436-020-0873-7,Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,R version 3.5.0,Analysis Software,3.5.0,,,,,,,,,,,,,,,"Statistical analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC) and R version 3.5.0"
pheatmap package,computational_tools,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,pheatmap package,Package/Library,,http://cran.r-project.org/web/packages/pheatmap/index.html,,,,,,,,,,,,,,The heatmap was generated using CRAN's pheatmap package ( http://cran.r-project.org/web/packages/pheatmap/index.html )
Limma package,computational_tools,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,Limma package,Package/Library,,http://www.bioconductor.org,,,,,,,,,,,,,,Statistical comparisons were done using R/Bioconductor's Limma package ( http://www.bioconductor.org )
GeneSpring GXv7.3.1,computational_tools,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,GeneSpring GXv7.3.1,Analysis Software,v7.3.1,,,,,,,,,,,,,,,Statistical comparisons were done using R/Bioconductor's Limma package ( http://www.bioconductor.org ) and GeneSpring GXv7.3.1 (Agilent Technologies)
CalcuSyn Version 2.1,computational_tools,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,CalcuSyn Version 2.1,Analysis Software,Version 2.1,,,,,,,,,,,,,,,"All data analysis was done using Calcusyn software (CalcuSyn Version 2.1, BioSoft)"
ggplot2,computational_tools,PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,ggplot2,Package/Library,v.3.3.5,,,,,,,,,,,,,,,The tSNE plot was visualized with ggplot2 (v.3.3.5)
SPSS v. 20.0,computational_tools,PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,SPSS v. 20.0,Analysis Software,v. 20.0,,,,,,,,,,,,,,,"...Statistical analysis was performed using Statistical Package for Social Sciences software (SPSS v. 20.0; Chicago, IL, USA)..."
SPSS 25,computational_tools,PMID:34646065,10.1155/2021/9386823,Survival and ,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,SPSS 25,Analysis Software,25,,,,,,,,,,,,,,,"All data were analyzed using statistical software (SPSS 25, IBM Co. Armonk, NY)"
Stratagene Mx3005 – MxPro QPCR-Software,computational_tools,PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,Stratagene Mx3005 – MxPro QPCR-Software,Analysis Software,2007,,,,,,,,,,,,,,,"Genotyping was performed using a real-time PCR system in the allelic discrimination mode (Stratagene Mx3005 – MxPro QPCR-Software, 2007)"
Python version 3.10,computational_tools,PMID:40352015,10.7759/cureus.82033,Development of a Machine Learning Algorithm for the Prediction of WHO Grade 1 Meningioma Recurrence.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,Python version 3.10,Analysis Software,3.10,,,,,,,,,,,,,,,"All statistics and models were conducted in Python version 3.10 (Python Software Foundation, Wilmington, Delaware, US)."
SPSS 17.0,computational_tools,PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,SPSS 17.0,Analysis Software,17.0,,,,,,,,,,,,,,,Statistical analysis was performed using the SPSS 17.0 statistics software
SPSS 12.0,computational_tools,PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,SPSS 12.0,Analysis Software,12.0,,,,,,,,,,,,,,,"All data were analyzed using SPSS 12.0 (SPSS Inc, Chicago, Illinois)"
PRISM (version 8),computational_tools,PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,PRISM (version 8),Analysis Software,8,,,,,,,,,,,,,,,"Statistical analyses were conducted with PRISM (version 8, GraphPad Software, Inc., San Diego, CA, USA)"
Trimmomatic v0.39,computational_tools,PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,Trimmomatic v0.39,Analysis Software,v0.39,,,,,,,,,,,,,,,Whole-exome sequencing FastQ files were trimmed by using Trimmomatic v 0.39
GATK V4.2,computational_tools,PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,GATK V4.2,Analysis Software,V4.2,,,,,,,,,,,,,,,Genomic analysis toolkit (GATK) V4.2 base quality score recalibration was also used to process BAM files
FlowJo 10.8,computational_tools,PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,FlowJo 10.8,Analysis Software,10.8,,,,,,,,,,,,,,,"Data analysis was performed using FlowJo 10.8, and cell cycle distribution was assigned by using the implemented models"
PhenoCapture 3.3,computational_tools,PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,PhenoCapture 3.3,Analysis Software,3.3,,,,,,,,,,,,,,,Images were captured every 15 min using a time-lapse image software (PhenoCapture 3.3)
Fiji 2.0,computational_tools,PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,Fiji 2.0,Analysis Software,2.0,,,,,,,,,,,,,,,Images were captured every 15 min using a time-lapse image software (PhenoCapture 3.3) and analyzed using Fiji 2.0
GeneAnalytics(v),computational_tools,PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,GeneAnalytics(v),Web Application,v,,,,,,,,,,,,,,,Pathway analysis was performed using GeneAnalytics(v)
SPSS 20.0,computational_tools,PMID:32733557,10.1155/2020/5976465,"Gene Expression, Network Analysis, and Drug Discovery of Neurofibromatosis Type 2-Associated Vestibular Schwannomas Based on Bioinformatics Analysis.",,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,SPSS 20.0,Analysis Software,20.0,,,,,,,,,,,,,,,Statistical analysis was conducted by SPSS 20.0 software.
GraphPad Prism Version 6,computational_tools,PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,GraphPad Prism Version 6,Analysis Software,6,,,,,,,,,,,,,,,"The IC50 was calculated using GraphPad Prism Version 6 (La Jolla, CA)."
GraphPad Prism version 8.0.1,computational_tools,PMID:39061138,10.3390/cancers16142498,A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,GraphPad Prism version 8.0.1,Analysis Software,8.0.1,,,,,,,,,,,,,,,"The significance of differences was evaluated either by one-way ANOVA, followed by Tukey's post hoc test to correct for multiple comparisons, or by Student's t-test for two groups using GraphPad Prism version 8.0.1"
R 4.4.2 software,computational_tools,PMID:40529476,10.1016/j.xjidi.2025.100380,Using Durometers to Quantify Stiffness as an Outcome Measure for Cutaneous Neurofibroma in Neurofibromatosis Type 1.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,R 4.4.2 software,Analysis Software,4.4.2,,,,,,,,,,,,,,,"Statistical analyses were performed using R 4.4.2 software (R Foundation for Statistical Computing, Vienna, Austria)"
IBM SPSS Statistics,computational_tools,PMID:39225289,10.1111/srt.70020,Comparing 3D imaging devices for the measurement of cutaneous neurofibromas in patients with Neurofibromatosis Type 1.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,IBM SPSS Statistics,Analysis Software,27.01,,,,,,,,,,,,,,,Statistical analyses were conducted using IBM SPSS Statistics (version 27.01)
R statistical package,computational_tools,PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,R statistical package,Analysis Software,,http://cran.r-project.org/,,,,,,,,,,,,,,All the analyses were implemented by the comprehensive statistical package R (http://cran.r-project.org/)
SPSS version 19.0,computational_tools,PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,SPSS version 19.0,Analysis Software,19.0,,,,,,,,,,,,,,,"The statistical analyses were undertaken using a licensed version of SPSS (version 19.0, SPSS Inc, Chicago, IL, USA) compatible with Windows"
R bioconductor,computational_tools,PMID:25340526,10.1371/journal.pone.0107760,Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,R bioconductor,Package/Library,,http://www.bioconductor.org/,,,,,,,,,,,,,,as well as R bioconductor (http://www.bioconductor.org/) tools for calculating similarity clusters on a Galaxy server
Stata 15,computational_tools,PMID:37174087,10.3390/cancers15092621,Vinblastine/Methotrexate for Debilitating and Progressive Plexiform Neurofibroma in Children and Young Adults with Neurofibromatosis Type 1: A Phase 2 Study.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,Stata 15,Analysis Software,15,,,,,,,,,,,,,,,"...All analyses were performed using Stata 15 (StataCorp, College Station, TX, USA)..."
samtools,computational_tools,PMID:39093127,10.1158/1078-0432.CCR-24-0797,Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,samtools,Command-line Tool,v1.17,,,,,,,,,,,,,,,Downsampling was repeated using seed values 0 to 4 in samtools v1.17
Picard,computational_tools,PMID:39093127,10.1158/1078-0432.CCR-24-0797,Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,Picard,Command-line Tool,v.4.0.1.2,,,,,,,,,,,,,,,"Fragment lengths, extracted from bam files using Picard (v.4.0.1.2)"
SPSS software v. 21,computational_tools,PMID:28725547,10.1016/j.nicl.2017.06.032,Spatial working memory in neurofibromatosis 1: Altered neural activity and functional connectivity.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,SPSS software v. 21,Analysis Software,21,,,,,,,,,,,,,,,Analyses of neuropsychological and clinical data were performed using SPSS software v. 21 (IBM)
Spectra Manager,computational_tools,PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,Spectra Manager,Analysis Software,V1.17.00,,,,,,,,,,,,,,,using the Spectra Manager control (V1. 17.00) and application (V1.3.00) software package (JASCO)
MATLAB vR2020b,computational_tools,PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,MATLAB vR2020b,Analysis Software,vR2020b,,,,,,,,,,,,,,,"Images were segmented using SPM12 v7771 (Wellcome Trust Centre for Neuroimaging, University College London, United Kingdom) through MATLAB vR2020b"
FastQC (RRID:SCR_014583),computational_tools,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,FastQC (RRID:SCR_014583),Analysis Software,,https://www.bioinformatics.babraham.ac.uk/projects/fastqc/,,,,,,,,,,,,,,All resulting FASTQ files passed quality control by FastQC (RRID:SCR_014583; https://www.bioinformatics.babraham.ac.uk/projects/fastqc/)
TrimGalore (RRID:SCR_011847),computational_tools,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,TrimGalore (RRID:SCR_011847),Analysis Software,0.4.5,https://www.bioinformatics.babraham.ac.uk/projects/trim_galore,,,,,,,,,,,,,,"RNA sequencing reads were 3′ trimmed for base quality 15 and adapter sequences using version 0.4.5 of TrimGalore (https://www.bioinformatics.babraham.ac.uk/projects/trim_galore, RRID:SCR_011847)"
STAR v2.6 (RRID:SCR_004463),computational_tools,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,STAR v2.6 (RRID:SCR_004463),Analysis Software,v2.6,,,,,,,,,,,,,,,and then aligned to human genome assembly hg19 with STAR v2.6 (RRID:SCR_004463) using default parameters
HTSeq v0.9.1 (RRID:SCR_005514),computational_tools,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,HTSeq v0.9.1 (RRID:SCR_005514),Analysis Software,v0.9.1,,,,,,,,,,,,,,,Read count tables were generated with HTSeq v0.9.1 (RRID:SCR_005514)
deepTools v3.1 (RRID:SCR_016366),computational_tools,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,deepTools v3.1 (RRID:SCR_016366),Analysis Software,v3.1,,,,,,,,,,,,,,,These library size factors were also used with deepTools v3.1 (RRID:SCR_016366) to create normalized bigwigs using bamCoverage
Homer v4.5 (RRID:SCR_010881),computational_tools,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,Homer v4.5 (RRID:SCR_010881),Analysis Software,v4.5,http://homer.ucsd.edu,,,,,,,,,,,,,,"Pathway enrichment (gene sets and GO) was performed on each cluster using Homer v4.5 (http://homer.ucsd.edu, RRID:SCR_010881)"
"featureCounts (v1.5.0-p1, RRID:SCR_012919)",computational_tools,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,"featureCounts (v1.5.0-p1, RRID:SCR_012919)",Analysis Software,v1.5.0-p1,,,,,,,,,,,,,,,"and used featureCounts (v1.5.0-p1, RRID:SCR_012919; ref. 79) to count RNA-seq fragments mapped to them"
"pheatmap (v.1.0.12, RRID:SCR_016418)",computational_tools,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,"pheatmap (v.1.0.12, RRID:SCR_016418)",Package/Library,v.1.0.12,,,,,,,,,,,,,,,"were subject to k-means clustering via pheatmap (v.1.0.12, RRID:SCR_016418), separately for the three classes of REs"
"Partek Genomics Suite (v 7.0, RRID:SCR_011860)",computational_tools,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,"Partek Genomics Suite (v 7.0, RRID:SCR_011860)",Analysis Software,v 7.0,,,,,,,,,,,,,,,"PCA of methylation data at all tiles (regions) was generated in Partek Genomics Suite (v 7.0, RRID:SCR_011860)"
"FCS Express 7 Research Edition (De Novo Software, Inc.; RRID:SCR_016431)",computational_tools,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,"FCS Express 7 Research Edition (De Novo Software, Inc.; RRID:SCR_016431)",Analysis Software,7 Research Edition,,,,,,,,,,,,,,,"All data were processed and analyzed with FCS Express 7 Research Edition (De Novo Software, Inc.; RRID:SCR_016431)"
Synapse,computational_tools,PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,Synapse,Database,,https://doi.org/10.7303/syn4939906,,,,,,,,,,,,,,...Primary files [15] were accessed from Single Agent Screens through Synapse https://doi.org/10.7303/syn4939906...
SPSS V.23,computational_tools,PMID:28848060,10.1136/jmedgenet-2017-104519,Genetic Severity Score predicts clinical phenotype in NF2.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,SPSS V.23,Analysis Software,V.23,,,,,,,,,,,,,,,Statistical analyses were undertaken using SPSS V.23
MATLAB software,computational_tools,PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,MATLAB software,Analysis Software,R2019a,,,,,,,,,,,,,,,"Electronic image files were processed using MATLAB software (MathWorks Inc., R2019a, USA)"
CASAVA v1.82,computational_tools,PMID:39669605,10.1016/j.gimo.2024.101816,Next-generation variant exon screening: Moving forward in routine genetic disease investigations.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,CASAVA v1.82,Analysis Software,v1.82,,,,,,,,,,,,,,,Raw image files were processed using CASAVA v1.82 for base calling and generating the raw sequencing data.
GraphPad Prism 5.0,computational_tools,PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,GraphPad Prism 5.0,Analysis Software,5.0,,,,,,,,,,,,,,,Statistical significance (p<0.05) was determined using the appropriate test as described in figure legends using GraphPad Prism 5.0 software
MATLAB® version R2007a,computational_tools,PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,MATLAB® version R2007a,Analysis Software,R2007a,,,,,,,,,,,,,,,"statistical hypothesis testing were performed by the software package MATLAB®, version R2007a (The MathWorks, Inc., Natick, MA, USA)"
CCK8,genetic_reagents,PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,CCK8,Other,,,,,,,,,,,,,,,,,,,,"Cell viability was evaluated using the Cell Counting Kit-8 (CCK8, Dojindo Laboratories, Kumamoto, Japan)"
oligo-dT,genetic_reagents,PMID:18670322,10.1097/MLG.0b013e318177e20b,Vestibular schwannoma quantitative polymerase chain reaction expression of estrogen and progesterone receptors.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,oligo-dT,Other,,,,,,,,,,,,,,,,,,,,"mRNA was selected by running total RNA over oligo-dT columns (Invitrogen, Carlsbad, CA)"
RNA extraction reagent,genetic_reagents,PMID:21726432,10.1186/1741-7015-9-82,MIA is a potential biomarker for tumour load in neurofibromatosis type 1.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,RNA extraction reagent,Other,,,,,,,,,,,,,,,,,,,,"RNA was isolated from the knee cartilage...using peqGOLD TriFast (PeqLab Biotechnologie GmbH, Erlangen, Germany)"
Reverse Transcriptase,genetic_reagents,PMID:21726432,10.1186/1741-7015-9-82,MIA is a potential biomarker for tumour load in neurofibromatosis type 1.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Reverse Transcriptase,Other,,,,,,,,,,,,,,,,,,,,"cDNA was synthesized from 1 μg of total RNA with MuLV Reverse Transcriptase (Applied Biosystems, Carlsbad, CA, USA)"
PCR Master Mix,genetic_reagents,PMID:21726432,10.1186/1741-7015-9-82,MIA is a potential biomarker for tumour load in neurofibromatosis type 1.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,PCR Master Mix,Other,,,,,,,,,,,,,,,,,,,,TaqMan Universal PCR Master Mix was then performed on an ABI PRISM 7900 Cycler (Applied Biosystems)
V-CSCW2,genetic_reagents,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,V-CSCW2,Viral,CSCW2,,,,,,,,,,,,,,,,,,,Ben-Men-1 cells were transduced with either NF2-CSCW2 or V-CSCW2
Long Template PCR enzymes,genetic_reagents,PMID:24958239,10.1186/gb-2014-15-6-r80,SVA retrotransposon insertion-associated deletion represents a novel mutational mechanism underlying large genomic copy number changes with non-recurrent breakpoints.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Long Template PCR enzymes,Other,,,,,,,,,,,,,,,,,,,,"Breakpoint-spanning PCRs were performed using the Expand Long Template PCR system (Roche, Mannheim, Germany)"
BigDye Terminator,genetic_reagents,PMID:24958239,10.1186/gb-2014-15-6-r80,SVA retrotransposon insertion-associated deletion represents a novel mutational mechanism underlying large genomic copy number changes with non-recurrent breakpoints.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,BigDye Terminator,Other,,,,,,,,,,,,,,,,,,,,"sequenced with the BigDye Terminator v3.1 Cycle Sequencing Kit (Life Technologies, Darmstadt, Germany)"
GenomeWalker adaptors,genetic_reagents,PMID:24958239,10.1186/gb-2014-15-6-r80,SVA retrotransposon insertion-associated deletion represents a novel mutational mechanism underlying large genomic copy number changes with non-recurrent breakpoints.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,GenomeWalker adaptors,Other,,,,,,,,,,,,,,,,,,,,"To perform GenomeWalker™ analysis (Clontech, Saint-Germain-en-Laye, France), genomic DNA (2.5 μg per experiment) was restriction digested"
Advantage 2 PCR enzymes,genetic_reagents,PMID:24958239,10.1186/gb-2014-15-6-r80,SVA retrotransposon insertion-associated deletion represents a novel mutational mechanism underlying large genomic copy number changes with non-recurrent breakpoints.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Advantage 2 PCR enzymes,Other,,,,,,,,,,,,,,,,,,,,PCRs were performed with the Advantage® 2 PCR Kit (Clontech)
M-PER,genetic_reagents,PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,M-PER,Other,,,,,,,,,,,,,,,,,,,,"Global protein extracts were attained using M-PER™ Mammalian Protein Extraction Reagent (Thermo Fisher Scientific, Cat.# 78501)"
BCA,genetic_reagents,PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,BCA,Other,,,,,,,,,,,,,,,,,,,,"and quantified using Pierce BCA Protein Assay Kit (Thermo Fisher Scientific, Cat.# PI23225)"
shRNA,genetic_reagents,PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,shRNA,Plasmid,pLKO.1,,,,,,,,,,,,,,,,,,,Abcg1 shRNA or control shGFP-containing pLKO.1 plasmid was co-transfected
RNA extraction kit,genetic_reagents,PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,RNA extraction kit,Other,,,,,,,,,,,,,,,,,,,,"total RNA was harvested with the RNeasy Mini Kit according to manufacturer's instructions (Qiagen Sciences, Germantown, MD)"
reverse transcription reagents,genetic_reagents,PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,reverse transcription reagents,Other,,,,,,,,,,,,,,,,,,,,"2 μg of RNA was converted to the more stable complimentary deoxyribonucleic acid (cDNA) strands with TaqMan reverse transcription reagents (Applied Biosystems, Foster city, CA)"
BrdU staining reagents,genetic_reagents,PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,BrdU staining reagents,Other,,,,,,,,,,,,,,,,,,,,Cells were then treated with Zymed ® BrdU Staining Kit (Invitrogen)
Annexin V-FITC,genetic_reagents,PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Annexin V-FITC,Other,,,,,,,,,,,,,,,,,,,,"The Annexin V-FITC Apoptosis Detection kit (Calbiochem, San Diego, Cat # PF032) was used following the manufacturer's instructions."
Nutlin-3,genetic_reagents,PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Nutlin-3,Other,,,,,,,,,,,,,,,,,,,,"Nutlin-3 (# S1778, Beyotime, Shanghai, China), MG-132 (# S1748, Beyotime) and Pifithrin (PFT)-α"
MG-132,genetic_reagents,PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,MG-132,Other,,,,,,,,,,,,,,,,,,,,"Nutlin-3 (# S1778, Beyotime, Shanghai, China), MG-132 (# S1748, Beyotime) and Pifithrin (PFT)-α"
FLAG,genetic_reagents,PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,FLAG,Plasmid,,,,,,,,,,,,,,,,,,,,"Gateway LR recombination according to the manufacturer's protocol to insert NF1, SPRED1, and RAS entry clones into transient mammalian expression vectors pCAN-FLAG-DEST"
HA,genetic_reagents,PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,HA,Plasmid,,,,,,,,,,,,,,,,,,,,"Gateway LR recombination according to the manufacturer's protocol to insert NF1, SPRED1, and RAS entry clones into transient mammalian expression vectors pCAN-FLAG-DEST and pCAN-HA-DEST"
packaging,genetic_reagents,PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,packaging,Plasmid,psPAX2,,,,,,,,,,,,,,,,,,,Lentiviral particles were then generated by equimolar cotransfection of these NF1 expression vectors with psPAX2 (Addgene 12260)
envelope,genetic_reagents,PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,envelope,Plasmid,pMD2.G,,,,,,,,,,,,,,,,,,,Lentiviral particles were then generated by equimolar cotransfection of these NF1 expression vectors with psPAX2 (Addgene 12260) and pMD2.G (Addgene 12259) packaging plasmids
DNA capture system,genetic_reagents,PMID:32107864,10.1002/mgg3.1180,Expanding the Noonan spectrum/RASopathy NGS panel: Benefits of adding NF1 and SPRED1.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,DNA capture system,Other,,,,,,,,,,,,,,,,,,,,NGS was performed by oligonucleotide hybridization‐based DNA capture (SureSelect; Agilent)
AMPure XP beads,genetic_reagents,PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,AMPure XP beads,Other,,,,,,,,,,,,,,,,,,,,"DNA was purified using Agencourt AMPure XP beads (Beckman Coulter, IN) in a ratio of 1.0–0.9 of PCR product to beads."
WT1-AS,genetic_reagents,PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,WT1-AS,Plasmid,pcDNA,,,,,,,,,,,,,,,,,,,The human lncRNA WT1-AS were cloned into plasmid cloning DNA (pcDNA) vector
cDNA synthesis,genetic_reagents,PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,cDNA synthesis,Other,,,,,,,,,,,,,,,,,,,,RNA was reverse transcribed in to complementary DNA (cDNA) using the commercial Transcriptor First strand cDNA synthesis kit (Roche Diagnostics)
WT1-AS,genetic_reagents,PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,WT1-AS,Plasmid,pmirGLO,,,,,,,,,,,,,,,,,,,"The WT1-AS sequence including the putative binding sites of miR-494-3p was subcloned and then inserted into the pmirGLO vector (Promega, Madison, Wisconsin)"
EndoPorter,genetic_reagents,PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,EndoPorter,Other,,,,,,,,,,,,,,,,,,,,"SynNF1 was transduced into fibroblasts using the transduction reagent EndoPorter (GeneTools, LLC)"
Control siRNA,genetic_reagents,PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Control siRNA,Other,,,,,,,,,,,,,,,,,,,,As a control the Allstar Negative Control siRNA (Qiagen) was used
Lipofectamine RNAiMAX,genetic_reagents,PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Lipofectamine RNAiMAX,Other,,,,,,,,,,,,,,,,,,,,using the Lipofectamine RNAiMAX transfection reagent (Life Technologies)
RNA extraction kit,genetic_reagents,PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,RNA extraction kit,Other,,,,,,,,,,,,,,,,,,,,"RNAs were isolated using RNeasy mini kit (QIAGEN, Valencia, CA)"
interferon alpha-2b,genetic_reagents,PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,interferon alpha-2b,Other,,,,,,,,,,,,,,,,,,,,PEGylated interferon alpha-2b was purchased at the Cincinnati Children's Hospital (National Drug Code 00085132302) pharmacy
RNA isolation reagent,genetic_reagents,PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,RNA isolation reagent,Other,,,,,,,,,,,,,,,,,,,,We isolated total RNA from frozen tissue and cells using the RNeasy kit (Qiagen)
MTS assay reagent,genetic_reagents,PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,MTS assay reagent,Other,,,,,,,,,,,,,,,,,,,,We conducted MTS assays for viable cell number on days 3–7 post-infection using the CellTiter 96® Aqueous One Solution Cell Proliferation Assay (Promega)
TUNEL assay reagent,genetic_reagents,PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,TUNEL assay reagent,Other,,,,,,,,,,,,,,,,,,,,"we fixed cells in 4% paraformaldehyde for the detection of nuclear DNA fragmentation with the DeadEnd Fluorometric TUNEL System (Promega; Madison, WI)"
Merlin(S518D) and Merlin(S518E) mutants,genetic_reagents,PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,Merlin(S518D) and Merlin(S518E) mutants,Other,,,,,,,,,,,,,,,,,,,,The Merlin(S518D) and Merlin(S518E) mutants were generated with the QuikChange II site-directed mutagenesis kit (Agilent Technologies)
Human Mapping 100K Set,genetic_reagents,PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Human Mapping 100K Set,Other,,,,,,,,,,,,,,,,,,,,Tumor genotyping was performed with the Human Mapping 100K Set platform ( Affymetrix )
GeneChip Human Genome U133 Plus 2.0 Arrays,genetic_reagents,PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,GeneChip Human Genome U133 Plus 2.0 Arrays,Other,,,,,,,,,,,,,,,,,,,,gene-expression data were obtained using GeneChip Human Genome U133 Plus 2.0 Arrays ( Affymetrix )
MIPE 4.0,genetic_reagents,PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,MIPE 4.0,Other,,,,,,,,,,,,,,,,,,,,"...screen a panel of 1912 small molecules (the MIPE 4.0 library [17]) against immortalized NF1 −/−, NF1 +/−, and NF1 +/+ cell lines..."
Agilent SureSelect-XT reagents,genetic_reagents,PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Agilent SureSelect-XT reagents,Other,,,,,,,,,,,,,,,,,,,,"DNA libraries were prepared using Agilent SureSelect-XT reagents (Agilent Technologies, Inc., Santa Clara, CA)"
sgRNA,genetic_reagents,PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,sgRNA,Plasmid,pU6(x),U6,,,,,,,,,,,,,,,,,,gRNAs targeting zebrafish nf2a/b were validated and cloned in the pU6(x):sgRNA#(x) vectors
ficoll,genetic_reagents,PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,ficoll,Other,,,,,,,,,,,,,,,,,,,,White blood cells were isolated using ficoll (Sigma-Aldrich) from fresh whole blood
PHA,genetic_reagents,PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,PHA,Other,,,,,,,,,,,,,,,,,,,,Lymphocyte growth was stimulated with 50 µl/ml PHA (Gibco)
IL-2,genetic_reagents,PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,IL-2,Other,,,,,,,,,,,,,,,,,,,,stimulated with 50 µl/ml PHA (Gibco) and 10 units/ml of IL-2 (Roche)
puromycin,genetic_reagents,PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,puromycin,Other,,,,,,,,,,,,,,,,,,,,one part was treated with 200 µg/ml of puromycin (Sigma-Aldrich) as an inhibitor of nonsense mediated RNA decay
RNeasy Plus micro columns,genetic_reagents,PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,RNeasy Plus micro columns,Other,,,,,,,,,,,,,,,,,,,,Total RNA was purified and DNAseI treated using RNeasy Plus micro columns (Qiagen)
IGT-T192V1 Plus panel,genetic_reagents,PMID:39669605,10.1016/j.gimo.2024.101816,Next-generation variant exon screening: Moving forward in routine genetic disease investigations.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,IGT-T192V1 Plus panel,Other,,,,,,,,,,,,,,,,,,,,ES was performed by standard procedures using the IGT-T192V1 Plus panel (Integrated DNA Technologies) to capture selected targets.
MBP fusion,genetic_reagents,PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,MBP fusion,Plasmid,pMAL-c2X,,,,,,,,,,,,,,,,,,,The cDNA fragments were cloned in pMAL-c2X vector (New England Biolabs) for the expression of recombinant proteins as MBP fusions
Bond Polymer Refine Kit,genetic_reagents,PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,Bond Polymer Refine Kit,Other,,,,,,,,,,,,,,,,,,,,"Detection was performed using the Bond Polymer Refine Kit (DS9800, Leica Biosystems)"
FOXP3/Transcription Factor Fixation/Permeabilization kit,genetic_reagents,PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,FOXP3/Transcription Factor Fixation/Permeabilization kit,Other,,,,,,,,,,,,,,,,,,,,"cells first underwent fixation and permeabilization using the eBioscience ™ FOXP3/Transcription Factor Fixation/Permeabilization kit (Thermo Fisher Scientific, #00552100,)"
KAPA RiboErase HMR,genetic_reagents,PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,KAPA RiboErase HMR,Other,,,,,,,,,,,,,,,,,,,,"depletion was performed with KAPA RiboErase HMR (Roche, #07962274001)"
TruSeq Stranded Total RNA Library Prep Gold kit,genetic_reagents,PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,TruSeq Stranded Total RNA Library Prep Gold kit,Other,,,,,,,,,,,,,,,,,,,,"samples were prepared with TruSeq ® Stranded Total RNA Library Prep Gold kit (Illumina, #20020599)"
reprogramming factors,genetic_reagents,PMID:28392281,10.1016/j.expneurol.2017.04.001,Human stem cell modeling in neurofibromatosis type 1 (NF1).,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,reprogramming factors,Viral,,,,,,,,,,,,,,,,,,,,"The first vectors used to generate iPSCs were gamma retroviruses, specifically murine leukemia retroviruses, chosen for their favorable long-term transgene expression"
reprogramming factors,genetic_reagents,PMID:28392281,10.1016/j.expneurol.2017.04.001,Human stem cell modeling in neurofibromatosis type 1 (NF1).,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,reprogramming factors,Viral,,,,,,,,,,,,,,,,,,,,"The first vectors used to generate iPSCs were gamma retroviruses, specifically murine leukemia retroviruses, chosen for their favorable long-term transgene expression"
reprogramming factors,genetic_reagents,PMID:28392281,10.1016/j.expneurol.2017.04.001,Human stem cell modeling in neurofibromatosis type 1 (NF1).,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,reprogramming factors,Viral,,,,,,,,,,,,,,,,,,,,"Lentiviral vectors, a retroviral subclass, can transduce both non-dividing and rapidly-dividing cells with efficiencies comparable to other retroviruses"
reprogramming factors,genetic_reagents,PMID:28392281,10.1016/j.expneurol.2017.04.001,Human stem cell modeling in neurofibromatosis type 1 (NF1).,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,reprogramming factors,Viral,,,,,,,,,,,,,,,,,,,,Adenoviral vectors are considered a non-integrative option for reprogramming factor delivery
reprogramming factors,genetic_reagents,PMID:28392281,10.1016/j.expneurol.2017.04.001,Human stem cell modeling in neurofibromatosis type 1 (NF1).,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,reprogramming factors,Viral,,,,,,,,,,,,,,,,,,,,Sendai viral vectors are another non-integrative reprogramming alternative
p21 ras activation assay,genetic_reagents,PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,p21 ras activation assay,Other,,,,,,,,,,,,,,,,,,,,"p21 ras activation was subsequently determined using a p21 ras activation pulldown assay kit (Upstate Biotechnology, Lake Placid, NY, USA)"
TUNEL,genetic_reagents,PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,TUNEL,Other,,,,,,,,,,,,,,,,,,,,"The TUNEL assay was conducted by using the TUNEL kit (Roche, Reinach, Switzerland)"
PLKO,genetic_reagents,PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,0.8,Experimental Usage,False,1.00,Medium,,,,,,,,,,,PLKO,Viral,,,,,,,,,,,,,,,,,,,,PLKO virus was used as an empty vector control
patient-derived xenograft models,patient_derived_models,PMID:41023593,10.1186/s10020-025-01353-9,Selective inhibition of BRAF and CRAF sensitizes NF1-deficient malignant peripheral nerve sheath tumors to MEK inhibitors.,,0.8,Experimental Usage,True,1.00,Medium,,,,,,,,,,,,,,,,,,,,,,,PDX,NF1-associated MPNST,NSG,MPNST,,,,,,efficacy studies in cell-line-derived and patient-derived xenograft models
S100,antibodies,PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,0.8,Experimental Usage,True,0.67,Medium,,,,S100,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,The following primary antibodies were used: rabbit anti-NF2 (Santa Cruz); mouse anti-p55 monoclonal (this study); mouse anti-S100 (SIGMA)
GFAP,antibodies,PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,0.8,Experimental Usage,True,0.67,Medium,,,,GFAP,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,mouse anti-GFAP (Chemicon) and rabbit anti-GFAP (SIGMA)
Caspr,antibodies,PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,0.8,Experimental Usage,True,0.67,Medium,,,,Caspr,Mouse,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"and mouse anti-Caspr, kindly provided by Dr. Elior Peles, The Weizmann Institute of Science, Rehovot, Israel"
"Various (phospho-S6, phospho-4EBP1, phospho-STAT3, AKT, etc.)",antibodies,PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,0.8,Experimental Usage,True,0.33,Medium,,,,"Various (phospho-S6, phospho-4EBP1, phospho-STAT3, AKT, etc.)",Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,"All antibodies were purchased from Cell Signaling Technology (Beverly, MD) and used at a 1:1,000 dilution"
CXCL12,antibodies,PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.8,Experimental Usage,True,0.33,Medium,,,,CXCL12,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Antibodies were obtained from Peprotech (CXCL12)
mCherry,antibodies,PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.8,Experimental Usage,True,0.33,Medium,,,,mCherry,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Clontech (Dsred (mCherry))
GFAP,antibodies,PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.8,Experimental Usage,True,0.33,Medium,,,,GFAP,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Invitrogen (GFAP)
PDE4A,antibodies,PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.8,Experimental Usage,True,0.33,Medium,,,,PDE4A,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Abcam (PDE4A & 58kD Golgi marker)
LCA,antibodies,PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.8,Experimental Usage,True,0.33,Medium,,,,LCA,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Pharmingen (LCA)
IBA-1,antibodies,PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.8,Experimental Usage,True,0.33,Medium,,,,IBA-1,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Wako (IBA-1)
phosphorylated protein kinase A substrate,antibodies,PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.8,Experimental Usage,True,0.33,Medium,,,,phosphorylated protein kinase A substrate,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Cell Signaling (phosphorylated protein kinase A (pPKA) substrate)
CNPase,antibodies,PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.8,Experimental Usage,True,0.33,Medium,,,,CNPase,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Sigma (CNPase)
phosphorylated CXCR4,antibodies,PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.8,Experimental Usage,True,0.33,Medium,,,,phosphorylated CXCR4,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,Antibody directed against phosphorylated CXCR4 (pCXCR4) was developed in our lab and previously described
pH3,antibodies,PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,0.8,Experimental Usage,True,0.33,Medium,,,,pH3,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,The embryos were incubated in anti-pH3 antibody overnight at 4°C
Sox2,antibodies,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.8,Experimental Usage,True,0.33,Medium,,,,Sox2,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Other sections were stained with antibodies against Sox2, Nanog, Oct 3/4 and beta-catenin"
Nanog,antibodies,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.8,Experimental Usage,True,0.33,Medium,,,,Nanog,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Other sections were stained with antibodies against Sox2, Nanog, Oct 3/4 and beta-catenin"
Oct 3/4,antibodies,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.8,Experimental Usage,True,0.33,Medium,,,,Oct 3/4,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Other sections were stained with antibodies against Sox2, Nanog, Oct 3/4 and beta-catenin"
beta-catenin,antibodies,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.8,Experimental Usage,True,0.33,Medium,,,,beta-catenin,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Other sections were stained with antibodies against Sox2, Nanog, Oct 3/4 and beta-catenin"
HEK293 cells,cell_lines,PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.95,Experimental Usage,False,0.67,Low,,,,,,,Kidney,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,HEK293 cells (6 × 10 5 ) were transfected with 1 µg of the wild type or the mutated minigene
HEK293T cells,cell_lines,PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.95,Experimental Usage,False,0.67,Low,,,,,,,Kidney,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"HEK293T cells (American Type Culture Collection [ATCC], CRL-3216)"
HeLa cells,cell_lines,PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.95,Experimental Usage,False,0.67,Low,,,,,,,Cervix,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,HeLa cells (ATCC CCL-2)
JHH-520 cell line,cell_lines,PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,,0.95,Experimental Usage,False,0.67,Low,,,,,,,Brain,,Glioblastoma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,glioblastoma neurosphere lines with previously characterized levels of NF1 expression: JHH-520 (NF1-deficient)
"HEK-293T cells (ATCC; cat. #CRL-3216, RRID:CVCL_0063)",cell_lines,PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.95,Experimental Usage,False,0.67,Low,,,,,,,Kidney,,,Embryonic stem cell,,,,,,,,,,,,,,,,,,,,,,"All MPNST cell lines (human and mouse) and HEK-293T cells (ATCC; cat. #CRL-3216, RRID:CVCL_0063) were cultured in DMEM:F-12 (1:1) high-glucose media"
HeLa cells,cell_lines,PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,0.95,Experimental Usage,False,0.67,Low,,,,,,,Cervix,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"The expression vector was transfected into HeLa cells (Lipofectamine LTX with Plus Reagent, Invitrogen)"
Agilent Human miRNA Microarray V2,genetic_reagents,PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,0.95,Experimental Usage,False,0.50,Low,,,,,,,,,,,Agilent Human miRNA Microarray V2,,,,,,,,,,,,,,,,,,,,,Hundred nanogram of total RNA per sample was labelled and hybridised to the Agilent Human miRNA microarray V2
mirdametinib,genetic_reagents,PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.95,Experimental Usage,False,0.50,Low,,,,,,,,,,,mirdametinib,,,,,,,,,,,,,,,,,,,,,"Mirdametinib (also known as PD0325901) has the chemical structure of N-[(2R)-2,3 dihydroxypropoxyl]-3,4-difluro-2-[(2-fluoro-4-iodophenyl) amino] benzamide"
BJFF.6,cell_lines,PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Brain,,,Embryonic stem cell,,,,,,,,,,,,,,,,,,,,,,NF1 patient heterozygous germline NF1 gene mutations were CRISPR/Cas9-engineered into a single commercially available male control human iPSC line (BJFF.6)
Normal human Schwann cells (Sciencell),cell_lines,PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,Normal human Schwann cells (Sciencell) were incubated in SCM (Sciencell) on PDL-coated plates
MCF7,cell_lines,PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Breast,,Breast adenocarcinoma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Human ER + MCF7 breast cancer cells (HTB-22), were grown in Dulbecco's modified eagle medium"
human retinal ganglion cells (hRGC),cell_lines,PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Eye,,,,,,,,,,,,,,,,,,,,,,,,,"Human retinal ganglion cells (hRGC), gifted from Dr. Donald Zack laboratory, were described in previous studies, being Brn3b-TdTomato positive"
DH10Bac cells,cell_lines,PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Bacterial,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,Final baculovirus expression clones were transformed into DH10Bac cells (Thermo Fisher Scientific)
BL21(DE3),cell_lines,PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Bacterial,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,E. coli expression clones were transformed into BL21(DE3) for expression
Sf9 cells,cell_lines,PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Insect,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,baculoviruses were generated by transfection of bacmid DNA into Sf9 cells
Tni-FNL cells,cell_lines,PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Insect,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,Titered viruses were used at a multiplicity of infection of 3 to infect Tni-FNL cells
HEK293T,cell_lines,PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Kidney,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,HEK293T and NF1-null 293T cells were maintained in DMEM with 10% fetal bovine serum
iSC,cell_lines,PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"The immortalized normal rat Schwann cell line iSC was provided by E. M. Shooter (Stanford University, Stanford, CA, USA)."
ipn 02.8,cell_lines,PMID:39110684,10.1371/journal.pone.0308207,Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon nanotube fibers.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Wild type Schwann cell (WT SC, NF+/+) line, ipn 02.8 were utilized for all experiments. The cells were extracted from human patients diagnosed with Plexiform Neurofibroma"
p53−/− mouse embryonic liver progenitor cells,cell_lines,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Liver,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,We performed a genome-wide CRISPR/Cas9-based knockout screen of P53-null mouse embryonic liver progenitor cells that overexpressed MYC
HEK-293T cells,cell_lines,PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Kidney,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"mutant transcripts were expressed in HEK-293T cells. The phosphorylation level of ELK1, which is a downstream substrate of the RAS/MAPK pathway"
HEK 293T,cell_lines,PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Kidney,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"HEK 293T and immortalized mouse Nf2 Schwann cells, a gift from D. Lallemand...were maintained in Dulbecco's minimum essential medium"
HEK 293T,cell_lines,PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Kidney,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,HEK 293 T and COS-7 cells were maintained in Dulbecco's Modified Eagle Medium (DMEM)
COS-7,cell_lines,PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Kidney,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,HEK 293 T and COS-7 cells were maintained in Dulbecco's Modified Eagle Medium (DMEM)
HEK 293T,cell_lines,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Kidney,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"To study hey1 promoter activity, we transfected HEK 293T cells plated in 24 well tissue culture plates"
CT26,cell_lines,PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Colon,,Colon cancer,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,The colon cancer cell line CT26 was injected subcutaneously into the right flank of 6–8-week-old female BALB/C mice
U937,cell_lines,PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Blood,,Leukemia,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Human U937 cells were cultured in RPMI 1640 medium with 5% FBS and antibiotics, and were differentiated to M1 macrophage-like cells"
Raji,cell_lines,PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Blood,,Burkitt's lymphoma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Raji, a human Burkitt's lymphoma cell line, was purchased from Sigma."
Eμ-ALL,cell_lines,PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Blood,,B-cell acute lymphoblastic leukemia,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"The Eμ-ALL cell line was derived from a lymphoid malignancy in an Eμ-myc transgenic mouse and upon intravenous injection, can develop B-ALL in C57Bl/6 mice"
ipn023λ,cell_lines,PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"immortalized human normal Schwann cell line ipn023λ, were generated by the Wallace's lab"
HEK-293T,cell_lines,PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Kidney,,,Embryonic stem cell,,,,,,,,,,,,,,,,,,,,,,"The SNF96.2 (CRL-2884, RRID: CVCL_K281) human MPNST cell line and the HEK-293T (CRL-3216, RRID: CVCL_0063) cell line were obtained from ATCC"
Drosophila Schneider (S2R+) cells,cell_lines,PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Drosophila Schneider (S2R+) cells, both WT and dNF1‐KO, were cultured at 25 °C in Schneider's media"
hTERT ipn02.3 2λ CRL‐3392,cell_lines,PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"NF1 and +/− NF1 immortalized human Schwann cell (SC) lines, derived from the ipn02.3 2λ (hTERT ipn02.3 2λ CRL‐3392) cell line"
OLN93 mouse oligodendrocyte cell line,cell_lines,PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Brain,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"OLN93 mouse oligodendrocyte cell line was kindly provided by Dr. C. Richter-Landsberg (Oldenburg University, Germany)"
RT4-D6PT2 schwannoma cell line,cell_lines,PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,Schwannoma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,The RT4-D6PT2 schwannoma cell line was obtained from the European Collection of Animal Cell Cultures
TC620 human oligodendroglioma cell line,cell_lines,PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Brain,,Oligodendroglioma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,The TC620 human oligodendroglioma cell line was a gift from Dr. A. Glassmann
STS26T,cell_lines,PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"sporadic MPNST cells (STS26T, D. Scoles) were seeded on poly-l-lysine–coated 12-mm circle glass coverslips"
HSC1λ,cell_lines,PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,Immortalized human Schwann cell (HSC1λ) and immortalized neurofibroma cell (ipNF06.2A) were obtained from Dr. Margaret Wallace's laboratory
iHSC1λ,cell_lines,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.9,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Cultured immortalized Schwann cells (iHSC1λ and iHSC2λ) were both derived from a patient's normal sciatic nerve, are NF1 wild-type, and were immortalized by hTERT and CDK4"
iHSC2λ,cell_lines,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.9,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Cultured immortalized Schwann cells (iHSC1λ and iHSC2λ) were both derived from a patient's normal sciatic nerve, are NF1 wild-type, and were immortalized by hTERT and CDK4"
"Human Schwann Cells (HSC, ScienCell Research Laboratories #1700)",cell_lines,PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Human Schwann cells (HSC, ScienCell Research Laboratories #1700) and Mouse Schwann Cells (MSC, ScienCell Research Laboratories #M1700-57) were cultured"
"Mouse Schwann Cells (MSC, ScienCell Research Laboratories #M1700-57)",cell_lines,PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Human Schwann cells (HSC, ScienCell Research Laboratories #1700) and Mouse Schwann Cells (MSC, ScienCell Research Laboratories #M1700-57) were cultured"
human endothelial colony forming cells (ECFC),cell_lines,PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Blood,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Pooled human endothelial colony forming cells (ECFC, endothelial outgrowth cells) were purchased from the Angio BioCore at Indiana University"
human microvascular endothelial cells (HMVEC),cell_lines,PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Blood,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Human microvascular endothelial cells (HMVEC) were purchased from Lonza (Allendale, NJ, USA)"
"Human Schwann cells (HSC; ScienCell, Carlsbad, CA)",cell_lines,PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Human Schwann cells (HSC; ScienCell, Carlsbad, CA) were maintained in culture at 37°C in an atmosphere of 5% carbon dioxide."
BL21(DE3) Star,cell_lines,PMID:28831766,10.1007/s12104-017-9768-1,NMR resonance assignments of the EVH1 domain of neurofibromin's recruitment factor Spred1.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Bacterial,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,The plasmid was transformed into the E. coli strain BL21(DE3) Star (Invitrogen)
iHSC1λ,cell_lines,PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Cultured immortalized Schwann cells (iHSC1λ and iHSC2λ) were both derived from a patient's normal sciatic nerve, are NF1 wild-type, and were immortalized by hTERT and CDK4 R24C"
iHSC2λ,cell_lines,PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Cultured immortalized Schwann cells (iHSC1λ and iHSC2λ) were both derived from a patient's normal sciatic nerve, are NF1 wild-type, and were immortalized by hTERT and CDK4 R24C"
S462,cell_lines,PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Immortalized human Schwann cell and MPNST cell lines (S462 [ 34 ], S462-TY [ 35 ], ST8814 [ 36 ], T265 [ 37 ], and STS-26T [ 38 ])"
S462-TY,cell_lines,PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Immortalized human Schwann cell and MPNST cell lines (S462 [ 34 ], S462-TY [ 35 ], ST8814 [ 36 ], T265 [ 37 ], and STS-26T [ 38 ])"
ST8814,cell_lines,PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Immortalized human Schwann cell and MPNST cell lines (S462 [ 34 ], S462-TY [ 35 ], ST8814 [ 36 ], T265 [ 37 ], and STS-26T [ 38 ])"
T265,cell_lines,PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Immortalized human Schwann cell and MPNST cell lines (S462 [ 34 ], S462-TY [ 35 ], ST8814 [ 36 ], T265 [ 37 ], and STS-26T [ 38 ])"
STS-26T,cell_lines,PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Immortalized human Schwann cell and MPNST cell lines (S462 [ 34 ], S462-TY [ 35 ], ST8814 [ 36 ], T265 [ 37 ], and STS-26T [ 38 ])"
Primary human Schwann cells (NHSC),cell_lines,PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,Primary human Schwann cells (NHSC) isolated from human spinal nerve were purchased from ScienCell Research Laboratories (Cat. #1700)
iHSCs,cell_lines,PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,Immortalized human Schwann cells (iHSCs) were acquired from the laboratory of Dr. Margaret Wallace
MPNST-SP-01,cell_lines,PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"The establishment of the MPNST-SP-01, MPNST-NF1-08, and MPNST-NF1-9 cell lines at the Catalan Institute of Oncology is described..."
NIH-3T3,cell_lines,PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Embryonic tissue,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,NIH-3T3 (obtained from American Type Culture Collection) cells were cultured in high-glucose DMEM
U87,cell_lines,PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Brain,,Glioma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"4 glioma cell lines (U87, U118, U251, and A172) were commercially procured from Shanghai Cell Bank of the Chinese Academy of Sciences"
U118,cell_lines,PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Brain,,Glioma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"4 glioma cell lines (U87, U118, U251, and A172) were commercially procured from Shanghai Cell Bank of the Chinese Academy of Sciences"
U251,cell_lines,PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Brain,,Glioma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"4 glioma cell lines (U87, U118, U251, and A172) were commercially procured from Shanghai Cell Bank of the Chinese Academy of Sciences"
A172,cell_lines,PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Brain,,Glioma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"4 glioma cell lines (U87, U118, U251, and A172) were commercially procured from Shanghai Cell Bank of the Chinese Academy of Sciences"
U87,cell_lines,PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Brain,,Glioblastoma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,Experiments were performed on human U87 and U251 glioblastoma cells
U251,cell_lines,PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Brain,,Glioblastoma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,Experiments were performed on human U87 and U251 glioblastoma cells
MiaPaCa-2,cell_lines,PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Pancreas,,Pancreatic carcinoma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,human pancreatic carcinoma cells (MiaPaCa-2 and PANC1)
PANC1,cell_lines,PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Pancreas,,Pancreatic carcinoma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,human pancreatic carcinoma cells (MiaPaCa-2 and PANC1)
BxPc3,cell_lines,PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Pancreas,,Pancreatic adenocarcinoma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,human pancreatic adenocarcinoma cells (BxPc3)
GBM1 cell line,cell_lines,PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Brain,,Glioblastoma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"glioblastoma neurosphere lines with previously characterized levels of NF1 expression: JHH-520 (NF1-deficient), GBM1 (NF1-intact)"
JHH-0879 cell line,cell_lines,PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Brain,,Glioblastoma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"glioblastoma neurosphere lines with previously characterized levels of NF1 expression: JHH-520 (NF1-deficient), GBM1 (NF1-intact), and JHH-0879 (NF1-intact)"
STS-26T,cell_lines,PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,90-8 and the sporadic MPNST-derived STS-26T (provided by Dr Eric Legius)
HS-Sch-2,cell_lines,PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,sporadic HS-Sch-2 (obtained from RIKEN)
CCD-1112Sk,cell_lines,PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Skin,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,the commercial human foreskin fibroblast (HFF) cell line CCD-1112Sk (ATCC)
STS26T,cell_lines,PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"MPNST cell lines STS26T, ST8814, ST88-3 S462, T265p21, S520, 90–8, and YST1...All cell lines were from NF1 patients except YST-1 and STS26T"
YST1,cell_lines,PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"MPNST cell lines STS26T, ST8814, ST88-3 S462, T265p21, S520, 90–8, and YST1...All cell lines were from NF1 patients except YST-1 and STS26T"
DS-red STS26T cell line,cell_lines,PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,Mice were injected s.c. with a stably transfected DS-red STS26T cell line
hTERT ipn02.3 2λ,cell_lines,PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"...and the normal Schwann cell line hTERT ipn02.3 2λ (ATCC, CRL-3392) were cultured in DMEM..."
U251,cell_lines,PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Brain,,Glioblastoma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"By selecting sub-populations of U251 glioblastoma cells, we observed that high expression of phosphorylated Merlin..."
C6 cells,cell_lines,PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Brain,,Glioma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,C6 rat glioma cells were injected into the optic nerve of Long-Evans rats and allowed to proliferate for 2 weeks
mouse embryonic fibroblasts (MEFs),cell_lines,PMID:28392281,10.1016/j.expneurol.2017.04.001,Human stem cell modeling in neurofibromatosis type 1 (NF1).,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Embryo,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,The first direct lineage conversion of post-mitotic neurons from mouse embryonic fibroblasts (MEFs) and tail-tip fibroblasts (TTFs)
tail-tip fibroblasts (TTFs),cell_lines,PMID:28392281,10.1016/j.expneurol.2017.04.001,Human stem cell modeling in neurofibromatosis type 1 (NF1).,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Skin,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,The first direct lineage conversion of post-mitotic neurons from mouse embryonic fibroblasts (MEFs) and tail-tip fibroblasts (TTFs)
BL21 (DE3) E.coli,cell_lines,PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Bacteria,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,Proteins were expressed in BL21 (DE3) E.coli and purified using Amersham HiTrap glutathione columns
STS26T,cell_lines,PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"The MPNST cell lines STS26T, T265, and ST8814 have been reported before and were gifted by Dr. Nancy Ratner"
STS26T,cell_lines,PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.9,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Authenticated human MPNST cell lines (sporadic STS26T, called 26T, Cellosaurus RRID: CVCL_8917"
ipn02.3,cell_lines,PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,Immortalised human Schwann cell lines with mutant NF1 (ipNF05.5 and 95.6) and wt NF1 (ipn02.3)
"normal human Schwann cells (Cat. No. 1700, ScienCell Research Laboratories)",cell_lines,PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,0.9,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Low passage normal human Schwann cells (Cat. No. 1700, ScienCell Research Laboratories, Carlsbad, CA, USA) were cultured on CellBIND dishes"
dll4,genetic_reagents,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,Development,False,0.50,Low,,,,,,,,,,,dll4,,,hsp70,,,,,,,,,,,,,,,,,,"We generated hsp70:dll4-P2A-GFP, hsp70:GFP-P2A-dlb, hsp70:GFP-P2A-hey1, hsp70:id2b-P2A-GFP, ubi:Cas9, u6:dll4-gRNAs and 1,2 u6:n3-gRNAs transgenic fish"
dlb,genetic_reagents,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,Development,False,0.50,Low,,,,,,,,,,,dlb,,,hsp70,,,,,,,,,,,,,,,,,,"We generated hsp70:dll4-P2A-GFP, hsp70:GFP-P2A-dlb, hsp70:GFP-P2A-hey1, hsp70:id2b-P2A-GFP, ubi:Cas9, u6:dll4-gRNAs and 1,2 u6:n3-gRNAs transgenic fish"
hey1,genetic_reagents,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,Development,False,0.50,Low,,,,,,,,,,,hey1,,,hsp70,,,,,,,,,,,,,,,,,,"We generated hsp70:dll4-P2A-GFP, hsp70:GFP-P2A-dlb, hsp70:GFP-P2A-hey1, hsp70:id2b-P2A-GFP, ubi:Cas9, u6:dll4-gRNAs and 1,2 u6:n3-gRNAs transgenic fish"
id2b,genetic_reagents,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,Development,False,0.50,Low,,,,,,,,,,,id2b,,,hsp70,,,,,,,,,,,,,,,,,,"We generated hsp70:dll4-P2A-GFP, hsp70:GFP-P2A-dlb, hsp70:GFP-P2A-hey1, hsp70:id2b-P2A-GFP, ubi:Cas9, u6:dll4-gRNAs and 1,2 u6:n3-gRNAs transgenic fish"
Cas9,genetic_reagents,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,Development,False,0.50,Low,,,,,,,,,,,Cas9,,,ubi,,,,,,,,,,,,,,,,,,"We generated hsp70:dll4-P2A-GFP, hsp70:GFP-P2A-dlb, hsp70:GFP-P2A-hey1, hsp70:id2b-P2A-GFP, ubi:Cas9, u6:dll4-gRNAs and 1,2 u6:n3-gRNAs transgenic fish"
dll4-gRNAs,genetic_reagents,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,Development,False,0.50,Low,,,,,,,,,,,dll4-gRNAs,,,u6,,,,,,,,,,,,,,,,,,"We generated hsp70:dll4-P2A-GFP, hsp70:GFP-P2A-dlb, hsp70:GFP-P2A-hey1, hsp70:id2b-P2A-GFP, ubi:Cas9, u6:dll4-gRNAs and 1,2 u6:n3-gRNAs transgenic fish"
n3-gRNAs,genetic_reagents,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,Development,False,0.50,Low,,,,,,,,,,,n3-gRNAs,,,u6,,,,,,,,,,,,,,,,,,"We generated hsp70:dll4-P2A-GFP, hsp70:GFP-P2A-dlb, hsp70:GFP-P2A-hey1, hsp70:id2b-P2A-GFP, ubi:Cas9, u6:dll4-gRNAs and 1,2 u6:n3-gRNAs transgenic fish"
hey1,genetic_reagents,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,Development,False,0.50,Low,,,,,,,,,,,hey1,,pXP1,,,,,,,,,,,,,,,,,,,A 3kb region upstream of the hey1 gene's transcription start site was amplified by PCR and cloned into Xho1/Kpn1 sites of the pXP1 plasmid to create 3kb-hey1:luciferase
dlb,genetic_reagents,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,Development,False,0.50,Low,,,,,,,,,,,dlb,,pCS2,,,,,,,,,,,,,,,,,,,"we generated pCS2+dlb-EGFP, pCS2+n3-EGFP and pCS2+id2b-EGFP constructs"
n3,genetic_reagents,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,Development,False,0.50,Low,,,,,,,,,,,n3,,pCS2,,,,,,,,,,,,,,,,,,,"we generated pCS2+dlb-EGFP, pCS2+n3-EGFP and pCS2+id2b-EGFP constructs"
id2b,genetic_reagents,PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,Development,False,0.50,Low,,,,,,,,,,,id2b,,pCS2,,,,,,,,,,,,,,,,,,,"we generated pCS2+dlb-EGFP, pCS2+n3-EGFP and pCS2+id2b-EGFP constructs"
CellTiter-Glo cell viability kit,genetic_reagents,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,CellTiter-Glo cell viability kit,,,,,,,,,,,,,,,,,,,,,Drug screening assays for all cell lines were carried out in a 384-well format using the CellTiter-Glo cell viability kit (Promega)
ADU-S100,genetic_reagents,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,ADU-S100,,,,,,,,,,,,,,,,,,,,,"50 μg of the STING agonist ADU-S100 (HY-12885B, MedChemExpress)"
SA3,genetic_reagents,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,SA3,,,,,,,,,,,,,,,,,,,,,"mice that were treated with the STING agonist SA3 (HY-103665, MedChemExpress)"
L-[18F]FETrp,genetic_reagents,PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,L-[18F]FETrp,,,,,,,,,,,,,,,,,,,,,"We studied a fluorine-18 labeled tryptophan positron emission tomography (PET) radiotracer, 1-(2-[18F]FETrp"
Gentamicin,genetic_reagents,PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,Gentamicin,,,,,,,,,,,,,,,,,,,,,Gentamicin (Sigma) and G418 (Corning) were reconstituted in sterile deionized water to a stock concentration of 50 mg/mL
G418,genetic_reagents,PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,G418,,,,,,,,,,,,,,,,,,,,,Gentamicin (Sigma) and G418 (Corning) were reconstituted in sterile deionized water
Ataluren,genetic_reagents,PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,Ataluren,,,,,,,,,,,,,,,,,,,,,Ataluren (MedChem Express) was reconstituted in sterile dimethyl sulfoxide (DMSO) to a stock concentration of 10 mM
Amplex Red glutamic acid/glutamate oxidase assay,genetic_reagents,PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,Amplex Red glutamic acid/glutamate oxidase assay,,,,,,,,,,,,,,,,,,,,,Glutamate released from wild-type and Nf1 cortical neurons was measured using the Amplex Red glutamic acid/glutsamate oxidase assay kit (Invitrogen)
EGFP,genetic_reagents,PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,EGFP,,,,,,,,,,,,,,,,,,,,,Neurite outgrowth was determined from low-density hippocampal neurons transfected with EGFP using Lipofectamine
Nestin-cre ER,genetic_reagents,PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,Nestin-cre ER,,,,,,,,,,,,,,,,,,,,,"For inducible experiments, Nestin-cre ER +; Nf1 flox/+  (tamoxifen+) mice were used as controls while Nestin-cre ER +; Nf1 flox/flox"
PD0325901,genetic_reagents,PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,PD0325901,,,,,,,,,,,,,,,,,,,,,"MEK inhibitor (PD0325901, Sigma) was dissolved in DMSO at a concentration of 25mg/ml"
HK2,genetic_reagents,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,HK2,,,,,,,,,,,,,,,,,,,,,"Human HK2 recombinant protein (0.5 μg; HXK0703, ATGEN) or total cell lysate"
D4ER,genetic_reagents,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,D4ER,,,,,,,,,,,,,,,,,,,,,cells were transfected with the ER‐targeted D4ER Ca2+ probe
GCAMP6f,genetic_reagents,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,GCAMP6f,,,,,,,,,,,,,,,,,,,,,cells were transfected with a cDNA encoding mitochondrial and nuclear GCAMP6f
mit-Aeqmut,genetic_reagents,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,mit-Aeqmut,,,,,,,,,,,,,,,,,,,,,cells were transfected with a plasmid encoding low‐affinity mitochondrial matrix aequorin (mit‐Aeqmut)
GFP-PHD,genetic_reagents,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,GFP-PHD,,,,,,,,,,,,,,,,,,,,,cells were transfected with a plasmid encoding the GFP‐tagged pleckstrin homology (PH) domain of PLC‐δ1 (GFP‐PHD)
miRNAeasy kit,genetic_reagents,PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,miRNAeasy kit,,,,,,,,,,,,,,,,,,,,,"Total RNA, including miRNA was extracted using the miRNAeasy kit (Qiagen Ltd, Crawley, West Sussex, UK)"
TaqMan miRNA assays,genetic_reagents,PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,TaqMan miRNA assays,,,,,,,,,,,,,,,,,,,,,"MicroRNA expression in each sample, and the cell line, was measured using TaqMan miRNA assays technology (Applied Biosystems Inc.)"
miR-29c,genetic_reagents,PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,miR-29c,,,,,,,,,,,,,,,,,,,,,"sNF96.2, was transfected in six-well plates using oligofectamine (Invitrogen) giving a final concentration of 100 nM of miRNA mimics (Dharmacon Inc.)"
selumetinib,genetic_reagents,PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,selumetinib,,,,,,,,,,,,,,,,,,,,,"selumetinib (Tocris, catalog 6815), ogerin (Tocris, catalog 5722)"
ogerin,genetic_reagents,PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,ogerin,,,,,,,,,,,,,,,,,,,,,"selumetinib (Tocris, catalog 6815), ogerin (Tocris, catalog 5722)"
GANT61,genetic_reagents,PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,GANT61,,,,,,,,,,,,,,,,,,,,,"GANT61 (Tocris, catalog 3191), LGK-974 (Selleckchem, catalog S7143)"
LGK-974,genetic_reagents,PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,LGK-974,,,,,,,,,,,,,,,,,,,,,"GANT61 (Tocris, catalog 3191), LGK-974 (Selleckchem, catalog S7143)"
PAM71,genetic_reagents,PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,PAM71,,,,,,,,,,,,,,,,,,,,,"PAM71 (MedChemExpress, catalog HY-134494), 8-(4-Chlorophenylthio)adenosine"
8CPT cAMP,genetic_reagents,PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,8CPT cAMP,,,,,,,,,,,,,,,,,,,,,"8-(4-Chlorophenylthio)adenosine 3′,5′-cyclic monophosphate (8CPT cAMP) (Abcam, catalog ab120424)"
Forskolin,genetic_reagents,PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,Forskolin,,,,,,,,,,,,,,,,,,,,,"Forskolin (MilliporeSigma, catalog F6886). They were prepared as indicated by the manufacturers"
DUSP6,genetic_reagents,PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,DUSP6,,,,,,,,,,,,,,,,,,,,,using the following pig TaqMan primers ( DUSP6 -Ss06941845_m1;  FOS  -Ss03390402_m1; normalized to the average of pig housekeeping genes
FOS,genetic_reagents,PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,FOS,,,,,,,,,,,,,,,,,,,,,using the following pig TaqMan primers ( DUSP6 -Ss06941845_m1;  FOS  -Ss03390402_m1; normalized to the average of pig housekeeping genes
Alexa Fluor 594-labeled dextrans,genetic_reagents,PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,0.9,Experimental Usage,False,0.50,Low,,,,,,,,,,,Alexa Fluor 594-labeled dextrans,,,,,,,,,,,,,,,,,,,,,"we electroporated the afferent fibers to the calyx of Held with Alexa Fluor 594-labeled dextrans (10,000 MW; Invitrogen)"
FiPS,cell_lines,PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.9,Experimental Usage,False,0.33,Low,,,,,,,Unknown,,,Embryonic stem cell,,,,,,,,,,,,,,,,,,,,,,"FiPS, a WT human iPSC line derived from fibroblast, and its isogenic NF1 iPSC generated by CRISPR"
TOP-10F' cells,cell_lines,PMID:12057013,10.1186/1471-2164-3-13,Complex splicing pattern generates great diversity in human NF1 transcripts.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Blood,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,The PCR products were cloned in the pCR2.1-TOPO-vector (Invitrogen) and transformed into TOP-10F' cells.
A549,cell_lines,PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Lung,,Non-small cell lung carcinoma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"The human non-small cell carcinoma cell line A549 was obtained from Cell Lines Resource, Karmanos Cancer Institute, Detroit, MI."
MCF10A,cell_lines,PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Breast,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"The human normal breast epithelial MCF10A cell line was obtained from Cell Lines Resource, Karmanos Cancer Institute, Detroit, MI"
LLC-PK1 ATCC CL-101,cell_lines,PMID:34630515,10.3389/fgene.2021.721045,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and ,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Kidney,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"In vitro design validation was performed using a porcine kidney epithelial cell line (LLC-PK1 ATCC CL-101 ™ ; American Type Culture Collection (ATCC), Manassas, VA)"
MIAPaCa-2,cell_lines,PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,0.85,Experimental Usage,False,0.67,Low,,,,,,,Pancreas,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Human PDAC cell lines MIAPaCa-2, Panc-1, BxPC-3, and AsPC-1 were acquired from American Type Culture Collection (ATCC, Rockville, MD, USA)"
Panc-1,cell_lines,PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,0.85,Experimental Usage,False,0.67,Low,,,,,,,Pancreas,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Human PDAC cell lines MIAPaCa-2, Panc-1, BxPC-3, and AsPC-1 were acquired from American Type Culture Collection (ATCC, Rockville, MD, USA)"
BxPC-3,cell_lines,PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,0.85,Experimental Usage,False,0.67,Low,,,,,,,Pancreas,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Human PDAC cell lines MIAPaCa-2, Panc-1, BxPC-3, and AsPC-1 were acquired from American Type Culture Collection (ATCC, Rockville, MD, USA)"
AsPC-1,cell_lines,PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,0.85,Experimental Usage,False,0.67,Low,,,,,,,Pancreas,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Human PDAC cell lines MIAPaCa-2, Panc-1, BxPC-3, and AsPC-1 were acquired from American Type Culture Collection (ATCC, Rockville, MD, USA)"
HPDE H6c7,cell_lines,PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,0.85,Experimental Usage,False,0.67,Low,,,,,,,Pancreas,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,Immortalized human pancreatic ductal epithelial (HPDE H6c7) cells were a kind gift from Dr. Ming-Sound Tsao at Ontario Cancer Institute
Human CD19scFv-CD28–4–1BB-CD3ζ CAR-T cells (PM-CAR1003),cell_lines,PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Blood,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,Human CD19scFv-CD28–4–1BB-CD3ζ CAR-T cells (PM-CAR1003) were purchased from Promab Biotechnologies
U2OS,cell_lines,PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Bone,,Osteosarcoma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,standard curves for quantitative analysis were prepared with serially diluted QuickPreps of ALT[+] U2OS and ALT[-] HEK293 cell lines
HEK293,cell_lines,PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Kidney,,,Embryonic stem cell,,,,,,,,,,,,,,,,,,,,,,standard curves for quantitative analysis were prepared with serially diluted QuickPreps of ALT[+] U2OS and ALT[-] HEK293 cell lines
Human meningeal cells (HMC),cell_lines,PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Brain,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,Human meningeal cells (HMC) were obtained from Sciencell™ and maintained in the manufacturer's recommended media at 5% CO2.
Normal human Schwann cells (NHSC),cell_lines,PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,Normal human Schwann cells (NHSC) from trauma victims and MPNST cell lines were cultured as described
S462,cell_lines,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.85,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Immortalized human Schwann cell and MPNST cell lines (S462 ( 45 ), S462-TY ( 35 ), ST8814 ( 46 ), T265 ( 47 ), and STS-26T ( 36 ))"
S462-TY,cell_lines,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.85,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Immortalized human Schwann cell and MPNST cell lines (S462 ( 45 ), S462-TY ( 35 ), ST8814 ( 46 ), T265 ( 47 ), and STS-26T ( 36 ))"
ST8814,cell_lines,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.85,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Immortalized human Schwann cell and MPNST cell lines (S462 ( 45 ), S462-TY ( 35 ), ST8814 ( 46 ), T265 ( 47 ), and STS-26T ( 36 ))"
T265,cell_lines,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.85,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Immortalized human Schwann cell and MPNST cell lines (S462 ( 45 ), S462-TY ( 35 ), ST8814 ( 46 ), T265 ( 47 ), and STS-26T ( 36 ))"
STS-26T,cell_lines,PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.85,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Immortalized human Schwann cell and MPNST cell lines (S462 ( 45 ), S462-TY ( 35 ), ST8814 ( 46 ), T265 ( 47 ), and STS-26T ( 36 ))"
HeLa cells,cell_lines,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Cervix,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Human cervix carcinoma HeLa cells, human breast cancer MDA‐MB‐231 cells, human malignant peripheral nerve sheath tumor S462 cells"
MDA-MB-231 cells,cell_lines,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Breast,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"human breast cancer MDA‐MB‐231 cells, human malignant peripheral nerve sheath tumor S462 cells"
4T1 cells,cell_lines,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Breast,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,mouse breast cancer 4T1 cells and mouse colorectal carcinoma CT26 cells
CT26 cells,cell_lines,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Colon,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"mouse colorectal carcinoma CT26 cells, mouse macrophage RAW 264.7 cells"
RAW 264.7 cells,cell_lines,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Blood,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"mouse macrophage RAW 264.7 cells and, mouse myoblast C2C12 cells"
C2C12 cells,cell_lines,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Muscle,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,mouse myoblast C2C12 cells were cultured in DMEM medium
COLO 741 cells,cell_lines,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Colon,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,colorectal carcinoma COLO 741 cells and B‐CLL MEC1 cells were cultured in RPMI 1640 medium
MEC1 cells,cell_lines,PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Blood,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,B‐CLL MEC1 cells were cultured in RPMI 1640 medium
WT-1 hiPSC line,cell_lines,PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Blood,,,Embryonic stem cell,,,,,,,,,,,,,,,,,,,,,,Two control NF1 (+/+) hiPSC lines (WT-1 and WT-2) purchased from Phenocell were also generated from control donors
WT-2 hiPSC line,cell_lines,PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Blood,,,Embryonic stem cell,,,,,,,,,,,,,,,,,,,,,,Two control NF1 (+/+) hiPSC lines (WT-1 and WT-2) purchased from Phenocell were also generated from control donors
U87 glioblastoma cells,cell_lines,PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Brain,,Glioblastoma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,Experiments were performed on human U87 glioblastoma cells (ATCC)
HEK293T,cell_lines,PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Kidney,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"compared with HEK293T cells, which are neurofibromin 1 wildtype (WT)"
HT1080,cell_lines,PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Connective tissue,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,compared with HT1080 WT for neurofibromin 1
HEK-293T,cell_lines,PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Kidney,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,HEK-293T cells were a gift from Luke Gilbert and cultured in Dulbecco's Modified Eagle Medium
CT10,cell_lines,PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Dental pulp,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"...three from individuals without NF1 (control group; CT10, CT11 and CT12). Participants were both men and women..."
CT11,cell_lines,PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Dental pulp,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"...three from individuals without NF1 (control group; CT10, CT11 and CT12). Participants were both men and women..."
CT12,cell_lines,PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Dental pulp,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"...three from individuals without NF1 (control group; CT10, CT11 and CT12). Participants were both men and women..."
CTL BJFF.6 hiPSCs,cell_lines,PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Skin,,,Embryonic stem cell,,,,,,,,,,,,,,,,,,,,,,The original CTL BJFF.6 hiPSCs were generated from commercially available human foreskin fibroblasts
293FT packaging cells,cell_lines,PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Kidney,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"To generate lentiviral supernatant, 293FT packaging cells were plated onto tissue culture plates"
MPNST,cell_lines,PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,MPNST was derived from a patient with a high grade peripheral nerve sheath tumor of the thigh
Human Schwann cells (HSCs),cell_lines,PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Human Schwann cells (HSCs) were purchased from ScienCell Research Laboratories (catalog no., 1700)."
HEK 293T cell line,cell_lines,PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Kidney,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,The HEK 293T cell line was purchased from ATCC
LN428 human glioblastoma multiforme (GBM) cell line,cell_lines,PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Brain,,Glioblastoma multiforme,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,LN428 human glioblastoma multiforme (GBM) cell line was a gift from Dr. Erwin van Meir
C2C12,cell_lines,PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Muscle,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,The C2C12 line is a subclone of a mouse myoblast cell line. These cells were purchased from the American Type Culture Collection (ATCC)
Mouse embryonic fibroblasts (MEFs),cell_lines,PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Embryonic tissue,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,Mouse embryonic fibroblasts (MEFs) from wildtype and Rabl6m/m C57Bl/6N mice were isolated and cultured
293T cells,cell_lines,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Kidney,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Human 293T cells (used for lentiviral packaging), sNF96.2 (a MPNST cell line derived from a patient with NF1, used as target cells)"
iHSCs,cell_lines,PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,iHSC lines were maintained and passaged at 37°C with 5% CO2 in DMEM high-glucose media supplemented with 10% FBS and penicillin/streptomycin
STS-26T,cell_lines,PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"STS-26T (19), HS-PSS, HS-sch2 (20), S462 (21), and sNF96.2 (22) cell lines were previously established in other laboratories."
HS-PSS,cell_lines,PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"STS-26T (19), HS-PSS, HS-sch2 (20), S462 (21), and sNF96.2 (22) cell lines were previously established in other laboratories."
HS-sch2,cell_lines,PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"STS-26T (19), HS-PSS, HS-sch2 (20), S462 (21), and sNF96.2 (22) cell lines were previously established in other laboratories."
S462,cell_lines,PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,Malignant Peripheral Nerve Sheath Tumor,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"STS-26T (19), HS-PSS, HS-sch2 (20), S462 (21), and sNF96.2 (22) cell lines were previously established in other laboratories."
AC028,cell_lines,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Brain,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,primary normal arachnoid AC028
HEK293T,cell_lines,PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Kidney,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,U87-MG and HEK293T cells were purchased from ATCC. Cell lines were regularly passaged and were cultured in Dulbecco's Modified Eagle Medium
293T,cell_lines,PMID:25026211,10.1016/j.ccr.2014.05.001,Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Kidney,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,FH-DCAF1 and FH-Lats1 (purified from 293T cells) were incubated in 20 μl reaction buffer
φNX packaging cell line,cell_lines,PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Kidney,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,The φNX packaging cell line (Orbigen) was transfected using Lipofectamine 2000
BY4743 background diploid yeast deletion strains,cell_lines,PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.",,0.85,Experimental Usage,False,0.67,Low,,,,,,,Yeast,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Diploid yeast deletion strains used for growth analyses were of the BY4743 background (MATa/MATα, his3∆1/his3∆1, leu2∆0/leu2∆0...)"
Y258 background haploid yeast MORF strain,cell_lines,PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.",,0.85,Experimental Usage,False,0.67,Low,,,,,,,Yeast,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"The haploid yeast MORF (Movable ORF) strain for RAS1 overexpression was of the Y258 background (MATa, pep 4-3, his 4-580...)"
M059J,cell_lines,PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Brain,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Primary normal human astrocytes (M059J) and 4 glioma cell lines (U87, U118, U251, and A172) were commercially procured from Shanghai Cell Bank"
HEK 293T,cell_lines,PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Kidney,,,Embryonic stem cell,,,,,,,,,,,,,,,,,,,,,,"co-transfected with the packaging plasmids psPAX (Addgene #12260) and pMD2.G (Addgene, #12259) into the human embryonic kidney (HEK) 293T cells"
Sf21 insect cells,cell_lines,PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Insect ovary,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Sf21 insect cells (Life Technologies, Carlsbad, CA, USA)...Sf21 cells were infected with saturating amounts"
Rosetta2(DE3) competent cells,cell_lines,PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Bacteria,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"The expression plasmids were transformed into the Rosetta2(DE3) competent cells (EMD Biosciences, Inc)"
Daoy,cell_lines,PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Brain,,Medulloblastoma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,expression and activity of catalytically active and inactive PDE4A1 constructs were determined first in Daoy medulloblastoma cells (American Type Culture Collection)
GL261,cell_lines,PMID:35118381,10.1093/noajnl/vdab184,Neutrophil depletion enhanced the ,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Brain,,Glioblastoma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"The mouse GL261 glioma cell line was obtained from the German Collection of Microorganisms and Cell Cultures (DSMZ), Germany, and was authenticated by DSMZ."
hTERT ipn02.3 2λ cell line,cell_lines,PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,Immortalized human normal (hTERT ipn02.3 2λ) and NF1 deficient neurofibroma Schwann cells
ipNF02.3 2λ,cell_lines,PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"...additional neurofibromin-competent cell lines, specifically human foreskin fibroblasts [HFF] and the Schwann cell lines ipNF02.3 2λ, ipNF02.8..."
ipNF02.8,cell_lines,PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"...additional neurofibromin-competent cell lines, specifically human foreskin fibroblasts [HFF] and the Schwann cell lines ipNF02.3 2λ, ipNF02.8..."
293FT,cell_lines,PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Kidney,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,Viral media was produced using 293FT cells transfected using Fugene 6 (Promega) in optiMEM (Gibco)
Primary normal rat Schwann cells,cell_lines,PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,Primary normal rat Schwann cells were isolated from the sciatic nerves of neonatal Sprague-Davey Rats
iSC,cell_lines,PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Normal, spontaneously immortal rat Schwann cell clones (iSC) isolated from sciatic nerves were a generous gift from E.M. Shooter"
MOLM-13,cell_lines,PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Blood,,Acute myeloid leukemia,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,Early-passage MOLM-13 cells (DSMZ) were cultured in RPMI media
293T lenti-X cells,cell_lines,PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Kidney,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,293T lenti-X cells (Takara Bio) with TransIT-LT1
H929,cell_lines,PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Blood,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"H929, U266B1, U2932, MCF7, and HT229 cell lines were selected based on historic demonstrations of their dependences on corresponding BCL-2-family members"
U266B1,cell_lines,PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Blood,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"H929, U266B1, U2932, MCF7, and HT229 cell lines were selected based on historic demonstrations of their dependences on corresponding BCL-2-family members"
U2932,cell_lines,PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Blood,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"H929, U266B1, U2932, MCF7, and HT229 cell lines were selected based on historic demonstrations of their dependences on corresponding BCL-2-family members"
MCF7,cell_lines,PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Breast,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"H929, U266B1, U2932, MCF7, and HT229 cell lines were selected based on historic demonstrations of their dependences on corresponding BCL-2-family members"
HT229,cell_lines,PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Colon,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"H929, U266B1, U2932, MCF7, and HT229 cell lines were selected based on historic demonstrations of their dependences on corresponding BCL-2-family members"
HCC1937,cell_lines,PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Breast,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"Except for MCF7, HT229, and HCC1937 (gifts from Dr. Bora Limb, MD Anderson Cancer Research Center, Houston, TX, USA), all cell lines were purchased from the American Type Culture Collection"
primary human Schwann cells (HSC),cell_lines,PMID:41001593,10.1080/23723556.2025.2561292,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"The primary human Schwann cells (HSC) were obtained by ScienCell (#1700, Carlsbad, CA, USA)"
Normal human Schwann cells (HSC),cell_lines,PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Nerve,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Normal human Schwann cells (HSC) (ScienCell Research Laboratories, Carlsbad, CA, USA) were grown on the poly-L-lysine-coated tissue culture plates"
B8 fibroblasts,cell_lines,PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,0.85,Experimental Usage,False,0.67,Low,,,,,,,Connective tissue,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Mouse fibroblast B8 cells (kindly provided by Ralf Stohwasser, Brandenburg Technical University Cottbus-Senftenberg)"
GSK2126458,genetic_reagents,PMID:29897904,10.1371/journal.pone.0197350,Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,GSK2126458,,,,,,,,,,,,,,,,,,,,,"Cell viability results showed that three agents (GSK2126458, Panobinostat, CUDC-907) had the greatest activity across schwannoma and meningioma cell systems"
Panobinostat,genetic_reagents,PMID:29897904,10.1371/journal.pone.0197350,Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,Panobinostat,,,,,,,,,,,,,,,,,,,,,"Cell viability results showed that three agents (GSK2126458, Panobinostat, CUDC-907) had the greatest activity across schwannoma and meningioma cell systems"
CUDC-907,genetic_reagents,PMID:29897904,10.1371/journal.pone.0197350,Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,CUDC-907,,,,,,,,,,,,,,,,,,,,,"Cell viability results showed that three agents (GSK2126458, Panobinostat, CUDC-907) had the greatest activity across schwannoma and meningioma cell systems"
Phusion polymerase,genetic_reagents,PMID:34630515,10.3389/fgene.2021.721045,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and ,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,Phusion polymerase,,,,,,,,,,,,,,,,,,,,,"we used Phusion polymerase (M0530S; New England Biolabs, Inc., Ipswitch, MA) to synthesize a gRNA in vitro transcription template"
T7 transcription,genetic_reagents,PMID:34630515,10.3389/fgene.2021.721045,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and ,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,T7 transcription,,,,,,,,,,,,,,,,,,,,,used for in vitro transcription of gRNA according to the manufacturer instructions (MEGAshortscript T7 Transcription Kit (AM1354); ThermoFisher Scientific
Q5 DNA polymerase,genetic_reagents,PMID:34630515,10.3389/fgene.2021.721045,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and ,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,Q5 DNA polymerase,,,,,,,,,,,,,,,,,,,,,"PCR was performed using Q5® Hot Start High-Fidelity DNA Polymerase (New England Biolabs, Inc.) according to manufacturer's suggestions"
PrimeSTAR GXL,genetic_reagents,PMID:34630515,10.3389/fgene.2021.721045,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and ,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,PrimeSTAR GXL,,,,,,,,,,,,,,,,,,,,,"the targeted region was PCR amplified with the hotstart PrimeSTAR GXL DNA polymerase (Takara Bio Inc., Mountain View, CA)"
INK128,genetic_reagents,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,INK128,,,,,,,,,,,,,,,,,,,,,"inhibitor drugs lapatinib, erlotinib, INK128/TAK-228, and BMS-754807 (Selleck Chemicals)"
TAK-228,genetic_reagents,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,TAK-228,,,,,,,,,,,,,,,,,,,,,"inhibitor drugs lapatinib, erlotinib, INK128/TAK-228, and BMS-754807 (Selleck Chemicals)"
BMS-754807,genetic_reagents,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,BMS-754807,,,,,,,,,,,,,,,,,,,,,"inhibitor drugs lapatinib, erlotinib, INK128/TAK-228, and BMS-754807 (Selleck Chemicals)"
lapatinib,genetic_reagents,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,lapatinib,,,,,,,,,,,,,,,,,,,,,"inhibitor drugs lapatinib, erlotinib, INK128/TAK-228, and BMS-754807 (Selleck Chemicals)"
erlotinib,genetic_reagents,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,erlotinib,,,,,,,,,,,,,,,,,,,,,"inhibitor drugs lapatinib, erlotinib, INK128/TAK-228, and BMS-754807 (Selleck Chemicals)"
rapamycin,genetic_reagents,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,rapamycin,,,,,,,,,,,,,,,,,,,,,rapamycin (EMD Millipore)
AZD2014,genetic_reagents,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,AZD2014,,,,,,,,,,,,,,,,,,,,,AZD2014 (obtained from AstraZeneca)
MM-121,genetic_reagents,PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,MM-121,,,,,,,,,,,,,,,,,,,,,MM-121 (generously provided by Merrimack Pharmaceuticals)
λ-phosphatase,genetic_reagents,PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,λ-phosphatase,,,,,,,,,,,,,,,,,,,,,Protein dephosphorylation was achieved by treating 20 μg of protein lysate with λ-phosphatase (New England Biolabs)
NeoTkp,genetic_reagents,PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,NeoTkp,,,,,,,,,,,,,,,,,,,,,"200 ng of each oligonucleotide primer (NeoTkp, NF31a, NF31b)"
NF31a,genetic_reagents,PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,NF31a,,,,,,,,,,,,,,,,,,,,,"200 ng of each oligonucleotide primer (NeoTkp, NF31a, NF31b)"
NF31b,genetic_reagents,PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,NF31b,,,,,,,,,,,,,,,,,,,,,"200 ng of each oligonucleotide primer (NeoTkp, NF31a, NF31b)"
R26 LacZR,genetic_reagents,PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,R26 LacZR,,,,,,,,,,,,,,,,,,,,,Both of inducible strains carry R26 LacZR  allele as a reporter.
Hematopoietic differentiation factors,genetic_reagents,PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,Hematopoietic differentiation factors,,,,,,,,,,,,,,,,,,,,,HPCs were generated using the STEMdiff hematopoietic kit (STEMCELL Technologies)
RNA extraction reagents,genetic_reagents,PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,RNA extraction reagents,,,,,,,,,,,,,,,,,,,,,"cells were harvested and RNA was isolated with the ReliaPrep RNA tissue kit (Promega, Fitchburg, USA)"
Reverse transcription reagents,genetic_reagents,PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,Reverse transcription reagents,,,,,,,,,,,,,,,,,,,,,"RNA was reverse transcribed into cDNA using the PrimeScript RT reagent kit (Takara Bio, Kusatsu, Japan)"
cAMP detection reagents,genetic_reagents,PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,cAMP detection reagents,,,,,,,,,,,,,,,,,,,,,"cAMP levels in hiMGL cells were determined using the cAMP ELISA kit (Cayman Chemical, Ann Arbor, MI, USA)"
Cytokine detection reagents,genetic_reagents,PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,Cytokine detection reagents,,,,,,,,,,,,,,,,,,,,,"The MILLIPLEX MAP human cytokine/chemokine/growth factor panel A – immunology multiplex assay (HCYTA-60K, Merck) was used"
rl Sem,genetic_reagents,PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,rl Sem,,,,,,,,,,,,,,,,,,,,,ERK was activated via expression of ERK with the gain-of-function mutation ERK 56 Sem (UAS-rl Sem).
nSyb,genetic_reagents,PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,nSyb,,,,,,,,,,,,,,,,,,,,,The following lines were obtained from the Bloomington Drosophila Stock Center (BDSC): nSyb (BDSC #51635)
R57C10,genetic_reagents,PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,R57C10,,,,,,,,,,,,,,,,,,,,,"The following lines were obtained from the Bloomington Drosophila Stock Center (BDSC): nSyb (BDSC #51635), R57C10 (39171)"
tsh-Gal4,genetic_reagents,PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,tsh-Gal4,,,,,,,,,,,,,,,,,,,,,"The following lines were obtained from the Bloomington Drosophila Stock Center (BDSC): nSyb (BDSC #51635), R57C10 (39171), 69B (1774), tsh-Gal4 (3040)"
Oct-TyrR-Gal4,genetic_reagents,PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,Oct-TyrR-Gal4,,,,,,,,,,,,,,,,,,,,,"The following lines were obtained from the Bloomington Drosophila Stock Center (BDSC): nSyb (BDSC #51635), R57C10 (39171), 69B (1774), tsh-Gal4 (3040), and Oct-TyrR-Gal4 (36494)."
PCB-Gal4,genetic_reagents,PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,PCB-Gal4,,,,,,,,,,,,,,,,,,,,,PCB-Gal4 (fatbody-Gal4) was previously generated by Ronald Kühnlein
Cre,genetic_reagents,PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,Cre,,,CNP,,,,,,,,,,,,,,,,,,a Schwann cell specific Cre-recombinase controlled by the CNP promoter (Cnp-Cre)
EGFR,genetic_reagents,PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,EGFR,,,CNP,,,,,,,,,,,,,,,,,,"MPNST predisposing alleles, Cnp-EGFR and conditional Trp53 alleles"
bevacizumab,genetic_reagents,PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,bevacizumab,,,,,,,,,,,,,,,,,,,,,"bevacizumab 5 mg/kg b.w., Avastin® 100 mg/25 ml, Roche, Basel, Switzerland"
bevacizumab,genetic_reagents,PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,bevacizumab,,,,,,,,,,,,,,,,,,,,,"murine bevacizumab 5 mg/kg b.w. (B20-4.1.1, 100 mg/25 ml, Roche, Basel, Switzerland)"
Cas9,genetic_reagents,PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,Cas9,,,,,,,,,,,,,,,,,,,,,One million cells were electroporated (1 pulse of 1400V for 30 ms) with 2 µg Flag-hCas9
PB7 transposase,genetic_reagents,PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,PB7 transposase,,,CMV,,,,,,,,,,,,,,,,,,500 ng of CMV-PB7 transposase
PD0325901,genetic_reagents,PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,PD0325901,,,,,,,,,,,,,,,,,,,,,MEK inhibitor PD0325901...Ten mice were treated with ATRA (15 mg/kg) or PD0325901 (10 mg/kg)
ATRA,genetic_reagents,PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,ATRA,,,,,,,,,,,,,,,,,,,,,all-trans retinoic acid (ATRA)...Ten mice were treated with ATRA (15 mg/kg) or PD0325901 (10 mg/kg)
SYBR premix EX Taq,genetic_reagents,PMID:32733557,10.1155/2020/5976465,"Gene Expression, Network Analysis, and Drug Discovery of Neurofibromatosis Type 2-Associated Vestibular Schwannomas Based on Bioinformatics Analysis.",,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,SYBR premix EX Taq,,,,,,,,,,,,,,,,,,,,,"Reverse transcription was carried out using SYBR premix EX Taq (Takara, Japan)"
SYBR Premix Ex Taq II,genetic_reagents,PMID:32733557,10.1155/2020/5976465,"Gene Expression, Network Analysis, and Drug Discovery of Neurofibromatosis Type 2-Associated Vestibular Schwannomas Based on Bioinformatics Analysis.",,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,SYBR Premix Ex Taq II,,,,,,,,,,,,,,,,,,,,,and SYBR Premix Ex Taq II (Takara) was used for qPCR
trastuzumab,genetic_reagents,PMID:18636037,10.1097/MAO.0b013e31817f7398,The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,trastuzumab,,,,,,,,,,,,,,,,,,,,,"trastuzumab (25 mg/kg in 0.25 ml normal saline i.p., Genentech, South San Francisco, CA)"
erlotinib,genetic_reagents,PMID:18636037,10.1097/MAO.0b013e31817f7398,The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,erlotinib,,,,,,,,,,,,,,,,,,,,,"erlotinib (50 mg/kg, Genentech, South San Francisco, CA), five days a week"
AZD2014,genetic_reagents,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,AZD2014,,,,,,,,,,,,,,,,,,,,,"AZD2014 (provided by AstraZeneca; Wilmington, DE)"
NE-PER Nuclear and Cytoplasmic Extraction Reagents,genetic_reagents,PMID:25026211,10.1016/j.ccr.2014.05.001,Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,NE-PER Nuclear and Cytoplasmic Extraction Reagents,,,,,,,,,,,,,,,,,,,,,Nuclear and non-nuclear fractions were prepared using NE-PER Nuclear and Cytoplasmic Extraction Reagents following manufacturer's instructions (Thermo Fisher Scientific).
EdU,genetic_reagents,PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,EdU,,,,,,,,,,,,,,,,,,,,,EdU detection was performed on 14 μm-thick cryosections using the Click-IT Plus EdU Alexa Fluor 488 Imaging Kit (Thermo Fisher Scientific)
PD0325901,genetic_reagents,PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,PD0325901,,,,,,,,,,,,,,,,,,,,,"For MEKi treatment, 1 μg/mL PD0325901 (Selleckchem, S1036) was added to cell culture for 72 hours."
Ketotifen fumarate,genetic_reagents,PMID:31527226,10.1158/1535-7163.MCT-19-0123,"Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of ",,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,Ketotifen fumarate,,,,,,,,,,,,,,,,,,,,,"Ketotifen fumarate was purchased from Sigma-Aldrich. In the prevention and intervention therapeutic studies, ketotifen 1 mg/mL was prepared in ddH2O and administered via oral gavage at 10 mg/kg once daily"
EdU detection,genetic_reagents,PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,EdU detection,,,,,,,,,,,,,,,,,,,,,Edu staining was performed using Click-it EdU Alexa Fluor 633 Image Kit (ThermoFisher C10340)
SCH23390,genetic_reagents,PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,SCH23390,,,,,,,,,,,,,,,,,,,,,"[3H]-SCH23390, [3H]-raclopride, [3H]-Win 35428 (PerkinElmer Life and Analytical Sciences; Shelton, CT)"
raclopride,genetic_reagents,PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,raclopride,,,,,,,,,,,,,,,,,,,,,"[3H]-SCH23390, [3H]-raclopride, [3H]-Win 35428 (PerkinElmer Life and Analytical Sciences; Shelton, CT)"
Win 35428,genetic_reagents,PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,Win 35428,,,,,,,,,,,,,,,,,,,,,"[3H]-SCH23390, [3H]-raclopride, [3H]-Win 35428 (PerkinElmer Life and Analytical Sciences; Shelton, CT)"
WC-10,genetic_reagents,PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,WC-10,,,,,,,,,,,,,,,,,,,,,"[3H]-WC-10, and [3H]-a-Dihydrotetrabenazine ([3H]-DTBZ; American Radiolabeled Chemicals; St. Louis, MO)"
DTBZ,genetic_reagents,PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,DTBZ,,,,,,,,,,,,,,,,,,,,,"[3H]-a-Dihydrotetrabenazine ([3H]-DTBZ; American Radiolabeled Chemicals; St. Louis, MO)"
raclopride,genetic_reagents,PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,raclopride,,,,,,,,,,,,,,,,,,,,,Mice were injected with ~200μCi of [11C]-raclopride (~2500 Ci/mmol specific activity) via the tail vein
telomere repeat sequence probe,genetic_reagents,PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,telomere repeat sequence probe,,,,,,,,,,,,,,,,,,,,,hybridization with a Cy3-labeled peptide nucleic acid (PNA) probe complementary to the mammalian telomere repeat sequence [(N-terminus to C-terminus) CCCTAACCCTAACCCTAA]
centromeric DNA repeats probe,genetic_reagents,PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,centromeric DNA repeats probe,,,,,,,,,,,,,,,,,,,,,an Alexa Fluor-488–labeled PNA probe specific to human centromeric DNA repeats was also included as a control to assess the validity of the hybridization
Active RAS Pull-Down Kit,genetic_reagents,PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,Active RAS Pull-Down Kit,,,,,,,,,,,,,,,,,,,,,Ras-GTP assays were performed with the Active RAS Pull-Down Kit (Thermo Fisher)
SU-11274,genetic_reagents,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,SU-11274,,,,,,,,,,,,,,,,,,,,,MM cells in log growth phase were treated with vehicle control or c-Met inhibitors SU-11274 (5 μM)
SGX2943,genetic_reagents,PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,SGX2943,,,,,,,,,,,,,,,,,,,,,or SGX2943 (5 μM Calbiochem) for 24 h before harvesting for protein extraction
REPLI-g FFPE,genetic_reagents,PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,REPLI-g FFPE,,,,,,,,,,,,,,,,,,,,,genomic DNA was isolated and subjected to whole genome amplification according to manufacturers instructions using the REPLI-g FFPE kit (Qiagen)
Rac1 N17,genetic_reagents,PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,Rac1 N17,,,,,,,,,,,,,,,,,,,,,dominant-negative Rac1 (Rac1 N17) as previously described [15]
APX3330,genetic_reagents,PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,APX3330,,,,,,,,,,,,,,,,,,,,,"Small-molecule Ref-1 inhibitors APX3330, APX2009 and APX2014 (Apexian Pharmaceuticals, Indianapolis, IN, USA)"
APX2009,genetic_reagents,PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,APX2009,,,,,,,,,,,,,,,,,,,,,"Small-molecule Ref-1 inhibitors APX3330, APX2009 and APX2014 (Apexian Pharmaceuticals, Indianapolis, IN, USA)"
APX2014,genetic_reagents,PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,APX2014,,,,,,,,,,,,,,,,,,,,,"Small-molecule Ref-1 inhibitors APX3330, APX2009 and APX2014 (Apexian Pharmaceuticals, Indianapolis, IN, USA)"
Mycoplasma detection primers,genetic_reagents,PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,Mycoplasma detection primers,,,,,,,,,,,,,,,,,,,,,"All cultures were routinely tested for mycoplasma contamination (LookOut Mycoplasma PCR detection kit, Sigma-Aldrich, St. Louis, MO, USA)"
Chariot protein delivery reagent,genetic_reagents,PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,0.85,Experimental Usage,False,0.50,Low,,,,,,,,,,,Chariot protein delivery reagent,,,,,,,,,,,,,,,,,,,,,"4 μL of the lipophilic cell permeation agent Chariot (Active Motif, Carlsbad, CA, USA) in 100 μL ddH2O"
2V6.11,cell_lines,PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.85,Experimental Usage,False,0.33,Low,,,,,,,Unknown,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,2V6.11 cells were purchased from Cytion Cell Lines Services LLC
293fs cells,cell_lines,PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.8,Experimental Usage,False,0.67,Low,,,,,,,Kidney,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,293fs cells were used to package lentivirus encoding individual sgRNA and Cas9
H358 cells,cell_lines,PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.8,Experimental Usage,False,0.67,Low,,,,,,,Lung,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,H358 cells (shared by the Kate O'Donnell laboratory at UT Southwestern) were KRAS mutant human lung cancer cells
LS141,cell_lines,PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.8,Experimental Usage,False,0.67,Low,,,,,,,Soft tissue,,Dedifferentiated liposarcoma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,LS141 and DDLS primary human cell lines were derived from two patients with high grade retroperitoneal dedifferentiated liposarcoma
DDLS,cell_lines,PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.8,Experimental Usage,False,0.67,Low,,,,,,,Soft tissue,,Dedifferentiated liposarcoma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,LS141 and DDLS primary human cell lines were derived from two patients with high grade retroperitoneal dedifferentiated liposarcoma
K562,cell_lines,PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.8,Experimental Usage,False,0.67,Low,,,,,,,Blood,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,Assembled TALENs were tested by transient transfection into K562 cells
HFFs,cell_lines,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.8,Experimental Usage,False,0.67,Low,,,,,,,Skin,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"HFFs (human foreskin fibroblasts, used as target cells) were maintained in DMEM"
NCI-H266,cell_lines,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.8,Experimental Usage,False,0.67,Low,,,,,,,Lung,,Lung carcinoma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"NCI-H266 (a lung carcinoma cell line, used as target cells)"
K562,cell_lines,PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.8,Experimental Usage,False,0.67,Low,,,,,,,Blood,,Chronic myelogenous leukemia,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"K562 (a chronic myelogenous leukemia cell line, used as target cells)"
Human Foreskin Fibroblast (HFF),cell_lines,PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.8,Experimental Usage,False,0.67,Low,,,,,,,Skin,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,The Human Foreskin Fibroblast (HFF) cell line was purchased from ATCC (American Type Culture Collection).
293T,cell_lines,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.8,Experimental Usage,False,0.67,Low,,,,,,,Kidney,,,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,Low passage 293T cells for large-scale lentiviral packaging were obtained from TRC
MethoCult® M3434,cell_lines,PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.",,0.8,Experimental Usage,False,0.67,Low,,,,,,,Blood,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"Colony forming unit granulocyte/macrophage (CFU-GM) progenitors were grown in MethoCult® (StemCell Technologies, Cat #03434)"
LN229,cell_lines,PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.8,Experimental Usage,False,0.67,Low,,,,,,,Brain,,Glioblastoma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"LN229 was obtained from ATCC, T98G was a gift from the Laterra laboratory, and both were cultured as recommended"
T98G,cell_lines,PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.8,Experimental Usage,False,0.67,Low,,,,,,,Brain,,Glioblastoma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,"LN229 was obtained from ATCC, T98G was a gift from the Laterra laboratory, and both were cultured as recommended"
E. coli DH10Multibac cells,cell_lines,PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,0.8,Experimental Usage,False,0.67,Low,,,,,,,Bacterial,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,E. coli DH10Multibac cells containing the modified baculoviral genome
GL261-luc,cell_lines,PMID:35118381,10.1093/noajnl/vdab184,Neutrophil depletion enhanced the ,,0.8,Experimental Usage,False,0.67,Low,,,,,,,Brain,,Glioblastoma,Cancer cell line,,,,,,,,,,,,,,,,,,,,,,GL261-luc cells were generated by infection of lentivirus carrying luciferase as described.
DH5α bacteria,cell_lines,PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,0.8,Experimental Usage,False,0.67,Low,,,,,,,Bacterial,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,"The fusion proteins, MBP-merlin-N and MBP-merlin-C, were expressed in the DH5α bacteria and purified using the amylose resin"
Neural stem cells,cell_lines,PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.8,Experimental Usage,False,0.67,Low,,,,,,,Brain,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,NSCs were obtained from the fetal brains of embryonic Day 14 pregnant Sprague‒Dawley rats
pan-T-cell isolation,genetic_reagents,PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,pan-T-cell isolation,,,,,,,,,,,,,,,,,,,,,"CD3+ T cells were purified from the lymph nodes using pan-T-cell isolation kit (Miltenyi Biotec, Auburn, CA)"
7-aminoactinomycin D,genetic_reagents,PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,7-aminoactinomycin D,,,,,,,,,,,,,,,,,,,,,Live cells were isolated from dead cells by staining with 7-aminoactinomycin D (Biolegend; 420403; 1:100)
Vecta Stain Elite ABC,genetic_reagents,PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,Vecta Stain Elite ABC,,,,,,,,,,,,,,,,,,,,,"the Vecta Stain Elite ABC kit (Vectorlabs, PK-6100) was used according to the manufacturer's protocol"
AT101,genetic_reagents,PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,AT101,,,,,,,,,,,,,,,,,,,,,"AT101 was provided by Ascenta Therapeutics (Malvern, PA)"
phospho-protein purification kit from Qiagen®,genetic_reagents,PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,phospho-protein purification kit from Qiagen®,,,,,,,,,,,,,,,,,,,,,Phospho-proteins were isolated from cell lysates using the commercially available phospho-protein purification kit from Qiagen®
cytoplasmic and nuclear extraction assay (Thermo Scientific),genetic_reagents,PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,cytoplasmic and nuclear extraction assay (Thermo Scientific),,,,,,,,,,,,,,,,,,,,,"To ascertain the cellular location of PDLIM2, a cytoplasmic and nuclear extraction assay (Thermo Scientific) was performed"
Taq polymerase,genetic_reagents,PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,Taq polymerase,,,,,,,,,,,,,,,,,,,,,"0.25 units of Taq polymerase (Perkin-Elmer Cetus) and a mixture of dATP, dCTP, dGTP and dTTP"
2.5S NGF,genetic_reagents,PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,2.5S NGF,,,,,,,,,,,,,,,,,,,,,"50 ng/ml nerve growth factor [2.5S NGF, Harlan Bio-products]"
rhGGF2,genetic_reagents,PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,rhGGF2,,,,,,,,,,,,,,,,,,,,,"amplified for 1 week in recombinant human glial growth factor (rhGGF2, Cambridge Neuroscience)"
MLN8237,genetic_reagents,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,MLN8237,,,,,,,,,,,,,,,,,,,,,AURKA specific inhibitor MLN8237 (Selleck Chemicals). Mice were treated by gavage once daily with 30mg/kg MLN8237
alamarBlue,genetic_reagents,PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,alamarBlue,,,,,,,,,,,,,,,,,,,,,Proliferation was evaluated by the alamarBlue TM cell viability assay (Invitrogen) after indicated days in culture
EdU,genetic_reagents,PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,EdU,,,,,,,,,,,,,,,,,,,,,EdU proliferation assay was performed using the Click-iT EdU Alexa Fluor 594 imaging kit (Thermo Fisher Scientific C10339)
trametinib,genetic_reagents,PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,trametinib,,,,,,,,,,,,,,,,,,,,,An FDA-approved small molecule MEK inhibitor (either trametinib or selumetinib) was used off-label to treat nine patients
selumetinib,genetic_reagents,PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,selumetinib,,,,,,,,,,,,,,,,,,,,,An FDA-approved small molecule MEK inhibitor (either trametinib or selumetinib) was used off-label to treat nine patients
calcein AM,genetic_reagents,PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,calcein AM,,,,,,,,,,,,,,,,,,,,,re-suspended in 1 mL of BSA/HBSS containing 1 mM calcein AM (Life Technologies) and 0.33 mM TO-PRO-3 iodide
TO-PRO-3 iodide,genetic_reagents,PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,TO-PRO-3 iodide,,,,,,,,,,,,,,,,,,,,,re-suspended in 1 mL of BSA/HBSS containing 1 mM calcein AM (Life Technologies) and 0.33 mM TO-PRO-3 iodide (Life Technologies)
Mycoplasma detection reagents,genetic_reagents,PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,Mycoplasma detection reagents,,,,,,,,,,,,,,,,,,,,,"cells were tested for mycoplasma using the Promokine Mycoplasma Test Kit I/C (Minerva Biolabs, Berlin, Germany)"
STR analysis reagents,genetic_reagents,PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,STR analysis reagents,,,,,,,,,,,,,,,,,,,,,Cell line identity (short tandem repeat analysis) was performed using the GenePrint 10 System (Promega)
Cell migration assay reagents,genetic_reagents,PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,Cell migration assay reagents,,,,,,,,,,,,,,,,,,,,,"Cell motility was assessed using the IncuCyte cell migration kit (Sartorius, Göttingen, Germany)"
verteporfin,genetic_reagents,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,verteporfin,,,,,,,,,,,,,,,,,,,,,"verteporfin (S1786, Selleckchem) and sorafenib p-Toluenesulfonate salt (S-8502, LC Laboratories) were dissolved in DMSO"
sorafenib p-Toluenesulfonate salt,genetic_reagents,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,sorafenib p-Toluenesulfonate salt,,,,,,,,,,,,,,,,,,,,,"verteporfin (S1786, Selleckchem) and sorafenib p-Toluenesulfonate salt (S-8502, LC Laboratories) were dissolved in DMSO"
imatinib mesylate,genetic_reagents,PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,imatinib mesylate,,,,,,,,,,,,,,,,,,,,,"Dobutamine hydrochloride (D0676, Sigma Aldrich) and imatinib mesylate (I-5508, LC Laboratories) were dissolved in distilled water"
CCK8,genetic_reagents,PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,CCK8,,,,,,,,,,,,,,,,,,,,,Viability was assessed using the Cell Counting Kit 8 (CCK8) from Dojindo Molecular Technologies
Everolimus,genetic_reagents,PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,Everolimus,,,,,,,,,,,,,,,,,,,,,Everolimus (RAD001) inhibits the mTOR and is currently FDA approved for several types of solid tumors
PD-0325901,genetic_reagents,PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,PD-0325901,,,,,,,,,,,,,,,,,,,,,"PD-0325901 (PD-901) inhibits MEK, a component of the MAPK pathway, and is currently in clinical trials"
β-Galactosidase,genetic_reagents,PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,β-Galactosidase,,,,,,,,,,,,,,,,,,,,,"stained using the Senescence β-Galactosidase Staining Kit (Cell Signaling Technology #9860, Danvers, MA, USA)"
Q5 Site-Directed Mutagenesis Kit,genetic_reagents,PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,Q5 Site-Directed Mutagenesis Kit,,,,,,,,,,,,,,,,,,,,,The R1320P mutation was created in a wild-type cDNA using the Q5 Site-Directed Mutagenesis Kit (New England Biolabs).
gadolinium contrast,genetic_reagents,PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,gadolinium contrast,,,,,,,,,,,,,,,,,,,,,"IV gadolinium contrast injection (0.1 ml/kg, Gadovist, Bayer Inc.)"
microbubbles,genetic_reagents,PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,microbubbles,,,,,,,,,,,,,,,,,,,,,"IV microbubble administration (0.02 ml/kg, Definity, Lantheus Medical Imaging, USA)"
FRAX597,genetic_reagents,PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,FRAX597,,,,,,,,,,,,,,,,,,,,,"FRAX597 (generously given by Dr. Joseph Kissil, The Scripps Research Institute, Jupiter, FL)"
EdU,genetic_reagents,PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,EdU,,,,,,,,,,,,,,,,,,,,,"The incorporated EdU were stained on top of BrdU staining with Click-iT™ EdU Cell Proliferation Kit for Imaging (ThemoFisher, Cat# C10337)"
lamotrigine,genetic_reagents,PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,lamotrigine,,,,,,,,,,,,,,,,,,,,,the HCN channel agonist lamotrigine rescued the electrophysiological and cognitive deficits
CytoTox 96,genetic_reagents,PMID:25340526,10.1371/journal.pone.0107760,Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,CytoTox 96,,,,,,,,,,,,,,,,,,,,,"Cytotoxic efficacy of the non-adherent spleen cells was assessed by adding them as effector cells to PNF-derived Schwann cells as target cells at a ratio of 1∶10 for 4 h using the CytoTox 96 Non-Radioactive Cytotoxicity assay (Promega, Fitchburg, WI)"
TruSeq Stranded Total RNA,genetic_reagents,PMID:25340526,10.1371/journal.pone.0107760,Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,TruSeq Stranded Total RNA,,,,,,,,,,,,,,,,,,,,,"Sequencing libraries were prepared using TruSeq Stranded Total RNA Sample Preparation kit (Illumina, San Diego, CA)"
SuperScript III,genetic_reagents,PMID:25340526,10.1371/journal.pone.0107760,Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,SuperScript III,,,,,,,,,,,,,,,,,,,,,"mRNA was reverse transcribed using SuperScript III First-Strand Synthesis System for RT-PCR (Invitrogen, Carlsabd, CA)"
RNA isolation kit,genetic_reagents,PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,RNA isolation kit,,,,,,,,,,,,,,,,,,,,,RNA from primary astrocytes was isolated using the RNeasy Mini Kit (Qiagen) according to the manufacturer's protocol
NAD+/NADH assay,genetic_reagents,PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,NAD+/NADH assay,,,,,,,,,,,,,,,,,,,,,"The NAD+/NADH ratio was measured using the NAD+/NADH colorimetric assay kit (Abcam, Waltham, MA, USA)"
SuperScript III,genetic_reagents,PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,SuperScript III,,,,,,,,,,,,,,,,,,,,,2 µg of total RNA was used to synthesize cDNA with the SuperScript III First-Strand Synthesis System (Thermo Fisher Scientific)
MitoSOX,genetic_reagents,PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,MitoSOX,,,,,,,,,,,,,,,,,,,,,Measurements of mitochondrial ROS were performed by MitoSOX (Thermo Fisher Scientific) staining
ispinesib,genetic_reagents,PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,ispinesib,,,,,,,,,,,,,,,,,,,,,"ispinesib (Selleckchem) or ARRY-520 (MedChemExpress), which selectively inhibit KIF11"
ARRY-520,genetic_reagents,PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,ARRY-520,,,,,,,,,,,,,,,,,,,,,"ispinesib (Selleckchem) or ARRY-520 (MedChemExpress), which selectively inhibit KIF11"
CNMCS Compartmental Protein Extraction Kit,genetic_reagents,PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,CNMCS Compartmental Protein Extraction Kit,,,,,,,,,,,,,,,,,,,,,"Mouse tissues were collected and lysed with the CNMCS Compartmental Protein Extraction Kit (Millipore, 2145)..."
tamoxifen,genetic_reagents,PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,tamoxifen,,,,,,,,,,,,,,,,,,,,,"Timed-pregnant FMPrC dams (gestational day 14–16) underwent oral gavage with 1mg tamoxifen (Sigma-Aldrich, St. Louis, MO)"
progesterone,genetic_reagents,PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,progesterone,,,,,,,,,,,,,,,,,,,,,"1mg tamoxifen (Sigma-Aldrich, St. Louis, MO) and 1 mg progesterone (Sigma-Aldrich, St. Louis, MO)"
DAPI,genetic_reagents,PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,DAPI,,,,,,,,,,,,,,,,,,,,,"followed by either Alexa-Fluor-tagged secondary antibodies (Invitrogen, Grand Island, NY) and DAPI counterstaining"
Vectastain Elite ABC,genetic_reagents,PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,Vectastain Elite ABC,,,,,,,,,,,,,,,,,,,,,or biotinylated secondary antibodies and Vectastain Elite ABC development
Kit Ligand,genetic_reagents,PMID:31527226,10.1158/1535-7163.MCT-19-0123,"Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of ",,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,Kit Ligand,,,,,,,,,,,,,,,,,,,,,"To determine if ketotifen had an in vivo effect on mast cell infiltration and degranulation, four-month old Nf1 mice were administered subcutaneous Kit Ligand as previously described"
ATP detection reagent,genetic_reagents,PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,ATP detection reagent,,,,,,,,,,,,,,,,,,,,,CellTiter-Glo 3D Reagent Promega CAT#G968B
IPA-3,genetic_reagents,PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,IPA-3,,,,,,,,,,,,,,,,,,,,,Cells were treated with IPA-3 (Sigma-Aldrich) a PAK group1 inhibitor (PAK1/2/3)
Q-proteome cell compartment kit,genetic_reagents,PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,Q-proteome cell compartment kit,,,,,,,,,,,,,,,,,,,,,were fractionated using the Q-proteome cell compartment kit (Qiagen) following manufacturer's instructions
Co-IP kit,genetic_reagents,PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,Co-IP kit,,,,,,,,,,,,,,,,,,,,,Co-IP experiments were performed without deviation from Co-IP kit protocol (Thermo Scientific)
Rneasy Mini Kit,genetic_reagents,PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,Rneasy Mini Kit,,,,,,,,,,,,,,,,,,,,,"Total RNA of cultured cells was extracted using the Rneasy Mini Kit (Qiagen, Germantown, MD)"
SuperScript III first-strand synthesis system,genetic_reagents,PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,SuperScript III first-strand synthesis system,,,,,,,,,,,,,,,,,,,,,500ng of RNA were reverse-transcribed using the SuperScript™ III first-strand synthesis system for RT-PCR (Life Technologies)
Power SYBR Green PCR master mix,genetic_reagents,PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,Power SYBR Green PCR master mix,,,,,,,,,,,,,,,,,,,,,quantitative real-time PCR (Q-PCR) using Power SYBR Green PCR master mix (Life Technologies)
Vybrant MTT cell proliferation assay kit,genetic_reagents,PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,Vybrant MTT cell proliferation assay kit,,,,,,,,,,,,,,,,,,,,,The Vybrant ® MTT cell proliferation assay kit quick protocol (Life Technologies) was employed
EdU detection,genetic_reagents,PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,EdU detection,,,,,,,,,,,,,,,,,,,,,EdU was detected in whole ganglion using the Click-It EdU kit per manufacturer's instructions (Life Technologies)
CellTiter-Glo,genetic_reagents,PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,CellTiter-Glo,,,,,,,,,,,,,,,,,,,,,"Cell viability was assessed using the CellTiter-Glo Luminescent Cell Viability Assay (Cat# G755B/G756B; Promega, Madison, WI, USA)"
RNA isolation kit,genetic_reagents,PMID:34647023,10.1093/noajnl/vdab129,A genetic mouse model with postnatal ,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,RNA isolation kit,,,,,,,,,,,,,,,,,,,,,Total RNA was isolated using the Direct-zol RNA Miniprep Kit (Zymo).
RNA library preparation kit,genetic_reagents,PMID:34647023,10.1093/noajnl/vdab129,A genetic mouse model with postnatal ,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,RNA library preparation kit,,,,,,,,,,,,,,,,,,,,,Libraries were prepared using the TruSeq Stranded Total RNA Library Prep Kit (Illumina)
Trametinib,genetic_reagents,PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,Trametinib,,,,,,,,,,,,,,,,,,,,,Trametinib (a MEK inhibitor) and BMP2 released locally at the fracture site
NSC23766,genetic_reagents,PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,NSC23766,,,,,,,,,,,,,,,,,,,,,"Pharmacologic inhibitor experiments used 104 cells per well (NSC23766, 10 µM; AG825, 10 µM; Sigma, St. Louis MO)"
AG825,genetic_reagents,PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,AG825,,,,,,,,,,,,,,,,,,,,,"Pharmacologic inhibitor experiments used 104 cells per well (NSC23766, 10 µM; AG825, 10 µM; Sigma, St. Louis MO)"
Rac1 activation Assay Kit,genetic_reagents,PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,Rac1 activation Assay Kit,,,,,,,,,,,,,,,,,,,,,"Active Rac1 (Rac1-GTP) was determined by PAK1-PBD affinity chromatography (Rac1 activation Assay Kit, Millipore, Bedford MA)"
Napabucasin,genetic_reagents,PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,Napabucasin,,,,,,,,,,,,,,,,,,,,,"STAT3 inhibitor Napabucasin (SelleckChem, Houston, TX, USA) was dissolved in 100% DMSO"
Ruxolitinib,genetic_reagents,PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,Ruxolitinib,,,,,,,,,,,,,,,,,,,,,JAK1/2 kinase inhibitor Ruxolitinib (SelleckChem) was dissolved in 100% DMSO
Ni-NTA resin,genetic_reagents,PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,0.8,Experimental Usage,False,0.50,Low,,,,,,,,,,,Ni-NTA resin,,,,,,,,,,,,,,,,,,,,,Recombinant wild-type Hsp90β was purified from the bacterial culture using a Ni-NTA purification system (Invitrogen)
BRGN,cell_lines,PMID:41001593,10.1080/23723556.2025.2561292,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor.,,0.8,Experimental Usage,False,0.33,Low,,,,,,,Unknown,,,Finite cell line,,,,,,,,,,,,,,,,,,,,,,BRGN control cells used in this study were previously described
standardised femoral rat fracture model,animal_models,PMID:26822862,10.1038/srep20010,Capturing the wide variety of impaired fracture healing phenotypes in Neurofibromatosis Type 1 with eight key factors: a computational study.,,0.75,Citation Only,False,1.00,Low,standardised femoral rat fracture model,No known disease,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,The geometrical domain of the computational model is deduced from the real callus geometry at three weeks post-fracture in a standardised femoral rat fracture model
WM nback task,clinical_assessment_tools,PMID:33963966,10.1007/s10803-021-05043-3,Cognitive and Electrophysiological Correlates of Working Memory Impairments in Neurofibromatosis Type 1.,,0.75,Experimental Usage,False,1.00,Low,,,,,,,,,,,,,,,,,,,,,,,,,,,WM nback task,performance test,pediatric,No,,EEG was recorded during a WM nback task. The NF1 group showed poorer performance on measures of WM as compared to the control group.
Ki-67/MIB-1 index,clinical_assessment_tools,PMID:40352015,10.7759/cureus.82033,Development of a Machine Learning Algorithm for the Prediction of WHO Grade 1 Meningioma Recurrence.,,0.75,Experimental Usage,False,1.00,Low,,,,,,,,,,,,,,,,,,,,,,,,,,,Ki-67/MIB-1 index,biomarker assay,adult,No,,"the meningioma recurrence score (MRS) generated by our machine learning algorithm revealed multiple predictive factors of recurrence, including age, female gender, and various histopathologic features, including the Ki-67/MIB-1 index."
electrophysiological measurements,clinical_assessment_tools,PMID:25012216,10.1186/s40478-014-0082-1,A neuronal function of the tumor suppressor protein merlin.,,0.75,Experimental Usage,False,1.00,Low,,,,,,,,,,,,,,,,,,,,,,,,,,,electrophysiological measurements,performance test,all ages,No,,Electrophysiological measurements are an indispensable tool for investigating the functional integrity of peripheral nerves in both the clinical and laboratory environment.
Diamond Digital color monitor (Mitsubishi Electric Australia),clinical_assessment_tools,PMID:24559228,10.1186/1866-1955-6-4,Abnormal late visual responses and alpha oscillations in neurofibromatosis type 1: a link to visual and attention deficits.,,0.75,Experimental Usage,False,1.00,Low,,,,,,,,,,,,,,,,,,,,,,,,,,,Diamond Digital color monitor (Mitsubishi Electric Australia),performance test,pediatric,No,,"The stimuli were presented in a CRT monitor (Diamond Digital color monitor, Mitsubishi Electric Australia, Rydalmere, NSW, Australia)"
HPLC/MS/MS method,clinical_assessment_tools,PMID:22961690,10.1002/pbc.24281,Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.,,0.75,Experimental Usage,False,1.00,Low,,,,,,,,,,,,,,,,,,,,,,,,,,,HPLC/MS/MS method,biomarker assay,pediatric,No,,Sorafenib plasma concentrations were measured using a validated HPLC/MS/MS method
SPSS 20.0,computational_tools,PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,,0.75,Experimental Usage,True,1.00,Low,,,,,,,,,,,,,,,SPSS 20.0,Analysis Software,20.0,,,,,,,,,,,,,,,All statistical procedures were performed in SPSS 20.0
CCK-8,genetic_reagents,PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.75,Experimental Usage,False,1.00,Low,,,,,,,,,,,CCK-8,Other,,,,,,,,,,,,,,,,,,,,"Cell viability was determined by Cell Counting Kit-8 (CCK-8) from Dojindo (Kumamoto, Japan)"
StemSep,genetic_reagents,PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.",,0.75,Experimental Usage,False,1.00,Low,,,,,,,,,,,StemSep,Other,,,,,,,,,,,,,,,,,,,,Lineage-marker-negative (Lin-) cells were purified through a 0.3-in StemSep negative selection column as per the manufacturer's instructions
RNA extraction reagent,genetic_reagents,PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,0.75,Experimental Usage,False,1.00,Low,,,,,,,,,,,RNA extraction reagent,Other,,,,,,,,,,,,,,,,,,,,Total cellular RNA was extracted from glioma tissues and cultured cells using the commercially procured TRIzol reagent (Invitrogen)
HiTrap Chelating Sepharose™ High Performance,genetic_reagents,PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,0.75,Experimental Usage,False,1.00,Low,,,,,,,,,,,HiTrap Chelating Sepharose™ High Performance,Other,,,,,,,,,,,,,,,,,,,,The supernatant ran through a 5 ml HiTrap Chelating Sepharose™ High Performance (GE healthcare) and washed extensively
Superdex 200 10/300 GL column,genetic_reagents,PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,0.75,Experimental Usage,False,1.00,Low,,,,,,,,,,,Superdex 200 10/300 GL column,Other,,,,,,,,,,,,,,,,,,,,Further purification followed by gel filtration chromatography using a Superdex 200 10/300 GL column (GE Healthcare)
luciferase,genetic_reagents,PMID:35118381,10.1093/noajnl/vdab184,Neutrophil depletion enhanced the ,,0.75,Experimental Usage,False,1.00,Low,,,,,,,,,,,luciferase,Viral,lentivirus,,,,,,,,,,,,,,,,,,,GL261-luc cells were generated by infection of lentivirus carrying luciferase as described.
MEM Alpha,genetic_reagents,PMID:24932921,10.1002/jbmr.2298,Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.,,0.75,Experimental Usage,False,1.00,Low,,,,,,,,,,,MEM Alpha,Other,,,,,,,,,,,,,,,,,,,,"Cells were pelleted and re-suspended in Minimum Essential Medium (MEM) Alpha (Life Technologies, CA, USA)"
RPMI 1640,genetic_reagents,PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,0.75,Experimental Usage,False,1.00,Low,,,,,,,,,,,RPMI 1640,Other,,,,,,,,,,,,,,,,,,,,complete medium consisting of RPMI 1640 supplemented with 12.5% FCS
Qiagen DNA Blood Midi/Mini kit,genetic_reagents,PMID:39669605,10.1016/j.gimo.2024.101816,Next-generation variant exon screening: Moving forward in routine genetic disease investigations.,,0.75,Experimental Usage,False,1.00,Low,,,,,,,,,,,Qiagen DNA Blood Midi/Mini kit,Other,,,,,,,,,,,,,,,,,,,,"A total of 50 ng of genomic DNA purified from peripheral blood (Qiagen DNA Blood Midi/Mini kit, Qiagen GmbH)"
Fast DNA Library Prep Set CW3045M,genetic_reagents,PMID:39669605,10.1016/j.gimo.2024.101816,Next-generation variant exon screening: Moving forward in routine genetic disease investigations.,,0.75,Experimental Usage,False,1.00,Low,,,,,,,,,,,Fast DNA Library Prep Set CW3045M,Other,,,,,,,,,,,,,,,,,,,,"The modified fragments were then ligated with barcoded adapters (Fast DNA Library Prep Set CW3045M, CWBIO Inc)."
His-p55,genetic_reagents,PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,0.75,Experimental Usage,False,1.00,Low,,,,,,,,,,,His-p55,Other,,,,,,,,,,,,,,,,,,,,Bacterially expressed His-p55 was immobilized on the CM5 sensor chip
Leibovitz's L15 medium,genetic_reagents,PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,,0.75,Experimental Usage,False,0.50,Low,,,,,,,,,,,Leibovitz's L15 medium,,,,,,,,,,,,,,,,,,,,,Embryos were decapitated in Leibovitz's L15 medium (Gibco)
DMEM,genetic_reagents,PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,,0.75,Experimental Usage,False,0.50,Low,,,,,,,,,,,DMEM,,,,,,,,,,,,,,,,,,,,,"transferred to approximately 10 ml of Dulbecco's Modified Eagle Medium (DMEM, Gibco)"
C1368,genetic_reagents,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.75,Experimental Usage,False,0.50,Low,,,,,,,,,,,C1368,,,,,,,,,,,,,,,,,,,,,Small-molecule AKIs were dissolved and diluted in DMSO/DMEM and included the pan-aurora inhibitors C1368 (Sigma)
VX680,genetic_reagents,PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.75,Experimental Usage,False,0.50,Low,,,,,,,,,,,VX680,,,,,,,,,,,,,,,,,,,,,pan-aurora inhibitors C1368 (Sigma) and VX680 (Selleck Chemicals)
DNA extraction kit,genetic_reagents,PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.75,Experimental Usage,False,0.50,Low,,,,,,,,,,,DNA extraction kit,,,,,,,,,,,,,,,,,,,,,DNA was isolated from harvested tissues using DNeasy blood and tissue kit (Qiagen) according to the manufacturer's protocol
RNA extraction kit,genetic_reagents,PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.75,Experimental Usage,False,0.50,Low,,,,,,,,,,,RNA extraction kit,,,,,,,,,,,,,,,,,,,,,Total RNA was extracted from cells and tissues using the RNeasy mini kit (Qiagen) following manufacturer's instructions
Human Universal Reference RNA,genetic_reagents,PMID:24980480,10.1186/1479-7364-8-10,Novel age-dependent targets in vestibular schwannomas.,,0.75,Experimental Usage,False,0.50,Low,,,,,,,,,,,Human Universal Reference RNA,,,,,,,,,,,,,,,,,,,,,"Sample RNA was processed in triplicate with serial dilutions of Human Universal Reference RNA (Stratagene, La Jolla, CA, USA)"
Ultra Low Cluster Plates,genetic_reagents,PMID:25026211,10.1016/j.ccr.2014.05.001,Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.,,0.75,Experimental Usage,False,0.50,Low,,,,,,,,,,,Ultra Low Cluster Plates,,,,,,,,,,,,,,,,,,,,,plated in 0.34% low melting temperature agarose (FMC Bioproducts) in complete medium at 2×10 4 (Meso-33 cells) or 1.2×10 4 (FC-1801 cells) per well in 24-well Ultra Low Cluster Plates (Costar).
Rapamycin,genetic_reagents,PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,0.75,Experimental Usage,False,0.50,Low,,,,,,,,,,,Rapamycin,,,,,,,,,,,,,,,,,,,,,"Rapamycin (LC Laboratories, catalog number R-5000; Supplementary Fig. S1A)"
NVP-BEZ235,genetic_reagents,PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,0.75,Experimental Usage,False,0.50,Low,,,,,,,,,,,NVP-BEZ235,,,,,,,,,,,,,,,,,,,,,"NVP-BEZ235 (LC Laboratories, catalog number 915019-65-7; Supplementary Fig. S1B)"
LY294002,genetic_reagents,PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,0.75,Experimental Usage,False,0.50,Low,,,,,,,,,,,LY294002,,,,,,,,,,,,,,,,,,,,,"and LY294002 (Calbiochem, San Diego CA) were purchased from commercial sources"
biocytin,genetic_reagents,PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,,0.75,Experimental Usage,False,0.50,Low,,,,,,,,,,,biocytin,,,,,,,,,,,,,,,,,,,,,0.2% biocytin was included in the intracellular pipette solution for later morphological identification
Gd-DTPA,genetic_reagents,PMID:17924978,10.1111/j.1750-3639.2007.00105.x,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.,,0.75,Experimental Usage,False,0.50,Low,,,,,,,,,,,Gd-DTPA,,,,,,,,,,,,,,,,,,,,,"all animals were intraperitoneally injected (1) a MR contrast agent, Gd-DTPA (Magnevist ®, Schering, Leverkusen, Germany) at a dose of 0.8 mL/kg"
